<SEC-DOCUMENT>0001999371-25-003629.txt : 20250401
<SEC-HEADER>0001999371-25-003629.hdr.sgml : 20250401
<ACCEPTANCE-DATETIME>20250401164644
ACCESSION NUMBER:		0001999371-25-003629
CONFORMED SUBMISSION TYPE:	DEF 14A
PUBLIC DOCUMENT COUNT:		26
CONFORMED PERIOD OF REPORT:	20250513
FILED AS OF DATE:		20250401
DATE AS OF CHANGE:		20250401

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARTIVION, INC.
		CENTRAL INDEX KEY:			0000784199
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				592417093
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEF 14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-13165
		FILM NUMBER:		25800461

	BUSINESS ADDRESS:	
		STREET 1:		1655 ROBERTS BOULEVARD N W
		CITY:			KENNESAW
		STATE:			GA
		ZIP:			30144
		BUSINESS PHONE:		7704193355

	MAIL ADDRESS:	
		STREET 1:		1655 ROBERTS BOULEVARD N W
		CITY:			KENNESAW
		STATE:			GA
		ZIP:			30144

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CRYOLIFE INC
		DATE OF NAME CHANGE:	19940526
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEF 14A
<SEQUENCE>1
<FILENAME>art-def14a_051325.htm
<DESCRIPTION>DEFINITIVE PROXY STATEMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:aort="http://Artivion.com/20241231">
<!-- Document Created by Quality EDGAR Solutions Single Source System -->
<!-- Ver. 7h3d0c70r.1.0 (tvnabbpndsdnf) [1743466617651-8041] -->
<head>
     <title>art-def14a_051325</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02C_ECD%2D2024 -->
<!-- Field: Set; Name: xdx; ID: xdx_03E_aort_Artivion.com_20241231 -->
<!-- Field: Set; Name: xdx; ID: xdx_04C_20240101_20241231 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_056_edei%2D%2DEntityCentralIndexKey_0000784199 -->
<!-- Field: Set; Name: xdx; ID: xdx_07A_XDX_art%2Ddef14a__051325.xdx -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_065_Ratio_4_xbrli%2D%2Dpure -->
<body>
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000004" name="dei:EntityCentralIndexKey">0000784199</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0010" name="dei:DocumentType">DEF 14A</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="aort-20241231.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2024-01-01to2024-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000784199</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000784199</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000784199</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000784199</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000784199</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_1">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000784199</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:typedMember dimension="ecd:MeasureAxis">
            <ecd:MeasureAxis.domain>1</ecd:MeasureAxis.domain>
          </xbrldi:typedMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_ecd_PeoMember_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000784199</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:EqtyAwrdsInSummryCompstnTblForAplblYrMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_ecd_PeoMember_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000784199</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_ecd_PeoMember_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000784199</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_ecd_PeoMember_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000784199</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_ecd_PeoMember_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000784199</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:EqtyAwrdsInSummryCompstnTblForAplblYrMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_ecd_PeoMember_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000784199</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_ecd_PeoMember_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000784199</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_ecd_PeoMember_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000784199</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_ecd_PeoMember_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000784199</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:EqtyAwrdsInSummryCompstnTblForAplblYrMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_ecd_PeoMember_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000784199</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_ecd_PeoMember_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000784199</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_ecd_PeoMember_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000784199</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_ecd_PeoMember_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000784199</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:EqtyAwrdsInSummryCompstnTblForAplblYrMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_ecd_PeoMember_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000784199</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_ecd_PeoMember_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000784199</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_ecd_PeoMember_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000784199</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_ecd_PeoMember_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000784199</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:EqtyAwrdsInSummryCompstnTblForAplblYrMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_ecd_PeoMember_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000784199</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_ecd_PeoMember_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000784199</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_ecd_PeoMember_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000784199</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_ecd_NonPeoNeoMember_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000784199</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:EqtyAwrdsInSummryCompstnTblForAplblYrMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_ecd_NonPeoNeoMember_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000784199</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_ecd_NonPeoNeoMember_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000784199</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_ecd_NonPeoNeoMember_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000784199</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_ecd_NonPeoNeoMember_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000784199</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:EqtyAwrdsInSummryCompstnTblForAplblYrMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_ecd_NonPeoNeoMember_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000784199</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_ecd_NonPeoNeoMember_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000784199</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_ecd_NonPeoNeoMember_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000784199</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_ecd_NonPeoNeoMember_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000784199</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:EqtyAwrdsInSummryCompstnTblForAplblYrMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_ecd_NonPeoNeoMember_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000784199</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_ecd_NonPeoNeoMember_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000784199</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_ecd_NonPeoNeoMember_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000784199</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_ecd_NonPeoNeoMember_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000784199</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:EqtyAwrdsInSummryCompstnTblForAplblYrMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_ecd_NonPeoNeoMember_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000784199</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_ecd_NonPeoNeoMember_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000784199</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_ecd_NonPeoNeoMember_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000784199</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_ecd_NonPeoNeoMember_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000784199</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:EqtyAwrdsInSummryCompstnTblForAplblYrMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_ecd_NonPeoNeoMember_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000784199</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_ecd_NonPeoNeoMember_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000784199</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_ecd_NonPeoNeoMember_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000784199</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_2">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000784199</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:typedMember dimension="ecd:MeasureAxis">
            <ecd:MeasureAxis.domain>2</ecd:MeasureAxis.domain>
          </xbrldi:typedMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_YearEnd2023Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000784199</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">aort:YearEnd2023Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_YearEnd2023Member_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000784199</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">aort:YearEnd2023Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_YearEnd2023Member_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000784199</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">aort:YearEnd2023Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_YearEnd2023Member_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000784199</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">aort:YearEnd2023Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_YearEnd2023Member_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000784199</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">aort:YearEnd2023Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_YearEnd2023Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000784199</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">aort:YearEnd2023Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_Vesting2024Member_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000784199</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">aort:Vesting2024Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_Vesting2024Member_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000784199</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">aort:Vesting2024Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_Vesting2024Member_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000784199</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">aort:Vesting2024Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_Vesting2024Member_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000784199</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">aort:Vesting2024Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_Vesting2024Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000784199</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">aort:Vesting2024Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_YearEnd2024Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000784199</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">aort:YearEnd2024Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_YearEnd2024Member_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000784199</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">aort:YearEnd2024Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_YearEnd2024Member_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000784199</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">aort:YearEnd2024Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_YearEnd2024Member_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000784199</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">aort:YearEnd2024Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_YearEnd2024Member_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000784199</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">aort:YearEnd2024Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_YearEnd2024Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000784199</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">aort:YearEnd2024Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Ratio">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
  <ix:relationship fromRefs="Fact000019" toRefs="Footnote000059"/>
  <ix:relationship fromRefs="Fact000020" toRefs="Footnote000059"/>
  <ix:relationship fromRefs="Fact000027" toRefs="Footnote000059"/>
  <ix:relationship fromRefs="Fact000028" toRefs="Footnote000059"/>
  <ix:relationship fromRefs="Fact000035" toRefs="Footnote000059"/>
  <ix:relationship fromRefs="Fact000036" toRefs="Footnote000059"/>
  <ix:relationship fromRefs="Fact000043" toRefs="Footnote000059"/>
  <ix:relationship fromRefs="Fact000044" toRefs="Footnote000059"/>
  <ix:relationship fromRefs="Fact000051" toRefs="Footnote000059"/>
  <ix:relationship fromRefs="Fact000052" toRefs="Footnote000059"/>
  <ix:relationship fromRefs="Fact000021" toRefs="Footnote000060"/>
  <ix:relationship fromRefs="Fact000022" toRefs="Footnote000060"/>
  <ix:relationship fromRefs="Fact000029" toRefs="Footnote000060"/>
  <ix:relationship fromRefs="Fact000030" toRefs="Footnote000060"/>
  <ix:relationship fromRefs="Fact000037" toRefs="Footnote000060"/>
  <ix:relationship fromRefs="Fact000038" toRefs="Footnote000060"/>
  <ix:relationship fromRefs="Fact000045" toRefs="Footnote000060"/>
  <ix:relationship fromRefs="Fact000046" toRefs="Footnote000060"/>
  <ix:relationship fromRefs="Fact000053" toRefs="Footnote000060"/>
  <ix:relationship fromRefs="Fact000054" toRefs="Footnote000060"/>
  <ix:relationship fromRefs="Fact000023" toRefs="Footnote000061"/>
  <ix:relationship fromRefs="Fact000024" toRefs="Footnote000061"/>
  <ix:relationship fromRefs="Fact000031" toRefs="Footnote000061"/>
  <ix:relationship fromRefs="Fact000032" toRefs="Footnote000061"/>
  <ix:relationship fromRefs="Fact000039" toRefs="Footnote000061"/>
  <ix:relationship fromRefs="Fact000040" toRefs="Footnote000061"/>
  <ix:relationship fromRefs="Fact000047" toRefs="Footnote000061"/>
  <ix:relationship fromRefs="Fact000048" toRefs="Footnote000061"/>
  <ix:relationship fromRefs="Fact000055" toRefs="Footnote000061"/>
  <ix:relationship fromRefs="Fact000056" toRefs="Footnote000061"/>
  <ix:relationship fromRefs="Fact000026" toRefs="Footnote000062"/>
  <ix:relationship fromRefs="Fact000034" toRefs="Footnote000062"/>
  <ix:relationship fromRefs="Fact000042" toRefs="Footnote000062"/>
  <ix:relationship fromRefs="Fact000050" toRefs="Footnote000062"/>
  <ix:relationship fromRefs="Fact000058" toRefs="Footnote000062"/>
  <ix:relationship fromRefs="Fact000076" toRefs="Footnote000105"/>
  <ix:relationship fromRefs="Fact000082" toRefs="Footnote000105"/>
  <ix:relationship fromRefs="Fact000088" toRefs="Footnote000105"/>
  <ix:relationship fromRefs="Fact000094" toRefs="Footnote000105"/>
  <ix:relationship fromRefs="Fact000100" toRefs="Footnote000105"/>
  <ix:relationship fromRefs="Fact000077" toRefs="Footnote000106"/>
  <ix:relationship fromRefs="Fact000083" toRefs="Footnote000106"/>
  <ix:relationship fromRefs="Fact000089" toRefs="Footnote000106"/>
  <ix:relationship fromRefs="Fact000095" toRefs="Footnote000106"/>
  <ix:relationship fromRefs="Fact000101" toRefs="Footnote000106"/>
  <ix:relationship fromRefs="Fact000078" toRefs="Footnote000107"/>
  <ix:relationship fromRefs="Fact000084" toRefs="Footnote000107"/>
  <ix:relationship fromRefs="Fact000090" toRefs="Footnote000107"/>
  <ix:relationship fromRefs="Fact000096" toRefs="Footnote000107"/>
  <ix:relationship fromRefs="Fact000102" toRefs="Footnote000107"/>
  <ix:relationship fromRefs="Fact000079" toRefs="Footnote000108"/>
  <ix:relationship fromRefs="Fact000085" toRefs="Footnote000108"/>
  <ix:relationship fromRefs="Fact000091" toRefs="Footnote000108"/>
  <ix:relationship fromRefs="Fact000097" toRefs="Footnote000108"/>
  <ix:relationship fromRefs="Fact000103" toRefs="Footnote000108"/>
  <ix:relationship fromRefs="Fact000080" toRefs="Footnote000109"/>
  <ix:relationship fromRefs="Fact000086" toRefs="Footnote000109"/>
  <ix:relationship fromRefs="Fact000092" toRefs="Footnote000109"/>
  <ix:relationship fromRefs="Fact000098" toRefs="Footnote000109"/>
  <ix:relationship fromRefs="Fact000104" toRefs="Footnote000109"/>
  <ix:relationship fromRefs="Fact000113" toRefs="Footnote000142"/>
  <ix:relationship fromRefs="Fact000119" toRefs="Footnote000142"/>
  <ix:relationship fromRefs="Fact000125" toRefs="Footnote000142"/>
  <ix:relationship fromRefs="Fact000131" toRefs="Footnote000142"/>
  <ix:relationship fromRefs="Fact000137" toRefs="Footnote000142"/>
  <ix:relationship fromRefs="Fact000114" toRefs="Footnote000143"/>
  <ix:relationship fromRefs="Fact000120" toRefs="Footnote000143"/>
  <ix:relationship fromRefs="Fact000126" toRefs="Footnote000143"/>
  <ix:relationship fromRefs="Fact000132" toRefs="Footnote000143"/>
  <ix:relationship fromRefs="Fact000138" toRefs="Footnote000143"/>
  <ix:relationship fromRefs="Fact000115" toRefs="Footnote000144"/>
  <ix:relationship fromRefs="Fact000121" toRefs="Footnote000144"/>
  <ix:relationship fromRefs="Fact000127" toRefs="Footnote000144"/>
  <ix:relationship fromRefs="Fact000133" toRefs="Footnote000144"/>
  <ix:relationship fromRefs="Fact000139" toRefs="Footnote000144"/>
  <ix:relationship fromRefs="Fact000116" toRefs="Footnote000145"/>
  <ix:relationship fromRefs="Fact000122" toRefs="Footnote000145"/>
  <ix:relationship fromRefs="Fact000128" toRefs="Footnote000145"/>
  <ix:relationship fromRefs="Fact000134" toRefs="Footnote000145"/>
  <ix:relationship fromRefs="Fact000140" toRefs="Footnote000145"/>
  <ix:relationship fromRefs="Fact000117" toRefs="Footnote000146"/>
  <ix:relationship fromRefs="Fact000123" toRefs="Footnote000146"/>
  <ix:relationship fromRefs="Fact000129" toRefs="Footnote000146"/>
  <ix:relationship fromRefs="Fact000135" toRefs="Footnote000146"/>
  <ix:relationship fromRefs="Fact000141" toRefs="Footnote000146"/>
  </ix:resources>
 </ix:header>
</div>


<div class="qes_page" style="border-bottom: black 2pt solid; margin: auto; height: 990pt; width: 765pt; position: relative; overflow: hidden">
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 45pt; left: 45pt; width: 675pt; position: absolute; height: 866.25pt">
				<p style="font: 10pt/normal Arial, sans-serif; margin: 4pt 0pt 8pt; text-transform: uppercase; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: uppercase; font-size: 14pt"><b>UNITED STATES<br/>SECURITIES AND EXCHANGE COMMISSION<br/></b></span><span style="text-transform: uppercase"><b>Washington, D.C. 20549</b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 4pt 0pt 8pt; text-transform: uppercase; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: uppercase; font-size: 14pt"><b><span id="xdx_90D_edei--DocumentType_dxL_c20240101__20241231_zlSNFi9WcfQ" title="::XDX::DEF 14A"><span style="-sec-ix-hidden: xdx2ixbrl0010">SCHEDULE&#160;14A</span></span></b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Proxy Statement Pursuant to Section 14(a) of the <br/>Securities Exchange Act of 1934<br/>(Amendment No.  )</b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: justify"><span style="text-transform: none">Filed
    by the Registrant <span style="font-family: Times New Roman, Times, serif; font-size: 14pt">&#9746;</span></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: justify"><span style="text-transform: none">Filed by a party other than the Registrant  </span><span style="text-transform: none; font-family: Times New Roman, Times, serif">&#11036;</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: justify"><span style="text-transform: none">Check the </span><span style="text-transform: none">appropriate box:</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt 45pt; text-transform: none; color: #000000; text-indent: -45pt; text-align: justify"><!--[if IE]><FONT style=" width: 45.0pt; text-indent: -36.0pt; display: inline-block;"><![endif]--><span style="width: 45pt; text-indent: 0; display: inline-block"><span style="text-transform: none; font-family: Times New Roman, Times, serif">&#11036;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none"></span><span style="text-transform: none">Preliminary </span><span style="text-transform: none">Proxy Statement</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt 45pt; text-transform: none; color: #000000; text-indent: -45pt; text-align: justify"><!--[if IE]><FONT style=" width: 45.0pt; text-indent: -36.0pt; display: inline-block;"><![endif]--><span style="width: 45pt; text-indent: 0; display: inline-block"><span style="text-transform: none; font-family: Times New Roman, Times, serif">&#11036;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none"></span><span style="text-transform: none"><b>Confidential, for Use of the Commission Only (as permitted </b></span><span style="text-transform: none"><b>by Rule&#160;14a-6(e)(2))</b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt 45pt; text-transform: none; color: #000000; text-indent: -45pt; text-align: justify"><!--[if IE]><FONT style=" width: 45.0pt; text-indent: -36.0pt; display: inline-block;"><![endif]--><span style="width: 45pt; text-indent: 0; display: inline-block"><span style="text-transform: none; font-family: Times New Roman, Times, serif; font-size: 14pt">&#9746;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Definitive </span><span style="text-transform: none">Proxy Statement</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt 45pt; text-transform: none; color: #000000; text-indent: -45pt; text-align: justify"><!--[if IE]><FONT style=" width: 45.0pt; text-indent: -36.0pt; display: inline-block;"><![endif]--><span style="width: 45pt; text-indent: 0; display: inline-block"><span style="text-transform: none; font-family: Times New Roman, Times, serif">&#11036;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Definitive </span><span style="text-transform: none">Additional Materials</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 24pt 45pt; text-transform: none; color: #000000; text-indent: -45pt; text-align: justify"><!--[if IE]><FONT style=" width: 45.0pt; text-indent: -36.0pt; display: inline-block;"><![endif]--><span style="width: 45pt; text-indent: 0; display: inline-block"><span style="text-transform: none; font-family: Times New Roman, Times, serif">&#11036;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Soliciting Material Pursuant </span><span style="text-transform: none">to &#167;240.14a-12</span></p>
				<div style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: center">
					<div style="border-width: 0pt; margin-left: -40pt; padding: 0pt; overflow: hidden; display: inline-block; width: 340.78pt; height: 49.84pt; text-align: left">
						<img src="art-def14a_051325img001.gif" alt="" style="vertical-align: top; margin-left: 0pt; width: 331.25pt; margin-top: 0pt; height: 50pt"/>

					</div>

				</div>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt; text-transform: none; color: #000000; text-indent: 22.5pt; border-bottom-style: solid; border-bottom-width: 1pt; text-align: center"><span style="text-transform: none; font-size: 16pt"><b><span id="xdx_90E_edei--EntityRegistrantName_c20240101__20241231_zJE8ko2HQuw4"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000011" name="dei:EntityRegistrantName">ARTIVION, INC.</ix:nonNumeric></span></b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 16pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: center"><span style="text-transform: none"><b>(Name of Registrant as Specified in </b></span><span style="text-transform: none"><b>Its Charter)</b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt; text-transform: none; color: #000000; text-indent: 22.5pt; border-bottom-style: solid; border-bottom-width: 1pt; text-align: center"><span style="text-transform: none; font-size: 16pt"><b>N/A</b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 16pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: center"><span style="text-transform: none"><b>(Name of Person(s) Filing Proxy Statement, if other than </b></span><span style="text-transform: none"><b>the Registrant)</b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: justify"><span style="text-transform: none">Payment of Filing Fee (Check all boxes </span><span style="text-transform: none">that apply):</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt 45pt; text-transform: none; color: #000000; text-indent: -45pt; text-align: justify"><!--[if IE]><FONT style=" width: 45.0pt; text-indent: -36.0pt; display: inline-block;"><![endif]--><span style="width: 45pt; text-indent: 0; display: inline-block"><span style="text-transform: none; font-family: Times New Roman, Times, serif; font-size: 14pt">&#9746;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">No </span><span style="text-transform: none">fee required</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt 45pt; text-transform: none; color: #000000; text-indent: -45pt; text-align: justify"><!--[if IE]><FONT style=" width: 45.0pt; text-indent: -36.0pt; display: inline-block;"><![endif]--><span style="width: 45pt; text-indent: 0; display: inline-block"><span style="text-transform: none; font-family: Times New Roman, Times, serif">&#11036;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Fee paid previously with </span><span style="text-transform: none">preliminary materials</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt 45pt; text-transform: none; color: #000000; text-indent: -45pt; text-align: justify"><!--[if IE]><FONT style=" width: 45.0pt; text-indent: -36.0pt; display: inline-block;"><![endif]--><span style="width: 45pt; text-indent: 0; display: inline-block"><span style="text-transform: none; font-family: Times New Roman, Times, serif">&#11036;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) </span><span style="text-transform: none">and 0-11</span></p>

			</div>

		</div>
		<div style="page-break-before: always">
			<p style="margin: 0pt; font-size: 5pt">&#8203;</p>

		</div>
		<div class="qes_page" style="border-bottom: black 2pt solid; margin: auto; height: 990pt; width: 765pt; position: relative; overflow: hidden">
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 301.25pt; left: 45pt; width: 675pt; position: absolute; height: 610.5pt">
				<div style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 17pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: center">
					<div style="border-width: 0pt; margin-left: -40pt; padding: 0pt; overflow: hidden; display: inline-block; width: 351.88pt; height: 121.88pt; text-align: left">
						<img src="art-def14a_051325img001.gif" alt="" style="vertical-align: top; margin-left: 6.25pt; width: 337.5pt; margin-top: 35pt; height: 48.75pt"/>

					</div>

				</div>
				<div style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-align: center">
					<table style="margin: 4pt auto 6pt; table-layout: fixed; width: 401.25pt; border-collapse: collapse">
						<tr style="margin: 0; height: 0">
							<td style="border-width: 0; margin: 0; padding: 0; width: 401.25pt">


							</td>

						</tr>
						<tr style="max-height: 118.99pt; min-height: 118.99pt; height: 118.99pt">
							<td style="border-top: #000000 1.4pt solid; border-bottom: #000000 1.4pt solid; padding: 2pt 4pt; border-right-width: 0pt; border-left-width: 0pt; vertical-align: middle; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: uppercase; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 14pt"><b>Notice of Annual Meeting<br/>and<br/>Proxy Statement</b></span></p>

							</td>

						</tr>
						<tr style="max-height: 105pt; min-height: 105pt; height: 105pt">
							<td style="border-top: #000000 1.4pt solid; padding: 2pt 4pt; border-right-width: 0pt; border-left-width: 0pt; vertical-align: middle; border-collapse: collapse; border-bottom-width: 0pt">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: uppercase; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 16pt"><b>2025 Annual Meeting of Stockholders<br/>May 13, 2025</b></span></p>

							</td>

						</tr>

					</table>

				</div>

			</div>

		</div>
		<div style="page-break-before: always">
			<p style="margin: 0pt; font-size: 5pt">&#8203;</p>

		</div>
		<div class="qes_page" style="border-bottom: black 2pt solid; margin: auto; height: 990pt; width: 765pt; position: relative; overflow: hidden">
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 911.25pt; left: 45pt; width: 675pt; position: absolute; height: 33.75pt">
				<div style="display: table-cell; vertical-align: bottom; width: 675pt; height: 33.75pt">

				<!--[if IE]><TABLE><TR style=" width: 675pt; height: 33.75pt;"><TD vAlign="bottom" style=" width: 675pt; height: 33.75pt;"><![endif]-->
					<div style="font: 12pt/normal Times New Roman, Times, serif; margin: 0pt; text-transform: none; color: #000000; text-align: left">
						<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 0pt; border-collapse: collapse">
							<tr style="margin: 0; height: 0">
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>

							</tr>
							<tr style="min-height: 0pt">
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">ARTIVION, INC. | 2025 Proxy Statement</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 0pt; line-height: 0pt">&#8203;</p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 0pt; line-height: 0pt">&#8203;</p>

								</td>

							</tr>

						</table>

					</div>


				<!--[if IE]></TD></TR></TABLE><![endif]-->
				</div>

			</div>
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 45pt; left: 45pt; width: 675pt; position: absolute; height: 866.25pt">
				<div style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: center">
					<div style="border-width: 0pt; margin-left: -40pt; padding: 0pt; overflow: hidden; display: inline-block; width: 340.78pt; height: 49.84pt; text-align: left">
						<img src="art-def14a_051325img001.gif" alt="" style="vertical-align: top; margin-left: 0pt; width: 331.25pt; margin-top: 0pt; height: 50pt"/>

					</div>

				</div>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt; text-transform: uppercase; color: #2b4b74; text-indent: 0pt; text-align: center"><span style="text-transform: uppercase"><b>1655 ROBERTS BOULEVARD, NW<br/>KENNESAW, GEORGIA 30144</b></span></p>
				<p style="border-bottom: #2b4b74 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0pt 247.5pt 10pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; color: #2b4b74"><b>&#160;</b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 4pt 0pt 8pt; text-transform: uppercase; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: uppercase"><b>NOTICE OF ANNUAL MEETING<br/>AND<br/>PROXY STATEMENT</b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">April </span><span style="text-transform: none">1, 2025&#160;</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">To </span><span style="text-transform: none; line-height: 12pt">Our Stockholders:</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">On behalf of the Board of Directors, we invite you to attend the Annual Meeting of Stockholders of Artivion, Inc. on May 13, 2025 at 9:00 a.m., ET. Given our successful use of the virtual-only format at our prior annual meetings, we have again adopted a virtual-only format for our Annual Meeting this year. The Annual Meeting will be accessible at the following website address: https://web.lumiconnect.com/295739807. After this year&#8217;s Annual Meeting, we intend to again evaluate the best method for holding our annual stockholder meetings </span><span style="text-transform: none; line-height: 12pt">going forward. </span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">Please review this Notice of Annual Meeting and Proxy Statement, which describes the formal business to be transacted and procedures for voting on matters to be considered during the <span style="text-transform: none; line-height: 12pt">Annual Meeting.</span></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">YOUR VOTE IS IMPORTANT. Regardless of whether you plan to attend the virtual Annual Meeting, we request that you please follow the instructions provided on the Notice or Proxy Card that you received by mail, and further described herein, and take a few minutes to review the Proxy Statement and vote your shares via internet, telephone, or mail. You may, of course, choose to attend the Annual Meeting virtually and vote your shares online during the meeting. If you wish to participate in the meeting, you will need your control number </span><span style="text-transform: none; line-height: 12pt">to join. </span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">However you choose to participate, we encourage you to review this Proxy Statement and vote </span><span style="text-transform: none; line-height: 12pt">your shares. </span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt 401.25pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; line-height: 12pt">Sincerely,</span></p>
				<div style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 8pt 401.25pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left">
					<div style="border-width: 0pt; padding: 0pt; overflow: hidden; display: inline-block; width: 132.6pt; height: 45pt; text-align: left">
						<img src="art-def14a_051325img002.gif" alt="" style="vertical-align: top; margin-left: 0pt; width: 132.5pt; margin-top: 0pt; height: 45pt"/>

					</div>

				</div>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt 401.25pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; line-height: 12pt">J. PATRICK MACKIN<br/>Chairman, President, and Chief </span><span style="text-transform: none; line-height: 12pt">Executive Officer</span></p>

			</div>

		</div>
		<div style="page-break-before: always">
			<p style="margin: 0pt; font-size: 5pt">&#8203;</p>

		</div>
		<div class="qes_page" style="border-bottom: black 2pt solid; margin: auto; height: 990pt; width: 765pt; position: relative; overflow: hidden">
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 911.25pt; left: 45pt; width: 675pt; position: absolute; height: 33.75pt">
				<div style="display: table-cell; vertical-align: bottom; width: 675pt; height: 33.75pt">

				<!--[if IE]><TABLE><TR style=" width: 675pt; height: 33.75pt;"><TD vAlign="bottom" style=" width: 675pt; height: 33.75pt;"><![endif]-->
					<div style="font: 12pt/normal Times New Roman, Times, serif; margin: 0pt; text-transform: none; color: #000000; text-align: left">
						<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 0pt; border-collapse: collapse">
							<tr style="margin: 0; height: 0">
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>

							</tr>
							<tr style="min-height: 0pt">
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">ARTIVION, INC. | 2025 Proxy Statement</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 0pt; line-height: 0pt">&#8203;</p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 0pt; line-height: 0pt">&#8203;</p>

								</td>

							</tr>

						</table>

					</div>


				<!--[if IE]></TD></TR></TABLE><![endif]-->
				</div>

			</div>
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 45pt; left: 45pt; width: 675pt; position: absolute; height: 866.25pt">
				<div style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: center">
					<div style="border-width: 0pt; margin-left: -40pt; padding: 0pt; overflow: hidden; display: inline-block; width: 340.78pt; height: 49.84pt; text-align: left">
						<img src="art-def14a_051325img001.gif" alt="" style="vertical-align: top; margin-left: 0pt; width: 331.25pt; margin-top: 0pt; height: 50pt"/>

					</div>

				</div>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt; text-transform: uppercase; color: #2b4b74; text-indent: 0pt; text-align: center"><span style="text-transform: uppercase"><b>1655 ROBERTS BOULEVARD, NW<br/>KENNESAW, GEORGIA 30144</b></span></p>
				<p style="border-bottom: #2b4b74 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0pt 247.5pt 10pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; color: #2b4b74"><b>&#160;</b></span></p>
				<p style="border-bottom: #7f7f7f 1pt solid; font: 12pt/normal Arial, sans-serif; margin: 18pt 0pt 15pt; text-transform: none; color: #2b4b74; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>NOTICE OF ANNUAL MEETING OF STOCKHOLDERS</b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: justify"><span style="text-transform: none"><b>TO THE STOCKHOLDERS </b></span><span style="text-transform: none"><b>OF ARTIVION,&#160;INC.:</b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">NOTICE IS HEREBY GIVEN that the Annual Meeting of Stockholders of ARTIVION,&#160;INC. (the &#8220;Annual Meeting&#8221;) will be held on May 13, 2025 at 9:00 a.m., ET. As in prior years, the Annual Meeting will be held as a virtual-only meeting. The Annual Meeting will be accessible at the following website address: https://web.lumiconnect.com/295739807, for the </span><span style="text-transform: none; line-height: 12pt">following purposes:</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt 45pt; text-transform: none; color: #000000; text-indent: -22.5pt; text-align: justify"><!--[if IE]><FONT style=" width: 22.5pt; text-indent: -18.0pt; display: inline-block;"><![endif]--><span style="width: 22.5pt; text-indent: 0; display: inline-block"><span style="text-transform: none">1.</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">To elect as directors the nine nominees named in the attached Proxy Statement to serve until the next Annual Meeting of Stockholders or until their successors are duly qualified or until their earlier death, resignation, </span><span style="text-transform: none">or removal.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt 45pt; text-transform: none; color: #000000; text-indent: -22.5pt; text-align: justify"><!--[if IE]><FONT style=" width: 22.5pt; text-indent: -18.0pt; display: inline-block;"><![endif]--><span style="width: 22.5pt; text-indent: 0; display: inline-block"><span style="text-transform: none">2.</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">To approve, by non-binding vote, the compensation paid to Artivion&#8217;s Named Executive Officers, as disclosed pursuant to Item 402 of Regulation S-K, including the Compensation Discussion and Analysis, compensation tables, and </span><span style="text-transform: none">narrative discussion.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt 45pt; text-transform: none; color: #000000; text-indent: -22.5pt; text-align: justify"><!--[if IE]><FONT style=" width: 22.5pt; text-indent: -18.0pt; display: inline-block;"><![endif]--><span style="width: 22.5pt; text-indent: 0; display: inline-block"><span style="text-transform: none">3.</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">To ratify the preliminary approval of Ernst &amp; Young LLP as the independent registered public accounting firm for the Company for the fiscal year ending December </span><span style="text-transform: none">31, 2025.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt 45pt; text-transform: none; color: #000000; text-indent: -22.5pt; text-align: justify"><!--[if IE]><FONT style=" width: 22.5pt; text-indent: -18.0pt; display: inline-block;"><![endif]--><span style="width: 22.5pt; text-indent: 0; display: inline-block"><span style="text-transform: none">4.</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">To approve additional funding of 3,570,000 shares for the Amended and Restated Artivion, Inc. 2020 Equity and Cash </span><span style="text-transform: none">Incentive Plan.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt 45pt; text-transform: none; color: #000000; text-indent: -22.5pt; text-align: justify"><!--[if IE]><FONT style=" width: 22.5pt; text-indent: -18.0pt; display: inline-block;"><![endif]--><span style="width: 22.5pt; text-indent: 0; display: inline-block"><span style="text-transform: none">5.</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">To transact such other business as may be properly brought before the Annual Meeting or any </span><span style="text-transform: none">adjournments thereof.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none">Only record holders of Artivion&#8217;s common stock at the close of business on March 17, 2025 will be eligible to vote during the Annual Meeting. Artivion would like for you to attend the Annual Meeting. However, if there is any chance that you may not be able to attend the Annual Meeting, please follow the instructions on the Notice or Proxy Card you received by mail to vote via internet, telephone, </span><span style="text-transform: none">or mail.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none"><b>Important notice regarding the availability of proxy materials for the Annual Meeting of Stockholders to be held on May 13, 2025.</b></span><span style="text-transform: none"> Pursuant to the rules promulgated by the Securities and Exchange Commission, we have elected to provide access to our proxy materials by notifying you of the availability of our proxy materials, including the Annual Meeting notice, Proxy Statement, and our 2024 Annual Report to Stockholders, both via internet at http://www.astproxyportal.com/ast/01609 and by providing the means whereby you can request a paper copy of proxy materials to be sent via </span><span style="text-transform: none">U.S. mail.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt 401.25pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: justify"><span style="text-transform: none">By Order of the Board </span><span style="text-transform: none">of Directors:</span></p>
				<div style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt 401.25pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left">
					<div style="border-width: 0pt; padding: 0pt; overflow: hidden; display: inline-block; width: 126.6pt; height: 61.5pt; text-align: left">
						<img src="art-def14a_051325img003.gif" alt="" style="vertical-align: top; margin-left: 0pt; width: 126.25pt; margin-top: 0pt; height: 61.25pt"/>

					</div>

				</div>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt 401.25pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">JEAN F. HOLLOWAY<br/>General Counsel and </span><span style="text-transform: none">Corporate Secretary</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: justify"><span style="text-transform: none">Date:  April </span><span style="text-transform: none">1, 2025</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none">An electronic copy of Artivion&#8217;s 2024 Annual Report to Stockholders, which includes Artivion&#8217;s Annual Report on Form&#160;10-K for the fiscal year ended December&#160;31, 2024, including financial statements, is available via the proxy information website provided on your proxy Notice or </span><span style="text-transform: none">Proxy Card.</span></p>

			</div>

		</div>
		<div style="page-break-before: always">
			<p style="margin: 0pt; font-size: 5pt">&#8203;</p>

		</div>
		<div class="qes_page" style="border-bottom: black 2pt solid; margin: auto; height: 990pt; width: 765pt; position: relative; overflow: hidden">
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 911.25pt; left: 45pt; width: 675pt; position: absolute; height: 33.75pt">
				<div style="display: table-cell; vertical-align: bottom; width: 675pt; height: 33.75pt">

				<!--[if IE]><TABLE><TR style=" width: 675pt; height: 33.75pt;"><TD vAlign="bottom" style=" width: 675pt; height: 33.75pt;"><![endif]-->
					<div style="font: 12pt/normal Times New Roman, Times, serif; margin: 0pt; text-transform: none; color: #000000; text-align: left">
						<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 0pt; border-collapse: collapse">
							<tr style="margin: 0; height: 0">
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>

							</tr>
							<tr style="min-height: 0pt">
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">ARTIVION, INC. | 2025 Proxy Statement</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 0pt; line-height: 0pt">&#8203;</p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 0pt; line-height: 0pt">&#8203;</p>

								</td>

							</tr>

						</table>

					</div>


				<!--[if IE]></TD></TR></TABLE><![endif]-->
				</div>

			</div>
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 45pt; left: 45pt; width: 675pt; position: absolute; height: 866.25pt">
				<p style="font: 10pt/normal Arial, sans-serif; margin: 4pt 0pt 8pt; text-transform: uppercase; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: uppercase"><b>TABLE OF CONTENTS</b></span></p>
				<div style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-align: justify">
					<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 10pt; border-collapse: collapse">
						<tr style="margin: 0; height: 0">
							<td style="border-width: 0; margin: 0; padding: 0; width: 641.25pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 33.75pt">


							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none"><b>Page</b></span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt 6pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0 11.25pt; text-transform: none; color: #000000; text-indent: -11.25pt; text-align: left"><span style="text-transform: none">QUESTIONS AND ANSWERS REGARDING THIS SOLICITATION AND VOTING DURING THE <br/>ANNUAL MEETING</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt 6pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">3</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt 6pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0 11.25pt; text-transform: none; color: #000000; text-indent: -11.25pt; text-align: left"><span style="text-transform: none"><b>PROPOSAL ONE &#8211; ELECTION OF DIRECTORS</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt 6pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">9</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt 6pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0 11.25pt; text-transform: none; color: #000000; text-indent: -11.25pt; text-align: left"><span style="text-transform: none">CORPORATE GOVERNANCE AND BOARD OF DIRECTORS MATTERS</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt 6pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">13</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt 6pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0 11.25pt; text-transform: none; color: #000000; text-indent: -11.25pt; text-align: left"><span style="text-transform: none">PROCEDURES FOR STOCKHOLDERS WHO WISH TO SUBMIT RECOMMENDATIONS TO THE <br/>BOARD OF DIRECTORS</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt 6pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">17</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt 6pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0 11.25pt; text-transform: none; color: #000000; text-indent: -11.25pt; text-align: left"><span style="text-transform: none">ARTIVION&#8217;S CODE OF CONDUCT</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt 6pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">18</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt 6pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0 11.25pt; text-transform: none; color: #000000; text-indent: -11.25pt; text-align: left"><span style="text-transform: none">CORPORATE RESPONSIBILITY</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt 6pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">18</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt 6pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0 11.25pt; text-transform: none; color: #000000; text-indent: -11.25pt; text-align: left"><span style="text-transform: none">POLICIES AND PROCEDURES FOR REVIEW, APPROVAL, OR RATIFICATION OF TRANSACTIONS <br/>WITH RELATED PARTIES</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt 6pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">18</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt 6pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0 11.25pt; text-transform: none; color: #000000; text-indent: -11.25pt; text-align: left"><span style="text-transform: none">COMPENSATION COMMITTEE INTERLOCKS AND INSIDER PARTICIPATION</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt 6pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">19</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt 6pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0 11.25pt; text-transform: none; color: #000000; text-indent: -11.25pt; text-align: left"><span style="text-transform: none">COMMUNICATION WITH THE BOARD OF DIRECTORS AND ITS COMMITTEES</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt 6pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">20</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt 6pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0 11.25pt; text-transform: none; color: #000000; text-indent: -11.25pt; text-align: left"><span style="text-transform: none">AVAILABILITY OF CORPORATE GOVERNANCE DOCUMENTS</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt 6pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">20</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt 6pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0 11.25pt; text-transform: none; color: #000000; text-indent: -11.25pt; text-align: left"><span style="text-transform: none">DIRECTOR COMPENSATION</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt 6pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">21</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt 6pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0 11.25pt; text-transform: none; color: #000000; text-indent: -11.25pt; text-align: left"><span style="text-transform: none">REPORT OF THE AUDIT COMMITTEE</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt 6pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">23</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt 6pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0 11.25pt; text-transform: none; color: #000000; text-indent: -11.25pt; text-align: left"><span style="text-transform: none"><b>PROPOSAL TWO &#8211; ADVISORY VOTE ON EXECUTIVE OFFICER COMPENSATION </b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt 6pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">25</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt 6pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0 11.25pt; text-transform: none; color: #000000; text-indent: -11.25pt; text-align: left"><span style="text-transform: none">COMPENSATION DISCUSSION AND ANALYSIS</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt 6pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">26</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt 6pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0 11.25pt; text-transform: none; color: #000000; text-indent: -11.25pt; text-align: left"><span style="text-transform: none">REPORT OF THE COMPENSATION COMMITTEE</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt 6pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">42</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt 6pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0 11.25pt; text-transform: none; color: #000000; text-indent: -11.25pt; text-align: left"><span style="text-transform: none">EXECUTIVE OFFICER COMPENSATION</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt 6pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">43</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt 6pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0 11.25pt; text-transform: none; color: #000000; text-indent: -11.25pt; text-align: left"><span style="text-transform: none">CERTAIN BENEFICIAL OWNERSHIP</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt 6pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">67</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt 6pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0 11.25pt; text-transform: none; color: #000000; text-indent: -11.25pt; text-align: left"><span style="text-transform: none"><b>PROPOSAL THREE &#8211; RATIFICATION OF THE PRELIMINARY APPROVAL OF THE INDEPENDENT REGISTERED PUBLIC <br/>
ACCOUNTING&#160;FIRM</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt 6pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">69</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt 6pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0 11.25pt; text-transform: none; color: #000000; text-indent: -11.25pt; text-align: left"><span style="text-transform: none"><b>PROPOSAL FOUR &#8211; APPROVAL OF ADDITIONAL FUNDING OF 3,570,000 SHARES FOR THE <br/>AMENDED AND RESTATED ARTIVION, INC. 2020 EQUITY AND CASH INCENTIVE PLAN</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt 6pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">71</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt 6pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0 11.25pt; text-transform: none; color: #000000; text-indent: -11.25pt; text-align: left"><span style="text-transform: none">HOUSEHOLDING</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt 6pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">74</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt 6pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0 11.25pt; text-transform: none; color: #000000; text-indent: -11.25pt; text-align: left"><span style="text-transform: none">TRANSACTION OF OTHER BUSINESS</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt 6pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">74</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt 6pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0 11.25pt; text-transform: none; color: #000000; text-indent: -11.25pt; text-align: left"><span style="text-transform: none">WHERE YOU CAN FIND ADDITIONAL INFORMATION</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt 6pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">74</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt 6pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0 11.25pt; text-transform: none; color: #000000; text-indent: -11.25pt; text-align: left"><span style="text-transform: none">APPENDIX A &#8211; NON-GAAP FINANCIAL MEASURE INFORMATION AND RECONCILIATION</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt 6pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">A-1</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt 6pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0 11.25pt; text-transform: none; color: #000000; text-indent: -11.25pt; text-align: left"><span style="text-transform: none">APPENDIX B &#8211;  AMENDED AND RESTATED ARTIVION, INC. 2020 EQUITY AND CASH INCENTIVE PLAN </span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt 6pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">B-1</span></p>

							</td>

						</tr>

					</table>

				</div>

			</div>

		</div>
		<div style="page-break-before: always">
			<p style="margin: 0pt; font-size: 5pt">&#8203;</p>

		</div>
		<div class="qes_page" style="border-bottom: black 2pt solid; margin: auto; height: 990pt; width: 765pt; position: relative; overflow: hidden">
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 911.25pt; left: 45pt; width: 675pt; position: absolute; height: 33.75pt">
				<div style="display: table-cell; vertical-align: bottom; width: 675pt; height: 33.75pt">

				<!--[if IE]><TABLE><TR style=" width: 675pt; height: 33.75pt;"><TD vAlign="bottom" style=" width: 675pt; height: 33.75pt;"><![endif]-->
					<div style="font: 12pt/normal Times New Roman, Times, serif; margin: 0pt; text-transform: none; color: #000000; text-align: left">
						<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 0pt; border-collapse: collapse">
							<tr style="margin: 0; height: 0">
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>

							</tr>
							<tr style="min-height: 0pt">
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">ARTIVION, INC. | 2025 Proxy Statement</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">3</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 0pt; line-height: 0pt">&#8203;</p>

								</td>

							</tr>

						</table>

					</div>


				<!--[if IE]></TD></TR></TABLE><![endif]-->
				</div>

			</div>
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 45pt; left: 45pt; width: 675pt; position: absolute; height: 866.25pt">
				<div style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: center">
					<div style="border-width: 0pt; padding: 0pt; overflow: hidden; display: inline-block; width: 340.78pt; height: 49.84pt; text-align: left">
						<img src="art-def14a_051325img001.gif" alt="" style="vertical-align: top; margin-left: 0pt; width: 331.25pt; margin-top: 0pt; height: 50pt"/>

					</div>

				</div>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: uppercase; color: #2b4b74; text-indent: 0pt; text-align: center"><span style="text-transform: uppercase"><b>1655 ROBERTS BOULEVARD, NW<br/>KENNESAW, GEORGIA 30144</b></span></p>
				<p style="border-bottom: #2b4b74 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0pt 247.5pt 10pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; color: #2b4b74"><b>&#160;</b></span></p>
				<p style="font: 12pt/normal Arial, sans-serif; margin: 4pt 0pt 15pt; text-transform: none; color: #2b4b74; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>PROXY STATEMENT<br/>FOR THE ANNUAL MEETING OF STOCKHOLDERS</b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">This Proxy Statement is furnished to our stockholders as of the close of business on March 17, 2025, the record date, for the solicitation of proxies by the Board of Directors of Artivion, Inc. (&#8220;Artivion,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; or &#8220;us&#8221;) for the Annual Meeting of Stockholders of Artivion (the &#8220;Annual Meeting&#8221;) to be held on May 13, 2025 at 9:00&#160;a.m., ET. The Annual Meeting will only be held virtually at the following web address: https://web.lumiconnect.com/295739807. The voting of shares will not affect a stockholder&#8217;s right to attend the Annual Meeting. A signed paper proxy may be changed by sending in a timely, but later dated, signed paper proxy. Any stockholder sending in or completing a proxy may also revoke it at any time before it is exercised by giving timely notice to Jean F. Holloway, General Counsel and Corporate Secretary, Artivion, Inc., 1655 Roberts Boulevard, NW, Kennesaw, Georgia 30144, (770) 419-3355. Artivion is providing notice of the Annual Meeting and access to the Proxy Statement and Annual Report via the &#8220;Notice and </span><span style="text-transform: none; line-height: 12pt">Access&#8221; method.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 5pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>QUESTIONS AND ANSWERS REGARDING THIS SOLICITATION <br/>AND VOTING DURING THE ANNUAL MEETING</b></span></p>
				<div style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 18pt; text-transform: none; color: #000000; text-align: justify">
					<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 14pt; border-collapse: collapse">
						<tr style="margin: 0; height: 0">
							<td style="border-width: 0; margin: 0; padding: 0; width: 157.5pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 15pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 502.5pt">


							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 0pt 0pt 6pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><b><i>Why am I receiving this </i></b></span><span style="text-transform: none; font-style: italic"><b><i>Proxy Statement?</i></b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt 0pt 6pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: justify"><span style="text-transform: none">You are receiving this Proxy Statement because you were a stockholder of record at the close of business on the record date of March 17, 2025. As a stockholder of record, you are invited to attend our Annual Meeting and are entitled to vote on the items of business described in this Proxy Statement. This Proxy Statement contains important information about the Annual Meeting and the items of business to be transacted at the Annual Meeting. You are strongly encouraged to read this Proxy Statement, which includes information that you may find useful in determining how </span><span style="text-transform: none">to vote.</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 0pt 0pt 6pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><b><i>&#160;</i></b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt 0pt 6pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: justify"><span style="text-transform: none">At the close of business on the record date, we had a total of 42,689,303 shares of common stock outstanding, excluding a total of 1,486,803 shares of treasury stock held by Artivion, which are not entitled to vote. Each outstanding share of common stock will be entitled to one vote, non-cumulative, at the </span><span style="text-transform: none">Annual Meeting.</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 0pt 0pt 6pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><b><i>What does it mean if I receive more than one Notice of Internet Availability of Proxy Materials or more than one set of </i></b></span><span style="text-transform: none; font-style: italic"><b><i>proxy materials?</i></b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt 0pt 6pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: justify"><span style="text-transform: none">It means that your shares are held in more than one account at the transfer agent and/or with banks or brokers. Please vote all of your shares. To ensure that all of your shares are voted, for each Notice or set of proxy materials, please submit your proxy by phone, via the internet, or, if you received printed copies of the proxy materials, by signing, dating, and returning the enclosed Proxy Card in the </span><span style="text-transform: none">enclosed envelope.</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 0pt 0pt 6pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><b><i>Who is entitled to attend and vote during the </i></b></span><span style="text-transform: none; font-style: italic"><b><i>Annual Meeting?</i></b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt 0pt 6pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: justify"><span style="text-transform: none">Only holders of record of shares of our common stock at the close of business on March 17, 2025 are entitled to notice of, to attend, and to vote during the Annual Meeting and to notice of any adjournments or postponements of such </span><span style="text-transform: none">Annual Meeting.</span></p>

							</td>

						</tr>

					</table>

				</div>

			</div>

		</div>
		<div style="page-break-before: always">
			<p style="margin: 0pt; font-size: 5pt">&#8203;</p>

		</div>
		<div class="qes_page" style="border-bottom: black 2pt solid; margin: auto; height: 990pt; width: 765pt; position: relative; overflow: hidden">
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 911.25pt; left: 45pt; width: 675pt; position: absolute; height: 33.75pt">
				<div style="display: table-cell; vertical-align: bottom; width: 675pt; height: 33.75pt">

				<!--[if IE]><TABLE><TR style=" width: 675pt; height: 33.75pt;"><TD vAlign="bottom" style=" width: 675pt; height: 33.75pt;"><![endif]-->
					<div style="font: 12pt/normal Times New Roman, Times, serif; margin: 0pt; text-transform: none; color: #000000; text-align: left">
						<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 0pt; border-collapse: collapse">
							<tr style="margin: 0; height: 0">
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>

							</tr>
							<tr style="min-height: 0pt">
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">ARTIVION, INC. | 2025 Proxy Statement</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">4</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 0pt; line-height: 0pt">&#8203;</p>

								</td>

							</tr>

						</table>

					</div>


				<!--[if IE]></TD></TR></TABLE><![endif]-->
				</div>

			</div>
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 45pt; left: 45pt; width: 675pt; position: absolute; height: 866.25pt">
				<div style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 18pt; text-transform: none; color: #000000; text-align: justify">
					<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 14pt; border-collapse: collapse">
						<tr style="margin: 0; height: 0">
							<td style="border-width: 0; margin: 0; padding: 0; width: 157.5pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 15pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 502.5pt">


							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 0pt 0pt 6pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><b><i>How many shares must be present or represented to conduct business during the Annual Meeting (that is, what constitutes </i></b></span><span style="text-transform: none; font-style: italic"><b><i>a quorum)?</i></b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt 0pt 6pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: justify"><span style="text-transform: none">Presence during the Annual Meeting, by attendance at the virtual meeting, or by representation at the virtual meeting by proxy, of at least a majority of the shares outstanding and entitled to vote during the Annual Meeting will constitute a quorum for the transaction of business. Shares represented during the Annual Meeting or by proxy are counted for quorum purposes, even if they are not voted on for one or more matters. Abstentions from voting and broker non-votes, as defined below, will be counted for the purpose of determining the presence or absence of a quorum for the transaction of business. The Corporate Secretary or Assistant Secretary of Artivion, in consultation with the inspector of election, who will be an agent of Equiniti Trust Company, LLC, shall determine the eligibility of persons present during the Annual Meeting to vote and whether the name signed on each Proxy Card corresponds to the name of a stockholder of Artivion. The Corporate Secretary or Assistant Secretary, based on such consultation, shall also determine whether or not a quorum exists during the Annual Meeting.  </span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 0pt 0pt 6pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><b><i>What items of business will be voted on during the </i></b></span><span style="text-transform: none; font-style: italic"><b><i>Annual Meeting?</i></b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt 0pt 6pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 10pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: justify"><span style="text-transform: none">The following items of business will be voted on during the </span><span style="text-transform: none">Annual Meeting:</span></p>
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt 45pt; text-transform: none; color: #000000; text-indent: -22.5pt; text-align: justify"><!--[if IE]><FONT style=" width: 22.5pt; text-indent: -18.0pt; display: inline-block;"><![endif]--><span style="width: 22.5pt; text-indent: 0; display: inline-block"><span style="text-transform: none">1.</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">To elect as directors the nine nominees named in the enclosed Proxy Statement to serve until the next Annual Meeting of Stockholders or until their successors are duly qualified or until their earlier death, resignation, </span><span style="text-transform: none">or removal.</span></p>
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt 45pt; text-transform: none; color: #000000; text-indent: -22.5pt; text-align: justify"><!--[if IE]><FONT style=" width: 22.5pt; text-indent: -18.0pt; display: inline-block;"><![endif]--><span style="width: 22.5pt; text-indent: 0; display: inline-block"><span style="text-transform: none">2.</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">To approve, by non-binding vote, the compensation paid to Artivion&#8217;s Named Executive Officers, as disclosed pursuant to Item 402 of Regulation S-K, including the Compensation Discussion and Analysis, compensation tables, and </span><span style="text-transform: none">narrative discussion.</span></p>
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt 45pt; text-transform: none; color: #000000; text-indent: -22.5pt; text-align: justify"><!--[if IE]><FONT style=" width: 22.5pt; text-indent: -18.0pt; display: inline-block;"><![endif]--><span style="width: 22.5pt; text-indent: 0; display: inline-block"><span style="text-transform: none">3.</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">To ratify the preliminary approval of Ernst &amp; Young LLP as the independent registered public accounting firm for the Company for the fiscal year ending December </span><span style="text-transform: none">31, 2025.</span></p>
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt 45pt; text-transform: none; color: #000000; text-indent: -22.5pt; text-align: justify"><!--[if IE]><FONT style=" width: 22.5pt; text-indent: -18.0pt; display: inline-block;"><![endif]--><span style="width: 22.5pt; text-indent: 0; display: inline-block"><span style="text-transform: none">4.</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">To approve additional funding of 3,570,000 shares for the Amended and Restated Artivion, Inc. 2020 Equity and Cash </span><span style="text-transform: none">Incentive Plan.</span></p>
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 0 45pt; text-transform: none; color: #000000; text-indent: -22.5pt; text-align: justify"><!--[if IE]><FONT style=" width: 22.5pt; text-indent: -18.0pt; display: inline-block;"><![endif]--><span style="width: 22.5pt; text-indent: 0; display: inline-block"><span style="text-transform: none">5.</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">To transact such other business as may be properly brought before the Annual Meeting or any </span><span style="text-transform: none">adjournments thereof.</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 0pt 0pt 6pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><b><i>What happens if additional matters are presented during the </i></b></span><span style="text-transform: none; font-style: italic"><b><i>Annual Meeting?</i></b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt 0pt 6pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: justify"><span style="text-transform: none">Other than the matters set forth in items 1-4 above, management is not aware of any matters that may come before the Annual Meeting. If any other matter or matters are properly brought before the Annual Meeting, the person(s) named as proxyholder(s) on your Notice or Proxy Card will have discretionary authority to vote the shares represented by the effective proxies as they </span><span style="text-transform: none">deem advisable.</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 0pt 0pt 6pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><b><i>How does the Board of Directors recommend that </i></b></span><span style="text-transform: none; font-style: italic"><b><i>I vote?</i></b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt 0pt 6pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 10pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: justify"><span style="text-transform: none">Our Board of Directors recommends that you vote </span><span style="text-transform: none">your shares:</span></p>
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt 45pt; text-transform: none; color: #000000; text-indent: -22.5pt; text-align: justify"><!--[if IE]><FONT style=" width: 22.5pt; text-indent: -18.0pt; display: inline-block;"><![endif]--><span style="width: 22.5pt; text-indent: 0; display: inline-block"><span style="text-transform: none">&#8226;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none"><b>FOR</b></span><span style="text-transform: none"> the election of each of the director nominees identified in this </span><span style="text-transform: none">Proxy Statement;</span></p>
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt 45pt; text-transform: none; color: #000000; text-indent: -22.5pt; text-align: justify"><!--[if IE]><FONT style=" width: 22.5pt; text-indent: -18.0pt; display: inline-block;"><![endif]--><span style="width: 22.5pt; text-indent: 0; display: inline-block"><span style="text-transform: none">&#8226;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none"><b>FOR</b></span><span style="text-transform: none"> the approval, on an advisory basis, of the compensation of our Named </span><span style="text-transform: none">Executive Officers; </span></p>
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt 45pt; text-transform: none; color: #000000; text-indent: -22.5pt; text-align: justify"><!--[if IE]><FONT style=" width: 22.5pt; text-indent: -18.0pt; display: inline-block;"><![endif]--><span style="width: 22.5pt; text-indent: 0; display: inline-block"><span style="text-transform: none">&#8226;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none"><b>FOR</b></span><span style="text-transform: none"> the ratification of the preliminary approval of Ernst &amp; Young LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, </span><span style="text-transform: none">2025; and </span></p>
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 0 45pt; text-transform: none; color: #000000; text-indent: -22.5pt; text-align: justify"><!--[if IE]><FONT style=" width: 22.5pt; text-indent: -18.0pt; display: inline-block;"><![endif]--><span style="width: 22.5pt; text-indent: 0; display: inline-block"><span style="text-transform: none">&#8226;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none"><b>FOR</b></span><span style="text-transform: none"> the approval of additional funding of 3,570,000 shares for the Amended and Restated Artivion, Inc. 2020 Equity and Cash </span><span style="text-transform: none">Incentive Plan.</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 0pt 0pt 6pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><b><i>What shares can I vote during the </i></b></span><span style="text-transform: none; font-style: italic"><b><i>Annual Meeting?</i></b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt 0pt 6pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: justify"><span style="text-transform: none">You may vote shares that you owned as of March 17, 2025, the record date, including shares held directly in your name as the </span><span style="text-transform: none; font-style: italic"><i>stockholder of record</i></span><span style="text-transform: none"> and all shares held for you as the </span><span style="text-transform: none; font-style: italic"><i>beneficial owner</i></span><span style="text-transform: none"> through a broker, trustee, or other nominee such as </span><span style="text-transform: none">a bank.</span></p>

							</td>

						</tr>

					</table>

				</div>

			</div>

		</div>
		<div style="page-break-before: always">
			<p style="margin: 0pt; font-size: 5pt">&#8203;</p>

		</div>
		<div class="qes_page" style="border-bottom: black 2pt solid; margin: auto; height: 990pt; width: 765pt; position: relative; overflow: hidden">
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 911.25pt; left: 45pt; width: 675pt; position: absolute; height: 33.75pt">
				<div style="display: table-cell; vertical-align: bottom; width: 675pt; height: 33.75pt">

				<!--[if IE]><TABLE><TR style=" width: 675pt; height: 33.75pt;"><TD vAlign="bottom" style=" width: 675pt; height: 33.75pt;"><![endif]-->
					<div style="font: 12pt/normal Times New Roman, Times, serif; margin: 0pt; text-transform: none; color: #000000; text-align: left">
						<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 0pt; border-collapse: collapse">
							<tr style="margin: 0; height: 0">
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>

							</tr>
							<tr style="min-height: 0pt">
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">ARTIVION, INC. | 2025 Proxy Statement</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">5</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 0pt; line-height: 0pt">&#8203;</p>

								</td>

							</tr>

						</table>

					</div>


				<!--[if IE]></TD></TR></TABLE><![endif]-->
				</div>

			</div>
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 45pt; left: 45pt; width: 675pt; position: absolute; height: 866.25pt">
				<div style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 18pt; text-transform: none; color: #000000; text-align: justify">
					<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 14pt; border-collapse: collapse">
						<tr style="margin: 0; height: 0">
							<td style="border-width: 0; margin: 0; padding: 0; width: 157.5pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 15pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 502.5pt">


							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td rowspan="2" style="border-width: 0pt; padding: 0pt 0pt 6pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 10pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><b><i>What is the difference between holding shares as a stockholder of record and as a </i></b></span><span style="text-transform: none; font-style: italic"><b><i>beneficial owner?</i></b></span></p>
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 0; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><b><i>&#160;</i></b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt 0pt 6pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: justify"><span style="text-transform: none">Some of our stockholders hold all or a portion of their shares through a broker or other nominee rather than directly in their own name. As summarized below, there are some distinctions between common stock held of record and those </span><span style="text-transform: none">owned beneficially.</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt 0pt 6pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: justify"><span style="text-transform: none; font-style: italic"><i>Stockholders of Record.</i></span><span style="text-transform: none"> If your shares are registered directly in your name with our transfer agent, you are considered the </span><span style="text-transform: none; font-style: italic"><i>stockholder of record</i></span><span style="text-transform: none"> with respect to those shares. As the </span><span style="text-transform: none; font-style: italic"><i>stockholder of record</i></span><span style="text-transform: none">, you have the right to vote your shares during the Annual Meeting or direct the proxyholder how to vote your shares on your behalf at the </span><span style="text-transform: none">Annual Meeting.</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 0pt 0pt 6pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><b><i>&#160;</i></b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt 0pt 6pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: justify"><span style="text-transform: none; font-style: italic"><i>Beneficial Owner.</i></span><span style="text-transform: none"> If your shares are held in a brokerage account or by another nominee, you are considered the </span><span style="text-transform: none; font-style: italic"><i>beneficial owner</i></span><span style="text-transform: none"> of shares held in </span><span style="text-transform: none; font-style: italic"><i>street name</i></span><span style="text-transform: none">. As the beneficial owner, you have the right to direct your broker, trustee, or nominee to vote your shares as you instruct. The broker, trustee, or other nominee may either vote during the Annual Meeting or grant a proxy and direct the proxyholder to vote your shares during the Annual Meeting as you have instructed. If you hold shares through a broker, trustee, or nominee, you may also vote your shares during the Annual Meeting, but only after you obtain a &#8220;legal proxy&#8221; from the broker, trustee, or nominee that holds your shares in advance of the Annual Meeting, giving you the right to vote your shares during the </span><span style="text-transform: none">Annual Meeting. </span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 0pt 0pt 6pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><b><i>Will my shares held in street name be voted if I do not </i></b></span><span style="text-transform: none; font-style: italic"><b><i>provide instructions?</i></b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt 0pt 6pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: justify"><span style="text-transform: none">Current NYSE rules allow brokers to vote shares on certain &#8220;routine&#8221; matters for which their customers do not provide voting instructions. If you own shares in street name through a broker, trustee, or other nominee, the ratification of the preliminary appointment of Ernst &amp; Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025 (Proposal 3) is considered a &#8220;routine&#8221; matter on which your broker may use its discretion to vote your shares without your instructions. The election of directors (Proposal 1), the advisory vote on the compensation of our Named Executive Officers (Proposal 2), and the proposal to approve additional funding of 3,570,000 shares for the Amended and Restated Artivion, Inc. 2020 Equity and Cash Incentive Plan (Proposal 4) are not &#8220;routine&#8221; proposals; therefore, your broker will be unable to vote your shares on these proposals if you do not instruct your broker how to vote, which is referred to as a </span><span style="text-transform: none">&#8220;broker non-vote.&#8221;</span></p>

							</td>

						</tr>

					</table>

				</div>

			</div>

		</div>
		<div style="page-break-before: always">
			<p style="margin: 0pt; font-size: 5pt">&#8203;</p>

		</div>
		<div class="qes_page" style="border-bottom: black 2pt solid; margin: auto; height: 990pt; width: 765pt; position: relative; overflow: hidden">
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 911.25pt; left: 45pt; width: 675pt; position: absolute; height: 33.75pt">
				<div style="display: table-cell; vertical-align: bottom; width: 675pt; height: 33.75pt">

				<!--[if IE]><TABLE><TR style=" width: 675pt; height: 33.75pt;"><TD vAlign="bottom" style=" width: 675pt; height: 33.75pt;"><![endif]-->
					<div style="font: 12pt/normal Times New Roman, Times, serif; margin: 0pt; text-transform: none; color: #000000; text-align: left">
						<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 0pt; border-collapse: collapse">
							<tr style="margin: 0; height: 0">
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>

							</tr>
							<tr style="min-height: 0pt">
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">ARTIVION, INC. | 2025 Proxy Statement</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">6</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 0pt; line-height: 0pt">&#8203;</p>

								</td>

							</tr>

						</table>

					</div>


				<!--[if IE]></TD></TR></TABLE><![endif]-->
				</div>

			</div>
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 45pt; left: 45pt; width: 675pt; position: absolute; height: 866.25pt">
				<div style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 18pt; text-transform: none; color: #000000; text-align: justify">
					<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 14pt; border-collapse: collapse">
						<tr style="margin: 0; height: 0">
							<td style="border-width: 0; margin: 0; padding: 0; width: 157.5pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 15pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 502.5pt">


							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 0pt 0pt 6pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><b><i>How can I vote my shares without attending the </i></b></span><span style="text-transform: none; font-style: italic"><b><i>Annual Meeting?</i></b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt 0pt 6pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 10pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: justify"><span style="text-transform: none">Whether you hold shares directly as the stockholder of record or as a beneficial owner, you may vote in advance of the Annual </span><span style="text-transform: none">Meeting by:</span></p>
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: justify"><span style="text-transform: none; font-style: italic"><i>Voting by Mail</i></span><span style="text-transform: none">. You may vote by filling out and returning your Proxy Card (if you are a stockholder of record) or by filling out and returning to your broker, trustee, or other nominee your voting instruction card (if you are a </span><span style="text-transform: none">beneficial owner).</span></p>
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: justify"><span style="text-transform: none; font-style: italic"><i>Voting by Internet</i></span><span style="text-transform: none">. If you are a stockholder of record, you may vote in advance of the Annual Meeting by following the instructions provided on your Proxy Card. Most brokers, trustees, and similar nominees also provide beneficial owners with the option to vote by Internet, although practices may vary. If you are a beneficial owner, you must follow the instructions provided to you by your broker, trustee, or other nominee on your voting </span><span style="text-transform: none">instruction card.</span></p>
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: justify"><span style="text-transform: none; font-style: italic"><i>Voting by Telephone. </i></span><span style="text-transform: none">If you are a stockholder of record, you may vote in advance of the Annual Meeting by telephone by following the instructions provided on your Proxy Card. Most brokers, trustees, and similar nominees also provide beneficial owners with the option to vote by telephone, although practices may vary. If you are a beneficial owner, you must follow the instructions provided to you by your broker, trustee, or other nominee on your voting </span><span style="text-transform: none">instruction card.</span></p>
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 0; text-transform: none; color: #000000; text-indent: 0pt; text-align: justify"><span style="text-transform: none">Whether you hold shares directly as the stockholder of record or as a beneficial owner, you may direct how your shares are voted without attending the Annual Meeting. If you provide specific instructions with regard to items of business to be voted on during the Annual Meeting, your shares will be voted as you instruct on those items. Proxies properly submitted to us that are signed but do not contain voting instructions and are not revoked prior to the Annual Meeting will be voted </span><span style="text-transform: none"><b>FOR</b></span><span style="text-transform: none"> the election of each of the director nominees identified in this Proxy Statement, </span><span style="text-transform: none"><b>FOR</b></span><span style="text-transform: none"> the approval, on an advisory basis, of the compensation of our Named Executive Officers, </span><span style="text-transform: none"><b>FOR</b></span><span style="text-transform: none"> the ratification of the preliminary approval of Ernst &amp; Young LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2025, and </span><span style="text-transform: none"><b>FOR</b></span><span style="text-transform: none"> the approval of the additional funding of 3,570,000 shares for the Amended and Restated Artivion, Inc. 2020 Equity and Cash </span><span style="text-transform: none">Incentive Plan. </span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 0pt 0pt 6pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><b><i>How can I vote my shares during the virtual </i></b></span><span style="text-transform: none; font-style: italic"><b><i>Annual Meeting?</i></b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt 0pt 6pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 10pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: justify"><span style="text-transform: none">Shares held in your name as the stockholder of record may be voted during the Annual Meeting. You will need your control number and the meeting password, artivion2025, to vote your shares at the Annual Meeting.  </span></p>
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: justify"><span style="text-transform: none">You may vote shares held beneficially in street name during the Annual Meeting only if you obtain a &#8220;legal proxy&#8221; from the broker, trustee, or nominee holding your shares that gives you the right to vote the shares during the Annual Meeting. After obtaining a valid legal proxy reflecting the number of shares of the Company that you held as of the record date of March 17, 2025, you may then register to attend the Annual Meeting by submitting proof of your legal proxy reflecting the number of your shares, along with your name and email address, to Equiniti Trust Company, LLC. Requests for registration should be directed to proxy@equiniti.com or to facsimile number (718) 765-8730. Written requests can be mailed to: Equiniti Trust Company, LLC, 55 Challenger Road, Floor 2, Ridgefield Park, New Jersey 07660. Requests for registration must be labeled as &#8220;Legal Proxy&#8221; and be received no later than 5:00 p.m., ET, on May 8, 2025. Upon completion of registration, meeting access information will be issued to beneficial stockholders by Equiniti Trust </span><span style="text-transform: none">Company, LLC.</span></p>
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 0; text-transform: none; color: #000000; text-indent: 0pt; text-align: justify"><span style="text-transform: none">Online access to the meeting will begin at 8:00 a.m., ET, and stockholders are encouraged to log in to the meeting early. The Annual Meeting will begin promptly at 9:00 a.m., ET.</span><span style="text-transform: none; font-style: italic"><b><i> Even if you plan to attend the Annual Meeting, we recommend that you also vote via Internet or telephone in advance to ensure that your vote will be counted if you later decide not to attend the </i></b></span><span style="text-transform: none; font-style: italic"><b><i>Annual Meeting.</i></b></span><span style="text-transform: none"></span></p>

							</td>

						</tr>

					</table>

				</div>

			</div>

		</div>
		<div style="page-break-before: always">
			<p style="margin: 0pt; font-size: 5pt">&#8203;</p>

		</div>
		<div class="qes_page" style="border-bottom: black 2pt solid; margin: auto; height: 990pt; width: 765pt; position: relative; overflow: hidden">
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 911.25pt; left: 45pt; width: 675pt; position: absolute; height: 33.75pt">
				<div style="display: table-cell; vertical-align: bottom; width: 675pt; height: 33.75pt">

				<!--[if IE]><TABLE><TR style=" width: 675pt; height: 33.75pt;"><TD vAlign="bottom" style=" width: 675pt; height: 33.75pt;"><![endif]-->
					<div style="font: 12pt/normal Times New Roman, Times, serif; margin: 0pt; text-transform: none; color: #000000; text-align: left">
						<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 0pt; border-collapse: collapse">
							<tr style="margin: 0; height: 0">
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>

							</tr>
							<tr style="min-height: 0pt">
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">ARTIVION, INC. | 2025 Proxy Statement</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">7</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 0pt; line-height: 0pt">&#8203;</p>

								</td>

							</tr>

						</table>

					</div>


				<!--[if IE]></TD></TR></TABLE><![endif]-->
				</div>

			</div>
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 45pt; left: 45pt; width: 675pt; position: absolute; height: 883.13pt">
				<div style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 18pt; text-transform: none; color: #000000; text-align: justify">
					<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 14pt; border-collapse: collapse">
						<tr style="margin: 0; height: 0">
							<td style="border-width: 0; margin: 0; padding: 0; width: 157.5pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 15pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 502.5pt">


							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 0pt 0pt 6pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><b><i>Can I change my vote or revoke </i></b></span><span style="text-transform: none; font-style: italic"><b><i>my proxy?</i></b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt 0pt 6pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: justify"><span style="text-transform: none">If you are the stockholder of record, and you have submitted a vote via the Internet, telephone, or by mail, you may revoke your vote by submitting a timely later-dated vote via the same process you used to cast your original vote. Note, Internet voting through www.voteproxy.com and telephone voting are available only until 11:59&#160;p.m., ET, the day before the Annual Meeting. You may also revoke your vote by providing written notice of revocation to our General Counsel and Corporate Secretary, Jean F. Holloway, or by attending the virtual Annual Meeting and voting in person. Attendance during the Annual Meeting will not cause your previously granted proxy to be revoked unless you specifically request such revocation. If you are a beneficial owner, you may revoke your vote by submitting a later-dated vote via the Internet or by telephone (if those options are available to you), or you may revoke your vote by submitting a new voting instruction card to your broker, trustee, or nominee, or, if you have obtained a &#8220;legal proxy&#8221; from your broker, trustee, or nominee giving you the right to vote your shares, by attending the Annual Meeting </span><span style="text-transform: none">and voting.</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 0pt 0pt 6pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><b><i>What do I need to attend the virtual </i></b></span><span style="text-transform: none; font-style: italic"><b><i>Annual Meeting?</i></b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt 0pt 6pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 10pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: justify"><span style="text-transform: none">Attendance during the Annual Meeting will be limited to our stockholders as of March 17, 2025, the record date, their authorized proxy holders, and guests </span><span style="text-transform: none">of Artivion.</span></p>
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: justify"><span style="text-transform: none; font-style: italic"><i>Attending the virtual Annual Meeting as a stockholder </i></span><span style="text-transform: none; font-style: italic"><i>of record.</i></span></p>
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: justify"><span style="text-transform: none">You will need your control number and the meeting password, artivion2025, to attend the </span><span style="text-transform: none">Annual Meeting.</span></p>
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: justify"><span style="text-transform: none; font-style: italic"><i>Registering to attend the virtual Annual Meeting as a </i></span><span style="text-transform: none; font-style: italic"><i>beneficial owner.</i></span></p>
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 0; text-transform: none; color: #000000; text-indent: 0pt; text-align: justify"><span style="text-transform: none">After obtaining a valid legal proxy from your broker, bank, or other agent, you may then register to attend the Annual Meeting by submitting proof of your legal proxy as described above in, &#8220;</span><span style="text-transform: none"><b>How can I vote my shares during the virtual </b></span><span style="text-transform: none"><b>Annual Meeting?</b></span><span style="text-transform: none">&#8221;</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 0pt 0pt 6pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><b><i>Is my </i></b></span><span style="text-transform: none; font-style: italic"><b><i>vote confidential?</i></b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt 0pt 6pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: justify"><span style="text-transform: none">Electronic votes, proxy cards, voting instructions, ballots, and voting tabulations that identify individual stockholders are not secret; however, all such materials will be handled in a manner intended to reasonably protect your voting privacy. Your vote will not be disclosed, except as required by law and except as required to our transfer agent to allow for the tabulation of votes and certification of the vote and to facilitate a successful </span><span style="text-transform: none">proxy solicitation.</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 0pt 0pt 6pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><b><i>How are votes counted and what vote is required to approve </i></b></span><span style="text-transform: none; font-style: italic"><b><i>each item?</i></b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt 0pt 6pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: justify"><span style="text-transform: none">Each outstanding share of common stock entitles the holder thereof to one vote on each matter considered during the Annual Meeting. Stockholders are not entitled to cumulate their votes in the election of directors or with respect to any other matter submitted to a vote of the stockholders pursuant to this </span><span style="text-transform: none">Proxy Statement.</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 0pt 0pt 6pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><b><i>&#160;</i></b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt 0pt 6pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: justify"><span style="text-transform: none">Nominees for election as directors will be elected by a plurality of the votes cast by the holders of shares entitled to vote in the election. Since there are nine directorships to be filled, this means that the nine individuals receiving the most &#8220;For&#8221; votes will be elected. Shares voted &#8220;Withhold,&#8221; abstentions, and broker non-votes will therefore not be relevant to the outcome. A broker non-vote occurs when a broker holding shares for a beneficial owner does not vote on a particular proposal because the broker does not have discretionary voting authority and has not received voting instructions from the </span><span style="text-transform: none">beneficial owner.</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 0pt 0pt 6pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><b><i>&#160;</i></b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt 0pt 6pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: justify"><span style="text-transform: none">The advisory votes cast &#8220;For&#8221; the approval of the compensation paid to Artivion&#8217;s Named Executive Officers, as disclosed pursuant to Item 402 of Regulation S-K, including the Compensation Discussion and Analysis, compensation tables, and narrative discussion, must constitute a majority of shares present, either in person or by proxy, and entitled to vote on this proposal in order for it to be approved. Accordingly, abstentions will have the same effect as an &#8220;Against&#8221; vote. Broker non-votes will have no effect on the outcome of </span><span style="text-transform: none">this proposal.</span></p>

							</td>

						</tr>

					</table>

				</div>

			</div>

		</div>
		<div style="page-break-before: always">
			<p style="margin: 0pt; font-size: 5pt">&#8203;</p>

		</div>
		<div class="qes_page" style="border-bottom: black 2pt solid; margin: auto; height: 990pt; width: 765pt; position: relative; overflow: hidden">
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 911.25pt; left: 45pt; width: 675pt; position: absolute; height: 33.75pt">
				<div style="display: table-cell; vertical-align: bottom; width: 675pt; height: 33.75pt">

				<!--[if IE]><TABLE><TR style=" width: 675pt; height: 33.75pt;"><TD vAlign="bottom" style=" width: 675pt; height: 33.75pt;"><![endif]-->
					<div style="font: 12pt/normal Times New Roman, Times, serif; margin: 0pt; text-transform: none; color: #000000; text-align: left">
						<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 0pt; border-collapse: collapse">
							<tr style="margin: 0; height: 0">
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>

							</tr>
							<tr style="min-height: 0pt">
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">ARTIVION, INC. | 2025 Proxy Statement</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">8</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 0pt; line-height: 0pt">&#8203;</p>

								</td>

							</tr>

						</table>

					</div>


				<!--[if IE]></TD></TR></TABLE><![endif]-->
				</div>

			</div>
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 45pt; left: 45pt; width: 675pt; position: absolute; height: 910.5pt">
				<div style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 18pt; text-transform: none; color: #000000; text-align: justify">
					<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 14pt; border-collapse: collapse">
						<tr style="margin: 0; height: 0">
							<td style="border-width: 0; margin: 0; padding: 0; width: 157.5pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 15pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 502.5pt">


							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt 0pt 6pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 10pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: justify"><span style="text-transform: none">The votes cast &#8220;For&#8221; ratification of the preliminary approval of the appointment of Ernst &amp; Young LLP as Artivion&#8217;s independent registered accounting firm must constitute a majority of shares present, either in person or by proxy, and entitled to vote on this proposal. Abstentions will have the same effect as an &#8220;Against&#8221; vote. Because brokers and other nominees have discretionary authority to vote on the ratification, we do not expect any broker non-votes in connection with </span><span style="text-transform: none">this item.</span></p>
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 0; text-transform: none; color: #000000; text-indent: 0pt; text-align: justify"><span style="text-transform: none">The votes cast &#8220;For&#8221; the approval of the additional funding of 3,570,000 shares for the Amended and Restated Artivion, Inc. 2020 Equity and Cash Incentive Plan must constitute a majority of shares present, either in person or by proxy, and entitled to vote on this proposal. Abstentions will have the same effect as an &#8220;Against&#8221; vote. Broker non-votes will have no effect on the outcome of this proposal.  </span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt 0pt 6pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: justify"><span style="text-transform: none">There are no rights of appraisal or similar dissenters&#8217; rights with respect to any matter to be acted upon pursuant to this </span><span style="text-transform: none">Proxy Statement.</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 0pt 0pt 6pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><b><i>What happens if the Annual Meeting </i></b></span><span style="text-transform: none; font-style: italic"><b><i>is adjourned?</i></b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt 0pt 6pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: justify"><span style="text-transform: none">Assuming the presence of a quorum, if our Annual Meeting is adjourned to another time and place, no additional notice of the adjourned meeting will be given if the time and place of the adjourned meeting is announced during the Annual Meeting, unless the adjournment is for more than 30 days, in which case a new record date must be fixed and notice of the adjourned meeting distributed. At the adjourned meeting, we may transact any items of business that might have been transacted during the </span><span style="text-transform: none">Annual Meeting.</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 0pt 0pt 6pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><b><i>Who should I contact if I experience technical difficulties accessing the virtual </i></b></span><span style="text-transform: none; font-style: italic"><b><i>Annual Meeting?</i></b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt 0pt 6pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: justify"><span style="text-transform: none">Equiniti Trust Company, LLC will provide technical support for all stockholders attending the Annual Meeting. Stockholders experiencing technical difficulties accessing the meeting may visit https://go.lumiglobal.com/faq for assistance. We encourage you to access the Annual Meeting starting one hour prior to the start time, leaving ample time for the </span><span style="text-transform: none">check-in process.</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 0pt 0pt 6pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><b><i>What else should I know about the virtual process for the </i></b></span><span style="text-transform: none; font-style: italic"><b><i>Annual Meeting?</i></b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt 0pt 6pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: justify"><span style="text-transform: none">Stockholders of record, or those who have received a &#8220;legal proxy,&#8221; will be able to submit questions related to the business of the meeting while attending the Annual Meeting from the time the meeting is first called to order through the end of the question-and-answer period and will be alerted prior to the end of the question-and-answer period. A replay of the Annual Meeting and a list of stockholder questions and Company answers will be available after the Annual </span><span style="text-transform: none">Meeting concludes.</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 0pt 0pt 6pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><b><i>Who is soliciting my vote, and who will bear the costs of </i></b></span><span style="text-transform: none; font-style: italic"><b><i>this solicitation?</i></b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt 0pt 6pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: justify"><span style="text-transform: none">The Proxy Statement is being solicited on behalf of our Board of Directors. We will bear the entire cost of solicitation of proxies, including preparation, assembly, printing, and delivery of this Proxy Statement, via electronic means or paper means upon stockholder request. In addition, our non-employee directors, executive officers, employees, and agents may also solicit proxies in person, by telephone, by electronic mail, or by other means of communication. We will not pay any additional compensation to our non-employee directors, executive officers, or other employees for </span><span style="text-transform: none">soliciting proxies.</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 0pt 0pt 6pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><b><i>Where can I find the voting results of the </i></b></span><span style="text-transform: none; font-style: italic"><b><i>Annual Meeting?</i></b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt 0pt 6pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: justify"><span style="text-transform: none">We intend to announce preliminary voting results during the Annual Meeting and publish the final voting results in a Current Report on Form&#160;8-K filed within four business days after the </span><span style="text-transform: none">Annual Meeting.</span></p>

							</td>

						</tr>

					</table>

				</div>

			</div>

		</div>
		<div style="page-break-before: always">
			<p style="margin: 0pt; font-size: 5pt">&#8203;</p>

		</div>
		<div class="qes_page" style="border-bottom: black 2pt solid; margin: auto; height: 990pt; width: 765pt; position: relative; overflow: hidden">
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 911.25pt; left: 45pt; width: 675pt; position: absolute; height: 33.75pt">
				<div style="display: table-cell; vertical-align: bottom; width: 675pt; height: 33.75pt">

				<!--[if IE]><TABLE><TR style=" width: 675pt; height: 33.75pt;"><TD vAlign="bottom" style=" width: 675pt; height: 33.75pt;"><![endif]-->
					<div style="font: 12pt/normal Times New Roman, Times, serif; margin: 0pt; text-transform: none; color: #000000; text-align: left">
						<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 0pt; border-collapse: collapse">
							<tr style="margin: 0; height: 0">
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>

							</tr>
							<tr style="min-height: 0pt">
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">ARTIVION, INC. | 2025 Proxy Statement</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">9</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 0pt; line-height: 0pt">&#8203;</p>

								</td>

							</tr>

						</table>

					</div>


				<!--[if IE]></TD></TR></TABLE><![endif]-->
				</div>

			</div>
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 45pt; left: 45pt; width: 675pt; position: absolute; height: 866.25pt">
				<div style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 18pt; text-transform: none; color: #000000; text-align: justify">
					<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 14pt; border-collapse: collapse">
						<tr style="margin: 0; height: 0">
							<td style="border-width: 0; margin: 0; padding: 0; width: 157.5pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 15pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 502.5pt">


							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 0pt 0pt 6pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><b><i>What is the deadline for submitting proposals for consideration at next year&#8217;s Annual Meeting of Stockholders or to nominate individuals to serve </i></b></span><span style="text-transform: none; font-style: italic"><b><i>as directors?</i></b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt 0pt 6pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 10pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: justify"><span style="text-transform: none">Appropriate stockholder proposals intended to be presented at Artivion&#8217;s 2026 Annual Meeting of Stockholders pursuant to Rule 14a-8 promulgated under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;) must be received by Artivion by December 2,&#160;2025 for inclusion in its Proxy Statement and form of proxy for such meeting. Stockholder proposals must comply with the requirements of Rule 14a-8 of the Exchange Act and any other applicable rules established by the Securities and Exchange Commission </span><span style="text-transform: none">(the &#8220;SEC&#8221;).</span></p>
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: justify"><span style="text-transform: none">Proposals of stockholders intended to be presented during the 2026 Annual Meeting of Stockholders without inclusion of such proposals in our Proxy Statement relating to such annual meeting must be received not later than the close of business on the 90th day and not earlier than the close of business on the 120th day prior to the first anniversary of the preceding year&#8217;s </span><span style="text-transform: none">annual meeting. </span></p>
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: justify"><span style="text-transform: none">Therefore, for the 2026 Annual Meeting of Stockholders, all stockholder proposals submitted outside of the stockholder proposal rules promulgated pursuant to Rule 14a-8 under the Exchange Act, including nominations for individuals to serve as non-employee directors, must be received by Artivion no later than February 12, 2026, but no earlier than January 13, 2026, to be considered timely and must include the information specified under our Bylaws. If the month and day of the next annual meeting is advanced or delayed by more than 30 calendar days from the month and day of the annual meeting to which this Proxy Statement relates, Artivion shall, in a timely manner, inform its stockholders of the change and the date by which proposals of stockholders must </span><span style="text-transform: none">be received.</span></p>
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 0; text-transform: none; color: #000000; text-indent: 0pt; text-align: justify"><span style="text-transform: none">In addition to the foregoing, to comply with the universal proxy rules, stockholders who intend to solicit proxies in support of director nominees other than the Company&#8217;s nominees must provide notice that sets forth the information required by our Bylaws and Rule 14a-19 under the Exchange Act no later than February 12, 2026, but no earlier than January </span><span style="text-transform: none">13, 2026. </span></p>

							</td>

						</tr>

					</table>

				</div>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 18pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none"></span></p>
				<p style="border-bottom: #7f7f7f 1pt solid; font: 12pt/normal Arial, sans-serif; margin: 4pt 0pt 15pt; text-transform: none; color: #2b4b74; text-indent: 0pt; text-align: left"><span style="text-transform: none"><b>PROPOSAL ONE &#8211; ELECTION OF DIRECTORS</b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">Artivion directors elected during the Annual Meeting on May 13, 2025 will hold office until the next annual meeting, until their successors are duly qualified, or until their earlier death, resignation, </span><span style="text-transform: none; line-height: 12pt">or removal. </span></p>
				<p style="font: italic 11pt/normal Arial, sans-serif; margin: 4pt 0pt 8pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><b><i>Director Nominees</i></b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">Each of the nominees currently serves as a director of Artivion. Should any director nominee become unable to accept nomination or election, the persons appointed on the Proxy Card intend, unless otherwise specifically instructed in the Proxy Statement, to vote for the election of such other nominee, if any, as the Board of Directors may recommend, or the Board may elect to reduce </span><span style="text-transform: none; line-height: 12pt">its size.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">The following table sets forth the name and age of each nominee, the period during which each such person has served as a director of Artivion, the number of shares of Artivion&#8217;s common stock beneficially owned, directly or indirectly, by such person, and the percentage of outstanding shares of Artivion&#8217;s common stock such ownership represented at the close of business on March 17, 2025, according to information maintained by Artivion. None of the shares of stock noted below are subject to a pledge or similar arrangement. Except for J. Patrick Mackin, our President, Chief Executive Officer, and Chairman of the Board of Directors, none of the nominees holds any other position or office </span><span style="text-transform: none; line-height: 12pt">with Artivion. </span></p>
				<div style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-align: center">
					<table style="margin: 4pt auto 10pt; table-layout: fixed; width: 520.93pt; border-collapse: collapse">
						<tr style="margin: 0; height: 0">
							<td style="border-width: 0; margin: 0; padding: 0; width: 120.93pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 67.49pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 59.99pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 36.25pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 66.25pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 66.25pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 143.75pt">


							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Name of Nominee</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Director<br/>Since</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Age</b></span></p>

							</td>
							<td colspan="3" style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Shares of Artivion<br/>Stock Beneficially<br/>Owned</b></span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt"><b>(1)</b></sup><sup style="text-transform: none; font-size: 8pt; line-height: 8pt"><b><br/></b></sup><span style="text-transform: none"><b>(#)</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Percentage of<br/>Outstanding Shares<br/>of Artivion Stock</b></span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt"><b>(4)</b></sup><span style="text-transform: none"><b><br/>(%)</b></span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Thomas F. Ackerman</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">2003</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">70</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">143,571</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><sup style="text-transform: none; font-size: 8pt; line-height: 10pt">(2)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; text-transform: none; color: #000000; margin-top: 0; margin-bottom: 0; text-align: center"><span style="text-transform: none">*</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Daniel J. Bevevino</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">2003</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">65</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">143,736</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><sup style="text-transform: none; font-size: 8pt; line-height: 10pt">(2)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; text-transform: none; color: #000000; margin-top: 0; margin-bottom: 0; text-align: center"><span style="text-transform: none">*</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Marna P. Borgstrom</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">2018</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">71</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">42,763</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><sup style="text-transform: none; font-size: 8pt; line-height: 10pt">(2)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; text-transform: none; color: #000000; margin-top: 0; margin-bottom: 0; text-align: center"><span style="text-transform: none">*</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">James W. Bullock</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">2016</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">68</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">62,322</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><sup style="text-transform: none; font-size: 8pt; line-height: 10pt">(2)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; text-transform: none; color: #000000; margin-top: 0; margin-bottom: 0; text-align: center"><span style="text-transform: none">*</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Jeffrey H. Burbank</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">2017</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">62</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">47,471</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><sup style="text-transform: none; font-size: 8pt; line-height: 10pt">(2)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; text-transform: none; color: #000000; margin-top: 0; margin-bottom: 0; text-align: center"><span style="text-transform: none">*</span></p>

							</td>

						</tr>

					</table>

				</div>

			</div>

		</div>
		<div style="page-break-before: always">
			<p style="margin: 0pt; font-size: 5pt">&#8203;</p>

		</div>
		<div class="qes_page" style="border-bottom: black 2pt solid; margin: auto; height: 990pt; width: 765pt; position: relative; overflow: hidden">
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 911.25pt; left: 45pt; width: 675pt; position: absolute; height: 33.75pt">
				<div style="display: table-cell; vertical-align: bottom; width: 675pt; height: 33.75pt">

				<!--[if IE]><TABLE><TR style=" width: 675pt; height: 33.75pt;"><TD vAlign="bottom" style=" width: 675pt; height: 33.75pt;"><![endif]-->
					<div style="font: 12pt/normal Times New Roman, Times, serif; margin: 0pt; text-transform: none; color: #000000; text-align: left">
						<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 0pt; border-collapse: collapse">
							<tr style="margin: 0; height: 0">
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>

							</tr>
							<tr style="min-height: 0pt">
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">ARTIVION, INC. | 2025 Proxy Statement</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">10</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 0pt; line-height: 0pt">&#8203;</p>

								</td>

							</tr>

						</table>

					</div>


				<!--[if IE]></TD></TR></TABLE><![endif]-->
				</div>

			</div>
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 45pt; left: 45pt; width: 675pt; position: absolute; height: 866.6pt">
				<div style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-align: center">
					<table style="margin: 4pt auto 10pt; table-layout: fixed; width: 520.93pt; border-collapse: collapse">
						<tr style="margin: 0; height: 0">
							<td style="border-width: 0; margin: 0; padding: 0; width: 120.93pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 67.49pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 59.99pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 36.25pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 56.25pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 66.25pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 143.75pt">


							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Name of Nominee</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Director<br/>Since</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Age</b></span></p>

							</td>
							<td colspan="3" style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Shares of Artivion<br/>Stock Beneficially<br/>Owned</b></span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt"><b>(1)</b></sup><sup style="text-transform: none; font-size: 8pt; line-height: 8pt"><b><br/></b></sup><span style="text-transform: none"><b>(#)</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Percentage of<br/>Outstanding Shares<br/>of Artivion Stock</b></span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt"><b>(4)</b></sup><span style="text-transform: none"><b><br/>(%)</b></span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Elizabeth A. Hoff</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">2022</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">59</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">25,064</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><sup style="text-transform: none; font-size: 8pt; line-height: 8pt">(2)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">*</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">J. Patrick Mackin</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">2014</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">58</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">1,328,648</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><sup style="text-transform: none; font-size: 8pt; line-height: 8pt">(3)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">3.1</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Jon W. Salveson</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">2012</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">60</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">123,515</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><sup style="text-transform: none; font-size: 8pt; line-height: 8pt">(2)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">*</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Anthony B. Semedo</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">2021</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">73</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">36,259</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><sup style="text-transform: none; font-size: 8pt; line-height: 8pt">(2)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">*</span></p>

							</td>

						</tr>

					</table>

				</div>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"></span></p>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 2pt 96.25pt; text-transform: none; color: #000000; text-indent: -16.88pt; text-align: justify"><!--[if IE]><FONT style=" width: 16.875pt; text-indent: -13.5pt; display: inline-block;"><![endif]--><span style="width: 16.87pt; text-indent: 0; display: inline-block"><span style="text-transform: none">*</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Ownership represents less than 1% of the outstanding shares of Artivion </span><span style="text-transform: none">common stock.</span></p>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 2pt 96.25pt; text-transform: none; color: #000000; text-indent: -16.88pt; text-align: justify"><!--[if IE]><FONT style=" width: 16.875pt; text-indent: -13.5pt; display: inline-block;"><![endif]--><span style="width: 16.87pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(1)</sup></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Except as otherwise noted, the nature of the beneficial ownership for all shares is sole voting and </span><span style="text-transform: none">investment power.</span></p>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 2pt 96.25pt; text-transform: none; color: #000000; text-indent: -16.88pt; text-align: justify"><!--[if IE]><FONT style=" width: 16.875pt; text-indent: -13.5pt; display: inline-block;"><![endif]--><span style="width: 16.87pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(2)</sup></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Includes 6,289 shares of unvested restricted stock granted on May 30, 2024. For Mr. Semedo, the amount includes 600 shares that Mr. Semedo owns indirectly through </span><span style="text-transform: none">his spouse. </span></p>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 2pt 96.25pt; text-transform: none; color: #000000; text-indent: -16.88pt; text-align: justify"><!--[if IE]><FONT style=" width: 16.875pt; text-indent: -13.5pt; display: inline-block;"><![endif]--><span style="width: 16.87pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(3)</sup></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Amount includes 555,160 options that are either presently exercisable or will become exercisable within 60 days after March 17, 2025. This amount also includes 274,812 shares of unvested restricted stock subject to forfeiture held by Mr.&#160;Mackin as of March 17, 2025. This amount does not include 91,795 shares earned under 2023 and 2024 performance stock unit awards that had not vested as of March 17, 2025 and that will not vest within 60 </span><span style="text-transform: none">days thereafter.</span></p>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 8pt 96.25pt; text-transform: none; color: #000000; text-indent: -16.88pt; text-align: justify"><!--[if IE]><FONT style=" width: 16.875pt; text-indent: -13.5pt; display: inline-block;"><![endif]--><span style="width: 16.87pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(4)</sup></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">There were 42,689,303 outstanding shares of Artivion common stock as of March 17, 2025, the </span><span style="text-transform: none">record date.</span></p>
				<p style="font: italic 11pt/normal Arial, sans-serif; margin: 4pt 0pt 8pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><b><i>2025 Director Nominees</i></b></span></p>
				<div style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center">
					<div style="border-width: 0pt; padding: 0pt; overflow: hidden; display: inline-block; width: 644.85pt; height: 167.97pt; text-align: left">
						<img src="art-def14a_051325img004.gif" alt="" style="vertical-align: top; margin-left: 0pt; width: 643.75pt; margin-top: 0pt; height: 167.5pt"/>

					</div>

				</div>
				<p style="font: italic 11pt/normal Arial, sans-serif; margin: 4pt 0pt 8pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><b><i>2025 Director Nominee Skills</i></b></span></p>
				<div style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-align: justify">
					<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 6pt; border-collapse: collapse">
						<tr style="margin: 0; height: 0">
							<td style="border-width: 0; margin: 0; padding: 0; width: 161.25pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 10pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 161.24pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 10pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 161.24pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 10pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 161.24pt">


							</td>

						</tr>
						<tr style="max-height: 26.55pt; min-height: 26.55pt; height: 26.55pt">
							<td style="border-width: 0pt; padding: 0pt; background-color: #2b4b74; vertical-align: middle; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; color: #ffffff; font-size: 8pt">CEO Experience</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: middle; border-collapse: collapse">


							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #2b4b74; vertical-align: middle; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; color: #ffffff; font-size: 8pt">Financial </span><span style="text-transform: none; color: #ffffff; font-size: 8pt">and Investor</span></p>
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 0; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; color: #ffffff; font-size: 8pt">Relations Expertise</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: middle; border-collapse: collapse">


							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #2b4b74; vertical-align: middle; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; color: #ffffff; font-size: 8pt">Medical </span><span style="text-transform: none; color: #ffffff; font-size: 8pt">Device and</span></p>
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 0; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; color: #ffffff; font-size: 8pt">Healthcare Expertise</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: middle; border-collapse: collapse">


							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #2b4b74; vertical-align: middle; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; color: #ffffff; font-size: 8pt">Legal, </span><span style="text-transform: none; color: #ffffff; font-size: 8pt">Compliance, and</span></p>
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 0; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; color: #ffffff; font-size: 8pt">Governance Experience</span></p>

							</td>

						</tr>
						<tr style="max-height: 8pt; min-height: 8pt; height: 8pt">
							<td style="border-width: 0pt; padding: 0pt; vertical-align: middle; border-collapse: collapse">


							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: middle; border-collapse: collapse">


							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: middle; border-collapse: collapse">


							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: middle; border-collapse: collapse">


							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: middle; border-collapse: collapse">


							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: middle; border-collapse: collapse">


							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: middle; border-collapse: collapse">


							</td>

						</tr>
						<tr style="max-height: 28.8pt; min-height: 28.8pt; height: 28.8pt">
							<td style="border-width: 0pt; padding: 0pt; background-color: #2b4b74; vertical-align: middle; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; color: #ffffff; font-size: 8pt">Sustainability Expertise</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: middle; border-collapse: collapse">


							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #2b4b74; vertical-align: middle; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; color: #ffffff; font-size: 8pt">Regulatory, Quality, and Patient (Product) </span><span style="text-transform: none; color: #ffffff; font-size: 8pt">Safety Experience</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: middle; border-collapse: collapse">


							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #2b4b74; vertical-align: middle; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; color: #ffffff; font-size: 8pt">Global Operations and Complex </span><span style="text-transform: none; color: #ffffff; font-size: 8pt">Organizations Experience</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: middle; border-collapse: collapse">


							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #2b4b74; vertical-align: middle; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; color: #ffffff; font-size: 8pt">Regulatory </span><span style="text-transform: none; color: #ffffff; font-size: 8pt">and Healthcare</span></p>
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 0; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; color: #ffffff; font-size: 8pt">Policy Experience</span></p>

							</td>

						</tr>
						<tr style="max-height: 8pt; min-height: 8pt; height: 8pt">
							<td style="border-width: 0pt; padding: 0pt; vertical-align: middle; border-collapse: collapse">


							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: middle; border-collapse: collapse">


							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: middle; border-collapse: collapse">


							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: middle; border-collapse: collapse">


							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: middle; border-collapse: collapse">


							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: middle; border-collapse: collapse">


							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: middle; border-collapse: collapse">


							</td>

						</tr>
						<tr style="max-height: 28.35pt; min-height: 28.35pt; height: 28.35pt">
							<td style="border-width: 0pt; padding: 0pt; background-color: #2b4b74; vertical-align: middle; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; color: #ffffff; font-size: 8pt">Public </span><span style="text-transform: none; color: #ffffff; font-size: 8pt">Company<br/>Board Experience</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: middle; border-collapse: collapse">


							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #2b4b74; vertical-align: middle; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; color: #ffffff; font-size: 8pt">Strategic Planning</span></p>
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 0; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; color: #ffffff; font-size: 8pt">Expertise</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: middle; border-collapse: collapse">


							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #2b4b74; vertical-align: middle; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; color: #ffffff; font-size: 8pt">Technology </span><span style="text-transform: none; color: #ffffff; font-size: 8pt">and<br/>Cybersecurity Experience</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: middle; border-collapse: collapse">


							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #2b4b74; vertical-align: middle; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; color: #ffffff; font-size: 8pt">Institutional Knowledge</span></p>

							</td>

						</tr>

					</table>

				</div>
				<p style="font: italic 11pt/normal Arial, sans-serif; margin: 4pt 0pt 8pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><b><i>Director Nominee Qualifications and Biographical Information</i></b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt"><b>Thomas F. Ackerman</b></span><span style="text-transform: none; line-height: 12pt"> has served as a director of Artivion since December&#160;2003. Until February 2017, Mr.&#160;Ackerman served as a consultant to Charles River Laboratories International, Inc. (NYSE: CRL) (&#8220;Charles River Laboratories&#8221;). Charles River Laboratories is a leading global provider of solutions that accelerate the early-stage drug discovery and development process, with a focus on in vivo biology, including research models and services required to enable in vivo drug discovery and development. Until early 2016, Mr. Ackerman served as a Senior Financial Advisor of Charles River Laboratories, a position he held since August 2015. From 2005 to 2015, he served as Executive Vice President and Chief Financial Officer of Charles River Laboratories. From 1999 to 2005, he served as Senior Vice President and Chief Financial Officer of Charles River Laboratories. From 1996 to 1999, Mr. Ackerman served as Vice President and Chief Financial Officer of Charles River Laboratories, where he had been employed since 1988. Mr. Ackerman is a director of the University of Massachusetts Amherst Foundation and serves on the audit committee of Olin College of Engineering. Mr. Ackerman received a B.S. in Accounting from the University of Massachusetts and became a Certified Public Accountant in 1979. Mr. Ackerman&#8217;s license is </span><span style="text-transform: none; line-height: 12pt">currently inactive.</span></p>

			</div>

		</div>
		<div style="page-break-before: always">
			<p style="margin: 0pt; font-size: 5pt">&#8203;</p>

		</div>
		<div class="qes_page" style="border-bottom: black 2pt solid; margin: auto; height: 990pt; width: 765pt; position: relative; overflow: hidden">
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 911.25pt; left: 45pt; width: 675pt; position: absolute; height: 33.75pt">
				<div style="display: table-cell; vertical-align: bottom; width: 675pt; height: 33.75pt">

				<!--[if IE]><TABLE><TR style=" width: 675pt; height: 33.75pt;"><TD vAlign="bottom" style=" width: 675pt; height: 33.75pt;"><![endif]-->
					<div style="font: 12pt/normal Times New Roman, Times, serif; margin: 0pt; text-transform: none; color: #000000; text-align: left">
						<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 0pt; border-collapse: collapse">
							<tr style="margin: 0; height: 0">
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>

							</tr>
							<tr style="min-height: 0pt">
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">ARTIVION, INC. | 2025 Proxy Statement</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">11</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 0pt; line-height: 0pt">&#8203;</p>

								</td>

							</tr>

						</table>

					</div>


				<!--[if IE]></TD></TR></TABLE><![endif]-->
				</div>

			</div>
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 45pt; left: 45pt; width: 675pt; position: absolute; height: 866.25pt">
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">The Board of Directors has determined that Mr. Ackerman should serve as a director of Artivion because of his expertise in accounting and financial reporting, particularly in the </span><span style="text-transform: none; line-height: 12pt">biotechnology industry.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt"><b>Daniel J. Bevevino</b></span><span style="text-transform: none; line-height: 12pt"> has served as a director of Artivion since December 2003. From 1996 until March 2008, Mr. Bevevino served as the Vice President and Chief Financial Officer of Respironics, Inc. (&#8220;Respironics&#8221;), a company that developed, manufactured, and marketed medical devices used primarily for the treatment of patients suffering from sleep and respiratory disorders. He was employed by Respironics beginning in 1988. In March 2008, Respironics was acquired by Royal Philips (NYSE: PHG) (&#8220;Philips&#8221;), whose businesses included a variety of medical solutions, including medical diagnostic imaging and patient monitoring systems, as well as businesses focused on energy efficient lighting and consumer products. From March 2008 to December 31, 2009, Mr. Bevevino was employed by Philips as Head of Post-Merger Integration &#8211; Respironics, as well as in various operating capacities, to help facilitate integration of the combined companies. He is currently an independent consultant providing interim chief financial officer services in the life sciences industry, and he currently serves as a director of one of the private companies for which he provides services. He began his career as a Certified Public Accountant with Ernst &amp; Young LLP. Mr. Bevevino&#8217;s license is currently inactive. Mr. Bevevino received a B.S. in Business Administration from Duquesne University and an MBA from the University of </span><span style="text-transform: none; line-height: 12pt">Notre Dame.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">The Board of Directors has determined that Mr. Bevevino should serve as a director of Artivion because of his expertise in accounting and financial reporting, particularly in the medical </span><span style="text-transform: none; line-height: 12pt">device industry.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt"><b>Marna P. Borgstrom </b></span><span style="text-transform: none; line-height: 12pt">has served as a director of Artivion since June 2018. From 2005 until March 2022, Ms. Borgstrom served as President, Chief Executive Officer, and a board member of Yale New Haven Health System, an integrated healthcare delivery system with approximately $5.88 billion in annual revenue, 2,681 patient beds, and 29,486 employees. During her tenure with Yale New Haven Health System, Ms. Borgstrom was instrumental in the health system&#8217;s growth, which over the last decade included an increase in revenue of 126%, patient beds of 26%, and employees of 60%. Ms. Borgstrom also played a significant role in integrating Yale New Haven Health System into a cohesive operating entity, increasing efficiencies and significantly reducing costs. During the challenging pandemic, Ms. Borgstrom and her team evolved care pathways for COVID-19 patients, such that Yale New Haven Health System was able to keep patients and employees safe and report mortality rates of less than 50% of the nation</span><span style="text-transform: none; line-height: 12pt">al average, despite treating a larger number of, and more medically complex, COVID-19 cases. Additionally, Ms. Borgstrom currently serves on the boards of (1) Marion Parke, a privately held company based in Minneapolis, Minnesota and (2) the Fair Haven Community Health Care Foundation, a privately held non-profit based in New Haven, Connecticut. Ms. Borgstrom received her Bachelor of Arts from Stanford University and a Masters in Public Health from </span><span style="text-transform: none; line-height: 12pt">Yale University.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">The Board of Directors has determined that Ms. Borgstrom should serve as a director of Artivion because of her extensive experience as a senior executive leading a large, complex organization in the healthcare sector, coupled with her knowledge of healthcare regulation and policy and her recognition within the </span><span style="text-transform: none; line-height: 12pt">healthcare industry.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt"><b>James W. Bullock</b></span><span style="text-transform: none; line-height: 12pt"> has served as a director of Artivion since October 2016. Mr. Bullock previously served as the President and Chief Executive Officer of Zyga Technology, Inc. (&#8220;Zyga Technology&#8221;), a privately-held medical device company focused on products that treat conditions of the lumbar spine, until January 2018, when RTI Surgical, Inc. (formerly NASDAQ: RTIX) acquired Zyga Technology. Prior to that, he served for six years as President and Chief Executive Officer of Atritech, Inc. (&#8220;Atritech&#8221;). Atritech was a privately held cardiovascular manufacturing company that was acquired by Boston Scientific Corporation (NYSE: BSX). Prior to that, he served for nine years as President, Chief Executive Officer, and board member of Endocardial Solutions, Inc. (NASDAQ: ECSI) (&#8220;Endocardial Solutions&#8221;), a cardiac-focused medical device company that was acquired by St. Jude Medical, which was itself acquired by Abbott Laboratories (NYSE: ABT). Mr. Bullock also served as President, Chief Executive Officer, and board member Stuart Medical, Inc., and he began his career working in a variety of sales and marketing leadership positions at Baxter International, Inc. (NYSE: BAX) and American Hospital Supply Corporation. Currently, in addition to Artivion&#8217;s Board of Directors, Mr. Bullock also serves as Chairman of the board of directors of Stimdia, Inc., a privately held company that conducts research for the development of medical devices for use in the critical care treatment of ventilator induced diaphragmatic dysfunction. Mr. Bullock also serves as Chairman of the board of directors of Surgical Information Science, Inc. and as a director of Intershunt Technologies, Inc., both private health companies. Mr. Bullock received a Bachelor of Science in Public Administration from the University </span><span style="text-transform: none; line-height: 12pt">of Arizona.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">The Board of Directors has determined that Mr. Bullock should serve as a director of Artivion because of his business acumen and substantial experience in the global medical device industry, particularly in the area of </span><span style="text-transform: none; line-height: 12pt">company growth. </span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt"><b>Jeffrey H. Burbank</b></span><span style="text-transform: none; line-height: 12pt"> has served as a director of Artivion since September 2017. From 2019 until March 2022, Mr. Burbank served as the Chief Technology Officer at Fresenius Medical Care North America, a division of Fresenius Medical Care AG &amp; Co. (NYSE: FMS) (&#8220;Fresenius Medical Care&#8221;), the world&#8217;s largest provider of products and services </span><span style="text-transform: none; line-height: 12pt">for individuals </span></p>

			</div>

		</div>
		<div style="page-break-before: always">
			<p style="margin: 0pt; font-size: 5pt">&#8203;</p>

		</div>
		<div class="qes_page" style="border-bottom: black 2pt solid; margin: auto; height: 990pt; width: 765pt; position: relative; overflow: hidden">
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 911.25pt; left: 45pt; width: 675pt; position: absolute; height: 33.75pt">
				<div style="display: table-cell; vertical-align: bottom; width: 675pt; height: 33.75pt">

				<!--[if IE]><TABLE><TR style=" width: 675pt; height: 33.75pt;"><TD vAlign="bottom" style=" width: 675pt; height: 33.75pt;"><![endif]-->
					<div style="font: 12pt/normal Times New Roman, Times, serif; margin: 0pt; text-transform: none; color: #000000; text-align: left">
						<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 0pt; border-collapse: collapse">
							<tr style="margin: 0; height: 0">
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>

							</tr>
							<tr style="min-height: 0pt">
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">ARTIVION, INC. | 2025 Proxy Statement</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">12</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 0pt; line-height: 0pt">&#8203;</p>

								</td>

							</tr>

						</table>

					</div>


				<!--[if IE]></TD></TR></TABLE><![endif]-->
				</div>

			</div>
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 45pt; left: 45pt; width: 675pt; position: absolute; height: 883.13pt">
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">with renal diseases. Prior to that, Mr. Burbank served as Chief Executive Officer and a member of the board of directors of NxStage Medical, Inc. (formerly NASDAQ: NXTM) (&#8220;NxStage Medical&#8221;), a leading medical technology company, positions he held since he founded NxStage Medical in 1998, until Fresenius Medical Care completed its acquisition of NxStage Medical in February 2019. Prior to founding NxStage Medical, Mr. Burbank was a co-founder of Vasca, Inc., a company that provided innovative implantable access devices, where he was the President and Chief Executive Officer, as well as Chairman of the board of directors. Mr. Burbank has over 30 years of senior leadership experience in the medical device industry, developing, marketing, and manufacturing products for end-stage renal disease patients. During his career he has been an inventor on over 50 U.S. patents for medical devices. Mr. Burbank received a Bachelor of Science in Industrial Engineering from </span><span style="text-transform: none; line-height: 12pt">Lehigh University.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">The Board of Directors has determined that Mr. Burbank should serve as a director of Artivion because of his business acumen and substantial senior leadership experience in the global medical </span><span style="text-transform: none; line-height: 12pt">device industry.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt"><b>Elizabeth A. Hoff</b></span><span style="text-transform: none; line-height: 12pt"> has served as a director of Artivion since October 2022. Ms. Hoff serves as President and Chief Executive Officer of SOMAVAC Medical Solutions, Inc., a company that develops, manufacturers, and distributes deep tissue negative pressure therapy as an alternative to traditional post-surgical fluid removal. Previously, Ms. Hoff served as the Chief Evangelist at Galen Data, Inc., a company that provides turn-key FDA and CE Mark compliant platform technology for medical device-to-cloud connectivity and data analysis, where she served since April 2023. Ms. Hoff has 30 years of experience in the medical device and diagnostics industries and in the commercialization of transformational technologies. Ms. Hoff has served in various senior leadership roles related to, or in, the medical device field, including serving as the Executive Director of Business Development and Strategy at DM Clinical Research and as Chief Executive Officer or as an executive at several medical device start-up companies. Ms. Hoff also founded Hoff Professional Services where she offered consulting and executive coaching services to medical device leaders. Earlier in her career, Ms. Hoff gained in-depth global experience in the aortic space, first at Guidant, leading Guidant&#8217;s endovascular expansion in Europe, and then as a Business Unit Leader at W. L. Gore, launching and leading the endovascular AAA and thoracic stent graft programs. She gained further senior executive experience at Medtronic as Vice President and General Manager, where she defined and drove a ten-fold expansion in Medtronic&#8217;s implantable cardiac diagnostic platform (now the LinQ product family). Ms. Hoff received her Bachelor of Arts in Managerial Studies and Psychology from </span><span style="text-transform: none; line-height: 12pt">Rice University.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">The Board of Directors has determined that Ms. Hoff should serve as a director of Artivion because of her extensive senior leadership and business experience in the medical device industry across public and private companies, including in the aortic </span><span style="text-transform: none; line-height: 12pt">technology space.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt"><b>J. Patrick Mackin</b></span><span style="text-transform: none; line-height: 12pt"> was named President and Chief Executive Officer of Artivion in September 2014. He was appointed to the Artivion Board of Directors in October 2014, and he was appointed Chairman of the Board of Directors in April 2015. Mr. Mackin has more than 30 years of experience in the medical device industry. Prior to joining Artivion, Mr.&#160;Mackin served as President of Cardiac Rhythm Disease Management, the then-largest operating division of Medtronic&#160;plc (NYSE: MDT) (&#8220;Medtronic&#8221;), from August 2007 to August 2014. At Medtronic, he previously held the positions of Vice President, Vascular, Western Europe and Vice President and General Manager, Endovascular Business Unit. Prior to joining Medtronic in 2002, Mr. Mackin worked for six years at Genzyme, Inc. (&#8220;Genzyme&#8221;), serving as Senior Vice President and General Manager for the Cardiovascular Surgery Business Unit and as Director of Sales, Surgical Products Division. Before joining Genzyme, Mr. Mackin spent four years at Deknatel/Snowden-Pencer, Inc. in various roles, and three years as a First Lieutenant in the U.S. Army. Mr. Mackin served as a director of Opsens, Inc. (TSXV: OPS and OTCQX: OPSSF), a fiber optic sensors manufacturer, from 2016 until that company was sold in December 2023. Mr. Mackin served as a director of Wright Medical Group N.V. (NASDAQ:&#160;WMGI) (&#8220;Wright Medical&#8221;), a global medical device company focused on extremities and biologics, from July 2018 until November 2020, when Wright Medical was acquired by Stryker Corporation (NYSE: SYK).</span><span style="text-transform: none; line-height: 12pt"> Mr. Mackin received an MBA from the Kellogg Graduate School of Management at Northwestern University and is a graduate of the U.S. Military Academy at </span><span style="text-transform: none; line-height: 12pt">West Point.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">The Board of Directors has determined that Mr.&#160;Mackin should serve as a director of Artivion because of his business acumen and substantial senior leadership experience in the global medical device industry. In addition, the Board of Directors believes that it is appropriate and valuable to have the President and Chief Executive Officer of Artivion serve as a member of the Board </span><span style="text-transform: none; line-height: 12pt">of Directors.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt"><b>Jon W. Salveson </b></span><span style="text-transform: none; line-height: 12pt">has served as a director of Artivion since May 2012. Mr. Salveson is the Vice Chairman, Investment Banking and Chairman of the Healthcare Investment Banking Group at Piper Sandler Companies (NYSE: PIPR), formerly Piper Jaffray Companies, a U.S. investment bank and asset management firm (&#8220;Piper Jaffray&#8221;). Mr. Salveson has served in his present position as Vice Chairman, Investment Banking since July 2010. Mr. Salveson was appointed Global Head of Investment Banking and a member of the Executive Committee of Piper Jaffray in 2004. He joined Piper Jaffray in 1993 as an associate, was elected Managing Director in 1999, and was named Group Head of Piper </span><span style="text-transform: none; line-height: 12pt">Jaffray&#8217;s international </span></p>

			</div>

		</div>
		<div style="page-break-before: always">
			<p style="margin: 0pt; font-size: 5pt">&#8203;</p>

		</div>
		<div class="qes_page" style="border-bottom: black 2pt solid; margin: auto; height: 990pt; width: 765pt; position: relative; overflow: hidden">
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 911.25pt; left: 45pt; width: 675pt; position: absolute; height: 33.75pt">
				<div style="display: table-cell; vertical-align: bottom; width: 675pt; height: 33.75pt">

				<!--[if IE]><TABLE><TR style=" width: 675pt; height: 33.75pt;"><TD vAlign="bottom" style=" width: 675pt; height: 33.75pt;"><![endif]-->
					<div style="font: 12pt/normal Times New Roman, Times, serif; margin: 0pt; text-transform: none; color: #000000; text-align: left">
						<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 0pt; border-collapse: collapse">
							<tr style="margin: 0; height: 0">
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>

							</tr>
							<tr style="min-height: 0pt">
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">ARTIVION, INC. | 2025 Proxy Statement</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">13</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 0pt; line-height: 0pt">&#8203;</p>

								</td>

							</tr>

						</table>

					</div>


				<!--[if IE]></TD></TR></TABLE><![endif]-->
				</div>

			</div>
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 45pt; left: 45pt; width: 675pt; position: absolute; height: 866.25pt">
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">healthcare investment banking group in 2001. Mr. Salveson served on the board of Asklepios Biopharmaceuticals, Inc., a private company specializing in gene therapy technologies, which was acquired by Bayer AG (ETR: BAYN) in 2020. Mr. Salveson also recently served on the Board of Directors of Nuwellis, Inc. (NASDAQ: NUWE), an early-stage medical device company, until 2023. Mr. Salveson received his undergraduate degree from St. Olaf College in 1987 and an M.M.M. in finance from the Kellogg Graduate School of Management at </span><span style="text-transform: none; line-height: 12pt">Northwestern University.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">The Board of Directors has determined that Mr. Salveson should serve as a director of Artivion because of his extensive experience in the healthcare industry and the medical technology sector, and, particularly, his extensive experience in strategic advisory roles for global healthcare companies in hundreds </span><span style="text-transform: none; line-height: 12pt">of transactions.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt"><b>Anthony B. Semedo </b></span><span style="text-transform: none; line-height: 12pt">has served as a director of Artivion since October 2021. Mr. Semedo has over 40 years of U.S. and international experience in the medical device industry. Until late 2019, Mr. Semedo served as Senior Vice President and President of Japan Operations at Medtronic, where he led multiple business units and functions. Through his tenure at Medtronic from 2002 to 2019, Mr. Semedo held several executive management positions, including Senior Vice President and President of the company&#8217;s Aortic, Peripheral, and Venous (APV) Division and Senior Vice President and President of Endovascular Innovations. During his time at Medtronic, Mr. Semedo also served as Vice President of Medtronic&#8217;s Japan Cardiovascular Business and as Global Vice President of Vascular Research and Development. Prior to 2002, Mr. Semedo spent time at Alaris Medical Systems, Eli Lilly &amp; Co., and Abbott Laboratories. Mr. Semedo received his Bachelor of Science in Engineering from the University </span><span style="text-transform: none; line-height: 12pt">of Massachusetts.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">The Board of Directors has determined that Mr. Semedo should serve as a director of Artivion because of his extensive knowledge of and extensive leadership experience in the medical device industry, including in the aortic </span><span style="text-transform: none; line-height: 12pt">technology space.</span></p>
				<p style="font: italic 11pt/normal Arial, sans-serif; margin: 4pt 0pt 8pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><b><i>Required Vote </i></b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">Nominees for election as directors will be elected by a plurality of the votes cast by the holders of shares entitled to vote in the election. Since there are nine directorships to be filled, the nine individuals receiving the most votes will be elected. Accordingly, abstentions and broker non-votes will not be relevant to </span><span style="text-transform: none; line-height: 12pt">the outcome.</span></p>
				<p style="font: italic 11pt/normal Arial, sans-serif; margin: 4pt 0pt 8pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><b><i>The Board of Directors&#8217; Recommendation </i></b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 4pt 0pt 8pt; text-transform: uppercase; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: uppercase"><b>THE BOARD OF DIRECTORS RECOMMENDS THAT YOU VOTE &#8220;FOR&#8221; EACH OF<br/> THE NINE NOMINEES FOR DIRECTOR LISTED IN THIS PROPOSAL ONE.</b></span></p>
				<p style="border-bottom: #7f7f7f 1pt solid; font: 12pt/normal Arial, sans-serif; margin: 4pt 0pt 15pt; text-transform: none; color: #2b4b74; text-indent: 0pt; text-align: left"><span style="text-transform: none"><b>CORPORATE GOVERNANCE AND BOARD OF DIRECTORS MATTERS</b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">Our Board of Directors believes that the purpose of corporate governance is to serve the interests of the Company and the Company&#8217;s stockholders in a manner that is consistent with the Board of Directors&#8217; fiduciary duties and the Company&#8217;s mission and core values. The Board of Directors has adopted and adheres to corporate governance practices that the Board of Directors and senior management believe promote this purpose, are sound, and represent best practices applicable to the Company. The Board of Directors reviews these practices on an ongoing basis and revises them </span><span style="text-transform: none; line-height: 12pt">as appropriate.</span></p>
				<p style="font: italic 11pt/normal Arial, sans-serif; margin: 4pt 0pt 8pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><b><i>Director Independence</i></b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">In connection with its annual review in the first quarter of 2025, and based on the information available to it, the Board of Directors determined that none of Mses. Borgstrom or Hoff, or Messrs. Ackerman, Bevevino, Bullock, Burbank, Salveson, or Semedo has or had a material relationship with Artivion and that each qualified as an independent director under NYSE </span><span style="text-transform: none; line-height: 12pt">Listing Standards.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">In addition to qualifying as &#8220;independent&#8221; within the meaning of Section 303A.02 of the NYSE Listing Company Standards, the Board of Directors has determined that each member of the Compensation Committee is a &#8220;non-employee director&#8221; within the meaning of Rule&#160;16b-3 under the Exchange Act. Further, in determining the independence of any director who will serve on the Compensation Committee, the Board of Directors considers all factors relevant to determining whether such director has a relationship with the Company that is material to the director&#8217;s ability to be independent from management in connection with the duties of a Compensation Committee member, including, but not limited to (i) the source of compensation of such director, including any consulting, advisory, or other compensatory fee paid by the Company to the director and (ii) whether such director is affiliated with the Company, one of its subsidiaries, or an affiliate of one of </span><span style="text-transform: none; line-height: 12pt">its subsidiaries. </span></p>

			</div>

		</div>
		<div style="page-break-before: always">
			<p style="margin: 0pt; font-size: 5pt">&#8203;</p>

		</div>
		<div class="qes_page" style="border-bottom: black 2pt solid; margin: auto; height: 990pt; width: 765pt; position: relative; overflow: hidden">
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 911.25pt; left: 45pt; width: 675pt; position: absolute; height: 33.75pt">
				<div style="display: table-cell; vertical-align: bottom; width: 675pt; height: 33.75pt">

				<!--[if IE]><TABLE><TR style=" width: 675pt; height: 33.75pt;"><TD vAlign="bottom" style=" width: 675pt; height: 33.75pt;"><![endif]-->
					<div style="font: 12pt/normal Times New Roman, Times, serif; margin: 0pt; text-transform: none; color: #000000; text-align: left">
						<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 0pt; border-collapse: collapse">
							<tr style="margin: 0; height: 0">
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>

							</tr>
							<tr style="min-height: 0pt">
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">ARTIVION, INC. | 2025 Proxy Statement</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">14</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 0pt; line-height: 0pt">&#8203;</p>

								</td>

							</tr>

						</table>

					</div>


				<!--[if IE]></TD></TR></TABLE><![endif]-->
				</div>

			</div>
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 45pt; left: 45pt; width: 675pt; position: absolute; height: 866.25pt">
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">In addition to qualifying as &#8220;independent&#8221; within the meaning of Section 303A.02 of the NYSE Listing Standards, the Board of Directors has determined that each member of the Audit Committee also meets the criteria of Section 303A.06 and Rule 10A-3 promulgated under the </span><span style="text-transform: none; line-height: 12pt">Exchange Act. </span></p>
				<p style="font: italic 11pt/normal Arial, sans-serif; margin: 4pt 0pt 8pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><b><i>The Board of Directors&#8217; Right to Retain Advisors</i></b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">The Board of Directors has authorized its committees to retain their own advisors, such as auditors, compensation consultants, search firms, legal counsel, and others, to the extent the applicable committee deems </span><span style="text-transform: none; line-height: 12pt">it appropriate. </span></p>
				<p style="font: italic 11pt/normal Arial, sans-serif; margin: 4pt 0pt 8pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><b><i>The Board of Directors&#8217; Leadership Structure</i></b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">Mr. Mackin, the President and Chief Executive Officer of Artivion, serves as Chairman of the Board of Directors. The Board of Directors believes that this structure promotes fluid communication and coordination between the Board of Directors and management. The Board of Directors also believes that Mr. Mackin is well-suited to fill both his management and Board of Directors roles and that the Board of Directors benefits from him serving these </span><span style="text-transform: none; line-height: 12pt">dual roles.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">To foster the Board of Directors&#8217; independence from management, the leadership structure of the Board of Directors also includes a Lead Director, a position held by an independent director. Mr. Burbank assumed the role of Lead Director in March 2021. The Lead Director has frequent contact with Mr. Mackin and other members of management on a broad range of matters and has additional corporate governance responsibilities for the Board of Directors, including presiding over all executive sessions of the Board. The Lead Director also serves as liaison between Mr. Mackin and the independent directors, approves meeting agendas and schedules to ensure there is sufficient time for discussion of all agenda items, approves certain information sent to the Board of Directors, and has the authority to call meetings of the independent directors. Stockholders can seek to directly consult with </span><span style="text-transform: none; line-height: 12pt">independent directors.</span></p>
				<p style="font: italic 11pt/normal Arial, sans-serif; margin: 4pt 0pt 8pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><b><i>The Board of Directors&#8217; Role in Risk Oversight</i></b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">The </span><span style="text-transform: none; line-height: 12pt">Board of Directors has an active role, as a whole and also at the committee level, in overseeing the management of our risks. Management is primarily responsible for risk management, and management reports directly to the committees and the Board of Directors with respect to risk management. The Board of Directors is responsible for general oversight of risks and regular review of information regarding our risks, including credit, information security (including cybersecurity and data privacy), the ethical and complaint use of artificial intelligence, liquidity, regulatory, sustainability, human capital, and operational risks. In its risk-oversight role, the Board of Directors periodically reviews the Company&#8217;s strategic plan, as well as an assessment of potential material risks facing </span><span style="text-transform: none; line-height: 12pt">the Company. </span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">In particular, the Compensation Committee is responsible for ensuring that our compensation policies and practices do not incent excessive or inappropriate risk-taking by employees or non-employee directors. The Compensation Committee also has oversight of Human Capital Management, and along with the Innovation and Healthcare Compliance and Audit Committees, culture. The Audit Committee, in coordination with Ernst &amp; Young LLP, our independent registered public accounting firm, is primarily responsible for oversight of our internal controls, operation of our internal audit, risk assessment, and risk management, including information security oversight, and various financial and compliance functions. The Audit Committee&#8217;s information security oversight role includes responsibility for overseeing the Company&#8217;s global information security and information technology risks, controls, and procedures and utilizing independent cybersecurity auditors to support that function where appropriate. More detail regarding the Audit Committee&#8217;s oversight of information security is located in the Report of the Audit Committee at page 24. The Corporate Governance Committee monitors risk by ensuring that proper corporate governance standards are maintained, that the Board of Directors is comprised of qualified directors, and that senior management is comprised of qualified executive officers. The Innovation and Healthcare Compliance Committee is primarily responsible for oversight of our healthcare compliance function, including our compliance with quality systems and regulatory assurance laws and regulations, as well as our compliance with other healthcare compliance laws and regulations. Together with the Audit Committee, the Innovation and Healthcare Compliance Committee also exercises oversight of Enterprise Risk Management and our compliance with certain laws and regulations, such as the European Union General Data Protection Regulation (&#8220;GDPR&#8221;) and the United States Foreign Corrupt Practices Act (&#8220;FCPA&#8221;), and policies such as our Code </span><span style="text-transform: none; line-height: 12pt">of Conduct.</span></p>

			</div>

		</div>
		<div style="page-break-before: always">
			<p style="margin: 0pt; font-size: 5pt">&#8203;</p>

		</div>
		<div class="qes_page" style="border-bottom: black 2pt solid; margin: auto; height: 990pt; width: 765pt; position: relative; overflow: hidden">
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 911.25pt; left: 45pt; width: 675pt; position: absolute; height: 33.75pt">
				<div style="display: table-cell; vertical-align: bottom; width: 675pt; height: 33.75pt">

				<!--[if IE]><TABLE><TR style=" width: 675pt; height: 33.75pt;"><TD vAlign="bottom" style=" width: 675pt; height: 33.75pt;"><![endif]-->
					<div style="font: 12pt/normal Times New Roman, Times, serif; margin: 0pt; text-transform: none; color: #000000; text-align: left">
						<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 0pt; border-collapse: collapse">
							<tr style="margin: 0; height: 0">
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>

							</tr>
							<tr style="min-height: 0pt">
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">ARTIVION, INC. | 2025 Proxy Statement</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">15</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 0pt; line-height: 0pt">&#8203;</p>

								</td>

							</tr>

						</table>

					</div>


				<!--[if IE]></TD></TR></TABLE><![endif]-->
				</div>

			</div>
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 45pt; left: 45pt; width: 675pt; position: absolute; height: 866.25pt">
				<p style="font: italic 11pt/normal Arial, sans-serif; margin: 0pt 0pt 8pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><b><i>Board of Directors and Committee Meetings, Annual Meeting of Stockholders, and Attendance</i></b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">During 2024, each director attended, either in person or virtually, at least 75% of the meetings of the Board of Directors and the committees of the Board of Directors on which the director served. In general, members of the Board of Directors become members of committees immediately following the Annual Meeting </span><span style="text-transform: none; line-height: 12pt">of Stockholders.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">The Board of Directors held twelve meetings during 2024. In addition, eight members of the Board of Directors attended the 2024 Annual Meeting of Stockholders, which was held virtually. The Company does not have a policy requiring directors to attend the annual meeting, but it encourages </span><span style="text-transform: none; line-height: 12pt">such attendance.</span></p>
				<p style="font: italic 11pt/normal Arial, sans-serif; margin: 4pt 0pt 8pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><b><i>Standing Committees of the Board of Directors; Committee Assignments</i></b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">During 2024, the Board of Directors had four standing committees: the Audit Committee; the Compensation Committee; the Corporate Governance Committee; and the Innovation and Healthcare Compliance Committee. During 2024, the Audit Committee met six times, the Compensation Committee met</span><span style="text-transform: none; line-height: 12pt"><b> </b></span><span style="text-transform: none; line-height: 12pt">eight times, the Corporate Governance Committee met five times, the Innovation and Healthcare Compliance Committee met four times, the Compensation Committee and the Corporate Governance Committee met jointly two times, and the Audit Committee and the Innovation and Healthcare Compliance Committee met jointly </span><span style="text-transform: none; line-height: 12pt">one time.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">The four standing committees are described below, and the following table lists the members of each of the standing committees as of the date of this </span><span style="text-transform: none; line-height: 12pt">Proxy Statement.</span></p>
				<div style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-align: center">
					<table style="margin: 4pt auto 10pt; table-layout: fixed; width: 630pt; border-collapse: collapse">
						<tr style="margin: 0; height: 0">
							<td style="border-width: 0; margin: 0; padding: 0; width: 291.25pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 82.5pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 97.5pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 80pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 78.75pt">


							</td>

						</tr>
						<tr style="min-height: 21.8pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Director</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Audit Committee</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Compensation Committee</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Corporate Governance Committee</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Innovation and Healthcare Compliance Committee</b></span></p>

							</td>

						</tr>
						<tr style="min-height: 8.1pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">J. Patrick Mackin, Chairman, President, and Chief Executive Officer</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 6.1pt; line-height: 6.1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 6.1pt; line-height: 6.1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 6.1pt; line-height: 6.1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 6.1pt; line-height: 6.1pt">&#8203;</p>

							</td>

						</tr>
						<tr style="min-height: 8.1pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Thomas F. Ackerman</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">Chair</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 6.1pt; line-height: 6.1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 6.1pt; line-height: 6.1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">&#8730;</span></p>

							</td>

						</tr>
						<tr style="min-height: 8.1pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Daniel J. Bevevino</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">&#8730;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">Chair</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 6.1pt; line-height: 6.1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 6.1pt; line-height: 6.1pt">&#8203;</p>

							</td>

						</tr>
						<tr style="min-height: 8.1pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Marna P. Borgstrom</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 6.1pt; line-height: 6.1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 6.1pt; line-height: 6.1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">&#8730;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">Chair</span></p>

							</td>

						</tr>
						<tr style="min-height: 8.1pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">James W. Bullock</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 6.1pt; line-height: 6.1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">&#8730;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 6.1pt; line-height: 6.1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">&#8730; </span></p>

							</td>

						</tr>
						<tr style="min-height: 7.35pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Jeffrey H. Burbank, Lead Director</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">&#8730;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 5.35pt; line-height: 5.35pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">Chair</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 5.35pt; line-height: 5.35pt">&#8203;</p>

							</td>

						</tr>
						<tr style="min-height: 10.8pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Elizabeth A. Hoff</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 8.8pt; line-height: 8.8pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 8.8pt; line-height: 8.8pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">&#8730;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">&#8730;</span></p>

							</td>

						</tr>
						<tr style="min-height: 9pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Jon W. Salveson</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 7pt; line-height: 7pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 7pt; line-height: 7pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">&#8730;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">&#8730;</span></p>

							</td>

						</tr>
						<tr style="min-height: 7.35pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Anthony B. Semedo</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 5.35pt; line-height: 5.35pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">&#8730;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 5.35pt; line-height: 5.35pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">&#8730;</span></p>

							</td>

						</tr>

					</table>

				</div>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt; font-style: italic"><b><i>Audit Committee </i></b></span><span style="text-transform: none; line-height: 12pt">&#8212; The Audit Committee operates under a written charter that sets out the committee&#8217;s functions and responsibilities. The Audit Committee currently consists of three non-employee directors: Mr. Ackerman, Chair, Mr. Bevevino, and Mr. Burbank. Mr. Ackerman, Mr. Bevevino, and Mr. Burbank served on the Audit Committee for all of 2024. Each of the members of the Audit Committee meets the independence requirements of Section&#160;303A.02 of the current NYSE Listing Standards and also meets the criteria of Section&#160;303A.06, as set forth in Rule 10A-3 promulgated under the Exchange Act, regarding listing standards related to audit committees. No member of the Audit Committee serves on the audit committee of more than three public companies. In addition, the Board of Directors has determined that all of the current members of the Audit Committee satisfy the definition of an &#8220;audit committee financial expert,&#8221; as promulgated by </span><span style="text-transform: none; line-height: 12pt">the SEC.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">The Audit Committee charter gives the Audit Committee the authority and responsibility for the appointment, retention, compensation, and oversight of Artivion&#8217;s independent registered public accounting firm, including preapproval of all audit and non-audit services to be performed by Artivion&#8217;s independent registered public accounting firm. The Audit Committee also oversees, and must review and approve, all significant related-party transactions. See Policies and Procedures for Review, Approval, or Ratification of Transactions with Related Parties beginning on page 18; see also the Report of the Audit Committee on </span><span style="text-transform: none; line-height: 12pt">page 23. </span></p>

			</div>

		</div>
		<div style="page-break-before: always">
			<p style="margin: 0pt; font-size: 5pt">&#8203;</p>

		</div>
		<div class="qes_page" style="border-bottom: black 2pt solid; margin: auto; height: 990pt; width: 765pt; position: relative; overflow: hidden">
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 911.25pt; left: 45pt; width: 675pt; position: absolute; height: 33.75pt">
				<div style="display: table-cell; vertical-align: bottom; width: 675pt; height: 33.75pt">

				<!--[if IE]><TABLE><TR style=" width: 675pt; height: 33.75pt;"><TD vAlign="bottom" style=" width: 675pt; height: 33.75pt;"><![endif]-->
					<div style="font: 12pt/normal Times New Roman, Times, serif; margin: 0pt; text-transform: none; color: #000000; text-align: left">
						<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 0pt; border-collapse: collapse">
							<tr style="margin: 0; height: 0">
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>

							</tr>
							<tr style="min-height: 0pt">
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">ARTIVION, INC. | 2025 Proxy Statement</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">16</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 0pt; line-height: 0pt">&#8203;</p>

								</td>

							</tr>

						</table>

					</div>


				<!--[if IE]></TD></TR></TABLE><![endif]-->
				</div>

			</div>
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 45pt; left: 45pt; width: 675pt; position: absolute; height: 866.25pt">
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">The </span><span style="text-transform: none; line-height: 12pt">Audit Committee:</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt 45pt; text-transform: none; color: #000000; text-indent: -22.5pt; text-align: justify"><!--[if IE]><FONT style=" width: 22.5pt; text-indent: -18.0pt; display: inline-block;"><![endif]--><span style="width: 22.5pt; text-indent: 0; display: inline-block"><span style="text-transform: none">&#8226;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Reviews the general scope of Artivion&#8217;s annual audit and the nature of services to be performed for Artivion in connection with it, acting as liaison between the Board of Directors and the independent registered public </span><span style="text-transform: none">accounting firm;</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt 45pt; text-transform: none; color: #000000; text-indent: -22.5pt; text-align: justify"><!--[if IE]><FONT style=" width: 22.5pt; text-indent: -18.0pt; display: inline-block;"><![endif]--><span style="width: 22.5pt; text-indent: 0; display: inline-block"><span style="text-transform: none">&#8226;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Reviews various Company policies, including those relating to accounting practices and internal control and information security systems </span><span style="text-transform: none">of Artivion; </span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt 45pt; text-transform: none; color: #000000; text-indent: -22.5pt; text-align: justify"><!--[if IE]><FONT style=" width: 22.5pt; text-indent: -18.0pt; display: inline-block;"><![endif]--><span style="width: 22.5pt; text-indent: 0; display: inline-block"><span style="text-transform: none">&#8226;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Reviews and monitors the performance of Artivion&#8217;s independent registered public accounting firm and is responsible for engaging or discharging Artivion&#8217;s independent registered public accounting firm and for assisting the Board of Directors in its oversight of risk management and legal and financial regulatory </span><span style="text-transform: none">requirements; and</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt 45pt; text-transform: none; color: #000000; text-indent: -22.5pt; text-align: justify"><!--[if IE]><FONT style=" width: 22.5pt; text-indent: -18.0pt; display: inline-block;"><![endif]--><span style="width: 22.5pt; text-indent: 0; display: inline-block"><span style="text-transform: none">&#8226;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Has the authority to, pursuant to its charter, delegate any of its decisions to a subcommittee of the Audit Committee consisting of two committee members or to the Chair alone, provided that a full report of any action taken is promptly made to the full </span><span style="text-transform: none">Audit Committee.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt; font-style: italic"><b><i>Compensation Committee </i></b></span><span style="text-transform: none; line-height: 12pt">&#8212; The Compensation Committee operates under a written charter that sets out the committee&#8217;s functions and responsibilities. The Compensation Committee currently consists of three non-employee directors: Mr. Bevevino, Chair, Mr. Bullock, and Mr. Semedo. Mr. Bevevino, Mr. Bullock, and Mr. Semedo served on the Compensation Committee for all of 2024. Each member of the Compensation Committee meets the independence requirements of Sections&#160;303A.02(a)(i) and (ii) of the current NYSE Listing Standards and is a non-employee director within the meaning of Rule 16b-3 under the </span><span style="text-transform: none; line-height: 12pt">Exchange Act. </span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">The </span><span style="text-transform: none; line-height: 12pt">Compensation Committee:</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt 45pt; text-transform: none; color: #000000; text-indent: -22.5pt; text-align: justify"><!--[if IE]><FONT style=" width: 22.5pt; text-indent: -18.0pt; display: inline-block;"><![endif]--><span style="width: 22.5pt; text-indent: 0; display: inline-block"><span style="text-transform: none">&#8226;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Reviews the performance of executive officers, including the Chief Executive Officer (in conjunction with the Corporate Governance Committee), and approves annual executive </span><span style="text-transform: none">officer compensation;</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt 45pt; text-transform: none; color: #000000; text-indent: -22.5pt; text-align: justify"><!--[if IE]><FONT style=" width: 22.5pt; text-indent: -18.0pt; display: inline-block;"><![endif]--><span style="width: 22.5pt; text-indent: 0; display: inline-block"><span style="text-transform: none">&#8226;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Oversees the issuance of stock options, restricted stock award</span><span style="text-transform: none">s, restricted stock units, performance stock units, and other stock rights and cash incentives under Artivion&#8217;s stock and </span><span style="text-transform: none">incentive plans; </span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt 45pt; text-transform: none; color: #000000; text-indent: -22.5pt; text-align: justify"><!--[if IE]><FONT style=" width: 22.5pt; text-indent: -18.0pt; display: inline-block;"><![endif]--><span style="width: 22.5pt; text-indent: 0; display: inline-block"><span style="text-transform: none">&#8226;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Approves, in conjunction with the Corporate Governance Committee and Board of Directors, separation packages </span><span style="text-transform: none">for officers; </span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt 45pt; text-transform: none; color: #000000; text-indent: -22.5pt; text-align: justify"><!--[if IE]><FONT style=" width: 22.5pt; text-indent: -18.0pt; display: inline-block;"><![endif]--><span style="width: 22.5pt; text-indent: 0; display: inline-block"><span style="text-transform: none">&#8226;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Reviews, approves, and certifies the performance metrics upon which a portion of the compensation of Artivion&#8217;s Chief Executive Officer and other executive officers </span><span style="text-transform: none">is based; </span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt 45pt; text-transform: none; color: #000000; text-indent: -22.5pt; text-align: justify"><!--[if IE]><FONT style=" width: 22.5pt; text-indent: -18.0pt; display: inline-block;"><![endif]--><span style="width: 22.5pt; text-indent: 0; display: inline-block"><span style="text-transform: none">&#8226;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Annually reviews, together with the Corporate Governance Committee, the Chief Executive Officer&#8217;s objectives and performance, recommends changes thereto, and together with the Corporate Governance Committee, sets the Chief Executive Officer&#8217;s compensation </span><span style="text-transform: none">package; and</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt 45pt; text-transform: none; color: #000000; text-indent: -22.5pt; text-align: justify"><!--[if IE]><FONT style=" width: 22.5pt; text-indent: -18.0pt; display: inline-block;"><![endif]--><span style="width: 22.5pt; text-indent: 0; display: inline-block"><span style="text-transform: none">&#8226;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Oversees certain aspects of the Company&#8217;s sustainability risks, including human </span><span style="text-transform: none">capital management. </span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">See Compensation Discussion and Analysis on page 26 for information concerning the Compensation Committee&#8217;s role, processes, and activities in overseeing </span><span style="text-transform: none; line-height: 12pt">executive compensation.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">Pursuant to its charter, the Compensation Committee has the authority to delegate any of its decisions to a subcommittee of the Compensation Committee consisting of two committee members, provided that a full report of any action taken is promptly made to the full </span><span style="text-transform: none; line-height: 12pt">Compensation Committee. </span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">The Compensation Committee has the power to retain, determine the terms of engagement and compensation of, and terminate any consultant that advises the </span><span style="text-transform: none; line-height: 12pt">Compensation Committee. </span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt; font-style: italic"><b><i>Corporate Governance Committee </i></b></span><span style="text-transform: none; line-height: 12pt">&#8212; The Corporate Governance Committee operates under a written charter that sets out the committee&#8217;s functions and responsibilities. The Corporate Governance Committee currently consists of four non-employee directors: Mr. Burbank, Chair, Ms. Borgstrom, Ms. Hoff, and Mr. Salveson. Mr. Burbank, Ms. Borgstrom, and Mr. Salveson served on the Corporate Governance Committee for all of 2024. Ms. Hoff was appointed to the Corporate Governance Committee effective March 1, 2024. Each of these individuals meets the independence requirements of Section&#160;303A.02 of the current NYSE </span><span style="text-transform: none; line-height: 12pt">Listing Standards. </span></p>

			</div>

		</div>
		<div style="page-break-before: always">
			<p style="margin: 0pt; font-size: 5pt">&#8203;</p>

		</div>
		<div class="qes_page" style="border-bottom: black 2pt solid; margin: auto; height: 990pt; width: 765pt; position: relative; overflow: hidden">
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 911.25pt; left: 45pt; width: 675pt; position: absolute; height: 33.75pt">
				<div style="display: table-cell; vertical-align: bottom; width: 675pt; height: 33.75pt">

				<!--[if IE]><TABLE><TR style=" width: 675pt; height: 33.75pt;"><TD vAlign="bottom" style=" width: 675pt; height: 33.75pt;"><![endif]-->
					<div style="font: 12pt/normal Times New Roman, Times, serif; margin: 0pt; text-transform: none; color: #000000; text-align: left">
						<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 0pt; border-collapse: collapse">
							<tr style="margin: 0; height: 0">
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>

							</tr>
							<tr style="min-height: 0pt">
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">ARTIVION, INC. | 2025 Proxy Statement</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">17</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 0pt; line-height: 0pt">&#8203;</p>

								</td>

							</tr>

						</table>

					</div>


				<!--[if IE]></TD></TR></TABLE><![endif]-->
				</div>

			</div>
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 45pt; left: 45pt; width: 675pt; position: absolute; height: 866.25pt">
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">The Corporate </span><span style="text-transform: none; line-height: 12pt">Governance Committee:</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt 45pt; text-transform: none; color: #000000; text-indent: -22.5pt; text-align: justify"><!--[if IE]><FONT style=" width: 22.5pt; text-indent: -18.0pt; display: inline-block;"><![endif]--><span style="width: 22.5pt; text-indent: 0; display: inline-block"><span style="text-transform: none">&#8226;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Recommends potential candidates for the Board </span><span style="text-transform: none">of Directors;</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt 45pt; text-transform: none; color: #000000; text-indent: -22.5pt; text-align: justify"><!--[if IE]><FONT style=" width: 22.5pt; text-indent: -18.0pt; display: inline-block;"><![endif]--><span style="width: 22.5pt; text-indent: 0; display: inline-block"><span style="text-transform: none">&#8226;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Oversees the annual self-evaluations of the Board of Directors, its committees, and </span><span style="text-transform: none">individual directors;</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt 45pt; text-transform: none; color: #000000; text-indent: -22.5pt; text-align: justify"><!--[if IE]><FONT style=" width: 22.5pt; text-indent: -18.0pt; display: inline-block;"><![endif]--><span style="width: 22.5pt; text-indent: 0; display: inline-block"><span style="text-transform: none">&#8226;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Recommends to the Board of Directors individuals for appointment as </span><span style="text-transform: none">executive officers; </span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt 45pt; text-transform: none; color: #000000; text-indent: -22.5pt; text-align: justify"><!--[if IE]><FONT style=" width: 22.5pt; text-indent: -18.0pt; display: inline-block;"><![endif]--><span style="width: 22.5pt; text-indent: 0; display: inline-block"><span style="text-transform: none">&#8226;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Oversees succession planning for the Board of Directors and officers, including the Chief </span><span style="text-transform: none">Executive Officer;</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt 45pt; text-transform: none; color: #000000; text-indent: -22.5pt; text-align: justify"><!--[if IE]><FONT style=" width: 22.5pt; text-indent: -18.0pt; display: inline-block;"><![endif]--><span style="width: 22.5pt; text-indent: 0; display: inline-block"><span style="text-transform: none">&#8226;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Evaluates each year, together with the Compensation Committee, the performance of Artivion&#8217;s Chief Executive Officer and sets the Chief Executive </span><span style="text-transform: none">Officer&#8217;s compensation;</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt 45pt; text-transform: none; color: #000000; text-indent: -22.5pt; text-align: justify"><!--[if IE]><FONT style=" width: 22.5pt; text-indent: -18.0pt; display: inline-block;"><![endif]--><span style="width: 22.5pt; text-indent: 0; display: inline-block"><span style="text-transform: none">&#8226;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Recommends to the Board of Directors how the other committees of the Board of Directors should be structured, which directors should be members of those committees, and which director should chair those </span><span style="text-transform: none">committees; and</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt 45pt; text-transform: none; color: #000000; text-indent: -22.5pt; text-align: justify"><!--[if IE]><FONT style=" width: 22.5pt; text-indent: -18.0pt; display: inline-block;"><![endif]--><span style="width: 22.5pt; text-indent: 0; display: inline-block"><span style="text-transform: none">&#8226;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Reviews and makes recommendations to the Board of Directors regarding the development of, and compliance with, the Company&#8217;s corporate governance guidelines, sustainability risk-mitigation efforts, and other governance policies, procedures, </span><span style="text-transform: none">and practices.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt; font-style: italic"><b><i>Innovation and Healthcare Compliance Committee </i></b></span><span style="text-transform: none; line-height: 12pt">&#8212; The Innovation and Healthcare Compliance Committee operates under a written charter that sets out the committee&#8217;s functions and responsibilities. The Innovation and Healthcare Compliance Committee currently consists of six non-employee directors: Ms. Borgstrom, Chair, Mr. Ackerman, Mr. Bullock, Ms. Hoff, Mr. Salveson, and Mr. Semedo. Mses. Borgstrom and Hoff and Messrs. Ackerman, Bullock, Salveson, and Semedo each served on the Innovation and Healthcare Compliance Committee for all of 2024. Each of these individuals meets the independence requirements of Section&#160;303A.02 of the current NYSE Listing Standards. The charter of the Innovation and Healthcare Compliance Committee requires that a majority of its members be independent.  </span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">The Innovation and Healthcare </span><span style="text-transform: none; line-height: 12pt">Compliance Committee:</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt 45pt; text-transform: none; color: #000000; text-indent: -22.5pt; text-align: justify"><!--[if IE]><FONT style=" width: 22.5pt; text-indent: -18.0pt; display: inline-block;"><![endif]--><span style="width: 22.5pt; text-indent: 0; display: inline-block"><span style="text-transform: none">&#8226;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Assists the Board of Directors in the general oversight of the Company&#8217;s ongoing scientific and technological innovation activities and initiatives, including research and development (&#8220;R&amp;D&#8221;), clinical, regulatory, and intellectual </span><span style="text-transform: none">property matters;</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt 45pt; text-transform: none; color: #000000; text-indent: -22.5pt; text-align: justify"><!--[if IE]><FONT style=" width: 22.5pt; text-indent: -18.0pt; display: inline-block;"><![endif]--><span style="width: 22.5pt; text-indent: 0; display: inline-block"><span style="text-transform: none">&#8226;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Assists the Company in its oversight of Artivion&#8217;s compliance with healthcare laws and regulations, including regulations and laws related to regulatory affairs and quality assurance, and general healthcare compliance, such as the </span><span style="text-transform: none">Anti-Kickback Statute;</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt 45pt; text-transform: none; color: #000000; text-indent: -22.5pt; text-align: justify"><!--[if IE]><FONT style=" width: 22.5pt; text-indent: -18.0pt; display: inline-block;"><![endif]--><span style="width: 22.5pt; text-indent: 0; display: inline-block"><span style="text-transform: none">&#8226;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Receives periodic reports from the Company&#8217;s senior management regarding quality and </span><span style="text-transform: none">regulatory compliance;</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt 45pt; text-transform: none; color: #000000; text-indent: -22.5pt; text-align: justify"><!--[if IE]><FONT style=" width: 22.5pt; text-indent: -18.0pt; display: inline-block;"><![endif]--><span style="width: 22.5pt; text-indent: 0; display: inline-block"><span style="text-transform: none">&#8226;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Provides input into certain regulatory affairs, quality assurance, and healthcare compliance </span><span style="text-transform: none">policies; and</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt 45pt; text-transform: none; color: #000000; text-indent: -22.5pt; text-align: justify"><!--[if IE]><FONT style=" width: 22.5pt; text-indent: -18.0pt; display: inline-block;"><![endif]--><span style="width: 22.5pt; text-indent: 0; display: inline-block"><span style="text-transform: none">&#8226;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Assists, jointly with the Audit Committee, in the oversight of the Company&#8217;s enterprise risk assessment and compliance with certain policies and procedures, such as the Company&#8217;s Code of Conduct and policies with respect to GDPR and </span><span style="text-transform: none">the FCPA.</span></p>
				<p style="border-bottom: #7f7f7f 1pt solid; font: 12pt/normal Arial, sans-serif; margin: 4pt 0pt 15pt; text-transform: none; color: #2b4b74; text-indent: 0pt; text-align: left"><span style="text-transform: none"><b>Procedures for Stockholders Who Wish to Submit Recommendations to the Board of Directors</b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">Stockholders may recommend potential candidates for director to the Corporate Governance Committee, in which case the Committee will consider whether to recommend that the Board of Directors nominate such person for election as a director. Stockholders who wish to recommend a director candidate should submit the candidate&#8217;s name and background information in writing, as well as a written statement from the individual of his or her consent to be named as a candidate and, if nominated and elected, to serve as a director. Stockholders should submit this information by following the procedures set forth below at Communication with the Board of Directors and its Committees on </span><span style="text-transform: none; line-height: 12pt">page 20. </span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 9pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">The policy of the Corporate Governance Committee is to give the same consideration to nominees recommended by stockholders that it gives to individuals whose names are submitted by management or non-employee directors, including whether the recommended candidate meets our minimum qualifications for directors, possesses appropriate skills and qualities, and whether requesting additional information or an interview is appropriate. When reviewing a potential candidate, the Corporate Governance Committee considers, among other things, demonstrated character, judgment, </span><span style="text-transform: none; line-height: 12pt">relevant business, </span></p>

			</div>

		</div>
		<div style="page-break-before: always">
			<p style="margin: 0pt; font-size: 5pt">&#8203;</p>

		</div>
		<div class="qes_page" style="border-bottom: black 2pt solid; margin: auto; height: 990pt; width: 765pt; position: relative; overflow: hidden">
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 911.25pt; left: 45pt; width: 675pt; position: absolute; height: 33.75pt">
				<div style="display: table-cell; vertical-align: bottom; width: 675pt; height: 33.75pt">

				<!--[if IE]><TABLE><TR style=" width: 675pt; height: 33.75pt;"><TD vAlign="bottom" style=" width: 675pt; height: 33.75pt;"><![endif]-->
					<div style="font: 12pt/normal Times New Roman, Times, serif; margin: 0pt; text-transform: none; color: #000000; text-align: left">
						<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 0pt; border-collapse: collapse">
							<tr style="margin: 0; height: 0">
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>

							</tr>
							<tr style="min-height: 0pt">
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">ARTIVION, INC. | 2025 Proxy Statement</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">18</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 0pt; line-height: 0pt">&#8203;</p>

								</td>

							</tr>

						</table>

					</div>


				<!--[if IE]></TD></TR></TABLE><![endif]-->
				</div>

			</div>
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 45pt; left: 45pt; width: 675pt; position: absolute; height: 900pt">
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 9pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">functional, and industry experience, degree of intellectual and business acumen, and the overall diversity of backgrounds and experiences of the Board of Directors. The Board of Directors and the Corporate Governance Committee believe it is important that the members of the Board of Directors represent a broad range of backgrounds and viewpoints. The Corporate Governance Committee&#8217;s process for identifying and evaluating nominees typically involves consideration of external candidates, including self-nominees, upon a vacancy or at a regularly scheduled meeting (generally, its meeting held in the first quarter of the year), and where appropriate, internal discussions, review of information concerning candidates, and interviews of selected candidates. From time to time, the Corporate Governance Committee has also engaged one or more executive search consulting firms to assist in the identification and recruitment of potential </span><span style="text-transform: none; line-height: 12pt">director candidates.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 9pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">The current Board of Directors&#8217; policy requires each director to offer to voluntarily resign upon a change in such director&#8217;s principal employment or line of business. The Corporate Governance Committee will then review whether such director continues to meet the needs of the Board of Directors and whether to make a recommendation to the Board of Directors that it should accept the director&#8217;s offer to resign. Upon Ms. Hoff&#8217;s change in principal employer in July 2024, from the position she held at the time she was reelected as a director by the stockholders in May 2024, Ms. Hoff tendered to the Board of Directors her offer of resignation. The Corp</span><span style="text-transform: none; line-height: 12pt">orate Governance Committee considered Ms. Hoff&#8217;s offer to resign and determined that it was in the best interests of Artivion for Ms. Hoff to continue serving on the Board of Directors following her change in principal employer and/or occupation.  </span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 9pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">The current Board of Directors&#8217; policy also limits the number of other public company boards on which Artivion directors may serve. Non-employee directors may serve on no more than three public company boards in addition to service on the Company&#8217;s Board of Directors, and the Chief Executive Officer&#8217;s service on the board of any other organization is restricted by his employment agreement with the Company and is subject to prior approval by the Board </span><span style="text-transform: none; line-height: 12pt">of Directors.</span></p>
				<p style="border-bottom: #7f7f7f 1pt solid; font: 12pt/normal Arial, sans-serif; margin: 4pt 0pt 15pt; text-transform: none; color: #2b4b74; text-indent: 0pt; text-align: left"><span style="text-transform: none"><b>Artivion&#8217;s Code of Conduct</b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 9pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">Artivion has established a Code of Conduct that: clarifies the Company&#8217;s standards of conduct, including in potentially challenging situations; makes clear that Artivion expects all employees, executive officers, and non-employee directors to abide by applicable legal and regulatory requirements and to understand and appreciate the ethical considerations of their decisions; and reaffirms the Company&#8217;s long-standing commitment to a culture of corporate and individual accountability and responsibility for the highest ethical and </span><span style="text-transform: none; line-height: 12pt">business practices.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 9pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">In addition to the Code of Conduct, the Company&#8217;s Chief Executive Officer, Chief Financial Officer, Chief Accounting Officer, Treasurer, Controller, Assistant Controller, and all other senior financial officers are also subject to the Company&#8217;s Code of Ethics for Senior Financial Officers. In the event that Artivion amends or waives any of the provisions of the Code of Conduct or Code of Ethics for Senior Financial Officers applicable to its Chief Executive Officer, Chief Financial Officer, Chief Accounting Officer, Treasurer, Controller, or Assistant Controller, the Company will disclose such information on the </span><span style="text-transform: none; line-height: 12pt">Company&#8217;s website.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 9pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">Artivion&#8217;s Code of Conduct and Code of Ethics for Senior Financial Officers, which are reviewed periodically, are published on the Company&#8217;s website </span><span style="text-transform: none; line-height: 12pt">at</span><span style="text-transform: none; line-height: 12pt; font-style: italic"><i> </i></span><span style="text-transform: none; line-height: 12pt">https://investors.artivion.com/corporate-governance/cryolifes-code-conduct.</span></p>
				<p style="border-bottom: #7f7f7f 1pt solid; font: 12pt/normal Arial, sans-serif; margin: 4pt 0pt 15pt; text-transform: none; color: #2b4b74; text-indent: 0pt; text-align: left"><span style="text-transform: none"><b>Corporate Responsibility</b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">In the second quarter of 2025, Artivion expects to publish its updated annual Corporate Responsibility Report, which highlights the Company&#8217;s sustainability initiatives, goals, and efforts (&#8220;Sustainability Efforts&#8221;). The Corporate Responsibility Report details several of Artivion&#8217;s Sustainability Efforts, including, but not limited to: (1) environmental initiatives to drive sustainability and limit Artivion&#8217;s carbon footprint, including a disclosure relative to the Task Force on Climate-Related Financial Disclosures; (2) initiatives to create a welcoming and empowering workplace for every member of the global team as they strive to fulfill Artivion&#8217;s mission to make leading-edge aortic technologies available to patients around the world; and (3) Board of Directors level initiatives to enhance the breadth of backgrounds and experiences represented on the Board and throughout the workforce, Board refreshment, and Board or Board committee oversight of some of the Company&#8217;s sustainability initiatives, including human capital management. The annual Corporate Responsibility Report is available on the Company&#8217;s website </span><span style="text-transform: none; line-height: 12pt">at https://investors.artivion.com/corporate-responsibility-report-esg. </span></p>
				<p style="border-bottom: #7f7f7f 1pt solid; font: 12pt/normal Arial, sans-serif; margin: 4pt 0pt 13pt; text-transform: none; color: #2b4b74; text-indent: 0pt; text-align: left"><span style="text-transform: none"><b>Policies and Procedures for Review, Approval, or Ratification of Transactions with Related Parties</b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">The Board of Directors has adopted policies and procedures for review, approval, or ratification of transactions with </span><span style="text-transform: none; line-height: 12pt">related parties.</span></p>

			</div>

		</div>
		<div style="page-break-before: always">
			<p style="margin: 0pt; font-size: 5pt">&#8203;</p>

		</div>
		<div class="qes_page" style="border-bottom: black 2pt solid; margin: auto; height: 990pt; width: 765pt; position: relative; overflow: hidden">
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 911.25pt; left: 45pt; width: 675pt; position: absolute; height: 33.75pt">
				<div style="display: table-cell; vertical-align: bottom; width: 675pt; height: 33.75pt">

				<!--[if IE]><TABLE><TR style=" width: 675pt; height: 33.75pt;"><TD vAlign="bottom" style=" width: 675pt; height: 33.75pt;"><![endif]-->
					<div style="font: 12pt/normal Times New Roman, Times, serif; margin: 0pt; text-transform: none; color: #000000; text-align: left">
						<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 0pt; border-collapse: collapse">
							<tr style="margin: 0; height: 0">
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>

							</tr>
							<tr style="min-height: 0pt">
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">ARTIVION, INC. | 2025 Proxy Statement</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">19</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 0pt; line-height: 0pt">&#8203;</p>

								</td>

							</tr>

						</table>

					</div>


				<!--[if IE]></TD></TR></TABLE><![endif]-->
				</div>

			</div>
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 45pt; left: 45pt; width: 675pt; position: absolute; height: 866.25pt">
				<p style="font: italic 11pt/normal Arial, sans-serif; margin: 0pt 0pt 8pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><b><i>Types of Transactions Covered</i></b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">It is our policy to enter into or ratify related party transactions only when the Board of Directors, acting through the Audit Committee or as otherwise in line with the Company&#8217;s policies described herein, determines that the related party transaction in question is in, or is not inconsistent with, the best interests of Artivion and its stockholders. We follow the policies and procedures below for any transaction in which we are, or are to be, a participant and the annual amount involved exceeds $50,000 and in which any related party, as defined below, had, has, or will have a direct or indirect interest. Pursuant to the policy, additional Audit Committee approval is not required for compensatory arrangements with an executive officer or non-employee director that are approved or ratified by the Compensation Committee or compensation received under our employee benefit plans that are available to </span><span style="text-transform: none; line-height: 12pt">all employees.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">The Company subjects the following related parties to these policies: non-employee directors (and nominees); executive officers; beneficial owners of more than 5% of our stock; any immediate family members of these persons; and any entity in which any of these persons is employed, or is a general partner or principal, or has a similar position, or in which the person has a 10% or greater beneficial </span><span style="text-transform: none; line-height: 12pt">ownership interest. </span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">Pursuant to the procedures described above, the Audit Committee ratified one transaction with a related party for 2024: Maxi Tyrs, the spouse of Florian Tyrs, who had been designated as an executive officer of the Company for the 2024 fiscal year, is employed by the Company&#8217;s Germany-based subsidiary, JOTEC GmbH. Ms. Tyrs served as JOTEC&#8217;s Director of Human Resources in EMEA during 2024 and JOTEC&#8217;s Director, Global Talent Acquisition and Employer Branding as of January 1, 2025. Ms. Tyrs earns approximately $204,000 in total annual compensation, which includes, as applicable, salary, any annual and special bonuses, and the value of any long-term incentive equity award granted in the applicable fiscal year. She also participates in general welfare and benefit plans that are available to similarly situated employees. As of January 1, 2025, Mr. Tyrs is no longer classified as an executive officer of </span><span style="text-transform: none; line-height: 12pt">the Company.</span></p>
				<p style="font: italic 11pt/normal Arial, sans-serif; margin: 4pt 0pt 8pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><b><i>Standards Applied and Persons Responsible for Approving Related Party Transactions</i></b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">The Corporate Secretary is responsible for submitting to the Audit Committee for its advance review and approval any related party transaction, other than ongoing transactions, into which we propose to enter. If the Corporate Secretary determines that it is not practicable or desirable to wait until the next regularly scheduled Audit Committee meeting, the Corporate Secretary will submit the related party transaction for approval or ratification to the Chair of the Audit Committee, who possesses delegated authority to act between Audit Committee meetings. The Chair will report any action the Chair takes under this delegated authority to the Audit Committee at its next regularly scheduled meeting and seek ratification of such approval. If any related party transaction occurs before the Audit Committee has approved it, the Corporate Secretary will submit the transaction to the Audit Committee for ratification as soon as reasonably practicable. If the Audit Committee does not ratify the transaction, the Audit Committee will direct management as to what action it proposes management take regarding </span><span style="text-transform: none; line-height: 12pt">the transaction.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">When considering a related party transaction, the Audit Committee will examine all factors it deems relevant. The Audit Committee, or its Chair, will approve only those transactions that they have determined in good faith are in the best interests of Artivion and </span><span style="text-transform: none; line-height: 12pt">its stockholders.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">The Corporate Secretary may delegate her duties under the policy to another officer of Artivion if the Corporate Secretary gives notice of the delegation to the Audit Committee at a regularly scheduled Audit </span><span style="text-transform: none; line-height: 12pt">Committee meeting. </span></p>
				<p style="font: italic 11pt/normal Arial, sans-serif; margin: 4pt 0pt 8pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><b><i>Review of Ongoing Transactions</i></b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">At least once per year, the Audit Committee reviews all related party transactions that are ongoing and have a remaining term of more than six months or remaining amounts payable to or receivable from Artivion of more than $50,000 annually. Based on all relevant facts and circumst</span><span style="text-transform: none; line-height: 12pt">ances, the Audit Committee will determine whether it is in, or not inconsistent with, the best interests of Artivion and its stockholders to continue, modify, or terminate the ongoing related </span><span style="text-transform: none; line-height: 12pt">party transaction.</span></p>
				<p style="border-bottom: #7f7f7f 1pt solid; font: 12pt/normal Arial, sans-serif; margin: 4pt 0pt 15pt; text-transform: none; color: #2b4b74; text-indent: 0pt; text-align: left"><span style="text-transform: none"><b>Compensation Committee Interlocks and Insider Participation</b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">None of our executive officers or employees have at any time, other than as noted herein and in the Policies and Procedures for Review, Approval, or Ratification of Transactions with Related Parties section above, had any relationship requiring disclosure by the Company. In addition, none of our executive officers currently serve, or served during fiscal 2024, as a member of the compensation committee of any other company that has or had an executive </span><span style="text-transform: none; line-height: 12pt">officer serving </span></p>

			</div>

		</div>
		<div style="page-break-before: always">
			<p style="margin: 0pt; font-size: 5pt">&#8203;</p>

		</div>
		<div class="qes_page" style="border-bottom: black 2pt solid; margin: auto; height: 990pt; width: 765pt; position: relative; overflow: hidden">
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 911.25pt; left: 45pt; width: 675pt; position: absolute; height: 33.75pt">
				<div style="display: table-cell; vertical-align: bottom; width: 675pt; height: 33.75pt">

				<!--[if IE]><TABLE><TR style=" width: 675pt; height: 33.75pt;"><TD vAlign="bottom" style=" width: 675pt; height: 33.75pt;"><![endif]-->
					<div style="font: 12pt/normal Times New Roman, Times, serif; margin: 0pt; text-transform: none; color: #000000; text-align: left">
						<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 0pt; border-collapse: collapse">
							<tr style="margin: 0; height: 0">
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>

							</tr>
							<tr style="min-height: 0pt">
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">ARTIVION, INC. | 2025 Proxy Statement</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">20</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 0pt; line-height: 0pt">&#8203;</p>

								</td>

							</tr>

						</table>

					</div>


				<!--[if IE]></TD></TR></TABLE><![endif]-->
				</div>

			</div>
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 45pt; left: 45pt; width: 675pt; position: absolute; height: 894pt">
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">as a member of our Board of Directors. None of our executive officers currently serve, or served during fiscal 2024, as a member of the board of directors of any other company that has or had an executive officer serving as a member of our </span><span style="text-transform: none; line-height: 12pt">Compensation Committee.</span></p>
				<p style="border-bottom: #7f7f7f 1pt solid; font: 12pt/normal Arial, sans-serif; margin: 4pt 0pt 15pt; text-transform: none; color: #2b4b74; text-indent: 0pt; text-align: left"><span style="text-transform: none"><b>Communication with the Board of Directors and Its Committees</b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">Interested parties may communicate with the Board of Directors, the Lead Director, the non-employee directors as a group, committee chairs, committees, and individual directors by directing communications to the Corporate Secretary, who will forward them as appropriate, unless they clearly constitute unsolicited general advertising or inappropriate material. Please send all communications in care of Jean F. Holloway, General Counsel and Corporate Secretary, Artivion,&#160;Inc., 1655 Roberts Boulevard, NW, Kennesaw, </span><span style="text-transform: none; line-height: 12pt">Georgia 30144.</span></p>
				<p style="border-bottom: #7f7f7f 1pt solid; font: 12pt/normal Arial, sans-serif; margin: 4pt 0pt 15pt; text-transform: none; color: #2b4b74; text-indent: 0pt; text-align: left"><span style="text-transform: none"><b>Availability of Corporate Governance Documents</b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">You may view current copies of the charters of the Audit, Compensation, Corporate Governance, and Innovation and Healthcare Compliance Committees, as well as the Company&#8217;s Code of Conduct and Corporate Governance Guidelines, on Artivion&#8217;s website </span><span style="text-transform: none; line-height: 12pt">at</span><span style="text-transform: none; line-height: 12pt; font-style: italic"><i> </i></span><span style="text-transform: none; line-height: 12pt">https://investors.artivion.com/corporate-governance/governance-highlights.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt; font-style: italic"><i>Notwithstanding anything to the contrary set forth in any of Artivion&#8217;s filings under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), or the Exchange Act that might incorporate other Artivion filings, including this Proxy Statement, in whole or in part, neither of the Reports of the Audit Committee and the Compensation Committee, set forth below, or any information contained on or accessible from our website or any other website shall be incorporated by reference into any </i></span><span style="text-transform: none; line-height: 12pt; font-style: italic"><i>such filings.</i></span></p>

			</div>

		</div>
		<div style="page-break-before: always">
			<p style="margin: 0pt; font-size: 5pt">&#8203;</p>

		</div>
		<div class="qes_page" style="border-bottom: black 2pt solid; margin: auto; height: 990pt; width: 765pt; position: relative; overflow: hidden">
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 911.25pt; left: 45pt; width: 675pt; position: absolute; height: 33.75pt">
				<div style="display: table-cell; vertical-align: bottom; width: 675pt; height: 33.75pt">

				<!--[if IE]><TABLE><TR style=" width: 675pt; height: 33.75pt;"><TD vAlign="bottom" style=" width: 675pt; height: 33.75pt;"><![endif]-->
					<div style="font: 12pt/normal Times New Roman, Times, serif; margin: 0pt; text-transform: none; color: #000000; text-align: left">
						<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 0pt; border-collapse: collapse">
							<tr style="margin: 0; height: 0">
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>

							</tr>
							<tr style="min-height: 0pt">
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">ARTIVION, INC. | 2025 Proxy Statement</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">21</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 0pt; line-height: 0pt">&#8203;</p>

								</td>

							</tr>

						</table>

					</div>


				<!--[if IE]></TD></TR></TABLE><![endif]-->
				</div>

			</div>
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 45pt; left: 45pt; width: 675pt; position: absolute; height: 866.25pt">
				<p style="font: 14pt/normal Arial, sans-serif; margin: 0pt 0pt 15pt; text-transform: none; color: #2b4b74; text-indent: 0pt; text-align: left"><span style="text-transform: none"><b>DIRECTOR COMPENSATION</b></span></p>
				<p style="border-bottom: #7f7f7f 1pt solid; font: 12pt/normal Arial, sans-serif; margin: 4pt 0pt 15pt; text-transform: none; color: #2b4b74; text-indent: 0pt; text-align: left"><span style="text-transform: none"><b>Elements of Non-Employee Director Compensation</b></span></p>
				<p style="font: italic 11pt/normal Arial, sans-serif; margin: 4pt 0pt 8pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><b><i>Restricted Stock Grants </i></b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">A portion of the non-employee directors&#8217; annual compensation is issued as restricted stock. The shares of restricted stock are issued each year generally following the Annual Meeting of Stockholders. With respect to 2024 grants, the Compensation and Corporate Governance Committees recommended, and the Board of Directors approved, a grant date value of $150,000 per non-employee director, and in May 2024, the Company granted 6,289 shares of restricted stock to each of the non-employee directors serving at the time of grant, which will vest on May 30, 2025. The amount and terms of the grants are subject to periodic reevaluation jointly by the Compensation and Corporate Governance Committees. All equity grants to non-employee directors in 2024 were made pursuant to the Amended and Restated Artivion, Inc. 2020 Equity and Cash Incentive Plan (the &#8220;2020 ECIP&#8221;). A non-employee director will forfeit any unvested portion of the award if s/he ceases to serve as a director, except under certain circumstances as described within the </span><span style="text-transform: none; line-height: 12pt">2020 ECIP.</span></p>
				<p style="font: italic 11pt/normal Arial, sans-serif; margin: 4pt 0pt 8pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><b><i>Board of Directors&#8217; Retainer and Committee Chair and Membership Fees</i></b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">Absent exceptional circumstances, every other year, the Compensation and Corporate Governance Committees each consider whether to adjust non-employee director compensation and recommend those adjustments, if any, to the Board </span><span style="text-transform: none; line-height: 12pt">of Directors.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">Each of the non-employee directors of Artivion receives an annual cash retainer for service on the Board of Directors, service on committees of the Board of Directors, service as Chair of a committee of the Board of Directors, and service as Lead Director, as applicable and as noted in the table below. Artivion pays all cash retainers on a prorated </span><span style="text-transform: none; line-height: 12pt">monthly basis.</span></p>
				<div style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-align: center">
					<table style="margin: 4pt auto 10pt; table-layout: fixed; width: 605pt; border-collapse: collapse">
						<tr style="margin: 0; height: 0">
							<td style="border-width: 0; margin: 0; padding: 0; width: 215pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 195pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 195pt">


							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td colspan="3" style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>2024 Board of Director Retainers</b></span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Annual Board Service</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">$55,000</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Lead Director</span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt">(1)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">$40,000</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>

						</tr>

					</table>

				</div>
				<div style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-align: center">
					<table style="margin: 4pt auto 10pt; table-layout: fixed; width: 605pt; border-collapse: collapse">
						<tr style="margin: 0; height: 0">
							<td style="border-width: 0; margin: 0; padding: 0; width: 215pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 195pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 195pt">


							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Committee</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Committee Chair Retainer</b></span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt"><b>(2)</b></sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Committee Membership Retainer</b></span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Audit</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">$20,000</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">$10,000</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Compensation</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">$20,000</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">$7,500</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Corporate Governance</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">$10,000</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">$5,000</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Innovation and Healthcare Compliance</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">$10,000</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">$5,000</span></p>

							</td>

						</tr>

					</table>

				</div>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 2pt 48.75pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(1)</sup></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">In addition to annual Board of Director </span><span style="text-transform: none">service retainer.</span></p>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 8pt 48.75pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(2)</sup></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Includes committee </span><span style="text-transform: none">membership retainer.</span></p>

			</div>

		</div>
		<div style="page-break-before: always">
			<p style="margin: 0pt; font-size: 5pt">&#8203;</p>

		</div>
		<div class="qes_page" style="border-bottom: black 2pt solid; margin: auto; height: 990pt; width: 765pt; position: relative; overflow: hidden">
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 911.25pt; left: 45pt; width: 675pt; position: absolute; height: 33.75pt">
				<div style="display: table-cell; vertical-align: bottom; width: 675pt; height: 33.75pt">

				<!--[if IE]><TABLE><TR style=" width: 675pt; height: 33.75pt;"><TD vAlign="bottom" style=" width: 675pt; height: 33.75pt;"><![endif]-->
					<div style="font: 12pt/normal Times New Roman, Times, serif; margin: 0pt; text-transform: none; color: #000000; text-align: left">
						<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 0pt; border-collapse: collapse">
							<tr style="margin: 0; height: 0">
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>

							</tr>
							<tr style="min-height: 0pt">
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">ARTIVION, INC. | 2025 Proxy Statement</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">22</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 0pt; line-height: 0pt">&#8203;</p>

								</td>

							</tr>

						</table>

					</div>


				<!--[if IE]></TD></TR></TABLE><![endif]-->
				</div>

			</div>
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 45pt; left: 45pt; width: 675pt; position: absolute; height: 866.25pt">
				<p style="border-bottom: #7f7f7f 1pt solid; font: 12pt/normal Arial, sans-serif; margin: 0pt 0pt 15pt; text-transform: none; color: #2b4b74; text-indent: 0pt; text-align: left"><span style="text-transform: none"><b>Fiscal</b></span><span style="font-variant: small-caps"><b> 2024 </b></span><span style="text-transform: none"><b>Director Compensation</b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none">The following table provides compensation information for the one-year period ended December 31, 2024 for each person who was a member of our Board of Directors in 2024, other than J. </span><span style="text-transform: none">Patrick Mackin.</span></p>
				<div style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-align: center">
					<table style="margin: 4pt auto 10pt; table-layout: fixed; width: 417.5pt; border-collapse: collapse">
						<tr style="margin: 0; height: 0">
							<td style="border-width: 0; margin: 0; padding: 0; width: 127.5pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 135pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 85pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 70pt">


							</td>

						</tr>
						<tr style="min-height: 22.5pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Name</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Retainers Earned or<br/>Paid in Cash</b></span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt"><b>(1)</b></sup><span style="text-transform: none"><b><br/>($)</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Annual Stock<br/>Awards</b></span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt"><b>(2)</b></sup><span style="text-transform: none"><b><br/>($)</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Total<br/>($)</b></span></p>

							</td>

						</tr>
						<tr style="min-height: 8.05pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">(a)</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">(b)</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">(c)</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">(d)</span></p>

							</td>

						</tr>
						<tr style="min-height: 13.3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Thomas F. Ackerman</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">80,000</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">149,993</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">229,993</span></p>

							</td>

						</tr>
						<tr style="min-height: 13.3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Daniel J. Bevevino</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">85,000</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">149,993</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">234,993</span></p>

							</td>

						</tr>
						<tr style="min-height: 13.3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Marna P. Borgstrom</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">70,000</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">149,993</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">219,993</span></p>

							</td>

						</tr>
						<tr style="min-height: 13.3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">James W. Bullock</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">67,500</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">149,993</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">217,493</span></p>

							</td>

						</tr>
						<tr style="min-height: 13.3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Jeffrey H. Burbank</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">115,000</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">149,993</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">264,993</span></p>

							</td>

						</tr>
						<tr style="min-height: 13.3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Elizabeth A. Hoff</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">64,167</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">149,993</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">214,160</span></p>

							</td>

						</tr>
						<tr style="min-height: 13.3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Jon W. Salveson</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">65,000</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">149,993</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">214,993</span></p>

							</td>

						</tr>
						<tr style="min-height: 13.3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Anthony B. Semedo</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">67,500</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">149,993</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">217,493</span></p>

							</td>

						</tr>
						<tr style="min-height: 13.3pt">
							<td colspan="4" style="border-width: 0pt; padding: 5pt 0pt 1.5pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 9pt/normal Arial, sans-serif; margin: 0px 0pt 1pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(1)</sup></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Amounts shown include annual Board of Director service retainer, committee Chair and committee membership retainers, and, for Mr. Burbank, a Lead Director retainer, earned by our non-employee directors during 2024. Note that the Annual Stock Awards, which are generally made shortly after the Company&#8217;s Annual Meeting each year, cover the one-year service period ending on the day preceding the Company&#8217;s Annual Meeting the following year.  </span></p>
								<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 0 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(2)</sup></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Amounts shown represent the aggregate grant date fair value of the 6,289 restricted shares granted to each non-employee director, as calculated in accordance with FASB ASC Topic 718. We issued the awards on May 30, 2024, and we valued them at $23.85 per share, which was the closing price on the grant date. See Notes 1 and 14 of the Notes to Consolidated Financial Statements filed with Artivion&#8217;s Annual Report on Form 10-K for the year ended December 31, 2024 for assumptions used in valuing restricted stock awards. The restricted stock represented here vests on May 30, 2025; accordingly, these shares remained subject to vesting restrictions as of December </span><span style="text-transform: none">31, 2024.</span></p>

							</td>

						</tr>

					</table>

				</div>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">J. Patrick Mackin, Chairman, President, and Chief Executive Officer received no compensation in 2024 for his services as a director of the Company. His compensation as an executive officer of the Company is detailed in the Summary Compensation Table on </span><span style="text-transform: none; line-height: 12pt">page 43.</span></p>
				<p style="border-bottom: #7f7f7f 1pt solid; font: 12pt/normal Arial, sans-serif; margin: 4pt 0pt 15pt; text-transform: none; color: #2b4b74; text-indent: 0pt; text-align: left"><span style="text-transform: none"><b>Director Stock Ownership Requirement</b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">In November 2015, the Compensation and Corporate Governance Committees approved a change to the non-employee director stock ownership requirement to five times the then-current annual Board of Director service retainer for non-employee directors. The Board of Directors reevaluates this stock ownership requirement typically on a biennial basis and did so recently in November 2024, concluding at that time, based on information provided by Willis Towers Watson and management, that these requirements remained appropriate. All non-employee directors currently satisfy </span><span style="text-transform: none; line-height: 12pt">this standard. </span></p>

			</div>

		</div>
		<div style="page-break-before: always">
			<p style="margin: 0pt; font-size: 5pt">&#8203;</p>

		</div>
		<div class="qes_page" style="border-bottom: black 2pt solid; margin: auto; height: 990pt; width: 765pt; position: relative; overflow: hidden">
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 911.25pt; left: 45pt; width: 675pt; position: absolute; height: 33.75pt">
				<div style="display: table-cell; vertical-align: bottom; width: 675pt; height: 33.75pt">

				<!--[if IE]><TABLE><TR style=" width: 675pt; height: 33.75pt;"><TD vAlign="bottom" style=" width: 675pt; height: 33.75pt;"><![endif]-->
					<div style="font: 12pt/normal Times New Roman, Times, serif; margin: 0pt; text-transform: none; color: #000000; text-align: left">
						<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 0pt; border-collapse: collapse">
							<tr style="margin: 0; height: 0">
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>

							</tr>
							<tr style="min-height: 0pt">
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">ARTIVION, INC. | 2025 Proxy Statement</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">23</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 0pt; line-height: 0pt">&#8203;</p>

								</td>

							</tr>

						</table>

					</div>


				<!--[if IE]></TD></TR></TABLE><![endif]-->
				</div>

			</div>
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 45pt; left: 45pt; width: 675pt; position: absolute; height: 866.25pt">
				<p style="border-bottom: #7f7f7f 1pt solid; font: 12pt/normal Arial, sans-serif; margin: 0pt 0pt 15pt; text-transform: none; color: #2b4b74; text-indent: 0pt; text-align: left"><span style="text-transform: none"><b>REPORT OF THE AUDIT COMMITTEE</b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">The Board of Directors maintains an Audit Committee of three non-employee directors. The Board of Directors and the Audit Committee believe that the Audit Committee&#8217;s current member composition satisfies the rules of the NYSE that govern audit committee composition, including the requirement that each audit committee member be an &#8220;Independent Director&#8221; as that term is defined by Sections 303A.02 and 303A.06 of the NYSE Listing Standards and Rule 10A-3 promulgated under the Securities Exchange Act </span><span style="text-transform: none; line-height: 12pt">of 1934.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">The Audit Committee oversees Artivion&#8217;s financial processes and the Company&#8217;s information security preparedness on behalf of the Board of Directors. Management has the primary responsibility for the financial statements and the reporting process, including the systems of internal controls. In fulfilling its oversight responsibilities, the Audit Committee reviewed the audited financial statements included in Artivion&#8217;s Annual Report on Form 10-K for fiscal 2024 and discussed them with management, including a discussion of the quality, not just the acceptability, of the accounting principles, the reasonableness of significant judgments, and the clarity of disclosures in the financial statements. The Board of Directors and the Audit Committee have adopted a written Audit Committee Charter. Since the first quarter of 2004, Artivion has retained an outside accounting firm to provide internal audit services. The internal audit function reports directly to the Audit Committee and, for administrative purposes, to the Chief </span><span style="text-transform: none; line-height: 12pt">Financial Officer.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">During fiscal 2024, management completed the documentation, testing, and evaluation of Artivion&#8217;s system of internal controls over financial reporting and the associated information security preparedness in response to the requirements set forth in Section&#160;404 of the Sarbanes-Oxley Act of 2002 and related regulations. The Audit Committee was kept informed of the progress of the evaluation and provided oversight and advice to management during the process. In connection with this oversight, the Audit Committee received periodic updates provided by management and Ernst&#160;&amp; Young LLP, Artivion&#8217;s independent registered public accounting firm since 2013, at each regularly scheduled Audit Committee meeting. The Audit Committee also reviewed the report of management on internal controls over financial reporting </span><span style="text-transform: none; line-height: 12pt">contained in Artivion&#8217;s Annual Report on Form&#160;10-K for fiscal 2024, as well as Ernst&#160;&amp; Young LLP&#8217;s Reports of Independent Registered Public Accounting Firm included in Artivion&#8217;s Annual Report on Form&#160;10-K for fiscal 2024 related to its audit of (i)&#160;Artivion&#8217;s consolidated financial statements and (ii)&#160;the effectiveness of Artivion&#8217;s internal controls over financial reporting. The Audit Committee continued to oversee Artivion&#8217;s efforts related to Artivion&#8217;s internal controls over financial reporting and management&#8217;s preparations for the evaluation thereof for </span><span style="text-transform: none; line-height: 12pt">fiscal 2024.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">The Audit Committee reviewed with Ernst&#160;&amp; Young LLP, who is responsible for expressing an opinion on the conformity of those audited financial statements with generally accepted accounting principles, their judgments as to the quality, not just the acceptability, of Artivion&#8217;s accounting principles and such other matters as are required to be discussed with the Audit Committee by the applicable requirements of the Public Company Accounting Oversight Board and the SEC. Ernst&#160;&amp; Young LLP also provided to the Audit Committee the written disclosures and the letter required by the applicable requirements of the Public Company Accounting Oversight Board regarding Ernst&#160;&amp; Young LLP&#8217;s communications with the Audit Committee concerning independence. The Audit Committee discussed with Ernst&#160;&amp; Young LLP and management its independence from management </span><span style="text-transform: none; line-height: 12pt">and Artivion. </span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">The Audit Committee discussed with Ernst&#160;&amp; Young LLP the overall scope and plans for its audit. The Audit Committee met with Ernst&#160;&amp; Young LLP, with and without management present, to discuss the results of its examination, its evaluation of Artivion&#8217;s internal controls, and the overall quality of Artivion&#8217;s financial reporting.  </span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">In connection with its review of Artivion&#8217;s accounting and financial controls, the Audit Committee discusses with management on a quarterly basis the adequacy of Artivion&#8217;s information security preparedness and the types of information technology risks, controls, and procedures, and any related issues that could affect the adequacy of Artivion&#8217;s internal controls or general operations, including as they relate to information security. Assessments of Artivion&#8217;s information security program, including evaluations about its policies, procedures, infrastructure, access control, and change management, were performed by the independent external auditing firms Ernst &amp; Young LLP, Hancock Askew &amp; Co., LLP, and RWT </span><span style="text-transform: none; line-height: 12pt">Crowe GmbH. </span></p>

			</div>

		</div>
		<div style="page-break-before: always">
			<p style="margin: 0pt; font-size: 5pt">&#8203;</p>

		</div>
		<div class="qes_page" style="border-bottom: black 2pt solid; margin: auto; height: 990pt; width: 765pt; position: relative; overflow: hidden">
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 911.25pt; left: 45pt; width: 675pt; position: absolute; height: 33.75pt">
				<div style="display: table-cell; vertical-align: bottom; width: 675pt; height: 33.75pt">

				<!--[if IE]><TABLE><TR style=" width: 675pt; height: 33.75pt;"><TD vAlign="bottom" style=" width: 675pt; height: 33.75pt;"><![endif]-->
					<div style="font: 12pt/normal Times New Roman, Times, serif; margin: 0pt; text-transform: none; color: #000000; text-align: left">
						<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 0pt; border-collapse: collapse">
							<tr style="margin: 0; height: 0">
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>

							</tr>
							<tr style="min-height: 0pt">
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">ARTIVION, INC. | 2025 Proxy Statement</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">24</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 0pt; line-height: 0pt">&#8203;</p>

								</td>

							</tr>

						</table>

					</div>


				<!--[if IE]></TD></TR></TABLE><![endif]-->
				</div>

			</div>
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 45pt; left: 45pt; width: 675pt; position: absolute; height: 866.25pt">
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">In reliance on the reviews and discussions referred to above, the Audit Committee members did not become aware of any material misstatements in the audited financial statements and recommended to the Board of Directors that the audited financial statements be included in Artivion&#8217;s Annual Report on Form&#160;10-K for the year ended December&#160;31, 2024 for filing with the SEC. The Audit Committee has preliminarily approved Ernst&#160;&amp; Young LLP as Artivion&#8217;s independent registered public accounting firm for </span><span style="text-transform: none; line-height: 12pt">fiscal 2025.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt 360pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none"><b>Audit Committee<br/></b></span><span style="text-transform: none">THOMAS F. ACKERMAN, CHAIR<br/>DANIEL J. BEVEVINO<br/>JEFFREY </span><span style="text-transform: none">H. BURBANK</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt; font-style: italic"><i>The foregoing audit committee report is not &#8220;soliciting material,&#8221; is not deemed &#8220;filed&#8221; with the SEC, and shall not be deemed incorporated by reference by any general statement incorporating by reference this Proxy Statement into any filing of the Company under the Securities Act of 1933, as amended, or under the Exchange Act, except to the extent the Company specifically incorporates this report </i></span><span style="text-transform: none; line-height: 12pt; font-style: italic"><i>by reference. </i></span></p>

			</div>

		</div>
		<div style="page-break-before: always">
			<p style="margin: 0pt; font-size: 5pt">&#8203;</p>

		</div>
		<div class="qes_page" style="border-bottom: black 2pt solid; margin: auto; height: 990pt; width: 765pt; position: relative; overflow: hidden">
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 911.25pt; left: 45pt; width: 675pt; position: absolute; height: 33.75pt">
				<div style="display: table-cell; vertical-align: bottom; width: 675pt; height: 33.75pt">

				<!--[if IE]><TABLE><TR style=" width: 675pt; height: 33.75pt;"><TD vAlign="bottom" style=" width: 675pt; height: 33.75pt;"><![endif]-->
					<div style="font: 12pt/normal Times New Roman, Times, serif; margin: 0pt; text-transform: none; color: #000000; text-align: left">
						<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 0pt; border-collapse: collapse">
							<tr style="margin: 0; height: 0">
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>

							</tr>
							<tr style="min-height: 0pt">
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">ARTIVION, INC. | 2025 Proxy Statement</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">25</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 0pt; line-height: 0pt">&#8203;</p>

								</td>

							</tr>

						</table>

					</div>


				<!--[if IE]></TD></TR></TABLE><![endif]-->
				</div>

			</div>
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 45pt; left: 45pt; width: 675pt; position: absolute; height: 866.25pt">
				<p style="border-bottom: #7f7f7f 1pt solid; font: 12pt/normal Arial, sans-serif; margin: 4pt 0pt 15pt; text-transform: none; color: #2b4b74; text-indent: 0pt; text-align: left"><span style="text-transform: none"><b>PROPOSAL TWO &#8211; ADVISORY VOTE ON EXECUTIVE OFFICER COMPENSATION</b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">Artivion seeks a non-binding vote from its stockholders to approve the compensation paid to our Named Executive Officers as disclosed in this Proxy Statement pursuant to Item&#160;402 of Regulation&#160;S-K, including the Compensation Discussion and Analysis, compensation tables, and narrative discussion. This vote is commonly referred to as a &#8220;Say on Pay&#8221; vote because it gives stockholders an opportunity to express their approval or disapproval of the Company&#8217;s executive officer </span><span style="text-transform: none; line-height: 12pt">pay practices.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">As discussed in detail in the Compensation Discussion and Analysis that follows, our executive officer compensation programs are designed to attract, retain, motivate, and reward executive officer talent that is able to, and appropriately incented to, deliver on Artivion&#8217;s short and long-term growth, on other strategic objectives, and on Artivion&#8217;s commitments to its stockholders, in particular, long-term value creation. We believe that the form and amount of compensation we provide to our current Named Executive Officers appropriately reflects their extensive management experience, continued high performance, and exceptional service to Artivion and </span><span style="text-transform: none; line-height: 12pt">our stockholders.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">During 2024, various economic, regulatory, and other unforeseen challenges&#8212;for example, persistently elevated, albeit declining, inflation, elevated interest rates, the continued transition in Europe to the new Medical Device Regulation (&#8220;MDR&#8221;), slower-than-expected regulatory approvals, and a November 2024 cyberattack (the &#8220;Cybersecurity Incident&#8221;) that temporarily disrupted the Company&#8217;s operations&#8212;impacted the Company&#8217;s business. Responsive, resilient, and effective leadership from management remained necessary to counteract these challenges and to continue to deliver on the Company&#8217;s objectives. Despite these external challenges, the management team delivered significant constant currency revenue and adjusted EBIDTA growth in 2024, and the Company&#8217;s stock price increased by nearly 60% during the year. As it does each year, the Compensation Committee considered how to incent such leadership, maintain positive morale among the Company&#8217;s employees, including the executive team, and retain key leaders in light of the Company&#8217;s aggressive growth objectives in 2024 and beyond. The Compensation Committee particularly focused on ways that it could incent continued high performance from the Company&#8217;s executive leadership during what was, and still is, a critical time for the Company given its growth objectives now and in the coming years and in view of the above-referenced, and other, headwinds. To facilitate stockholders&#8217; review of the executive officer compensation program, we are providing details regarding the program and the performance and payouts related thereto.       </span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">We invite you to consider the details of our executive officer compensation program as disclosed more fully throughout this Proxy Statement. Regardless of the outcome of this &#8220;Say on Pay&#8221; vote, Artivion welcomes input from its stockholders regarding executive officer compensation and other matters generally related to the Company&#8217;s success. We believe in a corporate governance structure that is responsive to stockholder concerns. We view this vote as a meaningful opportunity to gauge stockholder approval of our executive officer compensation policies. Given the information provided in this Proxy Statement, the Board of Directors asks you to approve the following </span><span style="text-transform: none; line-height: 12pt">advisory resolution: </span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none"><b><span>&#8220;Resolved, that Artivion&#8217;s stockholders approve, on an advisory basis, the compensation paid to Artivion&#8217;s Named Executive Officers, as disclosed in this </span></b></span><span style="text-transform: none"><b><span>Proxy Statement</span></b></span><span style="text-transform: none"><b>.&#8221;</b></span></p>
				<p style="font: italic 11pt/normal Arial, sans-serif; margin: 4pt 0pt 8pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><b><i>Required Vote </i></b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">The votes cast for this proposal must constitute a majority of shares present, either in person or by proxy, and entitled to vote on this proposal in order for it to be approved. Accordingly, abstentions will have the same effect as an &#8220;Against&#8221; vote and broker non-votes will have no effect. As previously disclosed and approved by the stockholders, the Board of Directors currently submits a Say on Pay proposal annually. The annual frequency of this disclosure and approval was the subject of a vote of the stockholders at the Company&#8217;s 2023 Annual Meeting and was supported by more than 96% of stockholders </span><span style="text-transform: none; line-height: 12pt">who voted. </span></p>
				<p style="font: italic 11pt/normal Arial, sans-serif; margin: 4pt 0pt 8pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><b><i>The Board of Directors&#8217; Recommendation </i></b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>THE BOARD OF DIRECTORS RECOMMENDS THAT YOU VOTE &#8220;FOR&#8221;<br/> THE APPROVAL OF THE COMPENSATION PAID TO ARTIVION&#8217;S NAMED </b></span><span style="text-transform: none"><b>EXECUTIVE OFFICERS.</b></span></p>

			</div>

		</div>
		<div style="page-break-before: always">
			<p style="margin: 0pt; font-size: 5pt">&#8203;</p>

		</div>
		<div class="qes_page" style="border-bottom: black 2pt solid; margin: auto; height: 990pt; width: 765pt; position: relative; overflow: hidden">
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 911.25pt; left: 45pt; width: 675pt; position: absolute; height: 33.75pt">
				<div style="display: table-cell; vertical-align: bottom; width: 675pt; height: 33.75pt">

				<!--[if IE]><TABLE><TR style=" width: 675pt; height: 33.75pt;"><TD vAlign="bottom" style=" width: 675pt; height: 33.75pt;"><![endif]-->
					<div style="font: 12pt/normal Times New Roman, Times, serif; margin: 0pt; text-transform: none; color: #000000; text-align: left">
						<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 0pt; border-collapse: collapse">
							<tr style="margin: 0; height: 0">
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>

							</tr>
							<tr style="min-height: 0pt">
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">ARTIVION, INC. | 2025 Proxy Statement</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">26</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 0pt; line-height: 0pt">&#8203;</p>

								</td>

							</tr>

						</table>

					</div>


				<!--[if IE]></TD></TR></TABLE><![endif]-->
				</div>

			</div>
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 45pt; left: 45pt; width: 675pt; position: absolute; height: 879pt">
				<p style="border-bottom: #7f7f7f 1pt solid; font: 12pt/normal Arial, sans-serif; margin: 0pt 0pt 15pt; text-transform: none; color: #2b4b74; text-indent: 0pt; text-align: left"><span style="text-transform: none"><b>COMPENSATION DISCUSSION AND ANALYSIS</b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">This Compensation Discussion and Analysis describes the principles, objectives, and features of our executive compensation program as applied to our Chief Executive Officer and the other named executive officers included in the Summary Compensation Table of this Proxy Statement (collectively, our &#8220;Named Executive Officers&#8221; or &#8220;NEOs&#8221;). For 2024, our </span><span style="text-transform: none; line-height: 12pt">NEOs were:</span></p>
				<div style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-align: justify">
					<table style="table-layout: fixed; width: 673.49pt; margin-top: 4pt; margin-bottom: 6pt; border-collapse: collapse">
						<tr style="margin: 0; height: 0">
							<td style="border-width: 0; margin: 0; padding: 0; width: 36pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 122.49pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 514.99pt">


							</td>

						</tr>
						<tr style="min-height: 19pt">
							<td style="border-width: 0pt; padding: 1.5pt 5.4pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8226;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 5.4pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">J. </span><span style="text-transform: none">Patrick Mackin</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 5.4pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">President, Chief Executive Officer, and Chairman of the Board </span><span style="text-transform: none">of Directors </span></p>

							</td>

						</tr>
						<tr style="min-height: 19pt">
							<td style="border-width: 0pt; padding: 1.5pt 5.4pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8226;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 5.4pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Lance </span><span style="text-transform: none">A. Berry</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 5.4pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Executive Vice President and Chief </span><span style="text-transform: none">Financial Officer</span></p>

							</td>

						</tr>
						<tr style="min-height: 19pt">
							<td style="border-width: 0pt; padding: 1.5pt 5.4pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8226;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 5.4pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Jean </span><span style="text-transform: none">F. Holloway</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 5.4pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Senior Vice President, General Counsel, Chief Compliance Officer, and </span><span style="text-transform: none">Corporate Secretary</span></p>

							</td>

						</tr>
						<tr style="min-height: 19pt">
							<td style="border-width: 0pt; padding: 1.5pt 5.4pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8226;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 5.4pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">John </span><span style="text-transform: none">E. Davis</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 5.4pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Senior Vice President, Chief </span><span style="text-transform: none">Commercial Officer</span></p>

							</td>

						</tr>
						<tr style="min-height: 19pt">
							<td style="border-width: 0pt; padding: 1.5pt 5.4pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8226;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 5.4pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Marshall </span><span style="text-transform: none">S. Stanton</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 5.4pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Senior Vice President, Clinical Research and </span><span style="text-transform: none">Chief&#160;Medical Officer</span></p>

							</td>

						</tr>

					</table>

				</div>
				<p style="border-bottom: #7f7f7f 1pt solid; font: 12pt/normal Arial, sans-serif; margin: 4pt 0pt 15pt; text-transform: none; color: #2b4b74; text-indent: 0pt; text-align: left"><span style="text-transform: none"><b>EXECUTIVE SUMMARY</b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">The Compensation Committee (referred to in this section as the &#8220;Committee&#8221;) generally considers and approves executive officer compensation each year at a meeting held in the first quarter of the fiscal year. These compensation decisions take into account a variety of information and analyses, including, but not limited to, alignment of compensation vehicles with the Committee&#8217;s Compensation Philosophy, prior-year Company and individual executive officer performance (including the Company&#8217;s share price), current-year performance expectations and key business objectives, any changes in roles and responsibilities of executives, the external environment for talent, and competitive market data and market trends from various sources, including from the Committee&#8217;s independent compensation consultant </span><span style="text-transform: none; line-height: 12pt">and management.</span></p>
				<p style="font: italic 11pt/normal Arial, sans-serif; margin: 4pt 0pt 8pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><b><i>2023 Say on Pay Vote and 2024 Program Decisions</i></b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">At Artivion&#8217;s Annual Meeting of Stockholders on May 14, 2024, 97% of the stockholder votes cast were in favor of our NEOs&#8217; 2023 compensation. This advisory vote indicated strong stockholder support for our executive officer compensation program, including our NEO compensation, and is consistent with the fact that over the past four years, on average, 94% of stockholder votes cast were in favor of our </span><span style="text-transform: none; line-height: 12pt">NEOs&#8217; compensation.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">The Committee considered these advisory vote results on the 2023 executive compensation plan as it made compensation decisions for 2024. Based in part on this consideration, and together with individual executive officer performance, retention considerations, and the Company&#8217;s actual and expected performance as of February 2024, including its share price, as well as competitive market data and recommendations from various sources, including from the Committee&#8217;s independent compensation consultant and management, beginning in the fourth quarter of 2023, and concluding in February&#160;2024, the Committee considered and approved the Company&#8217;s 2024 executive officer compensation programs as explained in more </span><span style="text-transform: none; line-height: 12pt">detail below. </span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">As it did in 2023, and as explained in more detail below, the Committee determined to use full-year metrics for the 2024 incentive programs; however, unlike in 2023, the Committee included a non-financial, R&amp;D-related metric for the annual performance share plan. The Committee then further considered the financial performance metrics and targets that would continue to incent the highest levels of performance from management during what was a critical time for the Company given its growth objectives, its commitments to deliver on stockholder value creation, and its desire to retain members of management it deemed key to the continued financial and operational success of the Company. The following is a summary of the Committee&#8217;s significant considerations and decisions made regarding NEO compensation </span><span style="text-transform: none; line-height: 12pt">for 2024:</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt 45pt; text-transform: none; color: #000000; text-indent: -22.5pt; text-align: justify"><!--[if IE]><FONT style=" width: 22.5pt; text-indent: -18.0pt; display: inline-block;"><![endif]--><span style="width: 22.5pt; text-indent: 0; display: inline-block"><span style="text-transform: none">&#8226;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Except for Mr. Berry, whose first full year as the Company&#8217;s CFO was 2024, NEOs received 2024 base salary increases of 3.5%-4.0% as compared to 2023, based on considerations such as personal </span><span style="text-transform: none">performance, Company performance, and </span><span style="text-transform: none">market positioning;</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt 45pt; text-transform: none; color: #000000; text-indent: -22.5pt; text-align: justify"><!--[if IE]><FONT style=" width: 22.5pt; text-indent: -18.0pt; display: inline-block;"><![endif]--><span style="width: 22.5pt; text-indent: 0; display: inline-block"><span style="text-transform: none">&#8226;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">The Committee maintained the same percent-of-salary targets for 2024 cash bonuses that it used in 2023 to reflect Company performance and market positioning, at the following percentages of base salary: Mr. Mackin at 100%; Mr. Berry at 60%; and Ms. Holloway, Mr. Davis, and Mr. Stanton </span><span style="text-transform: none">at 50%; </span></p>

			</div>

		</div>
		<div style="page-break-before: always">
			<p style="margin: 0pt; font-size: 5pt">&#8203;</p>

		</div>
		<div class="qes_page" style="border-bottom: black 2pt solid; margin: auto; height: 990pt; width: 765pt; position: relative; overflow: hidden">
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 911.25pt; left: 45pt; width: 675pt; position: absolute; height: 33.75pt">
				<div style="display: table-cell; vertical-align: bottom; width: 675pt; height: 33.75pt">

				<!--[if IE]><TABLE><TR style=" width: 675pt; height: 33.75pt;"><TD vAlign="bottom" style=" width: 675pt; height: 33.75pt;"><![endif]-->
					<div style="font: 12pt/normal Times New Roman, Times, serif; margin: 0pt; text-transform: none; color: #000000; text-align: left">
						<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 0pt; border-collapse: collapse">
							<tr style="margin: 0; height: 0">
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>

							</tr>
							<tr style="min-height: 0pt">
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">ARTIVION, INC. | 2025 Proxy Statement</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">27</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 0pt; line-height: 0pt">&#8203;</p>

								</td>

							</tr>

						</table>

					</div>


				<!--[if IE]></TD></TR></TABLE><![endif]-->
				</div>

			</div>
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 45pt; left: 45pt; width: 675pt; position: absolute; height: 866.25pt">
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt 45pt; text-transform: none; color: #000000; text-indent: -22.5pt; text-align: justify"><!--[if IE]><FONT style=" width: 22.5pt; text-indent: -18.0pt; display: inline-block;"><![endif]--><span style="width: 22.5pt; text-indent: 0; display: inline-block"><span style="text-transform: none">&#8226;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">As explained in more detail below, the Committee adopted the same financial metrics for the annual cash bonus plan and the annual performance share plan: (1) constant currency revenue growth and (2) adjusted EBITDA, concluding, with input from its advisors and management, that it was appropriate to use these metrics across both plans because they continued to be some of the most significant drivers of Company performance and stockholder value creation for 2024. The payout for the cash bonus was capped at 200% overall of target, inclusive of any adjustments for personal performance, and the payout for the performance share plan was also capped at 200% with no modifier for </span><span style="text-transform: none">personal performance;</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt 45pt; text-transform: none; color: #000000; text-indent: -22.5pt; text-align: justify"><!--[if IE]><FONT style=" width: 22.5pt; text-indent: -18.0pt; display: inline-block;"><![endif]--><span style="width: 22.5pt; text-indent: 0; display: inline-block"><span style="text-transform: none">&#8226;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">In addition, and as explained in more detail below, the Committee adopted a non-financial, R&amp;D-related metric as another metric for the annual performance share plan, concluding, with input from its advisors and management, that like constant currency revenue growth and adjusted EBITDA, these two R&amp;D milestones&#8212;(1) the submission of two AMDS PMA modules (i.e., pre-clinical in Q3 2024 and QMS/MFG in Q4 2024) and (2) the submission of the Arcevo LSA IDE in Q4 2024&#8212;were significant drivers of stockholder value creation for the coming years beyond 2024 as the Company prepares to bring its portfolio of aortic stent graft products to the US market;    </span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt 45pt; text-transform: none; color: #000000; text-indent: -22.5pt; text-align: justify"><!--[if IE]><FONT style=" width: 22.5pt; text-indent: -18.0pt; display: inline-block;"><![endif]--><span style="width: 22.5pt; text-indent: 0; display: inline-block"><span style="text-transform: none">&#8226;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Unlike in 2023, in 2024, the Committee decided to eliminate the use of options and to use only two types of annual equity vehicles (restricted stock units (&#8220;RSU&#8221;) and performance stock units (&#8220;PSU&#8221;)) for officer annual long-term incentive awards, determining that using only RSUs and PSUs was more in-line with current market trends and the Company&#8217;s proxy peers and better supported the Company&#8217;s compensation objectives. The allocation among the equity vehicles was split equally between RSUs </span><span style="text-transform: none">and PSUs; </span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt 45pt; text-transform: none; color: #000000; text-indent: -22.5pt; text-align: justify"><!--[if IE]><FONT style=" width: 22.5pt; text-indent: -18.0pt; display: inline-block;"><![endif]--><span style="width: 22.5pt; text-indent: 0; display: inline-block"><span style="text-transform: none">&#8226;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">The Committee increased the target annual equity value from 2023 to 2024 for all NEOs both as a reward for exceptional individual performance, and to bring annual equity targets more in-line with market medians for such officers, because those medians (particularly with respect to SVPs) increased over the past year. The target annual equity values for NEOs&#8217; annual equity in 2024 were as follows: Mr. Mackin&#8217;s was $3,608,903; Mr.&#160;Berry&#8217;s was $1,500,000; Mr. Davis&#8217;s was $800,000; Ms. Holloway&#8217;s was $795,000; and Mr. Stanton&#8217;s was $600,000. As in prior years, the 2024 annual equity grant gave executives the potential through superior performance to earn target equity payouts in range of the 75th </span><span style="text-transform: none">percentile; and</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt 45pt; text-transform: none; color: #000000; text-indent: -22.5pt; text-align: justify"><!--[if IE]><FONT style=" width: 22.5pt; text-indent: -18.0pt; display: inline-block;"><![endif]--><span style="width: 22.5pt; text-indent: 0; display: inline-block"><span style="text-transform: none">&#8226;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">In February 2024, the Committee adopted a framework for the cash bonus and performance stock plans and the metrics for the 2024 incentive plans. The Committee finalized and approved the full-year financial metrics for both the 2024 cash bonus and performance share plans as follows: (a) for the cash bonus plan, (1) a metric of constant currency revenue growth in 2024 versus 2023 with a target of 10%, weighted at 50%, and (2) a metric based on performance to target adjusted EBITDA with a target of $70 million, also weighted at 50%; and (b) for the performance share plan, the same metrics of constant currency revenue growth and adjusted EBITDA, weighted at 50% and 30%, respectively. In addition, for the performance share plan, the Committee finalized and approved the following non-financial R&amp;D-related metric, weighted at 20%: (1) the submission of two AMDS PMA modules to the US Food and Drug Administration (&#8220;FDA&#8221;) in 2024 (i.e., pre-clinical in Q3 2024 and QMS/MFG in Q4 2024) and (2) the submission of the Arcevo LSA IDE to the FDA in Q4 2024. If both R&amp;D milestones were achieved, then the payout for the R&amp;D metric was the greater of target (100%) or the weighted average achievement of the revenue and adjusted </span><span style="text-transform: none">EBITDA metrics.</span></p>
				<p style="font: italic 11pt/normal Arial, sans-serif; margin: 4pt 0pt 8pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><b><i>Incentive Plan Adjustments</i></b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">As discussed above, in February 2024, the Committee established financial metrics and targets for the cash bonus plan as well as the performance share plan. In February 2025, the Committee evaluated the Company&#8217;s full-year financial results for 2024, including the impact of and management&#8217;s response to the Cybersecurity Incident on those results. The Committee determined that the Cybersecurity Incident, while only temporarily disrupting the Company&#8217;s business operations, resulted in a $4.6 million impact on revenue and a $2.6 million impact on adjusted EBIDTA for fiscal 2024. The Committee further determined that, but for the Cybersecurity Incident, the Company&#8217;s 2024 proforma revenue likely would have been $393.1 million (10.7% constant currency growth), and its adjusted proforma EBITDA likely would have been $73.9 million (37% growth), as opposed to the Company&#8217;s actual results of $388.5 million in revenue (9.4% constant currency growth) and adjusted EBITDA of $71.3 million (32% growth). Based on these proforma results excluding the Cybersecurity Incident, the cash bonus plan payout would have been 148% and the performance share plan payout would have been 142%. Actual results, including the negative impact of the Cybersecurity Incident on revenue and adjusted EBITDA, would have reduced the incentive plan payouts to 116% and 104% for the cash bonus plan and performance share </span><span style="text-transform: none; line-height: 12pt">plan, respectively. </span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">Given that these reductions to the incentive plan payouts were largely beyond management&#8217;s control, coupled with the Committee&#8217;s view that management responded exceptionally well to the Cybersecurity Incident&#8212;e.g., (1) emergency shipments were supported within twenty-four hours, (2) the Company created manual workarounds to support </span><span style="text-transform: none; line-height: 12pt">the business, </span></p>

			</div>

		</div>
		<div style="page-break-before: always">
			<p style="margin: 0pt; font-size: 5pt">&#8203;</p>

		</div>
		<div class="qes_page" style="border-bottom: black 2pt solid; margin: auto; height: 990pt; width: 765pt; position: relative; overflow: hidden">
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 911.25pt; left: 45pt; width: 675pt; position: absolute; height: 33.75pt">
				<div style="display: table-cell; vertical-align: bottom; width: 675pt; height: 33.75pt">

				<!--[if IE]><TABLE><TR style=" width: 675pt; height: 33.75pt;"><TD vAlign="bottom" style=" width: 675pt; height: 33.75pt;"><![endif]-->
					<div style="font: 12pt/normal Times New Roman, Times, serif; margin: 0pt; text-transform: none; color: #000000; text-align: left">
						<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 0pt; border-collapse: collapse">
							<tr style="margin: 0; height: 0">
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>

							</tr>
							<tr style="min-height: 0pt">
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">ARTIVION, INC. | 2025 Proxy Statement</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">28</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 0pt; line-height: 0pt">&#8203;</p>

								</td>

							</tr>

						</table>

					</div>


				<!--[if IE]></TD></TR></TABLE><![endif]-->
				</div>

			</div>
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 45pt; left: 45pt; width: 675pt; position: absolute; height: 866.25pt">
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">including shipments, production, payroll, and order tracking, (3) the Company does not expect to lose any customers as a result of the Cybersecurity Incident, (4) the 2024 revenue and adjusted EBITDA remained within the Company&#8217;s guidance, and (5) the Company has continued to make all required SEC filings and other required reporting on a timely basis&#8212;combined with the stockholder value created during 2024 with the Company&#8217;s stock price increasing nearly 60%, the Committee determined that the appropriate approach would be to use discretion in considering performance against the revenue and adjusted EBITDA metrics. Accordingly, the Committee approved payouts under both the cash bonus and performance share plans at 130% of target, which is below the payouts based on proforma results under those plans discussed above had the Company never experienced the Cybersecurity Incident, but above the payouts based on </span><span style="text-transform: none; line-height: 12pt">actual results.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">Additionally, in February 2025, the Committee evaluated the Company&#8217;s performance against the above-described R&amp;D milestones. The Committee determined that while the Company did not file the Arcevo LSA IDE with the FDA until the first week of January 2025, the Company was prepared to submit the IDE in December 2024, but acquiesced to a request from the FDA that the Company not file the IDE until January 2025, a delay that will not likely impact the Company&#8217;s overall progress toward FDA approval. Accordingly, the Committee determined that the Company successfully achieved the R&amp;D metric, which was factored into the Committee&#8217;s decision to pay the cash bonus and performance share plans at 130% of target.  </span></p>
				<p style="font: italic 11pt/normal Arial, sans-serif; margin: 4pt 0pt 8pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><b><i>Pay-for-Performance Alignment, Including Incentive Plan Designs and Metrics</i></b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">The Committee believes it has developed a compensation program that ensures that the interests of the Company&#8217;s executive officers, including its NEOs, are aligned with those of its stockholders by strongly linking executive officer compensation with Company and pe</span><span style="text-transform: none; line-height: 12pt">rsonal performance at levels such that executive officers are incented to drive long-term value creation, especially given the Company&#8217;s growth objectives in the coming years. The key pay-for-performance aspects of the 2024 executive officer compensation program are </span><span style="text-transform: none; line-height: 12pt">described below:</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt 45pt; text-transform: none; color: #000000; text-indent: -22.5pt; text-align: justify"><!--[if IE]><FONT style=" width: 22.5pt; text-indent: -18.0pt; display: inline-block;"><![endif]--><span style="width: 22.5pt; text-indent: 0; display: inline-block"><span style="text-transform: none">&#8226;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">50% or more of each NEO&#8217;s total target direct compensation is in the form of variable pay tied to individual and </span><span style="text-transform: none">Company performance;</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt 45pt; text-transform: none; color: #000000; text-indent: -22.5pt; text-align: justify"><!--[if IE]><FONT style=" width: 22.5pt; text-indent: -18.0pt; display: inline-block;"><![endif]--><span style="width: 22.5pt; text-indent: 0; display: inline-block"><span style="text-transform: none">&#8226;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Short-term incentives are designed to be based on constant currency revenue growth and adjusted EBITDA, factors that are believed to create significant stockholder value creation, and over which executive officers are believed to have substantial control, and that are intended to incentivize executive officers to achieve Company target performance on these key </span><span style="text-transform: none">financial metrics;</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt 45pt; text-transform: none; color: #000000; text-indent: -22.5pt; text-align: justify"><!--[if IE]><FONT style=" width: 22.5pt; text-indent: -18.0pt; display: inline-block;"><![endif]--><span style="width: 22.5pt; text-indent: 0; display: inline-block"><span style="text-transform: none">&#8226;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Targets for short-term incentive opportunities are set at challenging levels designed to incentivize executive officers to achieve business growth at or above levels expected by stockholders, while setting up the Company for long-term success and </span><span style="text-transform: none">continued growth;</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt 45pt; text-transform: none; color: #000000; text-indent: -22.5pt; text-align: justify"><!--[if IE]><FONT style=" width: 22.5pt; text-indent: -18.0pt; display: inline-block;"><![endif]--><span style="width: 22.5pt; text-indent: 0; display: inline-block"><span style="text-transform: none">&#8226;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Annual long-term incentive opportunities are equity-based and include performance stock units, which are designed to be earned only if specified results at challenging levels for revenue, adjusted EBITDA, and key non-financial metrics are attained, thereby incentivizing executive officer performance that furthers the Company&#8217;s strategic goals and drives stockholder value. Such performance stock units, however, are not fully earned if such challenging levels are </span><span style="text-transform: none">not met; </span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt 45pt; text-transform: none; color: #000000; text-indent: -22.5pt; text-align: justify"><!--[if IE]><FONT style=" width: 22.5pt; text-indent: -18.0pt; display: inline-block;"><![endif]--><span style="width: 22.5pt; text-indent: 0; display: inline-block"><span style="text-transform: none">&#8226;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">NEOs are subject to stock ownership requirements to ensure alignment with stockholders and to encourage executive officers to maintain a long-term view of Company </span><span style="text-transform: none">performance; and</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt 45pt; text-transform: none; color: #000000; text-indent: -22.5pt; text-align: justify"><!--[if IE]><FONT style=" width: 22.5pt; text-indent: -18.0pt; display: inline-block;"><![endif]--><span style="width: 22.5pt; text-indent: 0; display: inline-block"><span style="text-transform: none">&#8226;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Our Clawback Policy is designed to diminish the likelihood that executive officers unjustly benefit in cash or equity from material misstatements in our financial statements, or from restatements that correct errors that are not material to previously issued financial statements but would result in a material misstatement if corrected or left uncorrected in a current financial </span><span style="text-transform: none">reporting period. </span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">As described in this Proxy Statement, in 2024, the executive officer compensation program effectively delivered pay-for-performance </span><span style="text-transform: none; line-height: 12pt">as follows:</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt 45pt; text-transform: none; color: #000000; text-indent: -22.5pt; text-align: justify"><!--[if IE]><FONT style=" width: 22.5pt; text-indent: -18.0pt; display: inline-block;"><![endif]--><span style="width: 22.5pt; text-indent: 0; display: inline-block"><span style="text-transform: none">&#8226;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">In 2024, we achieved constant currency revenue growth of 9.4%, and adjusted EBITDA of $71.3 million (a 32% increase over 2023), both of which were within the Company&#8217;s guidance. We also made three important regulatory filings with the FDA that are essential to the Company&#8217;s plans to bring its portfolio of aortic stent graft products to the US market. Without the Committee&#8217;s above-described adjustments, this performance resulted in payouts of 116% for the cash bonus plan (adjusted to 130%) and 104% for the annual performance share plan (adjusted </span><span style="text-transform: none">to 130%).</span></p>

			</div>

		</div>
		<div style="page-break-before: always">
			<p style="margin: 0pt; font-size: 5pt">&#8203;</p>

		</div>
		<div class="qes_page" style="border-bottom: black 2pt solid; margin: auto; height: 990pt; width: 765pt; position: relative; overflow: hidden">
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 911.25pt; left: 45pt; width: 675pt; position: absolute; height: 33.75pt">
				<div style="display: table-cell; vertical-align: bottom; width: 675pt; height: 33.75pt">

				<!--[if IE]><TABLE><TR style=" width: 675pt; height: 33.75pt;"><TD vAlign="bottom" style=" width: 675pt; height: 33.75pt;"><![endif]-->
					<div style="font: 12pt/normal Times New Roman, Times, serif; margin: 0pt; text-transform: none; color: #000000; text-align: left">
						<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 0pt; border-collapse: collapse">
							<tr style="margin: 0; height: 0">
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>

							</tr>
							<tr style="min-height: 0pt">
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">ARTIVION, INC. | 2025 Proxy Statement</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">29</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 0pt; line-height: 0pt">&#8203;</p>

								</td>

							</tr>

						</table>

					</div>


				<!--[if IE]></TD></TR></TABLE><![endif]-->
				</div>

			</div>
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 45pt; left: 45pt; width: 675pt; position: absolute; height: 866.25pt">
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">Throughout this Proxy Statement, we refer to revenue and adjusted EBITDA. Adjusted EBITDA reflects adjustments to measures reported under U.S. generally accepted accounting principles (&#8220;GAAP&#8221;). Appendix A to this Proxy Statement provides certain required information related to these non-GAAP measures, including a reconciliation to our audited U.S. GAAP financial statement measures for 2024, as presented in our 2024 Form 10-K filed on February </span><span style="text-transform: none; line-height: 12pt">28, 2025.</span></p>
				<p style="border-bottom: #7f7f7f 1pt solid; font: 12pt/normal Arial, sans-serif; margin: 4pt 0pt 15pt; text-transform: none; color: #2b4b74; text-indent: 0pt; text-align: left"><span style="text-transform: none"><b>ROLES AND RESPONSIBILITIES</b></span></p>
				<p style="font: italic 11pt/normal Arial, sans-serif; margin: 4pt 0pt 8pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><b><i>Compensation Committee</i></b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">The Committee determines and approves the compensation of Artivion&#8217;s executive officers, including the NEOs, except that it jointly determines and approves with the Corporate Governance Committee the compensation of Artivion&#8217;s Chief Executive Officer. The Committee is supported by the Chief Executive Officer, other executive officer management, an independent compensation consultant, and other advisors that the Committee, or management on its behalf, consults from time to time, as well as information and data supplied by each of these persons. The consultant attends Committee meetings when invited and provides input, information, and data as requested by the Committee. The Committee regularly meets in executive session without the Chief Executive Officer or any members of management present. For 2024, the Committee made compensation decisions based on its own considerations and analyses, the Compensation Philosophy of the Committee, as well as on information provided by and recommendations from the Committee&#8217;s independent compensation consultant, other advisors, and management. Our Chief Executive Officer does not exercise any decision-making authority over his own compensation and does not participate in Compensation or Corporate Governance Committee meetings or Board meetings regarding his own compensation, except during his annual performance review to discuss his own performance and compensation with those Committees or </span><span style="text-transform: none; line-height: 12pt">the Board.</span></p>
				<p style="font: italic 11pt/normal Arial, sans-serif; margin: 4pt 0pt 8pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><b><i>Independent Compensation Consultant</i></b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">The Committee has the authority to engage consultants, including compensation consultants, to assist with its responsibilities. With respect to general executive officer compensation decisions made during fiscal 2024 and regarding 2024 compensation, the Committee retained Willis Towers Watson as its primary compensation consultant for general executive officer compensation matters. The compensation consultant reports directly to the Committee, is directed by the Committee, and provides only those services authorized by the Committee. The compensation consultant provides no other services to Artivion. The compensation consultant generally performs an annual review of officer compensation and biennial review of non-employee director compensation, analyzes the relationship between executive officer pay, including that of our Chief Executive Officer, and Company performance, compares executive officer and non-employee director compensation against such compensation of appropriate comparable companies and industry standards, informs the Committee of emerging practices and trends, assists with special projects at the request of the Committee, and attends Committee meetings when invited. In February 2024, and again in February 2025, the Committee assessed the independence of Willis Towers Watson pursuant to applicable SEC and NYSE rules and concluded that Willis Towers Watson was independent and its work for the Committee did not raise any </span><span style="text-transform: none; line-height: 12pt">conflict-of-interest concerns. </span></p>

			</div>

		</div>
		<div style="page-break-before: always">
			<p style="margin: 0pt; font-size: 5pt">&#8203;</p>

		</div>
		<div class="qes_page" style="border-bottom: black 2pt solid; margin: auto; height: 990pt; width: 765pt; position: relative; overflow: hidden">
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 911.25pt; left: 45pt; width: 675pt; position: absolute; height: 33.75pt">
				<div style="display: table-cell; vertical-align: bottom; width: 675pt; height: 33.75pt">

				<!--[if IE]><TABLE><TR style=" width: 675pt; height: 33.75pt;"><TD vAlign="bottom" style=" width: 675pt; height: 33.75pt;"><![endif]-->
					<div style="font: 12pt/normal Times New Roman, Times, serif; margin: 0pt; text-transform: none; color: #000000; text-align: left">
						<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 0pt; border-collapse: collapse">
							<tr style="margin: 0; height: 0">
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>

							</tr>
							<tr style="min-height: 0pt">
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">ARTIVION, INC. | 2025 Proxy Statement</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">30</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 0pt; line-height: 0pt">&#8203;</p>

								</td>

							</tr>

						</table>

					</div>


				<!--[if IE]></TD></TR></TABLE><![endif]-->
				</div>

			</div>
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 45pt; left: 45pt; width: 675pt; position: absolute; height: 866.25pt">
				<p style="border-bottom: #7f7f7f 1pt solid; font: 12pt/normal Arial, sans-serif; margin: 0pt 0pt 15pt; text-transform: none; color: #2b4b74; text-indent: 0pt; text-align: left"><span style="text-transform: none"><b>COMPENSATION PHILOSOPHY AND OBJECTIVES</b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">The Committee&#8217;s Compensation Philosophy is to attract, retain, motivate, and reward executive officer talent that has the capability, and is appropriately incented, to deliver on the Company&#8217;s short and long-term growth and other strategic objectives and on the Company&#8217;s commitments to its stockholders, in particular long-term value creation. To that end, the Company has designed the compensation program to align with corporate strategy and short-term and long-term objectives, achieve market competitiveness, emphasize pay-for-performance, align with stockholder interests, balance the interests of key stakeholders, incent management to address unforeseen challenges, and recognize the unique attributes specific to Artivion and its executive officer team. Each primary component of compensation is intended to accomplish one or more of these objectives, as summarized in the </span><span style="text-transform: none; line-height: 12pt">table below. </span></p>
				<div style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-align: justify">
					<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 10pt; border-collapse: collapse">
						<tr style="margin: 0; height: 0">
							<td style="border-width: 0; margin: 0; padding: 0; width: 120pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 207.5pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 117.5pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 230pt">


							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Compensation Component</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Primary Purpose</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Form</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Performance Linkage</b></span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 3pt 1.5pt 2pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Base Salary</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 3pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Provide sufficiently competitive pay to attract, retain, motivate, and reward experienced and capable executive officer talent.</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 3pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">Cash</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 3pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Base salaries are determined based on individual executive officer performance, competitive market positioning, internal pay equity, and other factors. In addition, Company performance impacts the decision as to whether any salary adjustments are made when they are established in February of each year.   </span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 3pt 1.5pt 2pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Short-Term Incentive </span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 3pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Encourage and reward both individual achievement of performance objectives and aggregate Company performance against short-term financial and operating goals, maintain market competitiveness for top executive officer talent, and recognize the unique attributes an executive officer brings to the Company.</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 3pt 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">Cash</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 3pt 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Short-term incentive payouts are 100% performance-based, with the structure for fiscal 2024 having payouts based 50% on entire-year constant currency revenue growth during 2024 and 50% on entire-year adjusted EBITDA during 2024. The payout can then be increased or reduced by up to 20% based on individual executive officer performance, up to an overall cap of 200%.</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 2pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Long-Term Incentive &#8211; Annual Equity</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 3pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Encourage and reward long-term stockholder value creation, retain highly capable executive officer talent, and facilitate long-term stock ownership among our executive officer team to further align executive officer and stockholder interests.</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 3pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">Performance Stock Units </span></p>
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 0; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">Restricted Stock Units</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">PSUs are earned only if specific levels of Company performance are achieved during the relevant performance period. For fiscal 2024, annual PSU payouts were based 50% on entire-year constant currency revenue growth during 2024, 30% on entire-year adjusted EBITDA during 2024, and 20% on the Company&#8217;s achievement of a key R&amp;D metric during 2024, up to a cap of 200% for each individual metric and overall.</span></p>

							</td>

						</tr>

					</table>

				</div>

			</div>

		</div>
		<div style="page-break-before: always">
			<p style="margin: 0pt; font-size: 5pt">&#8203;</p>

		</div>
		<div class="qes_page" style="border-bottom: black 2pt solid; margin: auto; height: 990pt; width: 765pt; position: relative; overflow: hidden">
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 911.25pt; left: 45pt; width: 675pt; position: absolute; height: 33.75pt">
				<div style="display: table-cell; vertical-align: bottom; width: 675pt; height: 33.75pt">

				<!--[if IE]><TABLE><TR style=" width: 675pt; height: 33.75pt;"><TD vAlign="bottom" style=" width: 675pt; height: 33.75pt;"><![endif]-->
					<div style="font: 12pt/normal Times New Roman, Times, serif; margin: 0pt; text-transform: none; color: #000000; text-align: left">
						<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 0pt; border-collapse: collapse">
							<tr style="margin: 0; height: 0">
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>

							</tr>
							<tr style="min-height: 0pt">
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">ARTIVION, INC. | 2025 Proxy Statement</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">31</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 0pt; line-height: 0pt">&#8203;</p>

								</td>

							</tr>

						</table>

					</div>


				<!--[if IE]></TD></TR></TABLE><![endif]-->
				</div>

			</div>
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 45pt; left: 45pt; width: 675pt; position: absolute; height: 890.25pt">
				<p style="border-bottom: #7f7f7f 1pt solid; font: 12pt/normal Arial, sans-serif; margin: 0pt 0pt 15pt; text-transform: none; color: #2b4b74; text-indent: 0pt; text-align: left"><span style="text-transform: none"><b>COMPENSATION MIX</b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">The Committee approves the primary components of the executive officer compensation program and generally intends for it to provide more variable pay opportunities than fixed pay opportunities and to place significant weight on long-term incentive opportunities. The Committee believes that this results in a pay program that aligns pay and performance. The following table summarizes the original target pay mix for the NEOs for fiscal 2024 as determined by the Committee in </span><span style="text-transform: none; line-height: 12pt">February 2024.</span></p>
				<div style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-align: justify">
					<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 10pt; border-collapse: collapse">
						<tr style="margin: 0; height: 0">
							<td style="border-width: 0; margin: 0; padding: 0; width: 337.5pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 67.5pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 67.5pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 67.5pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 67.5pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 67.5pt">


							</td>

						</tr>
						<tr style="min-height: 12.45pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Compensation Component</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Mackin</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Berry</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Holloway</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Davis</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Stanton</b></span></p>

							</td>

						</tr>
						<tr style="min-height: 12.45pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Salary ($)</span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt">(1)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">806,904</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">500,000</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">425,639</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">406,855</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">409,593</span></p>

							</td>

						</tr>
						<tr style="min-height: 12.45pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Short-Term Incentive (at target) ($)</span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt">(2)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">806,904</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">300,000</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">212,820</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">203,428</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">204,797</span></p>

							</td>

						</tr>
						<tr style="min-height: 12.45pt">
							<td style="border-bottom: #000000 0.5pt solid; padding: 1.5pt 0pt; background-color: #dfe4ea; border-top-width: 0pt; border-right-width: 0pt; border-left-width: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Long-Term Incentive</span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt">(3)</sup><span style="text-transform: none"> </span></p>
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 0; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">- Annual Equity (Grant Date Fair Value at target) ($)</span></p>

							</td>
							<td style="border-bottom: #000000 0.5pt solid; padding: 1.5pt 0pt; background-color: #dfe4ea; border-top-width: 0pt; border-right-width: 0pt; border-left-width: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">3,608,101</span></p>

							</td>
							<td style="border-bottom: #000000 0.5pt solid; padding: 1.5pt 0pt; background-color: #dfe4ea; border-top-width: 0pt; border-right-width: 0pt; border-left-width: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">1,499,980</span></p>

							</td>
							<td style="border-bottom: #000000 0.5pt solid; padding: 1.5pt 0pt; background-color: #dfe4ea; border-top-width: 0pt; border-right-width: 0pt; border-left-width: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">794,989</span></p>

							</td>
							<td style="border-bottom: #000000 0.5pt solid; padding: 1.5pt 0pt; background-color: #dfe4ea; border-top-width: 0pt; border-right-width: 0pt; border-left-width: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">800,016</span></p>

							</td>
							<td style="border-bottom: #000000 0.5pt solid; padding: 1.5pt 0pt; background-color: #dfe4ea; border-top-width: 0pt; border-right-width: 0pt; border-left-width: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">599,992</span></p>

							</td>

						</tr>
						<tr style="min-height: 12.45pt">
							<td style="border-top: #000000 0.5pt solid; border-bottom: #000000 2.5pt double; padding: 1.5pt 0pt; border-right-width: 0pt; border-left-width: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Target Total Direct Compensation ($)</span></p>

							</td>
							<td style="border-top: #000000 0.5pt solid; border-bottom: #000000 2.5pt double; padding: 1.5pt 0pt; border-right-width: 0pt; border-left-width: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">5,221,909</span></p>

							</td>
							<td style="border-top: #000000 0.5pt solid; border-bottom: #000000 2.5pt double; padding: 1.5pt 0pt; border-right-width: 0pt; border-left-width: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">2,299,980</span></p>

							</td>
							<td style="border-top: #000000 0.5pt solid; border-bottom: #000000 2.5pt double; padding: 1.5pt 0pt; border-right-width: 0pt; border-left-width: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">1,433,448</span></p>

							</td>
							<td style="border-top: #000000 0.5pt solid; border-bottom: #000000 2.5pt double; padding: 1.5pt 0pt; border-right-width: 0pt; border-left-width: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">1,410,299</span></p>

							</td>
							<td style="border-top: #000000 0.5pt solid; border-bottom: #000000 2.5pt double; padding: 1.5pt 0pt; border-right-width: 0pt; border-left-width: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">1,214,382</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-top: #000000 2.5pt double; padding: 0pt; background-color: #dfe4ea; border-right-width: 0pt; border-left-width: 0pt; vertical-align: bottom; border-collapse: collapse; border-bottom-width: 0pt">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-top: #000000 2.5pt double; padding: 0pt; background-color: #dfe4ea; border-right-width: 0pt; border-left-width: 0pt; vertical-align: bottom; border-collapse: collapse; border-bottom-width: 0pt">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-top: #000000 2.5pt double; padding: 0pt; background-color: #dfe4ea; border-right-width: 0pt; border-left-width: 0pt; vertical-align: bottom; border-collapse: collapse; border-bottom-width: 0pt">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-top: #000000 2.5pt double; padding: 0pt; background-color: #dfe4ea; border-right-width: 0pt; border-left-width: 0pt; vertical-align: bottom; border-collapse: collapse; border-bottom-width: 0pt">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-top: #000000 2.5pt double; padding: 0pt; background-color: #dfe4ea; border-right-width: 0pt; border-left-width: 0pt; vertical-align: bottom; border-collapse: collapse; border-bottom-width: 0pt">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-top: #000000 2.5pt double; padding: 0pt; background-color: #dfe4ea; border-right-width: 0pt; border-left-width: 0pt; vertical-align: bottom; border-collapse: collapse; border-bottom-width: 0pt">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>

						</tr>
						<tr style="min-height: 12.45pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">% Fixed</span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt">(4)</sup></p>
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 0; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">% Variable</span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt">(5)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">15.5</span></p>
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 0; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">84.5</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">21.7</span></p>
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 0; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">78.3</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">29.7</span></p>
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 0; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">70.3</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">28.8</span></p>
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 0; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">71.2</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">33.7</span></p>
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 0; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">66.3</span></p>

							</td>

						</tr>
						<tr style="min-height: 12.45pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">% Short-Term Compensation</span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt">(6)</sup></p>
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 0; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">% Long-Term Compensation</span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt">(7)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">30.9</span></p>
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 0; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">69.1</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">34.8</span></p>
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 0; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">65.2</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">44.5</span></p>
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 0; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">55.5</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">43.3</span></p>
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 0; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">56.7</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">50.6</span></p>
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 0; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">49.4</span></p>

							</td>

						</tr>

					</table>

				</div>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 1pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(1) </sup></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Salary was set by the Committee in </span><span style="text-transform: none">February 2024.</span></p>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 1pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(2) </sup></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Like in 2023, Short-Term Incentive (cash bonus) was tied only to </span><span style="text-transform: none">financial metrics. </span></p>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 1pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(3) </sup></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Long-Term Incent</span><span style="text-transform: none">ive - Annual Equity is based on a grant date closing share price of $20.27.  </span></p>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 1pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(4) </sup></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Salary as a percentage of Target Total </span><span style="text-transform: none">Direct Compensation.</span></p>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 1pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(5) </sup></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Short-Term Incentive plus Long-Term Incentive as a percentage of Target Total </span><span style="text-transform: none">Direct Compensation.</span></p>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 1pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(6)</sup></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Salary plus Short-Term Incentive as a percentage of Target Total </span><span style="text-transform: none">Direct Compensation.</span></p>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 8pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(7)</sup></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Long-Term Incentive as a percentage of Target Total </span><span style="text-transform: none">Direct Compensation.</span></p>
				<p style="border-bottom: #7f7f7f 1pt solid; font: 12pt/normal Arial, sans-serif; margin: 4pt 0pt 15pt; text-transform: none; color: #2b4b74; text-indent: 0pt; text-align: left"><span style="text-transform: none"><b>MARKET ANALYSIS</b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">As part of its decision-making process, the Committee requests and reviews relevant market data regarding executive officer compensation levels, Company performance, and the relative relationship between executive officer pay and Company performance. The Committee, however, views this data as one of many inputs into its decision-making process, which also includes other assessments of the Company&#8217;s performance, assessments of each executive officer&#8217;s performance, the need to address unforeseen challenges, significant changes in roles and responsibilities, internal pay equity among executive officers, and </span><span style="text-transform: none; line-height: 12pt">retention considerations.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">Each year, the Committee reviews and considers an executive officer compensation study prepared by Willis Towers Watson, additional compensation data provided by management, and internal equity information. The executive officer compensation study is typically completed in the fourth quarter of the fiscal year and is used to inform the Committee&#8217;s decisions regarding the subsequent fiscal year&#8217;s compensation. Accordingly, the relevant study and market information reviewed by the Committee with regard to fiscal 2024 officer compensation was presented to the Committee in the fourth quarter of fiscal 2023. We refer to this study as the &#8220;2023 Study.&#8221; The Committee reconsidered the 2023 Study for continued applicability at its first quarter 2024 meetings. As in prior years, the 2023 Study assessed both the competitiveness of pay levels, generally and by certain specific positions, as well as the alignment of pay with Company performance.  </span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">The Company&#8217;s 2023 compensation peer group, which is described in more detail below, had median revenues of $359.2 million, based on the latest figures available at the time the 2023 Study was prepared, and median market capitalization as of June 2023 of $785.2 million. In addition to using officer pay information as disclosed by companies in the compensation peer group, the 2023 Study used survey data drawn from a compensation survey of U.S. companies, including medical device companies with targeted revenues of $200 million - $1 billion, in order to approximate the Company&#8217;s estimated revenue for 2024. With respect to all NEOs included in the 2023 Study, the data in the study was a blend of the 2023 peer group and the survey information. In each case, Willis Towers Watson trended the compensation data forward to January 1, 2024 by a factor of 3.0%.  </span></p>

			</div>

		</div>
		<div style="page-break-before: always">
			<p style="margin: 0pt; font-size: 5pt">&#8203;</p>

		</div>
		<div class="qes_page" style="border-bottom: black 2pt solid; margin: auto; height: 990pt; width: 765pt; position: relative; overflow: hidden">
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 911.25pt; left: 45pt; width: 675pt; position: absolute; height: 33.75pt">
				<div style="display: table-cell; vertical-align: bottom; width: 675pt; height: 33.75pt">

				<!--[if IE]><TABLE><TR style=" width: 675pt; height: 33.75pt;"><TD vAlign="bottom" style=" width: 675pt; height: 33.75pt;"><![endif]-->
					<div style="font: 12pt/normal Times New Roman, Times, serif; margin: 0pt; text-transform: none; color: #000000; text-align: left">
						<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 0pt; border-collapse: collapse">
							<tr style="margin: 0; height: 0">
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>

							</tr>
							<tr style="min-height: 0pt">
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">ARTIVION, INC. | 2025 Proxy Statement</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">32</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 0pt; line-height: 0pt">&#8203;</p>

								</td>

							</tr>

						</table>

					</div>


				<!--[if IE]></TD></TR></TABLE><![endif]-->
				</div>

			</div>
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 45pt; left: 45pt; width: 675pt; position: absolute; height: 866.25pt">
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">The following peer companies were used for the </span><span style="text-transform: none; line-height: 12pt">2023 Study.</span></p>
				<div style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt 22.5pt; text-transform: none; color: #000000; text-align: justify">
					<table style="table-layout: fixed; width: 283.75pt; margin-top: 4pt; margin-bottom: 10pt; border-collapse: collapse">
						<tr style="margin: 0; height: 0">
							<td style="border-width: 0; margin: 0; padding: 0; width: 198.75pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 85pt">


							</td>

						</tr>
						<tr style="min-height: 10.8pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Peer Company</b></span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt"><b>(1)</b></sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>FYE Revenue</b></span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt"><b>(2)</b></sup><sup style="text-transform: none; font-size: 8pt; line-height: 8pt"><b> </b></sup><span style="text-transform: none"><b>($)</b></span></p>

							</td>

						</tr>
						<tr style="min-height: 10.8pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Avanos Medical, Inc. </span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">814.3</span></p>

							</td>

						</tr>
						<tr style="min-height: 10.8pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Inogen, Inc.</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">369.0</span></p>

							</td>

						</tr>
						<tr style="min-height: 10.8pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Axogen, Inc. </span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">144.2</span></p>

							</td>

						</tr>
						<tr style="min-height: 10.8pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Orthofix Medical, Inc.</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">529.5</span></p>

							</td>

						</tr>
						<tr style="min-height: 10.8pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Glaukos Corp.</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">289.1</span></p>

							</td>

						</tr>
						<tr style="min-height: 10.8pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Nevro Corp.</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">414.9</span></p>

							</td>

						</tr>
						<tr style="min-height: 10.8pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Accuray Incorporated</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">439.3</span></p>

							</td>

						</tr>
						<tr style="min-height: 10.8pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Inari Medical, Inc. </span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">412.9</span></p>

							</td>

						</tr>
						<tr style="min-height: 10.8pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Tactile Systems Technology, Inc.</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">257.7</span></p>

							</td>

						</tr>
						<tr style="min-height: 10.8pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Alphatec Holdings, Inc. </span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">389.0</span></p>

							</td>

						</tr>
						<tr style="min-height: 10.8pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">AngioDynamics, Inc.</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">338.8</span></p>

							</td>

						</tr>
						<tr style="min-height: 10.8pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Zynex, Inc.</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">169.3</span></p>

							</td>

						</tr>
						<tr style="min-height: 10.8pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">AtriCure, Inc.</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">349.3</span></p>

							</td>

						</tr>
						<tr style="min-height: 10.8pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">iRhythm Technologies, Inc. </span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">430.0</span></p>

							</td>

						</tr>
						<tr style="min-height: 10.8pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Cutera, Inc.</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">249.4</span></p>

							</td>

						</tr>
						<tr style="min-height: 10.8pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Silk Road Medical, Inc.</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">150.7</span></p>

							</td>

						</tr>
						<tr style="min-height: 10.8pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Median</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">359.2</span></p>

							</td>

						</tr>
						<tr style="min-height: 10.8pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none"><b>Artivion&#8217;s 2024 Revenue</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>388.5</b></span></p>

							</td>

						</tr>

					</table>

				</div>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 1pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(1)</sup></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">The Committee believed that the pay practices of these companies provided a useful reference point for pay and performance comparisons at Artivion, especially considering Artivion&#8217;s </span><span style="text-transform: none">anticipated growth.</span></p>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 8pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(2)</sup></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Latest FYE revenue, in millions, at the time the peer group </span><span style="text-transform: none">was developed.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">The following survey source was used in the </span><span style="text-transform: none; line-height: 12pt">2023 Study:</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt 45pt; text-transform: none; color: #000000; text-indent: -22.5pt; text-align: justify"><!--[if IE]><FONT style=" width: 22.5pt; text-indent: -18.0pt; display: inline-block;"><![endif]--><span style="width: 22.5pt; text-indent: 0; display: inline-block"><span style="text-transform: none">&#8226;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">2023 Radford </span><span style="text-transform: none">Executive Survey.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">The peer companies were recommended by Willis Towers Watson and considered and approved by the Committee. In approving the peer group, the Committee considered the fact that each company is (or was at the time) publicly traded, operates in a similar industry, is similar in size, scope, and complexity, and is reasonably representative of our pool for executive officer talent, although Artivion routinely recruits from much larger medical device companies. The Committee also concluded that the companies are (or were at the time) within a reasonable range of Artivion&#8217;s historical, current, or projected revenues. Nonetheless, the Committee reviews and considers changes to the peer group and survey sources in connection with each year&#8217;s study. It does so to ensure that the peer group and survey sources continue to reflect appropriate reference points for Artivion. For example, in the third quarter of 2024, for purposes of evaluating the compensation to be paid to executives in fiscal year 2025, the Committee (at the recommendation of Willis Towers Watson) made several changes to the peer group that the Committee had used for its 2023 analysis, namely: (1) Glaukos Corp., Cutera, Inc., Zynex, Inc., and Silk Road Medical, Inc. were removed; and (2) Tandem Diabetes Care, Inc., STAAR Surgical Company, TransMedics Group, Inc., and Paragon 28, Inc. were added to the peer group. These changes were made to the peer group used for benchmarking 2025 executive compensation to address, among other things, consolidation and other strategic transactions in the medical device industry in 2024, and to ensure an appropriate balance of medical device companies with whom the Company competes for talent, both in terms of revenue, projected revenue growth, market capitalization, and </span><span style="text-transform: none; line-height: 12pt">workforce size.</span></p>
				<p style="border-bottom: #7f7f7f 1pt solid; font: 12pt/normal Arial, sans-serif; margin: 4pt 0pt 15pt; text-transform: none; color: #2b4b74; text-indent: 0pt; text-align: left"><span style="text-transform: none"><b>2024 COMPENSATION COMPONENTS</b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">The primary components of Artivion&#8217;s executive officer compensation program are base salary, short-term incentives, and long-term incentives. Artivion also provides executive officers with tax-deferred savings opportunities, participation in Company-wide benefits programs, and </span><span style="text-transform: none; line-height: 12pt">limited perquisites.</span></p>

			</div>

		</div>
		<div style="page-break-before: always">
			<p style="margin: 0pt; font-size: 5pt">&#8203;</p>

		</div>
		<div class="qes_page" style="border-bottom: black 2pt solid; margin: auto; height: 990pt; width: 765pt; position: relative; overflow: hidden">
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 911.25pt; left: 45pt; width: 675pt; position: absolute; height: 33.75pt">
				<div style="display: table-cell; vertical-align: bottom; width: 675pt; height: 33.75pt">

				<!--[if IE]><TABLE><TR style=" width: 675pt; height: 33.75pt;"><TD vAlign="bottom" style=" width: 675pt; height: 33.75pt;"><![endif]-->
					<div style="font: 12pt/normal Times New Roman, Times, serif; margin: 0pt; text-transform: none; color: #000000; text-align: left">
						<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 0pt; border-collapse: collapse">
							<tr style="margin: 0; height: 0">
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>

							</tr>
							<tr style="min-height: 0pt">
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">ARTIVION, INC. | 2025 Proxy Statement</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">33</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 0pt; line-height: 0pt">&#8203;</p>

								</td>

							</tr>

						</table>

					</div>


				<!--[if IE]></TD></TR></TABLE><![endif]-->
				</div>

			</div>
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 45pt; left: 45pt; width: 675pt; position: absolute; height: 874.42pt">
				<p style="font: italic 11pt/normal Arial, sans-serif; margin: 0pt 0pt 8pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><b><i>2024 Base Salary</i></b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">The Committee generally reviews base salary levels each February as part of its overall review and approval of the executive officer compensation program. Based on its review in late 2023 and early 2024, the Committee determined it was appropriate to increase the NEOs&#8217; base salaries, except for Mr. Berry, 3.5-4.0% above </span><span style="text-transform: none; line-height: 12pt">2023 levels.</span></p>
				<div style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-align: center">
					<table style="margin: 4pt auto 10pt; table-layout: fixed; width: 377.5pt; border-collapse: collapse">
						<tr style="margin: 0; height: 0">
							<td style="border-width: 0; margin: 0; padding: 0; width: 152.5pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 75pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 75pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 75pt">


							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td colspan="4" style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Comparison of 2023 and 2024 Base Salaries</b></span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Executive<br/>Officer</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>2023<br/>($)</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>2024<br/>($)</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Increase<br/>(%)</b></span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Mackin</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">775,869</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">806,904</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">4.0</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Berry</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">500,000</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">500,000</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">&#8212;</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Holloway</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">411,245</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">425,639</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">3.5</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Davis</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">391,207</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">406,855</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">4.0</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Stanton</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">395,742</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">409,593</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">3.5</span></p>

							</td>

						</tr>

					</table>

				</div>
				<p style="font: italic 11pt/normal Arial, sans-serif; margin: 4pt 0pt 8pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><i>Analysis</i></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none">The 2023 Study showed that the base salaries for our NEOs were within a competitive range of 95-111% of the median for similarly situated employees at companies in the Company&#8217;s peer group. Based on input from management and in consultation with Willis Towers Watson, the Committee approved merit increases for 2024 for all executive officers, except for Mr. Berry, of 3.5-4.0%. In approving salary increases for NEOs, the Committee considered current market positioning, both individual and Company performance during 2023, and the Company&#8217;s budget for salary increases generally for all employees. Mr. Berry&#8217;s 2023 salary was prorated based upon his December 4, 2023 start date, and was not increased for 2024 given his December 2023 start date and the fact that 2024 was his first full year as the </span><span style="text-transform: none">Company&#8217;s CFO. </span></p>
				<p style="font: italic 11pt/normal Arial, sans-serif; margin: 4pt 0pt 8pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><b><i>2024 Short-Term Incentives &#8211; The 2024 Cash Bonus Plan</i></b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">In February 2024, the Committee adopted the &#8220;2024 Cash Bonus Plan&#8221; as set forth above at page 28.    </span></p>
				<p style="font: italic 11pt/normal Arial, sans-serif; margin: 4pt 0pt 8pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><i>Analysis &#8211; Program Design</i></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none">The table below shows the performance metrics set for the 2024 Cash Bonus Plan as finalized in </span><span style="text-transform: none">February 2024.</span></p>
				<div style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-align: justify">
					<table style="table-layout: fixed; width: 676pt; margin-top: 4pt; margin-bottom: 10pt; border-collapse: collapse">
						<tr style="margin: 0; height: 0">
							<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 84.37pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 91.43pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 84.37pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 96.81pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 94pt">


							</td>

						</tr>
						<tr style="min-height: 12.95pt">
							<td colspan="6" style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>2024 Performance Goals</b></span></p>

							</td>

						</tr>
						<tr style="min-height: 12.95pt">
							<td style="border-bottom: #000000 0.5pt solid; padding: 1.5pt 0pt; border-top-width: 0pt; border-right-width: 0pt; border-left-width: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Performance Measure</b></span></p>

							</td>
							<td style="border-bottom: #000000 0.5pt solid; padding: 1.5pt 0pt; border-top-width: 0pt; border-right-width: 0pt; border-left-width: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Weight<br/>(%)</b></span></p>

							</td>
							<td style="border-bottom: #000000 0.5pt solid; padding: 1.5pt 0pt; border-top-width: 0pt; border-right-width: 0pt; border-left-width: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Threshold</b></span></p>

							</td>
							<td style="border-bottom: #000000 0.5pt solid; padding: 1.5pt 0pt; border-top-width: 0pt; border-right-width: 0pt; border-left-width: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Target</b></span></p>

							</td>
							<td style="border-bottom: #000000 0.5pt solid; padding: 1.5pt 0pt; border-top-width: 0pt; border-right-width: 0pt; border-left-width: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Stretch</b></span></p>

							</td>
							<td style="border-bottom: #000000 0.5pt solid; padding: 1.5pt 0pt; border-top-width: 0pt; border-right-width: 0pt; border-left-width: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Maximum</b></span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0 22.5pt; text-transform: none; color: #000000; text-indent: -22.5pt; text-align: left"><span style="text-transform: none">Revenue Growth Rate; Constant Currency (2024 v. 2023)</span></p>

							</td>
							<td style="padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">50</span></p>

							</td>
							<td style="padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">5.0% growth</span></p>

							</td>
							<td style="padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">10.0% growth</span></p>

							</td>
							<td style="padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">12.0% growth</span></p>

							</td>
							<td style="padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">16.0% growth</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Financial Metric Potential Payouts (%)</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">30</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">100</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">150</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">200</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">2024 Adjusted EBITDA</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">$57,400,000</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">$70,000,000</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">$72,500,000</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">$75,000,000</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Financial Metric Potential Payouts (%)</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">50</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">30</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">100</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">150</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">200</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td colspan="6" style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none"> - The final payout can be increased or decreased, up to 20%, based on an individual executive officer&#8217;s performance, subject to an overall cap of 200%.</span></p>

							</td>

						</tr>

					</table>

				</div>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">The Committee believed that the 2024 threshold and target performance levels for the constant currency revenue and adjusted EBITDA metrics were challenging and would drive stockholder value creation. In addition, the 2024 revenue and adjusted EBITDA target performance levels were within the range of 2024 guidance publicly announced by Artivion in the first </span><span style="text-transform: none; line-height: 12pt">quarter 2024. </span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">In arriving at its decision to approve the 2024 final metrics and payouts, the Committee took into consideration </span><span style="text-transform: none; line-height: 12pt">the following:</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 6pt 45pt; text-transform: none; color: #000000; text-indent: -22.5pt; text-align: justify"><!--[if IE]><FONT style=" width: 22.5pt; text-indent: -18.0pt; display: inline-block;"><![endif]--><span style="width: 22.5pt; text-indent: 0; display: inline-block"><span style="text-transform: none">&#8226;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">The Committee&#8217;s belief that the core plan design and its pay-for-performance orientation achieved the objectives of the Committee&#8217;s </span><span style="text-transform: none">Compensation Philosophy;</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 6pt 45pt; text-transform: none; color: #000000; text-indent: -22.5pt; text-align: justify"><!--[if IE]><FONT style=" width: 22.5pt; text-indent: -18.0pt; display: inline-block;"><![endif]--><span style="width: 22.5pt; text-indent: 0; display: inline-block"><span style="text-transform: none">&#8226;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">The Committee&#8217;s belief that the achievement of target constant currency revenue growth and adjusted EBITDA was key to incentivizing executive officers to achieve Company performance that will further the Company&#8217;s strategic business plan and ultimately deliver value to stockholders, without encouraging excessive risk taking</span><span style="text-transform: none"> by </span><span style="text-transform: none">executive officers;</span></p>

			</div>

		</div>
		<div style="page-break-before: always">
			<p style="margin: 0pt; font-size: 5pt">&#8203;</p>

		</div>
		<div class="qes_page" style="border-bottom: black 2pt solid; margin: auto; height: 990pt; width: 765pt; position: relative; overflow: hidden">
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 911.25pt; left: 45pt; width: 675pt; position: absolute; height: 33.75pt">
				<div style="display: table-cell; vertical-align: bottom; width: 675pt; height: 33.75pt">

				<!--[if IE]><TABLE><TR style=" width: 675pt; height: 33.75pt;"><TD vAlign="bottom" style=" width: 675pt; height: 33.75pt;"><![endif]-->
					<div style="font: 12pt/normal Times New Roman, Times, serif; margin: 0pt; text-transform: none; color: #000000; text-align: left">
						<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 0pt; border-collapse: collapse">
							<tr style="margin: 0; height: 0">
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>

							</tr>
							<tr style="min-height: 0pt">
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">ARTIVION, INC. | 2025 Proxy Statement</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">34</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 0pt; line-height: 0pt">&#8203;</p>

								</td>

							</tr>

						</table>

					</div>


				<!--[if IE]></TD></TR></TABLE><![endif]-->
				</div>

			</div>
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 45pt; left: 45pt; width: 675pt; position: absolute; height: 866.25pt">
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 6pt 45pt; text-transform: none; color: #000000; text-indent: -22.5pt; text-align: justify"><!--[if IE]><FONT style=" width: 22.5pt; text-indent: -18.0pt; display: inline-block;"><![endif]--><span style="width: 22.5pt; text-indent: 0; display: inline-block"><span style="text-transform: none">&#8226;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">The plan&#8217;s similarity to the short-term incentive plans of the Company&#8217;s peer </span><span style="text-transform: none">group companies;</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 6pt 45pt; text-transform: none; color: #000000; text-indent: -22.5pt; text-align: justify"><!--[if IE]><FONT style=" width: 22.5pt; text-indent: -18.0pt; display: inline-block;"><![endif]--><span style="width: 22.5pt; text-indent: 0; display: inline-block"><span style="text-transform: none">&#8226;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Artivion&#8217;s 2023 performance, and whether any changes to performance metrics were required to achieve 2024 business </span><span style="text-transform: none">goals; and </span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 6pt 45pt; text-transform: none; color: #000000; text-indent: -22.5pt; text-align: justify"><!--[if IE]><FONT style=" width: 22.5pt; text-indent: -18.0pt; display: inline-block;"><![endif]--><span style="width: 22.5pt; text-indent: 0; display: inline-block"><span style="text-transform: none">&#8226;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Recent historical payout levels that the Committee believed indicated that performance goals over the last few years had been set at reasonably </span><span style="text-transform: none">challenging levels.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">Overall, the Committee believed the 2024 Cash Bonus Plan was appropriately incentivizing given the executive officers&#8217; roles and authority within Artivion, and that the size of the incentives was appropriate based on the 2023 peer group information and internal pay </span><span style="text-transform: none; line-height: 12pt">equity considerations.</span></p>
				<p style="font: italic 11pt/normal Arial, sans-serif; margin: 4pt 0pt 8pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><i>Analysis &#8211; Plan Payout</i></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">As set forth above at page 28, the 2024 Cash Bonus Plan payouts in early 2025 were based on actual financial performance results of Artivion relative to the predetermined goals and adjusted by the Committee to account for the Committee&#8217;s overall assessment of management&#8217;s performance during 2024, including considering the impact of and management&#8217;s response to the Cybersecurity Incident.  </span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">Mr. Mackin&#8217;s 2023 Cash Bonus Plan payout in early 2025 was also based on the same considerations. The Board of Directors reviewed Mr. Mackin&#8217;s individual performance relative to his individual goals for 2024 and, after receiving the Committee&#8217;s certification of the 2024 performance metrics and the Committee&#8217;s recommendation to adjust the metrics to account for the Committee&#8217;s overall assessment of management&#8217;s performance during 2024, including considering the impact of and management&#8217;s response to the Cybersecurity Incident, approved the Chief Executive Officer&#8217;s bonus payout at the amount set </span><span style="text-transform: none; line-height: 12pt">forth below. </span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">The following tables show the performance results for the 2024 performance metrics, the payout as adjusted by the Committee as noted above, and that there were no personal-performance modifications to the short-term incentive paid to </span><span style="text-transform: none; line-height: 12pt">each NEO.</span></p>
				<div style="font: 12pt/normal Times New Roman, Times, serif; margin: 0pt; text-transform: none; color: #000000; text-align: center">
					<table style="margin: 4pt auto 0pt; table-layout: fixed; width: 569.96pt; border-collapse: collapse">
						<tr style="margin: 0; height: 0">
							<td style="border-width: 0; margin: 0; padding: 0; width: 240.9pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 61.87pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 95.62pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 92.81pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 78.75pt">


							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td colspan="5" style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>2024 Annual Incentive Program (Cash Bonus Plan)<br/>Actual vs. Target Performance </b></span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Performance Measure</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Weight <br/>(%)</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Actual<br/>Performance</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Target<br/>Performance</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Adjusted<br/>
Payout<br/>% of Target<br/>
(%)</b></span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0 22.5pt; text-transform: none; color: #000000; text-indent: -22.5pt; text-align: left"><span style="text-transform: none">Revenue Growth Rate; Constant Currency (2024 v. 2023)</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">50.0</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">9.4% growth</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">10.0% growth</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">130.0</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0 22.5pt; text-transform: none; color: #000000; text-indent: -22.5pt; text-align: left"><span style="text-transform: none">2024 Adjusted EBITDA</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">50.0</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">$71,300,000</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">$70,000,000</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">130.0</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td colspan="5" style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none"> - The final payout can be increased up to 20%, based on an individual executive officer&#8217;s performance. </span></p>
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 0; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none"> - The final payout cannot exceed 200% of target payout.</span></p>

							</td>

						</tr>

					</table>

				</div>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none">See Appendix A for further details regarding the adjusted </span><span style="text-transform: none">EBITDA measure.</span></p>
				<div style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-align: center">
					<table style="margin: 4pt auto 10pt; table-layout: fixed; width: 569.12pt; border-collapse: collapse">
						<tr style="margin: 0; height: 0">
							<td style="border-width: 0; margin: 0; padding: 0; width: 112.4pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 121.25pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 100.5pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 103.37pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 86.59pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 90pt">


							</td>

						</tr>
						<tr style="min-height: 12.95pt">
							<td colspan="6" style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>2024 Annual Incentive Program (Cash Bonus Plan)<br/>Actual vs. Target Payout</b></span></p>

							</td>

						</tr>
						<tr style="min-height: 12.95pt">
							<td style="white-space: nowrap; border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Executive Officer</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Actual<br/>Payout<br/>($)</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Target<br/>Payout<br/>($)</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Company<br/>Performance<br/>Adjusted <br/>Payout % of<br/>Target<br/>(%)</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Personal<br/>Performance<br/>Modifier<br/>(%)</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Adjusted Total Payout % of <br/>
Target <br/>(%)</b></span></p>

							</td>

						</tr>
						<tr style="min-height: 12.95pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Mackin</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 10pt 1.5pt 33px; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0px 0pt 0px 22px; text-transform: none; color: #000000"><span style="text-transform: none">1,048,975</span></p>

							</td>
							<td style="border-width: 0pt; padding-top: 1.5pt; padding-bottom: 1.5pt; padding-left: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">806,904</span></p>

							</td>
							<td style="border-width: 0pt; text-align: center; padding-top: 1.5pt; padding-bottom: 1.5pt; padding-left: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">130.0</span></p>

							</td>
							<td style="border-width: 0pt; text-align: center; padding-top: 1.5pt; padding-bottom: 1.5pt; padding-left: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">0.0</span></p>

							</td>
							<td style="border-width: 0pt; padding-top: 1.5pt; padding-bottom: 1.5pt; padding-left: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">130.0</span></p>

							</td>

						</tr>
						<tr style="min-height: 12.95pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Berry</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 10pt 1.5pt 0px; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0px 0pt 0px 66px; text-transform: none; color: #000000"><span style="text-transform: none">390,000</span></p>

							</td>
							<td style="border-width: 0pt; padding-top: 1.5pt; padding-bottom: 1.5pt; padding-left: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">300,000</span></p>

							</td>
							<td style="border-width: 0pt; text-align: center; padding-top: 1.5pt; padding-bottom: 1.5pt; padding-left: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">130.0</span></p>

							</td>
							<td style="border-width: 0pt; text-align: center; padding-top: 1.5pt; padding-bottom: 1.5pt; padding-left: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">0.0</span></p>

							</td>
							<td style="border-width: 0pt; padding-top: 1.5pt; padding-bottom: 1.5pt; padding-left: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">130.0</span></p>

							</td>

						</tr>
						<tr style="min-height: 12.95pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Holloway</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 10pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0px 0pt 0px 66px; text-transform: none; color: #000000"><span style="text-transform: none">276,665</span></p>

							</td>
							<td style="border-width: 0pt; padding-top: 1.5pt; padding-bottom: 1.5pt; padding-left: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">212,820</span></p>

							</td>
							<td style="border-width: 0pt; text-align: center; padding-top: 1.5pt; padding-bottom: 1.5pt; padding-left: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">130.0</span></p>

							</td>
							<td style="border-width: 0pt; text-align: center; padding-top: 1.5pt; padding-bottom: 1.5pt; padding-left: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">0.0</span></p>

							</td>
							<td style="border-width: 0pt; padding-top: 1.5pt; padding-bottom: 1.5pt; padding-left: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">130.0</span></p>

							</td>

						</tr>
						<tr style="min-height: 12.95pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Davis</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 10pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0px 0pt 0px 66px; text-transform: none; color: #000000"><span style="text-transform: none">264,456</span></p>

							</td>
							<td style="border-width: 0pt; padding-top: 1.5pt; padding-bottom: 1.5pt; padding-left: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">203,428</span></p>

							</td>
							<td style="border-width: 0pt; text-align: center; padding-top: 1.5pt; padding-bottom: 1.5pt; padding-left: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">130.0</span></p>

							</td>
							<td style="border-width: 0pt; text-align: center; padding-top: 1.5pt; padding-bottom: 1.5pt; padding-left: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">0.0</span></p>

							</td>
							<td style="border-width: 0pt; padding-top: 1.5pt; padding-bottom: 1.5pt; padding-left: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">130.0</span></p>

							</td>

						</tr>
						<tr style="min-height: 12.95pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Stanton</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 10pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0px 0pt 0px 66px; text-transform: none; color: #000000"><span style="text-transform: none">266,235</span></p>

							</td>
							<td style="border-width: 0pt; padding-top: 1.5pt; padding-bottom: 1.5pt; padding-left: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">204,797</span></p>

							</td>
							<td style="border-width: 0pt; text-align: center; padding-top: 1.5pt; padding-bottom: 1.5pt; padding-left: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">130.0</span></p>

							</td>
							<td style="border-width: 0pt; text-align: center; padding-top: 1.5pt; padding-bottom: 1.5pt; padding-left: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">0.0</span></p>

							</td>
							<td style="border-width: 0pt; padding-top: 1.5pt; padding-bottom: 1.5pt; padding-left: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">130.0</span></p>

							</td>

						</tr>

					</table>

				</div>

			</div>

		</div>
		<div style="page-break-before: always">
			<p style="margin: 0pt; font-size: 5pt">&#8203;</p>

		</div>
		<div class="qes_page" style="border-bottom: black 2pt solid; margin: auto; height: 990pt; width: 765pt; position: relative; overflow: hidden">
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 911.25pt; left: 45pt; width: 675pt; position: absolute; height: 33.75pt">
				<div style="display: table-cell; vertical-align: bottom; width: 675pt; height: 33.75pt">

				<!--[if IE]><TABLE><TR style=" width: 675pt; height: 33.75pt;"><TD vAlign="bottom" style=" width: 675pt; height: 33.75pt;"><![endif]-->
					<div style="font: 12pt/normal Times New Roman, Times, serif; margin: 0pt; text-transform: none; color: #000000; text-align: left">
						<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 0pt; border-collapse: collapse">
							<tr style="margin: 0; height: 0">
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>

							</tr>
							<tr style="min-height: 0pt">
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">ARTIVION, INC. | 2025 Proxy Statement</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">35</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 0pt; line-height: 0pt">&#8203;</p>

								</td>

							</tr>

						</table>

					</div>


				<!--[if IE]></TD></TR></TABLE><![endif]-->
				</div>

			</div>
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 45pt; left: 45pt; width: 675pt; position: absolute; height: 866.25pt">
				<p style="font: italic 11pt/normal Arial, sans-serif; margin: 0pt 0pt 8pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><b><i>2024 Long-Term Incentives &#8211; Annual Equity</i></b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">Based on input from management, and in consultation with Willis Towers Watson, starting in the fourth quarter of 2023, the Committee considered the 2024 Annual Long-Term Incentive Program, and in the design of the 2024 program, determined to use a mix of equity awards split equally between RSUs and PSUs. This mix may be altered for executive officers located outside of the U.S. to accommodate local </span><span style="text-transform: none; line-height: 12pt">tax issues.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">The Committee determined that the estimated grant date fair value of the awards under the Annual Long-Term Incentive Program in 2024 would be established at the levels disclosed in the table below to remain market competitive, as reflected in the 2023 Study. Market comparisons were based on the Company&#8217;s current financial statistics, such as annual revenue and market cap, as well as the anticipated growth of the Company and the continued increase in the complexity of the Company&#8217;s business following the acquisitions of JOTEC AG in fiscal 2017 and Ascyrus Medical LLC in fiscal 2020, the distribution agreement with Endospan Ltd., which commenced in 2019, the divestiture of the PerClot business with an ongoing transition manufacturing agreement with Baxter Healthcare Corp., the ongoing transition to the MDR in Europe, and the Company&#8217;s rapid growth in international markets, in particular the Asia Pacific and Latin American markets during 2023 and continuing </span><span style="text-transform: none; line-height: 12pt">into 2024. </span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">To arrive at the number of shares of RSUs and target PSUs to be granted, the Committee directed management to determine the number of units of restricted stock and target performance stock units using the closing share price of the Company&#8217;s stock on the grant date. Grants generally were made on the first permissible trading day following the Committee&#8217;s approval of such awards. In this instance, grant values approved by the Committee were converted to units using a stock price of $20.27 for the RSU and PSU grants, the closing price on February 23, 2024 when those grants were made.  </span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">For 2024, the Committee adopted the PSU performance measures as set forth above at </span><span style="text-transform: none; line-height: 12pt">page 28.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">The following table provides the 2024 equity awarded through the Annual Long-Term Incentive Program to the NEOs as approved by </span><span style="text-transform: none; line-height: 12pt">the Committee. </span></p>
				<div style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 8pt 22.5pt; text-transform: none; color: #000000; text-align: center">
					<table style="margin: 4pt auto 8pt; table-layout: fixed; width: 480pt; border-collapse: collapse">
						<tr style="margin: 0; height: 0">
							<td style="border-width: 0; margin: 0; padding: 0; width: 255pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 112.5pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 112.5pt">


							</td>

						</tr>
						<tr style="min-height: 12.95pt">
							<td colspan="3" style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>2024 Annual Equity Grant Level</b></span></p>

							</td>

						</tr>
						<tr style="min-height: 12.95pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Executive Officer</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Performance<br/>Stock<br/>Units</b></span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt"><b>(1)</b></sup><sup style="text-transform: none; font-size: 8pt; line-height: 8pt"><b><br/></b></sup><span style="text-transform: none"><b>(#)</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Restricted<br/>Stock Units</b></span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt"><b>(2)</b></sup><sup style="text-transform: none; font-size: 8pt; line-height: 8pt"><b><br/></b></sup><span style="text-transform: none"><b>(#)</b></span></p>

							</td>

						</tr>
						<tr style="min-height: 12.95pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0 3.75pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Mackin</span></p>

							</td>
							<td style="border-width: 0pt; text-align: center; padding-top: 1.5pt; padding-bottom: 1.5pt; padding-left: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">89,001</span></p>

							</td>
							<td style="border-width: 0pt; text-align: center; padding-top: 1.5pt; padding-bottom: 1.5pt; padding-left: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">89,001</span></p>

							</td>

						</tr>
						<tr style="min-height: 12.95pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0 3.75pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Berry</span></p>

							</td>
							<td style="border-width: 0pt; text-align: center; padding-top: 1.5pt; padding-bottom: 1.5pt; padding-left: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">37,000</span></p>

							</td>
							<td style="border-width: 0pt; text-align: center; padding-top: 1.5pt; padding-bottom: 1.5pt; padding-left: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">37,000</span></p>

							</td>

						</tr>
						<tr style="min-height: 12.95pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0 3.75pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Holloway</span></p>

							</td>
							<td style="border-width: 0pt; text-align: center; padding-top: 1.5pt; padding-bottom: 1.5pt; padding-left: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">19,610</span></p>

							</td>
							<td style="border-width: 0pt; text-align: center; padding-top: 1.5pt; padding-bottom: 1.5pt; padding-left: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">19,610</span></p>

							</td>

						</tr>
						<tr style="min-height: 12.95pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0 3.75pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Davis</span></p>

							</td>
							<td style="border-width: 0pt; text-align: center; padding-top: 1.5pt; padding-bottom: 1.5pt; padding-left: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">19,734</span></p>

							</td>
							<td style="border-width: 0pt; text-align: center; padding-top: 1.5pt; padding-bottom: 1.5pt; padding-left: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">19,734</span></p>

							</td>

						</tr>
						<tr style="min-height: 12.95pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0 3.75pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Stanton</span></p>

							</td>
							<td style="border-width: 0pt; text-align: center; padding-top: 1.5pt; padding-bottom: 1.5pt; padding-left: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">14,800</span></p>

							</td>
							<td style="border-width: 0pt; text-align: center; padding-top: 1.5pt; padding-bottom: 1.5pt; padding-left: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">14,800</span></p>

							</td>

						</tr>

					</table>

				</div>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 1pt 37.5pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(1)</sup></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Reflects the target performance stock unit award level. The actual number of PSU shares earned was based on performance factors determined by the Committee. Actual earned shares vest 1/3 on the later of the first anniversary of the award date or the first available date after the Committee certifies the prior year&#8217;s financial metric results (determined to be March 6, 2025, the first date that the awards could be released following the date that the Company filed its Form 10-K for fiscal 2024); 1/3 on the second anniversary of the award date; and 1/3 on the third anniversary of the </span><span style="text-transform: none">award date.</span></p>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 8pt 37.5pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(2)</sup></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Restricted stock units vest 1/3 on the first anniversary of the award date;1/3 on the second anniversary of the award date; and 1/3 on the third anniversary of the </span><span style="text-transform: none">award date.</span></p>
				<p style="font: italic 11pt/normal Arial, sans-serif; margin: 4pt 0pt 8pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><i>Analysis &#8211; Program Design </i></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">In approving the 2024 long-term incentive grant values awarded through the Annual Long-Term Incentive Plan in February 2024, the Committee considered the </span><span style="text-transform: none; line-height: 12pt">following factors:</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 8pt 45pt; text-transform: none; color: #000000; text-indent: -22.5pt; text-align: justify"><!--[if IE]><FONT style=" width: 22.5pt; text-indent: -18.0pt; display: inline-block;"><![endif]--><span style="width: 22.5pt; text-indent: 0; display: inline-block"><span style="text-transform: none">&#8226;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Updated market competitiveness analysis by the independent </span><span style="text-transform: none">compensation consultant;</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 8pt 45pt; text-transform: none; color: #000000; text-indent: -22.5pt; text-align: justify"><!--[if IE]><FONT style=" width: 22.5pt; text-indent: -18.0pt; display: inline-block;"><![endif]--><span style="width: 22.5pt; text-indent: 0; display: inline-block"><span style="text-transform: none">&#8226;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Increased size, geographic scope, and business complexity of the Company, and the continued expansion into Asia Pacific and Latin America, resulting in significant growth in those regions that included the creation of numerous new subsidiaries over the past </span><span style="text-transform: none">two years;</span></p>

			</div>

		</div>
		<div style="page-break-before: always">
			<p style="margin: 0pt; font-size: 5pt">&#8203;</p>

		</div>
		<div class="qes_page" style="border-bottom: black 2pt solid; margin: auto; height: 990pt; width: 765pt; position: relative; overflow: hidden">
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 911.25pt; left: 45pt; width: 675pt; position: absolute; height: 33.75pt">
				<div style="display: table-cell; vertical-align: bottom; width: 675pt; height: 33.75pt">

				<!--[if IE]><TABLE><TR style=" width: 675pt; height: 33.75pt;"><TD vAlign="bottom" style=" width: 675pt; height: 33.75pt;"><![endif]-->
					<div style="font: 12pt/normal Times New Roman, Times, serif; margin: 0pt; text-transform: none; color: #000000; text-align: left">
						<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 0pt; border-collapse: collapse">
							<tr style="margin: 0; height: 0">
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>

							</tr>
							<tr style="min-height: 0pt">
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">ARTIVION, INC. | 2025 Proxy Statement</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">36</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 0pt; line-height: 0pt">&#8203;</p>

								</td>

							</tr>

						</table>

					</div>


				<!--[if IE]></TD></TR></TABLE><![endif]-->
				</div>

			</div>
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 45pt; left: 45pt; width: 675pt; position: absolute; height: 866.25pt">
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 8pt 45pt; text-transform: none; color: #000000; text-indent: -22.5pt; text-align: justify"><!--[if IE]><FONT style=" width: 22.5pt; text-indent: -18.0pt; display: inline-block;"><![endif]--><span style="width: 22.5pt; text-indent: 0; display: inline-block"><span style="text-transform: none">&#8226;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Regulatory and clinical challenges associated with the transition to the MDR in Europe and the introduction of the Company&#8217;s aortic stent graft products into the U.S. market;  </span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 8pt 45pt; text-transform: none; color: #000000; text-indent: -22.5pt; text-align: justify"><!--[if IE]><FONT style=" width: 22.5pt; text-indent: -18.0pt; display: inline-block;"><![endif]--><span style="width: 22.5pt; text-indent: 0; display: inline-block"><span style="text-transform: none">&#8226;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">2023 personal and </span><span style="text-transform: none">Company performance;</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 8pt 45pt; text-transform: none; color: #000000; text-indent: -22.5pt; text-align: justify"><!--[if IE]><FONT style=" width: 22.5pt; text-indent: -18.0pt; display: inline-block;"><![endif]--><span style="width: 22.5pt; text-indent: 0; display: inline-block"><span style="text-transform: none">&#8226;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">The Committee&#8217;s continued desire to have a mix of value among restricted stock and performance stock units for the </span><span style="text-transform: none">annual awards;</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 8pt 45pt; text-transform: none; color: #000000; text-indent: -22.5pt; text-align: justify"><!--[if IE]><FONT style=" width: 22.5pt; text-indent: -18.0pt; display: inline-block;"><![endif]--><span style="width: 22.5pt; text-indent: 0; display: inline-block"><span style="text-transform: none">&#8226;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">The compensation program&#8217;s design, which emphasizes pay-for-performance and aligns executive officer performance (and resulting compensation) with </span><span style="text-transform: none">stockholder interests;</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 8pt 45pt; text-transform: none; color: #000000; text-indent: -22.5pt; text-align: justify"><!--[if IE]><FONT style=" width: 22.5pt; text-indent: -18.0pt; display: inline-block;"><![endif]--><span style="width: 22.5pt; text-indent: 0; display: inline-block"><span style="text-transform: none">&#8226;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Performance and retention incentives achieved through the use of annual equity </span><span style="text-transform: none">grants; and</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 8pt 45pt; text-transform: none; color: #000000; text-indent: -22.5pt; text-align: justify"><!--[if IE]><FONT style=" width: 22.5pt; text-indent: -18.0pt; display: inline-block;"><![endif]--><span style="width: 22.5pt; text-indent: 0; display: inline-block"><span style="text-transform: none">&#8226;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">The parameters of Artivion&#8217;s stockholder-approved equity plan, the 2020 ECIP, and the availability of shares under </span><span style="text-transform: none">that plan.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">The Committee determined vesting schedules in consultation with Willis Towers Watson and management and believed that such vesting provided the appropriate long-term incentive and retention for executive officers&#8217; continued employment. All annual long-term incentive (time-based) awards vest over a </span><span style="text-transform: none; line-height: 12pt">three-year period. </span></p>
				<p style="font: italic 11pt/normal Arial, sans-serif; margin: 4pt 0pt 8pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><i>Analysis &#8211; Plan Payout &#8211; PSUs Earned</i></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none">As set forth above at page 28, in arriving at its decision in February 2025 to certify the PSUs earned by NEOs, the Committee took into consideration the Company&#8217;s actual performance results relative to the above-described metrics and adjusted the payout to account for the Committee&#8217;s overall assessment of management&#8217;s performance during 2024, including considering the impact of and management&#8217;s response to the Cybersecurity Incident. The following table presents the threshold, target, and maximum performance levels associated with threshold, target, and maximum award opportunities, which fall on a sliding scale for the 2024 annual PSU award grants. The table also provides the actual performance level for 2024, as certified and adjusted by the Committee, together with the associated level of shares that </span><span style="text-transform: none">were earned.</span></p>
				<div style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-align: justify">
					<table style="table-layout: fixed; width: 674.31pt; margin-top: 4pt; margin-bottom: 10pt; border-collapse: collapse">
						<tr style="margin: 0; height: 0">
							<td style="border-width: 0; margin: 0; padding: 0; width: 233.75pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 92.5pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 84.37pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 110pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 82.43pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 71.25pt">


							</td>

						</tr>
						<tr style="min-height: 12.95pt">
							<td colspan="6" style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>2024 Performance Stock Units &#8211; Annual Award<br/>Actual vs. Threshold/Target/Maximum Performance</b></span></p>

							</td>

						</tr>
						<tr style="min-height: 12.95pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Performance Measure</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Threshold<br/>Performance</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Target<br/>Performance</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Maximum<br/>Performance</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Actual<br/>Performance</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Adjusted Payout <br/>% of Target (%)</b></span></p>

							</td>

						</tr>
						<tr style="min-height: 12.95pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0 3.75pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Revenue Growth Rate; Constant Currency (2024 v. 2023)</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">5.0% growth</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">10.0% growth</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">16.0% growth</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">9.4% growth</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">130.0</span></p>

							</td>

						</tr>
						<tr style="min-height: 12.95pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0 3.75pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Financial Metric Potential Payouts (%)</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">30</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">100</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">200</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">&#8212;</span></p>

							</td>

						</tr>
						<tr style="min-height: 12.95pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0 3.75pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">2024 Adjusted EBITDA</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">$57,400,000</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">$70,000,000</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">$75,000,000</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">$71,300,000</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">130.0</span></p>

							</td>

						</tr>
						<tr style="min-height: 12.95pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0 3.75pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Financial Metric Potential Payouts (%)</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">30</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">100</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">200</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">&#8212;</span></p>

							</td>

						</tr>
						<tr style="min-height: 12.95pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0 3.75pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">R&amp;D Metric Potential Payouts (%)</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">100</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">Achieved</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">130.0</span></p>

							</td>

						</tr>
						<tr style="min-height: 12.95pt">
							<td colspan="6" style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0pt 3.75pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">- Performance measures are weighted as follows: cc revenue growth rate at 50%; adjusted EBITDA at 30%; and R&amp;D milestones at 20%.</span></p>
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 0 3.75pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">- The combined resulting final payout, as adjusted, was 130.0% of target.</span></p>

							</td>

						</tr>

					</table>

				</div>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none">See Appendix A for further details regarding the constant currency and adjusted </span><span style="text-transform: none">EBITDA measures.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none">The 2024 PSU payouts in early 2025 were based on actual financial performance results of Artivion relative to the predetermined goals and adjusted by the Committee to account for the Committee&#8217;s overall assessment</span><span style="text-transform: none"> of management&#8217;s performance during 2024, including considering the impact of and management&#8217;s response to the Cybersecurity Incident, as set forth above at </span><span style="text-transform: none">page 28. </span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none">The PSU awards will vest based on the executive officer&#8217;s continued service: 1/3 of the shares earned vested on February 28, 2025 (following the Committee&#8217;s certification of the adjusted payout of shares under the performance metrics); 1/3 of the shares earned will vest on February 23, 2026; and the remaining 1/3 of the shares earned will vest on February 23, 2027, assuming that (i) the executive officer continues to be employed by the Company on those dates, (ii) if the executive officer is no longer employed, the Committee waives the employment requirement, or (iii) the executive officer has retired in accordance with the definition of Retirement set forth in Artivion&#8217;s PSU </span><span style="text-transform: none">grant agreement.</span></p>

			</div>

		</div>
		<div style="page-break-before: always">
			<p style="margin: 0pt; font-size: 5pt">&#8203;</p>

		</div>
		<div class="qes_page" style="border-bottom: black 2pt solid; margin: auto; height: 990pt; width: 765pt; position: relative; overflow: hidden">
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 911.25pt; left: 45pt; width: 675pt; position: absolute; height: 33.75pt">
				<div style="display: table-cell; vertical-align: bottom; width: 675pt; height: 33.75pt">

				<!--[if IE]><TABLE><TR style=" width: 675pt; height: 33.75pt;"><TD vAlign="bottom" style=" width: 675pt; height: 33.75pt;"><![endif]-->
					<div style="font: 12pt/normal Times New Roman, Times, serif; margin: 0pt; text-transform: none; color: #000000; text-align: left">
						<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 0pt; border-collapse: collapse">
							<tr style="margin: 0; height: 0">
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>

							</tr>
							<tr style="min-height: 0pt">
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">ARTIVION, INC. | 2025 Proxy Statement</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">37</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 0pt; line-height: 0pt">&#8203;</p>

								</td>

							</tr>

						</table>

					</div>


				<!--[if IE]></TD></TR></TABLE><![endif]-->
				</div>

			</div>
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 45pt; left: 45pt; width: 675pt; position: absolute; height: 879pt">
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">The following table shows the target payout and the adjusted payout of PSUs granted to each NEO based on the 2024 </span><span style="text-transform: none; line-height: 12pt">performance metrics.</span></p>
				<div style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-align: center">
					<table style="margin: 4pt auto 10pt; table-layout: fixed; width: 433.68pt; border-collapse: collapse">
						<tr style="margin: 0; height: 0">
							<td style="border-width: 0; margin: 0; padding: 0; width: 141.18pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 97.5pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 97.5pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 97.5pt">


							</td>

						</tr>
						<tr style="min-height: 12.95pt">
							<td colspan="4" style="border-bottom: Black 1pt solid; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>2024 Annual Incentive Program (Annual PSU Plan)<br/>Actual vs. Target Payout</b></span></p>

							</td>

						</tr>
						<tr style="min-height: 12.95pt">
							<td style="white-space: nowrap; border-bottom: Black 1pt solid; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Executive Officer</b></span></p>

							</td>
							<td style="border-bottom: Black 1pt solid; padding: 1.5pt 0pt 1.5pt 11px; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0 22px; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Actual<br/>Payout<br/>(Shares)</b></span></p>

							</td>
							<td style="border-bottom: Black 1pt solid; padding: 1.5pt 0pt 1.5pt 11px; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0 22px; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Target<br/>Payout<br/>(Shares)</b></span></p>

							</td>
							<td style="border-bottom: Black 1pt solid; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Adjusted Payout<br/>% of Target <br/>(%)</b></span></p>

							</td>

						</tr>
						<tr style="min-height: 12.95pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0 3.75pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Mackin</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 22pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">115,701</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 22pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">89,001</span></p>

							</td>
							<td style="border-width: 0pt; text-align: center; padding-top: 1.5pt; padding-bottom: 1.5pt; padding-left: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">130.0</span></p>

							</td>

						</tr>
						<tr style="min-height: 12.95pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0 3.75pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Berry</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 22pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">48,100</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 22pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">37,000</span></p>

							</td>
							<td style="border-width: 0pt; text-align: center; padding-top: 1.5pt; padding-bottom: 1.5pt; padding-left: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">130.0</span></p>

							</td>

						</tr>
						<tr style="min-height: 12.95pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0 3.75pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Holloway</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 22pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">25,493</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 22pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">19,610</span></p>

							</td>
							<td style="border-width: 0pt; text-align: center; padding-top: 1.5pt; padding-bottom: 1.5pt; padding-left: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">130.0</span></p>

							</td>

						</tr>
						<tr style="min-height: 12.95pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0 3.75pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Davis</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 22pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">25,654</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 22pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">19,734</span></p>

							</td>
							<td style="border-width: 0pt; text-align: center; padding-top: 1.5pt; padding-bottom: 1.5pt; padding-left: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">130.0</span></p>

							</td>

						</tr>
						<tr style="min-height: 12.95pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0 3.75pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Stanton</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 22pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">19,240</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 22pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">14,800</span></p>

							</td>
							<td style="border-width: 0pt; text-align: center; padding-top: 1.5pt; padding-bottom: 1.5pt; padding-left: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">130.0</span></p>

							</td>

						</tr>

					</table>

				</div>
				<p style="font: italic 11pt/normal Arial, sans-serif; margin: 4pt 0pt 8pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><b><i>2024 Annual Target Total Direct Compensation</i></b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none">The Committee believed that the blend of annual salary, cash bonus, RSUs, and PSUs appropriately achieved the performance, stockholder alignment, and retention objectives of Artivion&#8217;s compensation program. The Committee believes that the use of multiple award types is a common practice among industry peers and that the use of PSUs creates an even stronger alignment between pay and performance. The Committee believes that, in addition to incenting long-term performance, annual equity awards encourage continuous performance and retention by reflecting Company success (and changes in the stock price) year </span><span style="text-transform: none">over year. </span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none">The Committee used a value-based approach, rather than number of shares, to determine the size of 2024 annual equity grants, as it believed that such an approach more accurately matched the intended value of the equity and intended compensation. The Committee applied vesting schedules for the 2024 equity awards that it believes provided the appropriate annual long-term incentive to retain </span><span style="text-transform: none">executive officers.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none">In determining the individual components of the executive officers&#8217; 2024 annual compensation (i.e., salary, target short-term incentive, and annual long-term incentive), the Committee evaluated the resulting target annual total direct compensation against market benchmarks, as set forth below, accounting for the Committee&#8217;s desire to have target annual total direct compensation generally within a competitive range of the Company&#8217;s peer group median. The following table summarizes the NEOs&#8217; 2024 target annual total direct compensation, the peer group median, and the primary rationale for each NEO&#8217;s compensation at the </span><span style="text-transform: none">level shown.</span></p>
				<div style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt 22.5pt; text-transform: none; color: #000000; text-align: justify">
					<table style="table-layout: fixed; width: 629.37pt; margin-top: 4pt; margin-bottom: 10pt; border-collapse: collapse">
						<tr style="margin: 0; height: 0">
							<td style="border-width: 0; margin: 0; padding: 0; width: 123.75pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 132.49pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 95.62pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 277.49pt">


							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Executive<br/>Officer</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>2024 Target Total<br/>Direct Compensation<br/>Opportunity</b></span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt"><b>(1)</b></sup><span style="text-transform: none"><b> <br/>($)</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Peer Median</b></span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt"><b>(2)</b></sup><span style="text-transform: none"><b><br/>($)</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Primary Rationale</b></span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt"><b>(3)</b></sup></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0 3.75pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Mackin</span></p>

							</td>
							<td style="border-width: 0pt; text-align: center; padding-top: 1.5pt; padding-bottom: 1.5pt; padding-left: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">5,221,909</span></p>

							</td>
							<td style="border-width: 0pt; text-align: center; padding-top: 1.5pt; padding-bottom: 1.5pt; padding-left: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">4,665,000</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">Within a competitive range of the 50th percentile</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0 3.75pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Berry</span></p>

							</td>
							<td style="border-width: 0pt; text-align: center; padding-top: 1.5pt; padding-bottom: 1.5pt; padding-left: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">2,299,980</span></p>

							</td>
							<td style="border-width: 0pt; text-align: center; padding-top: 1.5pt; padding-bottom: 1.5pt; padding-left: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">2,200,000</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">Within a competitive range of the 50th percentile</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0 3.75pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Holloway</span></p>

							</td>
							<td style="border-width: 0pt; text-align: center; padding-top: 1.5pt; padding-bottom: 1.5pt; padding-left: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">1,433,448</span></p>

							</td>
							<td style="border-width: 0pt; text-align: center; padding-top: 1.5pt; padding-bottom: 1.5pt; padding-left: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">1,460,000</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">Within a competitive range of the 50th percentile</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0 3.75pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Davis</span></p>

							</td>
							<td style="border-width: 0pt; text-align: center; padding-top: 1.5pt; padding-bottom: 1.5pt; padding-left: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">1,410,299</span></p>

							</td>
							<td style="border-width: 0pt; text-align: center; padding-top: 1.5pt; padding-bottom: 1.5pt; padding-left: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">1,395,000</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">Within a competitive range of the 50th percentile</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0 3.75pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Stanton</span></p>

							</td>
							<td style="border-width: 0pt; text-align: center; padding-top: 1.5pt; padding-bottom: 1.5pt; padding-left: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">1,214,382</span></p>

							</td>
							<td style="border-width: 0pt; text-align: center; padding-top: 1.5pt; padding-bottom: 1.5pt; padding-left: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">1,185,000</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">Within a competitive range of the 50th percentile</span></p>

							</td>

						</tr>

					</table>

				</div>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 8pt 37.5pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(1)</sup></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Equity grant value based on a grant date closing share price of $20.27. Performance stock units are included at target </span><span style="text-transform: none">award levels/values.</span></p>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 8pt 37.5pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(2)</sup></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Based on data provided by Willis </span><span style="text-transform: none">Towers Watson.</span></p>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 8pt 37.5pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(3)</sup></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Competitive range for Chief Executive Officer, Chief Financial Officer, and Senior Vice Presidents total direct compensation is intended to be positioned at the market median; however, total direct compensation is intended to fall between the market median and 75</span><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">th</sup><span style="text-transform: none"> percentile, driven by superior performance. Willis Towers Watson provided guidance for compensation for </span><span style="text-transform: none">all NEOs. </span></p>
				<p style="font: italic 11pt/normal Arial, sans-serif; margin: 4pt 0pt 8pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><b><i>Equity and Cash Incentive Plans</i></b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none">In May 2015, the stockholders approved certain amendments to the 2009 Equity and Cash Incentive Plan (the &#8220;2009 ECIP&#8221;) that were recommended by the Board of Directors based on management&#8217;s recommendation and in consultation with Willis Towers Watson. The 2015 amendments included new provisions for cash-based incentive </span><span style="text-transform: none">payments that </span></p>

			</div>

		</div>
		<div style="page-break-before: always">
			<p style="margin: 0pt; font-size: 5pt">&#8203;</p>

		</div>
		<div class="qes_page" style="border-bottom: black 2pt solid; margin: auto; height: 990pt; width: 765pt; position: relative; overflow: hidden">
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 911.25pt; left: 45pt; width: 675pt; position: absolute; height: 33.75pt">
				<div style="display: table-cell; vertical-align: bottom; width: 675pt; height: 33.75pt">

				<!--[if IE]><TABLE><TR style=" width: 675pt; height: 33.75pt;"><TD vAlign="bottom" style=" width: 675pt; height: 33.75pt;"><![endif]-->
					<div style="font: 12pt/normal Times New Roman, Times, serif; margin: 0pt; text-transform: none; color: #000000; text-align: left">
						<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 0pt; border-collapse: collapse">
							<tr style="margin: 0; height: 0">
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>

							</tr>
							<tr style="min-height: 0pt">
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">ARTIVION, INC. | 2025 Proxy Statement</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">38</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 0pt; line-height: 0pt">&#8203;</p>

								</td>

							</tr>

						</table>

					</div>


				<!--[if IE]></TD></TR></TABLE><![endif]-->
				</div>

			</div>
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 45pt; left: 45pt; width: 675pt; position: absolute; height: 866.25pt">
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: justify"><span style="text-transform: none">were intended to comply with the requirements to be &#8220;qualified performance-based compensation&#8221; under Section 162(m) (&#8220;Section 162(m)&#8221;) of the Internal Revenue Code (as amended, the &#8220;Code&#8221;). In May 2016, the stockholders approved certain further amendments to the 2009 ECIP that were also recommended by the Board of Directors based on management&#8217;s recommendation and in consultation with Willis Towers Watson. The 2016 amendments included a separate, lower cap for awards to individual non-employee directors and a higher annual cap for awards to individual employees. In May 2018, the stockholders approved a proposal for authorization of an additional 1.9 million shares for the 2009 ECIP, which were registered in February 2019. The 2009 ECIP expired May </span><span style="text-transform: none">21, 2021. </span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none">At the 2020 Annual Meeting, the stockholders approved the 2020 ECIP and 2,675,000 shares of initial funding. In May 2023, the stockholders approved a proposal for authorization of an additional 3.04 million shares for the 2020 ECIP, which were registered in June 2023. All equity and incentive cash compensation delivered for work or performance in 2024 was issued under the 2020 ECIP.  </span></p>
				<p style="font: italic 11pt/normal Arial, sans-serif; margin: 4pt 0pt 8pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><b><i>2024 Deferred Compensation</i></b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none">The Artivion, Inc. Executive Deferred Compensation Plan allows certain key employees of Artivion, including the NEOs, to defer receipt of up to 75% of each of their salaries, commissions, and/or the cash portion of any bonus awarded pursuant to the short-term executive officer incentive plan. The plan&#8217;s administrative committee, subject to ratification and approval of the Committee, establishes the maximum and minimum percentages of bonus awards that plan participants may defer in each plan year. For 2024, these percentages were 0% for each of base salary and commissions and were 75% for the annual cash bonus. Because this plan provides for tax-deferred growth of deferred compensation, it is an incentive that the Company uses to attract and retain executive </span><span style="text-transform: none">officer-level talent.</span></p>
				<p style="font: italic 11pt/normal Arial, sans-serif; margin: 4pt 0pt 8pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><b><i>2024 Perquisites </i></b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none">It is Artivion&#8217;s policy not to provide perquisites to its executive officers without prior approval of the Committee. To the extent that perquisites are incidental to a business-related expense, such as personal use of a business club, the NEOs are generally required to reimburse Artivion for any incremental cost of such personal benefit. Other than these incidental personal benefits, none of our NEOs receive any perquisites that are not also provided on a non-discriminatory basis to all full-time employees, except for Mr. Mackin, whose compensation is discussed at Employment, Separation and Release, and Change of Control Agreements below, and except for supplemental disability insurance, airline club and other club memberships, auto allowance, and relocation assistance provided to certain of the NEOs. In keeping with Artivion&#8217;s practice with respect to all full-time employees, NEOs are also eligible to receive certain benefits upon achieving employment milestones, including receiving $5,000 upon reaching 15 years of service with Artivion and $10,000 upon reaching 20 and 25 years of service </span><span style="text-transform: none">with Artivion.</span></p>
				<p style="border-bottom: #7f7f7f 1pt solid; font: 12pt/normal Arial, sans-serif; margin: 4pt 0pt 15pt; text-transform: none; color: #2b4b74; text-indent: 0pt; text-align: left"><span style="text-transform: none"><b>EMPLOYMENT, SEPARATION AND RELEASE, AND CHANGE OF CONTROL AGREEMENTS</b></span></p>
				<p style="font: italic 11pt/normal Arial, sans-serif; margin: 4pt 0pt 8pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><b><i>Employment Agreement with J. Patrick Mackin</i></b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">In July 2014, the Board of Directors appointed Mr. Mackin as President and Chief Executive Officer effective September 3, 2014, and Artivion and Mr. Mackin entered into an employment agreement (the &#8220;Mackin Agreement&#8221;). The Mackin Agreement addresses Mr. Mackin&#8217;s role and responsibilities as our President and Chief Executive Officer, his rights to compensation and benefits during active employment, and his termination benefits. The Board of Directors determined that it was appropriate to provide Mr. Mackin with an employment agreement due to the Company&#8217;s desire to attract and retain high-performing individuals for </span><span style="text-transform: none; line-height: 12pt">this role.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">The material terms of the Mackin Agreement and his potential termination payments are further described and quantified at Potential Payments Upon Termination or Change of Control &#8211; J. Patrick Mackin beginning on </span><span style="text-transform: none; line-height: 12pt">page 52. </span></p>
				<p style="font: italic 11pt/normal Arial, sans-serif; margin: 4pt 0pt 8pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><b><i>Employment Agreements with Other Named Executive Officers</i></b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">Artivion is not party to employment agreements with Messrs. Berry, Davis, or Stanton or with Ms. Holloway that provide any guar</span><span style="text-transform: none; line-height: 12pt">antee of employment. They are </span><span style="text-transform: none; line-height: 12pt">at-will employees. </span></p>

			</div>

		</div>
		<div style="page-break-before: always">
			<p style="margin: 0pt; font-size: 5pt">&#8203;</p>

		</div>
		<div class="qes_page" style="border-bottom: black 2pt solid; margin: auto; height: 990pt; width: 765pt; position: relative; overflow: hidden">
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 911.25pt; left: 45pt; width: 675pt; position: absolute; height: 33.75pt">
				<div style="display: table-cell; vertical-align: bottom; width: 675pt; height: 33.75pt">

				<!--[if IE]><TABLE><TR style=" width: 675pt; height: 33.75pt;"><TD vAlign="bottom" style=" width: 675pt; height: 33.75pt;"><![endif]-->
					<div style="font: 12pt/normal Times New Roman, Times, serif; margin: 0pt; text-transform: none; color: #000000; text-align: left">
						<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 0pt; border-collapse: collapse">
							<tr style="margin: 0; height: 0">
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>

							</tr>
							<tr style="min-height: 0pt">
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">ARTIVION, INC. | 2025 Proxy Statement</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">39</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 0pt; line-height: 0pt">&#8203;</p>

								</td>

							</tr>

						</table>

					</div>


				<!--[if IE]></TD></TR></TABLE><![endif]-->
				</div>

			</div>
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 45pt; left: 45pt; width: 675pt; position: absolute; height: 866.25pt">
				<p style="font: italic 11pt/normal Arial, sans-serif; margin: 0pt 0pt 8pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><b><i>Change of Control Agreements with Other Named Executive Officers</i></b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">On November 21, 2016, Artivion entered into change of control agreements with Mr.&#160;Davis and Ms. Holloway. In August 2022, Artivion entered into new change of control agreements with Ms. Holloway and Mr. Davis; however, these new agreements contained only minor, non-substantive revisions to reflect Artivion&#8217;s rebranding and reincorporation into Delaware. In December 2023, Artivion entered into a change of control agreement with Mr. Berry. Mr. Mackin&#8217;s change of control arrangements are set forth in the Mackin Agreement. The change of control agreements, which automatically renew absent Company action, generally provide that the Company will pay a severance payment if the NEO is terminated by the Company without cause or the NEO terminates his or her own employment for good reason during a period extending from six months before to two years after a change of control of Artivion. This is a &#8220;double-trigger&#8221; provision that requires not only a change of control of Artivion but also an employment action before payments are required pursuant to the agreements. The Committee approved termination payments under the agreements for certain NEOs based on their officer status and ability to influence decisions regarding whether or not a change of control transaction should be pursued, with Mr. Berry, Ms. Holloway, and Mr. Davis each entitled to receive a payment of 1.5x base salary and cash bonus plus </span><span style="text-transform: none; line-height: 12pt">healthcare coverage.</span></p>
				<p style="border-bottom: #7f7f7f 1pt solid; font: 12pt/normal Arial, sans-serif; margin: 4pt 0pt 15pt; text-transform: none; color: #2b4b74; text-indent: 0pt; text-align: left"><span style="text-transform: none"><b>ADDITIONAL POLICIES AND PRACTICES</b></span></p>
				<p style="font: italic 11pt/normal Arial, sans-serif; margin: 4pt 0pt 8pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><b><i>Clawback Policy</i></b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">Artivion has a standalone Clawback Policy that requires the Company, acting through the Committee, to recover excess incentive compensation&#8212;in cash bonus or equity form&#8212;that was paid to any current or former officer during the three fiscal years prior to the Company issuing a material accounting restatement of its previously issued financial statements, or issuing a restatement that corrects errors that are not material to previously issued financial statements, but that would result in a material misstatement if corrected or left uncorrected in a current financial reporting period, as a result of noncompliance with any financial reporting requirement under federal securities law, unless the Committee determines that such recovery would be impracticable, as that term is defined in the Clawback Policy. Excess incentive compensation is defined in the Clawback Policy as incentive compensation that would not have been earned under the restated financial statements. The Clawback Policy does not require fault or negligence on the part of the officer for the clawback </span><span style="text-transform: none; line-height: 12pt">to occur. </span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">The Committee shall determine in its sole discretion, after consultation with its advisors and with the Audit Committee, whether a restatement of the Company&#8217;s financial statements is &#8220;material,&#8221; &#8220;corrects errors that are not material to previously issued financial statements, but that would result in a material misstatement if corrected or left uncorrected in a current financial reporting period,&#8221; or was &#8220;a result of noncompliance with any financial reporting requirement under the federal </span><span style="text-transform: none; line-height: 12pt">securities laws.&#8221;</span></p>
				<p style="font: italic 11pt/normal Arial, sans-serif; margin: 4pt 0pt 8pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><b><i>Stock Ownership Guidelines</i></b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">Artivion maintains stock ownership guidelines for executive officers that have been recommended and approved by the Committee, the Corporate Governance Committee, and the Board of Directors. The current stock ownership guidelines were adopted in November 2015 and require the following stock </span><span style="text-transform: none; line-height: 12pt">ownership requirements:</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt 45pt; text-transform: none; color: #000000; text-indent: -22.5pt; text-align: justify"><!--[if IE]><FONT style=" width: 22.5pt; text-indent: -18.0pt; display: inline-block;"><![endif]--><span style="width: 22.5pt; text-indent: 0; display: inline-block"><span style="text-transform: none">  </span><span style="text-transform: none">a.</span></span><!--[if IE]></FONT><![endif]--><span style="text-decoration: underline; text-transform: none"><span style="text-decoration: underline">Section 16 Officers</span></span><span style="text-transform: none">: Each Section 16 Officer of the Company shall continuously hold a value of the Company&#8217;s common stock equal to the value of a multiple of that officer&#8217;s then-current base salary at Artivion. The multiples applicable to such officers are </span><span style="text-transform: none">as follows:</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt 67.5pt; text-transform: none; color: #000000; text-indent: -22.5pt; text-align: justify"><!--[if IE]><FONT style=" width: 22.5pt; text-indent: -18.0pt; display: inline-block;"><![endif]--><span style="width: 22.5pt; text-indent: 0; display: inline-block"><span style="text-transform: none">i.</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Chief Executive Officer and President: 4x </span><span style="text-transform: none">base salary;</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt 67.5pt; text-transform: none; color: #000000; text-indent: -22.5pt; text-align: justify"><!--[if IE]><FONT style=" width: 22.5pt; text-indent: -18.0pt; display: inline-block;"><![endif]--><span style="width: 22.5pt; text-indent: 0; display: inline-block"><span style="text-transform: none">ii.</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Executive Vice Presidents and Senior Vice Presidents: 2x base </span><span style="text-transform: none">salary; and</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt 67.5pt; text-transform: none; color: #000000; text-indent: -22.5pt; text-align: justify"><!--[if IE]><FONT style=" width: 22.5pt; text-indent: -18.0pt; display: inline-block;"><![endif]--><span style="width: 22.5pt; text-indent: 0; display: inline-block"><span style="text-transform: none">iii.</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">All other Section 16 Officers: 1x </span><span style="text-transform: none">base salary.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt 45pt; text-transform: none; color: #000000; text-indent: -22.5pt; text-align: justify"><!--[if IE]><FONT style=" width: 22.5pt; text-indent: -18.0pt; display: inline-block;"><![endif]--><span style="width: 22.5pt; text-indent: 0; display: inline-block"><span style="text-transform: none">b.</span></span><!--[if IE]></FONT><![endif]--><span style="text-decoration: underline; text-transform: none"><span style="text-decoration: underline">Retention requirements</span></span><span style="text-transform: none">: Each Section 16 Officer who has not yet acquired ownership of the required value of common stock set forth above must retain at least 50% of the net number of shares acquired upon the exercise of any employee stock option or the vesting of any performance shares, restricted stock, or restricted stock units (the net number of shares acquired shall be the number of shares remaining after shares are tendered, sold, or netted to pay any applicable exercise price and </span><span style="text-transform: none">withholding taxes).</span></p>

			</div>

		</div>
		<div style="page-break-before: always">
			<p style="margin: 0pt; font-size: 5pt">&#8203;</p>

		</div>
		<div class="qes_page" style="border-bottom: black 2pt solid; margin: auto; height: 990pt; width: 765pt; position: relative; overflow: hidden">
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 911.25pt; left: 45pt; width: 675pt; position: absolute; height: 33.75pt">
				<div style="display: table-cell; vertical-align: bottom; width: 675pt; height: 33.75pt">

				<!--[if IE]><TABLE><TR style=" width: 675pt; height: 33.75pt;"><TD vAlign="bottom" style=" width: 675pt; height: 33.75pt;"><![endif]-->
					<div style="font: 12pt/normal Times New Roman, Times, serif; margin: 0pt; text-transform: none; color: #000000; text-align: left">
						<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 0pt; border-collapse: collapse">
							<tr style="margin: 0; height: 0">
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>

							</tr>
							<tr style="min-height: 0pt">
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">ARTIVION, INC. | 2025 Proxy Statement</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">40</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 0pt; line-height: 0pt">&#8203;</p>

								</td>

							</tr>

						</table>

					</div>


				<!--[if IE]></TD></TR></TABLE><![endif]-->
				</div>

			</div>
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 45pt; left: 45pt; width: 675pt; position: absolute; height: 873pt">
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 9pt 45pt; text-transform: none; color: #000000; text-indent: -22.5pt; text-align: justify"><!--[if IE]><FONT style=" width: 22.5pt; text-indent: -18.0pt; display: inline-block;"><![endif]--><span style="width: 22.5pt; text-indent: 0; display: inline-block"><span style="text-transform: none">c.</span></span><!--[if IE]></FONT><![endif]--><span style="text-decoration: underline; text-transform: none"><span style="text-decoration: underline">Waivers</span></span><span style="text-transform: none">: The Chairs of the Committee and the Corporate Governance Committee shall have the authority to grant waivers from these stock ownership requirements in compelling circumstances such as </span><span style="text-transform: none">undue hardship.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 9pt 45pt; text-transform: none; color: #000000; text-indent: -22.5pt; text-align: justify"><!--[if IE]><FONT style=" width: 22.5pt; text-indent: -18.0pt; display: inline-block;"><![endif]--><span style="width: 22.5pt; text-indent: 0; display: inline-block"><span style="text-transform: none">d. </span></span><!--[if IE]></FONT><![endif]--><span style="text-decoration: underline; text-transform: none"><span style="text-decoration: underline">Qualifying shares</span></span><span style="text-transform: none">: For purposes of satisfying these stock ownership requirements, the following shall be included: shares owned directly or indirectly (1) through a stock purchase plan sponsored by the Company; (2) by the person&#8217;s spouse; (3) in a revocable trust of which the person or the person&#8217;s spouse is the trustee; (4) any other shares related to or underlying vested or unvested restricted stock awards and performance share awards (after performance metric has been certified); or (5) vested RSUs and vested PSUs (at actual, earned levels and only if and to the extent that any applicable performance criteria have been satisfied). It shall not include shares held through any other form of indirect beneficial ownership or shares underlying unexercised options or unvested PSUs whose performance metric requirements were </span><span style="text-transform: none">not met.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 9pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">These guidelines became effective for all currently employed NEOs on November 17, 2015. As shown in the below table, as of March 17, 2025, all of our NEOs are in compliance with </span><span style="text-transform: none; line-height: 12pt">the guidelines. </span></p>
				<div style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-align: justify">
					<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 10pt; border-collapse: collapse">
						<tr style="margin: 0; height: 0">
							<td style="border-width: 0; margin: 0; padding: 0; width: 200pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 95pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 95pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 95pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 95pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 95pt">


							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td colspan="6" style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Executive Officer Stock Ownership</b></span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Executive Officer</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>2024 Base Salary ($)</b></span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt"><b>(1)</b></sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Multiple</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Required Value ($)</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Owned Shares</b></span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt"><b>(2)</b></sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Value of Owned Shares</b></span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt"><b>(3)</b></sup><span style="text-transform: none"><b><br/>($)</b></span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0 3.75pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Mackin</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">$806,904</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">4x</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 12pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">$3,227,616</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 18pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">865,283</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 12pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">20,836,015</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0 3.75pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Berry</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">$500,000</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">2x</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 12pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">$1,000,000</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 18pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">153,431</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 12pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">3,694,618</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0 3.75pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Holloway</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">$425,639</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">2x</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 12pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">$851,278</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 18pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">197,184</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 12pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">4,748,191</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0 3.75pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Davis</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">$406,855</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">2x</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 12pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">$813,710</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 18pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">208,778</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 12pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">5,027,374</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0 3.75pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Stanton</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">$409,593</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">2x</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 12pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">$819,186</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 18pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">115,880</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 12pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">2,790,390</span></p>

							</td>

						</tr>

					</table>

				</div>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 8pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(1)</sup></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">This amount represents the base salary as reported in the Summary Compensation Table on </span><span style="text-transform: none">page 43.</span></p>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 8pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(2)</sup></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Amount includes: (1) shares held of record by the spouses of executive officers as of March 17, 2025; and (2) shares of unvested restricted common stock subject to forfeiture held as of March 17, 2025 and shares earned under 2023 and 2024 performance stock unit awards that had not vested as of March 17, 2025. Amount does not include unexercised stock options that had not vested as of March </span><span style="text-transform: none">17, 2025.</span></p>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 8pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(3)</sup></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Based on the closing price of the Company&#8217;s common stock on the NYSE on March 17, 2025 </span><span style="text-transform: none">of $24.08.</span></p>
				<p style="font: italic 11pt/normal Arial, sans-serif; margin: 4pt 0pt 8pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><b><i>Insider Trading Policies and Procedures</i></b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 9pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt"><span id="xdx_901_eecd--InsiderTrdPoliciesProcAdoptedFlag_dbT_c20240101__20241231_zouV73bX2wm9" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBQb2xpY2llcyBhbmQgUHJvY2VkdXJlcwA_"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleantrue" id="Fact000012" name="ecd:InsiderTrdPoliciesProcAdoptedFlag">Artivion has adopted the Artivion, Inc. Insider Trading Policy and Guidelines with Respect to Certain Transactions in Securities (the &#8220;Insider Trading Policy&#8221;), which governs the purchase, sale and other dispositions of Artivion&#8217;s securities by all Artivion directors, officers, employees, and certain other covered persons.</ix:nonNumeric></span> We believe that the Insider Trading Policy, as well as procedures that Artivion follows with respect to its transactions in Company securities, are reasonably designed to promote compliance with insider trading laws, rules, and regulations, and listing standards applicable to </span><span style="text-transform: none; line-height: 12pt">the Company. </span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 9pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">Our Insider Trading Policy also prohibits all covered persons from engaging in derivative securities or hedging transactions with respect to the Company&#8217;s securities. Specifically, NEOs are prohibited from engaging in transactions in publicly traded options, such as puts and calls, and other derivative securities with respect to the Company&#8217;s securities. This prohibition extends to any hedging or similar transaction designed to decrease the risks associated with holding Company securities, including but not limited to prepaid variable contracts, equity swaps, collars, and exchange funds. Stock options, stock appreciation rights, and other securities issued pursuant to Company benefit plans or other compensatory arrangements with the Company are not subject to </span><span style="text-transform: none; line-height: 12pt">this prohibition.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 9pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">Furthermore, a short sale, which is the sale of a security that must be borrowed to make delivery, and &#8220;selling short a</span><span style="text-transform: none; line-height: 12pt">gainst the box,&#8221; which is transacting a sale with a delayed delivery, are prohibited with respect to Company securities under the Insider Trading Policy and NEOs may not engage in </span><span style="text-transform: none; line-height: 12pt">such transactions.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 9pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">The Insider Trading Policy is available for review at </span><span style="text-decoration: underline; text-transform: none; line-height: 12pt"><span style="text-decoration: underline">https://cryolife.gcs-web.com/insider-trading-policy</span></span><span style="text-transform: none; line-height: 12pt">, and was filed as Exhibit 19.1 to the Company&#8217;s Report on Form 10-K for the year ended December </span><span style="text-transform: none; line-height: 12pt">31, 2024.</span></p>
				<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" continuedAt="ConU000015-01" escape="true" id="Fact000015" name="ecd:AwardTmgMnpiDiscTextBlock"><p id="xdx_806_eecd--AwardTmgMnpiDiscTextBlock_dU_gL1ATMDTB-ZZI_zpIAA6jihWK3" style="font: italic 11pt/normal Arial, sans-serif; margin: 4pt 0pt 8pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><b><i>Equity Grant Policies and Practices</i></b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">The Committee generally adheres to a policy that the Company will not make equity grants during regular quarterly financial blackout periods and until two full trading days after the conclusion of such blackout period. We do not grant equity awards in anticipation of the release of material nonpublic information that is likely to result in changes to the price </span><span style="text-transform: none; line-height: 12pt">of our</span></p>

</ix:nonNumeric><p id="xdx_811_zUitOf7Z2gwe" style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt"></span></p>

			</div>

		</div>
		<div style="page-break-before: always">
			<p style="margin: 0pt; font-size: 5pt">&#8203;</p>

		</div>
		<div class="qes_page" style="border-bottom: black 2pt solid; margin: auto; height: 990pt; width: 765pt; position: relative; overflow: hidden">
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 911.25pt; left: 45pt; width: 675pt; position: absolute; height: 33.75pt">
				<div style="display: table-cell; vertical-align: bottom; width: 675pt; height: 33.75pt">

				<!--[if IE]><TABLE><TR style=" width: 675pt; height: 33.75pt;"><TD vAlign="bottom" style=" width: 675pt; height: 33.75pt;"><![endif]-->
					<div style="font: 12pt/normal Times New Roman, Times, serif; margin: 0pt; text-transform: none; color: #000000; text-align: left">
						<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 0pt; border-collapse: collapse">
							<tr style="margin: 0; height: 0">
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>

							</tr>
							<tr style="min-height: 0pt">
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">ARTIVION, INC. | 2025 Proxy Statement</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">41</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 0pt; line-height: 0pt">&#8203;</p>

								</td>

							</tr>

						</table>

					</div>


				<!--[if IE]></TD></TR></TABLE><![endif]-->
				</div>

			</div>
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 45pt; left: 45pt; width: 675pt; position: absolute; height: 866.25pt">
				<div id="xdx_C0A_gL1ATMDTB-ZZI_zr2Ya05ohFy3"><ix:continuation id="ConU000015-01"><p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">common stock, nor do we time the disclosure of material nonpublic information for the purpose of affecting the value of executive compensation. In the event of a special blackout period outside the regular quarterly financial blackout period, we consider the extent and nature of both the special blackout period and the equity grant(s) at issue. Unless the Committee determines otherwise, equity grant(s) may be made during special blackout periods outside the regular quarterly financial blackout period, depending upon the extent and nature of both the special blackout period and the equity grant(s) </span><span style="text-transform: none; line-height: 12pt">at issue.</span></p></ix:continuation></div>
				<p style="border-bottom: #7f7f7f 1pt solid; font: 12pt/normal Arial, sans-serif; margin: 4pt 0pt 15pt; text-transform: none; color: #2b4b74; text-indent: 0pt; text-align: left"><span style="text-transform: none"><b>TAX IMPACT OF COMPENSATION DECISIONS</b></span></p>
				<p style="font: italic 11pt/normal Arial, sans-serif; margin: 4pt 0pt 8pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><b><i>Section 162(m) </i></b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">Section 162(m) places a limit of $1 million per year on the amount of compensation paid to certain of our executive officers that is deductible by the Company for federal income tax purposes. Following changes to the law in 2018, Section 162(m) no longer contains an exception for &#8220;performance-based&#8221; compensation for arrangements that are not considered &#8220;grandfathered.&#8221; The Committee makes compensation decisions as appropriate to implement the Company&#8217;s Compensation Philosophy, with tax factors (including deductibility to the Company under Section 162(m)) being only one of many factors considered in implementing the </span><span style="text-transform: none; line-height: 12pt">Compensation Philosophy.</span></p>
				<p style="font: italic 11pt/normal Arial, sans-serif; margin: 4pt 0pt 8pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><b><i>Section 409A</i></b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">Since Section 409A of the Code, which deals with deferred compensation arrangements, was enacted, the Committee&#8217;s policy has been to structure all executive officer compensation arrangements to comply, to the extent feasible, with the provisions of Section 409A so that executive officers do not have to pay additional tax and Artivion does not incur additional withholding obligations. The Committee intends to continue </span><span style="text-transform: none; line-height: 12pt">this practice. </span></p>
				<p style="border-bottom: #7f7f7f 1pt solid; font: 12pt/normal Arial, sans-serif; margin: 4pt 0pt 15pt; text-transform: none; color: #2b4b74; text-indent: 0pt; text-align: left"><span style="text-transform: none"><b>FORWARD-LOOKING STATEMENTS</b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none">Statements made in this Proxy Statement that look forward in time or that express management&#8217;s beliefs, expectations, or hopes are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements reflect the views of management at the time such statements are made and are subject to a number of risks, uncertainties, estimates, and assumptions that may cause actual results to differ materially from current expectations. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Exchange Act. All statements other than statements of historical facts contained in this Proxy Statement may be forward-looking statements. In some cases, you can identify forward-looking statements by terms such as &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;intends,&#8221; &#8220;anticipates,&#8221; &#8220;indicates,&#8221; &#8220;remains,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;forecast,&#8221; &#8220;guidance,&#8221; &#8220;outlook,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;seeks,&#8221; &#8220;goals,&#8221; &#8220;targets&#8221; or the negative of these terms or other similar expressions. Additionally, forward-looking statements include statements that do not relate solely to historical facts, such as statements which identify uncertainties or trends, discuss the possible future effects of current known trends or uncertainties, or which indicate that the future effects of known trends or uncertainties cannot be predicted, guaranteed, or assured. Forward-looking statements contained in this Proxy Statement include, without limitation, statements regarding our outlook and future results of operations, including our profitability goals, our business strategy and plans for future operations, including our cost-savings initiatives, our expectations regarding bringing additional products to market, current plan, considerations, expectations and determinations regarding future compensation programs. These statements include those regarding future plans and intentions of the Committee and/or Board of Directors related to compensation decisions and expectations that certain performance targets for management are achievable. These future events may not occur as and when expected, if at all, and, together with the Company&#8217;s business, are subject to various risks and uncertainties. Along with risks specific to our business, management&#8217;s ability to attain certain performance targets is subject to risks affecting the economy generally and other factors that are beyond our control. For additional risks impacting the Company&#8217;s business, see the Risk Factors section of the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2024 at page 24. Additional risks and uncertainties are discussed from time to time in current, quarterly, and annual reports filed by the Company with the SEC, which are available on the SEC&#8217;s website at&#160;www.sec.gov. The Company assumes no obligation, and expressly disclaims any duty, to update publicly any such forward-looking statements, whether as a result of new information, future event, </span><span style="text-transform: none">or otherwise.</span></p>

			</div>

		</div>
		<div style="page-break-before: always">
			<p style="margin: 0pt; font-size: 5pt">&#8203;</p>

		</div>
		<div class="qes_page" style="border-bottom: black 2pt solid; margin: auto; height: 990pt; width: 765pt; position: relative; overflow: hidden">
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 911.25pt; left: 45pt; width: 675pt; position: absolute; height: 33.75pt">
				<div style="display: table-cell; vertical-align: bottom; width: 675pt; height: 33.75pt">

				<!--[if IE]><TABLE><TR style=" width: 675pt; height: 33.75pt;"><TD vAlign="bottom" style=" width: 675pt; height: 33.75pt;"><![endif]-->
					<div style="font: 12pt/normal Times New Roman, Times, serif; margin: 0pt; text-transform: none; color: #000000; text-align: left">
						<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 0pt; border-collapse: collapse">
							<tr style="margin: 0; height: 0">
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>

							</tr>
							<tr style="min-height: 0pt">
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">ARTIVION, INC. | 2025 Proxy Statement</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">42</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 0pt; line-height: 0pt">&#8203;</p>

								</td>

							</tr>

						</table>

					</div>


				<!--[if IE]></TD></TR></TABLE><![endif]-->
				</div>

			</div>
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 45pt; left: 45pt; width: 675pt; position: absolute; height: 866.25pt">
				<p style="border-bottom: #7f7f7f 1pt solid; font: 12pt/normal Arial, sans-serif; margin: 0pt 0pt 15pt; text-transform: none; color: #2b4b74; text-indent: 0pt; text-align: left"><span style="text-transform: none"><b>WEBSITES</b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">Links to websites included in this Proxy Statement are provided solely for convenience. Information contained on websites, including on our website, is not, and will not be deemed to be, a part of this Proxy Statement or incorporated by reference into any of our other filings with </span><span style="text-transform: none; line-height: 12pt">the SEC.</span></p>
				<p style="border-bottom: #7f7f7f 1pt solid; font: 12pt/normal Arial, sans-serif; margin: 4pt 0pt 15pt; text-transform: none; color: #2b4b74; text-indent: 0pt; text-align: left"><span style="text-transform: none"><b>REPORT OF THE COMPENSATION COMMITTEE</b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">The Committee reviewed and discussed the Compensation Discussion and Analysis with management. In reliance on this review and discussion, the Committee recommended to the Board of Directors that the Compensation Discussion and Analysis be included in Artivion&#8217;s 2025 Proxy Statement on Schedule 14A, for filing with </span><span style="text-transform: none; line-height: 12pt">the SEC.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt 360pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none"><b>Compensation Committee<br/></b></span><span style="text-transform: none">DANIEL J. BEVEVINO, CHAIR<br/>JAMES W. BULLOCK<br/>ANTHONY </span><span style="text-transform: none">B. SEMEDO</span></p>

			</div>

		</div>
		<div style="page-break-before: always">
			<p style="margin: 0pt; font-size: 5pt">&#8203;</p>

		</div>
		<div class="qes_page" style="border-bottom: black 2pt solid; margin: auto; height: 990pt; width: 765pt; position: relative; overflow: hidden">
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 911.25pt; left: 45pt; width: 675pt; position: absolute; height: 33.75pt">
				<div style="display: table-cell; vertical-align: bottom; width: 675pt; height: 33.75pt">

				<!--[if IE]><TABLE><TR style=" width: 675pt; height: 33.75pt;"><TD vAlign="bottom" style=" width: 675pt; height: 33.75pt;"><![endif]-->
					<div style="font: 12pt/normal Times New Roman, Times, serif; margin: 0pt; text-transform: none; color: #000000; text-align: left">
						<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 0pt; border-collapse: collapse">
							<tr style="margin: 0; height: 0">
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>

							</tr>
							<tr style="min-height: 0pt">
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">ARTIVION, INC. | 2025 Proxy Statement</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">43</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 0pt; line-height: 0pt">&#8203;</p>

								</td>

							</tr>

						</table>

					</div>


				<!--[if IE]></TD></TR></TABLE><![endif]-->
				</div>

			</div>
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 45pt; left: 45pt; width: 675pt; position: absolute; height: 866.25pt">
				<p style="font: 14pt/normal Arial, sans-serif; margin: 0pt 0pt 15pt; text-transform: none; color: #2b4b74; text-indent: 0pt; text-align: left"><span style="text-transform: none"><b>EXECUTIVE OFFICER COMPENSATION</b></span></p>
				<p style="border-bottom: #7f7f7f 1pt solid; font: 12pt/normal Arial, sans-serif; margin: 4pt 0pt 15pt; text-transform: none; color: #2b4b74; text-indent: 0pt; text-align: left"><span style="text-transform: none"><b>Summary Compensation Table</b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: uppercase; line-height: 12pt">T</span><span style="text-transform: none; line-height: 12pt">he following table sets forth information with respect to each of the Named Executive Officers&#160;&#8212; Mr. Mackin, our Chief Executive Officer; Mr. Berry, our Chief Financial Officer; and Ms. Holloway, Mr. Davis, and Mr. Stanton, who were the three most highly compensated of the other executive officers of Artivion employed at the end of </span><span style="text-transform: none; line-height: 12pt">fiscal 2024.</span></p>
				<div style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-align: left">
					<table style="table-layout: fixed; width: 674pt; margin-top: 4pt; margin-bottom: 10pt; border-collapse: collapse">
						<tr style="margin: 0; height: 0">
							<td style="border-width: 0; margin: 0; padding: 0; width: 106.5pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 41.25pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 60pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 57.5pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 67.5pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 61.25pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 83.75pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 85pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 55pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 56.25pt">


							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 8pt"><b>Name and<br/>Principal Position</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 8pt"><b>Year</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 8pt"><b>Salary</b></span><sup style="text-transform: none; font-size: 6pt; line-height: 6pt"><b>(1)</b></sup><span style="text-transform: none; font-size: 8pt"><b><br/>($)</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 8pt"><b>Bonus</b></span><sup style="text-transform: none; font-size: 6pt; line-height: 6pt"><b>(2)</b></sup><span style="text-transform: none; font-size: 8pt"><b><br/>($)</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 8pt"><b>Stock<br/>Awards</b></span><sup style="text-transform: none; font-size: 6pt; line-height: 6pt"><b>(3)</b></sup><span style="text-transform: none; font-size: 8pt"><b><br/>($)</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 8pt"><b>Option<br/>Awards</b></span><sup style="text-transform: none; font-size: 6pt; line-height: 6pt"><b>(4)</b></sup><span style="text-transform: none; font-size: 8pt"><b><br/>($)</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 8pt"><b>Non-Equity<br/>Incentive Plan<br/>Compensation</b></span><sup style="text-transform: none; font-size: 6pt; line-height: 6pt"><b>(5)</b></sup><span style="text-transform: none; font-size: 8pt"><b><br/>($)</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 8pt"><b>Change in<br/>Pension Value<br/>and Non-<br/>qualified Deferred<br/>Compensation<br/>Earnings<br/>($)</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 8pt"><b>All Other<br/>Compen-<br/>sation</b></span><sup style="text-transform: none; font-size: 6pt; line-height: 6pt"><b>(6)</b></sup><span style="text-transform: none; font-size: 8pt"><b><br/>($)</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 8pt"><b>Total</b></span><sup style="text-transform: none; font-size: 6pt; line-height: 6pt"><b>(7)</b></sup><span style="text-transform: none; font-size: 8pt"><b><br/>($)</b></span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><sup style="text-transform: none; font-size: 6pt; line-height: 6pt"><b>(a)</b></sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><sup style="text-transform: none; font-size: 6pt; line-height: 6pt"><b>(b)</b></sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><sup style="text-transform: none; font-size: 6pt; line-height: 6pt"><b>(c)</b></sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><sup style="text-transform: none; font-size: 6pt; line-height: 6pt"><b>(d)</b></sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><sup style="text-transform: none; font-size: 6pt; line-height: 6pt"><b>(e)</b></sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><sup style="text-transform: none; font-size: 6pt; line-height: 6pt"><b>(f)</b></sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><sup style="text-transform: none; font-size: 6pt; line-height: 6pt"><b>(g)</b></sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><sup style="text-transform: none; font-size: 6pt; line-height: 6pt"><b>(h)</b></sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><sup style="text-transform: none; font-size: 6pt; line-height: 6pt"><b>(i)</b></sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><sup style="text-transform: none; font-size: 6pt; line-height: 6pt"><b>(j)</b></sup></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td rowspan="3" style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 8pt">J. Patrick Mackin, Chairman, President and Chief Executive Officer</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 8pt">2024</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 8pt">806,904</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">3,608,101</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">1,048,975</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">47,960</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">5,511,940</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 8pt">2023</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 8pt">775,869</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">801,938</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">1,551,738</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">46,868</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">3,176,413</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 8pt">2022</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 8pt">749,632</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">3,419,012</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">2,168,245</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">835,090</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">44,361</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">7,216,340</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td rowspan="2" style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 8pt">Lance A. Berry, Executive Vice President, Chief Financial Officer</span><sup style="text-transform: none; font-size: 6pt; line-height: 6pt">(8)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 8pt">2024</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 8pt">500,000</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">1,499,980</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">390,000</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">184,053</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">2,574,033</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 8pt">2023</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 8pt">38,356</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">100,000</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">750,001</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">750,000</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">1,638,357</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td rowspan="3" style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; background-color: rgb(223,228,234); vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 8pt">Jean F. Holloway,</span></p>
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 0; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 8pt">Senior Vice President, General Counsel, Corporate Secretary, and Chief Compliance Officer</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: rgb(223,228,234); vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 8pt">2024</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: rgb(223,228,234); vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 8pt">425,639</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: rgb(223,228,234); vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: rgb(223,228,234); vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">794,989</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: rgb(223,228,234); vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: rgb(223,228,234); vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">276,665</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: rgb(223,228,234); vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: rgb(223,228,234); vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">18,120</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: rgb(223,228,234); vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">1,515,413</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 8pt">2023</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 8pt">411,245</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">152,289</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">411,245</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">18,940</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">993,719</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: rgb(223,228,234); vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 8pt">2022</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: rgb(223,228,234); vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 8pt">397,337</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: rgb(223,228,234); vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: rgb(223,228,234); vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">620,488</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: rgb(223,228,234); vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">409,167</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: rgb(223,228,234); vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">221,317</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: rgb(223,228,234); vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: rgb(223,228,234); vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">18,070</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: rgb(223,228,234); vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">1,666,379</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td rowspan="3" style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 8pt">John E. Davis, Senior Vice President, Chief Commercial Officer</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 8pt">2024</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 8pt">406,855</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">800,016</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">264,456</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">20,155</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">1,491,482</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 8pt">2023</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 8pt">391,207</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">151,388</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">391,207</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">19,603</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">953,405</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 8pt">2022</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 8pt">379,812</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">613,677</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">405,000</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">211,556</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">18,545</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">1,628,590</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td rowspan="3" style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; background-color: rgb(223,228,234); vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 8pt">Marshall S. Stanton, Senior Vice President, Clinical Research and Chief Medical Officer</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: rgb(223,228,234); vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 8pt">2024</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: rgb(223,228,234); vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 8pt">409,593</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: rgb(223,228,234); vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: rgb(223,228,234); vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">599,992</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: rgb(223,228,234); vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: rgb(223,228,234); vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">266,235</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: rgb(223,228,234); vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: rgb(223,228,234); vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">17,793</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: rgb(223,228,234); vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">1,293,613</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 8pt">2023</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 8pt">395,742</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">132,465</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">395,742</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">18,051</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">942,000</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: rgb(223,228,234); vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 8pt">2022</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: rgb(223,228,234); vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 8pt">384,216</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: rgb(223,228,234); vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: rgb(223,228,234); vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">623,985</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: rgb(223,228,234); vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">369,500</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: rgb(223,228,234); vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">214,008</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: rgb(223,228,234); vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: rgb(223,228,234); vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">17,322</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: rgb(223,228,234); vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">1,609,031</span></p>

							</td>

						</tr>

					</table>

				</div>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 1pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(1)</sup></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">For 2024, amount represents the base salary as approved in February 2024. For 2023, amount represents the base salary as approved in February 2023, other than Mr. Berry, whose base salary for 2023 was approved in November 2023 and was prorated based on the term of </span><span style="text-transform: none">his employment.</span></p>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 1pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(2)</sup></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">For 2023, Mr. Berry received a sign-on bonus </span><span style="text-transform: none">of $100,000.</span></p>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 1pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(3)</sup></span><!--[if IE]></FONT><![endif]--><sup style="text-transform: none; font-size: 7pt; line-height: 7pt"></sup><span style="text-transform: none">Amount reflects the aggregate grant date fair value of restricted stock and performance stock unit awards as calculated in accordance with FASB ASC Topic 718, disregarding the estimate of forfeitures. See Notes 1 and 14 of the Notes to Consolidated Financial Statements filed with Artivion&#8217;s Annual Report on Form 10-K for the year ended December 31, 2024 for assumptions we used in valuing these awards. The annual PSU awards paid out at 130.0% of target. If the 2024 PSUs were awarded at maximum payouts, it would change the stock awards to the following amounts: for Mr.&#160;Mackin $5,412,150; for Mr. Berry $2,249,970; for Ms. Holloway $1,192,485; for Mr. Davis $1,200,024; and for </span><span style="text-transform: none">Mr. Stanton $899,988. For 2022, and for the reasons described in the Compensation Discussion and Analysis in the Company&#8217;s 2024 Proxy Statement, under the heading &#8220;</span><span style="text-transform: none; font-style: italic"><i>November 2022 Acceleration of a Portion of the 2023 Annual Equity Grant</i></span><span style="text-transform: none">,&#8221; the amounts include a 2023 annual RSU grant that was accelerated to November 2022. The grant date fair values of those accelerated 2023 RSU grants were as follows: Mr. Mackin&#8217;s was $1,290,003; Ms. Holloway&#8217;s was $247,502; Mr. Davis&#8217;s was $246,002; and Mr. Stanton&#8217;s </span><span style="text-transform: none">was $214,500.</span></p>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 1pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(4) </sup></span><!--[if IE]></FONT><![endif]--><sup style="text-transform: none; font-size: 7pt; line-height: 7pt"></sup><span style="text-transform: none">Amount reflects the aggregate grant date fair value of stock option awards as calculated in accordance with FASB ASC Topic 718, disregarding the estimate of forfeitures. See Notes 1 and 14 of the Notes to Consolidated Financial Statements filed with Artivion&#8217;s Annual Report on Form 10-K for the year ended December 31, 2024 for assumptions we used in valuing the stock option awards. For 2023, Mr. Berry&#8217;s option award was part of his one-time, new-hire grant. For 2022, and for the reasons described in the Compensation Discussion and Analysis in the Company&#8217;s 2024 Proxy Statement, under the heading &#8220;</span><span style="text-transform: none; font-style: italic"><i>November 2022 Acceleration of a Portion of the 2023 Annual Equity Grant</i></span><span style="text-transform: none">,&#8221; the amounts include a 2023 annual option grant that was accelerated to November 2022. The grant date fair values of those accelerated 2023 option grants were as follows: Mr. Mackin&#8217;s was $1,290,003; Ms. Holloway&#8217;s was $247,502; Mr. Davis&#8217;s was $246,002; and Mr. Stanton&#8217;s </span><span style="text-transform: none">was $214,500.</span></p>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 1pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(5)</sup></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">For 2024, the amounts represent the revenue and adjusted EBITDA performance components of the awards earned pursuant to the applicable short-term incentive plan. For 2023 and 2022, the amounts represent the revenue performance components of the awards earned pursuant to the applicable short-term </span><span style="text-transform: none">incentive plan.</span></p>

			</div>

		</div>
		<div style="page-break-before: always">
			<p style="margin: 0pt; font-size: 5pt">&#8203;</p>

		</div>
		<div class="qes_page" style="border-bottom: black 2pt solid; margin: auto; height: 990pt; width: 765pt; position: relative; overflow: hidden">
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 911.25pt; left: 45pt; width: 675pt; position: absolute; height: 33.75pt">
				<div style="display: table-cell; vertical-align: bottom; width: 675pt; height: 33.75pt">

				<!--[if IE]><TABLE><TR style=" width: 675pt; height: 33.75pt;"><TD vAlign="bottom" style=" width: 675pt; height: 33.75pt;"><![endif]-->
					<div style="font: 12pt/normal Times New Roman, Times, serif; margin: 0pt; text-transform: none; color: #000000; text-align: left">
						<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 0pt; border-collapse: collapse">
							<tr style="margin: 0; height: 0">
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>

							</tr>
							<tr style="min-height: 0pt">
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">ARTIVION, INC. | 2025 Proxy Statement</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">44</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 0pt; line-height: 0pt">&#8203;</p>

								</td>

							</tr>

						</table>

					</div>


				<!--[if IE]></TD></TR></TABLE><![endif]-->
				</div>

			</div>
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 45pt; left: 45pt; width: 675pt; position: absolute; height: 877.5pt">
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 1pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(6)</sup></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Amounts include matching contributions and true-ups under the Company&#8217;s 401(k) plan, reimbursement of airline club and other club membership dues, and disability insurance premiums for NEOs. Fiscal 2022 amounts also include for Mr. Mackin, an $18,000 auto allowance. Fiscal 2023 amounts also include for Mr. Mackin, an $18,000 auto allowance. Fiscal 2024 amounts also include for Mr. Mackin, an $18,000 auto allowance, and for Mr. Berry, $131,740 to assist with </span><span style="text-transform: none">his relocation.</span></p>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 1pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(7) </sup></span><!--[if IE]></FONT><![endif]--><sup style="text-transform: none; font-size: 7pt; line-height: 7pt"></sup><span style="text-transform: none">For 2022, and for the reasons described in the Compensation Discussion and Analysis in the Company&#8217;s 2024 Proxy Statement, under the heading &#8220;</span><span style="text-transform: none; font-style: italic"><i>November 2022 Acceleration of a Portion of the 2023 Annual Equity Grant</i></span><span style="text-transform: none">,&#8221; the total amounts include a portion of the 2023 annual equity grant accelerated to November 2022, split equally between RSUs and options. The total grant date fair values of those accelerated 2023 RSU and option grants were as follows: Mr. Mackin&#8217;s was $2,580,004; Ms. Holloway&#8217;s was $495,000; Mr. Davis&#8217;s was $492,001; and Mr. Stanton&#8217;s was $428,998. Except for Mr. Berry, the NEOs total 2023 compensation, inclusive of the 2023 accelerated annual RSU and option grants was as follows: Mr. Mackin&#8217;s was $5,756,417; Ms. Holloway&#8217;s was $1,488,719; Mr. Davis&#8217;s was $1,445,406; and Mr. Stanton&#8217;s </span><span style="text-transform: none">was $1,370,998.</span></p>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 8pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(8)</sup></span><!--[if IE]></FONT><![endif]--><sup style="text-transform: none; font-size: 7pt; line-height: 7pt"></sup><span style="text-transform: none">Only 2024 and 2023 compensation is presented for Mr. Berry who was appointed Chief Financial Officer on </span><span style="text-transform: none">December&#160;4, 2023.</span></p>

			</div>

		</div>
		<div style="page-break-before: always">
			<p style="margin: 0pt; font-size: 5pt">&#8203;</p>

		</div>
		<div class="qes_page" style="border-bottom: black 2pt solid; margin: auto; height: 990pt; width: 765pt; position: relative; overflow: hidden">
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 911.25pt; left: 45pt; width: 675pt; position: absolute; height: 33.75pt">
				<div style="display: table-cell; vertical-align: bottom; width: 675pt; height: 33.75pt">

				<!--[if IE]><TABLE><TR style=" width: 675pt; height: 33.75pt;"><TD vAlign="bottom" style=" width: 675pt; height: 33.75pt;"><![endif]-->
					<div style="font: 12pt/normal Times New Roman, Times, serif; margin: 0pt; text-transform: none; color: #000000; text-align: left">
						<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 0pt; border-collapse: collapse">
							<tr style="margin: 0; height: 0">
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>

							</tr>
							<tr style="min-height: 0pt">
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">ARTIVION, INC. | 2025 Proxy Statement</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">45</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 0pt; line-height: 0pt">&#8203;</p>

								</td>

							</tr>

						</table>

					</div>


				<!--[if IE]></TD></TR></TABLE><![endif]-->
				</div>

			</div>
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 45pt; left: 45pt; width: 675pt; position: absolute; height: 866.25pt">
				<p style="border-bottom: #7f7f7f 1pt solid; font: 12pt/normal Arial, sans-serif; margin: 0pt 0pt 15pt; text-transform: none; color: #2b4b74; text-indent: 0pt; text-align: left"><span style="text-transform: none"><b>Grants of Plan-Based Awards</b></span></p>
				<div style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-align: justify">
					<table style="table-layout: fixed; width: 674.5pt; margin-top: 4pt; margin-bottom: 10pt; border-collapse: collapse">
						<tr style="margin: 0; height: 0">
							<td style="border-width: 0; margin: 0; padding: 0; width: 94.5pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 45pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 50pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 50pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 51.25pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 48.75pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 48.75pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 48.75pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 45pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 57.5pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 45pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 45pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 45pt">


							</td>

						</tr>
						<tr style="min-height: 76.8pt">
							<td rowspan="2" style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 8pt"><b>Name</b></span></p>

							</td>
							<td rowspan="2" style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 8pt"><b>Grant<br/>Date</b></span></p>

							</td>
							<td colspan="3" style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 8pt"><b>Estimated Possible Payouts<br/>Under Non-Equity Incentive<br/>Plan Awards</b></span><sup style="text-transform: none; font-size: 6pt; line-height: 6pt"><b>(1)</b></sup></p>

							</td>
							<td colspan="3" style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 8pt"><b>Estimated Possible Payouts<br/>Under Equity Incentive Plan<br/>Awards</b></span></p>

							</td>
							<td rowspan="2" style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 8pt"><b>All<br/>Other Stock Awards: Number of Shares of Stock or Units (#)</b></span></p>

							</td>
							<td rowspan="2" style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 8pt"><b>All Other Option Awards: Number of Securities Underlying Options<br/>(#)</b></span></p>

							</td>
							<td rowspan="2" style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 8pt"><b>Exercise or Base Price of Option Awards<br/>($/Sh)</b></span></p>

							</td>
							<td rowspan="2" style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 8pt"><b>Closing Market Price on Committ-ee Action Date<br/>($/Sh)</b></span></p>

							</td>
							<td rowspan="2" style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 8pt"><b>Grant Date Fair Value of Stock and Option Awards</b></span><sup style="text-transform: none; font-size: 6pt; line-height: 6pt"><b>(4)</b></sup><span style="text-transform: none; font-size: 8pt"><b><br/>($)</b></span></p>

							</td>

						</tr>
						<tr style="min-height: 21.42pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 8pt"><b>Threshold<br/>($)</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 8pt"><b>Target<br/>($)</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 8pt"><b>Maximum<br/>($)</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 8pt"><b>Threshold<br/>(#)</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 8pt"><b>Target<br/>(#)</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 8pt"><b>Maximum<br/>(#)</b></span></p>

							</td>

						</tr>
						<tr style="min-height: 13pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><sup style="text-transform: none; font-size: 6pt; line-height: 6pt"><b>(a)</b></sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><sup style="text-transform: none; font-size: 6pt; line-height: 6pt"><b>(b)</b></sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><sup style="text-transform: none; font-size: 6pt; line-height: 6pt"><b>(c)</b></sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><sup style="text-transform: none; font-size: 6pt; line-height: 6pt"><b>(d)</b></sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><sup style="text-transform: none; font-size: 6pt; line-height: 6pt"><b>(e)</b></sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><sup style="text-transform: none; font-size: 6pt; line-height: 6pt"><b>(f)</b></sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><sup style="text-transform: none; font-size: 6pt; line-height: 6pt"><b>(g)</b></sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><sup style="text-transform: none; font-size: 6pt; line-height: 6pt"><b>(h)</b></sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><sup style="text-transform: none; font-size: 6pt; line-height: 6pt"><b>(i)</b></sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><sup style="text-transform: none; font-size: 6pt; line-height: 6pt"><b>(j)</b></sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><sup style="text-transform: none; font-size: 6pt; line-height: 6pt"><b>(k)</b></sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><sup style="text-transform: none; font-size: 6pt; line-height: 6pt"><b>(l)</b></sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><sup style="text-transform: none; font-size: 6pt; line-height: 6pt"><b>(m)</b></sup></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td rowspan="3" style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 8pt">J. Patrick Mackin</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">2/23/24</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">242,071</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">806,904</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">1,613,808</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: rgb(223,228,234); vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">2/23/24</span><sup style="text-transform: none; font-size: 6pt; line-height: 6pt">(2)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: rgb(223,228,234); vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">89,001</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: rgb(223,228,234); vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">1,804,050</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">2/23/24</span><sup style="text-transform: none; font-size: 6pt; line-height: 6pt">(3)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">30,260</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">89,001</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">178,002</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">1,804,050</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 8pt">Lance A. Berry</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">2/23/24</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">90,000</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">300,000</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">600,000</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">2/23/24</span><sup style="text-transform: none; font-size: 6pt; line-height: 6pt">(2)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">37,000</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">749,990</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">2/23/24</span><sup style="text-transform: none; font-size: 6pt; line-height: 6pt">(3)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">12,580</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">37,000</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">74,000</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">749,990</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td rowspan="3" style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 8pt">Jean F. Holloway</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">2/23/24</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">63,846</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">212,820</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">425,640</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: rgb(223,228,234); vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">2/23/24</span><sup style="text-transform: none; font-size: 6pt; line-height: 6pt">(2)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: rgb(223,228,234); vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">19,610</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: rgb(223,228,234); vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">397,495</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">2/23/24</span><sup style="text-transform: none; font-size: 6pt; line-height: 6pt">(3)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">6,667</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">19,610</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">39,220</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">397,495</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td rowspan="3" style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 8pt">John E. Davis</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">2/23/24</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">61,028</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">203,428</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">406,856</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">2/23/24</span><sup style="text-transform: none; font-size: 6pt; line-height: 6pt">(2)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">19,734</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">400,008</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">2/23/24</span><sup style="text-transform: none; font-size: 6pt; line-height: 6pt">(3)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">6,710</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">19,734</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">39,468</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">400,008</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 8pt">Marshall S. Stanton</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">2/23/24</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">61,439</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">204,797</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">409,594</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: rgb(223,228,234); vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">2/23/24</span><sup style="text-transform: none; font-size: 6pt; line-height: 6pt">(2)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: rgb(223,228,234); vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">14,800</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: rgb(223,228,234); vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">299,996</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">2/23/24</span><sup style="text-transform: none; font-size: 6pt; line-height: 6pt">(3)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">5,032</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">14,800</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">29,600</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none; font-size: 8pt">299,996</span></p>

							</td>

						</tr>

					</table>

				</div>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 1pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(1)</sup></span><!--[if IE]></FONT><![endif]--><sup style="text-transform: none; font-size: 7pt; line-height: 7pt"></sup><span style="text-transform: none">These columns represent the awards granted to NEOs in February 2024 under our 2024 short-term incentive program (the Cash Bonus Plan) using the metrics of the 2024 Cash Bonus Plan approved by the Committee. Threshold for (i) the revenue component is 5.0% constant currency growth, which pays out at 30% of target and (ii) the adjusted EBITDA component is $57,400,000, which pays out at 30% of target, each weighted at 50%, resulting in a combined threshold payout at 30% of target. The personal performance modifier was designed to increase or decrease an award by 20%. The total cash bonus payout is capped at 200% of target. The threshold is calculated at target personal performance (no modifier up or down). While this table reflects the grant date value of the awards, as described on page 27, the Committee adjusted the cash bonus program payout to 130% of target based on Company performance and to account for the negative financial impact of the </span><span style="text-transform: none">Cybersecurity Incident.</span></p>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 1pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(2)</sup></span><!--[if IE]></FONT><![endif]--><sup style="text-transform: none; font-size: 7pt; line-height: 7pt"></sup><span style="text-transform: none">These rows represent awards of time-based restricted stock units that vest 1/3 on the first anniversary of the award date;1/3 on the second anniversary of the award date; and 1/3 on the third anniversary of the </span><span style="text-transform: none">award date.</span></p>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 1pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(3)</sup></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">These rows represent awards of performance stock units to our NEOs pursuant to the 2020 ECIP using the metrics of the 2024 performance share plan approved by the Committee.&#160;Threshold for (i) the revenue component is 5.0% constant currency growth, which pays out at 30% of target and is weighted at 50%, (ii) the adjusted EBITDA component is $57,400,000, which pays out at 30% of target and is weighted at 30%, and (iii) the R&amp;D component is achievement of one milestone, which pays out at the greater of 50% of target or 50% of the weighted average achievement of the revenue and adjusted EBITDA metrics and is weighted at 20%, resulting in a combined threshold payout at 34% of target. The total PSU bonus payout is capped at 200% of target. In regard to the annual PSU awards, granted February&#160;23,&#160;2024, 1/3 vested on the first anniversary of the grant date or the first available grant date following the Committee&#8217;s certification of the 2024 financial performance, whichever is later (for the 2024 award, 1/3 vested on March 6, 2025, the first date that the awards could be released following the date that the Company filed its Form 10-K for fiscal 2024), 1/3 will vest on the second anniversary of the grant date, and 1/3 will vest on the third anniversary of the grant date, assuming continuous employment through the vesting date. While this table reflects the grant date value of the awards, as described on page 27, the Committee adjusted the 2024 annual PSU award payouts to be awarded at 130% of target based on Company performance and to account for the negative financial impact of the </span><span style="text-transform: none">Cybersecurity Incident.</span></p>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 8pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(4)</sup></span><!--[if IE]></FONT><![endif]--><sup style="text-transform: none; font-size: 7pt; line-height: 7pt"></sup><span style="text-transform: none">Column (m) reflects the aggregate grant date fair value of restricted stock and performance stock unit awards as calculated in accordance with FASB ASC Topic 718, disregarding the estimate of forfeitures. For time-based RSUs and for PSUs, the calculation is based on the closing price of Artivion&#8217;s common stock on the date of grant. See Notes 1 and 14 of the Notes to Consolidated Financial Statements filed with Artivion&#8217;s Annual Report on Form 10-K for the year ended December 31, 2024 for assumptions we used in valuing </span><span style="text-transform: none">these awards.</span></p>

			</div>

		</div>
		<div style="page-break-before: always">
			<p style="margin: 0pt; font-size: 5pt">&#8203;</p>

		</div>
		<div class="qes_page" style="border-bottom: black 2pt solid; margin: auto; height: 990pt; width: 765pt; position: relative; overflow: hidden">
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 911.25pt; left: 45pt; width: 675pt; position: absolute; height: 33.75pt">
				<div style="display: table-cell; vertical-align: bottom; width: 675pt; height: 33.75pt">

				<!--[if IE]><TABLE><TR style=" width: 675pt; height: 33.75pt;"><TD vAlign="bottom" style=" width: 675pt; height: 33.75pt;"><![endif]-->
					<div style="font: 12pt/normal Times New Roman, Times, serif; margin: 0pt; text-transform: none; color: #000000; text-align: left">
						<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 0pt; border-collapse: collapse">
							<tr style="margin: 0; height: 0">
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>

							</tr>
							<tr style="min-height: 0pt">
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">ARTIVION, INC. | 2025 Proxy Statement</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">46</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 0pt; line-height: 0pt">&#8203;</p>

								</td>

							</tr>

						</table>

					</div>


				<!--[if IE]></TD></TR></TABLE><![endif]-->
				</div>

			</div>
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 45pt; left: 45pt; width: 675pt; position: absolute; height: 866.25pt">
				<p style="font: italic 11pt/normal Arial, sans-serif; margin: 0pt 0pt 8pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><b><i>Narrative Disclosure to Summary Compensation Table and Grants of Plan-Based Awards Table</i></b></span></p>
				<p style="font: italic 11pt/normal Arial, sans-serif; margin: 4pt 0pt 8pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><i>Equity Awards</i></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none">Equity awards, including long-term performance annual awards, granted in fiscal 2024 to our Named Executive Officers were subject to the terms of the 2020 ECIP and the equity </span><span style="text-transform: none">grant agreements.</span></p>
				<p style="font: italic 11pt/normal Arial, sans-serif; margin: 4pt 0pt 8pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><i>Actual Cash Compensation in Proportion to Target Total Direct Compensation</i></span></p>
				<div style="font: italic 11pt/normal Arial, sans-serif; margin: 4pt 0pt 8pt; text-transform: none; color: #000000; text-align: center">
					<table style="margin: 8pt auto; table-layout: fixed; width: 489.37pt; border-collapse: collapse">
						<tr style="margin: 0; height: 0">
							<td style="border-width: 0; margin: 0; padding: 0; width: 155.25pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 97.87pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 118.12pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 118.12pt">


							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td colspan="4" style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Salary (actual as paid) and Bonus Payouts (as adjusted and paid) in<br/>Proportion to Target Total Direct Compensation</b></span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td rowspan="2" style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Executive Officer</b></span></p>

							</td>
							<td rowspan="2" style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>% Salary</b></span></p>

							</td>
							<td colspan="2" style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Short-Term Incentive (Cash Bonus)</b></span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>% Bonus</b></span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt"><b>(1)</b></sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>% Non-Equity<br/>Incentive Plan</b></span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt"><b>(2)</b></sup></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">J. Patrick Mackin</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">15.5</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">0.0</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">20.1</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Lance A. Berry</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">21.7</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">0.0</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">17.0</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Jean F. Holloway</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">29.7</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">0.0</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">19.3</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">John E. Davis</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">28.8</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">0.0</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">18.8</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Marshall S. Stanton</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">33.7</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">0.0</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">21.9</span></p>

							</td>

						</tr>

					</table>

				</div>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 1pt 106.25pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(1)</sup></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Consistent with the Summary Compensation Table on page 43, the Bonus represents the personal performance component of the annual award paid pursuant to the short-term </span><span style="text-transform: none">incentive plan.</span></p>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 8pt 106.25pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(2) </sup></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Amounts represent the constant currency revenue and adjusted EBITDA performance components of the awards earned pursuant to the applicable short-term incentive plan and the </span><span style="text-transform: none">2020 ECIP.</span></p>

			</div>

		</div>
		<div style="page-break-before: always">
			<p style="margin: 0pt; font-size: 5pt">&#8203;</p>

		</div>
		<div class="qes_page" style="border-bottom: black 2pt solid; margin: auto; height: 990pt; width: 765pt; position: relative; overflow: hidden">
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 911.25pt; left: 45pt; width: 675pt; position: absolute; height: 33.75pt">
				<div style="display: table-cell; vertical-align: bottom; width: 675pt; height: 33.75pt">

				<!--[if IE]><TABLE><TR style=" width: 675pt; height: 33.75pt;"><TD vAlign="bottom" style=" width: 675pt; height: 33.75pt;"><![endif]-->
					<div style="font: 12pt/normal Times New Roman, Times, serif; margin: 0pt; text-transform: none; color: #000000; text-align: left">
						<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 0pt; border-collapse: collapse">
							<tr style="margin: 0; height: 0">
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>

							</tr>
							<tr style="min-height: 0pt">
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">ARTIVION, INC. | 2025 Proxy Statement</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">47</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 0pt; line-height: 0pt">&#8203;</p>

								</td>

							</tr>

						</table>

					</div>


				<!--[if IE]></TD></TR></TABLE><![endif]-->
				</div>

			</div>
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 45pt; left: 45pt; width: 675pt; position: absolute; height: 866.25pt">
				<p style="border-bottom: #7f7f7f 1pt solid; font: 12pt/normal Arial, sans-serif; margin: 0pt 0pt 15pt; text-transform: none; color: #2b4b74; text-indent: 0pt; text-align: left"><span style="text-transform: none"><b>Outstanding Equity Awards on December 31, 2024(*)</b></span></p>
				<div style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-align: justify">
					<table style="table-layout: fixed; width: 675.5pt; margin-top: 4pt; margin-bottom: 10pt; border-collapse: collapse">
						<tr style="margin: 0; height: 0">
							<td style="border-width: 0; margin: 0; padding: 0; width: 78pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 63.75pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 72.5pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 61.25pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 62.5pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 67.5pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 67.5pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 67.5pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 67.5pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 67.5pt">


							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td colspan="6" style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt"><b>Option Awards</b></span></p>

							</td>
							<td colspan="4" style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt"><b>Stock Awards</b></span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt"><b>Name</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt"><b>Number of<br/>Securities<br/>Underlying<br/>Unexercised<br/>Options<br/>Exercisable<br/>(#)</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt"><b>Number of<br/>Securities<br/>Underlying<br/>Unexercised<br/>Options<br/>Unexercisable<br/>(#)</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt"><b><br/>Number of<br/>Securities<br/>Underlying<br/>Unexercised<br/>Unearned<br/>Options<br/>(#)</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt"><b>Option<br/>Exercise <br/>Price<br/>($)</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt"><b>Option<br/>Expiration <br/>Date</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt"><b>Number of<br/>Shares or<br/>Units of Stock<br/>that Have Not<br/>Vested<br/>(#)</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt"><b>Market Value<br/>of Shares or<br/>Units of Stock<br/>that Have Not<br/>Vested<br/>($)</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt"><b>Equity Incentive<br/>Plan Awards:<br/>Number of<br/>Unearned<br/>Shares, Units,<br/>or Other Rights<br/>that Have Not<br/>Vested<br/>(#)</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt"><b>Equity Incentive<br/>Plan Awards:<br/>Market or<br/>Payout Value<br/>of Unearned<br/>Shares, Units,<br/>or Other Rights<br/>that Have Not<br/>Vested<br/>($)</b></span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><sup style="text-transform: none; font-size: 5pt; line-height: 5pt"><b>(a)</b></sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><sup style="text-transform: none; font-size: 5pt; line-height: 5pt"><b>(b)</b></sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><sup style="text-transform: none; font-size: 5pt; line-height: 5pt"><b>(c)</b></sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><sup style="text-transform: none; font-size: 5pt; line-height: 5pt"><b>(d)</b></sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><sup style="text-transform: none; font-size: 5pt; line-height: 5pt"><b>(e)</b></sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><sup style="text-transform: none; font-size: 5pt; line-height: 5pt"><b>(f)</b></sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><sup style="text-transform: none; font-size: 5pt; line-height: 5pt"><b>(g)</b></sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><sup style="text-transform: none; font-size: 5pt; line-height: 5pt"><b>(h)</b></sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><sup style="text-transform: none; font-size: 5pt; line-height: 5pt"><b>(i)</b></sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><sup style="text-transform: none; font-size: 5pt; line-height: 5pt"><b>(j)</b></sup></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 7pt">J. Patrick Mackin</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">75,615</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">21.55</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">3/12/2025</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">61,842</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">29.62</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">3/5/2026</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">86,296</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">26.24</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">2/19/2027</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">93,519</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">24.90</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">2/17/2028</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">84,364</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">42,182</span><sup style="text-transform: none; font-size: 5pt; line-height: 5pt">(1)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">18.44</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">2/23/2029</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">186,956</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">93,478</span><sup style="text-transform: none; font-size: 5pt; line-height: 5pt">(2)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">11.03</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">11/8/2029</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">47,627</span><sup style="text-transform: none; font-size: 5pt; line-height: 5pt">(3)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">1,361,656</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">10,537</span><sup style="text-transform: none; font-size: 5pt; line-height: 5pt">(4)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">301,253</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">116,954</span><sup style="text-transform: none; font-size: 5pt; line-height: 5pt">(5)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">3,343,715</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">29,323</span><sup style="text-transform: none; font-size: 5pt; line-height: 5pt">(6)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">838,345</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">89,001</span><sup style="text-transform: none; font-size: 5pt; line-height: 5pt">(9)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">2,544,539</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">115,701</span><span style="text-transform: none; font-size: 7pt">(10)</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">3,307,892</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 7pt">Lance A. Berry</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">31,211</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">62,422</span><sup style="text-transform: none; font-size: 5pt; line-height: 5pt">(7)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">17.83</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">12/6/2030</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">42,064</span><sup style="text-transform: none; font-size: 5pt; line-height: 5pt">(8)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">1,202,610</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">37,000</span><sup style="text-transform: none; font-size: 5pt; line-height: 5pt">(9)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">1,057,830</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">48,100</span><sup style="text-transform: none; font-size: 5pt; line-height: 5pt">(10)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">1,375,179</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 7pt">Jean F. Holloway</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">19,092</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">21.55</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">3/12/2025</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">12,787</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">29.62</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">3/5/2026</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">16,975</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">26.24</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">2/19/2027</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">19,247</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">24.90</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">2/17/2028</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">15,530</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">7,765</span><sup style="text-transform: none; font-size: 5pt; line-height: 5pt">(1)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">18.44</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">2/23/2029</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">35,870</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">17,934</span><sup style="text-transform: none; font-size: 5pt; line-height: 5pt">(2)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">11.03</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">11/8/2029</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">8,767</span><sup style="text-transform: none; font-size: 5pt; line-height: 5pt">(3)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">250,649</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">1,939</span><sup style="text-transform: none; font-size: 5pt; line-height: 5pt">(4)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">55,436</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">22,439</span><sup style="text-transform: none; font-size: 5pt; line-height: 5pt">(5)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">641,531</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">6,418</span><sup style="text-transform: none; font-size: 5pt; line-height: 5pt">(6)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">183,491</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">19,610</span><sup style="text-transform: none; font-size: 5pt; line-height: 5pt">(9)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">560,650</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">25,493</span><sup style="text-transform: none; font-size: 5pt; line-height: 5pt">(10)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">728,845</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 7pt">John E. Davis</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">15,910</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">21.55</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">3/12/2025</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">12,787</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">29.62</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">3/5/2026</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">10,802</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">26.24</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">2/19/2027</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">17,008</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">24.90</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">2/17/2028</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">15,274</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">7,637</span><sup style="text-transform: none; font-size: 5pt; line-height: 5pt">(1)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">18.44</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">2/23/2029</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">35,652</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">17,826</span><sup style="text-transform: none; font-size: 5pt; line-height: 5pt">(2)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">11.03</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">11/8/2029</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">8,623</span><sup style="text-transform: none; font-size: 5pt; line-height: 5pt">(3)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">246,532</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">1,908</span><sup style="text-transform: none; font-size: 5pt; line-height: 5pt">(4)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">54,550</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">22,303</span><sup style="text-transform: none; font-size: 5pt; line-height: 5pt">(5)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">637,643</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">6,368</span><sup style="text-transform: none; font-size: 5pt; line-height: 5pt">(6)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">182,061</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">19,734</span><sup style="text-transform: none; font-size: 5pt; line-height: 5pt">(9)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">564,195</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">25,654</span><sup style="text-transform: none; font-size: 5pt; line-height: 5pt">(10)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">733,448</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0 0pt; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>

						</tr>

					</table>

				</div>

			</div>

		</div>
		<div style="page-break-before: always">
			<p style="margin: 0pt; font-size: 5pt">&#8203;</p>

		</div>
		<div class="qes_page" style="border-bottom: black 2pt solid; margin: auto; height: 990pt; width: 765pt; position: relative; overflow: hidden">
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 911.25pt; left: 45pt; width: 675pt; position: absolute; height: 33.75pt">
				<div style="display: table-cell; vertical-align: bottom; width: 675pt; height: 33.75pt">

				<!--[if IE]><TABLE><TR style=" width: 675pt; height: 33.75pt;"><TD vAlign="bottom" style=" width: 675pt; height: 33.75pt;"><![endif]-->
					<div style="font: 12pt/normal Times New Roman, Times, serif; margin: 0pt; text-transform: none; color: #000000; text-align: left">
						<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 0pt; border-collapse: collapse">
							<tr style="margin: 0; height: 0">
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>

							</tr>
							<tr style="min-height: 0pt">
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">ARTIVION, INC. | 2025 Proxy Statement</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">48</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 0pt; line-height: 0pt">&#8203;</p>

								</td>

							</tr>

						</table>

					</div>


				<!--[if IE]></TD></TR></TABLE><![endif]-->
				</div>

			</div>
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 45pt; left: 45pt; width: 675pt; position: absolute; height: 881.25pt">
				<div style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-align: justify">
					<table style="table-layout: fixed; width: 675.5pt; margin-top: 4pt; margin-bottom: 10pt; border-collapse: collapse">
						<tr style="margin: 0; height: 0">
							<td style="border-width: 0; margin: 0; padding: 0; width: 78pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 63.75pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 72.5pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 61.25pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 62.5pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 67.5pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 67.5pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 67.5pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 67.5pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 67.5pt">


							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td colspan="6" style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt"><b>Option Awards</b></span></p>

							</td>
							<td colspan="4" style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt"><b>Stock Awards</b></span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt"><b>Name</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt"><b>Number of<br/>Securities<br/>Underlying<br/>Unexercised<br/>Options<br/>Exercisable<br/>(#)</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt"><b>Number of<br/>Securities<br/>Underlying<br/>Unexercised<br/>Options<br/>Unexercisable<br/>(#)</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt"><b><br/>Number of<br/>Securities<br/>Underlying<br/>Unexercised<br/>Unearned<br/>Options<br/>(#)</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt"><b>Option<br/>Exercise <br/>Price<br/>($)</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt"><b>Option<br/>Expiration <br/>Date</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt"><b>Number of<br/>Shares or<br/>Units of Stock<br/>that Have Not<br/>Vested<br/>(#)</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt"><b>Market Value<br/>of Shares or<br/>Units of Stock<br/>that Have Not<br/>Vested<br/>($)</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt"><b>Equity Incentive<br/>Plan Awards:<br/>Number of<br/>Unearned<br/>Shares, Units,<br/>or Other Rights<br/>that Have Not<br/>Vested<br/>(#)</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt"><b>Equity Incentive<br/>Plan Awards:<br/>Market or<br/>Payout Value<br/>of Unearned<br/>Shares, Units,<br/>or Other Rights<br/>that Have Not<br/>Vested<br/>($)</b></span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><sup style="text-transform: none; font-size: 5pt; line-height: 5pt"><b>(a)</b></sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><sup style="text-transform: none; font-size: 5pt; line-height: 5pt"><b>(b)</b></sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><sup style="text-transform: none; font-size: 5pt; line-height: 5pt"><b>(c)</b></sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><sup style="text-transform: none; font-size: 5pt; line-height: 5pt"><b>(d)</b></sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><sup style="text-transform: none; font-size: 5pt; line-height: 5pt"><b>(e)</b></sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><sup style="text-transform: none; font-size: 5pt; line-height: 5pt"><b>(f)</b></sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><sup style="text-transform: none; font-size: 5pt; line-height: 5pt"><b>(g)</b></sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><sup style="text-transform: none; font-size: 5pt; line-height: 5pt"><b>(h)</b></sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><sup style="text-transform: none; font-size: 5pt; line-height: 5pt"><b>(i)</b></sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><sup style="text-transform: none; font-size: 5pt; line-height: 5pt"><b>(j)</b></sup></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 7pt">Marshall S. Stanton</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">14,890</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">7,444</span><sup style="text-transform: none; font-size: 5pt; line-height: 5pt">(1)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">18.44</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">2/23/2029</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">31,087</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">15,543</span><sup style="text-transform: none; font-size: 5pt; line-height: 5pt">(2)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">11.03</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">11/8/2029</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">8,406</span><sup style="text-transform: none; font-size: 5pt; line-height: 5pt">(3)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">240,328</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">1,860</span><sup style="text-transform: none; font-size: 5pt; line-height: 5pt">(4)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">53,177</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">19,447</span><sup style="text-transform: none; font-size: 5pt; line-height: 5pt">(5)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">555,990</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">5,322</span><sup style="text-transform: none; font-size: 5pt; line-height: 5pt">(6)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">152,156</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">14,800</span><sup style="text-transform: none; font-size: 5pt; line-height: 5pt">(9)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">423,132</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">19,240</span><sup style="text-transform: none; font-size: 5pt; line-height: 5pt">(10)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 7pt">550,072</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: rgb(223,228,234); vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>

						</tr>

					</table>

				</div>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none"></span></p>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 0pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><span style="text-transform: none">* </span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">All values in this table are based on the closing price of the Company&#8217;s common stock on the NYSE on December 31, 2024 (the last trading day of 2024) </span><span style="text-transform: none">of $28.59.</span></p>

			</div>

		</div>
		<div style="page-break-before: always">
			<p style="margin: 0pt; font-size: 5pt">&#8203;</p>

		</div>
		<div class="qes_page" style="border-bottom: black 2pt solid; margin: auto; height: 990pt; width: 765pt; position: relative; overflow: hidden">
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 911.25pt; left: 45pt; width: 675pt; position: absolute; height: 33.75pt">
				<div style="display: table-cell; vertical-align: bottom; width: 675pt; height: 33.75pt">

				<!--[if IE]><TABLE><TR style=" width: 675pt; height: 33.75pt;"><TD vAlign="bottom" style=" width: 675pt; height: 33.75pt;"><![endif]-->
					<div style="font: 12pt/normal Times New Roman, Times, serif; margin: 0pt; text-transform: none; color: #000000; text-align: left">
						<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 0pt; border-collapse: collapse">
							<tr style="margin: 0; height: 0">
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>

							</tr>
							<tr style="min-height: 0pt">
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">ARTIVION, INC. | 2025 Proxy Statement</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">49</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 0pt; line-height: 0pt">&#8203;</p>

								</td>

							</tr>

						</table>

					</div>


				<!--[if IE]></TD></TR></TABLE><![endif]-->
				</div>

			</div>
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 45pt; left: 45pt; width: 675pt; position: absolute; height: 866.25pt">
				<div style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-align: justify">
					<table style="table-layout: fixed; width: 675.62pt; margin-top: 4pt; margin-bottom: 10pt; border-collapse: collapse">
						<tr style="margin: 0; height: 0">
							<td style="border-width: 0; margin: 0; padding: 0; width: 28.12pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 130pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 62.5pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 131.25pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 67.5pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 256.25pt">


							</td>

						</tr>
						<tr style="min-height: 18.75pt">
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 16.75pt; line-height: 16.75pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 8pt"><b>Type of Grant</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 8pt"><b>Grant Date</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 8pt"><b>Vesting Rate</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 8pt"><b>Vesting Dates</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 8pt"><b>Conditions</b></span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><sup style="text-transform: none; font-size: 6pt; line-height: 6pt">(1)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 8pt">Service-based stock options</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 8pt">2/23/2022</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 8pt">33</span><sup style="text-transform: none; font-size: 6pt; line-height: 6pt">1/3</sup><span style="text-transform: none; font-size: 8pt">% per year</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 8pt">2/23/2023</span></p>
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 8pt">2/23/2024</span></p>
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 0; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 8pt">2/23/2025</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 8pt">Continued employment through vesting date required.</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><sup style="text-transform: none; font-size: 6pt; line-height: 6pt">(2)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 8pt">Service-based stock options</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 8pt">11/8/2022</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 8pt">33</span><sup style="text-transform: none; font-size: 6pt; line-height: 6pt">1/3</sup><span style="text-transform: none; font-size: 8pt">% per year</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 8pt">11/8/2023</span></p>
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 8pt">11/8/2024</span></p>
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 0; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 8pt">11/8/2025</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 8pt">Continued employment through vesting date required.</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><sup style="text-transform: none; font-size: 6pt; line-height: 6pt">(3)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 8pt">Service-based restricted stock unit award</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 8pt">2/23/2022</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 8pt">100% cliff vesting</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 8pt">2/23/2025</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 8pt">Continued employment through vesting date required.</span></p>

							</td>

						</tr>
						<tr style="min-height: 27.7pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><sup style="text-transform: none; font-size: 6pt; line-height: 6pt">(4)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 8pt">Performance stock units</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 8pt">2/23/2022</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 8pt">&#8226;&#8194;50% on first anniversary of grant date, following certification of financial performance</span></p>
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 8pt">&#8226;&#8194;25% on second anniversary of grant date</span></p>
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 0; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 8pt">&#8226;&#8194;25% on third anniversary of grant date</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 8pt">2/23/2023</span></p>
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 8pt">2/23/2024</span></p>
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 0; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 8pt">2/23/2025</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 4pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 8pt">Number of shares based on certification of performance metrics for fiscal 2022, which the Compensation Committee certified in February 2023 (as described further above within the Compensation Discussion and Analysis). Number of shares shown is based on the total number of shares awarded (88.5% of target) pursuant to the performance metric. The first tranche of shares vested on 2/23/2023.</span></p>
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 0; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 8pt">Continued employment through vesting date required.</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><sup style="text-transform: none; font-size: 6pt; line-height: 6pt">(5)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 8pt">Service-based restricted stock unit award</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 8pt">11/8/2022</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 8pt">100% cliff vesting</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 8pt">11/8/2025</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 8pt">Continued employment through vesting date required.</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><sup style="text-transform: none; font-size: 6pt; line-height: 6pt">(6)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 8pt">Performance stock units</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 8pt">2/22/2023</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 8pt">&#8226;&#8194;50% on first anniversary of grant date, following certification of financial performance</span></p>
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 8pt">&#8226;&#8194;25% on second anniversary of grant date</span></p>
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 0; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 8pt">&#8226;&#8194;25% on third anniversary of grant date</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 8pt">2/23/2024</span></p>
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 8pt">2/22/2025</span></p>
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 0; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 8pt">2/22/2026</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 4pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 8pt">Number of shares based on certification of performance metrics for fiscal 2023, which the Compensation Committee determined in February 2024 (as described further above within the Compensation Discussion and Analysis). Number of shares shown reflects the total number of shares awarded (148.6% of target) pursuant to the performance metric, as none of the shares had time-vested as of 12/31/2023. The first tranche of earned shares vested on 2/23/2024.</span></p>
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 0; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 8pt">Continued employment through vesting date required.</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><sup style="text-transform: none; font-size: 6pt; line-height: 6pt">(7)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 8pt">Service-based stock options (new-hire grant)</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 8pt">12/6/2023</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 8pt">33</span><sup style="text-transform: none; font-size: 6pt; line-height: 6pt">1/3</sup><span style="text-transform: none; font-size: 8pt">% per year</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 8pt">12/6/2024</span></p>
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 8pt">12/6/2025</span></p>
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 0; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 8pt">12/6/2026</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 8pt">Continued employment through vesting date required.</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><sup style="text-transform: none; font-size: 6pt; line-height: 6pt">(8)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 8pt">Service-based restricted stock (new-hire grant)</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 8pt">12/6/2023</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 8pt">100% cliff vesting</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 8pt">12/6/2026</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 8pt">Continued employment through vesting date required.</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><sup style="text-transform: none; font-size: 6pt; line-height: 6pt">(9)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 8pt">Service-based restricted stock unit award</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 8pt">2/23/2024</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 8pt">33</span><sup style="text-transform: none; font-size: 6pt; line-height: 6pt">1/3</sup><span style="text-transform: none; font-size: 8pt">% per year</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 8pt">2/23/2025</span></p>
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 8pt">2/23/2026</span></p>
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 0; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 8pt">2/23/2027</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 8pt">Continued employment through vesting date required.</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><sup style="text-transform: none; font-size: 6pt; line-height: 6pt">(10)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 8pt">Performance stock units</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 8pt">2/23/2024</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 8pt">33</span><sup style="text-transform: none; font-size: 6pt; line-height: 6pt">1/3</sup><span style="text-transform: none; font-size: 8pt">% per year</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 8pt">2/23/2025</span></p>
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 8pt">2/23/2026</span></p>
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 0; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 8pt">2/23/2027</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 4pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 8pt">Number of shares based on certification of performance metrics for fiscal 2024, which the Compensation Committee determined in February 2025 (as described further above within the Compensation Discussion and Analysis). Number of shares shown reflects the total number of shares awarded (130% of target) pursuant to the performance metric, as none of the shares had time-vested as of 12/31/2024. The first tranche of earned shares vested on March 6, 2025, the first date that the awards could be released following the date that the Company filed its Form 10-K for fiscal 2024.</span></p>
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 0; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 8pt">Continued employment through vesting date required.</span></p>

							</td>

						</tr>

					</table>

				</div>

			</div>

		</div>
		<div style="page-break-before: always">
			<p style="margin: 0pt; font-size: 5pt">&#8203;</p>

		</div>
		<div class="qes_page" style="border-bottom: black 2pt solid; margin: auto; height: 990pt; width: 765pt; position: relative; overflow: hidden">
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 911.25pt; left: 45pt; width: 675pt; position: absolute; height: 33.75pt">
				<div style="display: table-cell; vertical-align: bottom; width: 675pt; height: 33.75pt">

				<!--[if IE]><TABLE><TR style=" width: 675pt; height: 33.75pt;"><TD vAlign="bottom" style=" width: 675pt; height: 33.75pt;"><![endif]-->
					<div style="font: 12pt/normal Times New Roman, Times, serif; margin: 0pt; text-transform: none; color: #000000; text-align: left">
						<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 0pt; border-collapse: collapse">
							<tr style="margin: 0; height: 0">
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>

							</tr>
							<tr style="min-height: 0pt">
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">ARTIVION, INC. | 2025 Proxy Statement</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">50</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 0pt; line-height: 0pt">&#8203;</p>

								</td>

							</tr>

						</table>

					</div>


				<!--[if IE]></TD></TR></TABLE><![endif]-->
				</div>

			</div>
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 45pt; left: 45pt; width: 675pt; position: absolute; height: 866.25pt">
				<p style="border-bottom: #7f7f7f 1pt solid; font: 12pt/normal Arial, sans-serif; margin: 0pt 0pt 15pt; text-transform: none; color: #2b4b74; text-indent: 0pt; text-align: left"><span style="text-transform: none"><b>Option Exercises and Stock Vested</b></span><sup style="text-transform: none; font-size: 10pt; line-height: 10pt"><b>(1)</b></sup></p>
				<div style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-align: left">
					<table style="table-layout: fixed; width: 674pt; margin-top: 4pt; margin-bottom: 10pt; border-collapse: collapse">
						<tr style="margin: 0; height: 0">
							<td style="border-width: 0; margin: 0; padding: 0; width: 181.5pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 132.5pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 101.25pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 15pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 138.75pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 105pt">


							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td colspan="2" style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Option Awards</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td colspan="2" style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Stock Awards</b></span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Name</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Number of Shares<br/>Acquired on Exercise<br/>(#)</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Value Realized<br/>on Exercise</b></span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt"><b>(2)</b></sup><span style="text-transform: none"><b><br/>($)</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Number of Shares<br/>Acquired on Vesting<br/>(#)</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Value Realized<br/>on Vesting</b></span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt"><b>(3)</b></sup><span style="text-transform: none"><b><br/>($)</b></span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><sup style="text-transform: none; font-size: 6pt; line-height: 6pt"><b>(a)</b></sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><sup style="text-transform: none; font-size: 6pt; line-height: 6pt"><b>(b)</b></sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><sup style="text-transform: none; font-size: 6pt; line-height: 6pt"><b>(c)</b></sup></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><sup style="text-transform: none; font-size: 6pt; line-height: 6pt"><b>(d)</b></sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><sup style="text-transform: none; font-size: 6pt; line-height: 6pt"><b>(e)</b></sup></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">J. Patrick Mackin</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 36pt 1.5pt 44px; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">59,225</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 20pt 1.5pt 22px; text-align: center; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">151,148</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 36pt 1.5pt 22px; text-align: center; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin-left: 22px; font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">151,108</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 18pt 1.5pt 0px; text-align: center; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin-left: 22px; font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">2,965,538</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Lance A. Berry</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 36pt 1.5pt 44px; vertical-align: bottom; border-collapse: collapse">
								<p style="margin-left: 22px; font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 20pt 1.5pt 33px; vertical-align: bottom; border-collapse: collapse">
								<p style="margin-left: 22px; font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 36pt 1.5pt 55px; vertical-align: bottom; border-collapse: collapse">
								<p style="margin-left: 22px; font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 18pt 1.5pt 44px; vertical-align: bottom; border-collapse: collapse">
								<p style="margin-left: 22px; font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">&#8212;</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Jean F. Holloway</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 36pt 1.5pt 22px; text-align: center; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin-left: 22px; font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">21,229</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 20pt 1.5pt 33px; text-align: center; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">36,089</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 36pt 1.5pt 33px; text-align: center; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin-left: 22px; font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">32,975</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 18pt 1.5pt 11px; text-align: center; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin-left: 22px; font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">641,527</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">John E. Davis</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 36pt 1.5pt 44px; text-align: center; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">13,562</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 20pt 1.5pt 33px; text-align: center; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">23,055</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 36pt 1.5pt 33px; text-align: center; vertical-align: bottom; border-collapse: collapse">
								<p style="margin-left: 22px; font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">27,065</span></p>

							</td>
							<td style="border-width: 0pt; text-align: center; padding: 1.5pt 18pt 1.5pt 11px; vertical-align: bottom; border-collapse: collapse">
								<p style="margin-left: 22px; font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">530,241</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Marshall S. Stanton</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 36pt 1.5pt 44px; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin-left: 22px; font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 20pt 1.5pt 33px; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin-left: 22px; font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 36pt 1.5pt 33px; text-align: center; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin-left: 22px; font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">26,802</span></p>

							</td>
							<td style="border-width: 0pt; text-align: center; padding: 1.5pt 18pt 1.5pt 11px; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin-left: 22px; font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">531,696</span></p>

							</td>

						</tr>

					</table>

				</div>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 1pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(1)</sup></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">This table provides information regarding stock option exercises and vesting of restricted stock and performance stock units </span><span style="text-transform: none">during 2024.</span></p>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 1pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(2)</sup></span><!--[if IE]></FONT><![endif]--><sup style="text-transform: none; font-size: 7pt; line-height: 7pt"></sup><span style="text-transform: none">Value Realized on Exercise is equal to the nu</span><span style="text-transform: none">mber of shares acquired multiplied by the difference between the exercise price and the share price on the NYSE at the time of exercise without regard to any proceeds that may have been received upon any sale of the </span><span style="text-transform: none">underlying shares.</span></p>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 8pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(3)</sup></span><!--[if IE]></FONT><![endif]--><sup style="text-transform: none; font-size: 7pt; line-height: 7pt"></sup><span style="text-transform: none">Value Realized on Vesting is equal to the number of shares acquired multiplied by the closing share price on the NYSE on the date of vesting, without regard to any proceeds that may have been received upon any sale of the </span><span style="text-transform: none">underlying shares.</span></p>
				<p style="border-bottom: #7f7f7f 1pt solid; font: 12pt/normal Arial, sans-serif; margin: 4pt 0pt 15pt; text-transform: none; color: #2b4b74; text-indent: 0pt; text-align: left"><span style="text-transform: none"><b>NONQUALIFIED DEFERRED COMPENSATION</b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">The Artivion, Inc. Executive Deferred Compensation Plan allows certain key employees of Artivion, including the Named Executive Officers, to defer receipt of some or all of their salaries, commissions, and/or the cash portion of any bonus awarded pursuant to the short-term executive officer incentive plan. The plan&#8217;s administrative committee, subject to ratification and approval of the Compensation Committee, establishes the maximum and minimum percentages of bonus awards that plan participants may defer in each plan year. These percentages were 0% for base salary and commissions and were 75% for the annual cash bonus for 2024. Plan participants may establish their respective deferral amounts for their base salaries and commissions prior to the beginning of each calendar year, and prior to July for their short-term incentive compensation for that year, which is calculated and paid after the completion of the </span><span style="text-transform: none; line-height: 12pt">plan year.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">The plan provides for tax-deferred growth of deferred compensation and, pursuant to the terms of the plan, Artivion agrees to distribute to participants the deferred amounts, credited/debited with hypothetical gains and/or losses linked to the performance of investment options selected by participants from among the non-proprietary investment options available under the plan. The plan does not have investment options that provide for above-market or preferential earnings. Distribution of all deferred compensation, including any gains or losses, occurs upon death, disability, retirement, or termination. Plan participants may elect to receive the distribution in a lump sum or in annual installments of up to 15 years, or via a combination thereof, upon death, disability, or retirement. Also, a plan participant may elect to receive distributions while still employed by Artivion if at least two years have elapsed from the plan year in which the deferred amounts would have otherwise been paid to the plan participant if not for the deferral. Distributions made while the plan participant is still employed by Artivion, and distributions made pursuant to termination, will be paid in a lump sum to the plan participant. Hardship withdrawals during any plan year may be made upon the occurrence of an unforeseeable emergency for a particular plan participant or if a plan participant receives a hardship distribution under Artivion&#8217;s 401(k) plan. All deferred amounts and deemed earnings thereon are fully vested at </span><span style="text-transform: none; line-height: 12pt">all times.</span></p>

			</div>

		</div>
		<div style="page-break-before: always">
			<p style="margin: 0pt; font-size: 5pt">&#8203;</p>

		</div>
		<div class="qes_page" style="border-bottom: black 2pt solid; margin: auto; height: 990pt; width: 765pt; position: relative; overflow: hidden">
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 911.25pt; left: 45pt; width: 675pt; position: absolute; height: 33.75pt">
				<div style="display: table-cell; vertical-align: bottom; width: 675pt; height: 33.75pt">

				<!--[if IE]><TABLE><TR style=" width: 675pt; height: 33.75pt;"><TD vAlign="bottom" style=" width: 675pt; height: 33.75pt;"><![endif]-->
					<div style="font: 12pt/normal Times New Roman, Times, serif; margin: 0pt; text-transform: none; color: #000000; text-align: left">
						<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 0pt; border-collapse: collapse">
							<tr style="margin: 0; height: 0">
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>

							</tr>
							<tr style="min-height: 0pt">
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">ARTIVION, INC. | 2025 Proxy Statement</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">51</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 0pt; line-height: 0pt">&#8203;</p>

								</td>

							</tr>

						</table>

					</div>


				<!--[if IE]></TD></TR></TABLE><![endif]-->
				</div>

			</div>
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 45pt; left: 45pt; width: 675pt; position: absolute; height: 866.25pt">
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">The following table presents components of nonqualified deferred compensation under the Executive Deferred Compensation Plan for each Named </span><span style="text-transform: none; line-height: 12pt">Executive Officer.</span></p>
				<div style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-align: left">
					<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 10pt; border-collapse: collapse">
						<tr style="margin: 0; height: 0">
							<td style="border-width: 0; margin: 0; padding: 0; width: 125pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 110pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 110pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 110pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 110pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 110pt">


							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Name</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Executive Officer<br/>Contributions in<br/>Fiscal 2024</b></span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt"><b>(1)</b></sup><span style="text-transform: none"><b><br/>($)</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Company<br/>Contributions in<br/>Fiscal 2024<br/>($)</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Aggregate<br/>Earnings in Fiscal<br/>2024</b></span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt"><b>(2)</b></sup><span style="text-transform: none"><b><br/>($)</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Aggregate<br/>Withdrawals and<br/>Distributions in<br/>Fiscal 2024<br/>($)</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Aggregate<br/>Balance at<br/>December 31,<br/>2024</b></span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt"><b>(3)</b></sup><span style="text-transform: none"><b><br/>($)</b></span></p>

							</td>

						</tr>
						<tr style="min-height: 10.3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><sup style="text-transform: none; font-size: 6pt; line-height: 6pt"><b>(a)</b></sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><sup style="text-transform: none; font-size: 6pt; line-height: 6pt"><b>(b)</b></sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><sup style="text-transform: none; font-size: 6pt; line-height: 6pt"><b>(c)</b></sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><sup style="text-transform: none; font-size: 6pt; line-height: 6pt"><b>(d)</b></sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><sup style="text-transform: none; font-size: 6pt; line-height: 6pt"><b>(e)</b></sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><sup style="text-transform: none; font-size: 6pt; line-height: 6pt"><b>(f)</b></sup></p>

							</td>

						</tr>
						<tr style="min-height: 9pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0 3.75pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">J. Patrick Mackin</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>

						</tr>
						<tr style="min-height: 9pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0 3.75pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Lance A. Berry</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>

						</tr>
						<tr style="min-height: 12.15pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0 3.75pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Jean F. Holloway</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">107,715</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">1,485,531</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0 3.75pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">John E. Davis</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">127,242</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">747,681</span></p>

							</td>

						</tr>
						<tr style="min-height: 9pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0 3.75pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Marshall S. Stanton</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">296,807</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">54,225</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">563,692</span></p>

							</td>

						</tr>

					</table>

				</div>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 1pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(1)</sup></span><!--[if IE]></FONT><![endif]--><sup style="text-transform: none; font-size: 7pt; line-height: 7pt"></sup><span style="text-transform: none">Contributions to the deferred compensation plan that relate to an executive officer&#8217;s deferrals from salary and/or annual short-term incentives are included in the amounts reflected in the &#8220;Salary&#8221; and &#8220;Bonus&#8221; columns, as applicable, of the Summary Compensation Table for fiscal 2024 on </span><span style="text-transform: none">page 43.</span></p>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 1pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(2)</sup></span><!--[if IE]></FONT><![endif]--><sup style="text-transform: none; font-size: 7pt; line-height: 7pt"></sup><span style="text-transform: none">A participant&#8217;s account under the Executive Deferred Compensation Plan is deemed to be invested in hypothetical investment options selected by the participant from among a menu of non-proprietary mutual funds. The account is credited/debited with gains and/or losses linked to the performance of those hypothetical investment options. The plan does not have investment options that provide for above-market or preferential earnings; accordingly, the amounts provided in this column are not included in column (h) of the Summary Compensation Table for fiscal 2024 on </span><span style="text-transform: none">page 43.</span></p>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 8pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(3)</sup></span><!--[if IE]></FONT><![endif]--><sup style="text-transform: none; font-size: 7pt; line-height: 7pt"></sup><span style="text-transform: none">Amounts shown include the executive officer&#8217;s contributions, withdrawals, and associated hypothetical gains/losses during 2024, as well as deferrals of salary and annual incentives (together with associated hypothetical earnings) from prior years&#8217; participation in the plan. The amounts shown in this column, with the exception of aggregate earnings, have been reported in the &#8220;Salary&#8221; and &#8220;Bonus&#8221; columns, as applicable, of the Summary Compensation Table of prior year Company Proxy Statements, if the individuals were listed as NEOs in those prior year periods. The total year prior contributions to the Executive Deferred Compensation Plan are as noted in the </span><span style="text-transform: none">table below.</span></p>
				<div style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-align: center">
					<table style="margin: 4pt auto 10pt; table-layout: fixed; width: 427.5pt; border-collapse: collapse">
						<tr style="margin: 0; height: 0">
							<td style="border-width: 0; margin: 0; padding: 0; width: 217.5pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 210pt">


							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Name</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Amount <br/>Previously <br/>Reported<br/>($)</b></span></p>

							</td>

						</tr>
						<tr style="min-height: 9pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0 3.75pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">J. Patrick Mackin</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">&#8212;</span></p>

							</td>

						</tr>
						<tr style="min-height: 9pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0 3.75pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Lance A. Berry</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">&#8212;</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0 3.75pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Jean F. Holloway</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">1,377,816</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0 3.75pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">John E. Davis</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">620,439</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0 3.75pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Marshall S. Stanton</span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt">(1)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">212,661</span></p>

							</td>

						</tr>

					</table>

				</div>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 8pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(1)</sup></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Mr. Stanton was not an NEO for fiscal 2023, so there was no amount reported in our 2024 Proxy Statement; however, the balance in his deferred compensation plan as of December 31, 2023 </span><span style="text-transform: none">was $212,661.</span></p>
				<div style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-align: center">
					<table style="margin: 4pt auto 10pt; table-layout: fixed; width: 427.5pt; border-collapse: collapse">
						<tr style="margin: 0; height: 0">
							<td style="border-width: 0; margin: 0; padding: 0; width: 341.25pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 86.25pt">


							</td>

						</tr>
						<tr style="min-height: 16.65pt">
							<td colspan="2" style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span id="art-def14a_051325a486"></span><span style="text-transform: none"><b>Investment Options Provided and Associated Return Rates</b></span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Investment Option</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Annual Return for FY 2024</b></span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Equity Income Division</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">15.50</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">LargeCap S&amp;P 500 Index Division</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">24.74</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">LargeCap Growth I Division</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">25.14</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">American Century VP Mid Cap Value Division</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">8.52</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Vanguard VIF Mid Cap Index Division</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">15.08</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Fidelity VIP MidCap Division</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">17.18</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Franklin Small Cap Value VIP Division</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">11.71</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Calvert VP Russell 2000 Small Cap Index Division</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">11.00</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">ClearBridge Variable Small Cap Growth Division</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">4.50</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Real Estate Securities Division</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">5.59</span></p>

							</td>

						</tr>

					</table>

				</div>

			</div>

		</div>
		<div style="page-break-before: always">
			<p style="margin: 0pt; font-size: 5pt">&#8203;</p>

		</div>
		<div class="qes_page" style="border-bottom: black 2pt solid; margin: auto; height: 990pt; width: 765pt; position: relative; overflow: hidden">
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 911.25pt; left: 45pt; width: 675pt; position: absolute; height: 33.75pt">
				<div style="display: table-cell; vertical-align: bottom; width: 675pt; height: 33.75pt">

				<!--[if IE]><TABLE><TR style=" width: 675pt; height: 33.75pt;"><TD vAlign="bottom" style=" width: 675pt; height: 33.75pt;"><![endif]-->
					<div style="font: 12pt/normal Times New Roman, Times, serif; margin: 0pt; text-transform: none; color: #000000; text-align: left">
						<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 0pt; border-collapse: collapse">
							<tr style="margin: 0; height: 0">
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>

							</tr>
							<tr style="min-height: 0pt">
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">ARTIVION, INC. | 2025 Proxy Statement</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">52</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 0pt; line-height: 0pt">&#8203;</p>

								</td>

							</tr>

						</table>

					</div>


				<!--[if IE]></TD></TR></TABLE><![endif]-->
				</div>

			</div>
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 45pt; left: 45pt; width: 675pt; position: absolute; height: 866.25pt">
				<div style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-align: center">
					<table style="margin: 4pt auto 10pt; table-layout: fixed; width: 427.5pt; border-collapse: collapse">
						<tr style="margin: 0; height: 0">
							<td style="border-width: 0; margin: 0; padding: 0; width: 341.25pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 86.25pt">


							</td>

						</tr>
						<tr style="min-height: 16.65pt">
							<td colspan="2" style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Investment Options Provided and Associated Return Rates</b></span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Investment Option</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Annual Return for FY 2024</b></span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">American Funds Insurance Series New World Fund Division</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">6.56</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Principal LifeTime Strategic Income Division</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">6.71</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Principal LifeTime 2020 Division</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">7.43</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Principal LifeTime 2030 Division</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">9.05</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Principal LifeTime 2040 Division</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">11.55</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Principal LifeTime 2050 Division</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">13.29</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Principal LifeTime 2060 Division</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">13.28</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Fidelity VIP Government Money Market Division</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">5.01</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">PIMCO VIT High Yield Division</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">6.90</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">PIMCO VIT Total Return Division</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">2.54</span></p>

							</td>

						</tr>

					</table>

				</div>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: center"><span style="text-transform: none"></span></p>
				<p style="border-bottom: #7f7f7f 1pt solid; font: 12pt/normal Arial, sans-serif; margin: 4pt 0pt 15pt; text-transform: none; color: #2b4b74; text-indent: 0pt; text-align: left"><span style="text-transform: none"><b>POTENTIAL PAYMENTS UPON TERMINATION OR CHANGE OF CONTROL</b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none">We have entered into certain agreements and maintain certain plans that will require us to provide compensation to the Named Executive Officers in the event of specified terminations of their employment or upon a change of control </span><span style="text-transform: none">of Artivion.</span></p>
				<p style="font: italic 11pt/normal Arial, sans-serif; margin: 4pt 0pt 8pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><b><i>Employment, Separation and Release, and Change of Control Agreements</i></b></span></p>
				<p style="font: italic 11pt/normal Arial, sans-serif; margin: 4pt 0pt 8pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><i>Employment Agreement with J. Patrick Mackin</i></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">Pursuant to the Mackin Agreement, Mr. Mackin will receive certain compensation upon the termination of his employment, other than termination for cause or voluntary termination without </span><span style="text-transform: none; line-height: 12pt">good reason.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">The Mackin Agreement has an initial term of three years following the effective date, extended by one day for each day beginning on the second anniversary of the effective date. The Mackin Agreement provides that commencing January&#160;1, 2015, Mr. Mackin is entitled to participate in annual long-term incentive opportunities as determined by the Compensation Committee consistent with those provided to similarly situated Artivion executive officers and in accordance with Artivion&#8217;s plans and applicable award agreements. Benefits currently include participation in Artivion&#8217;s plan-based awards with other Artivion executive officers for performance stock units, stock options, and restricted stock subject to continued employment and achievement of corporate and Board of Directors objectives set by the </span><span style="text-transform: none; line-height: 12pt">Compensation Committee.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none">The Mackin Agreement provides for an initial target cash bonus of 60% of base salary, a $200,000 signing bonus, a new-hire grant of options to purchase 400,000 shares of Company common stock, and a performance share grant with respect to 250,000 shares of Company common stock, the performance metric thereto having been determined satisfied by the Compensation Committee as of December 31, 2015. In the event Mr. Mackin&#8217;s employment is terminated without cause or Mr. Mackin resigns for good reason, he is entitled to a cash severance payment of 1.5x the sum of his base salary and annual cash bonus for the year of termination (or the prior year bonus if termination is prior to the date bonuses are awarded) paid in regular payroll installments over 18 months plus continued Company medical coverage for the same period. If Mr. Mackin&#8217;s employment is terminated without cause, or Mr. Mackin resigns for good reason during the period beginning six months prior to and ending two years following a change of control of the Company, Mr. Mackin is entitled to receive a termination payment, in lieu of the severance described in the prior sentence, of 2.5x the sum of his base salary and annual cash bonus for the year of termination (or the prior year bonus if termination is prior to the date bonuses are awarded), paid in a lump sum. The Mackin Agreement also includes various post-employment prohibitions regarding competing with us, soliciting our employees and customers, and disclosing our confidential information. Under the Mackin Agreement, Mr. Mackin must repay any portion </span><span style="text-transform: none">of severance payments he has received from the Company if he fails to comply with certain post-employment </span><span style="text-transform: none">protective covenants.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">For purposes of the Mackin Agreement, &#8220;cause&#8221; generally means (i) an intentional act of fraud, embezzlement, theft, or any other material violation of law that occurs during or in the course of the executive officer&#8217;s employment, (ii)&#160;intentional damage of Company assets, (iii) intentional disclosure of Company confidential information contrary to the Company&#8217;s policies, (iv) material breach of the executive officer&#8217;s obligations under the agreement, (v) intentional engagement by the executive officer in any activity that would constitute a breach of his duty of loyalty or of his assigned duties, (vi) intentional breach by the executive officer of any Company policies or procedures, (vii) willful and continued failure by </span><span style="text-transform: none; line-height: 12pt">the executive </span></p>

			</div>

		</div>
		<div style="page-break-before: always">
			<p style="margin: 0pt; font-size: 5pt">&#8203;</p>

		</div>
		<div class="qes_page" style="border-bottom: black 2pt solid; margin: auto; height: 990pt; width: 765pt; position: relative; overflow: hidden">
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 911.25pt; left: 45pt; width: 675pt; position: absolute; height: 33.75pt">
				<div style="display: table-cell; vertical-align: bottom; width: 675pt; height: 33.75pt">

				<!--[if IE]><TABLE><TR style=" width: 675pt; height: 33.75pt;"><TD vAlign="bottom" style=" width: 675pt; height: 33.75pt;"><![endif]-->
					<div style="font: 12pt/normal Times New Roman, Times, serif; margin: 0pt; text-transform: none; color: #000000; text-align: left">
						<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 0pt; border-collapse: collapse">
							<tr style="margin: 0; height: 0">
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>

							</tr>
							<tr style="min-height: 0pt">
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">ARTIVION, INC. | 2025 Proxy Statement</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">53</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 0pt; line-height: 0pt">&#8203;</p>

								</td>

							</tr>

						</table>

					</div>


				<!--[if IE]></TD></TR></TABLE><![endif]-->
				</div>

			</div>
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 45pt; left: 45pt; width: 675pt; position: absolute; height: 866.25pt">
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">officer to perform his assigned duties, other than as a result of incapacity due to physical or mental illness, (viii) executive officer is prevented from performing certain duties contemplated by the agreement by reason of an agreement with a prior employer, or (ix) willful conduct by the executive officer that is demonstrably and materially injurious to the Company, monetarily </span><span style="text-transform: none; line-height: 12pt">or otherwise.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">For purposes of the Mackin Agreement, &#8220;good reason&#8221; generally means (i) the assignment to the executive officer, without his consent, of any duties materially inconsistent with his position, authority, duties, or responsibilities, including changes in status, offices, or titles and any change in the executive officer&#8217;s reporting requirements that would cause him to report to an executive officer&#160;who is junior in seniority to the executive officer to whom he previously reported, (ii) requiring the executive officer to be based other than within 25 miles of Company headquarters as of the effective date, or (iii) any other action that results in a material diminution in his position, authority, duties, responsibilities, or aggregate base salary and </span><span style="text-transform: none; line-height: 12pt">cash bonus.</span></p>
				<p style="font: italic 11pt/normal Arial, sans-serif; margin: 4pt 0pt 8pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><b><i>Change of Control Agreements with Other Named Executive Officers</i></b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">On November 21, 2016, Artivion entered into change of control agreements with each of Mr. Davis and Ms. Holloway. In August 2022, Artivion entered into new change of control agreements with Ms. Holloway and Mr. Davis; however, these new agreements contained only minor, non-substantive revisions to reflect Artivion&#8217;s rebranding and reincorporation into Delaware. In December 2023, Artivion entered into a change of control agreement with Mr. Berry. The change of control agreements provide that the Company will pay severance payments if Messrs. Berry, or Davis or Ms. Holloway are terminated by the Company without cause or if s/he terminates the employment for good reason during a period extending from six months before to two years after a change of control of Artivion. This is a &#8220;double trigger&#8221; provision that requires not only a change of control of Artivion but also an adverse </span><span style="text-transform: none; line-height: 12pt">employment action.</span></p>
				<p style="font: italic 11pt/normal Arial, sans-serif; margin: 4pt 0pt 8pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><i>Terms of the Change of Control Agreements</i></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt 45pt; text-transform: none; color: #000000; text-indent: -22.5pt; text-align: justify"><!--[if IE]><FONT style=" width: 22.5pt; text-indent: -18.0pt; display: inline-block;"><![endif]--><span style="width: 22.5pt; text-indent: 0; display: inline-block"><span style="text-transform: none">&#8226;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">The initial term of the agreement for each of Mr. Davis and Ms. Holloway ended December 31,&#160;2022. The initial term of the agreement for Mr. Berry ended December 31,&#160;2023. Each of these agreements, however, will automatically renew at the end of the term and every year thereafter, for an additional one-year term, unless Artivion provides notice at least 30 days prior to the end of the then-current term that the agreement will not </span><span style="text-transform: none">be extended.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt 45pt; text-transform: none; color: #000000; text-indent: -22.5pt; text-align: justify"><!--[if IE]><FONT style=" width: 22.5pt; text-indent: -18.0pt; display: inline-block;"><![endif]--><span style="width: 22.5pt; text-indent: 0; display: inline-block"><span style="text-transform: none">&#8226;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">The severance payment is an amount equal to 1.5x for each of Mr. Berry, Ms. Holloway, and Mr. Davis the sum of the executive officer&#8217;s base salary as of the date of termination and his or her bonus compensation for the year in which the termination of employment occurs, or if the bonus for that year has not yet been awarded, the most recently awarded bonus compensation. The agreements also provide for 18 months of medical coverage for Messrs. Berry and Davis and </span><span style="text-transform: none">Ms. Holloway.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt 45pt; text-transform: none; color: #000000; text-indent: -22.5pt; text-align: justify"><!--[if IE]><FONT style=" width: 22.5pt; text-indent: -18.0pt; display: inline-block;"><![endif]--><span style="width: 22.5pt; text-indent: 0; display: inline-block"><span style="text-transform: none">&#8226;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Change of control, as defined in the agreement, means a change in the ownership of Artivion, a change in the effective control of Artivion, or a change in the ownership of a substantial portion of the assets of Artivion. Specifically, any of the following types of events would constitute a change of control under </span><span style="text-transform: none">the agreements:</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt 67.5pt; text-transform: none; color: #000000; text-indent: -22.5pt; text-align: justify"><!--[if IE]><FONT style=" width: 22.5pt; text-indent: -18.0pt; display: inline-block;"><![endif]--><span style="width: 22.5pt; text-indent: 0; display: inline-block"><span style="text-transform: none">o</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Any person, including a syndicate or group, acquires ownership of Artivion stock that, taken together with Artivion stock held by such person or group, constitutes more than 50% of the total voting power of the stock </span><span style="text-transform: none">of Artivion;</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt 67.5pt; text-transform: none; color: #000000; text-indent: -22.5pt; text-align: justify"><!--[if IE]><FONT style=" width: 22.5pt; text-indent: -18.0pt; display: inline-block;"><![endif]--><span style="width: 22.5pt; text-indent: 0; display: inline-block"><span style="text-transform: none">o</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Any person, including a syndicate or group, acquires ownership of stock of Artivion possessing 30% or more of the total voting power of </span><span style="text-transform: none">Artivion stock;</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt 67.5pt; text-transform: none; color: #000000; text-indent: -22.5pt; text-align: justify"><!--[if IE]><FONT style=" width: 22.5pt; text-indent: -18.0pt; display: inline-block;"><![endif]--><span style="width: 22.5pt; text-indent: 0; display: inline-block"><span style="text-transform: none">o</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">A majority of the members of Artivion&#8217;s Board of Directors are replaced during any 12-month period by individuals whose appointment or election is not endorsed by a majority of the Board of Directors prior to the date of appointment or </span><span style="text-transform: none">election; or</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt 67.5pt; text-transform: none; color: #000000; text-indent: -22.5pt; text-align: justify"><!--[if IE]><FONT style=" width: 22.5pt; text-indent: -18.0pt; display: inline-block;"><![endif]--><span style="width: 22.5pt; text-indent: 0; display: inline-block"><span style="text-transform: none">o</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Any person, including a syndicate or group, acquires assets from Artivion that have a total gross fair market value equal to more than 40% of the total gross fair market value of all Artivion assets immediately prior to </span><span style="text-transform: none">such acquisition.</span></p>

			</div>

		</div>
		<div style="page-break-before: always">
			<p style="margin: 0pt; font-size: 5pt">&#8203;</p>

		</div>
		<div class="qes_page" style="border-bottom: black 2pt solid; margin: auto; height: 990pt; width: 765pt; position: relative; overflow: hidden">
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 911.25pt; left: 45pt; width: 675pt; position: absolute; height: 33.75pt">
				<div style="display: table-cell; vertical-align: bottom; width: 675pt; height: 33.75pt">

				<!--[if IE]><TABLE><TR style=" width: 675pt; height: 33.75pt;"><TD vAlign="bottom" style=" width: 675pt; height: 33.75pt;"><![endif]-->
					<div style="font: 12pt/normal Times New Roman, Times, serif; margin: 0pt; text-transform: none; color: #000000; text-align: left">
						<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 0pt; border-collapse: collapse">
							<tr style="margin: 0; height: 0">
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>

							</tr>
							<tr style="min-height: 0pt">
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">ARTIVION, INC. | 2025 Proxy Statement</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">54</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 0pt; line-height: 0pt">&#8203;</p>

								</td>

							</tr>

						</table>

					</div>


				<!--[if IE]></TD></TR></TABLE><![endif]-->
				</div>

			</div>
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 45pt; left: 45pt; width: 675pt; position: absolute; height: 866.25pt">
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt 45pt; text-transform: none; color: #000000; text-indent: -22.5pt; text-align: justify"><!--[if IE]><FONT style=" width: 22.5pt; text-indent: -18.0pt; display: inline-block;"><![endif]--><span style="width: 22.5pt; text-indent: 0; display: inline-block"><span style="text-transform: none">&#8226;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">The agreements are not employment agreements and each respective officer&#8217;s employment is </span><span style="text-transform: none">&#8220;at will.&#8221;</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">We will not be required to make a severance payment in connection with the change of control agreements if we terminate an executive officer&#8217;s employment for &#8220;cause,&#8221; </span><span style="text-transform: none; line-height: 12pt">which means:</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt 45pt; text-transform: none; color: #000000; text-indent: -22.5pt; text-align: justify"><!--[if IE]><FONT style=" width: 22.5pt; text-indent: -18.0pt; display: inline-block;"><![endif]--><span style="width: 22.5pt; text-indent: 0; display: inline-block"><span style="text-transform: none">&#8226;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">An act of fraud, embezzlement, theft, or any other material violation of law that occurs during or in the course of the executive officer&#8217;s employment </span><span style="text-transform: none">with Artivion;</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt 45pt; text-transform: none; color: #000000; text-indent: -22.5pt; text-align: justify"><!--[if IE]><FONT style=" width: 22.5pt; text-indent: -18.0pt; display: inline-block;"><![endif]--><span style="width: 22.5pt; text-indent: 0; display: inline-block"><span style="text-transform: none">&#8226;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Intentional or grossly negligent damage by the executive officer to </span><span style="text-transform: none">Artivion assets;</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt 45pt; text-transform: none; color: #000000; text-indent: -22.5pt; text-align: justify"><!--[if IE]><FONT style=" width: 22.5pt; text-indent: -18.0pt; display: inline-block;"><![endif]--><span style="width: 22.5pt; text-indent: 0; display: inline-block"><span style="text-transform: none">&#8226;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Intentional or grossly negligent disclosure by the executive officer of Artivion&#8217;s confidential information contrary to </span><span style="text-transform: none">Artivion policies;</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt 45pt; text-transform: none; color: #000000; text-indent: -22.5pt; text-align: justify"><!--[if IE]><FONT style=" width: 22.5pt; text-indent: -18.0pt; display: inline-block;"><![endif]--><span style="width: 22.5pt; text-indent: 0; display: inline-block"><span style="text-transform: none">&#8226;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Material breach of the executive officer&#8217;s obligations under the agreement or other agreements </span><span style="text-transform: none">with Artivion;</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt 45pt; text-transform: none; color: #000000; text-indent: -22.5pt; text-align: justify"><!--[if IE]><FONT style=" width: 22.5pt; text-indent: -18.0pt; display: inline-block;"><![endif]--><span style="width: 22.5pt; text-indent: 0; display: inline-block"><span style="text-transform: none">&#8226;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Engagement by the executive officer in any activity that would constitute a breach of his or her duty of loyalty or of his or her </span><span style="text-transform: none">assigned duties;</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt 45pt; text-transform: none; color: #000000; text-indent: -22.5pt; text-align: justify"><!--[if IE]><FONT style=" width: 22.5pt; text-indent: -18.0pt; display: inline-block;"><![endif]--><span style="width: 22.5pt; text-indent: 0; display: inline-block"><span style="text-transform: none">&#8226;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Breach by the executive officer of any of Artivion&#8217;s policies </span><span style="text-transform: none">and procedures;</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt 45pt; text-transform: none; color: #000000; text-indent: -22.5pt; text-align: justify"><!--[if IE]><FONT style=" width: 22.5pt; text-indent: -18.0pt; display: inline-block;"><![endif]--><span style="width: 22.5pt; text-indent: 0; display: inline-block"><span style="text-transform: none">&#8226;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">The willful and continued failure by the executive officer to perform his or her assigned duties, other than as a result of incapacity due to physical or mental </span><span style="text-transform: none">illness; or</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt 45pt; text-transform: none; color: #000000; text-indent: -22.5pt; text-align: justify"><!--[if IE]><FONT style=" width: 22.5pt; text-indent: -18.0pt; display: inline-block;"><![endif]--><span style="width: 22.5pt; text-indent: 0; display: inline-block"><span style="text-transform: none">&#8226;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Willful conduct by the executive officer that is demonstrably and materially injurious to Artivion, monetarily </span><span style="text-transform: none">or otherwise.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">An executive officer may terminate his or her employment for &#8220;good reason&#8221; in connection with a change of control without forfeiting his or her severance pay if any of the following events occur during the term of </span><span style="text-transform: none; line-height: 12pt">the agreement:</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt 45pt; text-transform: none; color: #000000; text-indent: -22.5pt; text-align: justify"><!--[if IE]><FONT style=" width: 22.5pt; text-indent: -18.0pt; display: inline-block;"><![endif]--><span style="width: 22.5pt; text-indent: 0; display: inline-block"><span style="text-transform: none">&#8226;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">The assignment to the executive officer, without his or her consent, of any duties materially inconsistent with his or her position, authority, duties, or responsibilities, including changes in status, offices, or titles and any change in the executive officer&#8217;s reporting requirements that would cause him or her to report to an officer&#160;who is junior in seniority to the officer to whom he or she previously </span><span style="text-transform: none">reported; or</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt 45pt; text-transform: none; color: #000000; text-indent: -22.5pt; text-align: justify"><!--[if IE]><FONT style=" width: 22.5pt; text-indent: -18.0pt; display: inline-block;"><![endif]--><span style="width: 22.5pt; text-indent: 0; display: inline-block"><span style="text-transform: none">&#8226;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Any other action by Artivion or an acquiring company that results in a material diminution in his or her position, authority, duties, responsibilities, or aggregate compensation, excluding for this purpose an isolated, insubstantial, and inadvertent action taken in good faith and which is remedied by Artivion or an acquiring company within 30 days after receipt of notice from the </span><span style="text-transform: none">executive officer.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">The change of control agreements provide that we will pay any severance payment due in a lump sum not later than 30 days following the date of termination in the event of a termination following a change of control, or 30 days following a change of control in the event of a termination occurring within the six-month period preceding the change of control. We will delay pay</span><span style="text-transform: none; line-height: 12pt">ment of the severance payment until six months after the executive officer&#8217;s termination if necessary to prevent him or her from having to pay additional tax under Section 409A of the Code. We will also subject any severance payment to normal payroll tax withholding and compliance with </span><span style="text-transform: none; line-height: 12pt">non-compete obligations.</span></p>
				<p style="font: italic 11pt/normal Arial, sans-serif; margin: 4pt 0pt 8pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><i>Agreement Not to Solicit or Compete</i></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">Messrs. Berry and Davis and Ms. Holloway agree not to solicit any actual or prospective customers of Artivion with whom they have had contact for a competing business or to solicit employees of Artivion to leave Artivion. Messrs. Berry and Davis and Ms. Holloway agree, subject to applicable professional and ethical obligations and other legal requirements, not to join a competing business during the term of the agreement and for a period of one year following the termination of employment. Artivion or an acquiring company is not required to make the severance payment, and the officer is required to repay any portion of the severance payment already received, if he or she solicits customers or employees of Artivion during the term of the agreement and for a period of one year following the termination </span><span style="text-transform: none; line-height: 12pt">of employment.</span></p>

			</div>

		</div>
		<div style="page-break-before: always">
			<p style="margin: 0pt; font-size: 5pt">&#8203;</p>

		</div>
		<div class="qes_page" style="border-bottom: black 2pt solid; margin: auto; height: 990pt; width: 765pt; position: relative; overflow: hidden">
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 911.25pt; left: 45pt; width: 675pt; position: absolute; height: 33.75pt">
				<div style="display: table-cell; vertical-align: bottom; width: 675pt; height: 33.75pt">

				<!--[if IE]><TABLE><TR style=" width: 675pt; height: 33.75pt;"><TD vAlign="bottom" style=" width: 675pt; height: 33.75pt;"><![endif]-->
					<div style="font: 12pt/normal Times New Roman, Times, serif; margin: 0pt; text-transform: none; color: #000000; text-align: left">
						<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 0pt; border-collapse: collapse">
							<tr style="margin: 0; height: 0">
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>

							</tr>
							<tr style="min-height: 0pt">
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">ARTIVION, INC. | 2025 Proxy Statement</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">55</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 0pt; line-height: 0pt">&#8203;</p>

								</td>

							</tr>

						</table>

					</div>


				<!--[if IE]></TD></TR></TABLE><![endif]-->
				</div>

			</div>
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 45pt; left: 45pt; width: 675pt; position: absolute; height: 866.25pt">
				<p style="font: italic 11pt/normal Arial, sans-serif; margin: 0pt 0pt 8pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><b><i>Termination and Change of Control Payments</i></b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">The amount of compensation we would be required to pay to each Named Executive Officer under certain termination and change of control scenarios is provided in the tables beginning on page 56. Amounts included in the tables are estimates and are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Due to the number of factors that affect the nature and amount of any benefits provided upon the events discussed below, any actual amounts paid or distributed may differ materially. The tables provided in this section for all Named Executive Officers assume that the relevant termination or change of control event occurred on December 31, 2024, the last business day of Artivion&#8217;s 2024 </span><span style="text-transform: none; line-height: 12pt">fiscal year.</span></p>

			</div>

		</div>
		<div style="page-break-before: always">
			<p style="margin: 0pt; font-size: 5pt">&#8203;</p>

		</div>
		<div class="qes_page" style="border-bottom: black 2pt solid; margin: auto; height: 990pt; width: 765pt; position: relative; overflow: hidden">
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 911.25pt; left: 45pt; width: 675pt; position: absolute; height: 33.75pt">
				<div style="display: table-cell; vertical-align: bottom; width: 675pt; height: 33.75pt">

				<!--[if IE]><TABLE><TR style=" width: 675pt; height: 33.75pt;"><TD vAlign="bottom" style=" width: 675pt; height: 33.75pt;"><![endif]-->
					<div style="font: 12pt/normal Times New Roman, Times, serif; margin: 0pt; text-transform: none; color: #000000; text-align: left">
						<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 0pt; border-collapse: collapse">
							<tr style="margin: 0; height: 0">
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>

							</tr>
							<tr style="min-height: 0pt">
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">ARTIVION, INC. | 2025 Proxy Statement</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">56</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 0pt; line-height: 0pt">&#8203;</p>

								</td>

							</tr>

						</table>

					</div>


				<!--[if IE]></TD></TR></TABLE><![endif]-->
				</div>

			</div>
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 45pt; left: 45pt; width: 675pt; position: absolute; height: 866.25pt">
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none"><b>J. Patrick Mackin, Chairman, President, and Chief Executive Officer</b></span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt"><b>(1)</b></sup></p>
				<div style="font: 10pt/normal Arial, sans-serif; margin: 5pt 0pt 10pt; text-transform: none; color: #000000; text-align: left">
					<table style="table-layout: fixed; width: 675pt; margin-top: 9pt; margin-bottom: 10pt; border-collapse: collapse">
						<tr style="margin: 0; height: 0">
							<td style="border-width: 0; margin: 0; padding: 0; width: 123.75pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 78.75pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 78.75pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 78.75pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 78.75pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 78.75pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 78.75pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 78.75pt">


							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td colspan="8" style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Executive Officer Benefits and Payments Upon Termination ($)</b></span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>&#160;</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Voluntary<br/>Retirement</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Good<br/>Reason or<br/>Involuntary<br/>Not for<br/>Cause<br/>Termination</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>For Cause<br/>Termination</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Death</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Disability</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Change<br/>of Control<br/>Without<br/>Regard to<br/>Termination</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Certain<br/>Termination<br/>Events<br/>Following/<br/>Preceding a<br/>Change of<br/>Control</b></span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt"><b>(8)</b></sup></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0 11.25pt; text-transform: none; color: #000000; text-indent: -11.25pt; text-align: left"><span style="text-transform: none">Cash Compensation</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">1,048,975</span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt">(2)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">3,537,963</span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt">(3)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">1,048,975</span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt">(2)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">1,048,975</span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt">(2)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">1,048,975</span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt">(2)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">5,896,605</span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt">(4)</sup></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0 11.25pt; text-transform: none; color: #000000; text-indent: -11.25pt; text-align: left"><span style="text-transform: none">Accelerated Stock Option Exercisability</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">7,289,091</span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt">(5)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">7,289,091</span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt">(5)</sup></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0 11.25pt; text-transform: none; color: #000000; text-indent: -11.25pt; text-align: left"><span style="text-transform: none">Accrued Vacation Pay</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0 11.25pt; text-transform: none; color: #000000; text-indent: -11.25pt; text-align: left"><span style="text-transform: none">Medical Benefits</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">42,535</span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt">(6)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">42,535</span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt">(6)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">42,535</span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt">(6)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">42,535</span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt">(6)</sup></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0 11.25pt; text-transform: none; color: #000000; text-indent: -11.25pt; text-align: left"><span style="text-transform: none">Spread Value of Vested Options</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0 11.25pt; text-transform: none; color: #000000; text-indent: -11.25pt; text-align: left"><span style="text-transform: none">Accelerated Vesting of Restricted Stock and Performance Stock Units</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">10,934,017</span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt">(7)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">10,934,017</span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt">(7)</sup></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0 11.25pt; text-transform: none; color: #000000; text-indent: -11.25pt; text-align: left"><span style="text-transform: none"><b>Total</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none"><b>1,048,975</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none"><b>3,580,498</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none"><b>1,048,975</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none"><b>1,091,510</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none"><b>1,091,510</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none"><b>18,223,108</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none"><b>24,162,248</b></span></p>

							</td>

						</tr>

					</table>

				</div>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 1pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(1)</sup></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">This table assumes that all termination and change of control events occurred on December 31, 2024. See Employment, Separation and Release, and Change of Control Agreements &#8211; Employment Agreement with J. Patrick Mackin above at page [56] for a description of the </span><span style="text-transform: none">Mackin Agreement.</span></p>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 1pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(2)</sup></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Amount shown represents the Company-performance component of the 2024 annual incentive plan cash bonus that Mr. Mackin was entitled to on December 31, 2024. No amount is included for the personal performance component of the annual </span><span style="text-transform: none">incentive plan.</span></p>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 1pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(3)</sup></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Amount shown represents 1.5x the sum of Mr. Mackin&#8217;s 2024 annual base salary and his entire cash bonus for 2023, as the 2024 bonus had not been determined or distributed as of December 31, 2024. The Mackin Agreement provides for severance payments to be paid in 18 monthly installments, beginning 30 days following the employment termination date (subject to any delay in payment necessary to comply with Section 409A of the Code). Mr. Mackin&#8217;s estate would receive these severance payments upon his </span><span style="text-transform: none">subsequent death.</span></p>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 1pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(4)</sup></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Amount shown is equal to 2.5x the sum of Mr. Mackin&#8217;s 2024 annual base salary and his entire 2023 bonus, as the 2024 bonus had not been determined or distributed as of December 31, 2024. The Mackin Agreement provides for severance payments to be paid in 18 monthly installments, beginning 30 days following the employment termination date (subject to any delay in payment necessary to comply with Section 409A of the Code). This scenario assumes that following the change of control, Mr.&#160;Mackin terminated his employment for good reason, or we terminated his employment without cause. Mr. Mackin would also receive the amount shown if we terminated his employment without cause at any time within the six months prior to the change </span><span style="text-transform: none">of control.</span></p>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 1pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(5)</sup></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">The 2020 ECIP provides that the exercisability of outstanding options accelerates upon a change of control. The accelerated options had value on December 31, 2024, to the extent that the exercise prices of the options were lower than the closing price of our common stock on the NYSE on December 31, 2024 of $28.59.&#160;The value for each option is calculated as the difference between the exercise price of the option and the closing price of our common stock at the end of the fiscal year, to the </span><span style="text-transform: none">extent positive.</span></p>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 1pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(6)</sup></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Under the terms of the Mackin Agreement, if Mr. Mackin terminates his employment for good reason, we terminate his employment without cause, or he dies or becomes disabled, we would continue to provide him and his family with health benefits coverage, at our expense, for up to 18 months (or until he is provided comparable benefits by another employer).&#160;Amount shown represents the value of 18 months of coverage under our health plans, using costs in effect as of December </span><span style="text-transform: none">31, 2024.</span></p>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 1pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(7)  </sup></span><!--[if IE]></FONT><![endif]--><sup style="text-transform: none; font-size: 7pt; line-height: 7pt"></sup><span style="text-transform: none">The 2020 ECIP provides that all unvested shares of restricted stock and performance stock units become fully vested upon a change of control. The accelerated restricted stock and performance stock units are valued at the closing price of our common stock on the NYSE on December 31, 2024 of $28.59, and the 2024 performance stock units are assumed to have been earned at </span><span style="text-transform: none">target level.</span></p>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 8pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(8)</sup></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Under the terms of the Mackin Agreement, amounts shown that are otherwise payable to Mr. Mackin would be reduced if and to the extent that doing so would cause payments that are contingent on a change of control to not be subject to the excise tax under Section 4999 of the Code and thereby produce a greater net after-tax amount </span><span style="text-transform: none">to him.</span></p>

			</div>

		</div>
		<div style="page-break-before: always">
			<p style="margin: 0pt; font-size: 5pt">&#8203;</p>

		</div>
		<div class="qes_page" style="border-bottom: black 2pt solid; margin: auto; height: 990pt; width: 765pt; position: relative; overflow: hidden">
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 911.25pt; left: 45pt; width: 675pt; position: absolute; height: 33.75pt">
				<div style="display: table-cell; vertical-align: bottom; width: 675pt; height: 33.75pt">

				<!--[if IE]><TABLE><TR style=" width: 675pt; height: 33.75pt;"><TD vAlign="bottom" style=" width: 675pt; height: 33.75pt;"><![endif]-->
					<div style="font: 12pt/normal Times New Roman, Times, serif; margin: 0pt; text-transform: none; color: #000000; text-align: left">
						<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 0pt; border-collapse: collapse">
							<tr style="margin: 0; height: 0">
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>

							</tr>
							<tr style="min-height: 0pt">
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">ARTIVION, INC. | 2025 Proxy Statement</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">57</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 0pt; line-height: 0pt">&#8203;</p>

								</td>

							</tr>

						</table>

					</div>


				<!--[if IE]></TD></TR></TABLE><![endif]-->
				</div>

			</div>
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 45pt; left: 45pt; width: 675pt; position: absolute; height: 866.25pt">
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none"><b>Lance A. Berry, Executive Vice President and Chief Financial Officer</b></span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt"><b>(1)</b></sup></p>
				<div style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-align: left">
					<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 10pt; border-collapse: collapse">
						<tr style="margin: 0; height: 0">
							<td style="border-width: 0; margin: 0; padding: 0; width: 123.75pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 78.75pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 78.75pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 78.75pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 78.75pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 78.75pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 78.75pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 78.75pt">


							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td colspan="8" style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Executive Officer Benefits and Payments Upon Termination ($)</b></span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>&#160;</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Voluntary<br/>Termination</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Good<br/>Reason or<br/>Involuntary<br/>Not for<br/>Cause<br/>Termination</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>For Cause<br/>Termination</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Death</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Disability</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Change<br/>of Control<br/>Without<br/>Regard to<br/>Termination</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Certain<br/>Termination<br/>Events<br/>Following/<br/>Preceding a<br/>Change of<br/>Control</b></span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0 11.25pt; text-transform: none; color: #000000; text-indent: -11.25pt; text-align: left"><span style="text-transform: none">Cash Compensation</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">390,000</span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt">(2)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">390,000</span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt">(2)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">390,000</span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt">(2)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">390,000</span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt">(2)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">390,000</span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt">(2)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">750,000</span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt">(3)</sup></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0 11.25pt; text-transform: none; color: #000000; text-indent: -11.25pt; text-align: left"><span style="text-transform: none">Accelerated Stock Option Exercisability</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">1,007,491</span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt">(4)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">1,007,491</span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt">(4)</sup></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0 11.25pt; text-transform: none; color: #000000; text-indent: -11.25pt; text-align: left"><span style="text-transform: none">Accrued Vacation Pay</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0 11.25pt; text-transform: none; color: #000000; text-indent: -11.25pt; text-align: left"><span style="text-transform: none">Medical Benefits</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">42,625</span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt">(5)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">42,625</span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt">(5)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">42,625</span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt">(5)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">42,625</span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt">(5)</sup></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0 11.25pt; text-transform: none; color: #000000; text-indent: -11.25pt; text-align: left"><span style="text-transform: none">Spread Value of Vested Options</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0 11.25pt; text-transform: none; color: #000000; text-indent: -11.25pt; text-align: left"><span style="text-transform: none">Accelerated Vesting of Restricted Stock and Performance Stock Units</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">3,318,270</span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt">(6)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">3,318,270</span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt">(6)</sup></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0 11.25pt; text-transform: none; color: #000000; text-indent: -11.25pt; text-align: left"><span style="text-transform: none"><b>Total</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none"><b>390,000</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none"><b>432,625</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none"><b>390,000</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none"><b>432,625</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none"><b>432,625</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none"><b>4,325,761</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none"><b>5,118,386</b></span></p>

							</td>

						</tr>

					</table>

				</div>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 1pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(1)</sup></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">This table assumes that all termination events occurred on December </span><span style="text-transform: none">31, 2024.</span></p>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 1pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(2)</sup></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Amount shown represents the Company-performance components of the 2024 annual incentive plan that Mr. Berry was entitled to on December 31, 2024. No amount is included for the personal performance component of the annual </span><span style="text-transform: none">incentive plan.</span></p>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 1pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(3)</sup></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Amount shown represents 1.5x the sum of Mr. Berry&#8217;s 2024 annual base salary and his entire cash bonus for 2023, as the 2024 bonus had not been determined or distributed as of December 31, 2024. This amount assumes that following a change of control, Mr. Berry terminated his employment for good reason, or we terminated his employment without cause. Mr. Berry would also receive the amount shown if we terminated his employment without cause at any time within the six months prior to the change </span><span style="text-transform: none">of control.</span></p>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 1pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(4)</sup></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">The 2020 ECIP provides that the exercisability of outstanding options accelerates upon a change of control. The accelerated options had value on December 31, 2024, to the extent that the exercise price of the options were lower than the closing price of our common stock on the NYSE on December 31, 2024 of $28.59.&#160;The value for each option is calculated as the difference between the exercise price of the option and the closing price of our common stock at the end of the fiscal year, to the </span><span style="text-transform: none">extent positive.</span></p>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 1pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(5)</sup></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Under the terms of Mr. Berry&#8217;s change of control agreement, upon a change of control event, if Mr. Berry terminates his employment for good reason or we terminate his employment without cause, we would continue to provide him and his family with health benefits coverage, at our expense, for up to 18 months (or until he is provided comparable benefits by another employer).&#160;Amount shown represents the value of 18 months of coverage under our health plans, using costs in effect as of December </span><span style="text-transform: none">31, 2024.</span></p>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 8pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(6)</sup></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">The 2020 ECIP provides that all unvested shares of restricted stock and performance stock units become fully vested upon a change of control. The accelerated restricted stock and performance stock units are valued at the closing price of our common stock on the NYSE on December 31, 2024 of $28.59, and the 2024 performance stock units are assumed to have been earned at </span><span style="text-transform: none">target level.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 5pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none"><b></b></span></p>

			</div>

		</div>
		<div style="page-break-before: always">
			<p style="margin: 0pt; font-size: 5pt">&#8203;</p>

		</div>
		<div class="qes_page" style="border-bottom: black 2pt solid; margin: auto; height: 990pt; width: 765pt; position: relative; overflow: hidden">
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 911.25pt; left: 45pt; width: 675pt; position: absolute; height: 33.75pt">
				<div style="display: table-cell; vertical-align: bottom; width: 675pt; height: 33.75pt">

				<!--[if IE]><TABLE><TR style=" width: 675pt; height: 33.75pt;"><TD vAlign="bottom" style=" width: 675pt; height: 33.75pt;"><![endif]-->
					<div style="font: 12pt/normal Times New Roman, Times, serif; margin: 0pt; text-transform: none; color: #000000; text-align: left">
						<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 0pt; border-collapse: collapse">
							<tr style="margin: 0; height: 0">
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>

							</tr>
							<tr style="min-height: 0pt">
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">ARTIVION, INC. | 2025 Proxy Statement</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">58</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 0pt; line-height: 0pt">&#8203;</p>

								</td>

							</tr>

						</table>

					</div>


				<!--[if IE]></TD></TR></TABLE><![endif]-->
				</div>

			</div>
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 45pt; left: 45pt; width: 675pt; position: absolute; height: 866.25pt">
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none"><b>Jean F. Holloway, Senior Vice President, General Counsel, Corporate Secretary, and Chief Compliance Officer</b></span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt"><b>(1)</b></sup></p>
				<div style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-align: justify">
					<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 10pt; border-collapse: collapse">
						<tr style="margin: 0; height: 0">
							<td style="border-width: 0; margin: 0; padding: 0; width: 123.75pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 78.75pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 78.75pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 78.75pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 78.75pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 78.75pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 78.75pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 78.75pt">


							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td colspan="8" style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Executive Officer Benefits and Payments Upon Termination ($)</b></span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>&#160;</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Voluntary<br/>Termination</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Good<br/>Reason or<br/>Involuntary<br/>Not for<br/>Cause<br/>Termination</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>For Cause<br/>Termination</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Death</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Disability</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Change<br/>of Control<br/>Without<br/>Regard to<br/>Termination</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Certain<br/>Termination<br/>Events<br/>Following/<br/>Preceding a<br/>Change of<br/>Control</b></span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0 11.25pt; text-transform: none; color: #000000; text-indent: -11.25pt; text-align: left"><span style="text-transform: none">Cash Compensation</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">276,665</span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt">(2)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">276,665</span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt">(2)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">276,665</span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt">(2)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">276,665</span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt">(2)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">276,665</span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt">(2)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">1,255,326</span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt">(3)</sup></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0 11.25pt; text-transform: none; color: #000000; text-indent: -11.25pt; text-align: left"><span style="text-transform: none">Accelerated Stock Option Exercisability</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">1,386,672</span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt">(4)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">1,386,672</span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt">(4)</sup></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0 11.25pt; text-transform: none; color: #000000; text-indent: -11.25pt; text-align: left"><span style="text-transform: none">Accrued Vacation Pay</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0 11.25pt; text-transform: none; color: #000000; text-indent: -11.25pt; text-align: left"><span style="text-transform: none">Medical Benefits</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">25,167</span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt">(5)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">25,167</span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt">(5)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">25,167</span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt">(5)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">25,167</span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt">(5)</sup></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0 11.25pt; text-transform: none; color: #000000; text-indent: -11.25pt; text-align: left"><span style="text-transform: none">Spread Value of Vested Options</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0 11.25pt; text-transform: none; color: #000000; text-indent: -11.25pt; text-align: left"><span style="text-transform: none">Accelerated Vesting of Restricted Stock and Performance Stock Units</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">2,252,407</span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt">(6)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">2,252,407</span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt">(6)</sup></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0 11.25pt; text-transform: none; color: #000000; text-indent: -11.25pt; text-align: left"><span style="text-transform: none"><b>Total</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none"><b>276,665</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none"><b>301,832</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none"><b>276,665</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none"><b>301,832</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none"><b>301,832</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none"><b>3,639,079</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none"><b>4,919,572</b></span></p>

							</td>

						</tr>

					</table>

				</div>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 0pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: left"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(1)</sup></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">This table assumes that all termination events occurred on December </span><span style="text-transform: none">31, 2024.</span></p>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 0pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(2)</sup></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Amount shown represents the Company-performance components of the 2024 annual incentive plan that Ms. Holloway was entitled to on December 31, 2024. No amount is included for the personal performance component of the annual </span><span style="text-transform: none">incentive plan.</span></p>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 0pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(3)</sup></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Amount shown represents 1.5x the sum of Ms. Holloway&#8217;s 2024 annual base salary and her entire cash bonus for 2023, as the 2024 bonus had not been determined or distributed as of December 31, 2024. This amount assumes that following a change of control, Ms. Holloway terminated her employment for good reason, or we terminated her employment without cause. Ms. Holloway would also receive the amount shown if we terminated her employment without cause at any time within the six months prior to the change </span><span style="text-transform: none">of control.</span></p>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 0pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(4)</sup></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">The 2020 ECIP provides that the exercisability of outstanding options accelerates upon a change of control. The accelerated options had value on December 31, 2024, to the extent that the exercise prices of the options were lower than the closing price of our common stock on the NYSE on December 31, 2024 of $28.59.&#160;The value for each option is calculated as the difference between the exercise price of the option and the closing price of our common stock at the end of the fiscal year, to the </span><span style="text-transform: none">extent positive.</span></p>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 0pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(5)</sup></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Under the terms of Ms. Holloway&#8217;s change of control agreement, upon a change of control event, if Ms. Holloway terminates her employment for good reason or we terminate her employment without cause, we would continue to provide her and her family with health benefits coverage, at our expense, for up to 18 months (or until she is provided comparable benefits by another employer).&#160;Amount shown represents the value of 18 months of coverage under our health plans, using costs in effect as </span><span style="text-transform: none">of December&#160;31,&#160;2024.</span></p>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 0pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(6)</sup></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">The 2020 ECIP provides that all unvested shares of restricted stock and performance stock units become fully vested upon a change of control. The accelerated restricted stock and performance stock units are valued at the closing price of our common stock on the NYSE on December 31, 2024 of $28.59, and the 2024 performance stock units are assumed to have been earned at </span><span style="text-transform: none">target level.</span></p>

			</div>

		</div>
		<div style="page-break-before: always">
			<p style="margin: 0pt; font-size: 5pt">&#8203;</p>

		</div>
		<div class="qes_page" style="border-bottom: black 2pt solid; margin: auto; height: 990pt; width: 765pt; position: relative; overflow: hidden">
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 911.25pt; left: 45pt; width: 675pt; position: absolute; height: 33.75pt">
				<div style="display: table-cell; vertical-align: bottom; width: 675pt; height: 33.75pt">

				<!--[if IE]><TABLE><TR style=" width: 675pt; height: 33.75pt;"><TD vAlign="bottom" style=" width: 675pt; height: 33.75pt;"><![endif]-->
					<div style="font: 12pt/normal Times New Roman, Times, serif; margin: 0pt; text-transform: none; color: #000000; text-align: left">
						<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 0pt; border-collapse: collapse">
							<tr style="margin: 0; height: 0">
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>

							</tr>
							<tr style="min-height: 0pt">
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">ARTIVION, INC. | 2025 Proxy Statement</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">59</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 0pt; line-height: 0pt">&#8203;</p>

								</td>

							</tr>

						</table>

					</div>


				<!--[if IE]></TD></TR></TABLE><![endif]-->
				</div>

			</div>
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 45pt; left: 45pt; width: 675pt; position: absolute; height: 866.25pt">
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none"><b>John E. Davis, Senior Vice President, Chief Commercial Officer</b></span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt"><b>(1)</b></sup></p>
				<div style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-align: justify">
					<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 10pt; border-collapse: collapse">
						<tr style="margin: 0; height: 0">
							<td style="border-width: 0; margin: 0; padding: 0; width: 123.75pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 78.75pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 78.75pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 78.75pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 78.75pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 78.75pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 78.75pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 78.75pt">


							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td colspan="8" style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Executive Officer Benefits and Payments Upon Termination ($)</b></span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>&#160;</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Voluntary<br/>Termination</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Good<br/>Reason or<br/>Involuntary<br/>Not for<br/>Cause<br/>Termination</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>For Cause<br/>Termination</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Death</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Disability</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Change<br/>of Control<br/>Without<br/>Regard to<br/>Termination</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Certain<br/>Termination<br/>Events<br/>Following/<br/>Preceding a<br/>Change of<br/>Control</b></span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0 11.25pt; text-transform: none; color: #000000; text-indent: -11.25pt; text-align: left"><span style="text-transform: none">Cash Compensation</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">264,456</span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt">(2)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">264,456</span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt">(2)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">264,456</span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt">(2)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">264,456</span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt">(2)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">264,456</span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt">(2)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">1,197,093</span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt">(3)</sup></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0 11.25pt; text-transform: none; color: #000000; text-indent: -11.25pt; text-align: left"><span style="text-transform: none">Accelerated Stock Option Exercisability</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 3pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">1,371,771</span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt">(4)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">1,371,771</span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt">(4)</sup></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0 11.25pt; text-transform: none; color: #000000; text-indent: -11.25pt; text-align: left"><span style="text-transform: none">Accrued Vacation Pay</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0 11.25pt; text-transform: none; color: #000000; text-indent: -11.25pt; text-align: left"><span style="text-transform: none">Medical Benefits</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 3pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">25,167</span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt">(5)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">25,167</span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt">(5)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">25,167</span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt">(5)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">25,167</span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt">(5)</sup></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0 11.25pt; text-transform: none; color: #000000; text-indent: -11.25pt; text-align: left"><span style="text-transform: none">Spread Value of Vested Options</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0 11.25pt; text-transform: none; color: #000000; text-indent: -11.25pt; text-align: left"><span style="text-transform: none">Accelerated Vesting of Restricted Stock and Performance Stock Units</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">2,249,176</span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt">(6)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">2,249,176</span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt">(6)</sup></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0 11.25pt; text-transform: none; color: #000000; text-indent: -11.25pt; text-align: left"><span style="text-transform: none"><b>Total</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none"><b>264,456</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none"><b>289,623</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none"><b>264,456</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none"><b>289,623</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none"><b>289,623</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none"><b>3,620,947</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none"><b>4,843,207</b></span></p>

							</td>

						</tr>

					</table>

				</div>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 0pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(1)</sup></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">This table assumes that all termination events occurred on December </span><span style="text-transform: none">31, 2024.</span></p>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 0pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(2)</sup></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Amount shown represents the Company-performance components of the 2024 annual incentive plan that Mr. Davis was entitled to on December 31, 2024. No amount is included for the personal performance component of the annual </span><span style="text-transform: none">incentive plan.</span></p>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 0pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(3)</sup></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Amount shown represents 1.5x the sum of Mr. Davis&#8217;s 2024 annual base salary and his entire cash bonus for 2023, as the 2024 bonus had not been determined or distributed as of December 31, 2024. This amount assumes that following a change of control, Mr. Davis terminated his employment for good reason, or we terminated his employment without cause. Mr. Davis would also receive the amount shown if we terminated his employment without cause at any time within the six months prior to the change </span><span style="text-transform: none">of control.</span></p>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 0pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(4)</sup></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">The 2020 ECIP provides that the exercisability of outstanding options accelerates upon a change of control. The accelerated options had value on December 31, 2024, to the extent that the exercise prices of the options were lower than the closing price of our common stock on the NYSE on December 31, 2024 of $28.59.&#160;The value for each option is calculated as the difference between the exercise price of the option and the closing price of our common stock at the end of the fiscal year, to the </span><span style="text-transform: none">extent positive.</span></p>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 0pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(5)</sup></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Under the terms of Mr. Davis&#8217;s change of control agreement, upon a change of control event, if Mr. Davis terminates his employment for good reason or we terminate his employment without cause, we would continue to provide him and his family with health benefits coverage, at our expense, for up to 18 months (or until he is provided comparable benefits by another employer).&#160;Amount shown represents the value of 18 months of coverage under our health plans, using costs in effect as </span><span style="text-transform: none">of December&#160;31,&#160;2024.</span></p>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 0pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(6)</sup></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">The 2020 ECIP provides that all unvested shares of restricted stock and performance stock units become fully vested upon a change of control. The accelerated restricted stock and performance stock units are valued at the closing price of our common stock on the NYSE on December 31, 2024 of $28.59, and the 2024 performance stock units are assumed to have been earned at </span><span style="text-transform: none">target level.</span></p>

			</div>

		</div>
		<div style="page-break-before: always">
			<p style="margin: 0pt; font-size: 5pt">&#8203;</p>

		</div>
		<div class="qes_page" style="border-bottom: black 2pt solid; margin: auto; height: 990pt; width: 765pt; position: relative; overflow: hidden">
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 911.25pt; left: 45pt; width: 675pt; position: absolute; height: 33.75pt">
				<div style="display: table-cell; vertical-align: bottom; width: 675pt; height: 33.75pt">

				<!--[if IE]><TABLE><TR style=" width: 675pt; height: 33.75pt;"><TD vAlign="bottom" style=" width: 675pt; height: 33.75pt;"><![endif]-->
					<div style="font: 12pt/normal Times New Roman, Times, serif; margin: 0pt; text-transform: none; color: #000000; text-align: left">
						<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 0pt; border-collapse: collapse">
							<tr style="margin: 0; height: 0">
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>

							</tr>
							<tr style="min-height: 0pt">
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">ARTIVION, INC. | 2025 Proxy Statement</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">60</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 0pt; line-height: 0pt">&#8203;</p>

								</td>

							</tr>

						</table>

					</div>


				<!--[if IE]></TD></TR></TABLE><![endif]-->
				</div>

			</div>
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 45pt; left: 45pt; width: 675pt; position: absolute; height: 866.25pt">
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none"><b>Marshall S. Stanton, Senior Vice President, Clinical Research and Chief&#160;Medical Officer</b></span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt"><b>(1)</b></sup></p>
				<div style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-align: justify">
					<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 10pt; border-collapse: collapse">
						<tr style="margin: 0; height: 0">
							<td style="border-width: 0; margin: 0; padding: 0; width: 123.75pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 78.75pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 78.75pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 78.75pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 78.75pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 78.75pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 78.75pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 78.75pt">


							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td colspan="8" style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Executive Officer Benefits and Payments Upon Termination ($)</b></span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt"><b>(2)</b></sup></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>&#160;</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Voluntary<br/>Termination</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Good<br/>Reason or<br/>Involuntary<br/>Not for<br/>Cause<br/>Termination</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>For Cause<br/>Termination</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Death</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Disability</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Change<br/>of Control<br/>Without<br/>Regard to<br/>Termination</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Certain<br/>Termination<br/>Events<br/>Following/<br/>Preceding a<br/>Change of<br/>Control</b></span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0 11.25pt; text-transform: none; color: #000000; text-indent: -11.25pt; text-align: left"><span style="text-transform: none">Cash Compensation</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0 11.25pt; text-transform: none; color: #000000; text-indent: -11.25pt; text-align: left"><span style="text-transform: none">Accelerated Stock Option Exercisability</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">1,045,513</span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt">(3)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">1,045,513</span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt">(3)</sup></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0 11.25pt; text-transform: none; color: #000000; text-indent: -11.25pt; text-align: left"><span style="text-transform: none">Accrued Vacation Pay</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0 11.25pt; text-transform: none; color: #000000; text-indent: -11.25pt; text-align: left"><span style="text-transform: none">Medical Benefits</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0 11.25pt; text-transform: none; color: #000000; text-indent: -11.25pt; text-align: left"><span style="text-transform: none">Spread Value of Vested Options</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0 11.25pt; text-transform: none; color: #000000; text-indent: -11.25pt; text-align: left"><span style="text-transform: none">Accelerated Vesting of Restricted Stock and Performance Stock Units</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">1,847,915</span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt">(4)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">1,847,915</span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt">(4)</sup></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0 11.25pt; text-transform: none; color: #000000; text-indent: -11.25pt; text-align: left"><span style="text-transform: none"><b>Total</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none"><b>&#8212;</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none"><b>&#8212;</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none"><b>&#8212;</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none"><b>&#8212;</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none"><b>&#8212;</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none"><b>2,893,428</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none"><b>2,893,428</b></span></p>

							</td>

						</tr>

					</table>

				</div>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 1pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(1)</sup></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">This table assumes that the change of control event occurred on December </span><span style="text-transform: none">31, 2024.</span></p>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 1pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(2)</sup></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">While Mr. Stanton does not have a Change of Control Agreement with the Company, under the 2020 ECIP, he is entitled to accelerated vesting of certain unvested equity awards upon a change </span><span style="text-transform: none">of control.</span></p>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 1pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(3)</sup></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">The 2020 ECIP provides that the exercisability of outstanding options accelerates upon a change of control. The accelerated options had value on December 31, 2024, to the extent that the exercise prices of the options were lower than the closing price of our common stock on the NYSE on December 31, 2024 of $28.59.&#160;The value for each option is calculated as the difference between the exercise price of the option and the closing price of our common stock at the end of the fiscal year, to the </span><span style="text-transform: none">extent positive.</span></p>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 8pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(4)</sup></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">The 2020 ECIP provides that all unvested shares of restricted stock and performance stock units become fully vested upon a change of control. The accelerated restricted stock and performance stock units are valued at the closing price of our common stock on the NYSE on December 31, 2024 of $28.59, and the 2024 performance stock units are assumed to have been earned at </span><span style="text-transform: none">target level.</span></p>

			</div>

		</div>
		<div style="page-break-before: always">
			<p style="margin: 0pt; font-size: 5pt">&#8203;</p>

		</div>
		<div class="qes_page" style="border-bottom: black 2pt solid; margin: auto; height: 990pt; width: 765pt; position: relative; overflow: hidden">
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 911.25pt; left: 45pt; width: 675pt; position: absolute; height: 33.75pt">
				<div style="display: table-cell; vertical-align: bottom; width: 675pt; height: 33.75pt">

				<!--[if IE]><TABLE><TR style=" width: 675pt; height: 33.75pt;"><TD vAlign="bottom" style=" width: 675pt; height: 33.75pt;"><![endif]-->
					<div style="font: 12pt/normal Times New Roman, Times, serif; margin: 0pt; text-transform: none; color: #000000; text-align: left">
						<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 0pt; border-collapse: collapse">
							<tr style="margin: 0; height: 0">
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>

							</tr>
							<tr style="min-height: 0pt">
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">ARTIVION, INC. | 2025 Proxy Statement</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">61</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 0pt; line-height: 0pt">&#8203;</p>

								</td>

							</tr>

						</table>

					</div>


				<!--[if IE]></TD></TR></TABLE><![endif]-->
				</div>

			</div>
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 45pt; left: 45pt; width: 675pt; position: absolute; height: 866.25pt">
				<p style="font: italic 11pt/normal Arial, sans-serif; margin: 0pt 0pt 8pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><b><i>Compensation Risk Assessment</i></b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">The Compensation Committee has determined that our compensation policies and practices for our employees, including our Named Executive Officers, are not reasonably likely to have a material adverse effect on us because the potential for unacceptable risks that may be encouraged, directly or indirectly, through a compensation method is mitigated through policy or practice, the Company&#8217;s training programs, the Company&#8217;s internal controls, or external factors such as risk of civil or criminal prosecution, which are made known to employees </span><span style="text-transform: none; line-height: 12pt">through training.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">Our Compensation Committee routinely assesses our compensation policies and practices and takes this consideration into account as part of </span><span style="text-transform: none; line-height: 12pt">its review.</span></p>
				<p style="font: italic 11pt/normal Arial, sans-serif; margin: 4pt 0pt 8pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><b><i>Securities Authorized for Issuance Under Equity Compensation Plans</i></b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">The following table provides information as of December&#160;31, 2024, with respect to shares of Artivion common stock that may be issued under existing equity </span><span style="text-transform: none; line-height: 12pt">compensation plans.</span></p>
				<div style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-align: center">
					<table style="margin: 4pt auto 10pt; table-layout: fixed; width: 600pt; border-collapse: collapse">
						<tr style="margin: 0; height: 0">
							<td style="border-width: 0; margin: 0; padding: 0; width: 180pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 140pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 140pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 140pt">


							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td colspan="4" style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Securities Authorized for Issuance Under All Equity Compensation Plans</b></span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt"><b>(1)</b></sup></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Plan Category</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Number&#160;of&#160;<br/>Securities&#160;to&#160;be<br/> Issued Upon <br/>Exercise of<br/> Outstanding Options,<br/> PSUs, and RSUs</b></span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt"><b>(2)</b></sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Weighted&#160;Average&#160;<br/>Exercise Price&#160;<br/>of&#160;Outstanding<br/> Options,&#160;PSUs, <br/>and RSUs</b></span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt"><b>(3)</b></sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Number of Securities<br/>Remaining Available<br/>for  Future Issuance<br/>Under Equity<br/>Compensation Plans<br/> (Excluding Securities<br/> Reflected in Column<br/>(a))</b></span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt"><b>(4)</b></sup></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><sup style="text-transform: none; font-size: 6pt; line-height: 6pt"><b>(a)</b></sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><sup style="text-transform: none; font-size: 6pt; line-height: 6pt"><b>(b)</b></sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><sup style="text-transform: none; font-size: 6pt; line-height: 6pt"><b>(c)</b></sup></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0 11.25pt; text-transform: none; color: #000000; text-indent: -11.25pt; text-align: left"><span style="text-transform: none">Equity compensation plans approved by stockholders</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 33pt 1.5pt 11px; text-align: center; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin-left: 22px; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">3,398,949</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 40pt 1.5pt 11px; text-align: center; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin-left: 22px; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">$18.19</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 33pt 1.5pt 11px; text-align: center; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin-left: 22px; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">2,741,874</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0 11.25pt; text-transform: none; color: #000000; text-indent: -11.25pt; text-align: left"><span style="text-transform: none">Equity compensation plans not approved by stockholders</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 33pt 1.5pt 33px; text-align: center; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin-left: 44px; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 40pt 1.5pt 11px; text-align: center; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin-left: 44px; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 33pt 1.5pt 33px; text-align: center; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin-left: 44px; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">&#8212;</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0 11.25pt; text-transform: none; color: #000000; text-indent: -11.25pt; text-align: left"><span style="text-transform: none"><b>Total</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 33pt 1.5pt 11px; text-align: center; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin-left: 22px; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none"><b>3,398,949</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 40pt 1.5pt 11px; text-align: center; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin-left: 22px; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none"><b>$18.19</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 33pt 1.5pt 11px; text-align: center; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin-left: 22px; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none"><b>2,741,874</b></span></p>

							</td>

						</tr>

					</table>

				</div>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 1pt 37.5pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(1)</sup></span><!--[if IE]></FONT><![endif]--><sup style="text-transform: none; font-size: 7pt; line-height: 7pt"></sup><span style="text-transform: none">Plans include the 2020 ECIP and the Employee Stock Purchase Plan (&#8220;ESPP&#8221;). As of December 31, 2024, 2,033,373 shares remain available for grant in the 2020 ECIP and 708,501 shares remain available for grant in </span><span style="text-transform: none">the ESPP.</span></p>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 1pt 37.5pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(2)</sup></span><!--[if IE]></FONT><![endif]--><sup style="text-transform: none; font-size: 7pt; line-height: 7pt"></sup><span style="text-transform: none">Amounts in column (a) include 1,626,823 Stock Options, 1,171,219 RSUs, and 600,907 PSUs (including shares for which performance was not yet calculated as of December 31, 2024, which are calculated at maximum payout which is 282,027 shares above target). The amounts in column (a) do not include 50,312 Restricted Stock Awards (RSAs) that were unvested and outstanding as of December </span><span style="text-transform: none">31, 2024.</span></p>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 1pt 37.5pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(3)</sup></span><!--[if IE]></FONT><![endif]--><sup style="text-transform: none; font-size: 7pt; line-height: 7pt"></sup><span style="text-transform: none">Amounts in column (b) only reflect outstanding </span><span style="text-transform: none">Stock Options.</span></p>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 8pt 37.5pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(4)</sup></span><!--[if IE]></FONT><![endif]--><sup style="text-transform: none; font-size: 7pt; line-height: 7pt"></sup><span style="text-transform: none">Total includes 47,908 shares subject to purchase during our ESPP purchase period ending June 30, 2025, which is calculated using an estimated purchase price of $23.87, which equals 85% of the closing price of the Company&#8217;s common stock of</span><span style="text-transform: none"> $28.08 on January 2, 2025, the first trading day in the current ESPP </span><span style="text-transform: none">offering period.</span></p>

			</div>

		</div>
		<div style="page-break-before: always">
			<p style="margin: 0pt; font-size: 5pt">&#8203;</p>

		</div>
		<div class="qes_page" style="border-bottom: black 2pt solid; margin: auto; height: 990pt; width: 765pt; position: relative; overflow: hidden">
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 911.25pt; left: 45pt; width: 675pt; position: absolute; height: 33.75pt">
				<div style="display: table-cell; vertical-align: bottom; width: 675pt; height: 33.75pt">

				<!--[if IE]><TABLE><TR style=" width: 675pt; height: 33.75pt;"><TD vAlign="bottom" style=" width: 675pt; height: 33.75pt;"><![endif]-->
					<div style="font: 12pt/normal Times New Roman, Times, serif; margin: 0pt; text-transform: none; color: #000000; text-align: left">
						<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 0pt; border-collapse: collapse">
							<tr style="margin: 0; height: 0">
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>

							</tr>
							<tr style="min-height: 0pt">
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">ARTIVION, INC. | 2025 Proxy Statement</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">62</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 0pt; line-height: 0pt">&#8203;</p>

								</td>

							</tr>

						</table>

					</div>


				<!--[if IE]></TD></TR></TABLE><![endif]-->
				</div>

			</div>
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 45pt; left: 45pt; width: 675pt; position: absolute; height: 866.25pt">
				<p style="font: 14pt/normal Arial, sans-serif; margin: 0pt 0pt 15pt; text-transform: none; color: #2b4b74; text-indent: 0pt; text-align: left"><span style="text-transform: none"><b>OTHER INFORMATION</b></span></p>
				<p style="border-bottom: #7f7f7f 1pt solid; font: 12pt/normal Arial, sans-serif; margin: 4pt 0pt 15pt; text-transform: none; color: #2b4b74; text-indent: 0pt; text-align: left"><span style="text-transform: none"><b>CEO Pay Ratio Disclosure</b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">Pursuant to a mandate of the Dodd-Frank Wall Street Reform and Consumer Protection Act and Item 402(u) of Regulation S-K, we are providing disclosure of the ratio of the median employee&#8217;s annual total compensation to the total annual compensation of the principal executive officer (&#8220;PEO&#8221;). The Company&#8217;s PEO is </span><span style="text-transform: none; line-height: 12pt">Mr. Mackin.</span></p>
				<div style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-align: center">
					<table style="margin: 4pt auto 10pt; table-layout: fixed; width: 465pt; border-collapse: collapse">
						<tr style="margin: 0; height: 0">
							<td style="border-width: 0; margin: 0; padding: 0; width: 270pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 97.5pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 97.5pt">


							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>&#160;</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>PEO<br/>($)</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Median<br/>Employee</b></span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt"><b>(1)</b></sup><span style="text-transform: none"><b> <br/>($)</b></span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0 11.25pt; text-transform: none; color: #000000; text-indent: -11.25pt; text-align: left"><span style="text-transform: none">Total Compensation</span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt">(2)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">5,511,940</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">67,733</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0 11.25pt; text-transform: none; color: #000000; text-indent: -11.25pt; text-align: left"><span style="text-transform: none"><b>PEO to Median Employee Pay Ratio</b></span></p>

							</td>
							<td colspan="2" style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>81.4 : 1</b></span></p>

							</td>

						</tr>

					</table>

				</div>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 103.75pt 1pt 118.75pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(1)</sup></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">In calculating the CEO pay ratio for fiscal 2024, the Company used the same median employee identified in the prior year&#8217;s disclosure, as there have been no significant changes in employee compensation arrangements or workforce composition that would materially impact the pay ratio calculation. Base salary, commission payments, cash bonus, and equity awards were considered when determining the 2024 compensation of the median employee. All 2024 compensation not paid in U.S. dollars was converted to U.S. dollars using the exchange rate as of December&#160;31,&#160;2024. All equity was recorded at grant date fair value. Base salary was annualized for those employees that were not employed for the full year </span><span style="text-transform: none">of 2024.</span></p>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 103.75pt 8pt 118.75pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(2)</sup></span><!--[if IE]></FONT><![endif]--><sup style="text-transform: none; font-size: 7pt; line-height: 7pt"></sup><span style="text-transform: none">Total Compensation includes all components recorded in the Summary </span><span style="text-transform: none">Compensation Table.</span></p>

			</div>

		</div>
		<div style="page-break-before: always">
			<p style="margin: 0pt; font-size: 5pt">&#8203;</p>

		</div>
		<div class="qes_page" style="border-bottom: black 2pt solid; margin: auto; height: 990pt; width: 765pt; position: relative; overflow: hidden">
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 911.25pt; left: 45pt; width: 675pt; position: absolute; height: 33.75pt">
				<div style="display: table-cell; vertical-align: bottom; width: 675pt; height: 33.75pt">

				<!--[if IE]><TABLE><TR style=" width: 675pt; height: 33.75pt;"><TD vAlign="bottom" style=" width: 675pt; height: 33.75pt;"><![endif]-->
					<div style="font: 12pt/normal Times New Roman, Times, serif; margin: 0pt; text-transform: none; color: #000000; text-align: left">
						<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 0pt; border-collapse: collapse">
							<tr style="margin: 0; height: 0">
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>

							</tr>
							<tr style="min-height: 0pt">
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">ARTIVION, INC. | 2025 Proxy Statement</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">63</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 0pt; line-height: 0pt">&#8203;</p>

								</td>

							</tr>

						</table>

					</div>


				<!--[if IE]></TD></TR></TABLE><![endif]-->
				</div>

			</div>
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 45pt; left: 45pt; width: 675pt; position: absolute; height: 883.13pt">
				<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" continuedAt="Con000018-01" escape="true" id="Fact000018" name="ecd:PvpTableTextBlock"><p id="xdx_803_eecd--PvpTableTextBlock_dU_gL1PTTB-LPZPJ_z3K4kbMuhbdd" style="border-bottom: #7f7f7f 1pt solid; font: 12pt/normal Arial, sans-serif; margin: 0pt 0pt 15pt; text-transform: none; color: #2b4b74; text-indent: 0pt; text-align: left"><span style="text-transform: none"><b>Pay Versus Performance Disclosure</b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">This section provides disclosure about the relationship between executive compensation actually paid to our principal executive officer (&#8220;PEO&#8221;) and Non-PEO Named Executive Officers (NEOs) and certain financial performance measures of the Company for the fiscal years listed below. This disclosure has been prepared in accordance with Item 402(v) of Regulation S-K under the Securities Exchange Act of 1934 (the &#8220;Pay Versus Performance Rules&#8221;) and does not necessarily reflect how the Compensation Committee evaluates </span><span style="text-transform: none; line-height: 12pt">compensation decisions.</span></p>
				<div style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-align: left">
					<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 10pt; border-collapse: collapse">
						<tr style="margin: 0; height: 0">
							<td style="border-width: 0; margin: 0; padding: 0; width: 48.75pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 92.5pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 92.5pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 95pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 95pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 75pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 75pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 47.5pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 53.75pt">


							</td>

						</tr>
						<tr style="min-height: 24pt">
							<td rowspan="2" style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Year</b></span></p>

							</td>
							<td rowspan="2" style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Summary <br/>Compensation <br/>Table Total <br/>for PEO</b></span></p>

							</td>
							<td rowspan="2" style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Compensation <br/>Actually Paid <br/>to PEO</b></span></p>

							</td>
							<td rowspan="2" style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Average<br/>Summary <br/>Compensation <br/>Table Total for <br/>non-PEO NEOs</b></span></p>

							</td>
							<td rowspan="2" style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Average<br/>Compensation<br/>Actually Paid to <br/>non-PEO NEOs</b></span></p>

							</td>
							<td colspan="2" style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Value of initial fixed $100 Investment based on:</b></span></p>

							</td>
							<td rowspan="2" style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Net <br/>Income/<br/>(Loss) <br/>($mm)</b></span></p>

							</td>
							<td rowspan="2" style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>AORT<br/>Revenue<br/>Growth<br/>($mm)</b></span></p>

							</td>

						</tr>
						<tr style="min-height: 36pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>AORT Total Shareholder Return</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Index Total Shareholder Return</b></span></p>

							</td>

						</tr>
						<tr style="min-height: 13.2pt">
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 11.2pt; line-height: 11.2pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><sup style="text-transform: none; font-size: 6pt; line-height: 6pt"><b>(a)</b></sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><sup style="text-transform: none; font-size: 6pt; line-height: 6pt"><b>(a)</b></sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><sup style="text-transform: none; font-size: 6pt; line-height: 6pt"><b>(b)</b></sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><sup style="text-transform: none; font-size: 6pt; line-height: 6pt"><b>(b)</b></sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><sup style="text-transform: none; font-size: 6pt; line-height: 6pt"><b> (c) </b></sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><sup style="text-transform: none; font-size: 6pt; line-height: 6pt"><b> (c) </b></sup></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 11.2pt; line-height: 11.2pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><sup style="text-transform: none; font-size: 6pt; line-height: 6pt"><b>(d)</b></sup></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">2024</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_980_eecd--PeoTotalCompAmt_c20240101__20241231_fKGEp_zm0QVenOj7ak" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">$<ix:nonFraction name="ecd:PeoTotalCompAmt" contextRef="From2024-01-01to2024-12-31" id="Fact000019" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,511,940</ix:nonFraction></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98E_eecd--PeoActuallyPaidCompAmt_c20240101__20241231_fKGEp_zZereKucB3Wh" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">$<ix:nonFraction name="ecd:PeoActuallyPaidCompAmt" contextRef="From2024-01-01to2024-12-31" id="Fact000020" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,328,862</ix:nonFraction></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 12pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_981_eecd--NonPeoNeoAvgTotalCompAmt_c20240101__20241231_fKGIp_zMUYjSzkQlag" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">$<ix:nonFraction name="ecd:NonPeoNeoAvgTotalCompAmt" contextRef="From2024-01-01to2024-12-31" id="Fact000021" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,703,153</ix:nonFraction></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 12pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98C_eecd--NonPeoNeoAvgCompActuallyPaidAmt_c20240101__20241231_fKGIp_zOynJVMxkVj6" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">$<ix:nonFraction name="ecd:NonPeoNeoAvgCompActuallyPaidAmt" contextRef="From2024-01-01to2024-12-31" id="Fact000022" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,151,020</ix:nonFraction></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 19pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_987_eecd--TotalShareholderRtnAmt_pp2d_c20240101__20241231_fKGMp_zd7VfqqTbKWj" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">$<ix:nonFraction name="ecd:TotalShareholderRtnAmt" contextRef="From2024-01-01to2024-12-31" id="Fact000023" format="ixt:numdotdecimal" decimals="2" unitRef="USD">106</ix:nonFraction></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_980_eecd--PeerGroupTotalShareholderRtnAmt_pp2d_c20240101__20241231_fKGMp_zyYS5HrAnjKd" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">$<ix:nonFraction name="ecd:PeerGroupTotalShareholderRtnAmt" contextRef="From2024-01-01to2024-12-31" id="Fact000024" format="ixt:numdotdecimal" decimals="2" unitRef="USD">138</ix:nonFraction></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_983_eus-gaap--NetIncomeLoss_pn6n6_c20240101__20241231_z7zuSx1flaQg" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">($<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-12-31" id="Fact000025" format="ixt:numdotdecimal" decimals="-6" scale="6" sign="-" unitRef="USD">13</ix:nonFraction>)</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 10pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none"><span id="xdx_902_eecd--CoSelectedMeasureAmt_pid_dp_uRatio_c20240101__20241231_fKGQp_z8WLIkO2T6ca"><ix:nonFraction name="ecd:CoSelectedMeasureAmt" contextRef="From2024-01-01to2024-12-31" id="Fact000026" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">9</ix:nonFraction></span>%</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">2023</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_982_eecd--PeoTotalCompAmt_c20230101__20231231_fKGEp_zfnOwfBjhYAk" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">$<ix:nonFraction name="ecd:PeoTotalCompAmt" contextRef="From2023-01-012023-12-31" id="Fact000027" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,176,413</ix:nonFraction></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98B_eecd--PeoActuallyPaidCompAmt_c20230101__20231231_fKGEp_zrYEqJy72lZ9" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">$<ix:nonFraction name="ecd:PeoActuallyPaidCompAmt" contextRef="From2023-01-012023-12-31" id="Fact000028" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,225,878</ix:nonFraction></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 12pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_988_eecd--NonPeoNeoAvgTotalCompAmt_c20230101__20231231_fKGIp_zJBHUkUH2Ide" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">$<ix:nonFraction name="ecd:NonPeoNeoAvgTotalCompAmt" contextRef="From2023-01-012023-12-31" id="Fact000029" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,204,664</ix:nonFraction></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 12pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_982_eecd--NonPeoNeoAvgCompActuallyPaidAmt_c20230101__20231231_fKGIp_zXneGOu13Nkh" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">$<ix:nonFraction name="ecd:NonPeoNeoAvgCompActuallyPaidAmt" contextRef="From2023-01-012023-12-31" id="Fact000030" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,835,407</ix:nonFraction></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 19pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98B_eecd--TotalShareholderRtnAmt_pp2d_c20230101__20231231_fKGMp_znHI0kQMHLB4" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">$<ix:nonFraction name="ecd:TotalShareholderRtnAmt" contextRef="From2023-01-012023-12-31" id="Fact000031" format="ixt:numdotdecimal" decimals="2" unitRef="USD">66</ix:nonFraction></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98B_eecd--PeerGroupTotalShareholderRtnAmt_pp2d_c20230101__20231231_fKGMp_zYVNBCm6rrRe" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">$<ix:nonFraction name="ecd:PeerGroupTotalShareholderRtnAmt" contextRef="From2023-01-012023-12-31" id="Fact000032" format="ixt:numdotdecimal" decimals="2" unitRef="USD">124</ix:nonFraction></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_983_eus-gaap--NetIncomeLoss_pn6n6_c20230101__20231231_z9IlVv0kyaOe" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">($<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact000033" format="ixt:numdotdecimal" decimals="-6" scale="6" sign="-" unitRef="USD">31</ix:nonFraction>)</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 10pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none"><span id="xdx_906_eecd--CoSelectedMeasureAmt_pid_dp_uRatio_c20230101__20231231_fKGQp_zJqCpv1F1gy4"><ix:nonFraction name="ecd:CoSelectedMeasureAmt" contextRef="From2023-01-012023-12-31" id="Fact000034" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">12</ix:nonFraction></span>%</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">2022</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98D_eecd--PeoTotalCompAmt_c20220101__20221231_fKGEp_zR4yGZ9GY11d" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">$<ix:nonFraction name="ecd:PeoTotalCompAmt" contextRef="From2022-01-012022-12-31" id="Fact000035" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,216,340</ix:nonFraction></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98C_eecd--PeoActuallyPaidCompAmt_c20220101__20221231_fKGEp_zl63HFzvzmE8" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">$<ix:nonFraction name="ecd:PeoActuallyPaidCompAmt" contextRef="From2022-01-012022-12-31" id="Fact000036" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,718,496</ix:nonFraction></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 12pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_985_eecd--NonPeoNeoAvgTotalCompAmt_c20220101__20221231_fKGIp_zI6Jdml2MAbh" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">$<ix:nonFraction name="ecd:NonPeoNeoAvgTotalCompAmt" contextRef="From2022-01-012022-12-31" id="Fact000037" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,796,100</ix:nonFraction></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 12pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_987_eecd--NonPeoNeoAvgCompActuallyPaidAmt_c20220101__20221231_fKGIp_zReOaVmnjYtj" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">$<ix:nonFraction name="ecd:NonPeoNeoAvgCompActuallyPaidAmt" contextRef="From2022-01-012022-12-31" id="Fact000038" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,352,869</ix:nonFraction></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 19pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_983_eecd--TotalShareholderRtnAmt_pp2d_c20220101__20221231_fKGMp_zmg3DunzCWL9" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">$<ix:nonFraction name="ecd:TotalShareholderRtnAmt" contextRef="From2022-01-012022-12-31" id="Fact000039" format="ixt:numdotdecimal" decimals="2" unitRef="USD">45</ix:nonFraction></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98F_eecd--PeerGroupTotalShareholderRtnAmt_pp2d_c20220101__20221231_fKGMp_zqeRJJ32LCQi" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">$<ix:nonFraction name="ecd:PeerGroupTotalShareholderRtnAmt" contextRef="From2022-01-012022-12-31" id="Fact000040" format="ixt:numdotdecimal" decimals="2" unitRef="USD">114</ix:nonFraction></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_986_eus-gaap--NetIncomeLoss_pn6n6_c20220101__20221231_z79mLT4rGxF8" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">($<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31" id="Fact000041" format="ixt:numdotdecimal" decimals="-6" scale="6" sign="-" unitRef="USD">19</ix:nonFraction>)</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 10pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none"><span id="xdx_904_eecd--CoSelectedMeasureAmt_pid_dp_uRatio_c20220101__20221231_fKGQp_zSx47QbLlc4l"><ix:nonFraction name="ecd:CoSelectedMeasureAmt" contextRef="From2022-01-012022-12-31" id="Fact000042" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">9</ix:nonFraction></span>%</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">2021</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_988_eecd--PeoTotalCompAmt_c20210101__20211231_fKGEp_zqKfCvggwGpd" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">$<ix:nonFraction name="ecd:PeoTotalCompAmt" contextRef="From2021-01-012021-12-31" id="Fact000043" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,628,566</ix:nonFraction></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_985_eecd--PeoActuallyPaidCompAmt_c20210101__20211231_fKGEp_zrwzmhzQZah" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">$<ix:nonFraction name="ecd:PeoActuallyPaidCompAmt" contextRef="From2021-01-012021-12-31" id="Fact000044" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,712,538</ix:nonFraction></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 12pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_989_eecd--NonPeoNeoAvgTotalCompAmt_c20210101__20211231_fKGIp_ztLj3I6eryra" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">$<ix:nonFraction name="ecd:NonPeoNeoAvgTotalCompAmt" contextRef="From2021-01-012021-12-31" id="Fact000045" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,286,725</ix:nonFraction></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 12pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_986_eecd--NonPeoNeoAvgCompActuallyPaidAmt_c20210101__20211231_fKGIp_znvics2Yl6J9" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">$<ix:nonFraction name="ecd:NonPeoNeoAvgCompActuallyPaidAmt" contextRef="From2021-01-012021-12-31" id="Fact000046" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,108,935</ix:nonFraction></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 19pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_984_eecd--TotalShareholderRtnAmt_pp2d_c20210101__20211231_fKGMp_zucAsI1NEMnc" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">$<ix:nonFraction name="ecd:TotalShareholderRtnAmt" contextRef="From2021-01-012021-12-31" id="Fact000047" format="ixt:numdotdecimal" decimals="2" unitRef="USD">75</ix:nonFraction></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_983_eecd--PeerGroupTotalShareholderRtnAmt_pp2d_c20210101__20211231_fKGMp_zMZkWisB8G2b" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">$<ix:nonFraction name="ecd:PeerGroupTotalShareholderRtnAmt" contextRef="From2021-01-012021-12-31" id="Fact000048" format="ixt:numdotdecimal" decimals="2" unitRef="USD">140</ix:nonFraction></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_986_eus-gaap--NetIncomeLoss_pn6n6_c20210101__20211231_z6S4MUrTXi76" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">($<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31" id="Fact000049" format="ixt:numdotdecimal" decimals="-6" scale="6" sign="-" unitRef="USD">15</ix:nonFraction>)</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 10pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none"><span id="xdx_900_eecd--CoSelectedMeasureAmt_pid_dp_uRatio_c20210101__20211231_fKGQp_z1ayUznWyAX6"><ix:nonFraction name="ecd:CoSelectedMeasureAmt" contextRef="From2021-01-012021-12-31" id="Fact000050" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">16</ix:nonFraction></span>%</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">2020</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_982_eecd--PeoTotalCompAmt_c20200101__20201231_fKGEp_z96hQaOD7SK4" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">$<ix:nonFraction name="ecd:PeoTotalCompAmt" contextRef="From2020-01-012020-12-31" id="Fact000051" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,415,458</ix:nonFraction></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98A_eecd--PeoActuallyPaidCompAmt_c20200101__20201231_fKGEp_zfws7fXhhAP" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">$<ix:nonFraction name="ecd:PeoActuallyPaidCompAmt" contextRef="From2020-01-012020-12-31" id="Fact000052" format="ixt:numdotdecimal" decimals="0" unitRef="USD">327,652</ix:nonFraction></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 12pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98A_eecd--NonPeoNeoAvgTotalCompAmt_c20200101__20201231_fKGIp_zRyokeSdqbz4" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">$<ix:nonFraction name="ecd:NonPeoNeoAvgTotalCompAmt" contextRef="From2020-01-012020-12-31" id="Fact000053" format="ixt:numdotdecimal" decimals="0" unitRef="USD">977,089</ix:nonFraction></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 12pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_989_eecd--NonPeoNeoAvgCompActuallyPaidAmt_c20200101__20201231_fKGIp_z6QYG5t6ceQ6" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">$<ix:nonFraction name="ecd:NonPeoNeoAvgCompActuallyPaidAmt" contextRef="From2020-01-012020-12-31" id="Fact000054" format="ixt:numdotdecimal" decimals="0" unitRef="USD">454,642</ix:nonFraction></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 19pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_981_eecd--TotalShareholderRtnAmt_pp2d_c20200101__20201231_fKGMp_z6aqfg1PA1x8" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">$<ix:nonFraction name="ecd:TotalShareholderRtnAmt" contextRef="From2020-01-012020-12-31" id="Fact000055" format="ixt:numdotdecimal" decimals="2" unitRef="USD">87</ix:nonFraction></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98F_eecd--PeerGroupTotalShareholderRtnAmt_pp2d_c20200101__20201231_fKGMp_znhzzYGlr6Vf" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">$<ix:nonFraction name="ecd:PeerGroupTotalShareholderRtnAmt" contextRef="From2020-01-012020-12-31" id="Fact000056" format="ixt:numdotdecimal" decimals="2" unitRef="USD">118</ix:nonFraction></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_983_eus-gaap--NetIncomeLoss_pn6n6_c20200101__20201231_zV4bqmjmn2Vk" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">($<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-01-012020-12-31" id="Fact000057" format="ixt:numdotdecimal" decimals="-6" scale="6" sign="-" unitRef="USD">17</ix:nonFraction>)</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 10pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none"><span id="xdx_908_eecd--CoSelectedMeasureAmt_pid_dp_uRatio_c20200101__20201231_fKGQp_zmPpCRS169Oe">-<ix:nonFraction name="ecd:CoSelectedMeasureAmt" contextRef="From2020-01-012020-12-31" id="Fact000058" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Ratio">8</ix:nonFraction></span>%</span></p>

							</td>

						</tr>

					</table>

				</div>

<table cellpadding="0" cellspacing="0" style="font: 9pt/normal Arial, sans-serif; display: none; visibility: hidden; color: #000000; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 7pt; text-transform: none; line-height: 7pt"><sup id="xdx_F0F_zQv8MlvYYtHc">(a)</sup></span></td><td style="width: 5pt"/><td style="text-align: justify"><!--[if IE]></FONT><![endif]--><span id="xdx_F1D_znUqSEZuFBt6" style="text-transform: none"><ix:footnote id="Footnote000059" xml:lang="en-US">Mr. Mackin&#160;served
as our only PEO for&#160;each year.</ix:footnote></span></td>
</tr></table>
<table cellpadding="0" cellspacing="0" style="font: 9pt/normal Arial, sans-serif; display: none; visibility: hidden; color: #000000; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 7pt; text-transform: none; line-height: 7pt"><sup id="xdx_F04_zkz5q3evZk09">(b)</sup></span></td><td style="width: 5pt"/><td style="text-align: justify"><!--[if IE]></FONT><![endif]--><span id="xdx_F17_zTy3LCGejpx6" style="text-transform: none"><ix:footnote id="Footnote000060" xml:lang="en-US">Our Non-PEO NEOs in 2024
were Messrs. Berry, Davis and Stanton and Ms. Holloway. Our Non-PEO NEOs in 2023 were Messrs. Lee, Berry, Davis and Mses. Horton and
Holloway. Our Non-PEO NEOs in 2022 and 2021 were&#160;Messrs. Lee,&#160;Davis,&#160;Stanton&#160;and&#160;Ms. Holloway. Our Non-PEO NEOs
in 2020 were&#160;Messrs.&#160;Lee,&#160;Davis,&#160;Simpson,&#160;and&#160;Ms. Holloway.</ix:footnote></span></td>
</tr></table>
<table cellpadding="0" cellspacing="0" style="font: 9pt/normal Arial, sans-serif; display: none; visibility: hidden; color: #000000; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 7pt; text-transform: none; line-height: 7pt"><sup id="xdx_F00_zgpOwZGAqRzb">(c)</sup></span></td><td style="width: 5pt"/><td style="text-align: justify"><!--[if IE]></FONT><![endif]--><span id="xdx_F1E_zitB532hdF2h" style="text-transform: none"><ix:footnote id="Footnote000061" xml:lang="en-US">Shareholder returns reflect
$100 invested as of market close on December 31, 2019, the final trading day of fiscal 2019; Index Shareholder Return reflects S&amp;P
500 Health Care&#160;Equipment Index.</ix:footnote></span></td>
</tr></table>
<table cellpadding="0" cellspacing="0" style="font: 9pt/normal Arial, sans-serif; display: none; visibility: hidden; color: #000000; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 7pt; text-transform: none; line-height: 7pt"><sup id="xdx_F05_zyln938K39E6">(d)</sup></span></td><td style="width: 5pt"/><td style="text-align: justify"><!--[if IE]></FONT><![endif]--><span id="xdx_F11_zIX0QQRNIkx8" style="text-transform: none"><ix:footnote id="Footnote000062" xml:lang="en-US">In the Company&#8217;s
assessment, for the 2024 fiscal year, AORT revenue growth represents the most important financial performance measure that is not otherwise
required to be disclosed in the table that we used to link &#8220;compensation actually paid&#8221; to our NEOs, including our PEO, to
our performance. AORT revenue growth is an adjusted constant currency revenue measure calculated by adjusting for the exchange rate effect
on GAAP revenues. We define exchange rate effect as the year-over-year impact of foreign currency movements using current period foreign
currency rates applied to prior period transactional currency amounts. As discussed in the Compensation Discussion &amp; Analysis, constant
currency revenue growth as calculated in incentive plans may reflect additional adjustments to either the baseline (prior year revenue)
or current year results, to exclude the impact of discontinued businesses and other unplanned events that were outside of management&#8217;s
control. In 2023, we excluded the impact of the Company&#8217;s Cardiogenesis business. In 2022, we adjusted to exclude PerClot sales
that occurred in 2022 and 2021. In 2021, we measured growth in the second half of the year by comparing to the second half of 2019 rather
than 2020.</ix:footnote></span></td>
</tr></table>
<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000064" name="ecd:NamedExecutiveOfficersFnTextBlock"><div id="xdx_849_eecd--NamedExecutiveOfficersFnTextBlock_dU_z7OrBB38Rks2"></div>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 1pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(a)</sup></span><!--[if IE]></FONT><![endif]--><sup style="text-transform: none; font-size: 7pt; line-height: 7pt"></sup><span style="text-transform: none"><span id="xdx_908_eecd--PeoName_c20200101__20201231_znEPlCJI9E8b"><span id="xdx_90F_eecd--PeoName_c20210101__20211231_zY0OfcfAZp01"><span id="xdx_905_eecd--PeoName_c20220101__20221231_zZHCoC7y8gnc"><span id="xdx_904_eecd--PeoName_c20230101__20231231_zddNZUNYL4Qf"><span id="xdx_900_eecd--PeoName_c20240101__20241231_znX2Xqykizi6"><ix:nonNumeric contextRef="From2020-01-012020-12-31" id="Fact000065" name="ecd:PeoName"><ix:nonNumeric contextRef="From2021-01-012021-12-31" id="Fact000066" name="ecd:PeoName"><ix:nonNumeric contextRef="From2022-01-012022-12-31" id="Fact000067" name="ecd:PeoName"><ix:nonNumeric contextRef="From2023-01-012023-12-31" id="Fact000068" name="ecd:PeoName"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000069" name="ecd:PeoName">Mr. Mackin</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></span></span></span></span></span>&#160;served as our only PEO </span><span style="text-transform: none">for&#160;each year.</span></p>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 1pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(b)</sup></span><!--[if IE]></FONT><![endif]--><sup style="text-transform: none; font-size: 7pt; line-height: 7pt"></sup><span style="text-transform: none">Our Non-PEO NEOs in 2024 were Messrs. Berry, Davis and Stanton and Ms. Holloway. Our Non-PEO NEOs in 2023 were Messrs. Lee, Berry, Davis and Mses. Horton and Holloway. Our Non-PEO NEOs in 2022 and 2021 were&#160;Messrs. Lee,&#160;Davis,&#160;Stanton&#160;and&#160;Ms. Holloway. Our Non-PEO NEOs in 2020 </span><span style="text-transform: none">were&#160;Messrs.&#160;Lee,&#160;Davis,&#160;Simpson,&#160;and&#160;Ms. Holloway.</span></p>
</ix:nonNumeric><div id="xdx_85A_z4Lu9NCrLOdf" style="margin-bottom: 1pt"></div>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 1pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(c)</sup></span><!--[if IE]></FONT><![endif]--><sup style="text-transform: none; font-size: 7pt; line-height: 7pt"></sup><span style="text-transform: none">Shareholder returns reflect $100 invested as of market close on December 31, 2019, the final trading day of fiscal 2019; Index Shareholder Return reflects S&amp;P 500 Health </span><span style="text-transform: none">Care&#160;Equipment Index.</span></p>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 8pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(d)</sup></span><!--[if IE]></FONT><![endif]--><sup style="text-transform: none; font-size: 7pt; line-height: 7pt"></sup><span style="text-transform: none"><span id="xdx_906_eecd--NonGaapMeasureDescriptionTextBlock_c20240101__20241231__ecd--MeasureAxis__1_zGdKNsBUfWRl" class="xdx_phnt_RGlzY2xvc3VyZSAtIFBheSB2cyBQZXJmb3JtYW5jZSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-01-012024-12-31_1" escape="true" id="Fact000070" name="ecd:NonGaapMeasureDescriptionTextBlock">In the Company&#8217;s assessment, for the 2024 fiscal year, <span id="xdx_90D_eecd--CoSelectedMeasureName_c20240101__20241231_zqgOKiYCGonc"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000071" name="ecd:CoSelectedMeasureName">AORT revenue growth</ix:nonNumeric></span> represents the most important financial performance measure that is not otherwise required to be disclosed in the table that we used to link &#8220;compensation actually paid&#8221; to our NEOs, including our PEO, to our performance. AORT revenue growth is an adjusted constant currency revenue measure calculated by adjusting for the exchange rate effect on GAAP revenues. We define exchange rate effect as the year-over-year impact of foreign currency movements using current period foreign currency rates applied to prior period transactional currency amounts. As discussed in the Compensation Discussion &amp; Analysis, constant currency revenue growth as calculated in incentive plans may reflect additional adjustments to either the baseline (prior year revenue) or current year results, to exclude the impact of discontinued businesses and other unplanned events that were outside of management&#8217;s control. In 2023, we excluded the impact of the Company&#8217;s Cardiogenesis business. In 2022, we adjusted to exclude PerClot sales that occurred in 2022 and 2021. In 2021, we measured growth in the second half of the year by comparing to the second half of 2019 rather than 2020.</ix:nonNumeric></span></span></p>
				<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" continuedAt="Con000074-01" escape="true" id="Fact000074" name="ecd:AdjToPeoCompFnTextBlock"><p id="xdx_84D_eecd--AdjToPeoCompFnTextBlock_dU_gL2ATPCFTB-BR_z1I5XfViUMj8" style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">The following table sets forth a reconciliation from the Summary Compensation Table (&#8220;SCT&#8221;) to Compensation Actually Paid (&#8220;CAP&#8221;) to our PEO and for the average paid to our Non-PEO NEOs for each </span><span style="text-transform: none; line-height: 12pt">fiscal year.</span></p>
				</ix:nonNumeric></ix:nonNumeric><div style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-align: left">
					<ix:continuation continuedAt="ConU000018-01" id="Con000018-01"><ix:continuation continuedAt="ConU000074-01" id="Con000074-01"><table id="xdx_308_zVWZIriixLRa" summary="xdx: Disclosure - Pay vs Performance Disclosure" style="table-layout: fixed; width: 674.68pt; margin-top: 4pt; margin-bottom: 10pt; border-collapse: collapse">
						<tr style="margin: 0; height: 0">
							<td style="text-align: left; border-width: 0; margin: 0; padding: 0; width: 142.49pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 88.74pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 89.06pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 84.37pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 90pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 84.37pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 95.62pt">


							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="text-align: left; border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none"><b>Year</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>SCT<br/>Total</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Less Sum of<br/>Stock and<br/>Option Award<br/>Values from<br/>SCT</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Value of<br/>Current<br/>Year Equity<br/>Awards at<br/>12/31</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Change in<br/>Value of<br/>Unvested Prior<br/>Year Awards at<br/>12/31</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Change in<br/>Value of Prior<br/>Year Awards<br/>That Vested<br/>In Current<br/>Year</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Total<br/>Compensation<br/>Actually Paid</b></span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="text-align: left; border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="text-align: left; margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b> (e) </b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b> (f) </b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b> (g) </b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b> (h) </b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>(i)</b></span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="text-align: left; border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">2024</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98F_eecd--PeoTotalCompAmt_c20240101__20241231_zemY5XBdadxg" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">$<ix:nonFraction name="ecd:PeoTotalCompAmt" contextRef="From2024-01-01to2024-12-31" id="Fact000075" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,511,940</ix:nonFraction></span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 7pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_982_eecd--AdjToCompAmt_c20240101__20241231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--EqtyAwrdsInSummryCompstnTblForAplblYrMember_fKGUp_zpc4FwAn8mG" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">($<ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2024-01-012024-12-31_ecd_PeoMember_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" id="Fact000076" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,608,101</ix:nonFraction>)</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98B_eecd--AdjToCompAmt_c20240101__20241231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_fKGYp_zPM9LlTzo3K9" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">$<ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2024-01-012024-12-31_ecd_PeoMember_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" id="Fact000077" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,852,430</ix:nonFraction></span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 10pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98C_eecd--AdjToCompAmt_c20240101__20241231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_fKGcp_zobmolIoUIVj" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">$<ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2024-01-012024-12-31_ecd_PeoMember_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" id="Fact000078" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,370,222</ix:nonFraction></span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 10pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98C_eecd--AdjToCompAmt_c20240101__20241231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_fKGgp_zXPqHhvacd8d" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">$<ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2024-01-012024-12-31_ecd_PeoMember_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" id="Fact000079" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,202,370</ix:nonFraction></span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 11pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98F_eecd--PeoActuallyPaidCompAmt_c20240101__20241231_fKGkp_ziEqyW33lUP5" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">  $<ix:nonFraction name="ecd:PeoActuallyPaidCompAmt" contextRef="From2024-01-01to2024-12-31" id="Fact000080" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,328,862</ix:nonFraction></span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; text-align: left; padding: 1.5pt 0pt 1.5pt 3pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: left"><span style="text-transform: none">2023</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_983_eecd--PeoTotalCompAmt_c20230101__20231231_zy5Mge1YGukk" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">$<ix:nonFraction name="ecd:PeoTotalCompAmt" contextRef="From2023-01-012023-12-31" id="Fact000081" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,176,413</ix:nonFraction></span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 7pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_987_eecd--AdjToCompAmt_c20230101__20231231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--EqtyAwrdsInSummryCompstnTblForAplblYrMember_fKGUp_zHj7xU8g9oBc" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">&#8194; ($<ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2023-01-012023-12-31_ecd_PeoMember_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" id="Fact000082" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">801,938</ix:nonFraction>)</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_985_eecd--AdjToCompAmt_c20230101__20231231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_fKGYp_zMdhmvbrG5fi" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">$<ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2023-01-012023-12-31_ecd_PeoMember_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" id="Fact000083" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,771,014</ix:nonFraction></span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 10pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_980_eecd--AdjToCompAmt_c20230101__20231231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_fKGcp_zP3BA88jqry" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">$<ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2023-01-012023-12-31_ecd_PeoMember_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" id="Fact000084" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,775,817</ix:nonFraction></span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 10pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_980_eecd--AdjToCompAmt_c20230101__20231231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_fKGgp_zkWvh3ykRXfi" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">  $<ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2023-01-012023-12-31_ecd_PeoMember_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" id="Fact000085" format="ixt:numdotdecimal" decimals="0" unitRef="USD">304,572</ix:nonFraction></span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 11pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98A_eecd--PeoActuallyPaidCompAmt_c20230101__20231231_fKGkp_zVmA0VUBAb71" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">$<ix:nonFraction name="ecd:PeoActuallyPaidCompAmt" contextRef="From2023-01-012023-12-31" id="Fact000086" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,225,878</ix:nonFraction></span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; text-align: left; padding: 1.5pt 0pt 1.5pt 3pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: left"><span style="text-transform: none">2022</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98A_eecd--PeoTotalCompAmt_c20220101__20221231_zoGHyJZbiJbh" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">$<ix:nonFraction name="ecd:PeoTotalCompAmt" contextRef="From2022-01-012022-12-31" id="Fact000087" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,216,340</ix:nonFraction></span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 7pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98C_eecd--AdjToCompAmt_c20220101__20221231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--EqtyAwrdsInSummryCompstnTblForAplblYrMember_fKGUp_zijFSTRwDKz9" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">($<ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2022-01-012022-12-31_ecd_PeoMember_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" id="Fact000088" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,587,257</ix:nonFraction>)</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98C_eecd--AdjToCompAmt_c20220101__20221231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_fKGYp_z0bLeuqpqHVh" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">$<ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2022-01-012022-12-31_ecd_PeoMember_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" id="Fact000089" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,689,996</ix:nonFraction></span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 7pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_982_eecd--AdjToCompAmt_c20220101__20221231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_fKGcp_zOR7dMRuabv3" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">($<ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2022-01-012022-12-31_ecd_PeoMember_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" id="Fact000090" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,385,504</ix:nonFraction>)</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 7pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_984_eecd--AdjToCompAmt_c20220101__20221231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_fKGgp_zj603AnWzEs2" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">  ($<ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2022-01-012022-12-31_ecd_PeoMember_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" id="Fact000091" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">215,079</ix:nonFraction>)</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 11pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98B_eecd--PeoActuallyPaidCompAmt_c20220101__20221231_fKGkp_zxCNN0mEKMb9" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">$<ix:nonFraction name="ecd:PeoActuallyPaidCompAmt" contextRef="From2022-01-012022-12-31" id="Fact000092" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,718,496</ix:nonFraction></span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; text-align: left; padding: 1.5pt 0pt 1.5pt 3pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: left"><span style="text-transform: none">2021</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98E_eecd--PeoTotalCompAmt_c20210101__20211231_ztAU8dB027n9" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">$<ix:nonFraction name="ecd:PeoTotalCompAmt" contextRef="From2021-01-012021-12-31" id="Fact000093" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,628,566</ix:nonFraction></span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 7pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98B_eecd--AdjToCompAmt_c20210101__20211231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--EqtyAwrdsInSummryCompstnTblForAplblYrMember_fKGUp_zDFEgmTMRn73" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">($<ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2021-01-012021-12-31_ecd_PeoMember_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" id="Fact000094" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,977,494</ix:nonFraction>)</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98A_eecd--AdjToCompAmt_c20210101__20211231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_fKGYp_z7o9Mqn0GJV1" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">$<ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2021-01-012021-12-31_ecd_PeoMember_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" id="Fact000095" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,402,215</ix:nonFraction></span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 7pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98B_eecd--AdjToCompAmt_c20210101__20211231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_fKGcp_zc5hLlTdy1hk" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">&#8194; ($<ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2021-01-012021-12-31_ecd_PeoMember_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" id="Fact000096" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">495,663</ix:nonFraction>)</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 10pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98C_eecd--AdjToCompAmt_c20210101__20211231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_fKGgp_zyzTOoKZTUEh" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">$<ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2021-01-012021-12-31_ecd_PeoMember_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" id="Fact000097" format="ixt:numdotdecimal" decimals="0" unitRef="USD">154,913</ix:nonFraction></span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 11pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_984_eecd--PeoActuallyPaidCompAmt_c20210101__20211231_fKGkp_zD4ijklw5Ul8" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">$<ix:nonFraction name="ecd:PeoActuallyPaidCompAmt" contextRef="From2021-01-012021-12-31" id="Fact000098" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,712,538</ix:nonFraction></span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; text-align: left; padding: 1.5pt 0pt 1.5pt 3pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: left"><span style="text-transform: none">2020</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_980_eecd--PeoTotalCompAmt_c20200101__20201231_zdhn2cMbmx3b" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">$<ix:nonFraction name="ecd:PeoTotalCompAmt" contextRef="From2020-01-012020-12-31" id="Fact000099" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,415,458</ix:nonFraction></span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 7pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98C_eecd--AdjToCompAmt_c20200101__20201231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--EqtyAwrdsInSummryCompstnTblForAplblYrMember_fKGUp_zNz1YCiWqC9k" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">($<ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2020-01-012020-12-31_ecd_PeoMember_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" id="Fact000100" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,323,534</ix:nonFraction>)</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_980_eecd--AdjToCompAmt_c20200101__20201231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_fKGYp_z8lDHJMvAFRh" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">$<ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2020-01-012020-12-31_ecd_PeoMember_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" id="Fact000101" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,931,021</ix:nonFraction></span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 7pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98C_eecd--AdjToCompAmt_c20200101__20201231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_fKGcp_z7fZxiI4LKxj" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">($<ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2020-01-012020-12-31_ecd_PeoMember_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" id="Fact000102" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,326,940</ix:nonFraction>)</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 7pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98D_eecd--AdjToCompAmt_c20200101__20201231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_fKGgp_zDtII3fwInTk" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">($<ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2020-01-012020-12-31_ecd_PeoMember_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" id="Fact000103" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">368,352</ix:nonFraction>)</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 11pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98F_eecd--PeoActuallyPaidCompAmt_c20200101__20201231_fKGkp_zssJsD9lBFZ5" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">&#8194; $<ix:nonFraction name="ecd:PeoActuallyPaidCompAmt" contextRef="From2020-01-012020-12-31" id="Fact000104" format="ixt:numdotdecimal" decimals="0" unitRef="USD">327,652</ix:nonFraction></span></p>

							</td>

						</tr>

					</table>

				<table cellpadding="0" cellspacing="0" style="font: 9pt/normal Arial, sans-serif; display: none; visibility: hidden; color: #000000; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 7pt; text-transform: none; line-height: 7pt"><sup id="xdx_F05_zBhfDSiTlHrk">(e)</sup></span></td><td style="width: 5pt"/><td style="text-align: justify"><!--[if IE]></FONT><![endif]--><span id="xdx_F15_zuBc0O9oGre3" style="text-transform: none"><ix:footnote id="Footnote000105" xml:lang="en-US">Represents the grant date
fair value of equity-based awards made during the covered fiscal year as reported in the Summary&#160;Compensation Table.</ix:footnote></span></td>
</tr></table>
<table cellpadding="0" cellspacing="0" style="font: 9pt/normal Arial, sans-serif; display: none; visibility: hidden; color: #000000; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 7pt; text-transform: none; line-height: 7pt"><sup id="xdx_F09_zhLUB9FGOI76">(f)</sup></span></td><td style="width: 5pt"/><td style="text-align: justify"><!--[if IE]></FONT><![endif]--><span id="xdx_F11_z9fCcMfCAWB5" style="text-transform: none"><ix:footnote id="Footnote000106" xml:lang="en-US">Represents the year-end
fair value of equity awards that were made during the covered fiscal year and remained unvested as&#160;of the end of the covered fiscal
year.</ix:footnote></span></td>
</tr></table>
<table cellpadding="0" cellspacing="0" style="font: 9pt/normal Arial, sans-serif; display: none; visibility: hidden; color: #000000; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 7pt; text-transform: none; line-height: 7pt"><sup id="xdx_F04_zJNwH9gobYo7">(g)</sup></span></td><td style="width: 5pt"/><td style="text-align: justify"><!--[if IE]></FONT><![endif]--><span id="xdx_F1D_z7HeYnvfn6F6" style="text-transform: none"><ix:footnote id="Footnote000107" xml:lang="en-US">Represents the change as
of the end of the covered fiscal year (from the end of the prior fiscal year) in fair value of equity-based awards granted in prior fiscal
years that were still unvested as of the covered&#160;fiscal year-end.</ix:footnote></span></td>
</tr></table>
<table cellpadding="0" cellspacing="0" style="font: 9pt/normal Arial, sans-serif; display: none; visibility: hidden; color: #000000; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 7pt; text-transform: none; line-height: 7pt"><sup id="xdx_F00_zMc9VSmuo24k">(h)</sup></span></td><td style="width: 5pt"/><td style="text-align: justify"><!--[if IE]></FONT><![endif]--><span id="xdx_F15_zGLIg8Tf6rg7" style="text-transform: none"><ix:footnote id="Footnote000108" xml:lang="en-US">Represents the change as
of the vesting date (from the end of the prior fiscal year) in fair value of equity-based awards granted in prior fiscal years that vested
as of the end of or during the covered&#160;fiscal year.</ix:footnote></span></td>
</tr></table>
<table cellpadding="0" cellspacing="0" style="font: 9pt/normal Arial, sans-serif; display: none; visibility: hidden; color: #000000; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 7pt; text-transform: none; line-height: 7pt"><sup id="xdx_F0C_zhsBSlRhRjtj">(i)</sup></span></td><td style="width: 5pt"/><td style="text-align: justify"><!--[if IE]></FONT><![endif]--><span id="xdx_F12_zqUVtIkQNNNc" style="text-transform: none"><ix:footnote id="Footnote000109" xml:lang="en-US">Equal to summary compensation
total plus/minus any adjustments related to equity award values as reflected in&#160;this table. For purposes of calculating &#8220;compensation
actually paid,&#8221; the fair value of equity awards at year-end 2023 and 2024, and on vesting dates for awards that vested during 2024,
were all determined consistent with the approach used to value the awards at the grant date for purposes of the Summary Compensation
Table (refer to &#8220;Executive Officer Compensation &#8211; Summary Compensation Table&#8221; for additional information). For any
awards subject to performance conditions, the change in fair value as of the end of the covered fiscal year is calculated based on the
probable outcome of such conditions as of the last day of the fiscal year. The valuation assumptions used to calculate fair values do
not differ materially from those disclosed at the time of grant, other than as reflected in the table below, which summarizes option
fair values determined using the Black-Scholes model and related assumptions used to calculate Compensation Actually Paid for fiscal&#160;year
2024.</ix:footnote></span></td>
</tr></table>

				</ix:continuation><p id="xdx_851_zDckYHbgcnx5"></p>
				</ix:continuation><p id="xdx_815_zIU4X2XS4HRa"></p>
				</div>

			</div>

		</div>
		<div style="page-break-before: always">
			<p style="margin: 0pt; font-size: 5pt">&#8203;</p>

		</div>
		<div class="qes_page" style="border-bottom: black 2pt solid; margin: auto; height: 990pt; width: 765pt; position: relative; overflow: hidden">
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 911.25pt; left: 45pt; width: 675pt; position: absolute; height: 33.75pt">
				<div style="display: table-cell; vertical-align: bottom; width: 675pt; height: 33.75pt">

				<!--[if IE]><TABLE><TR style=" width: 675pt; height: 33.75pt;"><TD vAlign="bottom" style=" width: 675pt; height: 33.75pt;"><![endif]-->
					<div style="font: 12pt/normal Times New Roman, Times, serif; margin: 0pt; text-transform: none; color: #000000; text-align: left">
						<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 0pt; border-collapse: collapse">
							<tr style="margin: 0; height: 0">
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>

							</tr>
							<tr style="min-height: 0pt">
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">ARTIVION, INC. | 2025 Proxy Statement</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">64</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 0pt; line-height: 0pt">&#8203;</p>

								</td>

							</tr>

						</table>

					</div>


				<!--[if IE]></TD></TR></TABLE><![endif]-->
				</div>

			</div>
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 45pt; left: 45pt; width: 675pt; position: absolute; height: 866.25pt">
				<div id="xdx_C07_gL1PTTB-LPZPJ_zXv2gSKOSI"><ix:continuation id="ConU000018-01"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" continuedAt="Con000111-01" escape="true" id="Fact000111" name="ecd:AdjToNonPeoNeoCompFnTextBlock"><p id="xdx_845_eecd--AdjToNonPeoNeoCompFnTextBlock_dU_z2toD0Is021l" style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">The following table sets forth a reconciliation from the Summary Compensation Table (&#8220;SCT&#8221;) to Compensation Actually Paid (&#8220;CAP&#8221;) for the average paid to our Non-PEO NEOs for each </span><span style="text-transform: none; line-height: 12pt">fiscal year.</span></p>
				<div style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-align: left">
					<table id="xdx_30E_zR7V9Qb1fbKj" summary="xdx: Disclosure - Pay vs Performance Disclosure" style="table-layout: fixed; width: 674.68pt; margin-top: 4pt; margin-bottom: 10pt; border-collapse: collapse">
						<tr style="margin: 0; height: 0">
							<td style="text-align: left; border-width: 0; margin: 0; padding: 0; width: 142.49pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 88.74pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 89.06pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 84.37pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 90pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 84.37pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 95.62pt">


							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="text-align: left; border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none"><b>Year</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>SCT<br/>Total</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Less Sum of<br/>Stock and<br/>Option Award<br/>Values from<br/>SCT</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Value of<br/>Current<br/>Year Equity<br/>Awards at<br/>12/31</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Change in<br/>Value of<br/>Unvested Prior<br/>Year Awards at<br/>12/31</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Change in<br/>Value of Prior<br/>Year Awards<br/>That Vested<br/>In Current<br/>Year</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Total<br/>Compensation<br/>Actually Paid</b></span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="text-align: left; border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="text-align: left; margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b> (e) </b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b> (f) </b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b> (g) </b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b> (h) </b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>(i)</b></span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="text-align: left; border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">2024</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 11pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_988_eecd--NonPeoNeoAvgTotalCompAmt_c20240101__20241231_zkGc2nmxZYQd" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">$<ix:nonFraction name="ecd:NonPeoNeoAvgTotalCompAmt" contextRef="From2024-01-01to2024-12-31" id="Fact000112" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,703,153</ix:nonFraction></span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 8pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98D_eecd--AdjToCompAmt_c20240101__20241231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--EqtyAwrdsInSummryCompstnTblForAplblYrMember_fKGUp_z2j7FEeSfoSh" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">  ($<ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2024-01-012024-12-31_ecd_NonPeoNeoMember_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" id="Fact000113" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">923,744</ix:nonFraction>)</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 11pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_988_eecd--AdjToCompAmt_c20240101__20241231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_fKGYp_z8CEuZuUuvwd" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">$<ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2024-01-012024-12-31_ecd_NonPeoNeoMember_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" id="Fact000114" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,498,338</ix:nonFraction></span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 13pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_989_eecd--AdjToCompAmt_c20240101__20241231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_fKGcp_zWl8QtvFYeK8" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">  $<ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2024-01-012024-12-31_ecd_NonPeoNeoMember_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" id="Fact000115" format="ixt:numdotdecimal" decimals="0" unitRef="USD">642,469</ix:nonFraction></span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 13pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_985_eecd--AdjToCompAmt_c20240101__20241231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_fKGgp_zqpoBld2prm7" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">$<ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2024-01-012024-12-31_ecd_NonPeoNeoMember_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" id="Fact000116" format="ixt:numdotdecimal" decimals="0" unitRef="USD">230,805</ix:nonFraction></span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 14pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98A_eecd--NonPeoNeoAvgCompActuallyPaidAmt_c20240101__20241231_fKGkuKQ_____z8MWU3TdMpq3" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">$<ix:nonFraction name="ecd:NonPeoNeoAvgCompActuallyPaidAmt" contextRef="From2024-01-01to2024-12-31" id="Fact000117" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,151,020</ix:nonFraction></span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; text-align: left; padding: 1.5pt 0pt 1.5pt 3pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: left"><span style="text-transform: none">2023</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 11pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_986_eecd--NonPeoNeoAvgTotalCompAmt_c20230101__20231231_zFdGxPi6y5Z8" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">$<ix:nonFraction name="ecd:NonPeoNeoAvgTotalCompAmt" contextRef="From2023-01-012023-12-31" id="Fact000118" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,204,664</ix:nonFraction></span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 8pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_985_eecd--AdjToCompAmt_c20230101__20231231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--EqtyAwrdsInSummryCompstnTblForAplblYrMember_fKGUp_zDfLteTfhPq2" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">&#8194; ($<ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2023-01-012023-12-31_ecd_NonPeoNeoMember_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" id="Fact000119" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">498,431</ix:nonFraction>)</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 11pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98A_eecd--AdjToCompAmt_c20230101__20231231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_fKGYp_zs6fl3nop6ig" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">  $<ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2023-01-012023-12-31_ecd_NonPeoNeoMember_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" id="Fact000120" format="ixt:numdotdecimal" decimals="0" unitRef="USD">639,679</ix:nonFraction></span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 13pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_983_eecd--AdjToCompAmt_c20230101__20231231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_fKGcp_zjaU3jnmCvfc" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">&#8194; $<ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2023-01-012023-12-31_ecd_NonPeoNeoMember_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" id="Fact000121" format="ixt:numdotdecimal" decimals="0" unitRef="USD">443,711</ix:nonFraction></span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 13pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98F_eecd--AdjToCompAmt_c20230101__20231231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_fKGgp_ztA47rbIUUTd" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">  $<ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2023-01-012023-12-31_ecd_NonPeoNeoMember_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" id="Fact000122" format="ixt:numdotdecimal" decimals="0" unitRef="USD">45,783</ix:nonFraction></span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 14pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98B_eecd--NonPeoNeoAvgCompActuallyPaidAmt_c20230101__20231231_fKGkuKQ_____zcDfIdaGiIE3" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">$<ix:nonFraction name="ecd:NonPeoNeoAvgCompActuallyPaidAmt" contextRef="From2023-01-012023-12-31" id="Fact000123" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,835,407</ix:nonFraction></span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; text-align: left; padding: 1.5pt 0pt 1.5pt 3pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: left"><span style="text-transform: none">2022</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 11pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98C_eecd--NonPeoNeoAvgTotalCompAmt_c20220101__20221231_zeRwyvu6di9" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">$<ix:nonFraction name="ecd:NonPeoNeoAvgTotalCompAmt" contextRef="From2022-01-012022-12-31" id="Fact000124" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,796,100</ix:nonFraction></span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 8pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_987_eecd--AdjToCompAmt_c20220101__20221231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--EqtyAwrdsInSummryCompstnTblForAplblYrMember_fKGUp_zOvzRDZgXzKf" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">($<ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2022-01-012022-12-31_ecd_NonPeoNeoMember_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" id="Fact000125" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,124,197</ix:nonFraction>)</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 11pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_982_eecd--AdjToCompAmt_c20220101__20221231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_fKGYp_z5rmMRSYJEPf" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">  $<ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2022-01-012022-12-31_ecd_NonPeoNeoMember_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" id="Fact000126" format="ixt:numdotdecimal" decimals="0" unitRef="USD">955,981</ix:nonFraction></span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_988_eecd--AdjToCompAmt_c20220101__20221231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_fKGcp_zTfCoUsB2oCh" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none"> ($<ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2022-01-012022-12-31_ecd_NonPeoNeoMember_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" id="Fact000127" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">239,756</ix:nonFraction>)</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_985_eecd--AdjToCompAmt_c20220101__20221231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_fKGgp_zfUrvVcPTK38" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">($<ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2022-01-012022-12-31_ecd_NonPeoNeoMember_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" id="Fact000128" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">35,259</ix:nonFraction>)</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 14pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_980_eecd--NonPeoNeoAvgCompActuallyPaidAmt_c20220101__20221231_fKGkuKQ_____zU4Lx60upXQd" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">$<ix:nonFraction name="ecd:NonPeoNeoAvgCompActuallyPaidAmt" contextRef="From2022-01-012022-12-31" id="Fact000129" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,352,869</ix:nonFraction></span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; text-align: left; padding: 1.5pt 0pt 1.5pt 3pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: left"><span style="text-transform: none">2021</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 11pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98C_eecd--NonPeoNeoAvgTotalCompAmt_c20210101__20211231_zL0XxHkSKhyh" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">$<ix:nonFraction name="ecd:NonPeoNeoAvgTotalCompAmt" contextRef="From2021-01-012021-12-31" id="Fact000130" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,286,725</ix:nonFraction></span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 8pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_984_eecd--AdjToCompAmt_c20210101__20211231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--EqtyAwrdsInSummryCompstnTblForAplblYrMember_fKGUp_zrzfmxWnnKqi" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">&#8194; ($<ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2021-01-012021-12-31_ecd_NonPeoNeoMember_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" id="Fact000131" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">640,635</ix:nonFraction>)</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 11pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98C_eecd--AdjToCompAmt_c20210101__20211231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_fKGYp_z0HJT6cwQOn9" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">  $<ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2021-01-012021-12-31_ecd_NonPeoNeoMember_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" id="Fact000132" format="ixt:numdotdecimal" decimals="0" unitRef="USD">508,720</ix:nonFraction></span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_984_eecd--AdjToCompAmt_c20210101__20211231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_fKGcp_zmmkvk3v0Z2c" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">&#8194; ($<ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2021-01-012021-12-31_ecd_NonPeoNeoMember_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" id="Fact000133" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">72,575</ix:nonFraction>)</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 13pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_988_eecd--AdjToCompAmt_c20210101__20211231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_fKGgp_zvJoj1Ayeqtf" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">  $<ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2021-01-012021-12-31_ecd_NonPeoNeoMember_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" id="Fact000134" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,701</ix:nonFraction></span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 14pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98E_eecd--NonPeoNeoAvgCompActuallyPaidAmt_c20210101__20211231_fKGkuKQ_____zOPu6wZ4y4Hl" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">$<ix:nonFraction name="ecd:NonPeoNeoAvgCompActuallyPaidAmt" contextRef="From2021-01-012021-12-31" id="Fact000135" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,108,935</ix:nonFraction></span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; text-align: left; padding: 1.5pt 0pt 1.5pt 3pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: left"><span style="text-transform: none">2020</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 11pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_986_eecd--NonPeoNeoAvgTotalCompAmt_c20200101__20201231_zQVsMUpIEZr5" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">&#8194;$<ix:nonFraction name="ecd:NonPeoNeoAvgTotalCompAmt" contextRef="From2020-01-012020-12-31" id="Fact000136" format="ixt:numdotdecimal" decimals="0" unitRef="USD">977,089</ix:nonFraction></span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 8pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_988_eecd--AdjToCompAmt_c20200101__20201231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--EqtyAwrdsInSummryCompstnTblForAplblYrMember_fKGUp_zFL2z8REbYh4" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">&#8194; ($<ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2020-01-012020-12-31_ecd_NonPeoNeoMember_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" id="Fact000137" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">499,129</ix:nonFraction>)</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 11pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98C_eecd--AdjToCompAmt_c20200101__20201231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_fKGYp_zrPzWAnv5Luf" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">  $<ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2020-01-012020-12-31_ecd_NonPeoNeoMember_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" id="Fact000138" format="ixt:numdotdecimal" decimals="0" unitRef="USD">420,985</ix:nonFraction></span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98F_eecd--AdjToCompAmt_c20200101__20201231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_fKGcp_zHHqSQTbWNU6" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none"> ($<ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2020-01-012020-12-31_ecd_NonPeoNeoMember_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" id="Fact000139" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">371,199</ix:nonFraction>)</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_982_eecd--AdjToCompAmt_c20200101__20201231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_fKGgp_z548VFakKFve" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none"> ($<ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2020-01-012020-12-31_ecd_NonPeoNeoMember_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" id="Fact000140" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">73,105</ix:nonFraction>)</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 14pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_981_eecd--NonPeoNeoAvgCompActuallyPaidAmt_c20200101__20201231_fKGkuKQ_____zrf2LnU9tXX2" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">&#8194; $<ix:nonFraction name="ecd:NonPeoNeoAvgCompActuallyPaidAmt" contextRef="From2020-01-012020-12-31" id="Fact000141" format="ixt:numdotdecimal" decimals="0" unitRef="USD">454,642</ix:nonFraction></span></p>

							</td>

						</tr>

					</table>

				</div>

<table cellpadding="0" cellspacing="0" style="font: 9pt/normal Arial, sans-serif; display: none; visibility: hidden; color: #000000; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 7pt; text-transform: none; line-height: 7pt"><sup id="xdx_F04_zCsjhN8a9su7">(e)</sup></span></td><td style="width: 5pt"/><td style="text-align: justify"><!--[if IE]></FONT><![endif]--><span id="xdx_F10_zd6MihFDfz31" style="text-transform: none"><ix:footnote id="Footnote000142" xml:lang="en-US">Represents the grant date
fair value of equity-based awards made during the covered fiscal year as reported in the Summary&#160;Compensation Table.</ix:footnote></span></td>
</tr></table>
<table cellpadding="0" cellspacing="0" style="font: 9pt/normal Arial, sans-serif; display: none; visibility: hidden; color: #000000; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 7pt; text-transform: none; line-height: 7pt"><sup id="xdx_F0D_zfrxqZnFmsp8">(f)</sup></span></td><td style="width: 5pt"/><td style="text-align: justify"><!--[if IE]></FONT><![endif]--><span id="xdx_F1E_zaDZYrW4evr9" style="text-transform: none"><ix:footnote id="Footnote000143" xml:lang="en-US">Represents the year-end
fair value of equity awards that were made during the covered fiscal year and remained unvested as&#160;of the end of the covered fiscal
year.</ix:footnote></span></td>
</tr></table>
<table cellpadding="0" cellspacing="0" style="font: 9pt/normal Arial, sans-serif; display: none; visibility: hidden; color: #000000; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 7pt; text-transform: none; line-height: 7pt"><sup id="xdx_F00_zVKZL2f9N4jd">(g)</sup></span></td><td style="width: 5pt"/><td style="text-align: justify"><!--[if IE]></FONT><![endif]--><span id="xdx_F16_z33wktlgZdSh" style="text-transform: none"><ix:footnote id="Footnote000144" xml:lang="en-US">Represents the change as
of the end of the covered fiscal year (from the end of the prior fiscal year) in fair value of equity-based awards granted in prior fiscal
years that were still unvested as of the covered&#160;fiscal year-end.</ix:footnote></span></td>
</tr></table>
<table cellpadding="0" cellspacing="0" style="font: 9pt/normal Arial, sans-serif; display: none; visibility: hidden; color: #000000; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 7pt; text-transform: none; line-height: 7pt"><sup id="xdx_F09_zDSh6BEP3mZj">(h)</sup></span></td><td style="width: 5pt"/><td style="text-align: justify"><!--[if IE]></FONT><![endif]--><span id="xdx_F1B_z9Fy81mFQbD5" style="text-transform: none"><ix:footnote id="Footnote000145" xml:lang="en-US">Represents the change as
of the vesting date (from the end of the prior fiscal year) in fair value of equity-based awards granted in prior fiscal years that vested
as of the end of or during the covered&#160;fiscal year.</ix:footnote></span></td>
</tr></table>
<table cellpadding="0" cellspacing="0" style="font: 9pt/normal Arial, sans-serif; display: none; visibility: hidden; color: #000000; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 7pt; text-transform: none; line-height: 7pt"><sup id="xdx_F03_zyLPcLyHWWJe">(i)</sup></span></td><td style="width: 5pt"/><td style="text-align: justify"><!--[if IE]></FONT><![endif]--><span id="xdx_F1A_z7G5nx6ciLC7" style="text-transform: none"><ix:footnote id="Footnote000146" xml:lang="en-US">Equal to summary compensation
total plus/minus any adjustments related to equity award values as reflected in&#160;this table. For purposes of calculating &#8220;compensation
actually paid,&#8221; the fair value of equity awards at year-end 2023 and 2024, and on vesting dates for awards that vested during 2024,
were all determined consistent with the approach used to value the awards at the grant date for purposes of the Summary Compensation
Table (refer to &#8220;Executive Officer Compensation &#8211; Summary Compensation Table&#8221; for additional information). For any
awards subject to performance conditions, the change in fair value as of the end of the covered fiscal year is calculated based on the
probable outcome of such conditions as of the last day of the fiscal year. The valuation assumptions used to calculate fair values do
not differ materially from those disclosed at the time of grant, other than as reflected in the table below, which summarizes option
fair values determined using the Black-Scholes model and related assumptions used to calculate Compensation Actually Paid for fiscal&#160;year
2024.</ix:footnote></span></td>
</tr></table>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 1pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(i)</sup></span><!--[if IE]></FONT><![endif]--><sup style="text-transform: none; font-size: 7pt; line-height: 7pt"></sup><span style="text-transform: none">Equal to summary compensation total plus/minus any adjustments related to equity award values as reflected in&#160;this table. For purposes of calculating &#8220;compensation actually paid,&#8221; the fair value of equity awards at year-end 2023 and 2024, and on vesting dates for awards that vested during 2024, were all determined consistent with the approach used to value the awards at the grant date for purposes of the Summary Compensation Table (refer to &#8220;Executive Officer Compensation &#8211; Summary Compensation Table&#8221; for additional information). For any awards subject to performance conditions, the change in fair value as of the end of the covered fiscal year is calculated based on the probable outcome of such conditions as of the last day of the fiscal year. The valuation assumptions used to calculate fair values do not differ materially from those disclosed at the time of grant, other than as reflected in the table below, which summarizes option fair values determined using the Black-Scholes model and related assumptions used to calculate Compensation Actually Paid for </span><span style="text-transform: none">fiscal&#160;year 2024.</span></p>

				</ix:nonNumeric><div id="xdx_C0B_gL2ATPCFTB-BR_zwK9StH3wMCi" style="margin-bottom: 1pt"><ix:continuation id="ConU000074-01"><ix:continuation continuedAt="Con000111-02" id="Con000111-01"><p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 1pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(e)</sup></span><!--[if IE]></FONT><![endif]--><sup style="text-transform: none; font-size: 7pt; line-height: 7pt"></sup><span style="text-transform: none">Represents the grant date fair value of equity-based awards made during the covered fiscal year as reported in the </span><span style="text-transform: none">Summary&#160;Compensation Table.</span></p>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 1pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(f)</sup></span><!--[if IE]></FONT><![endif]--><sup style="text-transform: none; font-size: 7pt; line-height: 7pt"></sup><span style="text-transform: none">Represents the year-end fair value of equity awards that were made during the covered fiscal year and remained unvested as&#160;of the end of the covered </span><span style="text-transform: none">fiscal year.</span></p>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 1pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(g)</sup></span><!--[if IE]></FONT><![endif]--><sup style="text-transform: none; font-size: 7pt; line-height: 7pt"></sup><span style="text-transform: none">Represents the change as of the end of the covered fiscal year (from the end of the prior fiscal year) in fair value of equity-based awards granted in prior fiscal years that were still unvested as of the </span><span style="text-transform: none">covered&#160;fiscal year-end.</span></p>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 8pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(h)</sup></span><!--[if IE]></FONT><![endif]--><sup style="text-transform: none; font-size: 7pt; line-height: 7pt"></sup><span style="text-transform: none">Represents the change as of the vesting date (from the end of the prior fiscal year) in fair value of equity-based awards granted in prior fiscal years that vested as of the end of or during the </span><span style="text-transform: none">covered&#160;fiscal year.</span></p>
				<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" continuedAt="Con000148-01" escape="true" id="Fact000148" name="ecd:EqtyAwrdsAdjFnTextBlock"><div id="xdx_893_eecd--EqtyAwrdsAdjFnTextBlock_dU_zd3NhAsLpzpa"></div>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 8pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(i)</sup></span><!--[if IE]></FONT><![endif]--><sup style="text-transform: none; font-size: 7pt; line-height: 7pt"></sup><span style="text-transform: none">Equal to summary compensation total plus/minus any adjustments related to equity award values as reflected in&#160;this table. For purposes of calculating &#8220;compensation actually paid,&#8221; the fair value of equity awards at year-end 2023 and 2024, and on vesting dates for awards that vested during 2024, were all determined consistent with the approach used to value the awards at the grant date for purposes of the Summary Compensation Table (refer to &#8220;Executive Officer Compensation &#8211; Summary Compensation Table&#8221; for additional information). For any awards subject to performance conditions, the change in fair value as of the end of the covered fiscal year is calculated based on the probable outcome of such conditions as of the last day of the fiscal year. The valuation assumptions used to calculate fair values do not differ materially from those disclosed at the time of grant, other than as reflected in the table below, which summarizes option fair values determined using the Black-Scholes model and related assumptions used to calculate Compensation Actually Paid for </span><span style="text-transform: none">fiscal&#160;year 2024.</span></p>
				</ix:nonNumeric></ix:continuation><div style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-align: justify">
					<ix:continuation id="Con000111-02"><ix:continuation id="Con000148-01"><table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 10pt; border-collapse: collapse">
						<tr style="margin: 0; height: 0">
							<td style="border-width: 0; margin: 0; padding: 0; width: 100pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 110pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 93.75pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 92.49pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 63.74pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 107.5pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 107.5pt">


							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Valuation<br/>Purpose<br/>for PVP&#160;</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>AORT<br/>Stock<br/>Price</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>AORT<br/>Option<br/>Exercise<br/>Price</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Expected<br/>Term<br/>(years)</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Stock<br/>Price<br/>Volatility</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Risk-free<br/>Rate</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Option<br/>Fair<br/>Value</b></span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Year-end 2023</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><span id="xdx_905_eus-gaap--SharePrice_iI_pid_c20241231__us-gaap--VestingAxis__custom--YearEnd2023Member_zyoa1YBNpbDh" class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__">$<ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-12-31_custom_YearEnd2023Member" id="Fact000149" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">17.88</ix:nonFraction></span></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20241231__us-gaap--VestingAxis__custom--YearEnd2023Member__srt--RangeAxis__srt--MinimumMember_z5bT910B5iI4" class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__">$<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="AsOf2024-12-31_custom_YearEnd2023Member_srt_MinimumMember" id="Fact000150" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">11.03</ix:nonFraction></span> - <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20241231__us-gaap--VestingAxis__custom--YearEnd2023Member__srt--RangeAxis__srt--MaximumMember_zSNEB73O0Sbg" class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__">$<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="AsOf2024-12-31_custom_YearEnd2023Member_srt_MaximumMember" id="Fact000151" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">24.90</ix:nonFraction></span></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2023Member__srt--RangeAxis__srt--MinimumMember_zfuoYaTx9a6e" class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_YearEnd2023Member_srt_MinimumMember" format="ixt-sec:duryear" id="Fact000152" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">2.13</ix:nonNumeric></span> &#8211; <span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2023Member__srt--RangeAxis__srt--MaximumMember_z5wuLeKbg0cf" class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_YearEnd2023Member_srt_MaximumMember" format="ixt-sec:duryear" id="Fact000153" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">4.93</ix:nonNumeric></span></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2023Member_z9yVGAlW0uoc" class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2024-01-012024-12-31_custom_YearEnd2023Member" id="Fact000154" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">45</ix:nonFraction></span>%</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2023Member__srt--RangeAxis__srt--MinimumMember_zDHA9XJYwQOe" class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2024-01-012024-12-31_custom_YearEnd2023Member_srt_MinimumMember" id="Fact000155" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">3.85</ix:nonFraction></span>% - <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2023Member__srt--RangeAxis__srt--MaximumMember_z0ByHjPnHdCi" class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2024-01-012024-12-31_custom_YearEnd2023Member_srt_MaximumMember" id="Fact000156" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">4.20</ix:nonFraction></span>%</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><span id="xdx_907_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFairValuePerShare_pid_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2023Member__srt--RangeAxis__srt--MinimumMember_ze1eSKkm7EUc" class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__">$<ix:nonFraction name="aort:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFairValuePerShare" contextRef="From2024-01-012024-12-31_custom_YearEnd2023Member_srt_MinimumMember" id="Fact000157" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.11</ix:nonFraction></span> - <span id="xdx_90D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFairValuePerShare_pid_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2023Member__srt--RangeAxis__srt--MaximumMember_z1wedYtymmOh" class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__">$<ix:nonFraction name="aort:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFairValuePerShare" contextRef="From2024-01-012024-12-31_custom_YearEnd2023Member_srt_MaximumMember" id="Fact000158" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.89</ix:nonFraction></span></span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">2024 Vesting</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><span id="xdx_90A_eus-gaap--SharePrice_iI_pid_c20241231__us-gaap--VestingAxis__custom--Vesting2024Member__srt--RangeAxis__srt--MinimumMember_zeHkPyKExvF4" class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__">$<ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-12-31_custom_Vesting2024Member_srt_MinimumMember" id="Fact000159" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">18.81</ix:nonFraction></span> - <span id="xdx_90D_eus-gaap--SharePrice_iI_pid_c20241231__us-gaap--VestingAxis__custom--Vesting2024Member__srt--RangeAxis__srt--MaximumMember_zH7RgbVEMs58" class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__">$<ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-12-31_custom_Vesting2024Member_srt_MaximumMember" id="Fact000160" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">29.66</ix:nonFraction></span></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20241231__us-gaap--VestingAxis__custom--Vesting2024Member__srt--RangeAxis__srt--MinimumMember_zsBXXbgZNSHd" class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__">$<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="AsOf2024-12-31_custom_Vesting2024Member_srt_MinimumMember" id="Fact000161" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">11.03</ix:nonFraction></span> - <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20241231__us-gaap--VestingAxis__custom--Vesting2024Member__srt--RangeAxis__srt--MaximumMember_ziJ1ynfMcNij" class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__">$<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="AsOf2024-12-31_custom_Vesting2024Member_srt_MaximumMember" id="Fact000162" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">24.90</ix:nonFraction></span></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20240101__20241231__us-gaap--VestingAxis__custom--Vesting2024Member__srt--RangeAxis__srt--MinimumMember_zyE2UDf1ohbd" class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_Vesting2024Member_srt_MinimumMember" format="ixt-sec:duryear" id="Fact000163" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">2.00</ix:nonNumeric></span> &#8211; <span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20240101__20241231__us-gaap--VestingAxis__custom--Vesting2024Member__srt--RangeAxis__srt--MaximumMember_z8x2k6FvKVSj" class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_Vesting2024Member_srt_MaximumMember" format="ixt-sec:duryear" id="Fact000164" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">3.40</ix:nonNumeric></span></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20240101__20241231__us-gaap--VestingAxis__custom--Vesting2024Member_zqBT2vNbZH2e" class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2024-01-012024-12-31_custom_Vesting2024Member" id="Fact000165" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">45</ix:nonFraction></span>%</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20240101__20241231__us-gaap--VestingAxis__custom--Vesting2024Member__srt--RangeAxis__srt--MinimumMember_zAf0GFsQYSJ7" class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2024-01-012024-12-31_custom_Vesting2024Member_srt_MinimumMember" id="Fact000166" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">4.05</ix:nonFraction></span>% - <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20240101__20241231__us-gaap--VestingAxis__custom--Vesting2024Member__srt--RangeAxis__srt--MaximumMember_zruoGuGQVtce" class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2024-01-012024-12-31_custom_Vesting2024Member_srt_MaximumMember" id="Fact000167" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">4.64</ix:nonFraction></span>%</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><span id="xdx_906_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFairValuePerShare_pid_c20240101__20241231__us-gaap--VestingAxis__custom--Vesting2024Member__srt--RangeAxis__srt--MinimumMember_zqoe5lHLTR5k" class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__">$<ix:nonFraction name="aort:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFairValuePerShare" contextRef="From2024-01-012024-12-31_custom_Vesting2024Member_srt_MinimumMember" id="Fact000168" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.44</ix:nonFraction></span> - <span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFairValuePerShare_pid_c20240101__20241231__us-gaap--VestingAxis__custom--Vesting2024Member__srt--RangeAxis__srt--MaximumMember_z2zUAhP8h8wd" class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__">$<ix:nonFraction name="aort:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFairValuePerShare" contextRef="From2024-01-012024-12-31_custom_Vesting2024Member_srt_MaximumMember" id="Fact000169" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">19.34</ix:nonFraction></span></span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Year-end 2024</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><span id="xdx_90A_eus-gaap--SharePrice_iI_pid_c20241231__us-gaap--VestingAxis__custom--YearEnd2024Member_zIcNvc8rKnKg" class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__">$<ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-12-31_custom_YearEnd2024Member" id="Fact000170" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">28.59</ix:nonFraction></span></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20241231__us-gaap--VestingAxis__custom--YearEnd2024Member__srt--RangeAxis__srt--MinimumMember_zcefl9K22g16" class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__">$<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="AsOf2024-12-31_custom_YearEnd2024Member_srt_MinimumMember" id="Fact000171" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">11.03</ix:nonFraction></span> - <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20241231__us-gaap--VestingAxis__custom--YearEnd2024Member__srt--RangeAxis__srt--MaximumMember_z79asRnmmY7g" class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__">$<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="AsOf2024-12-31_custom_YearEnd2024Member_srt_MaximumMember" id="Fact000172" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">18.44</ix:nonFraction></span></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2024Member__srt--RangeAxis__srt--MinimumMember_zdOWKWyp5Xq4" class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_YearEnd2024Member_srt_MinimumMember" format="ixt-sec:duryear" id="Fact000173" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">2.15</ix:nonNumeric></span> &#8211; <span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2024Member__srt--RangeAxis__srt--MaximumMember_zba4BTXP2Uxf" class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_YearEnd2024Member_srt_MaximumMember" format="ixt-sec:duryear" id="Fact000174" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">3.93</ix:nonNumeric></span></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2024Member_zxqzATqctpVj" class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2024-01-012024-12-31_custom_YearEnd2024Member" id="Fact000175" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">45</ix:nonFraction></span>%</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2024Member__srt--RangeAxis__srt--MinimumMember_zS6AZcNjtIsg" class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2024-01-012024-12-31_custom_YearEnd2024Member_srt_MinimumMember" id="Fact000176" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">4.25</ix:nonFraction></span>% - <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2024Member__srt--RangeAxis__srt--MaximumMember_zdBzYd0oKpy9" class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2024-01-012024-12-31_custom_YearEnd2024Member_srt_MaximumMember" id="Fact000177" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">4.32</ix:nonFraction></span>%</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><span id="xdx_904_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFairValuePerShare_pid_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2024Member__srt--RangeAxis__srt--MinimumMember_zkhvEywZAjze" class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__">$<ix:nonFraction name="aort:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFairValuePerShare" contextRef="From2024-01-012024-12-31_custom_YearEnd2024Member_srt_MinimumMember" id="Fact000178" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">13.41</ix:nonFraction></span> - <span id="xdx_90E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFairValuePerShare_pid_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2024Member__srt--RangeAxis__srt--MaximumMember_zL4O8QW1feQ6" class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__">$<ix:nonFraction name="aort:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFairValuePerShare" contextRef="From2024-01-012024-12-31_custom_YearEnd2024Member_srt_MaximumMember" id="Fact000179" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">19.23</ix:nonFraction></span></span></p>

							</td>

						</tr>

					</table>
					</ix:continuation><div id="xdx_8A7_z9KbHUprOhfa"></div>
					</ix:continuation><div id="xdx_858_zGbldmmTkFHa"></div>
				</div>
				</ix:continuation></div>
			</ix:continuation></div>
			</div>

		</div>
		<div style="page-break-before: always">
			<p style="margin: 0pt; font-size: 5pt">&#8203;</p>

		</div>
		<div class="qes_page" style="border-bottom: black 2pt solid; margin: auto; height: 990pt; width: 765pt; position: relative; overflow: hidden">
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 911.25pt; left: 45pt; width: 675pt; position: absolute; height: 33.75pt">
				<div style="display: table-cell; vertical-align: bottom; width: 675pt; height: 33.75pt">

				<!--[if IE]><TABLE><TR style=" width: 675pt; height: 33.75pt;"><TD vAlign="bottom" style=" width: 675pt; height: 33.75pt;"><![endif]-->
					<div style="font: 12pt/normal Times New Roman, Times, serif; margin: 0pt; text-transform: none; color: #000000; text-align: left">
						<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 0pt; border-collapse: collapse">
							<tr style="margin: 0; height: 0">
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>

							</tr>
							<tr style="min-height: 0pt">
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">ARTIVION, INC. | 2025 Proxy Statement</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">65</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 0pt; line-height: 0pt">&#8203;</p>

								</td>

							</tr>

						</table>

					</div>


				<!--[if IE]></TD></TR></TABLE><![endif]-->
				</div>

			</div>
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 45pt; left: 45pt; width: 675pt; position: absolute; height: 900pt">
				<p style="font: italic 11pt/normal Arial, sans-serif; margin: 0pt 0pt 8pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><b><i>Relationships Between Compensation Actually Paid (CAP) and TSR, Net Income, and AORT Revenue </i></b></span><span style="text-transform: none; font-style: italic"><b><i>Growth</i></b></span></p>
				<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000181" name="ecd:CompActuallyPaidVsTotalShareholderRtnTextBlock"><div id="xdx_805_eecd--CompActuallyPaidVsTotalShareholderRtnTextBlock_dU_zO1GcF89duI8"></div>
				<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000183" name="ecd:TotalShareholderRtnVsPeerGroupTextBlock"><div id="xdx_848_eecd--TotalShareholderRtnVsPeerGroupTextBlock_dU_zkpJ0GDUpua"></div>
				<div style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 6pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center">
					<div style="border: #2b4b74 1pt solid; padding: 0pt; overflow: hidden; display: inline-block; width: 533.75pt; height: 271.88pt; text-align: left">
						<img src="art-def14a_051325img005.gif" alt="" style="vertical-align: top; margin-left: 16.25pt; width: 500pt; margin-top: 13.75pt; height: 245pt"/>

					</div>

				</div>
				</ix:nonNumeric><div id="xdx_857_zEiHRh02Mcj9"></div>
				</ix:nonNumeric><div id="xdx_815_zMVSRrkFC5D5"></div>
				<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000185" name="ecd:CompActuallyPaidVsNetIncomeTextBlock"><div id="xdx_805_eecd--CompActuallyPaidVsNetIncomeTextBlock_dU_zlVd058UsQq3"></div>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 6pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: center"><span style="text-transform: none">&#8203;</span></p>
				<div style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 6pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: center">
					<div style="border: #2b4b74 1pt solid; padding: 0pt; overflow: hidden; display: inline-block; width: 533.75pt; height: 271.88pt; text-align: left">
						<img src="art-def14a_051325img006.gif" alt="" style="vertical-align: top; margin-left: 16.25pt; width: 500pt; margin-top: 13.75pt; height: 245pt"/>

					</div>

				</div>
				</ix:nonNumeric><div id="xdx_814_zBn8sFmtruP9"></div>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 6pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: center"><span style="text-transform: none">&#8203;</span></p>

				<div style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 6pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: center">
				<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000187" name="ecd:CompActuallyPaidVsCoSelectedMeasureTextBlock"><div id="xdx_809_eecd--CompActuallyPaidVsCoSelectedMeasureTextBlock_dU_zeNOAulayHc"></div>
						<div style="border: #2b4b74 1pt solid; padding: 0pt; overflow: hidden; display: inline-block; width: 533.75pt; height: 271.88pt; text-align: left">
						<img src="art-def14a_051325img007.gif" alt="" style="vertical-align: top; margin-left: 16.25pt; width: 500pt; margin-top: 13.75pt; height: 245pt"/>

					</div>
				</ix:nonNumeric><div id="xdx_816_z2yeGB5O26Gk"></div>
				</div>

			</div>

		</div>
		<div style="page-break-before: always">
			<p style="margin: 0pt; font-size: 5pt">&#8203;</p>

		</div>
		<div class="qes_page" style="border-bottom: black 2pt solid; margin: auto; height: 990pt; width: 765pt; position: relative; overflow: hidden">
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 911.25pt; left: 45pt; width: 675pt; position: absolute; height: 33.75pt">
				<div style="display: table-cell; vertical-align: bottom; width: 675pt; height: 33.75pt">

				<!--[if IE]><TABLE><TR style=" width: 675pt; height: 33.75pt;"><TD vAlign="bottom" style=" width: 675pt; height: 33.75pt;"><![endif]-->
					<div style="font: 12pt/normal Times New Roman, Times, serif; margin: 0pt; text-transform: none; color: #000000; text-align: left">
						<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 0pt; border-collapse: collapse">
							<tr style="margin: 0; height: 0">
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>

							</tr>
							<tr style="min-height: 0pt">
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">ARTIVION, INC. | 2025 Proxy Statement</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">66</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 0pt; line-height: 0pt">&#8203;</p>

								</td>

							</tr>

						</table>

					</div>


				<!--[if IE]></TD></TR></TABLE><![endif]-->
				</div>

			</div>
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 45pt; left: 45pt; width: 675pt; position: absolute; height: 866.25pt">
				<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" continuedAt="Con000189-01" escape="true" id="Fact000189" name="ecd:TabularListTableTextBlock"><p id="xdx_802_eecd--TabularListTableTextBlock_dU_z1ShjrTHVRtk" style="font: italic 11pt/normal Arial, sans-serif; margin: 0pt 0pt 8pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><b><i>Most Important Financial Measures Related to 2024 Officer Compensation</i></b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">In accordance with the Pay Versus Performance Rules, the following table lists the financial performance measures that, in the Company&#8217;s assessment, represent the most important financial performance measures used to link &#8220;compensation actually paid&#8221; to our Named Executive Officers, for fiscal year 2024, to Company performance. As discussed in the Compensation Discussion and Analysis, the annual short-term incentive plan used revenue growth (constant&#160;currency) and adjusted EBITDA as the primary financial measures for 2024. Annual PSUs granted during 2024 also were earned based on revenue growth (constant currency) and adjusted EBITDA. In 2024, we also applied an R&amp;D-related metric for our annual performance share plan, which consisted of two milestones: (1) the submission of two AMDS PMA modules (i.e., pre-clinical in Q3 2024 and QMS/MFG in Q4 2024) and (2) the submission of the Arcevo LSA IDE in </span><span style="text-transform: none; line-height: 12pt">Q4 2024.</span></p>
				</ix:nonNumeric><div style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-align: center">
					<ix:continuation id="Con000189-01"><table id="xdx_30C_zwZ55xSk42o1" summary="xdx: Disclosure - Pay vs Performance Disclosure" style="margin: 4pt auto 10pt; table-layout: fixed; width: 300pt; border-collapse: collapse">
						<tr style="margin: 0; height: 0">
							<td style="border-width: 0; margin: 0; padding: 0; width: 300pt">


							</td>

						</tr>
						<tr style="min-height: 0pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Key Financial Measures</b></span></p>

							</td>

						</tr>
						<tr style="min-height: 0pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><span id="xdx_902_eecd--MeasureName_c20240101__20241231__ecd--MeasureAxis__1_z0TGH43SagAd"><ix:nonNumeric contextRef="From2024-01-012024-12-31_1" id="Fact000190" name="ecd:MeasureName">AORT Revenue Growth (constant currency)</ix:nonNumeric></span></span></p>

							</td>

						</tr>
						<tr style="min-height: 0pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><span id="xdx_908_eecd--MeasureName_c20240101__20241231__ecd--MeasureAxis__2_zJHNhr6uLbw5"><ix:nonNumeric contextRef="From2024-01-012024-12-31_2" id="Fact000191" name="ecd:MeasureName">Adjusted EBITDA</ix:nonNumeric></span></span></p>

							</td>

						</tr>

					</table>
				</ix:continuation><div id="xdx_816_zHV5kutYBgSe"></div>
				</div>

			</div>

		</div>
		<div style="page-break-before: always">
			<p style="margin: 0pt; font-size: 5pt">&#8203;</p>

		</div>
		<div class="qes_page" style="border-bottom: black 2pt solid; margin: auto; height: 990pt; width: 765pt; position: relative; overflow: hidden">
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 911.25pt; left: 45pt; width: 675pt; position: absolute; height: 33.75pt">
				<div style="display: table-cell; vertical-align: bottom; width: 675pt; height: 33.75pt">

				<!--[if IE]><TABLE><TR style=" width: 675pt; height: 33.75pt;"><TD vAlign="bottom" style=" width: 675pt; height: 33.75pt;"><![endif]-->
					<div style="font: 12pt/normal Times New Roman, Times, serif; margin: 0pt; text-transform: none; color: #000000; text-align: left">
						<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 0pt; border-collapse: collapse">
							<tr style="margin: 0; height: 0">
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>

							</tr>
							<tr style="min-height: 0pt">
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">ARTIVION, INC. | 2025 Proxy Statement</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">67</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 0pt; line-height: 0pt">&#8203;</p>

								</td>

							</tr>

						</table>

					</div>


				<!--[if IE]></TD></TR></TABLE><![endif]-->
				</div>

			</div>
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 45pt; left: 45pt; width: 675pt; position: absolute; height: 866.25pt">
				<p style="border-bottom: #7f7f7f 1pt solid; font: 12pt/normal Arial, sans-serif; margin: 0pt 0pt 15pt; text-transform: none; color: #2b4b74; text-indent: 0pt; text-align: left"><span style="text-transform: none"><b>CERTAIN BENEFICIAL OWNERSHIP</b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">The name and business address of each person or entity who beneficially owned more than 5% of the outstanding shares of common stock of Artivion on March 17, 2025, based on information available to us, together with the number of shares owned and the percentage of outstanding shares that ownership represents, is set forth in the following table. The table also shows information concerning beneficial ownership by the Named Executive Officers and by all current non-employee directors and officers as a group. The number of shares beneficially owned is determined under the rules of the SEC, and the information is not necessarily indicative of beneficial ownership for any other purpose. Under those rules, beneficial ownership includes any shares as to which the individual has sole or shared voting power or investment power and also</span><span style="text-transform: none; line-height: 12pt"> any shares that the individual has the right to acquire within 60&#160;days after March 17, 2025, through the exercise of any stock option or other right. Unless otherwise indicated, each person has sole investment and voting powers, or shares such powers with his or her spouse, with respect to the shares set forth in the following table. To Artivion&#8217;s knowledge, none of the shares shown in the table below are subject to a pledge or </span><span style="text-transform: none; line-height: 12pt">similar arrangement.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">The beneficial ownership percentages set forth in the table below are based on 42,689,303 shares of common stock issued and outstanding as of March </span><span style="text-transform: none; line-height: 12pt">17, 2025.</span></p>
				<div style="font: 10pt/normal Arial, sans-serif; margin: 0pt; text-transform: none; color: #000000; text-align: left">
					<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 0pt; border-collapse: collapse">
						<tr style="margin: 0; height: 0">
							<td style="border-width: 0; margin: 0; padding: 0; width: 350pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 152.5pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 172.5pt">


							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Beneficial Owner</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Number of Shares of<br/>Artivion Common Stock<br/>Beneficially Owned (#)</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Percentage of<br/>Outstanding Shares of<br/>Artivion Common<br/>Stock (%)</b></span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">J. Patrick Mackin</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">1,328,648</span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt">(1)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">3.1</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Lance A. Berry</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">152,576</span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt">(2)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">*</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Jean F. Holloway</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">285,155</span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt">(3)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">*</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">John E. Davis</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">287,652</span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt">(4)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">*</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Marshall S. Stanton</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">153,815</span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt">(5)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">*</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Thomas F. Ackerman</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">143,571</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">*</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Daniel J. Bevevino</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">143,736</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">*</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Marna P. Borgstrom</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">42,763</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">*</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">James W. Bullock</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">62,322</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">*</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Jeffrey H. Burbank</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">47,471</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">*</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Elizabeth A. Hoff</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">25,064</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">*</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Jon W. Salveson</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">123,515</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">*</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Anthony B. Semedo</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">36,259</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">*</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Blackrock, Inc.</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">6,514,785</span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt">(6)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">15.3</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Macquarie Group Limited</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">2,873,431</span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt">(7)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">6.7</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">The Vanguard Group, Inc.</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">2,630,873</span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt">(8)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">6.2</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Perceptive Advisors LLC</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">2,383,978</span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt">(9)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">5.6</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Morgan Stanley</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">2,375,713</span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt">(10)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">5.6</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">All current directors, Named Executive Officers, and other officers as a group (19 persons)</span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt">(12)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">3,266,079</span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt">(11)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">7.6</span></p>

							</td>

						</tr>

					</table>

				</div>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 8pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt; font-style: italic"><i>*</i></sup></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Ownership represents less than 1% of outstanding Artivion </span><span style="text-transform: none">common stock.</span></p>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 1pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(1) </sup></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Amount includes 555,160 options that are either presently exercisable or will become exercisable within 60 days after March 17, 2025. This amount also includes 274,812 shares of unvested restricted stock subject to forfeiture which Mr.&#160;Mackin holds as of March 17, 2025. This amount does not include 91,795 shares earned under 2023 and 2024 performance stock unit awards that had not vested as of March 17, 2025, and that will not vest within 60 </span><span style="text-transform: none">days thereafter.</span></p>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 1pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(2)</sup></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Amount includes 31,211 options that are either presently exercisable or will become exercisable within 60 days after March 17, 2025. This amount also includes 101,165 shares of unvested restricted stock subject to forfeiture which Mr.&#160;Berry holds as of March 17, 2025. This amount does not include 32,066 shares earned under 2023 and 2024 performance stock unit awards that had not vested as of March 17, 2025, and that will not vest within 60 </span><span style="text-transform: none">days thereafter.</span></p>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 8pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(3) </sup></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Amount includes 108,174 options that are either presently exercisable or will become exercisable within 60 days after March 17, 2025. This amount also includes 58,928 shares of unvested restricted stock subject to forfeiture which Ms. Holloway holds as of March 17, 2025. This amount does not include 20,203 shares earned under 2023 and 2024 performance stock unit awards that had not vested as of March 17, 2025, and that will not vest within 60 </span><span style="text-transform: none">days thereafter.</span></p>

			</div>

		</div>
		<div style="page-break-before: always">
			<p style="margin: 0pt; font-size: 5pt">&#8203;</p>

		</div>
		<div class="qes_page" style="border-bottom: black 2pt solid; margin: auto; height: 990pt; width: 765pt; position: relative; overflow: hidden">
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 911.25pt; left: 45pt; width: 675pt; position: absolute; height: 33.75pt">
				<div style="display: table-cell; vertical-align: bottom; width: 675pt; height: 33.75pt">

				<!--[if IE]><TABLE><TR style=" width: 675pt; height: 33.75pt;"><TD vAlign="bottom" style=" width: 675pt; height: 33.75pt;"><![endif]-->
					<div style="font: 12pt/normal Times New Roman, Times, serif; margin: 0pt; text-transform: none; color: #000000; text-align: left">
						<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 0pt; border-collapse: collapse">
							<tr style="margin: 0; height: 0">
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>

							</tr>
							<tr style="min-height: 0pt">
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">ARTIVION, INC. | 2025 Proxy Statement</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">68</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 0pt; line-height: 0pt">&#8203;</p>

								</td>

							</tr>

						</table>

					</div>


				<!--[if IE]></TD></TR></TABLE><![endif]-->
				</div>

			</div>
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 45pt; left: 45pt; width: 675pt; position: absolute; height: 866.25pt">
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 1pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(4) </sup></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Amount includes 99,160 options that are either presently exercisable or will become exercisable within 60 days after March 17, 2025. This amount also includes 59,760 shares of unvested restricted stock subject to forfeiture that Mr. Davis holds as of March 17, 2025. This amount does not include 20,286 shares earned under 2023 and 2024 performance stock unit awards that had not vested as of March 17, 2025, and that will not vest within 60 </span><span style="text-transform: none">days thereafter.</span></p>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 1pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(5)</sup><sup style="text-transform: none; font-size: 7pt; line-height: 7pt; font-style: italic"><i> </i></sup></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Amount includes 53,421 options that are either presently exercisable or will become exercisable within 60 days after March 17, 2025. This amount also includes 47,711 shares of unvested restricted stock subject to forfeiture that Mr. Stanton holds as of March 17, 2025. This amount does not include 15,486 shares earned under 2023 and 2024 performance stock unit awards that had not vested as of March 17, 2025, and that will not vest within 60 </span><span style="text-transform: none">days thereafter.</span></p>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 1pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(6)</sup><sup style="text-transform: none; font-size: 7pt; line-height: 7pt; font-style: italic"><i> </i></sup></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Information based on Schedule&#160;13G/A filed on November 8, 2024 by BlackRock, Inc. (&#8220;BlackRock&#8221;). Per this schedule, BlackRock has the sole power to vote, or to direct the vote of, and sole power to dispose, or to direct the disposition of, these shares of Artivion common stock. The address for BlackRock is BlackRock, Inc., 50 Hudson Yards, New York, New </span><span style="text-transform: none">York 10001.</span></p>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 1pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(7)</sup></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Information based on Schedule&#160;13G/A filed on February 14, 2024 by Macquarie Group Limited (&#8220;Macquarie&#8221;). Per this schedule, Macquarie has the power to vote, or to direct the vote of, and power to dispose, or to direct the disposition of, these shares of Artivion common stock. The address for Macquarie is Macquarie Group Limited, 50 Martin Place, Sydney, New South </span><span style="text-transform: none">Wales, Australia.</span></p>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 1pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(8) </sup></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Information based on Schedule&#160;13G/A filed on February 13, 2024 by The Vanguard Group, Inc. (&#8220;Vanguard&#8221;). Per this schedule, Vanguard has the power to vote, or to direct the vote of, and power to dispose, or to direct the disposition of, these shares of Artivion common stock. The address for Vanguard is The Vanguard Group, Inc., 100 Vanguard Blvd, Malvern, </span><span style="text-transform: none">Pennsylvania 19355.</span></p>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 1pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(9)</sup></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Information based on Schedule&#160;13G filed on March 11, 2024 by Perceptive Advisors LLC (&#8220;Perceptive Advisors&#8221;). Per this schedule, Perceptive Advisors has the power to vote, or to direct the vote of, and power to dispose, or to direct the disposition of, these shares of Artivion common stock. The address for Perceptive Advisors is 51 Astor Place, 10</span><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">th</sup><span style="text-transform: none"> Floor, New York, New </span><span style="text-transform: none">York 10003.</span></p>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 1pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(10)</sup></span><!--[if IE]></FONT><![endif]--><sup style="text-transform: none; font-size: 7pt; line-height: 7pt"></sup><span style="text-transform: none">Information based on Schedule&#160;13G/A filed on February 12, 2024 by Morgan Stanley. Per this schedule, Morgan Stanley has the power to vote, or to direct the vote of, and power to dispose, or to direct the disposition of, these shares of Artivion common stock. The address for Morgan Stanley is 1585 Broadway New York, New </span><span style="text-transform: none">York 10036.</span></p>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 0pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(11)</sup></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Amount includes:</span></p>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 0pt 15pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: justify"><span style="text-transform: none">1,032,902 options that are presently exercisable or will become exercisable within 60&#160;days after March </span><span style="text-transform: none">17, 2025;</span></p>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 0pt 15pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: justify"><span style="text-transform: none">4,731 shares held of record by the spouses or trusts of executive officers and </span><span style="text-transform: none">directors; and</span></p>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 0pt 15pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: justify"><span style="text-transform: none">738,766 shares of unvested restricted common stock subject to forfeiture that all current directors, NEOs, and other officers hold as a group as of March </span><span style="text-transform: none">17, 2025.</span></p>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 0pt 15pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: justify"><span style="text-transform: none">This amount does not include 231,899 shares earned under 2023 and 2024 performance stock unit awards that had not vested as of March 17, 2025, and that will not vest within 60 </span><span style="text-transform: none">days thereafter.</span></p>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 8pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(12)</sup></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">The business address for all Artivion non-employee directors and employees is: c/o Artivion,&#160;Inc., 1655 Roberts Boulevard, NW, Kennesaw, </span><span style="text-transform: none">Georgia 30144.</span></p>

			</div>

		</div>
		<div style="page-break-before: always">
			<p style="margin: 0pt; font-size: 5pt">&#8203;</p>

		</div>
		<div class="qes_page" style="border-bottom: black 2pt solid; margin: auto; height: 990pt; width: 765pt; position: relative; overflow: hidden">
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 911.25pt; left: 45pt; width: 675pt; position: absolute; height: 33.75pt">
				<div style="display: table-cell; vertical-align: bottom; width: 675pt; height: 33.75pt">

				<!--[if IE]><TABLE><TR style=" width: 675pt; height: 33.75pt;"><TD vAlign="bottom" style=" width: 675pt; height: 33.75pt;"><![endif]-->
					<div style="font: 12pt/normal Times New Roman, Times, serif; margin: 0pt; text-transform: none; color: #000000; text-align: left">
						<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 0pt; border-collapse: collapse">
							<tr style="margin: 0; height: 0">
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>

							</tr>
							<tr style="min-height: 0pt">
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">ARTIVION, INC. | 2025 Proxy Statement</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">69</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 0pt; line-height: 0pt">&#8203;</p>

								</td>

							</tr>

						</table>

					</div>


				<!--[if IE]></TD></TR></TABLE><![endif]-->
				</div>

			</div>
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 45pt; left: 45pt; width: 675pt; position: absolute; height: 879pt">
				<p style="border-bottom: #7f7f7f 1pt solid; font: 12pt/normal Arial, sans-serif; margin: 0pt 0pt 15pt; text-transform: none; color: #2b4b74; text-indent: 0pt; text-align: left"><span style="text-transform: none"><b>PROPOSAL THREE &#8211; RATIFICATION OF THE PRELIMINARY APPROVAL OF THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; font-size: 11pt; font-style: italic"><b><i>General Information</i></b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">The Audit Committee has preliminarily approved the appointment of Ernst &amp; Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, subject to the negotiation of fees and other terms for the 2025 engagement. The Board of Directors recommends that the Company&#8217;s stockholders ratify the preliminary approval of Ernst &amp; Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025. Representatives of Ernst &amp; Young LLP are expected to attend the 2025 Annual Meeting, and representatives of the firm will have the opportunity to make a statement at the meeting if they desire to do so and will be available to respond to </span><span style="text-transform: none; line-height: 12pt">appropriate questions.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">The submission of the preliminary approval of Ernst &amp; Young LLP for ratification by stockholders is not legally required; however, the Board of Directors believes that such submission is consistent with best practices in corporate governance and is an opportunity for stockholders to provide direct feedback to the Board of Directors on an important issue of corporate governance, the selection of our independent registered public accounting firm. If the stockholders do not ratify the approval of Ernst &amp; Young LLP, the preliminary selection of such firm as the independent registered public accounting firm for the Company will be reconsidered by the Audit Committee, provided that the Audit Committee retains sole authority with respect to all decisions regarding the engagement of the Company&#8217;s independent registered public accounting firm, including the decision as to whether or not the 2025 appointment will stand, regardless of whether the stockholders vote to ratify </span><span style="text-transform: none; line-height: 12pt">the approval.</span></p>
				<p style="font: italic 11pt/normal Arial, sans-serif; margin: 4pt 0pt 8pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><b><i>Fees Incurred for Work Performed by the Independent Registered Public Accounting Firm for Fiscal 2024 and Fiscal 2023</i></b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">The following table presents Ernst &amp; Young LLP&#8217;s professional service fees for the audit of the Company&#8217;s annual financial statements for fiscal years ending 2023 and 2024, as well as fees for other services rendered during </span><span style="text-transform: none; line-height: 12pt">those periods.</span></p>
				<div style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-align: center">
					<table style="margin: 4pt auto 10pt; table-layout: fixed; width: 322.5pt; border-collapse: collapse">
						<tr style="margin: 0; height: 0">
							<td style="border-width: 0; margin: 0; padding: 0; width: 134.99pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 93.75pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 93.75pt">


							</td>

						</tr>
						<tr style="min-height: 12.8pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>&#160;</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>2024</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>2023</b></span></p>

							</td>

						</tr>
						<tr style="min-height: 12.8pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Audit fees</span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt">(1)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">$2,905,739</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">$2,409,952</span></p>

							</td>

						</tr>
						<tr style="min-height: 12.8pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Audit-related fees</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>

						</tr>
						<tr style="min-height: 12.8pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Tax fees</span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt">(2)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">$20,000</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>

						</tr>
						<tr style="min-height: 12.8pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">All other fees</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">&#8212;</span></p>

							</td>

						</tr>
						<tr style="min-height: 12.8pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Total</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">$2,925,739</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">$2,409,952</span></p>

							</td>

						</tr>

					</table>

				</div>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 176.25pt 1pt 191.25pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(1) </sup></span><!--[if IE]></FONT><![endif]--><sup style="text-transform: none; font-size: 7pt; line-height: 7pt"></sup><span style="text-transform: none">Includes work performed for the audit of our annual consol</span><span style="text-transform: none">idated financial statements, the review of financial statements included in our quarterly Form&#160;10-Q reports, the audit of internal control over financial reporting, and the services that an independent auditor would customarily provide in connection with statutory requirements, regulatory filings, and similar engagements for the fiscal year, such as comfort letters, attest services, consents, and assistance with review of documents filed with </span><span style="text-transform: none">the SEC.</span></p>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 176.25pt 8pt 191.25pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(2)</sup></span><!--[if IE]></FONT><![endif]--><sup style="text-transform: none; font-size: 7pt; line-height: 7pt"></sup><span style="text-transform: none">Includes tax compliance and </span><span style="text-transform: none">reporting services.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">The Company&#8217;s Audit Committee approved all of the services described above. The Audit Committee has determined that the payments made to Ernst &amp; Young LLP for these services are compatible with maintaining such </span><span style="text-transform: none; line-height: 12pt">firm&#8217;s independence.</span></p>
				<p style="font: italic 11pt/normal Arial, sans-serif; margin: 4pt 0pt 8pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><b><i>Audit Committee&#8217;s Preapproval Policies and Procedures</i></b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">The Audit Committee has the sole authority to appoint or replace, compensate, and oversee the work of any independent registered public accounting firm, who must be, when required, a registered firm as defined by law whose purpose is the preparation or issuance of an audit report or related work. The independent registered public accounting firm&#8217;s reports and other communications are to be delivered directly to the Audit Committee, and the Audit Committee is responsible for the resolution of disagreements between management and the independent registered public accounting firm regarding financial reporting, if any. The Audit Committee annually evaluates the qualifications and performance of the independent registered public accounting firm, including those of its lead partner, and reports on such evaluation to the Board </span><span style="text-transform: none; line-height: 12pt">of Directors.</span></p>

			</div>

		</div>
		<div style="page-break-before: always">
			<p style="margin: 0pt; font-size: 5pt">&#8203;</p>

		</div>
		<div class="qes_page" style="border-bottom: black 2pt solid; margin: auto; height: 990pt; width: 765pt; position: relative; overflow: hidden">
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 911.25pt; left: 45pt; width: 675pt; position: absolute; height: 33.75pt">
				<div style="display: table-cell; vertical-align: bottom; width: 675pt; height: 33.75pt">

				<!--[if IE]><TABLE><TR style=" width: 675pt; height: 33.75pt;"><TD vAlign="bottom" style=" width: 675pt; height: 33.75pt;"><![endif]-->
					<div style="font: 12pt/normal Times New Roman, Times, serif; margin: 0pt; text-transform: none; color: #000000; text-align: left">
						<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 0pt; border-collapse: collapse">
							<tr style="margin: 0; height: 0">
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>

							</tr>
							<tr style="min-height: 0pt">
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">ARTIVION, INC. | 2025 Proxy Statement</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">70</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 0pt; line-height: 0pt">&#8203;</p>

								</td>

							</tr>

						</table>

					</div>


				<!--[if IE]></TD></TR></TABLE><![endif]-->
				</div>

			</div>
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 45pt; left: 45pt; width: 675pt; position: absolute; height: 866.25pt">
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">The Audit Committee preapproves all audit and non-audit services performed by the independent registered public accounting firm and all engagement fees and terms in connection therewith, except as otherwise permitted by federal law and regulations. To date, no services have been approved by the Audit Committee pursuant to 17 CFR 210.2-01(c)(7)(i)(C), which provides a limited exception to the requirement that services be approved in advance by the Audit Committee if certain conditions </span><span style="text-transform: none; line-height: 12pt">are met.</span></p>
				<p style="font: italic 11pt/normal Arial, sans-serif; margin: 4pt 0pt 8pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><b><i>Required Vote</i></b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">The votes cast &#8220;For&#8221; this proposal must constitute a majority of shares present, either in person or by proxy, and entitled to vote on this proposal. Abstentions will have the same effect as an &#8220;Against&#8221; vote. Because brokers and other nominees have discretionary authority to vote on the ratification, we do not expect any broker non-votes in connection with </span><span style="text-transform: none; line-height: 12pt">this item.</span></p>
				<p style="font: italic 11pt/normal Arial, sans-serif; margin: 4pt 0pt 8pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><b><i>The Board of Directors&#8217; Recommendation</i></b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 4pt 0pt 8pt; text-transform: uppercase; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: uppercase"><b>THE BOARD OF DIRECTORS RECOMMENDS THAT YOU VOTE &#8220;FOR&#8221; THE <br/>RATIFICATION OF The Preliminary approval of ERNST &amp; YOUNG LLP AS OUR <br/>INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM.</b></span></p>

			</div>

		</div>
		<div style="page-break-before: always">
			<p style="margin: 0pt; font-size: 5pt">&#8203;</p>

		</div>
		<div class="qes_page" style="border-bottom: black 2pt solid; margin: auto; height: 990pt; width: 765pt; position: relative; overflow: hidden">
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 911.25pt; left: 45pt; width: 675pt; position: absolute; height: 33.75pt">
				<div style="display: table-cell; vertical-align: bottom; width: 675pt; height: 33.75pt">

				<!--[if IE]><TABLE><TR style=" width: 675pt; height: 33.75pt;"><TD vAlign="bottom" style=" width: 675pt; height: 33.75pt;"><![endif]-->
					<div style="font: 12pt/normal Times New Roman, Times, serif; margin: 0pt; text-transform: none; color: #000000; text-align: left">
						<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 0pt; border-collapse: collapse">
							<tr style="margin: 0; height: 0">
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>

							</tr>
							<tr style="min-height: 0pt">
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">ARTIVION, INC. | 2025 Proxy Statement</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">71</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 0pt; line-height: 0pt">&#8203;</p>

								</td>

							</tr>

						</table>

					</div>


				<!--[if IE]></TD></TR></TABLE><![endif]-->
				</div>

			</div>
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 45pt; left: 45pt; width: 675pt; position: absolute; height: 866.25pt">
				<p style="border-bottom: #7f7f7f 1pt solid; font: 12pt/normal Arial, sans-serif; margin: 0pt 0pt 15pt; text-transform: none; color: #2b4b74; text-indent: 0pt; text-align: left"><span style="text-transform: none"><b>PROPOSAL FOUR &#8211; APPROVAL OF ADDITIONAL FUNDING OF 3,570,000 SHARES FOR THE AMENDED AND RESTATED ARTIVION, INC. 2020 EQUITY AND CASH INCENTIVE PLAN</b></span></p>
				<p style="font: italic 11pt/normal Arial, sans-serif; margin: 4pt 0pt 8pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><b><i>General Information</i></b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">The Amended and Restated Artivion, Inc. 2020 Equity and Cash Incentive Plan (the &#8220;ECIP&#8221;), attached hereto as Appendix B, is the governing vehicle through which the Company awards equity and cash incentive compensation to employees and non-employee directors. We are recommending that the stockholders approve additional funding of 3,570,000 shares for </span><span style="text-transform: none; line-height: 12pt">the ECIP.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">Our Board of Directors proposes the addition of 3,570,000 shares of authorized but unissued shares of our common stock (&#8220;Common Stock&#8221;) to the 874,696 shares currently remaining in the ECIP (2,675,000 shares of Common Stock were approved by stockholders in 2020 for the ECIP when the plan was created, and an additional 3,040,000 shares of Common Stock were approved by stockholders in 2023). The ECIP expires in May 2030, but we believe that there will be an insufficient number of shares remaining in the ECIP for the Company to make employees&#8217; and non-employee directors&#8217; annual equity grants in Q1 2026 if not replenished through </span><span style="text-transform: none; line-height: 12pt">this proposal.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">We believe that approval of the additional 3,570,000 shares to the ECIP is in the best interests of the Company and our stockholders because it will enable us to continue to grant equity-based compensation to our key employees, as well as our non-employee directors. Our Board of Directors believes that the achievement of long-term objectives and employee retention are fostered through equity awards that vest over time. By approving the addition of these shares to the ECIP, our stockholders will enable us to continue to offer competitive compensation packages that are linked to Common Stock performance and to continue recruiting and retaining highly qualified employees, including officers, and non-employee directors, through our long-term incentive plans, annual non-employee director grants, and through one-time equity grants (e.g., sign-on grants). Our Board of Directors further believes that, if this proposal is not approved, our ability to align the interests of key employees with stockholders through equity-based compensation will be compromised, which will impair our ability to achieve our business objectives, disrupt our compensation program, and impede our ability to recruit and retain high quality employees and directors. In addition, if we cannot offer equity compensation, we would have to increase our use of cash compensation, which could have an adverse impact on our operations and </span><span style="text-transform: none; line-height: 12pt">business plans.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">In advising stockholders to vote for this proposal, the Board of Directors and the Compensation Committee, in consultation with management and Willis Towers Watson, the Compensation Committee&#8217;s independent compensation advisory firm, considered many factors, including stockholder support at the 2020 annual meeting for the ECIP, including the addition of 2,675,000 shares into the plan, stockholder support at the 2023 annual meeting for an additional 3,040,000 shares for the ECIP, the remaining shares available for grant under the ECIP, the number of previously awarded shares, options, and other awards outstanding under the ECIP, our equity utilization rates, our compensation program design, the Compensation Committee&#8217;s Compensation Philosophy, and our business plans and operations. In addition, our Board and the Compensation Committee believe this proposal is reasonable when compared to peer group practices, stockholder viewpoints, and proxy advisory firm guidelines. The Board and the Compensation Committee also believe that the funding level will ensure we have the means to provide competitive long-term incentive compensation to retain key employees, attract new talent, and further align the interests of equity recipients with those </span><span style="text-transform: none; line-height: 12pt">of stockholders.</span></p>
				<p style="font: italic 11pt/normal Arial, sans-serif; margin: 4pt 0pt 8pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><b><i>Material Differences Following Amendment of the ECIP</i></b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">Following stockholder approval of this Proposal Four, the only material difference to the ECIP will be an increase in the total number of authorized shares under the ECIP from 5,715,000 shares to 9,285,000 shares. In all other material respects, the terms of the ECIP will remain </span><span style="text-transform: none; line-height: 12pt">the same.</span></p>

			</div>

		</div>
		<div style="page-break-before: always">
			<p style="margin: 0pt; font-size: 5pt">&#8203;</p>

		</div>
		<div class="qes_page" style="border-bottom: black 2pt solid; margin: auto; height: 990pt; width: 765pt; position: relative; overflow: hidden">
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 911.25pt; left: 45pt; width: 675pt; position: absolute; height: 33.75pt">
				<div style="display: table-cell; vertical-align: bottom; width: 675pt; height: 33.75pt">

				<!--[if IE]><TABLE><TR style=" width: 675pt; height: 33.75pt;"><TD vAlign="bottom" style=" width: 675pt; height: 33.75pt;"><![endif]-->
					<div style="font: 12pt/normal Times New Roman, Times, serif; margin: 0pt; text-transform: none; color: #000000; text-align: left">
						<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 0pt; border-collapse: collapse">
							<tr style="margin: 0; height: 0">
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>

							</tr>
							<tr style="min-height: 0pt">
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">ARTIVION, INC. | 2025 Proxy Statement</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">72</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 0pt; line-height: 0pt">&#8203;</p>

								</td>

							</tr>

						</table>

					</div>


				<!--[if IE]></TD></TR></TABLE><![endif]-->
				</div>

			</div>
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 45pt; left: 45pt; width: 675pt; position: absolute; height: 866.25pt">
				<p style="font: italic 11pt/normal Arial, sans-serif; margin: 0pt 0pt 8pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><b><i>Key Terms of the ECIP</i></b></span></p>
				<div style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-align: justify">
					<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 10pt; border-collapse: collapse">
						<tr style="margin: 0; height: 0">
							<td style="border-width: 0; margin: 0; padding: 0; width: 300pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 15pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 360pt">


							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 3pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><i>Plan Term</i></span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 3pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">10 years, or until May 20, 2030</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 3pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><i>Eligible Participants</i></span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 3pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">All non-employee directors and employees (including consultants and agents) of the Company or its subsidiaries who are selected by the Compensation Committee. As of March 17, 2025 the approximate number of non-employee directors, employees, consultants, and agents who are eligible to participate in the ECIP is 8, 371, 0, and 0, respectively</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 3pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><i>Shares Authorized</i></span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 3pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">9,285,000 shares following approval of 3,570,000 share increase</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 3pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><i>Maximum Additional Shares Authorized as a Percent of Outstanding Shares (as of March 17, 2025)</i></span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 3pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Approximately 8.4% (10.4% including the remaining shares in the plan)</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 3pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><i>Award Types</i></span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 3pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Options (Incentive Stock Options and Non-Qualified Options), Stock Appreciation Rights, Stock Unit Awards, Restricted Stock Awards, Restricted Stock Unit Awards, Performance Share Awards, and Cash-Based Awards</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 3pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><i>Individual Share Limits</i></span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 3pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 4pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">The maximum number of Options and/or SARs granted in a given fiscal year is 800,000 for any employee and 75,000 for any non-employee director; and</span></p>
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 0; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">The maximum number of awards other than Options and/or SARs granted in a given fiscal year is 500,000 for any employee and 500,000 for any non-employee director</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 3pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><i>Individual Cash-Based Award Limits</i></span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 3pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">The maximum dollar amount that may be covered by all Cash-Based Awards granted to any individual during any fiscal year under the Plan is $2 million for employees and $500,000 for non-employee directors</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 3pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><i>Vesting Period</i></span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 3pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 4pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Determined by the Compensation Committee, but no less than 12 months from date of grant,</span></p>
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 4pt 22.5pt; text-transform: none; color: #000000; text-indent: -22.5pt; text-align: justify"><!--[if IE]><FONT style=" width: 22.5pt; text-indent: -18.0pt; display: inline-block;"><![endif]--><span style="width: 22.5pt; text-indent: 0; display: inline-block"><span style="text-transform: none">&#8226;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">except for the Compensation Committee&#8217;s discretion to provide for accelerated vesting or exercisability in connection with death, disability, retirement, or certain change of control </span><span style="text-transform: none">events, and</span></p>
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 0 22.5pt; text-transform: none; color: #000000; text-indent: -22.5pt; text-align: justify"><!--[if IE]><FONT style=" width: 22.5pt; text-indent: -18.0pt; display: inline-block;"><![endif]--><span style="width: 22.5pt; text-indent: 0; display: inline-block"><span style="text-transform: none">&#8226;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">except that up to five percent (5%) of the aggregate number of shares of Stock authorized for issuance under the Plan can become vested or exercisable without regard to service or 12-month </span><span style="text-transform: none">vesting requirements</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 3pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><i>Stock Option Exercise Period</i></span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 3pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Determined by the Compensation Committee, but no more than seven years from the date of grant</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 3pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><i>Stock Option Exercise Price</i></span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 3pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Not less than the fair market value on date of grant, defined as the closing price on the NYSE on the day of the grant</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 3pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><i>Prohibited</i></span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 3pt 0pt; background-color: #dfe4ea; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 4pt 22.5pt; text-transform: none; color: #000000; text-indent: -22.5pt; text-align: justify"><!--[if IE]><FONT style=" width: 22.5pt; text-indent: -18.0pt; display: inline-block;"><![endif]--><span style="width: 22.5pt; text-indent: 0; display: inline-block"><span style="text-transform: none">&#8226;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Repricing without </span><span style="text-transform: none">stockholder approval,</span></p>
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 4pt 22.5pt; text-transform: none; color: #000000; text-indent: -22.5pt; text-align: justify"><!--[if IE]><FONT style=" width: 22.5pt; text-indent: -18.0pt; display: inline-block;"><![endif]--><span style="width: 22.5pt; text-indent: 0; display: inline-block"><span style="text-transform: none">&#8226;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Reload options,</span></p>
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 4pt 22.5pt; text-transform: none; color: #000000; text-indent: -22.5pt; text-align: justify"><!--[if IE]><FONT style=" width: 22.5pt; text-indent: -18.0pt; display: inline-block;"><![endif]--><span style="width: 22.5pt; text-indent: 0; display: inline-block"><span style="text-transform: none">&#8226;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Acceleration of payment or vesting of any award other than for death, disability, retirement, or change in </span><span style="text-transform: none">control, or</span></p>
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 0 22.5pt; text-transform: none; color: #000000; text-indent: -22.5pt; text-align: justify"><!--[if IE]><FONT style=" width: 22.5pt; text-indent: -18.0pt; display: inline-block;"><![endif]--><span style="width: 22.5pt; text-indent: 0; display: inline-block"><span style="text-transform: none">&#8226;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">Dividend and Dividend Equivalents on Options </span><span style="text-transform: none">and SARs</span></p>

							</td>

						</tr>

					</table>

				</div>

			</div>

		</div>
		<div style="page-break-before: always">
			<p style="margin: 0pt; font-size: 5pt">&#8203;</p>

		</div>
		<div class="qes_page" style="border-bottom: black 2pt solid; margin: auto; height: 990pt; width: 765pt; position: relative; overflow: hidden">
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 911.25pt; left: 45pt; width: 675pt; position: absolute; height: 33.75pt">
				<div style="display: table-cell; vertical-align: bottom; width: 675pt; height: 33.75pt">

				<!--[if IE]><TABLE><TR style=" width: 675pt; height: 33.75pt;"><TD vAlign="bottom" style=" width: 675pt; height: 33.75pt;"><![endif]-->
					<div style="font: 12pt/normal Times New Roman, Times, serif; margin: 0pt; text-transform: none; color: #000000; text-align: left">
						<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 0pt; border-collapse: collapse">
							<tr style="margin: 0; height: 0">
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>

							</tr>
							<tr style="min-height: 0pt">
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">ARTIVION, INC. | 2025 Proxy Statement</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">73</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 0pt; line-height: 0pt">&#8203;</p>

								</td>

							</tr>

						</table>

					</div>


				<!--[if IE]></TD></TR></TABLE><![endif]-->
				</div>

			</div>
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 45pt; left: 45pt; width: 675pt; position: absolute; height: 883.13pt">
				<p style="font: italic 11pt/normal Arial, sans-serif; margin: 0pt 0pt 8pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><b><i>Current Awards Outstanding</i></b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 8pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">Set forth below is information regarding shares currently outstanding under the ECIP, as well as the shares remaining for grant under the ECIP. The Company made the final portion of its annual equity grants to employees on February 28, 2025, and those awards are included in the </span><span style="text-transform: none; line-height: 12pt">below data.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 8pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">Selected Data as of March </span><span style="text-transform: none; line-height: 12pt">17, 2025:</span></p>
				<div style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-align: center">
					<table style="margin: 4pt auto 10pt; table-layout: fixed; width: 540pt; border-collapse: collapse">
						<tr style="margin: 0; height: 0">
							<td style="border-width: 0; margin: 0; padding: 0; width: 465pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 75pt">


							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Stock Options outstanding</span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt">(1)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">1,455,909</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Weighted average exercise price of Options outstanding</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">$18.05</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Weighted average remaining contractual life of Options outstanding</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">3.71 years</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0pt 22.5pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Share Awards Outstanding</span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt">(2)</sup></p>
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 0pt 22.5pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Restricted Share Awards outstanding</span></p>
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 0pt 22.5pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Restricted Share Units outstanding</span></p>
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 0 22.5pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Performance Share Units outstanding (at target performance)</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">1,774,031</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Shares remaining for grant under the ECIP</span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt">(3)</sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">874,696</span></p>

							</td>

						</tr>

					</table>

				</div>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 71.25pt 1pt 75pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(1)</sup></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">No stock options outstanding have Dividend </span><span style="text-transform: none">Equivalent Rights.</span></p>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 71.25pt 1pt 75pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(2)</sup></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">RSAs, RSUs, and PSUs are all included in the total number of Share Awards Outstanding. RSAs are included because they have not vested, even though ownership rights, such as voting, have transferred. PSUs are counted </span><span style="text-transform: none">at target.</span></p>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 71.25pt 8pt 75pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(3)</sup></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none">This number does not include 664,049 shares available under the Employee Stock Purchase Plan. Under the ECIP, stock-based awards are granted from a pool of available shares, with stock options counting as 1 share and restricted shares, performance shares, and restricted share units (full</span><span style="text-transform: none"> value awards) counting as 1.5 shares. Artivion has no equity plans with outstanding awards other than </span><span style="text-transform: none">the ECIP.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 6pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: left"><span style="text-transform: none; line-height: 12pt">For additional information regarding stock-based awards previously granted, please see the Company&#8217;s consolidated financial statements in the Company&#8217;s Annual Report on Form 10-K for the year ended December </span><span style="text-transform: none; line-height: 12pt">31, 2024.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 6pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">Outstanding awards and shares available for future grants under the ECIP (&#8220;overhang&#8221;) total 4,104,636 and represent 9.6% of our 42,689,303 outstanding shares of Common Stock, as of the proxy record date. If the additional shares are approved by our stockholders, the additional 3,570,000 shares under the plan would increase our overhang at such time </span><span style="text-transform: none; line-height: 12pt">to 18.0%.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 6pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">For the number of securities authorized for issuance under all equity compensation plans as of December 31, 2024, </span><span style="text-transform: none; line-height: 12pt; font-style: italic"><i>see</i></span><span style="text-transform: none; line-height: 12pt"> table </span><span style="text-transform: none; line-height: 12pt; font-style: italic"><i>Securities Authorized for Issuance Under All Equity Compensation Plans</i></span><span style="text-transform: none; line-height: 12pt"> at </span><span style="text-transform: none; line-height: 12pt">page 59.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 6pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">Based on the factors considered by our Board of Directors, we estimate that the 874,696 shares available for grant under</span><span style="text-transform: none; color: #ff0000; line-height: 12pt"> </span><span style="text-transform: none; line-height: 12pt">the ECIP as of March&#160;17, 2025 (the record date), plus the addition of 3,570,000 shares, will provide a sufficient number of shares to enable us to continue to make equity grants the Board of Directors believes are necessary to best achieve corporate goals for at least </span><span style="text-transform: none; line-height: 12pt">two-to-three years.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 6pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">Because of the discretionary nature of any future awards under the ECIP, the amount of such awards is not determinable at this time with respect to the Company&#8217;s non-employee directors, executive officers (including the Named Executive Officers), or the Company&#8217;s other employees. Information regarding bonus opportunities, options, and restricted stock units granted in fiscal 2024 to certain executive officers of the Company under the Company&#8217;s existing plans is set forth in the table captioned </span><span style="text-transform: none; line-height: 12pt; font-style: italic"><i>Grants of Plan-Based Awards </i></span><span style="text-transform: none; line-height: 12pt">at page 45, and information regarding outstanding Options and restricted stock under those plans is set forth in the table captioned </span><span style="text-transform: none; line-height: 12pt; font-style: italic"><i>Outstanding Equity Awards on December&#160;31, 2024</i></span><span style="text-transform: none; line-height: 12pt"> at page 47. Information regarding restricted stock granted in fiscal 2024 to the Company&#8217;s non-employee directors pursuant to the ECIP is set forth under </span><span style="text-transform: none; line-height: 12pt; font-style: italic"><i>Fiscal 2024 Director Compensation</i></span><span style="text-transform: none; line-height: 12pt"> at </span><span style="text-transform: none; line-height: 12pt">page 22.</span></p>
				<p style="font: italic 11pt/normal Arial, sans-serif; margin: 4pt 0pt 8pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><b><i>Required Vote</i></b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">The votes cast &#8220;For&#8221; this proposal must constitute a majority of shares present, either in person or by proxy, and entitled to vote on this proposal. Abstentions will have the same effect as an &#8220;Against&#8221; vote. Broker non-votes will have no effect on the outcome of </span><span style="text-transform: none; line-height: 12pt">this proposal.</span></p>
				<p style="font: italic 11pt/normal Arial, sans-serif; margin: 4pt 0pt 8pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><b><i>The Board of Directors&#8217; Recommendation</i></b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 4pt 0pt 8pt; text-transform: uppercase; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: uppercase"><b>THE BOARD OF DIRECTORS RECOMMENDS THAT YOU VOTE &#8220;FOR&#8221; THE APPROVAL OF <br/>ADDITIONAL FUNDING OF 3,570,000 SHARES FOR THE Amended and Restated ARTIVION, INC. <br/>2020 EQUITY AND CASH INCENTIVE PLAN.</b></span></p>

			</div>

		</div>
		<div style="page-break-before: always">
			<p style="margin: 0pt; font-size: 5pt">&#8203;</p>

		</div>
		<div class="qes_page" style="border-bottom: black 2pt solid; margin: auto; height: 990pt; width: 765pt; position: relative; overflow: hidden">
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 911.25pt; left: 45pt; width: 675pt; position: absolute; height: 33.75pt">
				<div style="display: table-cell; vertical-align: bottom; width: 675pt; height: 33.75pt">

				<!--[if IE]><TABLE><TR style=" width: 675pt; height: 33.75pt;"><TD vAlign="bottom" style=" width: 675pt; height: 33.75pt;"><![endif]-->
					<div style="font: 12pt/normal Times New Roman, Times, serif; margin: 0pt; text-transform: none; color: #000000; text-align: left">
						<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 0pt; border-collapse: collapse">
							<tr style="margin: 0; height: 0">
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>

							</tr>
							<tr style="min-height: 0pt">
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">ARTIVION, INC. | 2025 Proxy Statement</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">74</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 0pt; line-height: 0pt">&#8203;</p>

								</td>

							</tr>

						</table>

					</div>


				<!--[if IE]></TD></TR></TABLE><![endif]-->
				</div>

			</div>
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 45pt; left: 45pt; width: 675pt; position: absolute; height: 866.25pt">
				<p style="border-bottom: #7f7f7f 1pt solid; font: 12pt/normal Arial, sans-serif; margin: 0pt 0pt 15pt; text-transform: none; color: #2b4b74; text-indent: 0pt; text-align: left"><span style="text-transform: uppercase"><b>Householding</b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">For those stockholders who request paper copies of the Proxy documents and share the same last name and address, they may receive only one copy of our Annual Report and Proxy Statement, unless we receive contrary instructions from any stockholder at that address. This is referred to as &#8220;householding.&#8221; If you are receiving only one copy of the Annual Report and Proxy Statement and prefer to receive multiple copies, additional copies will be provided to you promptly upon written or oral request. All communications should be directed as indicated on the instructions that were included on the notice mailing or to Jean F. Holloway, General Counsel and Corporate Secretary, Artivion, Inc., 1655 Roberts Boulevard, NW, Kennesaw, Georgia 30144, </span><span style="text-transform: none; line-height: 12pt">(770) 419-3355.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">If you are a beneficial owner, you can request additional copies of the Annual Report and Proxy Statement, or you can request householding by notifying your broker, bank, </span><span style="text-transform: none; line-height: 12pt">or nominee.</span></p>
				<p style="border-bottom: #7f7f7f 1pt solid; font: 12pt/normal Arial, sans-serif; margin: 4pt 0pt 15pt; text-transform: none; color: #2b4b74; text-indent: 0pt; text-align: left"><span style="text-transform: none"><b>TRANSACTION OF OTHER BUSINESS</b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">As of the date of this Proxy Statement, the Board of Directors is not aware of any matters other than those set forth herein and in the Notice of Annual Meeting of Stockholders that will come before the meeting. Should any other matters arise requiring the vote of stockholders, it is intended that proxies will be voted in respect thereto in accordance with the best judgment of the person or persons voting </span><span style="text-transform: none; line-height: 12pt">the proxies.</span></p>
				<p style="border-bottom: #7f7f7f 1pt solid; font: 12pt/normal Arial, sans-serif; margin: 4pt 0pt 15pt; text-transform: none; color: #2b4b74; text-indent: 0pt; text-align: left"><span style="text-transform: none"><b>WHERE YOU CAN FIND ADDITIONAL INFORMATION</b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">Upon the written request of any record or beneficial owner of common stock of Artivion whose proxy was solicited in connection with the 2025 Annual Meeting, Artivion will furnish such owner, without charge, a copy of its Annual Report on Form&#160;10-K without exhibits for its fiscal year ended December&#160;31, 2024. Requests for a copy of such Annual Report on Form&#160;10-K should be addressed to Jean F. Holloway, General Counsel and Corporate Secretary, Artivion,&#160;Inc., 1655 Roberts Boulevard, NW, Kennesaw, Georgia 30144. Copies of this Proxy Statement and our Annual Report on Form 10-K for the year ended December 31, 2024, may also be obtained without charge through the SEC&#8217;s website </span><span style="text-transform: none; line-height: 12pt">at </span><span style="text-decoration: underline; text-transform: none; line-height: 12pt"><span style="text-decoration: underline">www.sec.gov</span></span><span style="text-transform: none; line-height: 12pt">.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">In addition, we file annual, quarterly, and current reports, proxy statements, and other information with the SEC. You may read and copy any document we file with the SEC at the SEC&#8217;s Public Reference Room located at 100 F Street, NE, Washington, D.C. 20549. You may call the SEC at 1-800-SEC-0330 for further information about the SEC&#8217;s public reference rooms. Our SEC filings are also available to the public at the SEC&#8217;s website at </span><span style="text-decoration: underline; text-transform: none; line-height: 12pt"><span style="text-decoration: underline">www.sec.gov</span></span><span style="text-transform: none; line-height: 12pt"> and through our website </span><span style="text-transform: none; line-height: 12pt">at </span><span style="text-decoration: underline; text-transform: none; line-height: 12pt"><span style="text-decoration: underline">https://investors.artivion.com/</span></span><span style="text-transform: none; line-height: 12pt">.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">It is important that proxies be voted promptly. Stockholders who do not expect to attend the meeting in person are urged to vote their proxies online, by telephone, or by mail, following the instructions at the beginning of this </span><span style="text-transform: none; line-height: 12pt">Proxy Statement.</span></p>
				<div style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-align: justify">
					<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 6pt; border-collapse: collapse">
						<tr style="margin: 0; height: 0">
							<td style="border-width: 0; margin: 0; padding: 0; width: 337.5pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 337.5pt">


							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 2pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">By Order of the Board of Directors:</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 2pt 0pt; vertical-align: top; border-collapse: collapse">
								<div style="font: 10pt/normal Arial, sans-serif; margin: 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left">
									<div style="border-width: 0pt; padding: 0pt; overflow: hidden; display: inline-block; width: 139.75pt; height: 39.02pt; text-align: left">
										<img src="art-def14a_051325img002.gif" alt="" style="vertical-align: top; margin-left: 0pt; width: 140pt; margin-top: 0pt; height: 38.75pt"/>

									</div>

								</div>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 2pt 0pt; vertical-align: top; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none"> J. PATRICK MACKIN<br/> Chairman, President, and Chief Executive Officer</span></p>

							</td>

						</tr>

					</table>

				</div>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: justify"><span style="text-transform: none">Date: April </span><span style="text-transform: none">1, 2025</span></p>

			</div>

		</div>
		<div style="page-break-before: always">
			<p style="margin: 0pt; font-size: 5pt">&#8203;</p>

		</div>
		<div class="qes_page" style="border-bottom: black 2pt solid; margin: auto; height: 990pt; width: 765pt; position: relative; overflow: hidden">
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 911.25pt; left: 45pt; width: 675pt; position: absolute; height: 33.75pt">
				<div style="display: table-cell; vertical-align: bottom; width: 675pt; height: 33.75pt">

				<!--[if IE]><TABLE><TR style=" width: 675pt; height: 33.75pt;"><TD vAlign="bottom" style=" width: 675pt; height: 33.75pt;"><![endif]-->
					<div style="font: 12pt/normal Times New Roman, Times, serif; margin: 0pt; text-transform: none; color: #000000; text-align: left">
						<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 0pt; border-collapse: collapse">
							<tr style="margin: 0; height: 0">
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>

							</tr>
							<tr style="min-height: 0pt">
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">ARTIVION, INC. | 2025 Proxy Statement</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">A-1</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 0pt; line-height: 0pt">&#8203;</p>

								</td>

							</tr>

						</table>

					</div>


				<!--[if IE]></TD></TR></TABLE><![endif]-->
				</div>

			</div>
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 45pt; left: 45pt; width: 675pt; position: absolute; height: 866.25pt">
				<p style="border-bottom: #7f7f7f 1pt solid; font: 12pt/normal Arial, sans-serif; margin: 0pt 0pt 15pt; text-transform: none; color: #2b4b74; text-indent: 0pt; text-align: left"><span style="text-transform: none"><b>APPENDIX A &#8211; NON-GAAP FINANCIAL MEASURE INFORMATION AND RECONCILIATION AND IMPACTS RELATED TO THE CYBERSECURITY INCIDENT</b></span></p>
				<p style="font: italic 11pt/normal Arial, sans-serif; margin: 4pt 0pt 8pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><b><i>Non-GAAP Financial Measure Information and Reconciliation</i></b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">The 2024 annual Cash Bonus and Annual Equity Grant were awarded based, in part, on the achievement of pre-determined levels of constant currency revenue growth and adjusted EBITDA. The use of these non-GAAP adjusted performance measures was intended to create a stronger performance incentive by focusing on controllable variables within the core business and to minimize unintended consequences by excluding items that were highly variable or difficult to predict during the </span><span style="text-transform: none; line-height: 12pt">goal-setting process.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">The table below provides a reconciliation of 2024 net loss under GAAP to 2024 adjusted </span><span style="text-transform: none; line-height: 12pt">EBITDA, non-GAAP:</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 4pt 0pt 8pt; text-transform: uppercase; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-style: italic"><b><i>2024 Adjusted EBITDA Reconciliation (in thousands)</i></b></span></p>
				<div style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-align: center">
					<table style="margin: 4pt auto 10pt; table-layout: fixed; width: 487.49pt; border-collapse: collapse">
						<tr style="margin: 0; height: 0">
							<td style="border-width: 0; margin: 0; padding: 0; width: 408.74pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 11.25pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 54.31pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 13.18pt">


							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none"><b>2024 Net loss, GAAP</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none"><b>$</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none"><b>(13,359</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none"><b>)</b></span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Interest expense</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">34,277</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Interest income</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">(1,467</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">)</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Income tax expense</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">5,845</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Depreciation and amortization expense</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">24,205</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Non-cash compensation</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">14,242</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Business development, integration, and severance income</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">(6,102</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">)</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Loss on extinguishment of debt</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">3,669</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Cybersecurity incident</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">4,583</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Loss on foreign currency revaluation</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none"> </span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">5,369</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none"><b>2024 Adjusted EBITDA, non-GAAP</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none"><b>$</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none"><b>71,262</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>

						</tr>

					</table>

				</div>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">The table below provides a reconciliation of GAAP to </span><span style="text-transform: none; line-height: 12pt">non-GAAP revenues:</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 4pt 0pt 8pt; text-transform: uppercase; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-style: italic"><b><i>Reconciliation of GAAP to Non-GAAP Revenues (in thousands)</i></b></span></p>
				<div style="font: 10pt/normal Arial, sans-serif; margin: 4pt 0pt 8pt; text-transform: uppercase; color: #000000; text-align: left">
					<table style="table-layout: fixed; width: 676.25pt; margin-top: 8pt; margin-bottom: 8pt; border-collapse: collapse">
						<tr style="margin: 0; height: 0">
							<td style="border-width: 0; margin: 0; padding: 0; width: 391.25pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 60pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 15pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 60pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 15pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 60pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 15pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 60pt">


							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>2024</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td colspan="5" style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>2023</b></span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>US GAAP</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>US GAAP</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Exchange Rate Effect</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Constant Currency</b></span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Aortic stent grafts</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">123,081</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">107,469</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">1,052</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">108,521</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">On-X</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">83,982</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">74,528</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">(8</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">)</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">74,520</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Surgical sealants</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">73,898</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">68,016</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">39</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">68,055</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Other</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">9,269</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">11,172</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">8</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">11,180</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Preservation services</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">98,307</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">92,819</span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">(34</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">)</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">92,785</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none"><b>Total</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none"><b>388,537</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none"><b>354,004</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none"><b>1,057</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none"><b>355,061</b></span></p>

							</td>

						</tr>

					</table>

				</div>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">These numbers are intended to be, and should be, evaluated in the context of the full information provided in our Annual Report on Form 10-K, including the financial statements presented in accordance with GAAP, the footnotes thereto, and the accompanying management&#8217;s discussion and analysis, as well as in our other filings with </span><span style="text-transform: none; line-height: 12pt">the SEC.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">The methods used by the Company to calculate these non-GAAP financial measures may differ significantly from methods used by other companies to compute similar measures. As a result, any non-GAAP financial measure presented herein may not be comparable to similar measures provided by </span><span style="text-transform: none; line-height: 12pt">other companies.</span></p>

			</div>

		</div>
		<div style="page-break-before: always">
			<p style="margin: 0pt; font-size: 5pt">&#8203;</p>

		</div>
		<div class="qes_page" style="border-bottom: black 2pt solid; margin: auto; height: 990pt; width: 765pt; position: relative; overflow: hidden">
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 911.25pt; left: 45pt; width: 675pt; position: absolute; height: 33.75pt">
				<div style="display: table-cell; vertical-align: bottom; width: 675pt; height: 33.75pt">

				<!--[if IE]><TABLE><TR style=" width: 675pt; height: 33.75pt;"><TD vAlign="bottom" style=" width: 675pt; height: 33.75pt;"><![endif]-->
					<div style="font: 12pt/normal Times New Roman, Times, serif; margin: 0pt; text-transform: none; color: #000000; text-align: left">
						<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 0pt; border-collapse: collapse">
							<tr style="margin: 0; height: 0">
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>

							</tr>
							<tr style="min-height: 0pt">
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">ARTIVION, INC. | 2025 Proxy Statement</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">A-2</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 0pt; line-height: 0pt">&#8203;</p>

								</td>

							</tr>

						</table>

					</div>


				<!--[if IE]></TD></TR></TABLE><![endif]-->
				</div>

			</div>
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 45pt; left: 45pt; width: 675pt; position: absolute; height: 866.25pt">
				<p style="font: italic 11pt/normal Arial, sans-serif; margin: 0pt 0pt 8pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><b><i>Impacts Related to the Cybersecurity Incident</i></b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">As explained above in the Compensation Discussion and Analysis, the Company&#8217;s Compensation Committee determined that, but for the Cybersecurity Incident, the Company&#8217;s 2024 proforma revenue likely would have been $393.1 million (10.7% constant currency growth), and its adjusted proforma EBITDA likely would have been $73.9 million (37% growth), as opposed to the Company&#8217;s actual results of $388.5 million in revenue (9.4% constant currency growth) and adjusted EBITDA of $71.3 million (32% growth). The table below provides additional detail regarding the impact of the Cybersecurity In</span><span style="text-transform: none; line-height: 12pt">cident on the Company&#8217;s revenues and </span><span style="text-transform: none; line-height: 12pt">adjusted EBITDA.</span></p>
				<div style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-align: center">
					<table style="margin: 4pt auto 10pt; table-layout: fixed; width: 435pt; border-collapse: collapse">
						<tr style="margin: 0; height: 0">
							<td style="border-width: 0; margin: 0; padding: 0; width: 255pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 90pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 90pt">


							</td>

						</tr>
						<tr style="min-height: 13pt">
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 11pt; line-height: 11pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Revenue</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Adj. EBITDA</b></span></p>

							</td>

						</tr>
						<tr style="min-height: 10.75pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none"><b>Actual</b></span></p>
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 0; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><b><i>Constant Currency Growth Rate</i></b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>$389M</b></span></p>
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 0; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-style: italic"><b><i>9.4% CC</i></b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>$71M</b></span></p>
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 0; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-style: italic"><b><i>32%</i></b></span></p>

							</td>

						</tr>
						<tr style="min-height: 12.5pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none"><b>Impacts from Cybersecurity Incident:</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 10.5pt; line-height: 10.5pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 10.5pt; line-height: 10.5pt">&#8203;</p>

							</td>

						</tr>
						<tr style="min-height: 12.5pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Orders prepared, not shipped</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">$1M</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">$0.5M</span></p>

							</td>

						</tr>
						<tr style="min-height: 12.5pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Product availability delays due to manual workarounds</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">$3.5M</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">$2M</span></p>

							</td>

						</tr>
						<tr style="min-height: 12.5pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none"><b>Excluding Cybersecurity Incident</b></span></p>
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 0; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><b><i>Constant Currency Growth Rate</i></b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>$393M</b></span></p>
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 0; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-style: italic"><b><i>10.7% CC</i></b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>$74M</b></span></p>
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 0; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-style: italic"><b><i>37%</i></b></span></p>

							</td>

						</tr>

					</table>

				</div>

			</div>

		</div>
		<div style="page-break-before: always">
			<p style="margin: 0pt; font-size: 5pt">&#8203;</p>

		</div>
		<div class="qes_page" style="border-bottom: black 2pt solid; margin: auto; height: 990pt; width: 765pt; position: relative; overflow: hidden">
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 911.25pt; left: 45pt; width: 675pt; position: absolute; height: 33.75pt">
				<div style="display: table-cell; vertical-align: bottom; width: 675pt; height: 33.75pt">

				<!--[if IE]><TABLE><TR style=" width: 675pt; height: 33.75pt;"><TD vAlign="bottom" style=" width: 675pt; height: 33.75pt;"><![endif]-->
					<div style="font: 12pt/normal Times New Roman, Times, serif; margin: 0pt; text-transform: none; color: #000000; text-align: left">
						<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 0pt; border-collapse: collapse">
							<tr style="margin: 0; height: 0">
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>

							</tr>
							<tr style="min-height: 0pt">
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">ARTIVION, INC. | 2025 Proxy Statement</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">B-1</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 0pt; line-height: 0pt">&#8203;</p>

								</td>

							</tr>

						</table>

					</div>


				<!--[if IE]></TD></TR></TABLE><![endif]-->
				</div>

			</div>
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 45pt; left: 45pt; width: 675pt; position: absolute; height: 866.25pt">
				<p style="border-bottom: #7f7f7f 1pt solid; font: 12pt/normal Arial, sans-serif; margin: 0pt 0pt 15pt; text-transform: none; color: #2b4b74; text-indent: 0pt; text-align: left"><span style="text-transform: none"><b>APPENDIX B &#8211; AMENDED AND RESTATED ARTIVION, INC. 2020 EQUITY AND CASH INCENTIVE PLAN</b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 5pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: uppercase"><b>AMENDED AND RESTATED ARTIVION, INC.<br/></b></span><span style="text-transform: none"><b>2020 EQUITY AND CASH INCENTIVE PLAN</b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">SECTION 1<br/>GENERAL</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">1.1</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 6pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt"><b>Purpose</b></span><span style="text-transform: none; line-height: 12pt">.  The Amended and Restated Artivion, Inc. 2020 Equity and Cash Incentive Plan (the &#8220;Plan&#8221;) has been established by Artivion, Inc. (the &#8220;Company&#8221;)</span><sup style="text-transform: none; font-size: 8pt; line-height: 8pt">1</sup><span style="text-transform: none; line-height: 12pt"> to (i) attract, retain, and reward persons eligible to participate in the Plan; (ii) motivate Participants (as defined in Section 1.2 below), by means of appropriate incentives, to achieve annual and long-term goals; (iii) provide equity compensation to Directors of the Company; (iv) provide incentive compensation opportunities to employee Participants that are competitive with those of companies with whom the Company competes for talent; and (iv) further align Participants&#8217; interests with those of the Company&#8217;s stockholders through compensation that is based on the Company&#8217;s common stock; and thereby promote the long-term interests of the Company and its Subsidiaries, as Subsidiaries are defined in Section 11(i), including the growth in value of the Company&#8217;s equity and enhancement of long-term stockholder return. Pursuant to the Plan, Participants may receive Options, SARs, Other Stock Awards, or Cash-Based Awards, each as defined herein (collectively referred to </span><span style="text-transform: none; line-height: 12pt">as &#8220;Awards&#8221;).</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">1.2</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 6pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt"><b>Participation</b></span><span style="text-transform: none; line-height: 12pt">.  Subject to the terms and conditions of the Plan, the Committee (as defined in Section 8) shall determine and designate, from time to time, from among the Eligible Grantees, as defined in Section 11(f), those persons who will be granted one or more Awards under the Plan, and thereby become &#8220;Participants&#8221; in the Plan.  In the discretion of the Committee, a Participant may be granted any Award permitted under the provisions of the Plan, and more than one Award may be granted to a Participant.  Subject to the provisions of Section 8.2(e), Awards may be granted as alternatives to or replacement of awards outstanding under the Plan, or any other plan or arrangement of the Company or a Subsidiary (including a plan or arrangement of a business or entity, all or a portion of which is acquired by the Company or </span><span style="text-transform: none; line-height: 12pt">a Subsidiary).</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">1.3</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 6pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt"><b>Operation, Administration, and Definitions</b></span><span style="text-transform: none; line-height: 12pt">.  The operation and administration of the Plan, including the Awards made under the Plan, shall be subject to the provisions of Section 7 (relating to operation and administration). Capitalized terms in the Plan shall be defined as set forth in the Plan (including the definition provisions of Section 11 of </span><span style="text-transform: none; line-height: 12pt">the Plan).</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">SECTION 2<br/>OPTIONS </span><span style="text-transform: none">AND SARS</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">2.1</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 6pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt"><b>Definitions.</b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 45pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">(a)</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 36pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt">The grant of an &#8220;Option&#8221; entitles the Participant to purchase shares of Stock at an Exercise Price established by the Committee. Options granted under this Section 2 may either be Incentive Stock Options (&#8220;ISOs&#8221;) or Non</span><span style="text-transform: none; line-height: 12pt"><b>-</b></span><span style="text-transform: none; line-height: 12pt">Qualified Options (&#8220;NQOs&#8221;), as determined in the discretion of the Committee.  An &#8220;ISO&#8221; is an Option that is intended to satisfy the requirements applicable to an &#8220;incentive stock option&#8221; described in Section 422(b) of the Code.  An &#8220;NQO&#8221; is an Option that is not intended to be an &#8220;incentive stock option&#8221; as that term is described in Section 422(b) of </span><span style="text-transform: none; line-height: 12pt">the Code.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 45pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">(b)</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 36pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt">A stock appreciation right (a &#8220;SAR&#8221;) entitles the Participant to receive, in cash or Stock (as determined in accordance with Subsection 2.5), value equal to (or otherwise based on) the excess of: (a) the Fair Market Value (as defined in Section 11) of a specified number of shares of Stock at the time of exercise; over (b) an Exercise Price established by </span><span style="text-transform: none; line-height: 12pt">the Committee.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">2.2</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 6pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt"><b>Exercise Price</b></span><span style="text-transform: none; line-height: 12pt">.  The Exercise Price of each Option and SAR granted under this Section 2 shall be not less than 100% of the Fair Market Value of a share of Stock on the date of grant of the Award, unless a higher price is established by the Committee or determined by a method established by the Committee at the time the Option or SAR </span><span style="text-transform: none; line-height: 12pt">is granted.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">2.3.</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 6pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt"><b>Exercise</b></span><span style="text-transform: none; line-height: 12pt">.  An Option and an SAR shall be exercisable in accordance with such terms and conditions and during such periods as may be established by the Committee, before or </span><span style="text-transform: none; line-height: 12pt">after grant.</span></p>

			</div>
			<div style="border-width: 0pt; padding: 0pt; max-height: 866.25pt; left: 45pt; bottom: 78.75pt; width: 675pt; position: absolute">
				<hr style="border-width: 0pt; background-color: #000000; margin-left: 0pt; width: 72pt; margin-top: -1pt; margin-bottom: 0pt; height: 1pt"/>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 0pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><!--[if IE]><FONT style=" width: 15.000000000000004pt; text-indent: -12.000000000000004pt; display: inline-block;"><![endif]--><span style="width: 15pt; text-indent: 0; display: inline-block"><span style="text-transform: none">1</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none"> On January 4, 2022, the Company&#8217;s Board of Directors approved amending the Plan to reflect the Company&#8217;s name change from CryoLife, Inc. to Artivion, Inc., and the Company&#8217;s reincorporation from Florida </span><span style="text-transform: none">to Delaware.</span></p>

			</div>

		</div>
		<div style="page-break-before: always">
			<p style="margin: 0pt; font-size: 5pt">&#8203;</p>

		</div>
		<div class="qes_page" style="border-bottom: black 2pt solid; margin: auto; height: 990pt; width: 765pt; position: relative; overflow: hidden">
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 911.25pt; left: 45pt; width: 675pt; position: absolute; height: 33.75pt">
				<div style="display: table-cell; vertical-align: bottom; width: 675pt; height: 33.75pt">

				<!--[if IE]><TABLE><TR style=" width: 675pt; height: 33.75pt;"><TD vAlign="bottom" style=" width: 675pt; height: 33.75pt;"><![endif]-->
					<div style="font: 12pt/normal Times New Roman, Times, serif; margin: 0pt; text-transform: none; color: #000000; text-align: left">
						<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 0pt; border-collapse: collapse">
							<tr style="margin: 0; height: 0">
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>

							</tr>
							<tr style="min-height: 0pt">
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">ARTIVION, INC. | 2025 Proxy Statement</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">B-2</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 0pt; line-height: 0pt">&#8203;</p>

								</td>

							</tr>

						</table>

					</div>


				<!--[if IE]></TD></TR></TABLE><![endif]-->
				</div>

			</div>
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 45pt; left: 45pt; width: 675pt; position: absolute; height: 866.25pt">
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">2.4</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 6pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt"><b>Payment of Option Exercise Price</b></span><span style="text-transform: none; line-height: 12pt">.  The payment of the Exercise Price of an Option granted under this Section 2 shall be subject to </span><span style="text-transform: none; line-height: 12pt">the following:</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 45pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">(a)</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 36pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt">Subject to the following provisions of this Subsection 2.4, the full Exercise Price for shares of Stock purchased upon the exercise of any Option shall be paid at the time of such exercise (except that, in the case of an exercise arrangement approved by the Committee and described in paragraph 2.4(c), payment may be made as soon as practicable after </span><span style="text-transform: none; line-height: 12pt">the exercise).</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 45pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">(b)</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 36pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt">The Exercise Price shall be payable in cash or by tendering (by actual delivery of shares) unrestricted shares of Stock that are acceptable to the Committee, valued at Fair Market Value as of the day the shares are tendered, or in any combination of cash or shares, as determined by </span><span style="text-transform: none; line-height: 12pt">the Committee.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 45pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">(c)</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 36pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt">To the extent permitted by applicable law, a Participant may elect to pay the Exercise Price upon the exercise of an Option by irrevocably authorizing a third party to sell shares of Stock (or a sufficient portion of the shares) acquired upon exercise of the Option and remit to the Company a sufficient portion of the sale proceeds to pay the entire Exercise Price and any tax withholding resulting from </span><span style="text-transform: none; line-height: 12pt">such exercise.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">2.5</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 6pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt"><b>Settlement of Award</b></span><span style="text-transform: none; line-height: 12pt">.  Shares of Stock delivered pursuant to the exercise of an Option or an SAR shall be subject to such conditions, restrictions and contingencies as the Committee may establish in the applicable Award Agreement.  Settlement of SARs may be made in shares of Stock (valued at their Fair Market Value at the time of exercise), in cash, or in a combination thereof, as determined in the discretion of the Committee.  The Committee, in its discretion, may impose such conditions, restrictions and contingencies with respect to shares of Stock acquired pursuant to the exercise of an Option or an SAR as the Committee determines to </span><span style="text-transform: none; line-height: 12pt">be desirable.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">2.6</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 6pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt"><b>Restrictions on Options and SAR Awards</b></span><span style="text-transform: none; line-height: 12pt">.  Each Option and SAR shall be subject to </span><span style="text-transform: none; line-height: 12pt">the following:</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 45pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">(a)</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 36pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt">The term of any Option or SAR granted under the Plan shall not exceed seven years from the date </span><span style="text-transform: none; line-height: 12pt">of grant.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 45pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">(b) </span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 36pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt">No option or SAR shall carry dividend rights or dividend </span><span style="text-transform: none; line-height: 12pt">equivalent rights.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 45pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">(c)</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 36pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt">Any such Award shall be subject to such conditions, restrictions and contingencies as the Committee </span><span style="text-transform: none; line-height: 12pt">shall determine.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">SECTION 3<br/>OTHER </span><span style="text-transform: none">STOCK AWARDS</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">3.1</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 6pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt"><b>Definitions</b></span><span style="text-transform: none; line-height: 12pt">.</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 36pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt">The term &#8220;Other Stock Awards&#8221; means any of </span><span style="text-transform: none; line-height: 12pt">the following:</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 45pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">(a)</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 36pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt">A &#8220;Stock Unit&#8221; Award is the grant of a right to receive shares of Stock in </span><span style="text-transform: none; line-height: 12pt">the future.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 45pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">(b)</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 36pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt">A &#8220;Performance Share&#8221; Award is a grant of a right to receive shares of Stock or Stock Units, which is contingent on the achievement of performance or other objectives during a </span><span style="text-transform: none; line-height: 12pt">specified period.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 45pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">(c)</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 36pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt">A &#8220;Restricted Stock&#8221; Award is a grant of shares of Stock, and a &#8220;Restricted Stock Unit&#8221; Award is the grant of a right to receive shares of Stock in the future, with such shares of Stock or right to future delivery of such shares of Stock subject to a risk of forfeiture or other restrictions that will lapse upon the achievement of one or more goals relating to completion of service by the Participant, or achievement of performance or other objectives, as determined by </span><span style="text-transform: none; line-height: 12pt">the Committee.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">3.2</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 6pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt"><b>Restrictions on Other Stock Awards</b></span><span style="text-transform: none; line-height: 12pt">.  Each Stock Unit Award, Restricted Stock Award, Restricted Stock Unit Award and Performance Share Award shall be subject to such conditions, restrictions and contingencies as the Committee </span><span style="text-transform: none; line-height: 12pt">shall determine.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; line-height: 12pt">SECTION </span><span style="text-transform: none; line-height: 12pt">4<br/>CASH</span><span style="text-transform: none; line-height: 12pt"><b>-</b></span><span style="text-transform: none; line-height: 12pt">BASED AWARDS</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">4.1</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 6pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt"><b>Definitions</b></span><span style="text-transform: none; line-height: 12pt">.  The term &#8220;Cash-Based Award&#8221; means a right or other interest granted to a Participant under Section 4.2 of the Plan that may be denominated or payable in cash, other than an Award pursuant to which the amount of cash is determined by reference to the value of a specific number of shares o</span><span style="text-transform: none; line-height: 12pt">f Stock. For the avoidance of doubt, dividend equivalents constitute </span><span style="text-transform: none; line-height: 12pt">Cash</span><span style="text-transform: none; line-height: 12pt"><b>-</b></span><span style="text-transform: none; line-height: 12pt">Based Awards.</span></p>

			</div>

		</div>
		<div style="page-break-before: always">
			<p style="margin: 0pt; font-size: 5pt">&#8203;</p>

		</div>
		<div class="qes_page" style="border-bottom: black 2pt solid; margin: auto; height: 990pt; width: 765pt; position: relative; overflow: hidden">
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 911.25pt; left: 45pt; width: 675pt; position: absolute; height: 33.75pt">
				<div style="display: table-cell; vertical-align: bottom; width: 675pt; height: 33.75pt">

				<!--[if IE]><TABLE><TR style=" width: 675pt; height: 33.75pt;"><TD vAlign="bottom" style=" width: 675pt; height: 33.75pt;"><![endif]-->
					<div style="font: 12pt/normal Times New Roman, Times, serif; margin: 0pt; text-transform: none; color: #000000; text-align: left">
						<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 0pt; border-collapse: collapse">
							<tr style="margin: 0; height: 0">
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>

							</tr>
							<tr style="min-height: 0pt">
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">ARTIVION, INC. | 2025 Proxy Statement</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">B-3</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 0pt; line-height: 0pt">&#8203;</p>

								</td>

							</tr>

						</table>

					</div>


				<!--[if IE]></TD></TR></TABLE><![endif]-->
				</div>

			</div>
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 45pt; left: 45pt; width: 675pt; position: absolute; height: 866.25pt">
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">4.2</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 6pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt"><b>Grant of Cash-Based Awards</b></span><span style="text-transform: none; line-height: 12pt">.  The Committee is authorized to grant Awards to Participants in the form of Cash</span><span style="text-transform: none; line-height: 12pt"><b>-</b></span><span style="text-transform: none; line-height: 12pt">Based Awards, as deemed by the Committee to be consistent with the purposes of the Plan, subject to such vesting and other conditions as the Committee shall determine in its sole discretion.  At the time of the grant of Cash-Based Awards, the Committee may place restrictions on the payout or vesting of Cash-Based Awards that shall lapse, in whole or in part, only upon the attainment of Performance Goals.  The Committee shall determine the terms and conditions of such Awards at the date of grant.  The maximum dollar amount that may be covered by all Cash-Based Awards granted to any individual during any fiscal year under the Plan is $2 million for employees and $500,000 for non-employee directors.  At the discretion of the Committee, Cash-Based Awards under this Plan may be issued jointly under this Plan and any other cash incentive or similar plan of the Company; provided, however, that if a Cash-Based Award is issued under this Plan and another plan of the Company, to the extent of a conflict in the provisions of this Plan and the other plan, the terms of this Plan </span><span style="text-transform: none; line-height: 12pt">shall control.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; line-height: 12pt">SECTION </span><span style="text-transform: none; line-height: 12pt">5<br/>PERFORMANCE</span><span style="text-transform: none; line-height: 12pt"><b>-</b></span><span style="text-transform: none; line-height: 12pt">BASED COMPENSATION</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">5.1</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 6pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt"><b>Grant of Performance-Based Compensation</b></span><span style="text-transform: none; line-height: 12pt">.  The Committee may determine that any Awards granted to a Covered Employee shall be considered performance-based compensation, in which case the provisions of this Section 5 shall apply.  When Awards are made under this Section 5, the Committee shall establish in writing (i) the objective Performance Goals that must be met, (ii) the period during which performance will be measured, (iii) the maximum amounts that may be paid if the Performance Goals are met, and (iv) any other conditions that the Committee </span><span style="text-transform: none; line-height: 12pt">deems appropriate.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">5.2</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 6pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt"><b>Pre-establishment of Performance Goals</b></span><span style="text-transform: none; line-height: 12pt">.  Performance Goals will, barring unusual or compelling circumstances, be pre-established by the Committee in writing not later than 90 days after the commencement of the period of service to which the Performance Goal relates, provided that the outcome is substantially uncertain at the time the Committee actually established </span><span style="text-transform: none; line-height: 12pt">the goal.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">5.3</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 6pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt"><b>Adjustments to Performance Goals</b></span><span style="text-transform: none; line-height: 12pt">.  The Committee in its sole discretion shall have the authority to make adjustments to the Performance Goals in recognition of unusual or non-recurring events affecting the Company or any Subsidiary of the Company or the financial statements of the Company or any Subsidiary of the Company, in response to anticipated or actual changes in applicable laws or regulations, including changes in generally accepted accounting principles or practices, or to account for items of gain, loss or expense determined to be extraordinary or unusual in nature or infrequent in occurrence or related to the disposal of a segment or product line of a business, as applicable. In addition, the Committee may specify that certain equitable adjustments to the Performance Goals will be made during the applicable performance period, provided such specification occurs </span><span style="text-transform: none; line-height: 12pt">in writing.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">5.4</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 6pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt"><b>Certification of Performance Results</b></span><span style="text-transform: none; line-height: 12pt">.  The Committee shall certify the satisfaction of the Performance Goal for the applicable performance period specified in the Award agreement after the performance period ends and prior to any payment with respect to the Award. The Committee shall determine the amount, if any, to be paid pursuant to each Award based on the achievement of the Performance Goals and the satisfaction of all other terms of the </span><span style="text-transform: none; line-height: 12pt">Award agreement.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">5.5</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 6pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt"><b>Payment Upon Death or Disability or Other Circumstances</b></span><span style="text-transform: none; line-height: 12pt">.  The Committee may authorize that Awards under this Section 5 shall be payable, in whole or in part, in the event of the Participant&#8217;s death or disability, or under </span><span style="text-transform: none; line-height: 12pt">other circumstances.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; line-height: 12pt">SECTION 6<br/>STOCK SUBJECT TO </span><span style="text-transform: none; line-height: 12pt">THE PLAN</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">6.1</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 6pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt"><b>Awards Subject to Plan</b></span><span style="text-transform: none; line-height: 12pt">.  Awards granted under the Plan shall be subject to </span><span style="text-transform: none; line-height: 12pt">the following:</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 45pt; text-align: justify"><span style="text-transform: none; line-height: 12pt"> (a)</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 36pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt">Subject to the following provisions of this Subsection 6.1, the maximum number of shares of Stock that may be delivered to Participants and their beneficiaries under the Plan shall be 9,285,000 shares of Stock, including the remainder of any shares available and issuable under the Plan as of May 13, 2025, less the number of non-forfeited shares of Stock subject to outstanding Awards that have been granted but not yet vested. Shares of Stock issuable hereunder may, in whole or in part, be authorized but unissued shares or shares of Stock that shall have been or may be reacquired by the Company in the open market, in private transactions or otherwise. Notwithstanding the foregoing, with respect to SARs that are settled in Stock, the aggregate number of shares of Stock subject to the SAR grant shall be counted against the shares available for issuance under the Plan as one share for every share subject thereto, regardless of the number of shares used to settle the SAR upon exercise. For every share of Stock awarded hereunder in respect of Other Stock Awards, the maximum number of shares reserved for grant hereunder shall be reduced by </span><span style="text-transform: none; line-height: 12pt">1.5 shares.</span></p>

			</div>

		</div>
		<div style="page-break-before: always">
			<p style="margin: 0pt; font-size: 5pt">&#8203;</p>

		</div>
		<div class="qes_page" style="border-bottom: black 2pt solid; margin: auto; height: 990pt; width: 765pt; position: relative; overflow: hidden">
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 911.25pt; left: 45pt; width: 675pt; position: absolute; height: 33.75pt">
				<div style="display: table-cell; vertical-align: bottom; width: 675pt; height: 33.75pt">

				<!--[if IE]><TABLE><TR style=" width: 675pt; height: 33.75pt;"><TD vAlign="bottom" style=" width: 675pt; height: 33.75pt;"><![endif]-->
					<div style="font: 12pt/normal Times New Roman, Times, serif; margin: 0pt; text-transform: none; color: #000000; text-align: left">
						<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 0pt; border-collapse: collapse">
							<tr style="margin: 0; height: 0">
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>

							</tr>
							<tr style="min-height: 0pt">
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">ARTIVION, INC. | 2025 Proxy Statement</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">B-4</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 0pt; line-height: 0pt">&#8203;</p>

								</td>

							</tr>

						</table>

					</div>


				<!--[if IE]></TD></TR></TABLE><![endif]-->
				</div>

			</div>
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 45pt; left: 45pt; width: 675pt; position: absolute; height: 883.13pt">
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 45pt; text-align: justify"><span style="text-transform: none; line-height: 12pt"> (b)</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 36pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt">Subject to adjustment in accordance with Subsections 6.2 and 6.3, the following additional maximums are imposed under the Plan: the maximum number of shares of Stock that may be covered by Awards granted to any one individual pursuant to Section 2 (relating to Options and SARs) shall be 800,000 for employees and 75,000 for non-employee directors during any fiscal year and the maximum number of shares of Stock that may be covered by Other Stock Awards granted to any one individual pursuant to Section 3 shall be 500,000 for employees and 500,000 for non-employee directors during any fiscal </span><span style="text-transform: none; line-height: 12pt">year; and</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 45pt; text-align: justify"><span style="text-transform: none; line-height: 12pt"> (c)</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 36pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt">To the extent any shares of Stock covered by an Award are not delivered to a Participant or beneficiary because the Award is forfeited or canceled, or the shares of Stock are not delivered because the Award is settled in cash, such shares shall not be deemed to have been delivered for purposes of determining the maximum number of shares of Stock available for delivery under the Plan.  To the extent that shares of Stock subject to Other Stock Awards, and the issuance of which reduced the maximum number of shares authorized for issuance under the Plan by 1.5 shares, are forfeited or cancelled, or if such an Award terminates or expires without a distribution of shares to the Participant, the number of shares of Stock remaining for Award grants hereunder shall be increased by 1.5 for each share forfeited, cancelled or otherwise not delivered. Shares of Stock shall not again be available if such shares are surrendered or withheld as payment of either the exercise price of an Award and/ or withholding taxes in respect of an Award.  Awards that are settled solely in cash shall not reduce the number of shares of Stock available for Awards. Upon the exercise of any Award granted in tandem with any other Award, such related Awards shall be cancelled to the extent of the number of shares of Stock as to which the Award is exercised and, notwithstanding the foregoing, such number of shares shall no longer be available for Awards under the Plan.  The maximum number of shares of Stock available for delivery under the Plan shall not be reduced for shares subject to plans assumed by the Company in an acquisition of an interest in </span><span style="text-transform: none; line-height: 12pt">another company.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">6.2</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 6pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt"><b>Adjustments for Changes in Capitalization</b></span><span style="text-transform: none; line-height: 12pt">.  If the outstanding shares of Stock are changed into or exchanged for a different number or kind of shares or other securities of the Company by reason of any recapitalization, reclassification, stock split, stock dividend, combination, subdivision or similar transaction, or if the Company makes an extraordinary dividend or distribution to its stockholders (including without limitation to implement a spinoff) (each, a &#8220;Corporate Transaction&#8221;</span><span style="text-transform: none; line-height: 12pt">) then, subject to any required action by the stockholders of the Company, the number and kind of shares of Company stock available under the Plan or subject to any limit or maximum hereunder shall automatically be proportionately adjusted, with no action required on the part of the Committee or otherwise. Subject to any required action by the stockholders, the number and kind of shares covered by each outstanding Award, and the price per share in each such Award, shall also be automatically proportionately adjusted for any increase or decrease in the number of issued shares of the Company resulting from a Corporate Transaction or any other increase or decrease in the number of such shares, or any decrease in the value of such shares, effected without receipt of consideration by the Company.  Notwithstanding the foregoing, no fractional shares shall be issued or made subject to an Option, SAR or Other Stock Award in making the foregoing adjustments.  All adjustments made pursuant to this Section shall be final, conclusive and binding upon the holders of Options, SARs and Other </span><span style="text-transform: none; line-height: 12pt">Stock Awards.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">6.3</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 6pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt"><b>Certain Mergers and Other Extraordinary Events</b></span><span style="text-transform: none; line-height: 12pt">.  If the Company merges or consolidates with another corporation, or if the Company is liquidated or sells or otherwise disposes of substantially all of its assets while unexercised Options or other Awards remain outstanding under this Plan, (A) subject to the provisions of clause (C) below, after the effective date of the merger, consolidation, liquidation, sale or other disposition, as the case may be, whether or not the Company is the surviving corporation, each holder of an outstanding Option or other Award shall be entitled, upon exercise of that Option or Award or in place of it, as the case may be, to receive, at the option of the Committee and in lieu of shares of Stock, (i) the number and class or classes of shares of Stock or other securities or property to which the holder would have been entitled if, immediately prior to the merger, consolidation, liquidation, sale or other disposition, the holder had been the holder of record of a number of shares of Stock equal to the number of shares of Stock as to which that Option may be exercised or are subject to the Award or (ii) shares of stock of the company that is the surviving corporation in such merger, consolidation, liquidation, sale or other disposition having a value, as of the date of payment under Subsection 6.3(i) as determined by the Committee in its sole discretion, equal to the value of the shares of Stock or other securities or property otherwise payable under Subsection 6.3(i); (B) whether or not the Company is the surviving corporation, if Options or other Awards have not already become exercisable, the Board of Directors may waive any limitations set forth in or imposed pursuant to this Plan so that all Options or other Awards, from and after a date prior to the effective date of that merger, consolidation, liquidation, sale or other disposition, as the case may be, specified by the Board of Directors, shall be exercisable in full; and (C) all outstanding Options or SARs may be cancelled by the Board of Directors as of the effective date of any merger, consolidation, liquidation, sale or other disposition, provided that with respect to a merger or consolidation the Company is not the surviving company, and provided further that any optionee or SAR holder shall have the right immediately prior to such event to exercise his or her Option or SAR to the extent such optionee or holder is otherwise able to do so in accordance with this Plan or his or her individual Option or SAR agreement; provided, further, that any such cancellation pursuant to this Section 6.3 shall be contingent upon the payment to the affected </span><span style="text-transform: none; line-height: 12pt">Participants of </span></p>

			</div>

		</div>
		<div style="page-break-before: always">
			<p style="margin: 0pt; font-size: 5pt">&#8203;</p>

		</div>
		<div class="qes_page" style="border-bottom: black 2pt solid; margin: auto; height: 990pt; width: 765pt; position: relative; overflow: hidden">
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 911.25pt; left: 45pt; width: 675pt; position: absolute; height: 33.75pt">
				<div style="display: table-cell; vertical-align: bottom; width: 675pt; height: 33.75pt">

				<!--[if IE]><TABLE><TR style=" width: 675pt; height: 33.75pt;"><TD vAlign="bottom" style=" width: 675pt; height: 33.75pt;"><![endif]-->
					<div style="font: 12pt/normal Times New Roman, Times, serif; margin: 0pt; text-transform: none; color: #000000; text-align: left">
						<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 0pt; border-collapse: collapse">
							<tr style="margin: 0; height: 0">
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>

							</tr>
							<tr style="min-height: 0pt">
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">ARTIVION, INC. | 2025 Proxy Statement</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">B-5</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 0pt; line-height: 0pt">&#8203;</p>

								</td>

							</tr>

						</table>

					</div>


				<!--[if IE]></TD></TR></TABLE><![endif]-->
				</div>

			</div>
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 45pt; left: 45pt; width: 675pt; position: absolute; height: 866.25pt">
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">an amount equal to (i) in the case of any out</span><span style="text-transform: none; line-height: 12pt"><b>-</b></span><span style="text-transform: none; line-height: 12pt">of</span><span style="text-transform: none; line-height: 12pt"><b>-</b></span><span style="text-transform: none; line-height: 12pt">the</span><span style="text-transform: none; line-height: 12pt"><b>-</b></span><span style="text-transform: none; line-height: 12pt">money Option or SAR, cash, property or a combination thereof having an aggregate value equal to the value of such Option or SAR, as determined by the Committee or the Board of Directors, as applicable, in its sole discretion, and (ii) in the case of an in</span><span style="text-transform: none; line-height: 12pt"><b>-</b></span><span style="text-transform: none; line-height: 12pt">the</span><span style="text-transform: none; line-height: 12pt"><b>-</b></span><span style="text-transform: none; line-height: 12pt">money Option or SAR, cash, property or a combination thereof having an aggregate value equal to the excess of the value of the per-share amount of consideration paid pursuant to the merger, consolidation, liquidation, sale or other disposition, as the case may be, giving rise to such cancellation, over the exercise price of such Option or SAR multiplied by the number of shares of Stock subject to the Option </span><span style="text-transform: none; line-height: 12pt">or SAR.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">Any adjustments pursuant to this Subsection 6.3 shall be made by the Board or Committee, as the case may be, whose determination in that respect shall be final, binding and conclusive, regardless of whether or not any such adjustment shall have the result of causing an ISO to cease to qualify as </span><span style="text-transform: none; line-height: 12pt">an ISO.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">6.4</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 6pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt"><b>Changes in Par Value</b></span><span style="text-transform: none; line-height: 12pt">.  In the event of a change in the shares of the Company as presently constituted, which is limited to a change of all of its authorized shares with par value into the same number of shares with a different par value or without par value, the shares resulting from any such change shall be deemed to be the shares within the meaning of </span><span style="text-transform: none; line-height: 12pt">this Plan.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">6.5</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 6pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt"><b>Limitation on Grantees&#8217; Rights</b></span><span style="text-transform: none; line-height: 12pt">.  Except as hereinbefore expressly provided in this Section 6, a Participant shall have no rights by reason of any subdivision or consolidation of shares of stock of any class or the payment of any stock dividend or any other increase or decrease in the number of shares of stock of any class or by reason of any dissolution, liquidation, merger, or consolidation or spin</span><span style="text-transform: none; line-height: 12pt"><b>-</b></span><span style="text-transform: none; line-height: 12pt">off of assets or stock of another corporation, and any issue by the Company of shares of stock of any class, shall not affect, and no adjustment by reason thereof shall be made with respect to, the number or price of shares of Stock subject to an Award, unless the Committee shall </span><span style="text-transform: none; line-height: 12pt">otherwise determine.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">6.6</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 6pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt"><b>Company Right and Power</b></span><span style="text-transform: none; line-height: 12pt">.  The grant of any Award pursuant to this Plan shall not adversely affect in any way the right or power of the Company (A) to make adjustments, reclassifications, reorganizations or changes of its capital or business structure, (B) to merge or consolidate, (C) to dissolve, liquidate or sell or transfer all or any part of its business or assets or (D) to issue any bonds, debentures, preferred or other preference stock ahead of or affecting </span><span style="text-transform: none; line-height: 12pt">the Stock.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">6.7</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 6pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt"><b>Fractional Shares</b></span><span style="text-transform: none; line-height: 12pt">.  If any action described in this Section 6 results in a fractional share for any Participant under any Award hereunder, such fraction shall be completely disregarded, and the Participant shall be entitled only to the whole number of shares resulting from </span><span style="text-transform: none; line-height: 12pt">such adjustment.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; line-height: 12pt">SECTION 7<br/>OPERATION </span><span style="text-transform: none; line-height: 12pt">AND ADMINISTRATION</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">7.1</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 6pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt"><b>Effective Date; Duration</b></span><span style="text-transform: none; line-height: 12pt">.  The Plan is effective as of the date of its initial approval by the stockholders of the Company at the 2020 Annual Meeting of Shareholders, to be held on May&#160;20, 2020. The Plan will have a duration of ten years from May 20, 2020, and provided that in the event of Plan termination, the Plan shall remain in effect so long as any Awards under it are outstanding; provided further, however, that no Award may be granted under the Plan on a date that is more than ten years from May </span><span style="text-transform: none; line-height: 12pt">20, 2020.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">7.2</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 6pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt"><b>Vesting</b></span><span style="text-transform: none; line-height: 12pt">.  Notwithstanding anything in the Plan to the contrary, all Options, SARs, and Other Awards (including, but not limited to, performance-based awards) shall vest or become exercisable no earlier than twelve months from the date on which such Award is granted, except for the Committee&#8217;s discretion to provide for accelerated vesting or exercisability in connection with death, disability, retirement, or events as described above at Section 6.3, and except that up to five percent (5%) of the aggregate number of shares of Stock authorized for issuance under the Plan may be issued pursuant to Options, SARs, and Other Awards without regard to the service vesting and exercisability requirements of this Section </span><span style="text-transform: none; line-height: 12pt">7.2. The term of any Award granted under the Plan will not exceed seven years from the date </span><span style="text-transform: none; line-height: 12pt">of grant.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">7.3</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 6pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt"><b>Uncertificated Stock</b></span><span style="text-transform: none; line-height: 12pt">.  To the extent that the Plan provides for issuance of stock certificates to reflect the issuance of shares of Stock, the issuance may be effectuated on a non</span><span style="text-transform: none; line-height: 12pt"><b>-</b></span><span style="text-transform: none; line-height: 12pt">certificated basis, to the extent not prohibited by applicable law or the applicable rules of any </span><span style="text-transform: none; line-height: 12pt">stock exchange.</span></p>

			</div>

		</div>
		<div style="page-break-before: always">
			<p style="margin: 0pt; font-size: 5pt">&#8203;</p>

		</div>
		<div class="qes_page" style="border-bottom: black 2pt solid; margin: auto; height: 990pt; width: 765pt; position: relative; overflow: hidden">
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 911.25pt; left: 45pt; width: 675pt; position: absolute; height: 33.75pt">
				<div style="display: table-cell; vertical-align: bottom; width: 675pt; height: 33.75pt">

				<!--[if IE]><TABLE><TR style=" width: 675pt; height: 33.75pt;"><TD vAlign="bottom" style=" width: 675pt; height: 33.75pt;"><![endif]-->
					<div style="font: 12pt/normal Times New Roman, Times, serif; margin: 0pt; text-transform: none; color: #000000; text-align: left">
						<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 0pt; border-collapse: collapse">
							<tr style="margin: 0; height: 0">
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>

							</tr>
							<tr style="min-height: 0pt">
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">ARTIVION, INC. | 2025 Proxy Statement</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">B-6</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 0pt; line-height: 0pt">&#8203;</p>

								</td>

							</tr>

						</table>

					</div>


				<!--[if IE]></TD></TR></TABLE><![endif]-->
				</div>

			</div>
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 45pt; left: 45pt; width: 675pt; position: absolute; height: 869.1pt">
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">7.4</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 6pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt"><b>Tax Withholding</b></span><span style="text-transform: none; line-height: 12pt">.  All distributions under the Plan are subject to withholding of all applicable taxes, and the Committee may condition the delivery of any shares or other benefits under the Plan on satisfaction of the applicable withholding obligations. The Committee, in its discretion, and subject to such requirements as the Committee may impose prior to the occurrence of such withholding, may permit such withholding obligations to be satisfied through cash payment by the Participant, through the surrender of shares of Stock which the Participant already owns, or through the surrender of unrestricted shares of Stock to which the Participant is otherwise entitled under the Plan, but only to the extent of the minimum amount required to be withheld under </span><span style="text-transform: none; line-height: 12pt">applicable law.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">7.5</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 6pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt"><b>Use of Shares</b></span><span style="text-transform: none; line-height: 12pt">.  Subject to the overall limitation on the number of shares of Stock that may be delivered under the Plan, the Committee may use available shares of Stock as the form of payment for compensation, grants or rights earned or due under any other compensation plans or arrangements of the Company or a Subsidiary, including the plans and arrangements of the Company or a Subsidiary assumed in </span><span style="text-transform: none; line-height: 12pt">business combinations.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">7.6</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 6pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt"><b>Dividends and Dividend Equivalents</b></span><span style="text-transform: none; line-height: 12pt">.  An Award, excluding Options and SAR Awards,  may provide the Participant with the right to receive dividend payments or dividend equivalent payments with respect to Stock subject to the Award (both before and after the Stock subject to the Award is earned or vested), which payments may be either made currently or credited to an account for the Participant, and may be settled in cash or Stock as determined by the Committee.  Any such settlements, and any such crediting of dividends or dividend equivalents or reinvestment in shares of Stock, may be subject to such conditions, restrictions and contingencies as the Committee shall establish, including the reinvestment of such credited amounts in Stock equivalents.  In the event an Award is conditioned on the achievement of one or more Performance Goals, any dividend payments or dividend equivalent payments will only be earned, vested or acquired to the extent the underlying Stock subject to the Award is earned, vested </span><span style="text-transform: none; line-height: 12pt">or acquired.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">7.7</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 6pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt"><b>Payments</b></span><span style="text-transform: none; line-height: 12pt">.  Awards may be settled through cash payments, the delivery of shares of Stock, the granting of replacement Awards, or any combination thereof as the Committee shall determine.  Any Award settlement, including payment deferrals, may be subject to such conditions, restrictions and contingencies as the Committee shall determine.  The Committee may permit or require the deferral of any Award payment, subject to such rules and procedures as it </span><span style="text-transform: none; line-height: 12pt">may establish.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">7.8</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 6pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt"><b>Transferability</b></span><span style="text-transform: none; line-height: 12pt">.  Except as otherwise provided by the Committee, Awards under the Plan are not transferable except as designated by the Participant by will or by the laws of descent </span><span style="text-transform: none; line-height: 12pt">and distribution.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">7.9</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 6pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt"><b>Form and Time of Elections</b></span><span style="text-transform: none; line-height: 12pt">.  Unless otherwise specified herein, each election required or permitted to be made by any Participant or other person entitled to benefits under the Plan, and any permitted modification, or revocation thereof, shall be in writing filed with the Committee at such times, in such form, and subject to such restrictions and limitations, not inconsistent with the terms of the Plan, as the Committee </span><span style="text-transform: none; line-height: 12pt">shall require.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 15pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">7.10</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 6pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt"><b>Agreement with Company</b></span><span style="text-transform: none; line-height: 12pt">.  An Award under the Plan shall be subject to such terms and conditions, not inconsistent with the Plan, as the Committee shall, in its sole discretion, prescribe. The terms and conditions of any Award to any Participant, other than cash awards, shall be reflected in such form of a written or electronic document as is determined by the Committee.  A copy of such document shall be made available to the Participant, and the Committee may, but need not, require that the Participant sign a copy of such document or otherwise indicate his or her consent. Such document is referred to in the Plan as an &#8220;Award Agreement&#8221; regardless of whether any Participant signature </span><span style="text-transform: none; line-height: 12pt">is required.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 15pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">7.11</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 6pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt"><b>Action by Company or Subsidiary</b></span><span style="text-transform: none; line-height: 12pt">.  Any action required or permitted to be taken by the Company or any Subsidiary under this Plan shall be by action of its Board of Directors, or by action of one or more members of the Board (including a committee of the Board) who are duly authorized to act for the Board, or (except to the extent prohibited by applicable law or applicable rules of any stock exchange) by a duly authorized officer of </span><span style="text-transform: none; line-height: 12pt">such company.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 15pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">7.12</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 6pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt"><b>Gender and Number</b></span><span style="text-transform: none; line-height: 12pt">.  Where the context admits, words in any gender shall include any other gender, words in the singular shall include the plural and the plural shall include </span><span style="text-transform: none; line-height: 12pt">the singular.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 15pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">7.13</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 6pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt"><b>Limitation of </b></span><span style="text-transform: none; line-height: 12pt"><b>Implied Rights.</b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 45pt; text-align: justify"><span style="text-transform: none; line-height: 12pt"> (a)</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 36pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt">Neither a Participant nor any other person shall, by reason of participation in the Plan, acquire any right in or title to any assets, funds or property of the Company or any Subsidiary whatsoever, including, without limitation, any specific funds, assets, or other property which the Company or any Subsidiary, in its sole discretion, may set aside in anticipation of a liability under the Plan.  A Participant shall have only a contractual right to the Stock or amounts, if any, payable under the Plan, unsecured by any assets of the Company or any Subsidiary, and nothing contained in the Plan shall constitute a guarantee that the assets of the Company or any Subsidiary shall be sufficient to pay any benefits to </span><span style="text-transform: none; line-height: 12pt">any person.</span></p>

			</div>

		</div>
		<div style="page-break-before: always">
			<p style="margin: 0pt; font-size: 5pt">&#8203;</p>

		</div>
		<div class="qes_page" style="border-bottom: black 2pt solid; margin: auto; height: 990pt; width: 765pt; position: relative; overflow: hidden">
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 911.25pt; left: 45pt; width: 675pt; position: absolute; height: 33.75pt">
				<div style="display: table-cell; vertical-align: bottom; width: 675pt; height: 33.75pt">

				<!--[if IE]><TABLE><TR style=" width: 675pt; height: 33.75pt;"><TD vAlign="bottom" style=" width: 675pt; height: 33.75pt;"><![endif]-->
					<div style="font: 12pt/normal Times New Roman, Times, serif; margin: 0pt; text-transform: none; color: #000000; text-align: left">
						<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 0pt; border-collapse: collapse">
							<tr style="margin: 0; height: 0">
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>

							</tr>
							<tr style="min-height: 0pt">
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">ARTIVION, INC. | 2025 Proxy Statement</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">B-7</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 0pt; line-height: 0pt">&#8203;</p>

								</td>

							</tr>

						</table>

					</div>


				<!--[if IE]></TD></TR></TABLE><![endif]-->
				</div>

			</div>
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 45pt; left: 45pt; width: 675pt; position: absolute; height: 866.25pt">
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt"> (b)</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 36pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt">The Plan does not constitute a contract of employment, and selection as a Participant will not give any participating employee the right to be retained in the employ of the Company or any Subsidiary, nor any right or claim to any benefit under the Plan, unless such right or claim has specifically accrued under the terms of the Plan. Except as otherwise provided in the Plan, no Award under the Plan shall confer upon the holder thereof any rights as a stockholder of the Company prior to the date on which the individual fulfills all conditions for receipt of </span><span style="text-transform: none; line-height: 12pt">such rights.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 15pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">7.14</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 6pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt"><b>Evidence</b></span><span style="text-transform: none; line-height: 12pt">.  Evidence required of anyone under the Plan may be by certificate, affidavit, document or other information which the person acting on it considers pertinent and reliable, and shall be signed, made or presented by the proper party </span><span style="text-transform: none; line-height: 12pt">or parties.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 15pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">7.15</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 6pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt"><b>Termination of Employment Following Change in Control</b></span><span style="text-transform: none; line-height: 12pt; font-style: italic"><i>.</i></span><span style="text-transform: none; line-height: 12pt">  In the event that the employment of a Participant who is an employee of the Company or a Subsidiary is terminated by the Company during the six</span><span style="text-transform: none; line-height: 12pt"><b>-</b></span><span style="text-transform: none; line-height: 12pt">month period following a Change in Control, all of such Participant&#8217;s outstanding Options and SARs may thereafter be exercised by the Participant, to the extent that such Options and SARs were exercisable as of the date of such termination of employment (x) for a period of six&#160;months from such date of termination or (y) until expiration of the stated term of such Option or SAR, whichever period is </span><span style="text-transform: none; line-height: 12pt">the shorter.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 15pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">7.16</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 6pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt"><b>Section 409A</b></span><span style="text-transform: none; line-height: 12pt; font-style: italic"><i>.</i></span><span style="text-transform: none; line-height: 12pt">  It is intended that all Options and SARs granted under the Plan shall be exempt from the provisions of Section&#160;409A of the Code and that all Other Stock Awards under the Plan, to the extent that they constitute &#8220;non-qualified deferred compensation&#8221; within the meaning of Section&#160;409A of the Code, will comply with Section&#160;409A of the Code (and any regulations and guidelines issued thereunder). The Plan and any Award Agreements issued hereunder may be amended in any respect deemed by the Board or the Committee to be necessary in order to preserve compliance with Section&#160;409A of the Code or any </span><span style="text-transform: none; line-height: 12pt">successor section of </span><span style="text-transform: none; line-height: 12pt">the Code.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 15pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">7.17</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 6pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt">Regulations and </span><span style="text-transform: none; line-height: 12pt">Other Approvals.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 45pt; text-align: justify"><span style="text-transform: none; line-height: 12pt"> (a)</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 36pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt">The obligation of the Company to sell or deliver Stock with respect to any Award granted under the Plan or make any other distribution of benefits under the Plan shall be subject to all applicable laws, rules and regulations, including all applicable federal and state securities laws (including, without limitation, the requirements of the Securities Act of 1933) and all applicable requirements of any securities exchange or similar entity, and the obtaining of all such approvals by governmental agencies as may be deemed necessary or appropriate by </span><span style="text-transform: none; line-height: 12pt">the Committee.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 45pt; text-align: justify"><span style="text-transform: none; line-height: 12pt"> (b)</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 36pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt">Each Award is subject to the requirement that, if at any time the Committee determines, in its absolute discretion, that the listing, registration or qualification of Stock issuable pursuant to the Plan is required by any securities exchange or under any state or federal law, or the consent or approval of any governmental regulatory body is necessary or desirable as a condition of, or in connection with, the grant of an Award or the issuance of Stock, no such Award shall be granted or payment made or Stock issued, in whole or in part, unless listing, registration, qualification, consent or approval, as applicable, has been effected or obtained free of any conditions not acceptable to </span><span style="text-transform: none; line-height: 12pt">the Committee.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 45pt; text-align: justify"><span style="text-transform: none; line-height: 12pt"> (c)</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 36pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt">In the event that the disposition of Stock acquired pursuant to the Plan is not covered by a then current registration statement under the Securities Act of 1933 and is not otherwise exempt from such registration, such Stock shall be restricted against transfer to the extent required by the Securities Act of 1933, as amended, or regulations thereunder, and applicable state securities laws, and the Committee may require a Participant receiving Stock pursuant to the Plan, as a condition precedent to receipt of such Stock, to represent to the Company in writing that the Stock acquired by such Participant is acquired for investment only and not with a view </span><span style="text-transform: none; line-height: 12pt">to distribution.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 45pt; text-align: justify"><span style="text-transform: none; line-height: 12pt"> (d)</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 36pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt">With respect to persons subject to Section 16 of the Securities and Exchange Act of 1934, as amended, it is the intent of the Company that the Plan and all transactions under the Plan comply with all applicable provisions of </span><span style="text-transform: none; line-height: 12pt">Rule 16b-3.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 15pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">7.18</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 6pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt"><b>Awards to Employees Subject to Taxation Outside of the United States</b></span><span style="text-transform: none; line-height: 12pt">.  Without amending the Plan, Awards may be granted to Participants who are foreign nationals or who are employed outside the United States or both, on such terms and conditions different from those specified in the Plan as may, in the judgment of the Committee, be necessary or desirable to further the purposes of the Plan. Such different terms and conditions may be reflected in Addenda to the Plan or in the applicable Award Agreement. However, no such different terms or conditions shall be employed if such terms or conditions constitute, or in effect result in, an increase in the aggregate number of shares which may be issued under the Plan or a change in the definition of </span><span style="text-transform: none; line-height: 12pt">Eligible Grantee.</span></p>

			</div>

		</div>
		<div style="page-break-before: always">
			<p style="margin: 0pt; font-size: 5pt">&#8203;</p>

		</div>
		<div class="qes_page" style="border-bottom: black 2pt solid; margin: auto; height: 990pt; width: 765pt; position: relative; overflow: hidden">
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 911.25pt; left: 45pt; width: 675pt; position: absolute; height: 33.75pt">
				<div style="display: table-cell; vertical-align: bottom; width: 675pt; height: 33.75pt">

				<!--[if IE]><TABLE><TR style=" width: 675pt; height: 33.75pt;"><TD vAlign="bottom" style=" width: 675pt; height: 33.75pt;"><![endif]-->
					<div style="font: 12pt/normal Times New Roman, Times, serif; margin: 0pt; text-transform: none; color: #000000; text-align: left">
						<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 0pt; border-collapse: collapse">
							<tr style="margin: 0; height: 0">
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>

							</tr>
							<tr style="min-height: 0pt">
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">ARTIVION, INC. | 2025 Proxy Statement</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">B-8</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 0pt; line-height: 0pt">&#8203;</p>

								</td>

							</tr>

						</table>

					</div>


				<!--[if IE]></TD></TR></TABLE><![endif]-->
				</div>

			</div>
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 45pt; left: 45pt; width: 675pt; position: absolute; height: 866.25pt">
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; line-height: 12pt">SECTION 8<br/>COMMITTEE</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">8.1</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 6pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt"><b>Administration</b></span><span style="text-transform: none; line-height: 12pt">.  The authority to control and manage the operation and administration of the Plan shall be vested in a committee (the &#8220;Committee&#8221;) in accordance with this Section 8.  The Committee shall be selected by the Board and shall consist solely of two or more members of the Board who are non-employee Directors within the meaning of Rule 16b</span><span style="text-transform: none; line-height: 12pt"><b>-</b></span><span style="text-transform: none; line-height: 12pt">3 under the Securities Exchange Act of 1934, as amended.  If the Committee does not exist, or for any other reason determined by the Board, the Board may take any action under the Plan that would otherwise be the responsibility of the Committee. Unless otherwise determined by the Board, Artivion&#8217;s Compensation Committee shall be designated as the </span><span style="text-transform: none; line-height: 12pt">&#8220;Committee&#8221; hereunder.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">8.2</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 6pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt"><b>Powers of Committee</b></span><span style="text-transform: none; line-height: 12pt">.  The Committee&#8217;s administration of the Plan shall be subject to </span><span style="text-transform: none; line-height: 12pt">the following:</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 45pt; text-align: justify"><span style="text-transform: none; line-height: 12pt"> (a)</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 36pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt">Subject to the provisions of the Plan, the Committee will have the authority and discretion to select from among the Eligible Grantees those persons who shall receive Awards, to determine the time or times of receipt, to determine the types of Awards and the number or value of shares or amount of cash covered by the Awards, to establish the terms, conditions, performance criteria, restrictions, and other provisions of such Awards, and (subject to the restrictions imposed by Section&#160;9) to cancel or suspend Awards, and to waive or otherwise modify any vesting or other restrictions contained in awards. The Committee may also, without obtaining stockholder approval, amend any outstanding award to provide the holder thereof with additional rights or benefits of the type otherwise permitted by the Plan, including without limitation, extending the term thereof; provided, however, that in no event may the term of any Option or SAR exceed </span><span style="text-transform: none; line-height: 12pt">seven years.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 45pt; text-align: justify"><span style="text-transform: none; line-height: 12pt"> (b)</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 36pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt">The Committee will have the authority and discretion to interpret the Plan, to establish, amend, and rescind any rules and regulations relating to the Plan, to determine the terms and provisions of any Award Agreement made pursuant to the Plan, and to make all other determinations that may be necessary or advisable for the administration of </span><span style="text-transform: none; line-height: 12pt">the Plan.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 45pt; text-align: justify"><span style="text-transform: none; line-height: 12pt"> (c)</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 36pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt">Any interpretation of the Plan by the Committee and any decision made by it under the Plan is final and binding on </span><span style="text-transform: none; line-height: 12pt">all persons.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 45pt; text-align: justify"><span style="text-transform: none; line-height: 12pt"> (d)</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 36pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt">In controlling and managing the operation and administration of the Plan, the Committee shall take action in a manner that conforms to the certificate of incorporation and by-laws of the Company, and applicable state </span><span style="text-transform: none; line-height: 12pt">corporate law.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 45pt; text-align: justify"><span style="text-transform: none; line-height: 12pt"> (e)</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 36pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt">Subject to Section&#160;6.2 hereof, neither the Board, the Committee nor their respective delegates shall have the authority to (i) re</span><span style="text-transform: none; line-height: 12pt"><b>-</b></span><span style="text-transform: none; line-height: 12pt">price (or cancel and regrant) any Option, SAR or, if applicable, other Award at a lower exercise, base or purchase price, (ii) take any other action (whether in the form of an amendment, cancellation or replacement grant, or a cash</span><span style="text-transform: none; line-height: 12pt"><b>-</b></span><span style="text-transform: none; line-height: 12pt">out of underwater options) that has the effect of repricing an Option, SAR or other Award, or (iii) grant any Option, SAR or other Award that contains a so-called &#8220;reload&#8221; feature under which additional Options, SARs or other Awards are granted automatically to the Grantee upon exercise of the original Option, SAR or Award, without in each instance first obtaining the approval of the </span><span style="text-transform: none; line-height: 12pt">Company&#8217;s stockholders.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 45pt; text-align: justify"><span style="text-transform: none; line-height: 12pt"> (f)</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 36pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt">Anything in the Plan to the contrary notwithstanding, neither the Board nor the Committee may accelerate the payment or vesting of any Option, SAR or other Award except in the event of death, disability, retirement or a Change </span><span style="text-transform: none; line-height: 12pt">in Control.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">8.3</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 6pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt"><b>Delegation by Committee</b></span><span style="text-transform: none; line-height: 12pt">.  Except to the extent prohibited by applicable law or the applicable rules of a stock exchange, the Committee may allocate all or any portion of its responsibilities and powers to any one or more of its members and may delegate all or any part of its responsibilities and powers hereunder, including without limitation, the power to designate Participants hereunder and determine the amount, timing and terms of Awards hereunder, to any person or persons selected by it, including without limitation, any executive officer of the Company. Any such allocation or delegation may be revoked by the Committee at </span><span style="text-transform: none; line-height: 12pt">any time.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">8.4</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 6pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt"><b>Information to be Furnished to Committee</b></span><span style="text-transform: none; line-height: 12pt">.  The Company and Subsidiaries shall furnish the Committee with such data and information as it determines may be required for it to discharge its duties. The records of the Company and Subsidiaries as to an employee&#8217;s or Participant&#8217;s employment, termination of employment, leave of absence, reemployment and compensation shall be conclusive unless the Committee determines such records to be incorrect. Participants and other persons entitled to benefits under the Plan must furnish the Committee such evidence, data or information as the Committee considers desirable to carry out the terms of </span><span style="text-transform: none; line-height: 12pt">the Plan.</span></p>

			</div>

		</div>
		<div style="page-break-before: always">
			<p style="margin: 0pt; font-size: 5pt">&#8203;</p>

		</div>
		<div class="qes_page" style="border-bottom: black 2pt solid; margin: auto; height: 990pt; width: 765pt; position: relative; overflow: hidden">
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 911.25pt; left: 45pt; width: 675pt; position: absolute; height: 33.75pt">
				<div style="display: table-cell; vertical-align: bottom; width: 675pt; height: 33.75pt">

				<!--[if IE]><TABLE><TR style=" width: 675pt; height: 33.75pt;"><TD vAlign="bottom" style=" width: 675pt; height: 33.75pt;"><![endif]-->
					<div style="font: 12pt/normal Times New Roman, Times, serif; margin: 0pt; text-transform: none; color: #000000; text-align: left">
						<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 0pt; border-collapse: collapse">
							<tr style="margin: 0; height: 0">
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>

							</tr>
							<tr style="min-height: 0pt">
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">ARTIVION, INC. | 2025 Proxy Statement</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">B-9</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 0pt; line-height: 0pt">&#8203;</p>

								</td>

							</tr>

						</table>

					</div>


				<!--[if IE]></TD></TR></TABLE><![endif]-->
				</div>

			</div>
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 45pt; left: 45pt; width: 675pt; position: absolute; height: 866.25pt">
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">8.5</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 6pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt"><b>Indemnification</b></span><span style="text-transform: none; line-height: 12pt; font-style: italic"><i>.</i></span><span style="text-transform: none; line-height: 12pt">  Each person who is or sh</span><span style="text-transform: none; line-height: 12pt">all have been a member of the Committee, or the Board, shall be indemnified and held harmless by the Company against and from any loss, cost, liability or expense that may be imposed upon or reasonably incurred by him or her in connection with or resulting from any claim, action, suit or proceeding to which he or she may be a party or in which he or she may be involved by reason of any action taken or failure to act under the Plan and against and from any and all amounts paid by him or her in settlement thereof, with the Company&#8217;s approval, or paid by him or her in satisfaction of any judgment in any such action, suit or proceeding against him or her, provided he or she shall give the Company an opportunity, at its own expense, to handle and defend the same before he or she undertakes to handle and defend it on his or her own behalf. The foregoing right of indemnification shall be in addition to any other rights of indemnification or elimination of liability to which such persons may be entitled under the Company&#8217;s Certificate of Incorporation or Bylaws, as a matter of law, or otherwise, or any power that the Company may have to indemnify them or hold </span><span style="text-transform: none; line-height: 12pt">them harmless.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; line-height: 12pt">SECTION 9<br/>AMENDMENT </span><span style="text-transform: none; line-height: 12pt">AND TERMINATION</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 45pt; text-align: justify"><span style="text-transform: none; line-height: 12pt"> (a)</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 36pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt">The Plan may be terminated or amended by the Board of Directors at any time, except that the following actions may not be taken without </span><span style="text-transform: none; line-height: 12pt">stockholder approval:</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 90pt; text-align: justify"><span style="text-transform: none; line-height: 12pt"> (i)</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 36pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt">any increase in the number of shares that may be issued under the Plan (except by certain adjustments provided for under </span><span style="text-transform: none; line-height: 12pt">the Plan);</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 90pt; text-align: justify"><span style="text-transform: none; line-height: 12pt"> (ii)</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 36pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt">any change in the class of persons eligible to receive Awards under </span><span style="text-transform: none; line-height: 12pt">the Plan;</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 90pt; text-align: justify"><span style="text-transform: none; line-height: 12pt"> (iii)</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 36pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt">any change in the requirements of Section 2.2 hereof regarding the Exercise Price of Options </span><span style="text-transform: none; line-height: 12pt">and SARs;</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 90pt; text-align: justify"><span style="text-transform: none; line-height: 12pt"> (iv)</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 36pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt">any re</span><span style="text-transform: none; line-height: 12pt"><b>-</b></span><span style="text-transform: none; line-height: 12pt">pricing or cancellation and regrant of any Option or, if applicable, other Award at a lower exercise, base or purchase price, whether in the form of an amendment, cancellation or replacement grant, or a cash-out of underwater options or any action that provides for Awards that contain a so</span><span style="text-transform: none; line-height: 12pt"><b>-</b></span><span style="text-transform: none; line-height: 12pt">called &#8220;reload&#8221; feature under which additional Options or other Awards are granted automatically to the Grantee upon exercise of the original Option or </span><span style="text-transform: none; line-height: 12pt">Award; or</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 90pt; text-align: justify"><span style="text-transform: none; line-height: 12pt"> (v)</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 36pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt">any other amendment to the Plan that would require approval of the Company&#8217;s stockholders under applicable law, regulation </span><span style="text-transform: none; line-height: 12pt">or rule.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">Notwithstanding any of the foregoing, adjustments pursuant to paragraph 6.2 shall not be subject to the foregoing limitations of this </span><span style="text-transform: none; line-height: 12pt">Section 9.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 45pt; text-align: justify"><span style="text-transform: none; line-height: 12pt"> (b)</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 36pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt">Options, SARs and other Awards may not be granted under the Plan after the date of termination of the Plan, but Options and SARs granted prior to that date shall continue to be exercisable according to their terms and other Awards shall continue to vest in accordance with </span><span style="text-transform: none; line-height: 12pt">their terms.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; line-height: 12pt">SECTION 10<br/>CHANGE </span><span style="text-transform: none; line-height: 12pt">IN CONTROL</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">Subject to the provisions of paragraph 6.2 (relating to the adjustment of shares), and except as otherwise provided in the Plan or the Award Agreement reflecting the applicable Award, upon the occurrence of a Change in Control as defined in </span><span style="text-transform: none; line-height: 12pt">Section 11:</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 45pt; text-align: justify"><span style="text-transform: none; line-height: 12pt"> (a)</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 36pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt">All outstanding Options (regardless of whether in tandem with SARs) shall become </span><span style="text-transform: none; line-height: 12pt">fully exercisable.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 45pt; text-align: justify"><span style="text-transform: none; line-height: 12pt"> (b)</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 36pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt">All outstanding SARs (regardless of whether in tandem with Options) shall become </span><span style="text-transform: none; line-height: 12pt">fully exercisable.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 45pt; text-align: justify"><span style="text-transform: none; line-height: 12pt"> (c)</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 36pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt">All Stock Units, Restricted Stock, Restricted Stock Units, Performance Shares and other Awards, other than Cash-Based Awards, shall become fully vested.  Whether or not Cash</span><span style="text-transform: none; line-height: 12pt"><b>-</b></span><span style="text-transform: none; line-height: 12pt">Based Awards shall vest upon a Change in Control shall be determined by the Committee in its discretion, either at or </span><span style="text-transform: none; line-height: 12pt">after grant.</span></p>

			</div>

		</div>
		<div style="page-break-before: always">
			<p style="margin: 0pt; font-size: 5pt">&#8203;</p>

		</div>
		<div class="qes_page" style="border-bottom: black 2pt solid; margin: auto; height: 990pt; width: 765pt; position: relative; overflow: hidden">
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 911.25pt; left: 45pt; width: 675pt; position: absolute; height: 33.75pt">
				<div style="display: table-cell; vertical-align: bottom; width: 675pt; height: 33.75pt">

				<!--[if IE]><TABLE><TR style=" width: 675pt; height: 33.75pt;"><TD vAlign="bottom" style=" width: 675pt; height: 33.75pt;"><![endif]-->
					<div style="font: 12pt/normal Times New Roman, Times, serif; margin: 0pt; text-transform: none; color: #000000; text-align: left">
						<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 0pt; border-collapse: collapse">
							<tr style="margin: 0; height: 0">
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>

							</tr>
							<tr style="min-height: 0pt">
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">ARTIVION, INC. | 2025 Proxy Statement</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">B-10</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 0pt; line-height: 0pt">&#8203;</p>

								</td>

							</tr>

						</table>

					</div>


				<!--[if IE]></TD></TR></TABLE><![endif]-->
				</div>

			</div>
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 45pt; left: 45pt; width: 675pt; position: absolute; height: 866.25pt">
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; line-height: 12pt">SECTION </span><span style="text-transform: none; line-height: 12pt">11<br/>DEFINED TERMS</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">In addition to the other definitions contained herein, the following definitions </span><span style="text-transform: none; line-height: 12pt">shall apply:</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 45pt; text-align: justify"><span style="text-transform: none; line-height: 12pt"> (a)</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 36pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt"><b>Award</b></span><span style="text-transform: none; line-height: 12pt">.  The term &#8220;Award&#8221; shall mean any award or benefit granted under the Plan, including, without limitation, the grant of Options, SARs, Other Stock Awards and </span><span style="text-transform: none; line-height: 12pt">Cash-Based awards.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 45pt; text-align: justify"><span style="text-transform: none; line-height: 12pt"> (b)</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 36pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt"><b>Board</b></span><span style="text-transform: none; line-height: 12pt">.  The term &#8220;Board&#8221; shall mean the Board of Directors of </span><span style="text-transform: none; line-height: 12pt">the Company.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 45pt; text-align: justify"><span style="text-transform: none; line-height: 12pt"> (c)</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 36pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt"><b>Change in Control</b></span><span style="text-transform: none; line-height: 12pt">.  &#8220;Change in Control&#8221; means a change in the ownership or effective control of, or in the ownership of a substantial portion of the assets of, the Company, as described in paragraphs (i) through </span><span style="text-transform: none; line-height: 12pt">(iii) below.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 90pt; text-align: justify"><span style="text-transform: none; line-height: 12pt"> (i)</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 36pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt"><b>Change in Ownership of the Company</b></span><span style="text-transform: none; line-height: 12pt">.  A change in the ownership of the Company shall occur on the date that any one person, or more than one person acting as a group (within the meaning of paragraph (iv)), acquires ownership of the Company stock that, together with the Company stock held by such person or group, constitutes more than 50% of the total voting power of the stock of </span><span style="text-transform: none; line-height: 12pt">the Company.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 135pt; text-align: justify"><span style="text-transform: none; line-height: 12pt"> (A)</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 36pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt">If any one person or more than one person acting as a group (within the meaning of paragraph (iv) below), is considered to own more than 50% of the total voting power of the stock of the Company, the acquisition of additional the Company stock by such person or persons shall not be considered to cause a change in the ownership of the Company or to cause a change in the effective control of the Company (within the meaning of paragraph </span><span style="text-transform: none; line-height: 12pt">(ii) below).</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 135pt; text-align: justify"><span style="text-transform: none; line-height: 12pt"> (B)</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 36pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt">An increase in the percentage of the Company stock owned by any one person, or persons acting as a group (within the meaning of paragraph (iv) below), as a result of a transaction in which the Company acquires its stock in exchange for property, shall be treated as an acquisition of stock for purposes of this </span><span style="text-transform: none; line-height: 12pt">paragraph (i).</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 135pt; text-align: justify"><span style="text-transform: none; line-height: 12pt"> (C)</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 36pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt">Except as provided in (B) above, the provisions of this paragraph (i)&#160;shall apply only to the transfer or issuance of the Company stock if such stock remains outstanding after such transfer </span><span style="text-transform: none; line-height: 12pt">or issuance.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 90pt; text-align: justify"><span style="text-transform: none; line-height: 12pt"> (ii)</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 36pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt">Change in Effective Control of </span><span style="text-transform: none; line-height: 12pt">the Company.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 135pt; text-align: justify"><span style="text-transform: none; line-height: 12pt"> (A)</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 36pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt">A change in the effective control of the Company shall occur on the date that either of (1) or (2) </span><span style="text-transform: none; line-height: 12pt">below occurs:</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 180pt; text-align: justify"><span style="text-transform: none; line-height: 12pt"> (1)</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 36pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt">Any one person, or more than one person acting as a group (within the meaning of paragraph (iv)&#160;below), acquires (or has acquired during the 12 month period ending on the date of the most recent acquisition by such person or persons) ownership of stock of the Company possessing 30% or more of the total voting power of the stock of the </span><span style="text-transform: none; line-height: 12pt">Company; or</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 180pt; text-align: justify"><span style="text-transform: none; line-height: 12pt"> (2)</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 36pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt">A majority of the members of the Board are replaced during any 12-month period by Directors whose appointment or election is not endorsed by a majority of the Board prior to the date of the appointment </span><span style="text-transform: none; line-height: 12pt">or election.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 135pt; text-align: justify"><span style="text-transform: none; line-height: 12pt"> (B)</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 36pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt">A change in effective control of the Company also may occur with respect to any transaction in which either of the Company or the other entity involved in a transaction experiences a Change of Control event described in paragraphs (i) </span><span style="text-transform: none; line-height: 12pt">or (iii).</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 135pt; text-align: justify"><span style="text-transform: none; line-height: 12pt"> (C)</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 36pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt">If any one person, or more than one person acting as a group (within the meaning of paragraph (iv)&#160;below), is considered to effectively control the Company (within the meaning of this paragraph (ii)), the acquisition of additional control of the Company by the same person or persons shall not be considered to cause a change in the effective control of the Company (or to cause a change in the ownership of the Company within the meaning of paragraph </span><span style="text-transform: none; line-height: 12pt">(i) above).</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 90pt; text-align: justify"><span style="text-transform: none; line-height: 12pt"> (iii)</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 36pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt"><b>Change in Ownership of a Substantial Portion of the Company&#8217;s Assets</b></span><span style="text-transform: none; line-height: 12pt">.  A change in the ownership of a substantial portion of the Company&#8217;s assets shall occur on the date that any one person, or more than one person acting as a group (within the meaning of paragraph (iv)&#160;below), acquires (or has acquired during the 12 month period ending on the date of the most recent acquisition by such person or persons) assets from the Company that have a total gross fair market value (within the meaning of paragraph (iii)(B)) equal to or more than 40% of the total gross fair market value of all of the assets of the Company immediately prior to such acquisition </span><span style="text-transform: none; line-height: 12pt">or acquisitions.</span></p>

			</div>

		</div>
		<div style="page-break-before: always">
			<p style="margin: 0pt; font-size: 5pt">&#8203;</p>

		</div>
		<div class="qes_page" style="border-bottom: black 2pt solid; margin: auto; height: 990pt; width: 765pt; position: relative; overflow: hidden">
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 911.25pt; left: 45pt; width: 675pt; position: absolute; height: 33.75pt">
				<div style="display: table-cell; vertical-align: bottom; width: 675pt; height: 33.75pt">

				<!--[if IE]><TABLE><TR style=" width: 675pt; height: 33.75pt;"><TD vAlign="bottom" style=" width: 675pt; height: 33.75pt;"><![endif]-->
					<div style="font: 12pt/normal Times New Roman, Times, serif; margin: 0pt; text-transform: none; color: #000000; text-align: left">
						<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 0pt; border-collapse: collapse">
							<tr style="margin: 0; height: 0">
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>

							</tr>
							<tr style="min-height: 0pt">
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">ARTIVION, INC. | 2025 Proxy Statement</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">B-11</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 0pt; line-height: 0pt">&#8203;</p>

								</td>

							</tr>

						</table>

					</div>


				<!--[if IE]></TD></TR></TABLE><![endif]-->
				</div>

			</div>
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 45pt; left: 45pt; width: 675pt; position: absolute; height: 866.25pt">
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 135pt; text-align: justify"><span style="text-transform: none; line-height: 12pt"> (A)</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 36pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt">A transfer of the Company&#8217;s assets shall not be treated as a change in the ownership of such assets if the assets are transferred to one or more of </span><span style="text-transform: none; line-height: 12pt">the following:</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 180pt; text-align: justify"><span style="text-transform: none; line-height: 12pt"> (1)</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 36pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt">A shareholder of the Company (immediately before the as</span><span style="text-transform: none; line-height: 12pt">set transfer) in exchange for or with respect to the </span><span style="text-transform: none; line-height: 12pt">Company stock;</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 180pt; text-align: justify"><span style="text-transform: none; line-height: 12pt"> (2)</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 36pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt">An entity, 50% or more of the total value or voting power of which is owned, directly or indirectly, by </span><span style="text-transform: none; line-height: 12pt">the Company;</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 180pt; text-align: justify"><span style="text-transform: none; line-height: 12pt"> (3)</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 36pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt">A person, or more than one person acting as a group (within the meaning of paragraph (iv)&#160;below) that owns, directly or indirectly, 50% or more of the total value or voting power of all of the outstanding stock of the </span><span style="text-transform: none; line-height: 12pt">Company; or</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 180pt; text-align: justify"><span style="text-transform: none; line-height: 12pt"> (4)</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 36pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt">An entity, at least 50% of the total value or voting power of which is owned, directly or indirectly, by a person described in </span><span style="text-transform: none; line-height: 12pt">paragraph (iii)(A)(3).</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">For purposes of this paragraph (iii)(A), and except as otherwise provided, a person&#8217;s status is determined immediately after the transfer </span><span style="text-transform: none; line-height: 12pt">of assets.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 135pt; text-align: justify"><span style="text-transform: none; line-height: 12pt"> (B)</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 36pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt">For purposes of this paragraph (iii), gross fair market value means the value of all the Company assets, or the value of the assets being disposed of, determined without regard to any liabilities associated with </span><span style="text-transform: none; line-height: 12pt">such assets.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 90pt; text-align: justify"><span style="text-transform: none; line-height: 12pt"> (iv)</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 36pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt">For purposes of this Section 11(c), persons shall be considered to be acting as a group if they are owners of an entity that enters into a merger, consolidation, purchase, or acquisition of assets, or similar business transaction with the Company.  If a person, including an entity shareholder, owns stock in the Company and another entity with which the Company enters into a merger, consolidation, purchase, or acquisition of stock, or similar business transaction, such shareholder shall be considered to be acting as a group with the other shareholders in a corporation only to the extent of the ownership in that corporation prior to the transaction giving rise to the change and not with respect to the ownership interest in the other corporation.  Persons shall not be considered to be acting as a group solely because they purchase or own stock of the Company at the same time, or as a result of the same public offering of the </span><span style="text-transform: none; line-height: 12pt">Company&#8217;s stock.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 45pt; text-align: justify"><span style="text-transform: none; line-height: 12pt"> (d)</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 36pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt"><b>Code</b></span><span style="text-transform: none; line-height: 12pt">.  The term &#8220;Code&#8221; means the Internal Revenue Code of 1986, as amended. A reference to any provision of the Code shall include reference to any successor provision of </span><span style="text-transform: none; line-height: 12pt">the Code.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 45pt; text-align: justify"><span style="text-transform: none; line-height: 12pt"> (e)</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 36pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt"><b>Covered Employee</b></span><span style="text-transform: none; line-height: 12pt">.  The term &#8220;Covered Employee&#8221; means an Eligible Grantee who is, or who is anticipated to become, between the time of grant and payment of the Award, a &#8220;covered employee,&#8221; as such term is defined in Section 162(m)(3) of the Code (or any successor </span><span style="text-transform: none; line-height: 12pt">section thereof).</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 45pt; text-align: justify"><span style="text-transform: none; line-height: 12pt"> (f)</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 36pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt"><b>Eligible Grantee</b></span><span style="text-transform: none; line-height: 12pt">. The term &#8220;Eligible Grantee&#8221; shall mean any director, officer, employee, consultant, or agent of the Company or a Subsidiary, as determined by the Committee in its sole discretion. An Award may be granted to an eligible grantee, in connection with hiring, retention or otherwise, prior to the date the eligible grantee first performs services for the Company or the Subsidiaries, provided that such Award shall not become vested prior to the date the eligible grantee first performs such services or the director assumes </span><span style="text-transform: none; line-height: 12pt">his position.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 45pt; text-align: justify"><span style="text-transform: none; line-height: 12pt"> (g)</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 36pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt"><b>Fair Market Value</b></span><span style="text-transform: none; line-height: 12pt">.  For purposes of determining the &#8220;Fair Market Value&#8221; of a share of Stock as of any date, then the &#8220;Fair Market Value&#8221; as of that date shall be the closing sale price of the Stock on that date on the New York </span><span style="text-transform: none; line-height: 12pt">Stock Exchange.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 45pt; text-align: justify"><span style="text-transform: none; line-height: 12pt"> (h)</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 36pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt"><b>Performance Goals</b></span><span style="text-transform: none; line-height: 12pt">.  The term &#8220;Performance Goals&#8221; means performance goals based on the attainment by the Company or any Subsidiary of the Company (or any division or business unit of any such entity), or any two or more of the foregoing, of performance goals established by the Committee in its sole discretion, based on one or more of the following criteria, which shall not be required to be calculated in accordance with GAAP and which may be adjusted measures: (1) return on total stockholders&#8217; equity; (2) earnings per share of Stock; (3) earnings before any or all of interest, taxes, minority interest, depreciation and amortization; (4) economic profit; (5) sales or revenues; (6) return on assets, capital or investment; (7) market share; (8) control of operating or non-operating expenses; (9) reductions in certain costs (including reductions in inventories or accounts receivable or reductions in operating expenses); (10) operating profit; (11) operating cash flow; (12) free cash flow; (13) return on capital or increase in pretax earnings; (14) net earnings; (15) margins; (16) market price of the Company&#8217;s securities; (17) pre-tax earnings; (18) net after</span><span style="text-transform: none; line-height: 12pt"><b>-</b></span><span style="text-transform: none; line-height: 12pt">tax earnings per share; (19) working capital targets; (20) working capital and the ratio of sales to net working capital; (21) earnings </span><span style="text-transform: none; line-height: 12pt">before interest, </span></p>

			</div>

		</div>
		<div style="page-break-before: always">
			<p style="margin: 0pt; font-size: 5pt">&#8203;</p>

		</div>
		<div class="qes_page" style="border-bottom: black 2pt solid; margin: auto; height: 990pt; width: 765pt; position: relative; overflow: hidden">
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 911.25pt; left: 45pt; width: 675pt; position: absolute; height: 33.75pt">
				<div style="display: table-cell; vertical-align: bottom; width: 675pt; height: 33.75pt">

				<!--[if IE]><TABLE><TR style=" width: 675pt; height: 33.75pt;"><TD vAlign="bottom" style=" width: 675pt; height: 33.75pt;"><![endif]-->
					<div style="font: 12pt/normal Times New Roman, Times, serif; margin: 0pt; text-transform: none; color: #000000; text-align: left">
						<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 0pt; border-collapse: collapse">
							<tr style="margin: 0; height: 0">
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>
								<td style="border-width: 0; margin: 0; padding: 0; width: 225pt">


								</td>

							</tr>
							<tr style="min-height: 0pt">
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">ARTIVION, INC. | 2025 Proxy Statement</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="font: 12pt/normal Times New Roman, Times, serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; font-size: 9pt; font-family: Arial, sans-serif">B-12</span></p>

								</td>
								<td style="border-width: 0pt; padding: 0pt; vertical-align: top; border-collapse: collapse">
									<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 0pt; line-height: 0pt">&#8203;</p>

								</td>

							</tr>

						</table>

					</div>


				<!--[if IE]></TD></TR></TABLE><![endif]-->
				</div>

			</div>
			<div class="qes_textframe" style="border-width: 0pt; padding: 0pt; top: 45pt; left: 45pt; width: 675pt; position: absolute; height: 866.25pt">
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">taxes, depreciation and amortization (&#8220;EBITDA&#8221;); (22) sales of one or more products or service offerings; (23) control of operating and/or non-operating expenses; (24) any combination of, or a specified increase in, any of the foregoing; and (25) general comparisons with other peer companies or industry groups or classifications with regard to one or more of the foregoing criteria. The relative weights of the criteria that comprise the Performance Goals shall be determined by the Committee in its sole discretion. In establishing the Performance Goals for a performance period, the Committee may establish different Performance Goals for individual Participants or groups of Participants.  Subject to the limitations in Section 5, the Committee in its sole discretion shall have the authority to make equitable adjustments to the Performance Goals in recognition of unusual or non-recurring events affecting the Company or any Subsidiary of the Company or the financial statements of the Company or any Subsidiary of the Company, in response to changes in applicable laws or regulations, including changes in generally accepted accounting principles or practices, or to account for items of gain, loss or expense determined to be extraordinary or unusual in nature or infrequent in occurrence or related to the disposal of a segment of a business, as applicable, or otherwise as the Committee deems appropriate.  Performance Goals may include a threshold level of performance below which no Award will be earned, a level of performance at which the target amount of an Award will be earned and a level of performance at which the maximum amount of the Award will be earned.  &#8220;Performance Goals&#8221; shall also mean any other factors directly tied to the performance of the Company and/or one or more divisions and/or Subsidiaries or other performance criteria designated by </span><span style="text-transform: none; line-height: 12pt">the Committee.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 45pt; text-align: justify"><span style="text-transform: none; line-height: 12pt"> (i)</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 36pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt"><b>Subsidiaries</b></span><span style="text-transform: none; line-height: 12pt">.  The term &#8220;Subsidiary&#8221; means any present or future subsidiary corporation of the Company within the meaning of Section 424(f) of the Code, and any present or future business venture designated by the Committee in which the Company has a significant interest, as determined in the discretion of </span><span style="text-transform: none; line-height: 12pt">the Committee.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 45pt; text-align: justify"><span style="text-transform: none; line-height: 12pt"> (j)</span><!--[if IE]><FONT style=" width: 36.0pt; text-indent: 0.0pt; display: inline-block;"><![endif]--><span style="width: 36pt; text-indent: 0; display: inline-block"><span>&#160;</span></span><!--[if IE]></FONT><![endif]--><span style="text-transform: none; line-height: 12pt"><b>Stock</b></span><span style="text-transform: none; line-height: 12pt">.  The term &#8220;Stock&#8221; shall mean shares of common stock of </span><span style="text-transform: none; line-height: 12pt">the Company.</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none; line-height: 12pt">SECTION </span><span style="text-transform: none; line-height: 12pt">12<br/>GOVERNING LAW</span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">This Plan shall be governed by, and construed in accordance with, the laws of the State </span><span style="text-transform: none; line-height: 12pt">of Delaware.</span></p>

			</div>

		</div>

	<div style="page-break-before: always">
			<p style="margin: 0pt; font-size: 5pt">&#8203;</p>

		</div>


<p style="font: bold 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 85.8pt 0pt 84.95pt; text-align: center">&#160;</p>

<p style="font: bold 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 85.8pt 0pt 84.95pt; text-align: center"></p>

<p style="font: bold 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 85.8pt 0pt 84.95pt; text-align: center"><span style="font-size: 12pt; color: #231F20">ANNUAL MEETING OF STOCKHOLDERS OF</span></p>



<p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&#160;</p>

<p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><img src="proxycard001.jpg" alt=""/>&#160;</p>

<p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&#160;</p>

<p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 12pt"><b>May
13, 2025</b></span></p>

<p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&#160;</p>

<p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"><b>GO
GREEN</b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 2in; text-align: justify; color: #231F20"><span style="font-size: 8pt">e-Consent makes it easy to go paperless. With e-Consent, you can quickly access your proxy material, statements and other
eligible documents online, while reducing costs, clutter and paper waste. Enroll today via https://equiniti.com/us/ast-access
to enjoy online access.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 156.55pt 0pt 155.65pt; text-align: center">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 1in; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt; color: #231F20"><b><span style="text-decoration: underline">NOTICE
OF INTERNET AVAILABILITY OF PROXY MATERIAL</span>:</b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 2in; text-align: center; text-indent: 0; color: #231F20">The Notice of Meeting, proxy statement and proxy card <br/>
are available at http://www.astproxyportal.com/ast/01609</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 176.1pt 0pt 175.2pt; text-align: center; text-indent: -0.1pt; color: #231F20">&#160;</p>

<p style="font: 18pt Arial, Helvetica, Sans-Serif; margin: 0pt 2in; text-align: center; text-indent: 0; color: #231F20"><span style="font-size: 18pt">Please
sign, date and mail <br/>
your proxy card in the <br/>
envelope provided as soon <br/>
as possible.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 156.55pt 0pt 154.3pt; text-align: center; color: #231F20">&#160;</p>

<p style="margin-top: 0; margin-bottom: 0; text-align: center"><img src="proxycard002.jpg" alt=""/><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">&#160;Please detach along perforated line and mail in the envelope provided.&#160;<img src="proxycard002.jpg" alt=""/></span></p>

<p style="margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 6pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"> <tr style="vertical-align: top; text-align: justify">
<td style="width: 2%; background-color: Black"/><td style="width: 46%; text-align: left; padding-left: 0.25in"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 12pt">20930303000000000000 1</span></td><td style="text-align: left; width: 52%; padding-left: 60pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 12pt">051325</span></td>
</tr> </table>

<p style="margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify"><span style="font-size: 6pt">&#160;</span></p>

<p style="margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify"></p>

<!-- Field: Rule-Page --><div style="text-align: left"><div style="border-top: Black 1pt solid; font-size: 1pt; width: 100%">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt; color: #231F20"><span style="font-size: 6pt; color: Black">THE
BOARD OF DIRECTORS RECOMMENDS A VOTE FOR THE ELECTION OF THE DIRECTOR NOMINEES NAMED BELOW, FOR APPROVAL OF THE COMPENSATION PAID
TO ARTIVION&#8217;S NAMED EXECUTIVE OFFICERS, FOR RATIFICATION OF THE PRELIMINARY APPROVAL OF ERNST &amp; YOUNG LLP AS THE INDEPENDENT
REGISTERED PUBLIC ACCOUNTING FIRM FOR THE COMPANY FOR THE FISCAL YEAR ENDING DECEMBER 31, 2025, AND FOR THE APPROVAL OF ADDITIONAL
FUNDING OF 3,570,000 SHARES FOR THE AMENDED AND RESTATED ARTIVION, INC. 2020 EQUITY AND CASH INCENTIVE PLAN.</span></p>

<p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><span style="font-size: 4pt">&#160;</span></p>

<p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 7pt"><b>PLEASE SIGN, DATE AND RETURN PROMPTLY IN THE ENCLOSED ENVELOPE. PLEASE MARK YOUR VOTE IN BLUE OR BLACK INK AS SHOWN HERE </b></span><b><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">&#9746;</span></b></p>

<!-- Field: Rule-Page --><div style="text-align: left"><div style="border-top: Black 1pt solid; font-size: 1pt; width: 100%">&#160;</div></div><!-- Field: /Rule-Page -->
<div style="position: relative; float: left; width: 46%"><table cellspacing="0" cellpadding="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
 <tr style="vertical-align: top"><td colspan="4" style="border-right: Black 1pt solid; padding-top: 10pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt; color: #231F20">1.
                                       ELECTION OF DIRECTORS</span></td></tr>
<tr style="vertical-align: top">
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-right: Black 1pt solid"><span style="font-size: 8pt">&#160;</span></td></tr>
<tr style="vertical-align: top">
    <td style="padding-bottom: 8pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 8pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-right: Black 1pt solid; padding-bottom: 8pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt; color: #231F20"><b>NOMINEES:</b></span></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: left; vertical-align: top"><span style="font-size: 12pt">&#160;&#9744;</span></td>
    <td style="text-align: left; vertical-align: middle"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt; color: #231F20"><b>FOR ALL NOMINEES</b></span></td>
    <td colspan="2" rowspan="5" style="border-right: Black 1pt solid"><p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #231F20"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">O&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="font-size: 8pt">Thomas F. Ackerman</span></p>
        <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #231F20"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">O&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="font-size: 8pt">Daniel J. Bevevino</span></p>
        <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #231F20"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">O&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="font-size: 8pt">Marna P. Borgstrom</span></p>
        <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #231F20"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">O&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="font-size: 8pt">James W. Bullock</span></p>
        <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #231F20"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">O&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="font-size: 8pt">Jeffrey H. Burbank</span></p>
        <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #231F20"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">O&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="font-size: 8pt">Elizabeth A. Hoff</span></p>
        <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 8.65pt; text-indent: -8.65pt; color: #231F20"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">O&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="font-size: 8pt">J. Patrick Mackin</span></p>
        <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 8.65pt; text-indent: -8.65pt; color: #231F20"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">O&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="font-size: 8pt">Jon W. Salveson</span></p>
        <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 8.65pt; text-indent: -8.65pt; color: #231F20"><span style="font: 8pt Arial, Helvetica, Sans-Serif">O&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="font-size: 8pt">Anthony B. Semedo</span></p></td></tr>
<tr style="vertical-align: top">
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: left; vertical-align: middle"><span style="font-size: 12pt">&#160;&#9744;</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"><b>WITHHOLD AUTHORITY<br/>
    FOR ALL NOMINEES</b></span></td></tr>
<tr style="vertical-align: top">
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: left; vertical-align: middle"><span style="font-size: 12pt">&#160;&#9744;</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt; color: #231F20"><b>FOR ALL EXCEPT </b></span><span style="font-size: 8pt"><br/>
    <span style="font-family: Arial, Helvetica, Sans-Serif; color: #231F20">(See instructions below)</span></span></td></tr>
<tr style="vertical-align: top">
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-right: Black 1pt solid"><span style="font-size: 8pt">&#160;</span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-right: Black 1pt solid">&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-right: Black 1pt solid">&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-right: Black 1pt solid">&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-right: Black 1pt solid">&#160;</td></tr>
<tr style="vertical-align: top">
    <td colspan="4" style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-left: 0.9in; text-indent: -0.9in; padding-top: 10pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 7pt; color: #231F20"><b><span style="text-decoration: underline">INSTRUCTIONS:</span>&#160;</b>&#160;&#160;&#160;To
    withhold authority to vote for any individual nominee(s), mark <b>&#8220;FOR ALL EXCEPT&#8221;</b> and fill in the circle
    next to each nominee you wish to withhold, as shown here: </span><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt; color: #231F20">&#9679;</span></td></tr>
<tr style="vertical-align: top">
    <td colspan="4" style="border-right: Black 1pt solid; padding-left: 0.7in; text-indent: -0.7in"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt; color: #231F20"><b>&#160;</b></span></td></tr>
<tr style="vertical-align: top">
    <td colspan="4" style="border-right: Black 1pt solid; padding-left: 0.7in; text-indent: -0.7in">&#160;</td></tr>
<tr style="vertical-align: top">
    <td colspan="4" style="border-right: Black 1pt solid; padding-left: 0.7in; text-indent: -0.7in">&#160;</td></tr>
<tr style="vertical-align: top">
    <td colspan="4" style="border-right: Black 1pt solid; padding-left: 0.7in; text-indent: -0.7in">&#160;</td></tr>
<tr style="vertical-align: top">
    <td colspan="4" style="border-right: Black 1pt solid; padding-left: 0.7in; text-indent: -0.7in">&#160;</td></tr>
<tr style="vertical-align: top">
    <td colspan="4" style="border-right: Black 1pt solid; padding-left: 0.7in; text-indent: -0.7in">&#160;</td></tr>
<tr style="vertical-align: top">
    <td colspan="3" style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt; color: #231F20">To change the address on your account, please check the box at right and indicate your new address in the address space above.
Please note that changes to the registered name(s) on the account may not be submitted via this method.</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: middle"><span style="font-size: 8pt">&#160;</span><span style="font-size: 12pt">&#9744;</span></td></tr>
<tr style="vertical-align: top">
    <td style="width: 10%"><span style="font-size: 1pt">&#160;</span></td>
    <td style="width: 43%"><span style="font-size: 1pt">&#160;</span></td>
    <td style="width: 36%"><span style="font-size: 1pt">&#160;</span></td>
    <td style="width: 11%"><span style="font-size: 1pt">&#160;</span></td></tr>
 </table>


</div>
<div style="position: relative; float: right; width: 52%">

<p style="margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
 <tr style="vertical-align: top">
    <td style="width: 82%"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 7pt">&#160;</span></td>
    <td style="width: 6%; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 7pt; color: #231F20">FOR</span></td>
    <td style="width: 6%; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 7pt; color: #231F20">&#160;AGAINST&#160;</span></td>
    <td style="width: 6%; text-align: center"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 7pt; color: #231F20">ABSTAIN</span></td></tr>
<tr style="vertical-align: top">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">2. To approve, by non-binding vote, the compensation paid to Artivion's Named Executive Officers, as disclosed pursuant to Item
402 of Regulation S-K, including the Compensation Discussion and Analysis, compensation tables, and narrative discussion.</span></td>
    <td style="text-align: center; vertical-align: middle"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"><span style="font-size: 12pt">&#9744;</span></span></td>
    <td style="text-align: center; vertical-align: middle"><span style="font-size: 12pt">&#9744;</span></td>
    <td style="text-align: center; vertical-align: middle"><span style="font-size: 12pt">&#9744;</span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: center; vertical-align: bottom"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 7pt">FOR</span></td>
    <td style="text-align: center; vertical-align: bottom"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 7pt">AGAINST</span></td>
    <td style="text-align: center; vertical-align: bottom"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 7pt">ABSTAIN</span></td></tr>
<tr style="vertical-align: top">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">3. To ratify the preliminary approval of Ernst &amp; Young LLP as the independent registered public accounting firm for the company
for the fiscal year ending December 31, 2025.</span></td>
    <td style="text-align: center; vertical-align: middle"><span style="font-size: 12pt">&#9744;</span></td>
    <td style="text-align: center; vertical-align: middle"><span style="font-size: 12pt">&#9744;</span></td>
    <td style="text-align: center; vertical-align: middle"><span style="font-size: 12pt">&#9744;</span></td></tr>
<tr style="vertical-align: top">
    <td style="padding-top: 10pt">&#160;</td>
    <td style="text-align: center; vertical-align: bottom; padding-top: 10pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 7pt">FOR</span></td>
    <td style="text-align: center; vertical-align: bottom; padding-top: 10pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 7pt">AGAINST</span></td>
    <td style="text-align: center; vertical-align: bottom; padding-top: 10pt"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 7pt">ABSTAIN</span></td></tr>
<tr style="vertical-align: top">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">4. To approve additional funding of 3,570,000 shares for the Amended and Restated Artivion, Inc. 2020 Equity and Cash Incentive
Plan.</span></td>
    <td style="text-align: center; vertical-align: middle"><span style="font-size: 12pt">&#9744;</span></td>
    <td style="text-align: center; vertical-align: middle"><span style="font-size: 12pt">&#9744;</span></td>
    <td style="text-align: center; vertical-align: middle"><span style="font-size: 12pt">&#9744;</span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">5. In their discretion, upon such other matters as may properly come before the meeting.</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">&#160;</span></td></tr>
 </table>


<p style="margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify">&#160;&#160;</p>

<p style="margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"><b>THE PROXIES SHALL VOTE AS SPECIFIED ABOVE, OR IF NO DIRECTION IS MADE, THIS PROXY WILL BE VOTED FOR EACH OF THE LISTED NOMINEES,
FOR APPROVAL OF THE COMPENSATION PAID TO ARTIVION'S NAMED EXECUTIVE OFFICERS, IN FAVOR OF THE RATIFICATION OF ERNST &amp;
YOUNG LLP, AND FOR THE APPROVAL OF ADDITIONAL FUNDING OF 3,570,000 SHARES FOR THE AMENDED AND RESTATED ARTIVION, INC. 2020
EQUITY AND CASH INCENTIVE PLAN. SHOULD A NOMINEE BE UNABLE TO SERVE, THIS PROXY MAY BE VOTED FOR A SUBSTITUTE SELECTED BY
THE BOARD OF DIRECTORS.</b></span></p>
</div>
<div style="clear: both"></div>
<table cellspacing="0" cellpadding="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
 <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; width: 20%; padding-top: 3pt; padding-bottom: 3pt; text-align: left; vertical-align: bottom"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt; color: #231F20">Signature
    of Stockholder</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; width: 20%; padding-top: 3pt; padding-bottom: 3pt; text-align: left; vertical-align: bottom"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-right: Black 1pt solid; width: 5%; padding-top: 3pt; padding-bottom: 3pt; text-align: left; vertical-align: bottom"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt; color: #231F20">&#160;&#160;Date:</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; width: 5%; padding-top: 3pt; padding-bottom: 3pt; text-align: left; vertical-align: bottom"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-right: Black 1pt solid; width: 20%; padding-top: 3pt; padding-bottom: 3pt; padding-left: 0.125in; text-align: left; vertical-align: bottom"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt; color: #231F20">Signature
    of Stockholder</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; width: 20%; padding-top: 3pt; padding-bottom: 3pt; text-align: left; vertical-align: bottom"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-right: Black 1pt solid; width: 5%; padding-top: 3pt; padding-bottom: 3pt; text-align: left; vertical-align: bottom"><span style="font-size: 8pt">&#160;&#160;<span style="font-family: Arial, Helvetica, Sans-Serif; color: #231F20">Date:</span></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; width: 5%; padding-top: 3pt; padding-bottom: 3pt; text-align: left; vertical-align: bottom"><span style="font-size: 8pt">&#160;</span></td></tr>
 </table>


<p style="margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify"></p>

<p style="margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
 <tr style="vertical-align: top">
    <td style="width: 2%"><span style="font-size: 8pt">&#160;</span></td>
    <td rowspan="2" style="width: 96%; padding-left: 0.375in; text-indent: -0.375in"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt; color: #231F20"><b>Note:
    </b></span><span style="font-size: 8pt; color: #231F20">&#160;&#160;Please sign exactly as your name or names appear on this Proxy. When shares are held jointly, each holder should sign. When
signing as executor, administrator, attorney, trustee or guardian, please give full title as such. If the signer is a corporation,
please sign full corporate name by duly authorized officer, giving full title as such. If signer is a partnership, please
sign in partnership name by authorized person.</span></td>
    <td style="width: 2%"><span style="font-size: 8pt">&#160;</span></td></tr>
<tr style="vertical-align: top">
    <td style="background-color: Black"><span style="font-size: 8pt">&#160;</span></td>
    <td style="background-color: Black"><span style="font-size: 8pt">&#160;</span></td></tr>
 </table>


<p style="margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify"></p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->




<p style="margin: 0">&#160;</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
 <tr style="vertical-align: top; text-align: left">
    <td style="width: 98%; text-align: right; padding-right: 1in"><span style="font-family: Arial, Helvetica, Sans-Serif">0</span></td>
    <td style="width: 2%; background-color: Black">&#160;</td></tr>
 </table>

<p style="margin: 0"></p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<p style="margin: 0"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 89.4pt 0pt 89.65pt; text-align: center; color: #231F20"><span style="font-size: 14pt"><b>ARTIVION,
INC.</b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 89.4pt 0pt 89.65pt; text-align: center; color: #231F20">&#160;</p>

<p style="font: bold 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 89.4pt 0pt 89.75pt; text-align: center; color: #231F20"><span style="font-size: 12pt">PROXY SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS <br/>
FOR USE AT THE ANNUAL MEETING ON MAY 13, 2025</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 5.55pt 0pt 5.95pt; text-align: justify; text-indent: 25.7pt; color: #231F20">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 5.55pt 0pt 5.95pt; text-align: justify; text-indent: 25.7pt; color: #231F20"><span style="font-size: 12pt">The undersigned stockholder hereby appoints J. PATRICK MACKIN, JEAN F. HOLLOWAY, and JASON P. GRIER, or either of them, with
full power of substitution, to act as proxy for, and to vote the stock of, the undersigned at the Annual Meeting of Stockholders
of ARTIVION, INC. to be held live via the Internet at https://web.lumiconnect.com/295739807 (password: artivion2025) at 9:00
a.m. Eastern Time on May 13, 2025, and any adjournments thereof.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 4.9pt 0pt 5.95pt; text-align: justify; text-indent: 27.7pt; color: #231F20">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 4.9pt 0pt 5.95pt; text-align: justify; text-indent: 27.7pt; color: #231F20"><span style="font-size: 12pt">The undersigned acknowledges receipt of Notice of the Annual Meeting and Proxy Statement, each dated April 1, 2025, and grants
authority to said proxies, or their substitutes, and ratifies and confirms all that said proxies may lawfully do in the undersigned's
name, place, and stead. The undersigned instructs said proxies to vote as indicated below and in their discretion on any other
matter that may properly come before the meeting or any adjournment of the meeting.</span></p>

<p style="font: bold 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 89.4pt 0pt 86.45pt; text-align: center; color: #231F20">&#160;</p>

<p style="font: bold 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 89.4pt 0pt 86.45pt; text-align: center; color: #231F20"><span style="font-size: 12pt">(Continued
and to be signed on the reverse side)</span></p>



<p style="margin: 0">&#160;</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<p style="margin: 0"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
 <tr style="vertical-align: top; text-align: left">
    <td style="width: 2%; background-color: Black"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 48%; padding-left: 0.12in"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">1.1</span></td>
    <td style="width: 48%; text-align: right; padding-right: 0.12in"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">14475</span></td>
    <td style="width: 2%; background-color: Black"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</span></td></tr>
 </table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>



<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->


	</body>

</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>2
<FILENAME>aort-20241231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.0b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +6spw7xRiXhun8uCbn1MSaePqbP9w5dz2elBtm90HSkaLy8h49YEQiCwVMxm0fIO -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:aort="http://Artivion.com/20241231" elementFormDefault="qualified" targetNamespace="http://Artivion.com/20241231">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://Artivion.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://Artivion.com/role/AssumptionsUsedToCalculateCompensationActuallyPaid" id="AssumptionsUsedToCalculateCompensationActuallyPaid">
          <link:definition>999007 - Disclosure - Assumptions used to calculate Compensation Actually Paid</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="aort-20241231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="aort-20241231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="aort-20241231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
    <import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
    <import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
    <import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
    <import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd" />
    <element id="aort_YearEnd2023Member" name="YearEnd2023Member" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aort_Vesting2024Member" name="Vesting2024Member" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aort_YearEnd2024Member" name="YearEnd2024Member" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aort_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFairValuePerShare" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFairValuePerShare" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>3
<FILENAME>aort-20241231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.0b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://Artivion.com/role/Cover" xlink:href="aort-20241231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://Artivion.com/role/AssumptionsUsedToCalculateCompensationActuallyPaid" xlink:href="aort-20241231.xsd#AssumptionsUsedToCalculateCompensationActuallyPaid" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosureWithAdditionalMeasures" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosureWithAdditionalMeasures" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpTable" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsToCompensation" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpAdjustmentsToCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TabularListsByExecutiveCategory" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TabularListsByExecutiveCategory" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TabularListMeasures" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TabularListMeasures" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpMeasures" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpMeasures" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpExecutiveCategoriesOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpAdjustmentsOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#IndividualsOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTypeOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TradingArrangmentsOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ForgoneRecoveries" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ForgoneRecoveries" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/OutstandingRecoveries" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#OutstandingRecoveries" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardsCloseToMnpiDisc" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardsCloseToMnpiDisc" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangementsByInd" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangemenstByInd" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/Defaults" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#Defaults" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://Artivion.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://Artivion.com/role/AssumptionsUsedToCalculateCompensationActuallyPaid" xlink:title="999007 - Disclosure - Assumptions used to calculate Compensation Actually Paid">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaapVestingAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapVestingAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapVestingAxis" xlink:to="loc_us-gaapVestingDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapVestingAxis" xlink:to="loc_us-gaapVestingDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aort-20241231.xsd#aort_YearEnd2023Member" xlink:label="loc_aortYearEnd2023Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_aortYearEnd2023Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="aort-20241231.xsd#aort_Vesting2024Member" xlink:label="loc_aortVesting2024Member_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_aortVesting2024Member_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="aort-20241231.xsd#aort_YearEnd2024Member" xlink:label="loc_aortYearEnd2024Member_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_aortYearEnd2024Member_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharePrice_190" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_190" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_190" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_190" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_190" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="aort-20241231.xsd#aort_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFairValuePerShare" xlink:label="loc_aortSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFairValuePerShare_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_aortSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFairValuePerShare_190" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/AwardTypeOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>aort-20241231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.0b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis" xlink:label="ecd_MeasureAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MeasureAxis" xlink:to="ecd_MeasureAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MeasureAxis_lbl" xml:lang="en-US">Measure [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis" xlink:label="ecd_ExecutiveCategoryAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ExecutiveCategoryAxis" xlink:to="ecd_ExecutiveCategoryAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ExecutiveCategoryAxis_lbl" xml:lang="en-US">Executive Category [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoMember" xlink:label="ecd_PeoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoMember" xlink:to="ecd_PeoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoMember_lbl" xml:lang="en-US">PEO [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis" xlink:label="ecd_AdjToCompAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToCompAxis" xlink:to="ecd_AdjToCompAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToCompAxis_lbl" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:label="ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:to="ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_lbl" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:label="ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:to="ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_lbl" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:label="ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:to="ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_lbl" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:label="ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:to="ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_lbl" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoMember" xlink:label="ecd_NonPeoNeoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonPeoNeoMember" xlink:to="ecd_NonPeoNeoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonPeoNeoMember_lbl" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingAxis_lbl" xml:lang="en-US">Vesting [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="aort-20241231.xsd#aort_YearEnd2023Member" xlink:label="aort_YearEnd2023Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aort_YearEnd2023Member" xlink:to="aort_YearEnd2023Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aort_YearEnd2023Member_lbl" xml:lang="en-US">Year-end 2023 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aort-20241231.xsd#aort_Vesting2024Member" xlink:label="aort_Vesting2024Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aort_Vesting2024Member" xlink:to="aort_Vesting2024Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aort_Vesting2024Member_lbl" xml:lang="en-US">2024 Vesting [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aort-20241231.xsd#aort_YearEnd2024Member" xlink:label="aort_YearEnd2024Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aort_YearEnd2024Member" xlink:to="aort_YearEnd2024Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aort_YearEnd2024Member_lbl" xml:lang="en-US">Year-end 2024 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable" xlink:label="ecd_PvpTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PvpTable" xlink:to="ecd_PvpTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PvpTable_lbl" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock" xlink:label="ecd_PvpTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PvpTableTextBlock" xlink:to="ecd_PvpTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PvpTableTextBlock_lbl" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName" xlink:label="ecd_CoSelectedMeasureName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CoSelectedMeasureName" xlink:to="ecd_CoSelectedMeasureName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CoSelectedMeasureName_lbl" xml:lang="en-US">Company Selected Measure Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock" xlink:label="ecd_NamedExecutiveOfficersFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="ecd_NamedExecutiveOfficersFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NamedExecutiveOfficersFnTextBlock_lbl" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock" xlink:label="ecd_PeerGroupIssuersFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeerGroupIssuersFnTextBlock" xlink:to="ecd_PeerGroupIssuersFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeerGroupIssuersFnTextBlock_lbl" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock" xlink:label="ecd_ChangedPeerGroupFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ChangedPeerGroupFnTextBlock" xlink:to="ecd_ChangedPeerGroupFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ChangedPeerGroupFnTextBlock_lbl" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt" xlink:label="ecd_PeoTotalCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoTotalCompAmt" xlink:to="ecd_PeoTotalCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoTotalCompAmt_lbl" xml:lang="en-US">PEO Total Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt" xlink:label="ecd_PeoActuallyPaidCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoActuallyPaidCompAmt" xlink:to="ecd_PeoActuallyPaidCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoActuallyPaidCompAmt_lbl" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock" xlink:label="ecd_AdjToPeoCompFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToPeoCompFnTextBlock" xlink:to="ecd_AdjToPeoCompFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToPeoCompFnTextBlock_lbl" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt" xlink:label="ecd_NonPeoNeoAvgTotalCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="ecd_NonPeoNeoAvgTotalCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonPeoNeoAvgTotalCompAmt_lbl" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:label="ecd_NonPeoNeoAvgCompActuallyPaidAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="ecd_NonPeoNeoAvgCompActuallyPaidAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonPeoNeoAvgCompActuallyPaidAmt_lbl" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:label="ecd_AdjToNonPeoNeoCompFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="ecd_AdjToNonPeoNeoCompFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToNonPeoNeoCompFnTextBlock_lbl" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:label="ecd_EquityValuationAssumptionDifferenceFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="ecd_EquityValuationAssumptionDifferenceFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_EquityValuationAssumptionDifferenceFnTextBlock_lbl" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:label="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:label="ecd_CompActuallyPaidVsNetIncomeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="ecd_CompActuallyPaidVsNetIncomeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsNetIncomeTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:label="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:label="ecd_TotalShareholderRtnVsPeerGroupTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="ecd_TotalShareholderRtnVsPeerGroupTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TotalShareholderRtnVsPeerGroupTextBlock_lbl" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:label="ecd_CompActuallyPaidVsOtherMeasureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="ecd_CompActuallyPaidVsOtherMeasureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsOtherMeasureTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock" xlink:label="ecd_TabularListTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TabularListTableTextBlock" xlink:to="ecd_TabularListTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TabularListTableTextBlock_lbl" xml:lang="en-US">Tabular List, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt" xlink:label="ecd_TotalShareholderRtnAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TotalShareholderRtnAmt" xlink:to="ecd_TotalShareholderRtnAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TotalShareholderRtnAmt_lbl" xml:lang="en-US">Total Shareholder Return Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt" xlink:label="ecd_PeerGroupTotalShareholderRtnAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="ecd_PeerGroupTotalShareholderRtnAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeerGroupTotalShareholderRtnAmt_lbl" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net Income (Loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt" xlink:label="ecd_CoSelectedMeasureAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CoSelectedMeasureAmt" xlink:to="ecd_CoSelectedMeasureAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CoSelectedMeasureAmt_lbl" xml:lang="en-US">Company Selected Measure Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt" xlink:label="ecd_OtherPerfMeasureAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OtherPerfMeasureAmt" xlink:to="ecd_OtherPerfMeasureAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OtherPerfMeasureAmt_lbl" xml:lang="en-US">Other Performance Measure, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt" xlink:label="ecd_AdjToCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToCompAmt" xlink:to="ecd_AdjToCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToCompAmt_lbl" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName" xlink:label="ecd_PeoName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoName" xlink:to="ecd_PeoName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoName_lbl" xml:lang="en-US">PEO Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName" xlink:label="ecd_MeasureName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MeasureName" xlink:to="ecd_MeasureName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MeasureName_lbl" xml:lang="en-US">Measure Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock" xlink:label="ecd_NonGaapMeasureDescriptionTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="ecd_NonGaapMeasureDescriptionTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonGaapMeasureDescriptionTextBlock_lbl" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock" xlink:label="ecd_Additional402vDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Additional402vDisclosureTextBlock" xlink:to="ecd_Additional402vDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Additional402vDisclosureTextBlock_lbl" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock" xlink:label="ecd_PnsnBnftsAdjFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PnsnBnftsAdjFnTextBlock" xlink:to="ecd_PnsnBnftsAdjFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PnsnBnftsAdjFnTextBlock_lbl" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjFnTextBlock" xlink:label="ecd_EqtyAwrdsAdjFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_EqtyAwrdsAdjFnTextBlock" xlink:to="ecd_EqtyAwrdsAdjFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_EqtyAwrdsAdjFnTextBlock_lbl" xml:lang="en-US">Equity Awards Adjustments, Footnote [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable" xlink:label="ecd_ErrCompRecoveryTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ErrCompRecoveryTable" xlink:to="ecd_ErrCompRecoveryTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ErrCompRecoveryTable_lbl" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis" xlink:label="ecd_RestatementDateAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDateAxis" xlink:to="ecd_RestatementDateAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDateAxis_lbl" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="ecd_IndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_IndividualAxis" xlink:to="ecd_IndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_IndividualAxis_lbl" xml:lang="en-US">Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate" xlink:label="ecd_RestatementDeterminationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDeterminationDate" xlink:to="ecd_RestatementDeterminationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDeterminationDate_lbl" xml:lang="en-US">Restatement Determination Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt" xlink:label="ecd_AggtErrCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AggtErrCompAmt" xlink:to="ecd_AggtErrCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AggtErrCompAmt_lbl" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock" xlink:label="ecd_ErrCompAnalysisTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ErrCompAnalysisTextBlock" xlink:to="ecd_ErrCompAnalysisTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ErrCompAnalysisTextBlock_lbl" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:label="ecd_StkPrcOrTsrEstimationMethodTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="ecd_StkPrcOrTsrEstimationMethodTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_StkPrcOrTsrEstimationMethodTextBlock_lbl" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt" xlink:label="ecd_OutstandingAggtErrCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingAggtErrCompAmt" xlink:to="ecd_OutstandingAggtErrCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingAggtErrCompAmt_lbl" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:label="ecd_AggtErrCompNotYetDeterminedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="ecd_AggtErrCompNotYetDeterminedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AggtErrCompNotYetDeterminedTextBlock_lbl" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName" xlink:label="ecd_ForgoneRecoveryIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryIndName" xlink:to="ecd_ForgoneRecoveryIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:label="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_lbl" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:label="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_lbl" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:label="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_lbl" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:label="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_lbl" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName" xlink:label="ecd_OutstandingRecoveryIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryIndName" xlink:to="ecd_OutstandingRecoveryIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_OutstandingRecoveryIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt" xlink:label="ecd_OutstandingRecoveryCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryCompAmt" xlink:to="ecd_OutstandingRecoveryCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingRecoveryCompAmt_lbl" xml:lang="en-US">Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:label="ecd_RestatementDoesNotRequireRecoveryTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="ecd_RestatementDoesNotRequireRecoveryTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDoesNotRequireRecoveryTextBlock_lbl" xml:lang="en-US">Restatement does not require Recovery</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable" xlink:label="ecd_AwardsCloseToMnpiDiscTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscTable" xlink:to="ecd_AwardsCloseToMnpiDiscTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscTable_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="ecd_AwardTmgMnpiDiscTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiDiscTextBlock" xlink:to="ecd_AwardTmgMnpiDiscTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMnpiDiscTextBlock_lbl" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock" xlink:label="ecd_AwardTmgMethodTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMethodTextBlock" xlink:to="ecd_AwardTmgMethodTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMethodTextBlock_lbl" xml:lang="en-US">Award Timing Method</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag" xlink:label="ecd_AwardTmgPredtrmndFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgPredtrmndFlag" xlink:to="ecd_AwardTmgPredtrmndFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgPredtrmndFlag_lbl" xml:lang="en-US">Award Timing Predetermined</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="ecd_AwardTmgMnpiCnsdrdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag_lbl" xml:lang="en-US">Award Timing MNPI Considered</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="ecd_AwardTmgHowMnpiCnsdrdTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock_lbl" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag" xlink:label="ecd_MnpiDiscTimedForCompValFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MnpiDiscTimedForCompValFlag" xlink:to="ecd_MnpiDiscTimedForCompValFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MnpiDiscTimedForCompValFlag_lbl" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:label="ecd_AwardsCloseToMnpiDiscTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="ecd_AwardsCloseToMnpiDiscTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscTableTextBlock_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName" xlink:label="ecd_AwardsCloseToMnpiDiscIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscIndName" xlink:to="ecd_AwardsCloseToMnpiDiscIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_AwardsCloseToMnpiDiscIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt" xlink:label="ecd_AwardUndrlygSecuritiesAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardUndrlygSecuritiesAmt" xlink:to="ecd_AwardUndrlygSecuritiesAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardUndrlygSecuritiesAmt_lbl" xml:lang="en-US">Underlying Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice" xlink:label="ecd_AwardExrcPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardExrcPrice" xlink:to="ecd_AwardExrcPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardExrcPrice_lbl" xml:lang="en-US">Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue" xlink:label="ecd_AwardGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardGrantDateFairValue" xlink:to="ecd_AwardGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardGrantDateFairValue_lbl" xml:lang="en-US">Fair Value as of Grant Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct" xlink:label="ecd_UndrlygSecurityMktPriceChngPct" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_UndrlygSecurityMktPriceChngPct" xlink:to="ecd_UndrlygSecurityMktPriceChngPct_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_UndrlygSecurityMktPriceChngPct_lbl" xml:lang="en-US">Underlying Security Market Price Change</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable" xlink:label="ecd_TradingArrByIndTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TradingArrByIndTable" xlink:to="ecd_TradingArrByIndTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TradingArrByIndTable_lbl" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis" xlink:label="ecd_TradingArrAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TradingArrAxis" xlink:to="ecd_TradingArrAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TradingArrAxis_lbl" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="ecd_MtrlTermsOfTrdArrTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock_lbl" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName" xlink:label="ecd_TrdArrIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndName" xlink:to="ecd_TrdArrIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_TrdArrIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle" xlink:label="ecd_TrdArrIndTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndTitle" xlink:to="ecd_TrdArrIndTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrIndTitle_lbl" xml:lang="en-US">Title</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="ecd_Rule10b51ArrAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrAdoptedFlag" xlink:to="ecd_Rule10b51ArrAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrAdoptedFlag_lbl" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="ecd_NonRule10b51ArrAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrAdoptedFlag" xlink:to="ecd_NonRule10b51ArrAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrAdoptedFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate" xlink:label="ecd_TrdArrAdoptionDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrAdoptionDate" xlink:to="ecd_TrdArrAdoptionDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrAdoptionDate_lbl" xml:lang="en-US">Adoption Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="ecd_Rule10b51ArrTrmntdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrTrmntdFlag" xlink:to="ecd_Rule10b51ArrTrmntdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrTrmntdFlag_lbl" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="ecd_NonRule10b51ArrTrmntdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrTrmntdFlag" xlink:to="ecd_NonRule10b51ArrTrmntdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrTrmntdFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate" xlink:label="ecd_TrdArrTerminationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrTerminationDate" xlink:to="ecd_TrdArrTerminationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrTerminationDate_lbl" xml:lang="en-US">Termination Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate" xlink:label="ecd_TrdArrExpirationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrExpirationDate" xlink:to="ecd_TrdArrExpirationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrExpirationDate_lbl" xml:lang="en-US">Expiration Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration" xlink:label="ecd_TrdArrDuration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrDuration" xlink:to="ecd_TrdArrDuration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrDuration_lbl" xml:lang="en-US">Arrangement Duration</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="ecd_InsiderTradingPoliciesProcLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTradingPoliciesProcLineItems" xlink:to="ecd_InsiderTradingPoliciesProcLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTradingPoliciesProcLineItems_lbl" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_lbl" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Share Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="aort-20241231.xsd#aort_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFairValuePerShare" xlink:label="aort_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFairValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aort_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFairValuePerShare" xlink:to="aort_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFairValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aort_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFairValuePerShare_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Fair Value per Share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aort_YearEnd2023Member" xlink:to="aort_YearEnd2023Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aort_YearEnd2023Member_doc" xml:lang="en-US">Year-end 2023.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aort_YearEnd2024Member" xlink:to="aort_YearEnd2024Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aort_YearEnd2024Member_doc" xml:lang="en-US">Year-end 2024.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aort_Vesting2024Member" xlink:to="aort_Vesting2024Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aort_Vesting2024Member_doc" xml:lang="en-US">2024 Vesting.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aort_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFairValuePerShare" xlink:to="aort_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFairValuePerShare_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aort_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFairValuePerShare_doc" xml:lang="en-US">Fair value per share of options.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryIndName" xlink:to="ecd_OutstandingRecoveryIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingRecoveryIndName_2_lbl" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscIndName" xlink:to="ecd_AwardsCloseToMnpiDiscIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscIndName_2_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndName" xlink:to="ecd_TrdArrIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrIndName_2_lbl" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>aort-20241231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.0b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://Artivion.com/role/Cover" xlink:href="aort-20241231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://Artivion.com/role/AssumptionsUsedToCalculateCompensationActuallyPaid" xlink:href="aort-20241231.xsd#AssumptionsUsedToCalculateCompensationActuallyPaid" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ErrCompDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTimingDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingPoliciesProc" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://Artivion.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:title="995410 - Disclosure - Pay vs Performance Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems" xlink:label="loc_ecdPayVsPerformanceDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable" xlink:label="loc_ecdPvpTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPvpTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis" xlink:label="loc_ecdMeasureAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdMeasureAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis" xlink:label="loc_ecdExecutiveCategoryAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdExecutiveCategoryAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember" xlink:label="loc_ecdAllExecutiveCategoriesMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdExecutiveCategoryAxis" xlink:to="loc_ecdAllExecutiveCategoriesMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoMember" xlink:label="loc_ecdPeoMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAllExecutiveCategoriesMember" xlink:to="loc_ecdPeoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoMember" xlink:label="loc_ecdNonPeoNeoMember" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAllExecutiveCategoriesMember" xlink:to="loc_ecdNonPeoNeoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis" xlink:label="loc_ecdAdjToCompAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdAdjToCompAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember" xlink:label="loc_ecdAllAdjToCompMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAdjToCompAxis" xlink:to="loc_ecdAllAdjToCompMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:label="loc_ecdEqtyAwrdsInSummryCompstnTblForAplblYrMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAllAdjToCompMember" xlink:to="loc_ecdEqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:label="loc_ecdYrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAllAdjToCompMember" xlink:to="loc_ecdYrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:label="loc_ecdChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAllAdjToCompMember" xlink:to="loc_ecdChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:label="loc_ecdChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAllAdjToCompMember" xlink:to="loc_ecdChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock" xlink:label="loc_ecdPvpTableTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPvpTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName" xlink:label="loc_ecdCoSelectedMeasureName" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdCoSelectedMeasureName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock" xlink:label="loc_ecdNamedExecutiveOfficersFnTextBlock" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdNamedExecutiveOfficersFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock" xlink:label="loc_ecdPeerGroupIssuersFnTextBlock" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeerGroupIssuersFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock" xlink:label="loc_ecdChangedPeerGroupFnTextBlock" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdChangedPeerGroupFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt" xlink:label="loc_ecdPeoTotalCompAmt" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoTotalCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt" xlink:label="loc_ecdPeoActuallyPaidCompAmt" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoActuallyPaidCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock" xlink:label="loc_ecdAdjToPeoCompFnTextBlock" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdAdjToPeoCompFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt" xlink:label="loc_ecdNonPeoNeoAvgTotalCompAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdNonPeoNeoAvgTotalCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:label="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:label="loc_ecdAdjToNonPeoNeoCompFnTextBlock" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdAdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:label="loc_ecdEquityValuationAssumptionDifferenceFnTextBlock" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdEquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:label="loc_ecdCompActuallyPaidVsTotalShareholderRtnTextBlock" />
      <link:presentationArc order="2120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdCompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:label="loc_ecdCompActuallyPaidVsNetIncomeTextBlock" />
      <link:presentationArc order="2130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdCompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:label="loc_ecdCompActuallyPaidVsCoSelectedMeasureTextBlock" />
      <link:presentationArc order="2140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdCompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:label="loc_ecdTotalShareholderRtnVsPeerGroupTextBlock" />
      <link:presentationArc order="2150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdTotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:label="loc_ecdCompActuallyPaidVsOtherMeasureTextBlock" />
      <link:presentationArc order="2160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdCompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock" xlink:label="loc_ecdTabularListTableTextBlock" />
      <link:presentationArc order="2170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdTabularListTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt" xlink:label="loc_ecdTotalShareholderRtnAmt" />
      <link:presentationArc order="2180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdTotalShareholderRtnAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt" xlink:label="loc_ecdPeerGroupTotalShareholderRtnAmt" />
      <link:presentationArc order="2190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdPeerGroupTotalShareholderRtnAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="2200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt" xlink:label="loc_ecdCoSelectedMeasureAmt" />
      <link:presentationArc order="2210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdCoSelectedMeasureAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt" xlink:label="loc_ecdOtherPerfMeasureAmt" />
      <link:presentationArc order="2220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdOtherPerfMeasureAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt" xlink:label="loc_ecdAdjToCompAmt" />
      <link:presentationArc order="2230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdAdjToCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName" xlink:label="loc_ecdPeoName" />
      <link:presentationArc order="2240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdPeoName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName" xlink:label="loc_ecdMeasureName" />
      <link:presentationArc order="2250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdMeasureName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock" xlink:label="loc_ecdNonGaapMeasureDescriptionTextBlock" />
      <link:presentationArc order="2260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdNonGaapMeasureDescriptionTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock" xlink:label="loc_ecdAdditional402vDisclosureTextBlock" />
      <link:presentationArc order="2270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdAdditional402vDisclosureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock" xlink:label="loc_ecdPnsnBnftsAdjFnTextBlock" />
      <link:presentationArc order="2280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPnsnBnftsAdjFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjFnTextBlock" xlink:label="loc_ecdEqtyAwrdsAdjFnTextBlock" />
      <link:presentationArc order="2290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdEqtyAwrdsAdjFnTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:title="995440 - Disclosure - Recovery of Erroneously Awarded Compensation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems" xlink:label="loc_ecdRecoveryOfErrCompDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable" xlink:label="loc_ecdErrCompRecoveryTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecdErrCompRecoveryTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis" xlink:label="loc_ecdRestatementDateAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdErrCompRecoveryTable" xlink:to="loc_ecdRestatementDateAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdErrCompRecoveryTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate" xlink:label="loc_ecdRestatementDeterminationDate" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecdRestatementDeterminationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt" xlink:label="loc_ecdAggtErrCompAmt" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdAggtErrCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock" xlink:label="loc_ecdErrCompAnalysisTextBlock" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdErrCompAnalysisTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:label="loc_ecdStkPrcOrTsrEstimationMethodTextBlock" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdStkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt" xlink:label="loc_ecdOutstandingAggtErrCompAmt" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdOutstandingAggtErrCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:label="loc_ecdAggtErrCompNotYetDeterminedTextBlock" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdAggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName" xlink:label="loc_ecdForgoneRecoveryIndName" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdForgoneRecoveryIndName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:label="loc_ecdForgoneRecoveryDueToExpenseOfEnforcementAmt" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:label="loc_ecdForgoneRecoveryDueToViolationOfHomeCountryLawAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:label="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:label="loc_ecdForgoneRecoveryExplanationOfImpracticabilityTextBlock" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName" xlink:label="loc_ecdOutstandingRecoveryIndName" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdOutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt" xlink:label="loc_ecdOutstandingRecoveryCompAmt" />
      <link:presentationArc order="2120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdOutstandingRecoveryCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:label="loc_ecdRestatementDoesNotRequireRecoveryTextBlock" />
      <link:presentationArc order="2130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdRestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:title="995443 - Disclosure - Award Timing Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems" xlink:label="loc_ecdAwardTmgDiscLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable" xlink:label="loc_ecdAwardsCloseToMnpiDiscTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardsCloseToMnpiDiscTable" xlink:to="loc_ecdIndividualAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="loc_ecdAwardTmgMnpiDiscTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMnpiDiscTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock" xlink:label="loc_ecdAwardTmgMethodTextBlock" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMethodTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag" xlink:label="loc_ecdAwardTmgPredtrmndFlag" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgPredtrmndFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="loc_ecdAwardTmgMnpiCnsdrdFlag" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMnpiCnsdrdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="loc_ecdAwardTmgHowMnpiCnsdrdTextBlock" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag" xlink:label="loc_ecdMnpiDiscTimedForCompValFlag" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdMnpiDiscTimedForCompValFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:label="loc_ecdAwardsCloseToMnpiDiscTableTextBlock" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName" xlink:label="loc_ecdAwardsCloseToMnpiDiscIndName" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt" xlink:label="loc_ecdAwardUndrlygSecuritiesAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardUndrlygSecuritiesAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice" xlink:label="loc_ecdAwardExrcPrice" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardExrcPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue" xlink:label="loc_ecdAwardGrantDateFairValue" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct" xlink:label="loc_ecdUndrlygSecurityMktPriceChngPct" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdUndrlygSecurityMktPriceChngPct" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:title="995445 - Disclosure - Insider Trading Arrangements">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems" xlink:label="loc_ecdInsiderTradingArrLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable" xlink:label="loc_ecdTradingArrByIndTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTradingArrByIndTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis" xlink:label="loc_ecdTradingArrAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdTradingArrByIndTable" xlink:to="loc_ecdTradingArrAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember" xlink:label="loc_ecdAllTradingArrangementsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdTradingArrAxis" xlink:to="loc_ecdAllTradingArrangementsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdTradingArrByIndTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="loc_ecdMtrlTermsOfTrdArrTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdMtrlTermsOfTrdArrTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName" xlink:label="loc_ecdTrdArrIndName" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle" xlink:label="loc_ecdTrdArrIndTitle" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrIndTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="loc_ecdRule10b51ArrAdoptedFlag" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdRule10b51ArrAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="loc_ecdNonRule10b51ArrAdoptedFlag" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdNonRule10b51ArrAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate" xlink:label="loc_ecdTrdArrAdoptionDate" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrAdoptionDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="loc_ecdRule10b51ArrTrmntdFlag" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdRule10b51ArrTrmntdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="loc_ecdNonRule10b51ArrTrmntdFlag" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdNonRule10b51ArrTrmntdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate" xlink:label="loc_ecdTrdArrTerminationDate" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrTerminationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate" xlink:label="loc_ecdTrdArrExpirationDate" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrExpirationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration" xlink:label="loc_ecdTrdArrDuration" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrDuration" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:title="995447 - Disclosure - Insider Trading Policies and Procedures">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="loc_ecdInsiderTradingPoliciesProcLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="loc_ecdInsiderTrdPoliciesProcAdoptedFlag" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingPoliciesProcLineItems" xlink:to="loc_ecdInsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:label="loc_ecdInsiderTrdPoliciesProcNotAdoptedTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingPoliciesProcLineItems" xlink:to="loc_ecdInsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://Artivion.com/role/AssumptionsUsedToCalculateCompensationActuallyPaid" xlink:title="999007 - Disclosure - Assumptions used to calculate Compensation Actually Paid">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaapVestingAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapVestingAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingAxis" xlink:to="loc_us-gaapVestingDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aort-20241231.xsd#aort_YearEnd2023Member" xlink:label="loc_aortYearEnd2023Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_aortYearEnd2023Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aort-20241231.xsd#aort_Vesting2024Member" xlink:label="loc_aortVesting2024Member" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_aortVesting2024Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aort-20241231.xsd#aort_YearEnd2024Member" xlink:label="loc_aortYearEnd2024Member" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_aortYearEnd2024Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aort-20241231.xsd#aort_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFairValuePerShare" xlink:label="loc_aortSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFairValuePerShare" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_aortSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFairValuePerShare" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>art-def14a_051325img001.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 art-def14a_051325img001.gif
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M<':NKP7#3CA"24T$.@      Y0   !     !       +<')I;G1/=71P=70
M   %     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT
M   /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4
M 0      #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %,
M90!T '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U
M:6QT:6Y0<F]O_V8    )<')O;V9#35E+ #A"24T$.P     "+0   !     !
M       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O
M;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
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M969T56YT1B-2;'0               !4;W @56YT1B-2;'0
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M24T$#0      !    !XX0DE-!!D       0    >.$))30/S       )
M       ! #A"24TG$       "@ !          $X0DE- _4      $@ +V9F
M  $ ;&9F  8     _P ! "]F9@ ! *&9F@ &       ! #(    ! %H    &
M       ! #4    ! "T    &       !.$))30/X      !P  #_________
M____________________ ^@     _____________________________P/H
M     /____________________________\#Z     #_________________
M____________ ^@  #A"24T$"       $     $   )    "0      X0DE-
M!$0      !     "   "0    D      .$))300>       $     #A"2?]-
M!!H      T\    &              !U   #(     T 00!R '0 :0!V &D
M;P!N %\ 3 !O &< ;P    $                          0
M   #(    '4                      0                         0
M     0       &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T
M,0    0     5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M
M;&]N9P   '4     4F=H=&QO;F<   ,@    !G/_;&EC97-6;$QS     4]B
M:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG          =G
M<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X
M   -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E
M $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @
M;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG    =0    !2
M9VAT;&]N9P   R     #_W5R;%1%6%0    !        ;G5L;%1%6%0    !
M        37-G951%6%0    !       &86QT5&%G5$585     $       YC
M96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH
M;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M"79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0
M   +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO
M;O]E    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M      QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<
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M-]5L.#U\/?U=G__9 #A"24T$(0      5P    $!    #P!! &0 ;P!B &4
M( !0 &@ ;P!T &\ <P!H &\ <    !0 00!D*0!O &( 90 @ %  : !O '0
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MXI0 M?F#@9 $)I0[";GE(Z[E.T9T7WE1C6M4$$B&!)U*  W6\ TT4[P/>%
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M=,4R0U %Q'9M"X6!.L  "G &TB 8KS=<&5$)&+!>Z@,$@"-FT,8#[Y,$0#
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M"P;%!?T."(3*]T9KH:T#?C#F9%6@T(  FIFD_N+9!B>>H[B5@&-S?__P"M9
M#O! #R_Q$F9E#MZ@"ZOP!EN=SNC6J4!@!0)I74.J!!*0 (EPLPHI%P-1W4S)
MP1S<. ^E=)A(ATB0 PP WCD"!IJ:A'P$?D+0EY  6SOV2@LQ%J0>%D?-G?P@
M#XWCD8FS [6*3)=DQA\ZR81$#_9:T09M!NECB1^FYCA@ 191$B;QF0\R[OF
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MW NW %=U$5[R7Y:G-^ID);-S>3E'+'UN'B9X.88XF1W1%26@@"JCGF\Q$5S
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M4(ARZ8@B%,8=B0!XN <8<( =V)$WJ;9WZQ$=D(!/H9>/NI?4$"J,,A<7F46
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M(8G@JF]BF]QKN=X0APO0'OD[#Z=(F(1#NP&(ASG\%Z!H$/QX2,00HD7( ,C
M*(BH#%UY@J2 " JP P9!G-8 %R>1D+[((!]8 @60!X&@!1Z@FP)YJJFZ&!Q
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ML0L5?9B'7XV('7F*10F""-:61OL$\QO/M6D(O\L;V0F53:[A!R87I:!@P,V
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M]UY\\NG=Y4IDY7>LW?RD8T&(H+$HD8%VR0&H0)#VM\\\/(0WQ)%UVHD5AA:
MNG8^'D+$7)<CO@C$FSK*4UU=?*O$:!)8Z<!#)4?Q&'AWZF3 ED1Z@5XD$CX
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M&15*TAJ[- 8Z13#4&817$/-%[&-H:=1:+H80?=Q#'#;H05U:TA/.#&$)8DO
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M3CB!$F##N>0A[8!'X)4E153%--6-)ZZ8QU@%F=+0"EW3'/PB670&$  B%9I
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MAC=4P.;6R0X!7EN\0S(YZYXZZ'A(*),!,H6&BF%P8_6DWKM1K8<^D"(/"BK
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M]"45"($;Q!3X(4'O.F#&TP[B79!H<YLGM\<] ,B>G)/[Z+)X  5A1'N*%(5
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M !& KH&(K<WJ:EH(< >[!NJ*;D0XBYX4(5U2PPU-YJA\8QX6X$G,JS0@R#J
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M)(! "QXL!_PZ[[13JK3'^I 1JQ(BJ@N=JB*<A8 B!WY9T^:!@%#%AB'+5R4
M&N:$&"I]2&4[FDB@L.QP[-KLAQEY:-5.GN'!F1[I)5[BR;)F,&R $MKQZB%-
M,S2#'DQ@$OT."-2K+$\=1NYW!U8A783UMMR7'Y8!!RE[!+V#C9>]+BAB&_AJ
MR%#'CB7(=G)  [ A%2K@DWQ@9P"B")(=.Y @$:+CT3Y]_!HZ? @QHL2&#//E
M 2)$"$:#0# .$9*DHZ=\$_]+FCQI<I^G'3V&A 02!,B0(1TS!L&SCQ]#E#P=
MWC.# \@.(3,U"A2R0X>.#/-Z.N6W3Q&#(#9E(E&BI B0'%5<#NEA8=X]E#F?
MFBVY+U;0CA^!($FR(\C'(!FTE3V+-R_421UA8K2*%*.0"^7T&N;)<-^9F$&2
M&#28-(@.FHKLS<,B-,A0HD-TR)W9PY/$NX=+\WN7P;-0MQR%!'D-1*'ID_M"
M,<@ 9(G!F09QY #2PV"2)#92W5NHK^*^??UFCX:JTU]B>%MD5B$(Q(=V($F&
M',SX]0-IYP[W.:LYD^U;)!UU4(!7>J?)?D![)/F!$";1C*Z'$.&2 P\[#)$5
M9#O_%*%5$+*1QT]S_*@35$8=&:013$@L\5$\$,G'8$0<YK-.1VUT%M-0;6FD
M%#L/C:?7/F8H]1I1&"F!1&="7="47AR6=X\8.OB0A%+#(>&$1CM4 =(0/SC
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M=EDB(="(/7[:@0ERHBLTMLR"%U"-?A;ERI@@+G[W8(0"LO.1_^W&-2#IUUN
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M3<BT/U0T# =P 32"9$+A+:G8-'0V3*HV&9LR!YR0"^1@#O(P#_.%#Y8Q#^]
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M$O=P!7?H)WMMP3MP?'!@!!< "Y-L&N9  #:  YJ\'C[@K#N0!B3:WB9AH/M
M!D/[,TF@R4ESE0;W$.P0 ,"9;4JA&QCA  = #0V1#[/N3R5Q#RB ?N](0%9
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M4Y$!B-P=0794R<$ 5%F))#&OYIEND0<%&W2TW-$U1PZL68'L%N+Q(]8<0GP
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)0+WHY6 ! 0 [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>art-def14a_051325img002.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 art-def14a_051325img002.gif
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M[_#P\/'Q\?+R\O/S\_3T]/7U]?;V]O?W]_CX^/GY^?KZ^OS\_/W]_?___P
M                     "'Y!       (?\+26UA9V5-86=I8VL.9V%M;6$]
M,"XT-30U-#4 (?\+34=+.$))33 P,##_.$))300E       0NX_P& AFA+\!
M'L3I -I9'#A"24T$.@      Y0   !     !       +<')I;G1/=71P=70
M   %     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT
M   /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4
M 0      #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %,
M90!T '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U
M:6QT:6Y0<F]O_V8    )<')O;V9#35E+ #A"24T$.P     "+0   !     !
M       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O
M;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
M $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P    !2
M9" @9&]U8D!OX            $=R;B!D;W5B0&_@            0O]L("!D
M;W5B0&_@            0G)D5%5N=$8C4FQT                0FQD(%5N
M=$8C4FQT                4G-L=%5N=$8C4'AL0'+            *=F5C
M=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',     4&=00P    !,
M969T56YT1B-2;'0               !4;W @56YT1B-2;'0
M  !38VP@56YT1B-0<F- 60           !!C<F]P5VAE;E!R:6YT:6YG8F]O
M;      .8W)O<%)E8W1";W1T;VUL;VYG  #_       ,8W)O<%)E8W1,969T
M;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T
M5&]P;&]N9P      .$))30/M       0 /H    !  $ ^@    $  3A"24T$
M)@      #@             _@   .$))300-       $    6CA"24T$&0
M    !    !XX0DE- _,       D           $ .$))32<0       *  $
M         3A"24T#]       $@ U     0 M    !@       3A"24T#]P
M    '   ______________________________\#Z   .$))300(       0
M     0   D    )      #A"24T$'@      !      X0DE-!!H      T4
M   &              "6   !N@    @ 30!! %, 5 !% %( +0 R     0
M                       !              &Z    E@
M       !                         !     !        ;G5L;     (
M   &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9_\
M         $QE9G1L;VYG          !"=&]M;&]N9P   )8     4F=H=&QO
M;F<   &Z    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90
M !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O
M<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D
M %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC
M     0       %)C=#$    $     %1O<"!L;V[_9P          3&5F=&QO
M;F<          $)T;VUL;VYG    E@    !29VAT;&]N9P   ;H    #=7)L
M5$585     $       !N=6QL5$585     $       !-<V=E5$585     $
M      9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $
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M;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,
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M VGKSW.$'-QF-K=YXS[7/KG^KG;ZV?\ 'J?2!--]I'OMRLC>3W].U^-7_P"
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M'&>%H1 <($3@I$+OU%85$R^V5$X?V<&VPR%P4'5$3[Z\=E]$*Q(18$1$6.4
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MD4,P@$/#>HT [L , P4SDDNYR^R],N6/@6#T ]$L__Q\096-,WBB)1%&!'K
M%MR'98 7@1J/E;)$IT^$&;X8!2Q2D0IDW"\"#O0.-+)"27$7I0,6M9<J]'80
M@M$'P90D!_$Q' 824#,*Y5%N79$?BS<11^ Z3'%@=X<1GW)Q A$F.!5[48.
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MRP(U%: >[X VQ-$#/6 "5G<6 N  (H #1) %D< ,S' *<. $/8 #(E!UN>D
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9Y$B2)4V>/ D/Y4J6+5V^A!E3YDR' 0$ .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>art-def14a_051325img003.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 art-def14a_051325img003.gif
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M'L3I -I9'#A"24T$.@      Y0   !     !       +<')I;G1/=71P=70
M   %     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT
M   /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4
M 0      #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %,
M90!T '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U
M:6QT:6Y0<F]O_V8    )<')O;V9#35E+ #A"24T$.P     "+0   !     !
M       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O
M;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
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M969T56YT1B-2;'0               !4;W @56YT1B-2;'0
M  !38VP@56YT1B-0<F- 60           !!C<F]P5VAE;E!R:6YT:6YG8F]O
M;      .8W)O<%)E8W1";W1T;VUL;VYG  #_       ,8W)O<%)E8W1,969T
M;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T
M5&]P;&]N9P      .$))30/M       0 /H    !  $ ^@    $  3A"24T$
M)@      #@             _@   .$))300-       $    6CA"24T$&0
M    !    !XX0DE- _,       D           $ .$))32<0       *  $
M         3A"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"A
MF9H !@       0 R_P    $ 6@    8       $ -0    $ +0    8
M  $X0DE- _@      '   /____________________________\#Z     #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z   .$))300(
M   0     0   D    )      #A"24T$'@      !      X0DE-!!H
M T4    &              #-   !I@    @ 30!! %, 5 !% %( +0 S /\
M  $                          0             !I@   ,T
M             0                         0     0       &YU;&P
M   "    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO
M;F<          $QE9G1L;VYG          !"=&]M;&]N9P   ,T     4F=H
M=&QO;F<   &F    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC
M90   !(    '<VQI8V5)1&QO;F<         !V?_<F]U<$E$;&]N9P
M   &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E
M9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S
M3V)J8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F
M=&QO;F<          $)T;VUL;VYG    S0    !29VAT;&]N9P   :8    #
M=7)L5$585     $       !N=6QL5$585     $       !-<V=E5$585
M  $       9A;'1486=4_T585     $       YC96QL5&5X=$ES2%1-3&)O
M;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE;G5M
M#T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG;F5N=6T
M   /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO<E1Y<&5E
M;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P3W5T<V5T
M;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E
M=/]L;VYG          MR:6=H=$]U='-E=&QO;F<      #A"24T$*
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M &( 90 @ %  : !O '0 ;P!S &@ ;P!P    % !! &0 ;P!B &4 ( !0 &@
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MH6]#RZTJ_1!%!(Q@C##>([,]:($&_# ! (ABE#B^\"$-G55886B&)("#),X
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M#CSB#9]@!!%  D-0"M@P/:F@ C[ "S:X9RYQ$OGP"3Z0 KQ05YY33//P"3=
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M1) )Y8 ,@" #67 ,[%.P92%Y#X0%,> +3Q(2Z+ /ST &+_ "AZ!6Z=$.4L
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M!&;@#SXK(CVQ#H^ !4C@!%V0"&ZQ$6D!)9\0 CD@EY2G4;)K&<;P!A,@ 2]
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M#"B@TD*\E-@'5AB#$JB"7F H>KBB#9" .:"&Z6HC?92A?7 &(G" #NB  LB
M/SB&//G"KK.$*. !>*L,7+D';S@%&8   7B 1J D_5M&9Y""(["%:E"%(K
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MT($0<(!!P#[R&H]]Z 5<(X @< 8S6QZ7A ?\ZC)BH ,B0 7?P,7LR=/="H
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MFE">H4&(^GHRY'N/?;A:'T"&V]7/%@""#1B !E#>]E-DF8")9Y"#)T"$-ZB
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M\3[2W)(?Q,!#$3!!OKQJA2;D@,,$OB".O7*60TJ$2#7P< 9D)+2.4N%.,MZ
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M$$/@@S1(3B?WFA\,1!@#XNF4<#S.#C0".,3%^B7@@>S#*-  *T *J^S"%N3
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M\I3"#VP!.5RA>8T#)ES!)5"<AWXHB":$-53"!@P !(C "-C_  ^P@F#)B4C
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M=/$&'LT"'/ !+FP:L2FOT?)$M;[ #G0A\[G8@.W!%CA#C2"K]A8G/L2#)K3
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M "2 &[B! C#! 3#!))P!(F2".-@U3K$B/Z>V$>H,3Y0%,78!"@!  !P <@N
M!CP!&BR#)K$P<(^LO]4#*X3! ##   0 =R-!(]@Q3,CT=$LL3-2#,5#"(_B!
M&Q3"*.C".%3B>.=M1PP%7)+#-X1#NB4B(/UU?"?FL:X*N_9WXI[5N?"W@*?F
CKV094!YXVN:%IQ@X@ROE"$.&OT6XA5\XAF>XAF]XG00$ #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>art-def14a_051325img004.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 art-def14a_051325img004.gif
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M^/+Z^??[^_K]^?C\^_K\_?O\_?O]_?W^_/W]_O[__O[______P
M
M
M
M
M
M
M
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M"Q7$6[[&>[[Z"WT7D)B+=JAL>[]C"+\+C'FPN[V&YG59X+ZVF[3ZJ[Z%"UD
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M9F5MULLLQ&"-?CO,SFA\SP>[!UM0 WI] VZ@=GBMUS7 UWOWUWO=UV/G!C6
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M4J9-G3Z%&I4CS30KK5[%FE7K5JX2MP0 &^!&UZ]AQW;%6A;LV3T"P"*HX3:
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M9'?$=N&'9\JJ)71'?F",P?2]^:!4N(]XZ1L5.6I231XV0U.SQPM[U&@MV=0
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M[]Q7PMVOU_7Q#08_ DB!NMJNA7 \1*LT-(J @\(XUBNU4S,]#*.XU$.CSVM
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M*'L%'GG*9OW6WZS,UFF5?V7_N*]PEELZ3K<*46SZ)?LI?N\DU )^FRD6&!F
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M2NP0!P,SD" V$!C-\1Q?3!AGXL^*$9YT$0]U D/(RLZF4/NXL>8<0->\2GK
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M?+:%_G0LH;",7M/4JI8@^T00V4)!LR5RA^I@?PXE+S>TUI)6/!>"LA3?RE4
MV#94R?5#6;=L46QU6S=>=6)=U]9='R)F<_5#Y;8U4O1FO0!>5_1FUY9X@Q=P
M'<%?AW=6C5=Q18YQ@^17'[>&A-5@7^Z'2%$ AW)T/_(NOS%;&/5CV>+_SJXI
MG])[&40RVZTJTR1:/S9U[RU<6]019/<AZ%=$[]?$\M=^T19F755$;<!5=<)M
M>Y=F135%;2!P015.%0!6:?4 6D-7.Y16 ^"!V0)ZD9!7>]41JK1Z_[>G'WN2
M-2F,=IC (!>V4-67%BO54C'U6:ZW8N?L[.1RA4/+ .4(J@#%8[M6?NVM!A2@
M._<7B(7X?TN,B'5B?_>@3!&@!LH4@WGW@&O5-?;@!AIX3DG6=Z]31;NS=LWT
M7NU45[.X1+<X1>=4@_5->E>"+206A+>':TL2(!\'!N[ -<! ,VV8&_ELN[:M
M KG5'^'Q(13SYX8,C_,8#/K84A'R3DX7=66RY/;7-2)9Q2)93"4T1!_"@*78
M@M.4+5I7 /*50V671ED78C-4 /@65S\YE!W!"^X7C?--C=?X(53%C1OH*JD1
MVF:GU-@"#F(SC],206GY@].D1QN5+>21W/]X<PR 6;:ND+N2%$;@-WX?F>0F
MF2VN&<4F>0L2P$,'H 9<-(HWF9,QV)/S=H'98HQMU)4_% ?8@FX#0  0@)5U
M=0O.N374.8,[^48+8G<>HM-L&8"F.9<?XA7+)B@MKGN;&3*-X"BU=DMP^9@?
M0M8(5"<4>J&C4O,VUWT]A(=[N)I'+IL?0J1-C*1;0Y/=0 '8]$R5=T;N=583
MX&U3E7AM='5=PPM:&I8= 0=H6I]C-$\YN(,Y.J 11X0;U"?C\6W,4D@QFDAW
MK;384DTJDWR)]>? $-&:.ML,$CZ(66T V4%!6N1(VJ01B*QWEV8K.$7E],1(
M^3K?5 #0N<3<X#O_7[JF?3?%%'>N:Z"N?;I&@;J?.^DA_I.HG>=KCAJI8ZUL
ML ^Y##FKB9+/;-$CMK5)C)FJQX_<(M6Q90L&D8Q)!KI1?3CDQMJ(*9FT9T23
MX?4 G%A"[=;$XE8GW&",+QB!;@!YB_<A7KM?]WEW;5M%PWBW_S6H>Y5Z"=MY
M/IN@B_5A*A?!/%*S)W5C4:.K/22B+;O)1LU:G3NTGOG/HKD[GC:&0EO?1MMU
M5\RLHYB= Z YO[2E)_BN8;N!RYDMT%2M$\ &\GEYW9NM=WN^8;>^[QNW@5MG
MA=M"'F*R/T4%CJ"[-Z("CJ"-/X3!'5QZ/)H2V>(%,B8_%78NLWM2'_8@_P>[
M2/+DJX>5+&$.8S<\U33.$5@-1J@;)L,[W\;;=EO,K#5Y@./Y(=S M'4BMW5"
M55/4G=E"3*=SQ_>Y7 > BA-WGX6\._U5I^]-EH/DH0/E2:2<D5#31L!#QY:B
M J9 P=6DD=_'8JN$:-DB]D[\6K,5FIL$CKNVAW3"PF=M:L]\N?HS:Y_5.Z::
MFK^V[F)<IDN,K,49=T>:O-L;@6]7K0$W9^_;QB64<$GV &*:R'\:OR==)_Z;
MTOV:GW',GR$Q6Z@<E+3<0++\+XPI6_(\CAU!#YEE4)%K!XYVSHDT\Q351L:W
MS55":$=-=&%=MEKXGZ.Z.RI;S[_U[OK\I@?WS_]U7"?V0)-?=XH'7<:3W- A
M%GE;&\ KW1%R?)^S_=K1.P"RT]HSW5^W/=/!W7BC=\ )W!%^_5$^?8BN'$9&
MW2]*'5B"'=43DUF.-5EW/6-3D2V.0+J;@V)MW5%3?=;0=]^7Z^8F$S]:W,7#
M6K23W7_)&Y9-6M ?PL9?%=LCGL<]66S!?0!<-+:#5])9%*=Y&G;[VD9I%.1Q
M7+9_^]H%'+#' O6 I=TSZMT_)-[[8MYKI>$)VA&2>5$2EL@0WGO#H+,AA,T'
MGN = <[IK(:+7K:@6\7O7#A.';0?7KPC/I(I/N*7.%316[U7U;7S>VQ3E.6;
MW57+>.1QO('A]-O+'7__U7KM@=O)[0W*@\2#:Y[OE$D%(N ()$0-5IPB+@ *
M] 0*+D#G">#OGR0/$)\B^CX"E"!2IN##%_\(&O_Q)R+R 1\2!U\B"O_P$Y\8
M&?\@-3\B.#_P/U^9'N(,IL# [T3@I;7@+X4>BU:%H]Y0TYR[(:36EY[I*9K.
M"CGW0ZM/&EJ.D+(YZAWK]_SIBKW0R;T^2-KB"UA"O[E,JQV!./Z=D==&]T"V
M89>_)5@GTMJ!H=_[P=]5Q3_E_WK3.=T1(IQ=^*XC.E\&$VL+CR1!AF1UA*1P
M:IDC ,*1DCR.SIQQ5# "@846"#J:H@:ADH4+CS@Z<A APCP5**K0F%')0XH$
M_QHBA"B1HD6,&C=V)&"QY062-&O:O(DSI\Z=)#]J!  TJ-"A1(L:/8HTJ=*E
M3)LZ?0IU:,L7'*I:O8HUJ]:M7+.R6-,2X9@>#\J:/8LVK=JU;-NZ?0LWKMRY
M=.,ZX.$GK",H+WGZ_6LS0LNHA L;/HPXL>*@&@.%Z HYLN3)E"M;EDQ%XYBZ
MG#M[_KRVC,9%I-_,!(Q:ITB$BUN[?@T[=E"M:?3:OHT[M^[=>@/X#K!%]V_@
M>A'\KI%[>'#<>P3X7M[2B_/A ]SL-NX; 6X<PP-X0;@'^V\$;MP,MZ[1C8+N
M 0[@*'Y<8_CNY,W_1N](/'+>_/O[;QE#5K)I-$5J!O\>B. 4%ZFT40H+74#0
M1 PA=,1"$4!QDH41*D0 A M6M-%I)E5(0 0;/D@0B3 UB*) $WYX888:"L2A
MAR3&E(>#'49($D*G(0ADD#DIR)IL1AZ)9)( M.3$94Y*AH9><P0!6I567HEE
MEIP1H5<>1Q@@9)@^%:EDF6:>>5A+2SS)9IMNO@E9&QI1J66==M;%@QQZ3=%7
MF'Z9^!.:@@Y*Z%"T_8=HHHHNRNAV"""@P&WJ'1   C7LT6A_;N!0 P[XZ;;'
M%C;8L,6G_&W:J:F9KKIJ@%@-J%&??LYZH((JQO0C 2N,M)!($E(448$KGD'3
M!8[DP2&N)!GKB$(6$;OLL<G_^DC2KL+Z2E.P#$)+D;'(KNA(KM;V&"ZMYAY8
MP6"%KLLNDHW!Z283A>A5! 1WWHMOOOJB)89>:JAP;FH9.=)NP08?J5$=\"[,
M<,-=L="2O?M.G*\0>87U9< XC4GPP1Y_3-BAK(Y,<LDFGXQRRBJO#*" L;6T
M@L8R[V0K@WD4>RQ%!.6J*Z\' 9RM(SI:I$9-/Q-P=-!#YQSMS03L3-.X"R5-
M4D0.6N1TMTPO1.W,7ML4$YD@CTUV46HZ3!D,>N@5AL04OPUWW' Y (%H84UA
MP=<XI1MHV7[_353+: ].>)M7:/2%W(IC"4:7,>M- (9B T[YQR*SC'GFFF_.
M>><K_[MZE9$:%0TYY#6#**S6CBS$=TW&"BO1$;+/'M&->]6$886QSRY[[:CC
MO'KK.*>^.^^^6Y3Z@PB1RW/I,D<T>>72LZM1&H5SY0)88<'AP^+>?Z\X$!>W
MI 28SB^T:]_3KW^P1E9<#W_\D*V-4/?@WS^7 SG8C1!I9S1_+L&HCWT$1-/E
M/(? !"IP@0Q4&>BL(CJ-Y.U\,SO=BI+7H>5E<'7#XUIN;*<B!NGN@[^+UNJ8
MY3I>$4 W%4(>\)A'P9E90%T%K&&96N("^5GE<&'Q YWP!\0@VLD(\VJ)ER@X
M,!LJ<5 M>8P.GQ@_&&C$#T*LHEMX0 >]\&5F8>O8$K\8F_\#-G",9"RC&<GX
MP*H@+"4QU)@%76C"%Z40=HY0P07NB,<[OF0EN%L00NR81SSN487*6]T,.1@M
MXM4QD(*\X LITK4VGFLU7@2C)1?#)!TR(1#T<IL5/PG*NO!O=#K2&]^B=\E4
M*J8E38"B*PL7)804(92T-(L0BMB2(W#(7 9P2"55"<RHB/&,Q"RF,8_9*I?!
M"B&RDF28WDC(#4+2$1.D2 IX19!2W@2.)#E:-G7"S4)ZL)H+N6;JOHF3<$IS
MF@!T)I!.^<M@RI,I"8NBG,(R!ATXH);\[.=:<J"GL'2AF0%+'RKGB5!Z(D1A
MKVQHPPBAD1WXDY;]"DL>@$8K@\;_,Z$<-516:H/,D(ITI"057.@BR$9W^@F:
M&$3A0G)'$Y$("T._FM%I8K)+ O"M(S2E":!N&DV7PI0D,J5(3TGR4T?&D9TJ
MG14E-]K1J+9$!H7[BI3(,M&L3G2?%FL):73I->A!-:ID%<I4'8K6-]% (W/0
M:BAU,$I'+*(+[3R06,N*5Z ,LZ1\[:M?.Y=&#K@K5DU]YH>4JCK55=,GPF(6
M1@D@DF^!"PH4B<!!).18HDJKA(G=X&)EM,''1M990=6@![596'31,*]DU4@6
M"$<%1/20"/ST01&*0 0=<*8'LU2+#HAP6ZRZU4Z-L^CC L8QUBJ7,0AY;5J?
MZR3M.8*V_\,%)5Y&LPB!$#0UR5UN1_?ZU_"*=[S)?-4:4YK:6AU6G2[M5>PP
M1)#4Q>0,O4-(*;'F"#74]PR[G&]]A<:@EIIV-4HX GP)Z=\C0&]I D8DTDZ"
MVO3^Y:G>E:I&<M@P&G R+%_PY"=W,(>P]%8N$,B+6KC4DC)XN+I5<@!<_557
M(-VUPJS%(71O3!G9(D2W+/ZD X;0O^P>*X1V'2"-@PE>\BIYR4R^36"3I!')
M2C@U+'VD2GP)!7.2) 5B?4BND*<"7RHAIP3@<DNF\.72.O@(6-;REKN,Y@!;
MN<P.(?*4=R+ @QXYE:QD& ONV9(Q2+26.T#(%WK0@R_4C\1P0/](6H+@"#\4
MH0=!:#0<>EPG+&IQNP>ZII'WG-!,XGC47,F,6#!-RT:'10T1_DMW08WDCS9Y
MUK2N]9,'2Z$[4U"/.:D KVD"QSN2F22^O@"G_?+KO27;0!8@IZYWTD58([2>
M\)(N6^W'SQ"/^ %%<$1;X=*#$#OZ+"5V!+8A$.(?HOI*0\"E1L!J6#U+.Y@V
M)K6]KP)H=:^[B@#=D[/],N-YJS+)M2ZXP45Z:UQ+^=D,1VS#'ZXQ0,E;X$H\
M6[QT/,5Z^=,'WD8+!!P!AQ5[7-&.",.XS0+I2Y\EY?O64G&-^-@#,6OB%+=D
M2]YW[WM#3",B;_G]]BD^O90/,#,?:\W_"TCP@RM]Z6A4YGD/"_$[JS/J5!=2
MM(^N2FH_"08;;LD7>.Q/15.W+CV(-&U/7A9%;_L!'W=$SX,PAL2A90=C",,#
MX!Z$'30Z#!*%0!$:[8<Q$*'GH:R;7OX')"+1'.M+K'?.1\U#1\C=YZ$DHE?S
M<%R:?9KQ2)<UTS\/^J:;%\H;&7;553KUTZL>,!(W.N<):''+9$\O8W%KH\D"
M 40/&BX[T/@#T/Z ,3A"W[]WA'#1HH,=HT7MW'9$$<:W QU<; RJ#KE;KQL6
M)1P;)T5__3QO_GA2=QW;E ?EBU<=XT(NWOM_2WKHWP]_E"4<UU!?O3M5, 4[
MVW__.;DZ^[^H_W64$7E31'S^M&/=QE:[)Q? EQ?'5Q9Q8'QLT6AC5Q9Y(5$(
MZ$.V]0"*UF%EL0-Y08'^M$] 9E$9 QB2LW[_QSZ.%WYI)44(047EQT]YLB?'
MIGBNIX)^XWZU=@,UX(,_^(-;L 68<AL]Z(/0P5=&6 -(&'^9,G\*QW]1*(4/
MUWHY"( :L2:3P000%19&0'C\9&C>=EMYX0<*"!? AQ .&'S.QQ:0]FUEP7$J
MAX#')WS'!W=KIU45-1IOT&HW 4]6F'75TX+0%4ML*(/]U&YZ88(T<4@I"(@>
MLX.T)A[L,1Y,B!#Z\5>8J!=;$"E-^!]/^'0Q-X6C2(J2]&J/6$ !R/\5:L,V
M7]A/B&,6$-!H;Q@7:!B!:"%\>!B+"+%[)D==W1:#9B%\^>1S+A90_?,0_V83
M%(:*-J<1@36(4(1Q9GB(M/1R&@$(HLB,S5@YD3AKDTB)\1$6FMA7Y(@0;I
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M,:50"G_YJ9]]Z)\SDP*SHP+P6*<RXVF.**2%<E8<P(_>]H_KYH8"Z0@)VA;
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MD@$[![<58G[0G6@!?+4I%F.(KW !:2)KL&AAD7!P6R17K_MV?K>1M1.+$(&
M816+-I%7J5HB=F[QD&:1?&[7%H';%G6(:B:W>7=K)BT[7B\+'[YAK)<HCHZ
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M$O^&7_M\D;9[[WL6M,D6IXRV90B'%RFC!'N7Y%G$GBP;_1M>8ZP1F1L 9CS
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M#[!0!XD?#=U0&QU2.XL)*%B!Q801">" _PP/"UB!\GP)(L5,EOB"NG00$N
M'RV4SYS1%)W2KH2), B2!VD #E@ !WF6(J#-Y013-VVSF,B#(TW2\<  #M
M[7A2*!#0O'S3O23$'-W1R'  DO] T_4+@OJ$2S\-NI<X)A^(3LA8  X@ ?O8
M@2#X@B 5TD7=U!V3"3GE3SK-C@T@B0*("PLPT3V5"4X-4Y<8 R*@4,J0U$G-
M$@S=SC9=56.1B3D8TRN-C"SM )(1$K^*"5PMUL>CB3, T16X ..$BR4EB0D@
MBPBX@!4XT=5456-E5)8XT!:%CRPEB2UMD!W(4)C(5IV;B6,*$EA%"$(E"0:0
M#*5"IDP=4'.M5R7SB2E0@B-(@0N8R+&P4Y+(@*ZH@ M(@2-0 A2E"7N=LI>
M@R+HU<1H5W=U$!WP@2*PU5M=V&ZQB3D8@R\H@B!P-L*050XH <+0@1X(@B((
M@V%56(W_?5F^ XYDG0(0/0*;O5F<'<J2D +EK F8_327\(-C"MG)(-F2M0\A
M"0,V[=.?=<VF@(,QB%KYF=J'[0$4* D04"HBH-J+C=IY_=*F#5NQ>XXLF HK
M< JQ'2]=#8,B\(%U%8AO)0E@C0U++8*OU=2T'43A"(0+(XZ\_=O8&XZ2Y  9
MP%; U:B:@(./5:J$D-B2>%=XB]>NM8G#)2*H&*62: *HJ%S.K3ZG<$6CH]?.
M'4&?@%J/E9\?$(T3:#;6;3:51:8'0]O1!:69D(&ID,-RG5W=9<,9&(W==2:H
ML%V2T!W<+8[?K:LZ& TL.%[FM423B+]^:=Y@J@F^)0D76$<V__!;Z:VKDJ#
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M6YK^UD]WXH]\GL?VXOAY+T  !&"3+4@  1" !,!YAW #!4@3!& .?E_RI!@
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M7PT58.PIH62T1UW5&0B27V'LGO<1#>I% $3H%I<=@1%"!!(:$__)\5^ZG=3
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M5](9 /Z?6R;F4C)%8/;/#6P!HUA26T[F6Q)?NHQ9@JQ %S(3Z1T'P676"JR
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<5@]=6\-U7,OU4(/U7-OU7>.U3Z/U7A=R0   .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>art-def14a_051325img005.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 art-def14a_051325img005.gif
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M^/___P
M
M
M
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M"6C''-BDK1N9NXD#O^#* GR7LPO$D_F_1'P8,GJ[.'H8QKS$D6Q8?.G,)"P
MES#$L+N;H R]DCG+A^RYU'L8P[S!@XL#:QS&ITS*O]#+; S,PDR;Q4R<7'RS
MM]NP3WR_>5S'JFJ@>+S./HRYUGR;WDRS8<P!KBS.=GG$ NS,CZS"T3P@M$#(
M^$R7Y=L#X_P+7"R9]XR]Z$RU>"FW5RS.ZMRZ"@#0&ER; TV<LXO/=;F[P$S,
MT8O+"*C+&_\8PQV<G!Z-E]6,Q)-9S;V+T7I\ERZ=EPRMQ)#\T%Q""ZUKN85L
MRTJ;N1';HLH,GES,NE=;E^CLP71:FSM=RUS-O%[-Q>;\"[E R JPQMV[?S2M
M@4I;Q6M,FU4MF>Y+RW6IN;5[NR=MET7-Q@Z-U#$JT5[;U-G+RK0IP/4,GJU[
MO^K\"VZ]Q0AMM8[! 5[MR?/+O'7KN'UM?FN=@:O+O*DLLSG<RKNKP;QP&%(<
MRP/LR$:=V=$<HQPL !S P2A+V+FIT,8I"V#MSVZ2IU8]OYWLS[!=FQD\F;0
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MA*G,?&G(5LP+M\[BK%W3+-">_'Z9F_GO !_PA_F_, KI=3F;_]OK19[E9ZX
MDRV>94S!KQV9ZT[64YW:UEZS[AV_IGWFIO[M^3Y^XDZ!.A",H6 +OP"]/:#
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M,1ZKU*7H,9L9" ^W\R%OYW6/\G-O"98-94$W>)5H]_]\>G=$I'9K9_2*AT?
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MBD@)NBBCC3KZZ$D\2CHI56.>EQ$O:M6%0Y89!5GE0TIN](J3<BD0Y2^DVB6
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M-A NY6$P"HK/HCXS(#A+VIG Z1 ]ZJ-"^BT:6IT<6G2Y>*3[8:*\J:5;^IT
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MD(>I\F*Y('@LA=F$%<I<)C/_F^G,9T(SFM*4YB.-^;_Y26R1]8/ES2RV$B2
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4O<GVM\,]0BV-.]WK;O>[KR@@ #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>art-def14a_051325img006.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 art-def14a_051325img006.gif
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MTN+AX?#P\/___P
M                                                 "'Y! $
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M?_D*'DRX\*>Y*P,GKFO7+V-G-1DIQI17<N6GE2<_NVRXL^?/H,<&1KSH)&<
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MQ_A#\M1L\K-/[U:>?B8-^1//^UT/@Y6?9%Y^_G%=H\5>!NX8I6<PE@+@ 6.
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MFA%WO@?_A.7G2P'R@T8XAQ]8>DSH@7CXA"/8AZI8?'_8"B]R%SW!*B+P*F9
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M(\Z=Z[INS5&;*AI*!J_,F-^^"\ N1O"&X_]CYN-R[&JF0=FZK;39K;#,P[[
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M]/62+] S'YBXF-,.F_N20_F5;_FF(,&:?R+/H"*R61%C<O$L3NL4PBN@\+8
M#@R#S*.%/ N'S N)W!+-8!RS(*0G9/M[K?C C[R[W_^Q17VKYY\XPN^^>Q_F
M&WX8=Z($>5+D?((1N6D&MAGA ]20@" @\$58"'"(F*BXR-CH^ @9"=!"66EY
MB9FIN<EYV2BH="8Z*JHA*"(J2+K**JHD*&#6.LI4(1!*.@8[-OLJ( D<+"DH
M7&Q\C/Q)# DKO.SXG"RM&! P?1W<I(W-W>W]#1XN?@PZ:WZ.GJ[>:CKN_@YO
MW#E/7\\9C^]=N,__E=]H+Z# >8<$\4IU:U486*&8"&!RILPN5PG"L%HHR.(J
MB>5:Z4I(2A"_?_\&FCQ921DN5AX$09"E:ETIE^MDY9K8RA=)8-%V^H36#&A/
MH4,1P2JZL]I/8]J:+'T*-:K_U$@=95J]BG7FU*U<$:'\*K#KUGYDGX(]2Z^@
M@(-G3&E@!0&6B)9CQ-@2D$#6W8>DR"2 99,41@%B9MF"P$JD(;'<T#K>I'+6
M8 @898HQ):AP5A& >R%]]_GHHZ-(29-6]#FJZ=5!J9Y6)OII-:7 9@N;;1M9
M4\:\>_M.5C6K\.'L?OT^#N^Q<D_(?Y(=^7.Y]!9JV?IB]9&U (V^7"I1@CDX
M> UQ!570H$&CJ\R)!Q%JCFSZ\LB&38<)C-UT1>%B&)K325)KB;#&B':+:&?<
M@ F*A6!LKCE(U(+_X(9;)!761B%M3&T#7X<>,@@2<2**V,Z')DHCGW(GYO,<
M="2E__A8=:.0P=XJ8OREGWIG<*8=*B%IQQ:- OBXBF(K @.C8_2U8D9+IHE0
MAD>D0: 95F'@^-)_J8E3%(*H12,@  T>N"547@8#X8,2QI/AA8U0B*$UB.16
MS&Y'WHGG.,&-R.=5)>8)*"-)HA6H.RTN5M*@8,DX2EP>,,E$>><Q@9\H8X0'
M2P55BB(D:S/^5<$L1A:ZB**+%ACB+&.(@.-1.G)*'FD>5)I.=PF0<0Z ^80I
MYC*^/L.K@+P"A5R:PPS+3)G?Y$8;G8O ::&&<\I99U/67HMMMMINRVVWWGX+
M;KCBCDMNN>:>>RX&J?;)KCJFA(!NO/+.2V^]VM9@*DKV[O_++[I.'$H(%?UN
MF^])/&@3P5JD^!)E3MNE8\88$H]!:TVV5%#Q&0(,(/# 'I/+0\$F::ON2N@(
MTJH N,Y21G=OK4/&7A4TK"4&\SJS9J]&Y:PSF0LBBRJI/I.CK#<:2NN(4LXF
MC30 2TOR<=123TUUU?V6W&[6[@H K]5>?]TOOB(+!';9\E(!,!=5CRW0P4TD
MS-899GP7-RFFT*RUC=_A7:0 9EL=,MOVD+RN.8+,+1<Z@[TJ6:M*9+RP #;+
MBV:7"9:6L[ \$ROTSIN/5G0W1U/+M#5/,]+T(:E#8F?GKK_^I<EYSS[*G[#?
M*7A MX,#L#_QY&X/H^O@17M6H1__"7P]2YXL@"@\OGR.?^C8NFFNQU^#^<[%
M:+[]YT]E?ZSWL(EO-+6K)]+L^>B3OOZ&3NT./ZF":/!=_?;?CW_^^M\?QL3^
M_P_  /K/%O%#7O((4D!N],YW[C@@ @TBDXBMK'A6N=Z)'-B)Y6T$(@A9CP!"
M)8J,X0AZGC$/Y%BAJWA@CAC7X]YJ.-<59 %-0>0;VH1LHSZGI8]]J%M=#AG1
MN@0*T40-*J(1CXC$,PVQ0QB\QQ*OT;MW-!$RO:H;!;5F01--41,:'(4O-!(3
M)[WL2ASLB_14E:D3HC"+P-F<:7 FH3$%+88RG*%::O@E/(H.6F\:'0^?Y<,?
M*B*(3RQD_[&2B,A$*E*/AC3+%C'12&E$<1R/A&05KU@\-GJHDLPAD^PL=10E
M"(D,/'I8*<L8D;UHICLK<1)AKI)">*3FA>'+8QXSI\EP&,N6H+.@'<71ICZN
M[X_4""0Q'4'(2"ISF<R\'2<MT4QC+% <STS))3$YNUS"IYJ4Z*(H!L,:$'9*
M !! SUX$ #U6CB)EK/FD!_^AK#<2A4RHPB4C05.F7_[REK+AH^JD=;IB$C.@
MR.10- ^*T(1^B)O442@P)OD-A@H/FUG39G,DBBIWBN)&K)G5**ZD'8QY\8Q&
MU&@L\7FL7JV0D9:[ISN*EL]=UM.EY=.A'P4:K8$*,A')=*A/?_\*U)U@-*B.
MF*8W, I!BF*1IIODIC='888P>  S])O@*,I02EA 0';J1$B#3&I1G*54I?4D
MVIK"Z@V8DD^>XT-K,G8X+4 ><UHZG2L0#4K4O.IUK]@8*E\38=3&./6:2FV7
M6WWC5P5IM#WI\!_?9G?2EZ[U<G'<9UF_1$>>U'"141G=/]N4H=()LUKO^ZMI
M3XO:4@TVM8> Z#60JK#"&I:I3%QM[(;7/-E.[["N&2M9[RB-8-%6E_'$(R*G
M<E/0!I-IHQ5&3UD+7=4^,[J)JB9U 1!8% TVJ;KE$V]YD]B=+;9OW;7><+N7
M.05I#[C!Q24=Q6=9SRGQ)Z3S[",(.DS_N;KONOQ5A&W[2\W_0M>U\=EN;,LK
MHN\R)KQJ&6\NK(C@=\+SK, R3FOTV5(;<F6&,D435^@$U_L*\FGX;<1S 9Q:
M :/XJ"IF;7;E8>#SH&?&--Z?C6^,8R4(<,<*%@N#>^7@"->JQS"DX2]8&!3+
MAFE81&[O:U0:7_A42&DE)C'2G%5B$^-UQ=!M,9=?Z^74OE@8L%VDF<\\W]?]
M>$]"AF63+WM+MAHQSD_V'&^.Z#KEVM6F^A6H/YV[Y2^C-LR"+K!U5TS@8/RX
MEVC6S@(RL(%(1]H"$Y@  ^:\NS47KLTRB2Q*VUI9.1JYCK])<^="*PDK_Q'5
MQSAQH?5*Z%<7_V/1T1US)&CMDT,Q4]-!YG0)?3++\\*Q.1W.\YZGXFI9!S76
MRD82LUT,L%D_&Q^ZWG6+V>QK=7A:EJ";<+.-L=.H)/O;#ITVN0%B;M0F^A&X
M_D>UK7UH3V8;*]O^GK#/#<QC2V7<^#YHNOOME7^?UM:"(G2CCSB !U1ZX1.(
M= ;8J4A2\7K>;KXWP"_.TT!C/*$"!WB[^;MNZ4Z7T0<O.6<#-7&*=_K-&U<V
MOUO>R([W^^,@#WG X_T)Z)%AQSSON<_#D&,;\ZA0*5>YMED>73Q?_.4P+Z3,
M\4WSFD?;$;A&I]'7\1&B7_N(,J:QU[\.]K"+70,B"#IFFNXSI0.<Z?]H'^+3
MSQWU_MJ\ZB2\NCFRCO*MFWSO$6_['9&(<;;[O8!O)W?<Y;YNNMN]L4C/Q^$W
MC.G!UWGP ! \Y3.-\\O??.3]3K3B%W\.O /J\9KO4)27KO'2+['PWR8]XJ=^
MB,^#'HT6EXKK57^<QE/7\K@7&NN;?7NIOUOVL\]/[:,2]1(H?_G,;[[SGP_]
MZ$N?^;U7;^]Y7_V\<Q[WP7]]BV)O\+H7?Q2BSU/RIX_^]*L?^ME72_6QWWX\
M_5[9W?=^BUP0_O%+Z?A0.?_Z_P^ T1=_I[=VJ1=_SI1YI5=_  8P62 #"8@:
MXJ=_Y2=_TQ: %XB!RG> N@==\'> *S)_LE;_=7Q'@H#W(;TC!-M7(!(X?A2(
M.Q:8@3&X?A_(@:GE@1^H11!X>2-8@CUH:LW1.TB ?X_$#"Q8?"YH0#K("#+(
MA.BW@4D4> :(@YT3@J]&?.T2,3ZGA3WG$/SG;H>R!3E A*-AA*N 'A2'A" (
M@TW(ALXW@,>%>J4UA9BG@@J8?_JW"FD('[WS UM4A+B%367P6+2G=4JX"&V(
MB-37?HD4A7(XA[!3A85VA7BHAWL(,$?P@!CTA^=0!F' (TIP'^90!DPP567(
M)$KP $?Q (\3>C4H16N8B&WXB*5W@[.(')$H:),X@:XH#@"S!2GH0)M80J2Q
M'Z1@!K5 &E;A%ZQQ_RMWQXN4!(NQV(2V>'FU2(V(98A^IXLM^(SAT#M&,(3
M(XRLD%6F83+9<101U"H5\!U[D1>$J'UUZ C2B(C7.'C6:(\+EHUMMXU'V(WB
ML 6'D@4WD#SC>!/STQ\/@2,B!4KE5!ZYI0Y=^# ?!0NH=)"%*(^-0(^RF(]H
MAX\=R16X^&7].'N5:"(T< 0 TX>Y8Y"CX"2(H3'-8P85( (9TQTR056L<!<:
M99)-M8^(L)%L"))-]Y%#:7N&Z(-)22 2=X=X2'[_& Z4\ .72 ."TY(S,20=
M-&0QL359:8;8=@8]65L_>0A!.8VEUVB-:)3Q6$DDIY1*Z7M-Z91A"97@4/\)
M-Q"0+;(%.L V5WD&+PD3$&E>@KE;>&%59H CC -*7K@4_F>6&8B6:1F':SEZ
M2+EIEK*%F:F%3!!T]1,7<9F-5C>7B\F4E. "1@ P0!".IN*7DU$96TF8G(@C
M"<"*,6,>SLB8T1&-CQF D8EF:DF9%9B1#3::6E&:PUD0IKAX8CF6E2 $>?D<
M#E@P?GD&YY01:G23,C$&*1,>&@ YS'E1N\F;_^>;9P:<P9F$G 0ZO79UME.9
MH:F<=@>>X7D),I"2A[*2BD*=3;(:4*(E7+D.96"= N!1N(F1Z@D,XPF9Z-EO
M1<F@0F69[&ET[FE^<GD.9SAO\WF+F> "4WDH0JC_GV2(#JL"<8IY!MD9H)AR
M% E0/1?)EFV9H IZ@0^*;PY*HXX7H<79%KG9F!9J.+$I9!IZ')R0 ]!)%F$X
M*-39-REC52,%H.BPC'CQ.)=Q%"U*FB\ZAI(@HS-ZH]]FHUV:'#E:G!0JG,@I
M)J;8B9\8BBQ#BAB:%4Q 8R9ZI5AJ"2Z !"JYFM*AI#^".*?@,$]J#HAI'GBS
MG32Q?P<*HUJZI0 (ILWVI8T*C<@)EL5'IB\(GX.YHJ]RC-8I'.-TF7/ZGIS@
MH2V"B2FRIZ,0$\_SIT#:"H/1I&<P&! FI-A(E@"PJ(P*J:_VJ+EJEV(ZFI6:
MG@@*#498CJ1QCJLA'"HZ_UZS2JN=( -9 (; J*<BRJ:HFEN^ $*K@**%":0<
M<6 N&JK"&@FW2IZ\*FB[:J[=$&:3.GO JH:7NG_HE)!,L)"!H0L."0M9@1&.
MTXH\ZA/VX )  ##@.*W#6D)@E%MBM*KKT!VTDI#?^I3^^B+B2:[LEZY<AJX7
M"V:2^JGM*K$0"J\L8:BJ,),U.8Q8(:@/<4:'BJB=H -&V@];0) J0JUY&$JC
M5$J*N:U."A(/6Z"B(*"=87PMZX<Q6K%.J+$HEK%)FPSKVK&@YZX7Y*-8Z2.
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MOV5GO,1>-.31?7=JRR57K 8)H*4;XJQ98&W2>TMQ9$V?;TV<]4$: WS7,)W
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MCG<=0F ^%'@,K$'00I>25/UN<C9$#5""-6(>])PG/;<YXGG3<QA%M/>J:$"
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M@R1(-]6S@G.E<T+(<44G@61W@[&D?T,&@,+W@DV(@2YH_WHPZ(.VI&-6F"-
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>,:LY)W%=LYO?+)0@PGG.=,8)?^N,YSSK><Z!   [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>art-def14a_051325img007.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 art-def14a_051325img007.gif
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MGZ"1B(B9I9.<I)N=H)R>H9V?HIZ@HZ>EIK:TM<3#Q-/2TN+AX?#P\/___P
M
M
M                                                 "'Y! $
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MJ%.K7LU(]&BSGY5ZCLW9T.QGMRF3CNO:\NEDIFNS'DZ\^./<FW?[]HG<]F\
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M>WB9E[=@=X I 4]P$#VPEI^)=]"WF(;9=U* $!=PD5#0F%J9EB99 09)!3V
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MN;3PI2:AM2WX$2&ZK!N!F(.)F)_;G-]HJ/SJNAD&NVUUJ7=:K=/YC: :IP9
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M H4]UYQ-;,DBB*UV=AS8=O'FDJ&]VJQ=;T70U4- V3-MV:U=V[9]V[9& 1!
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M[[N\DS^_+SCZ]9(SGT7NCCVAQO3KV[^/?['\9<X'JMKT3Q2H;<*#:O\$=%!
M#CPQQ1,+'?2/>>B)1^$Q^TTBX84:>J/>AAYJ1D]<\+TCWR82G(ABBBJN>.)"
M^;T(XX>:</*4B]RA0DLL_@ URHT+[3@*41$ZYF&%1BHC8Y)*YM/ADDYZY!Y<
M(]:S'H" 78DEEE) P>5H1#[Y2'^X2&$0CBXF(!U04AA@P"U6?O)F+E]J>&2=
M((")9Y[;-*EGG^=$*=>4-9T79Y;_AAXZ4(9^BHG*4:6@(E1T@&$'IP!*D6E
MHG->:.>1?GX*:CCCA$KJ-\9%)BAYA2+*:JN*]LGH)SR<.*  #IPXFR=>U@>0
M !!Z(M2O3/TU9)*=&EEJLLH2PN>RSE8"**JI*K=JJ]9F^:J>L7I"WX[0T>>
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MJ%!AWVHI09DI6"*NXTJN77&LIHJNJ&JC%,.N>MFJ[?K_JNL@K_.J?(U&J31
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M62GDJH3EK'^3FVRYF_30F^3G=8;Y!+=6A&97>AU'K#5ZH9YFJK:2FF_)K*)
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M*:I[<SNRS5J[-(J6MA2@@[2^P@-2[OM:YJN,R NYGNK_FK30$M&[G4HBO9)
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M756R_MP\TM*9?>L1]./%Z94**.HM-C[*LE1%3:GA7N'KC.'# @7LDY#<G>J
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MZJID"I$Y:J.A^H=$JIAM>I=JBG25-ZNTNJO_V:N/&8W 2JK(:G>M^IN)N8$
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MI!-XPJ'RI ()P2BJP9/)PDU1ERB\2ZH:J^F(J2VKD2U<P@*JM8:*_Z8#:<2
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(>K_W^QL( #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>proxycard001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 proxycard001.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ +0#Z P$1  (1 0,1 ?_$ ,L   (# 0 " P$
M      D*!@<(!0$$  (+ P$  @$% 0              !@<%  $#! @"$
M!0($! ,#!P8("@L    ! @,$!08' !$2""$3% DQ%19!42)A<3(CM1<*@;$S
M)'8X\$(TM#4W=SF1<D-3="55=;88H<%CTU1%996E5AD1  $"! 0"!0<)!P4
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M\IRT<D#X>8W6S*(AP'+$?<*!^U5KEOJA)]I6D]<;%.^W4L)?9_AJ ([8NL1
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M>,_6(W;^K3:'YB8T>DPDG:-_<NRSN@]S5&N7S!I2M?LXM.6C7*S=5K*((K2
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M2ETE$ #///!9XC7FWV^P-;1HEARI 2E9!GI2G@>N(3;%MJ:FXNWNJ24-*,T
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M,<H@(IG,'@(AAA>(5Y?L.[Z2YTX!TMF:?K)PF.WA YM:C;K+(]2J T+<4/\
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MA1@XYHE 0U&0+[@P=>'5Z_)MRLE1DP\="IY">()B"W%0)KK4XC-U/M)[.';
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M;Q36\)_E$D&?/ZT_1#7-JZ"B+76YHJWL"@5M$TA3<3!,TP*0!$K!FDB=130
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HAY"?2=+R^FZ?2'*Z?D_5<G3]'3\.7AC2;X^]GC.<YQ<Q[V,D6C__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>proxycard002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 proxycard002.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ &0 ( P$1  (1 0,1 ?_$ ',  0$
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<K2<1=S^*!((V5NBRD&[J;51$WV3Z'\^IH1__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">DEF 14A<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ARTIVION, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000784199<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure<br></strong></div></th>
<th class="th" colspan="5">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTableTextBlock', window );">Pay vs Performance Disclosure, Table</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"><p id="xdx_803_eecd--PvpTableTextBlock_dU_gL1PTTB-LPZPJ_z3K4kbMuhbdd" style="border-bottom: #7f7f7f 1pt solid; font: 12pt/normal Arial, sans-serif; margin: 0pt 0pt 15pt; text-transform: none; color: #2b4b74; text-indent: 0pt; text-align: left"><span style="text-transform: none"><b>Pay Versus Performance Disclosure</b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">This section provides disclosure about the relationship between executive compensation actually paid to our principal executive officer (&#8220;PEO&#8221;) and Non-PEO Named Executive Officers (NEOs) and certain financial performance measures of the Company for the fiscal years listed below. This disclosure has been prepared in accordance with Item 402(v) of Regulation S-K under the Securities Exchange Act of 1934 (the &#8220;Pay Versus Performance Rules&#8221;) and does not necessarily reflect how the Compensation Committee evaluates </span><span style="text-transform: none; line-height: 12pt">compensation decisions.</span></p>
				<div style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-align: left">
					<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 10pt; border-collapse: collapse">
						<tr style="margin: 0; height: 0">
							<td style="border-width: 0; margin: 0; padding: 0; width: 48.75pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 92.5pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 92.5pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 95pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 95pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 75pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 75pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 47.5pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 53.75pt">


							</td>

						</tr>
						<tr style="min-height: 24pt">
							<td rowspan="2" style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Year</b></span></p>

							</td>
							<td rowspan="2" style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Summary <br/>Compensation <br/>Table Total <br/>for PEO</b></span></p>

							</td>
							<td rowspan="2" style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Compensation <br/>Actually Paid <br/>to PEO</b></span></p>

							</td>
							<td rowspan="2" style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Average<br/>Summary <br/>Compensation <br/>Table Total for <br/>non-PEO NEOs</b></span></p>

							</td>
							<td rowspan="2" style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Average<br/>Compensation<br/>Actually Paid to <br/>non-PEO NEOs</b></span></p>

							</td>
							<td colspan="2" style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Value of initial fixed $100 Investment based on:</b></span></p>

							</td>
							<td rowspan="2" style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Net <br/>Income/<br/>(Loss) <br/>($mm)</b></span></p>

							</td>
							<td rowspan="2" style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>AORT<br/>Revenue<br/>Growth<br/>($mm)</b></span></p>

							</td>

						</tr>
						<tr style="min-height: 36pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>AORT Total Shareholder Return</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Index Total Shareholder Return</b></span></p>

							</td>

						</tr>
						<tr style="min-height: 13.2pt">
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 11.2pt; line-height: 11.2pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><sup style="text-transform: none; font-size: 6pt; line-height: 6pt"><b>(a)</b></sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><sup style="text-transform: none; font-size: 6pt; line-height: 6pt"><b>(a)</b></sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><sup style="text-transform: none; font-size: 6pt; line-height: 6pt"><b>(b)</b></sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><sup style="text-transform: none; font-size: 6pt; line-height: 6pt"><b>(b)</b></sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><sup style="text-transform: none; font-size: 6pt; line-height: 6pt"><b> (c) </b></sup></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><sup style="text-transform: none; font-size: 6pt; line-height: 6pt"><b> (c) </b></sup></p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 11.2pt; line-height: 11.2pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><sup style="text-transform: none; font-size: 6pt; line-height: 6pt"><b>(d)</b></sup></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">2024</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_980_eecd--PeoTotalCompAmt_c20240101__20241231_fKGEp_zm0QVenOj7ak" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">$5,511,940</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98E_eecd--PeoActuallyPaidCompAmt_c20240101__20241231_fKGEp_zZereKucB3Wh" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">$12,328,862</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 12pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_981_eecd--NonPeoNeoAvgTotalCompAmt_c20240101__20241231_fKGIp_zMUYjSzkQlag" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">$1,703,153</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 12pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98C_eecd--NonPeoNeoAvgCompActuallyPaidAmt_c20240101__20241231_fKGIp_zOynJVMxkVj6" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">$3,151,020</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 19pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_987_eecd--TotalShareholderRtnAmt_pp2d_c20240101__20241231_fKGMp_zd7VfqqTbKWj" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">$106</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_980_eecd--PeerGroupTotalShareholderRtnAmt_pp2d_c20240101__20241231_fKGMp_zyYS5HrAnjKd" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">$138</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_983_eus-gaap--NetIncomeLoss_pn6n6_c20240101__20241231_z7zuSx1flaQg" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">($13)</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 10pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none"><span id="xdx_902_eecd--CoSelectedMeasureAmt_pid_dp_uRatio_c20240101__20241231_fKGQp_z8WLIkO2T6ca">9</span>%</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">2023</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_982_eecd--PeoTotalCompAmt_c20230101__20231231_fKGEp_zfnOwfBjhYAk" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">$3,176,413</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98B_eecd--PeoActuallyPaidCompAmt_c20230101__20231231_fKGEp_zrYEqJy72lZ9" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">$7,225,878</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 12pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_988_eecd--NonPeoNeoAvgTotalCompAmt_c20230101__20231231_fKGIp_zJBHUkUH2Ide" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">$1,204,664</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 12pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_982_eecd--NonPeoNeoAvgCompActuallyPaidAmt_c20230101__20231231_fKGIp_zXneGOu13Nkh" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">$1,835,407</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 19pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98B_eecd--TotalShareholderRtnAmt_pp2d_c20230101__20231231_fKGMp_znHI0kQMHLB4" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">$66</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98B_eecd--PeerGroupTotalShareholderRtnAmt_pp2d_c20230101__20231231_fKGMp_zYVNBCm6rrRe" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">$124</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_983_eus-gaap--NetIncomeLoss_pn6n6_c20230101__20231231_z9IlVv0kyaOe" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">($31)</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 10pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none"><span id="xdx_906_eecd--CoSelectedMeasureAmt_pid_dp_uRatio_c20230101__20231231_fKGQp_zJqCpv1F1gy4">12</span>%</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">2022</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98D_eecd--PeoTotalCompAmt_c20220101__20221231_fKGEp_zR4yGZ9GY11d" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">$7,216,340</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98C_eecd--PeoActuallyPaidCompAmt_c20220101__20221231_fKGEp_zl63HFzvzmE8" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">$4,718,496</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 12pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_985_eecd--NonPeoNeoAvgTotalCompAmt_c20220101__20221231_fKGIp_zI6Jdml2MAbh" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">$1,796,100</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 12pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_987_eecd--NonPeoNeoAvgCompActuallyPaidAmt_c20220101__20221231_fKGIp_zReOaVmnjYtj" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">$1,352,869</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 19pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_983_eecd--TotalShareholderRtnAmt_pp2d_c20220101__20221231_fKGMp_zmg3DunzCWL9" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">$45</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98F_eecd--PeerGroupTotalShareholderRtnAmt_pp2d_c20220101__20221231_fKGMp_zqeRJJ32LCQi" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">$114</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_986_eus-gaap--NetIncomeLoss_pn6n6_c20220101__20221231_z79mLT4rGxF8" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">($19)</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 10pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none"><span id="xdx_904_eecd--CoSelectedMeasureAmt_pid_dp_uRatio_c20220101__20221231_fKGQp_zSx47QbLlc4l">9</span>%</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">2021</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_988_eecd--PeoTotalCompAmt_c20210101__20211231_fKGEp_zqKfCvggwGpd" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">$4,628,566</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_985_eecd--PeoActuallyPaidCompAmt_c20210101__20211231_fKGEp_zrwzmhzQZah" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">$3,712,538</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 12pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_989_eecd--NonPeoNeoAvgTotalCompAmt_c20210101__20211231_fKGIp_ztLj3I6eryra" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">$1,286,725</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 12pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_986_eecd--NonPeoNeoAvgCompActuallyPaidAmt_c20210101__20211231_fKGIp_znvics2Yl6J9" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">$1,108,935</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 19pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_984_eecd--TotalShareholderRtnAmt_pp2d_c20210101__20211231_fKGMp_zucAsI1NEMnc" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">$75</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_983_eecd--PeerGroupTotalShareholderRtnAmt_pp2d_c20210101__20211231_fKGMp_zMZkWisB8G2b" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">$140</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_986_eus-gaap--NetIncomeLoss_pn6n6_c20210101__20211231_z6S4MUrTXi76" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">($15)</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 10pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none"><span id="xdx_900_eecd--CoSelectedMeasureAmt_pid_dp_uRatio_c20210101__20211231_fKGQp_z1ayUznWyAX6">16</span>%</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">2020</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_982_eecd--PeoTotalCompAmt_c20200101__20201231_fKGEp_z96hQaOD7SK4" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">$3,415,458</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98A_eecd--PeoActuallyPaidCompAmt_c20200101__20201231_fKGEp_zfws7fXhhAP" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">$327,652</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 12pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98A_eecd--NonPeoNeoAvgTotalCompAmt_c20200101__20201231_fKGIp_zRyokeSdqbz4" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">$977,089</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 12pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_989_eecd--NonPeoNeoAvgCompActuallyPaidAmt_c20200101__20201231_fKGIp_z6QYG5t6ceQ6" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">$454,642</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 19pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_981_eecd--TotalShareholderRtnAmt_pp2d_c20200101__20201231_fKGMp_z6aqfg1PA1x8" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none">$87</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98F_eecd--PeerGroupTotalShareholderRtnAmt_pp2d_c20200101__20201231_fKGMp_znhzzYGlr6Vf" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">$118</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_983_eus-gaap--NetIncomeLoss_pn6n6_c20200101__20201231_zV4bqmjmn2Vk" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none">($17)</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 10pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"><span style="text-transform: none"><span id="xdx_908_eecd--CoSelectedMeasureAmt_pid_dp_uRatio_c20200101__20201231_fKGQp_zmPpCRS169Oe">-8</span>%</span></p>

							</td>

						</tr>

					</table>

				</div>

<table cellpadding="0" cellspacing="0" style="font: 9pt/normal Arial, sans-serif; display: none; visibility: hidden; color: #000000; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 7pt; text-transform: none; line-height: 7pt"><sup id="xdx_F0F_zQv8MlvYYtHc">(a)</sup></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span id="xdx_F1D_znUqSEZuFBt6" style="text-transform: none">Mr. Mackin&#160;served
as our only PEO for&#160;each year.</span></td>
</tr></table>
<table cellpadding="0" cellspacing="0" style="font: 9pt/normal Arial, sans-serif; display: none; visibility: hidden; color: #000000; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 7pt; text-transform: none; line-height: 7pt"><sup id="xdx_F04_zkz5q3evZk09">(b)</sup></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span id="xdx_F17_zTy3LCGejpx6" style="text-transform: none">Our Non-PEO NEOs in 2024
were Messrs. Berry, Davis and Stanton and Ms. Holloway. Our Non-PEO NEOs in 2023 were Messrs. Lee, Berry, Davis and Mses. Horton and
Holloway. Our Non-PEO NEOs in 2022 and 2021 were&#160;Messrs. Lee,&#160;Davis,&#160;Stanton&#160;and&#160;Ms. Holloway. Our Non-PEO NEOs
in 2020 were&#160;Messrs.&#160;Lee,&#160;Davis,&#160;Simpson,&#160;and&#160;Ms. Holloway.</span></td>
</tr></table>
<table cellpadding="0" cellspacing="0" style="font: 9pt/normal Arial, sans-serif; display: none; visibility: hidden; color: #000000; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 7pt; text-transform: none; line-height: 7pt"><sup id="xdx_F00_zgpOwZGAqRzb">(c)</sup></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span id="xdx_F1E_zitB532hdF2h" style="text-transform: none">Shareholder returns reflect
$100 invested as of market close on December 31, 2019, the final trading day of fiscal 2019; Index Shareholder Return reflects S&amp;P
500 Health Care&#160;Equipment Index.</span></td>
</tr></table>
<table cellpadding="0" cellspacing="0" style="font: 9pt/normal Arial, sans-serif; display: none; visibility: hidden; color: #000000; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 7pt; text-transform: none; line-height: 7pt"><sup id="xdx_F05_zyln938K39E6">(d)</sup></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span id="xdx_F11_zIX0QQRNIkx8" style="text-transform: none">In the Company&#8217;s
assessment, for the 2024 fiscal year, AORT revenue growth represents the most important financial performance measure that is not otherwise
required to be disclosed in the table that we used to link &#8220;compensation actually paid&#8221; to our NEOs, including our PEO, to
our performance. AORT revenue growth is an adjusted constant currency revenue measure calculated by adjusting for the exchange rate effect
on GAAP revenues. We define exchange rate effect as the year-over-year impact of foreign currency movements using current period foreign
currency rates applied to prior period transactional currency amounts. As discussed in the Compensation Discussion &amp; Analysis, constant
currency revenue growth as calculated in incentive plans may reflect additional adjustments to either the baseline (prior year revenue)
or current year results, to exclude the impact of discontinued businesses and other unplanned events that were outside of management&#8217;s
control. In 2023, we excluded the impact of the Company&#8217;s Cardiogenesis business. In 2022, we adjusted to exclude PerClot sales
that occurred in 2022 and 2021. In 2021, we measured growth in the second half of the year by comparing to the second half of 2019 rather
than 2020.</span></td>
</tr></table>
<div id="xdx_849_eecd--NamedExecutiveOfficersFnTextBlock_dU_z7OrBB38Rks2"></div>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 1pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(a)</sup></span><sup style="text-transform: none; font-size: 7pt; line-height: 7pt"></sup><span style="text-transform: none"><span id="xdx_908_eecd--PeoName_c20200101__20201231_znEPlCJI9E8b"><span id="xdx_90F_eecd--PeoName_c20210101__20211231_zY0OfcfAZp01"><span id="xdx_905_eecd--PeoName_c20220101__20221231_zZHCoC7y8gnc"><span id="xdx_904_eecd--PeoName_c20230101__20231231_zddNZUNYL4Qf"><span id="xdx_900_eecd--PeoName_c20240101__20241231_znX2Xqykizi6">Mr. Mackin</span></span></span></span></span>&#160;served as our only PEO </span><span style="text-transform: none">for&#160;each year.</span></p>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 1pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(b)</sup></span><sup style="text-transform: none; font-size: 7pt; line-height: 7pt"></sup><span style="text-transform: none">Our Non-PEO NEOs in 2024 were Messrs. Berry, Davis and Stanton and Ms. Holloway. Our Non-PEO NEOs in 2023 were Messrs. Lee, Berry, Davis and Mses. Horton and Holloway. Our Non-PEO NEOs in 2022 and 2021 were&#160;Messrs. Lee,&#160;Davis,&#160;Stanton&#160;and&#160;Ms. Holloway. Our Non-PEO NEOs in 2020 </span><span style="text-transform: none">were&#160;Messrs.&#160;Lee,&#160;Davis,&#160;Simpson,&#160;and&#160;Ms. Holloway.</span></p>
<div id="xdx_85A_z4Lu9NCrLOdf" style="margin-bottom: 1pt"></div>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 1pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(c)</sup></span><sup style="text-transform: none; font-size: 7pt; line-height: 7pt"></sup><span style="text-transform: none">Shareholder returns reflect $100 invested as of market close on December 31, 2019, the final trading day of fiscal 2019; Index Shareholder Return reflects S&amp;P 500 Health </span><span style="text-transform: none">Care&#160;Equipment Index.</span></p>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 8pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(d)</sup></span><sup style="text-transform: none; font-size: 7pt; line-height: 7pt"></sup><span style="text-transform: none"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFBheSB2cyBQZXJmb3JtYW5jZSBEaXNjbG9zdXJlAA__" id="xdx_906_eecd--NonGaapMeasureDescriptionTextBlock_c20240101__20241231__ecd--MeasureAxis__1_zGdKNsBUfWRl">In the Company&#8217;s assessment, for the 2024 fiscal year, <span id="xdx_90D_eecd--CoSelectedMeasureName_c20240101__20241231_zqgOKiYCGonc">AORT revenue growth</span> represents the most important financial performance measure that is not otherwise required to be disclosed in the table that we used to link &#8220;compensation actually paid&#8221; to our NEOs, including our PEO, to our performance. AORT revenue growth is an adjusted constant currency revenue measure calculated by adjusting for the exchange rate effect on GAAP revenues. We define exchange rate effect as the year-over-year impact of foreign currency movements using current period foreign currency rates applied to prior period transactional currency amounts. As discussed in the Compensation Discussion &amp; Analysis, constant currency revenue growth as calculated in incentive plans may reflect additional adjustments to either the baseline (prior year revenue) or current year results, to exclude the impact of discontinued businesses and other unplanned events that were outside of management&#8217;s control. In 2023, we excluded the impact of the Company&#8217;s Cardiogenesis business. In 2022, we adjusted to exclude PerClot sales that occurred in 2022 and 2021. In 2021, we measured growth in the second half of the year by comparing to the second half of 2019 rather than 2020.</span></span></p>
				<p id="xdx_84D_eecd--AdjToPeoCompFnTextBlock_dU_gL2ATPCFTB-BR_z1I5XfViUMj8" style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">The following table sets forth a reconciliation from the Summary Compensation Table (&#8220;SCT&#8221;) to Compensation Actually Paid (&#8220;CAP&#8221;) to our PEO and for the average paid to our Non-PEO NEOs for each </span><span style="text-transform: none; line-height: 12pt">fiscal year.</span></p>
				<table id="xdx_308_zVWZIriixLRa" style="table-layout: fixed; width: 674.68pt; margin-top: 4pt; margin-bottom: 10pt; border-collapse: collapse" summary="xdx: Disclosure - Pay vs Performance Disclosure">
						<tr style="margin: 0; height: 0">
							<td style="text-align: left; border-width: 0; margin: 0; padding: 0; width: 142.49pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 88.74pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 89.06pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 84.37pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 90pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 84.37pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 95.62pt">


							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="text-align: left; border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none"><b>Year</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>SCT<br/>Total</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Less Sum of<br/>Stock and<br/>Option Award<br/>Values from<br/>SCT</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Value of<br/>Current<br/>Year Equity<br/>Awards at<br/>12/31</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Change in<br/>Value of<br/>Unvested Prior<br/>Year Awards at<br/>12/31</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Change in<br/>Value of Prior<br/>Year Awards<br/>That Vested<br/>In Current<br/>Year</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Total<br/>Compensation<br/>Actually Paid</b></span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="text-align: left; border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="text-align: left; margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b> (e) </b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b> (f) </b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b> (g) </b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b> (h) </b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>(i)</b></span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="text-align: left; border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">2024</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98F_eecd--PeoTotalCompAmt_c20240101__20241231_zemY5XBdadxg" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">$5,511,940</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 7pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_982_eecd--AdjToCompAmt_c20240101__20241231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--EqtyAwrdsInSummryCompstnTblForAplblYrMember_fKGUp_zpc4FwAn8mG" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">($3,608,101)</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98B_eecd--AdjToCompAmt_c20240101__20241231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_fKGYp_zPM9LlTzo3K9" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">$5,852,430</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 10pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98C_eecd--AdjToCompAmt_c20240101__20241231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_fKGcp_zobmolIoUIVj" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">$3,370,222</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 10pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98C_eecd--AdjToCompAmt_c20240101__20241231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_fKGgp_zXPqHhvacd8d" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">$1,202,370</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 11pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98F_eecd--PeoActuallyPaidCompAmt_c20240101__20241231_fKGkp_ziEqyW33lUP5" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">  $12,328,862</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; text-align: left; padding: 1.5pt 0pt 1.5pt 3pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: left"><span style="text-transform: none">2023</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_983_eecd--PeoTotalCompAmt_c20230101__20231231_zy5Mge1YGukk" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">$3,176,413</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 7pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_987_eecd--AdjToCompAmt_c20230101__20231231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--EqtyAwrdsInSummryCompstnTblForAplblYrMember_fKGUp_zHj7xU8g9oBc" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">&#8194; ($801,938)</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_985_eecd--AdjToCompAmt_c20230101__20231231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_fKGYp_zMdhmvbrG5fi" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">$1,771,014</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 10pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_980_eecd--AdjToCompAmt_c20230101__20231231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_fKGcp_zP3BA88jqry" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">$2,775,817</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 10pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_980_eecd--AdjToCompAmt_c20230101__20231231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_fKGgp_zkWvh3ykRXfi" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">  $304,572</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 11pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98A_eecd--PeoActuallyPaidCompAmt_c20230101__20231231_fKGkp_zVmA0VUBAb71" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">$7,225,878</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; text-align: left; padding: 1.5pt 0pt 1.5pt 3pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: left"><span style="text-transform: none">2022</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98A_eecd--PeoTotalCompAmt_c20220101__20221231_zoGHyJZbiJbh" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">$7,216,340</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 7pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98C_eecd--AdjToCompAmt_c20220101__20221231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--EqtyAwrdsInSummryCompstnTblForAplblYrMember_fKGUp_zijFSTRwDKz9" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">($5,587,257)</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98C_eecd--AdjToCompAmt_c20220101__20221231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_fKGYp_z0bLeuqpqHVh" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">$4,689,996</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 7pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_982_eecd--AdjToCompAmt_c20220101__20221231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_fKGcp_zOR7dMRuabv3" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">($1,385,504)</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 7pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_984_eecd--AdjToCompAmt_c20220101__20221231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_fKGgp_zj603AnWzEs2" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">  ($215,079)</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 11pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98B_eecd--PeoActuallyPaidCompAmt_c20220101__20221231_fKGkp_zxCNN0mEKMb9" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">$4,718,496</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; text-align: left; padding: 1.5pt 0pt 1.5pt 3pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: left"><span style="text-transform: none">2021</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98E_eecd--PeoTotalCompAmt_c20210101__20211231_ztAU8dB027n9" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">$4,628,566</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 7pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98B_eecd--AdjToCompAmt_c20210101__20211231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--EqtyAwrdsInSummryCompstnTblForAplblYrMember_fKGUp_zDFEgmTMRn73" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">($2,977,494)</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98A_eecd--AdjToCompAmt_c20210101__20211231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_fKGYp_z7o9Mqn0GJV1" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">$2,402,215</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 7pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98B_eecd--AdjToCompAmt_c20210101__20211231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_fKGcp_zc5hLlTdy1hk" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">&#8194; ($495,663)</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 10pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98C_eecd--AdjToCompAmt_c20210101__20211231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_fKGgp_zyzTOoKZTUEh" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">$154,913</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 11pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_984_eecd--PeoActuallyPaidCompAmt_c20210101__20211231_fKGkp_zD4ijklw5Ul8" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">$3,712,538</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; text-align: left; padding: 1.5pt 0pt 1.5pt 3pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: left"><span style="text-transform: none">2020</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_980_eecd--PeoTotalCompAmt_c20200101__20201231_zdhn2cMbmx3b" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">$3,415,458</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 7pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98C_eecd--AdjToCompAmt_c20200101__20201231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--EqtyAwrdsInSummryCompstnTblForAplblYrMember_fKGUp_zNz1YCiWqC9k" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">($2,323,534)</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_980_eecd--AdjToCompAmt_c20200101__20201231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_fKGYp_z8lDHJMvAFRh" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">$1,931,021</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 7pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98C_eecd--AdjToCompAmt_c20200101__20201231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_fKGcp_z7fZxiI4LKxj" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">($2,326,940)</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 7pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98D_eecd--AdjToCompAmt_c20200101__20201231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_fKGgp_zDtII3fwInTk" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">($368,352)</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 11pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98F_eecd--PeoActuallyPaidCompAmt_c20200101__20201231_fKGkp_zssJsD9lBFZ5" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">&#8194; $327,652</span></p>

							</td>

						</tr>

					</table>

				<table cellpadding="0" cellspacing="0" style="font: 9pt/normal Arial, sans-serif; display: none; visibility: hidden; color: #000000; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 7pt; text-transform: none; line-height: 7pt"><sup id="xdx_F05_zBhfDSiTlHrk">(e)</sup></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span id="xdx_F15_zuBc0O9oGre3" style="text-transform: none">Represents the grant date
fair value of equity-based awards made during the covered fiscal year as reported in the Summary&#160;Compensation Table.</span></td>
</tr></table>
<table cellpadding="0" cellspacing="0" style="font: 9pt/normal Arial, sans-serif; display: none; visibility: hidden; color: #000000; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 7pt; text-transform: none; line-height: 7pt"><sup id="xdx_F09_zhLUB9FGOI76">(f)</sup></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span id="xdx_F11_z9fCcMfCAWB5" style="text-transform: none">Represents the year-end
fair value of equity awards that were made during the covered fiscal year and remained unvested as&#160;of the end of the covered fiscal
year.</span></td>
</tr></table>
<table cellpadding="0" cellspacing="0" style="font: 9pt/normal Arial, sans-serif; display: none; visibility: hidden; color: #000000; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 7pt; text-transform: none; line-height: 7pt"><sup id="xdx_F04_zJNwH9gobYo7">(g)</sup></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span id="xdx_F1D_z7HeYnvfn6F6" style="text-transform: none">Represents the change as
of the end of the covered fiscal year (from the end of the prior fiscal year) in fair value of equity-based awards granted in prior fiscal
years that were still unvested as of the covered&#160;fiscal year-end.</span></td>
</tr></table>
<table cellpadding="0" cellspacing="0" style="font: 9pt/normal Arial, sans-serif; display: none; visibility: hidden; color: #000000; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 7pt; text-transform: none; line-height: 7pt"><sup id="xdx_F00_zMc9VSmuo24k">(h)</sup></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span id="xdx_F15_zGLIg8Tf6rg7" style="text-transform: none">Represents the change as
of the vesting date (from the end of the prior fiscal year) in fair value of equity-based awards granted in prior fiscal years that vested
as of the end of or during the covered&#160;fiscal year.</span></td>
</tr></table>
<table cellpadding="0" cellspacing="0" style="font: 9pt/normal Arial, sans-serif; display: none; visibility: hidden; color: #000000; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 7pt; text-transform: none; line-height: 7pt"><sup id="xdx_F0C_zhsBSlRhRjtj">(i)</sup></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span id="xdx_F12_zqUVtIkQNNNc" style="text-transform: none">Equal to summary compensation
total plus/minus any adjustments related to equity award values as reflected in&#160;this table. For purposes of calculating &#8220;compensation
actually paid,&#8221; the fair value of equity awards at year-end 2023 and 2024, and on vesting dates for awards that vested during 2024,
were all determined consistent with the approach used to value the awards at the grant date for purposes of the Summary Compensation
Table (refer to &#8220;Executive Officer Compensation &#8211; Summary Compensation Table&#8221; for additional information). For any
awards subject to performance conditions, the change in fair value as of the end of the covered fiscal year is calculated based on the
probable outcome of such conditions as of the last day of the fiscal year. The valuation assumptions used to calculate fair values do
not differ materially from those disclosed at the time of grant, other than as reflected in the table below, which summarizes option
fair values determined using the Black-Scholes model and related assumptions used to calculate Compensation Actually Paid for fiscal&#160;year
2024.</span></td>
</tr></table>

				<p id="xdx_851_zDckYHbgcnx5"></p>
				<p id="xdx_845_eecd--AdjToNonPeoNeoCompFnTextBlock_dU_z2toD0Is021l" style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">The following table sets forth a reconciliation from the Summary Compensation Table (&#8220;SCT&#8221;) to Compensation Actually Paid (&#8220;CAP&#8221;) for the average paid to our Non-PEO NEOs for each </span><span style="text-transform: none; line-height: 12pt">fiscal year.</span></p>
				<div style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-align: left">
					<table id="xdx_30E_zR7V9Qb1fbKj" style="table-layout: fixed; width: 674.68pt; margin-top: 4pt; margin-bottom: 10pt; border-collapse: collapse" summary="xdx: Disclosure - Pay vs Performance Disclosure">
						<tr style="margin: 0; height: 0">
							<td style="text-align: left; border-width: 0; margin: 0; padding: 0; width: 142.49pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 88.74pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 89.06pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 84.37pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 90pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 84.37pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 95.62pt">


							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="text-align: left; border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none"><b>Year</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>SCT<br/>Total</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Less Sum of<br/>Stock and<br/>Option Award<br/>Values from<br/>SCT</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Value of<br/>Current<br/>Year Equity<br/>Awards at<br/>12/31</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Change in<br/>Value of<br/>Unvested Prior<br/>Year Awards at<br/>12/31</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Change in<br/>Value of Prior<br/>Year Awards<br/>That Vested<br/>In Current<br/>Year</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Total<br/>Compensation<br/>Actually Paid</b></span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="text-align: left; border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="text-align: left; margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b> (e) </b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b> (f) </b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b> (g) </b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b> (h) </b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>(i)</b></span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="text-align: left; border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">2024</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 11pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_988_eecd--NonPeoNeoAvgTotalCompAmt_c20240101__20241231_zkGc2nmxZYQd" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">$1,703,153</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 8pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98D_eecd--AdjToCompAmt_c20240101__20241231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--EqtyAwrdsInSummryCompstnTblForAplblYrMember_fKGUp_z2j7FEeSfoSh" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">  ($923,744)</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 11pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_988_eecd--AdjToCompAmt_c20240101__20241231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_fKGYp_z8CEuZuUuvwd" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">$1,498,338</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 13pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_989_eecd--AdjToCompAmt_c20240101__20241231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_fKGcp_zWl8QtvFYeK8" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">  $642,469</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 13pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_985_eecd--AdjToCompAmt_c20240101__20241231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_fKGgp_zqpoBld2prm7" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">$230,805</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 14pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98A_eecd--NonPeoNeoAvgCompActuallyPaidAmt_c20240101__20241231_fKGkuKQ_____z8MWU3TdMpq3" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">$3,151,020</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; text-align: left; padding: 1.5pt 0pt 1.5pt 3pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: left"><span style="text-transform: none">2023</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 11pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_986_eecd--NonPeoNeoAvgTotalCompAmt_c20230101__20231231_zFdGxPi6y5Z8" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">$1,204,664</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 8pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_985_eecd--AdjToCompAmt_c20230101__20231231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--EqtyAwrdsInSummryCompstnTblForAplblYrMember_fKGUp_zDfLteTfhPq2" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">&#8194; ($498,431)</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 11pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98A_eecd--AdjToCompAmt_c20230101__20231231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_fKGYp_zs6fl3nop6ig" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">  $639,679</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 13pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_983_eecd--AdjToCompAmt_c20230101__20231231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_fKGcp_zjaU3jnmCvfc" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">&#8194; $443,711</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 13pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98F_eecd--AdjToCompAmt_c20230101__20231231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_fKGgp_ztA47rbIUUTd" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">  $45,783</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 14pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98B_eecd--NonPeoNeoAvgCompActuallyPaidAmt_c20230101__20231231_fKGkuKQ_____zcDfIdaGiIE3" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">$1,835,407</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; text-align: left; padding: 1.5pt 0pt 1.5pt 3pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: left"><span style="text-transform: none">2022</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 11pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98C_eecd--NonPeoNeoAvgTotalCompAmt_c20220101__20221231_zeRwyvu6di9" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">$1,796,100</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 8pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_987_eecd--AdjToCompAmt_c20220101__20221231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--EqtyAwrdsInSummryCompstnTblForAplblYrMember_fKGUp_zOvzRDZgXzKf" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">($1,124,197)</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 11pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_982_eecd--AdjToCompAmt_c20220101__20221231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_fKGYp_z5rmMRSYJEPf" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">  $955,981</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_988_eecd--AdjToCompAmt_c20220101__20221231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_fKGcp_zTfCoUsB2oCh" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none"> ($239,756)</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_985_eecd--AdjToCompAmt_c20220101__20221231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_fKGgp_zfUrvVcPTK38" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">($35,259)</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 14pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_980_eecd--NonPeoNeoAvgCompActuallyPaidAmt_c20220101__20221231_fKGkuKQ_____zU4Lx60upXQd" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">$1,352,869</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; text-align: left; padding: 1.5pt 0pt 1.5pt 3pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: left"><span style="text-transform: none">2021</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 11pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98C_eecd--NonPeoNeoAvgTotalCompAmt_c20210101__20211231_zL0XxHkSKhyh" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">$1,286,725</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 8pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_984_eecd--AdjToCompAmt_c20210101__20211231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--EqtyAwrdsInSummryCompstnTblForAplblYrMember_fKGUp_zrzfmxWnnKqi" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">&#8194; ($640,635)</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 11pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98C_eecd--AdjToCompAmt_c20210101__20211231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_fKGYp_z0HJT6cwQOn9" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">  $508,720</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_984_eecd--AdjToCompAmt_c20210101__20211231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_fKGcp_zmmkvk3v0Z2c" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">&#8194; ($72,575)</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 13pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_988_eecd--AdjToCompAmt_c20210101__20211231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_fKGgp_zvJoj1Ayeqtf" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">  $26,701</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 14pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98E_eecd--NonPeoNeoAvgCompActuallyPaidAmt_c20210101__20211231_fKGkuKQ_____zOPu6wZ4y4Hl" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">$1,108,935</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; text-align: left; padding: 1.5pt 0pt 1.5pt 3pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: left"><span style="text-transform: none">2020</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 11pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_986_eecd--NonPeoNeoAvgTotalCompAmt_c20200101__20201231_zQVsMUpIEZr5" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">&#8194;$977,089</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 8pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_988_eecd--AdjToCompAmt_c20200101__20201231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--EqtyAwrdsInSummryCompstnTblForAplblYrMember_fKGUp_zFL2z8REbYh4" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">&#8194; ($499,129)</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 11pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98C_eecd--AdjToCompAmt_c20200101__20201231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_fKGYp_zrPzWAnv5Luf" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">  $420,985</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98F_eecd--AdjToCompAmt_c20200101__20201231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_fKGcp_zHHqSQTbWNU6" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none"> ($371,199)</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_982_eecd--AdjToCompAmt_c20200101__20201231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_fKGgp_z548VFakKFve" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none"> ($73,105)</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 14pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_981_eecd--NonPeoNeoAvgCompActuallyPaidAmt_c20200101__20201231_fKGkuKQ_____zrf2LnU9tXX2" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">&#8194; $454,642</span></p>

							</td>

						</tr>

					</table>

				</div>

<table cellpadding="0" cellspacing="0" style="font: 9pt/normal Arial, sans-serif; display: none; visibility: hidden; color: #000000; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 7pt; text-transform: none; line-height: 7pt"><sup id="xdx_F04_zCsjhN8a9su7">(e)</sup></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span id="xdx_F10_zd6MihFDfz31" style="text-transform: none">Represents the grant date
fair value of equity-based awards made during the covered fiscal year as reported in the Summary&#160;Compensation Table.</span></td>
</tr></table>
<table cellpadding="0" cellspacing="0" style="font: 9pt/normal Arial, sans-serif; display: none; visibility: hidden; color: #000000; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 7pt; text-transform: none; line-height: 7pt"><sup id="xdx_F0D_zfrxqZnFmsp8">(f)</sup></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span id="xdx_F1E_zaDZYrW4evr9" style="text-transform: none">Represents the year-end
fair value of equity awards that were made during the covered fiscal year and remained unvested as&#160;of the end of the covered fiscal
year.</span></td>
</tr></table>
<table cellpadding="0" cellspacing="0" style="font: 9pt/normal Arial, sans-serif; display: none; visibility: hidden; color: #000000; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 7pt; text-transform: none; line-height: 7pt"><sup id="xdx_F00_zVKZL2f9N4jd">(g)</sup></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span id="xdx_F16_z33wktlgZdSh" style="text-transform: none">Represents the change as
of the end of the covered fiscal year (from the end of the prior fiscal year) in fair value of equity-based awards granted in prior fiscal
years that were still unvested as of the covered&#160;fiscal year-end.</span></td>
</tr></table>
<table cellpadding="0" cellspacing="0" style="font: 9pt/normal Arial, sans-serif; display: none; visibility: hidden; color: #000000; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 7pt; text-transform: none; line-height: 7pt"><sup id="xdx_F09_zDSh6BEP3mZj">(h)</sup></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span id="xdx_F1B_z9Fy81mFQbD5" style="text-transform: none">Represents the change as
of the vesting date (from the end of the prior fiscal year) in fair value of equity-based awards granted in prior fiscal years that vested
as of the end of or during the covered&#160;fiscal year.</span></td>
</tr></table>
<table cellpadding="0" cellspacing="0" style="font: 9pt/normal Arial, sans-serif; display: none; visibility: hidden; color: #000000; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 7pt; text-transform: none; line-height: 7pt"><sup id="xdx_F03_zyLPcLyHWWJe">(i)</sup></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span id="xdx_F1A_z7G5nx6ciLC7" style="text-transform: none">Equal to summary compensation
total plus/minus any adjustments related to equity award values as reflected in&#160;this table. For purposes of calculating &#8220;compensation
actually paid,&#8221; the fair value of equity awards at year-end 2023 and 2024, and on vesting dates for awards that vested during 2024,
were all determined consistent with the approach used to value the awards at the grant date for purposes of the Summary Compensation
Table (refer to &#8220;Executive Officer Compensation &#8211; Summary Compensation Table&#8221; for additional information). For any
awards subject to performance conditions, the change in fair value as of the end of the covered fiscal year is calculated based on the
probable outcome of such conditions as of the last day of the fiscal year. The valuation assumptions used to calculate fair values do
not differ materially from those disclosed at the time of grant, other than as reflected in the table below, which summarizes option
fair values determined using the Black-Scholes model and related assumptions used to calculate Compensation Actually Paid for fiscal&#160;year
2024.</span></td>
</tr></table>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 1pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(i)</sup></span><sup style="text-transform: none; font-size: 7pt; line-height: 7pt"></sup><span style="text-transform: none">Equal to summary compensation total plus/minus any adjustments related to equity award values as reflected in&#160;this table. For purposes of calculating &#8220;compensation actually paid,&#8221; the fair value of equity awards at year-end 2023 and 2024, and on vesting dates for awards that vested during 2024, were all determined consistent with the approach used to value the awards at the grant date for purposes of the Summary Compensation Table (refer to &#8220;Executive Officer Compensation &#8211; Summary Compensation Table&#8221; for additional information). For any awards subject to performance conditions, the change in fair value as of the end of the covered fiscal year is calculated based on the probable outcome of such conditions as of the last day of the fiscal year. The valuation assumptions used to calculate fair values do not differ materially from those disclosed at the time of grant, other than as reflected in the table below, which summarizes option fair values determined using the Black-Scholes model and related assumptions used to calculate Compensation Actually Paid for </span><span style="text-transform: none">fiscal&#160;year 2024.</span></p>

				<div id="xdx_C0B_gL2ATPCFTB-BR_zwK9StH3wMCi" style="margin-bottom: 1pt"><p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 1pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(e)</sup></span><sup style="text-transform: none; font-size: 7pt; line-height: 7pt"></sup><span style="text-transform: none">Represents the grant date fair value of equity-based awards made during the covered fiscal year as reported in the </span><span style="text-transform: none">Summary&#160;Compensation Table.</span></p>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 1pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(f)</sup></span><sup style="text-transform: none; font-size: 7pt; line-height: 7pt"></sup><span style="text-transform: none">Represents the year-end fair value of equity awards that were made during the covered fiscal year and remained unvested as&#160;of the end of the covered </span><span style="text-transform: none">fiscal year.</span></p>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 1pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(g)</sup></span><sup style="text-transform: none; font-size: 7pt; line-height: 7pt"></sup><span style="text-transform: none">Represents the change as of the end of the covered fiscal year (from the end of the prior fiscal year) in fair value of equity-based awards granted in prior fiscal years that were still unvested as of the </span><span style="text-transform: none">covered&#160;fiscal year-end.</span></p>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 8pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(h)</sup></span><sup style="text-transform: none; font-size: 7pt; line-height: 7pt"></sup><span style="text-transform: none">Represents the change as of the vesting date (from the end of the prior fiscal year) in fair value of equity-based awards granted in prior fiscal years that vested as of the end of or during the </span><span style="text-transform: none">covered&#160;fiscal year.</span></p>
				<div id="xdx_893_eecd--EqtyAwrdsAdjFnTextBlock_dU_zd3NhAsLpzpa"></div>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 8pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(i)</sup></span><sup style="text-transform: none; font-size: 7pt; line-height: 7pt"></sup><span style="text-transform: none">Equal to summary compensation total plus/minus any adjustments related to equity award values as reflected in&#160;this table. For purposes of calculating &#8220;compensation actually paid,&#8221; the fair value of equity awards at year-end 2023 and 2024, and on vesting dates for awards that vested during 2024, were all determined consistent with the approach used to value the awards at the grant date for purposes of the Summary Compensation Table (refer to &#8220;Executive Officer Compensation &#8211; Summary Compensation Table&#8221; for additional information). For any awards subject to performance conditions, the change in fair value as of the end of the covered fiscal year is calculated based on the probable outcome of such conditions as of the last day of the fiscal year. The valuation assumptions used to calculate fair values do not differ materially from those disclosed at the time of grant, other than as reflected in the table below, which summarizes option fair values determined using the Black-Scholes model and related assumptions used to calculate Compensation Actually Paid for </span><span style="text-transform: none">fiscal&#160;year 2024.</span></p>
				<div style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-align: justify">
					<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 10pt; border-collapse: collapse">
						<tr style="margin: 0; height: 0">
							<td style="border-width: 0; margin: 0; padding: 0; width: 100pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 110pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 93.75pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 92.49pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 63.74pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 107.5pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 107.5pt">


							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Valuation<br/>Purpose<br/>for PVP&#160;</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>AORT<br/>Stock<br/>Price</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>AORT<br/>Option<br/>Exercise<br/>Price</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Expected<br/>Term<br/>(years)</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Stock<br/>Price<br/>Volatility</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Risk-free<br/>Rate</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Option<br/>Fair<br/>Value</b></span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Year-end 2023</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_905_eus-gaap--SharePrice_iI_pid_c20241231__us-gaap--VestingAxis__custom--YearEnd2023Member_zyoa1YBNpbDh">$17.88</span></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20241231__us-gaap--VestingAxis__custom--YearEnd2023Member__srt--RangeAxis__srt--MinimumMember_z5bT910B5iI4">$11.03</span> - <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20241231__us-gaap--VestingAxis__custom--YearEnd2023Member__srt--RangeAxis__srt--MaximumMember_zSNEB73O0Sbg">$24.90</span></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2023Member__srt--RangeAxis__srt--MinimumMember_zfuoYaTx9a6e">2.13</span> &#8211; <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2023Member__srt--RangeAxis__srt--MaximumMember_z5wuLeKbg0cf">4.93</span></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2023Member_z9yVGAlW0uoc">45</span>%</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2023Member__srt--RangeAxis__srt--MinimumMember_zDHA9XJYwQOe">3.85</span>% - <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2023Member__srt--RangeAxis__srt--MaximumMember_z0ByHjPnHdCi">4.20</span>%</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_907_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFairValuePerShare_pid_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2023Member__srt--RangeAxis__srt--MinimumMember_ze1eSKkm7EUc">$3.11</span> - <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_90D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFairValuePerShare_pid_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2023Member__srt--RangeAxis__srt--MaximumMember_z1wedYtymmOh">$9.89</span></span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">2024 Vesting</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_90A_eus-gaap--SharePrice_iI_pid_c20241231__us-gaap--VestingAxis__custom--Vesting2024Member__srt--RangeAxis__srt--MinimumMember_zeHkPyKExvF4">$18.81</span> - <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_90D_eus-gaap--SharePrice_iI_pid_c20241231__us-gaap--VestingAxis__custom--Vesting2024Member__srt--RangeAxis__srt--MaximumMember_zH7RgbVEMs58">$29.66</span></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20241231__us-gaap--VestingAxis__custom--Vesting2024Member__srt--RangeAxis__srt--MinimumMember_zsBXXbgZNSHd">$11.03</span> - <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20241231__us-gaap--VestingAxis__custom--Vesting2024Member__srt--RangeAxis__srt--MaximumMember_ziJ1ynfMcNij">$24.90</span></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20240101__20241231__us-gaap--VestingAxis__custom--Vesting2024Member__srt--RangeAxis__srt--MinimumMember_zyE2UDf1ohbd">2.00</span> &#8211; <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20240101__20241231__us-gaap--VestingAxis__custom--Vesting2024Member__srt--RangeAxis__srt--MaximumMember_z8x2k6FvKVSj">3.40</span></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20240101__20241231__us-gaap--VestingAxis__custom--Vesting2024Member_zqBT2vNbZH2e">45</span>%</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20240101__20241231__us-gaap--VestingAxis__custom--Vesting2024Member__srt--RangeAxis__srt--MinimumMember_zAf0GFsQYSJ7">4.05</span>% - <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20240101__20241231__us-gaap--VestingAxis__custom--Vesting2024Member__srt--RangeAxis__srt--MaximumMember_zruoGuGQVtce">4.64</span>%</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_906_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFairValuePerShare_pid_c20240101__20241231__us-gaap--VestingAxis__custom--Vesting2024Member__srt--RangeAxis__srt--MinimumMember_zqoe5lHLTR5k">$3.44</span> - <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFairValuePerShare_pid_c20240101__20241231__us-gaap--VestingAxis__custom--Vesting2024Member__srt--RangeAxis__srt--MaximumMember_z2zUAhP8h8wd">$19.34</span></span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Year-end 2024</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_90A_eus-gaap--SharePrice_iI_pid_c20241231__us-gaap--VestingAxis__custom--YearEnd2024Member_zIcNvc8rKnKg">$28.59</span></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20241231__us-gaap--VestingAxis__custom--YearEnd2024Member__srt--RangeAxis__srt--MinimumMember_zcefl9K22g16">$11.03</span> - <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20241231__us-gaap--VestingAxis__custom--YearEnd2024Member__srt--RangeAxis__srt--MaximumMember_z79asRnmmY7g">$18.44</span></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2024Member__srt--RangeAxis__srt--MinimumMember_zdOWKWyp5Xq4">2.15</span> &#8211; <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2024Member__srt--RangeAxis__srt--MaximumMember_zba4BTXP2Uxf">3.93</span></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2024Member_zxqzATqctpVj">45</span>%</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2024Member__srt--RangeAxis__srt--MinimumMember_zS6AZcNjtIsg">4.25</span>% - <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2024Member__srt--RangeAxis__srt--MaximumMember_zdBzYd0oKpy9">4.32</span>%</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_904_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFairValuePerShare_pid_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2024Member__srt--RangeAxis__srt--MinimumMember_zkhvEywZAjze">$13.41</span> - <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_90E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFairValuePerShare_pid_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2024Member__srt--RangeAxis__srt--MaximumMember_zL4O8QW1feQ6">$19.23</span></span></p>

							</td>

						</tr>

					</table>
					<div id="xdx_8A7_z9KbHUprOhfa"></div>
					<div id="xdx_858_zGbldmmTkFHa"></div>
				</div>
				</div>
			<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_CoSelectedMeasureName', window );">Company Selected Measure Name</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">AORT revenue growth<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NamedExecutiveOfficersFnTextBlock', window );">Named Executive Officers, Footnote</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"><div id="xdx_849_eecd--NamedExecutiveOfficersFnTextBlock_dU_z7OrBB38Rks2"></div>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 1pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(a)</sup></span><sup style="text-transform: none; font-size: 7pt; line-height: 7pt"></sup><span style="text-transform: none"><span id="xdx_908_eecd--PeoName_c20200101__20201231_znEPlCJI9E8b"><span id="xdx_90F_eecd--PeoName_c20210101__20211231_zY0OfcfAZp01"><span id="xdx_905_eecd--PeoName_c20220101__20221231_zZHCoC7y8gnc"><span id="xdx_904_eecd--PeoName_c20230101__20231231_zddNZUNYL4Qf"><span id="xdx_900_eecd--PeoName_c20240101__20241231_znX2Xqykizi6">Mr. Mackin</span></span></span></span></span>&#160;served as our only PEO </span><span style="text-transform: none">for&#160;each year.</span></p>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 1pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(b)</sup></span><sup style="text-transform: none; font-size: 7pt; line-height: 7pt"></sup><span style="text-transform: none">Our Non-PEO NEOs in 2024 were Messrs. Berry, Davis and Stanton and Ms. Holloway. Our Non-PEO NEOs in 2023 were Messrs. Lee, Berry, Davis and Mses. Horton and Holloway. Our Non-PEO NEOs in 2022 and 2021 were&#160;Messrs. Lee,&#160;Davis,&#160;Stanton&#160;and&#160;Ms. Holloway. Our Non-PEO NEOs in 2020 </span><span style="text-transform: none">were&#160;Messrs.&#160;Lee,&#160;Davis,&#160;Simpson,&#160;and&#160;Ms. Holloway.</span></p>
<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PeoTotalCompAmt', window );">PEO Total Compensation Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 5,511,940<span></span>
</td>
<td class="nump">$ 3,176,413<span></span>
</td>
<td class="nump">$ 7,216,340<span></span>
</td>
<td class="nump">$ 4,628,566<span></span>
</td>
<td class="nump">$ 3,415,458<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PeoActuallyPaidCompAmt', window );">PEO Actually Paid Compensation Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">$ 12,328,862<span></span>
</td>
<td class="nump">7,225,878<span></span>
</td>
<td class="nump">4,718,496<span></span>
</td>
<td class="nump">3,712,538<span></span>
</td>
<td class="nump">327,652<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToPeoCompFnTextBlock', window );">Adjustment To PEO Compensation, Footnote</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"><p id="xdx_84D_eecd--AdjToPeoCompFnTextBlock_dU_gL2ATPCFTB-BR_z1I5XfViUMj8" style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">The following table sets forth a reconciliation from the Summary Compensation Table (&#8220;SCT&#8221;) to Compensation Actually Paid (&#8220;CAP&#8221;) to our PEO and for the average paid to our Non-PEO NEOs for each </span><span style="text-transform: none; line-height: 12pt">fiscal year.</span></p>
				<table id="xdx_308_zVWZIriixLRa" style="table-layout: fixed; width: 674.68pt; margin-top: 4pt; margin-bottom: 10pt; border-collapse: collapse" summary="xdx: Disclosure - Pay vs Performance Disclosure">
						<tr style="margin: 0; height: 0">
							<td style="text-align: left; border-width: 0; margin: 0; padding: 0; width: 142.49pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 88.74pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 89.06pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 84.37pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 90pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 84.37pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 95.62pt">


							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="text-align: left; border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none"><b>Year</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>SCT<br/>Total</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Less Sum of<br/>Stock and<br/>Option Award<br/>Values from<br/>SCT</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Value of<br/>Current<br/>Year Equity<br/>Awards at<br/>12/31</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Change in<br/>Value of<br/>Unvested Prior<br/>Year Awards at<br/>12/31</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Change in<br/>Value of Prior<br/>Year Awards<br/>That Vested<br/>In Current<br/>Year</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Total<br/>Compensation<br/>Actually Paid</b></span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="text-align: left; border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="text-align: left; margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b> (e) </b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b> (f) </b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b> (g) </b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b> (h) </b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>(i)</b></span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="text-align: left; border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">2024</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98F_eecd--PeoTotalCompAmt_c20240101__20241231_zemY5XBdadxg" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">$5,511,940</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 7pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_982_eecd--AdjToCompAmt_c20240101__20241231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--EqtyAwrdsInSummryCompstnTblForAplblYrMember_fKGUp_zpc4FwAn8mG" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">($3,608,101)</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98B_eecd--AdjToCompAmt_c20240101__20241231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_fKGYp_zPM9LlTzo3K9" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">$5,852,430</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 10pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98C_eecd--AdjToCompAmt_c20240101__20241231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_fKGcp_zobmolIoUIVj" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">$3,370,222</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 10pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98C_eecd--AdjToCompAmt_c20240101__20241231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_fKGgp_zXPqHhvacd8d" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">$1,202,370</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 11pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98F_eecd--PeoActuallyPaidCompAmt_c20240101__20241231_fKGkp_ziEqyW33lUP5" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">  $12,328,862</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; text-align: left; padding: 1.5pt 0pt 1.5pt 3pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: left"><span style="text-transform: none">2023</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_983_eecd--PeoTotalCompAmt_c20230101__20231231_zy5Mge1YGukk" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">$3,176,413</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 7pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_987_eecd--AdjToCompAmt_c20230101__20231231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--EqtyAwrdsInSummryCompstnTblForAplblYrMember_fKGUp_zHj7xU8g9oBc" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">&#8194; ($801,938)</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_985_eecd--AdjToCompAmt_c20230101__20231231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_fKGYp_zMdhmvbrG5fi" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">$1,771,014</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 10pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_980_eecd--AdjToCompAmt_c20230101__20231231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_fKGcp_zP3BA88jqry" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">$2,775,817</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 10pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_980_eecd--AdjToCompAmt_c20230101__20231231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_fKGgp_zkWvh3ykRXfi" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">  $304,572</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 11pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98A_eecd--PeoActuallyPaidCompAmt_c20230101__20231231_fKGkp_zVmA0VUBAb71" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">$7,225,878</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; text-align: left; padding: 1.5pt 0pt 1.5pt 3pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: left"><span style="text-transform: none">2022</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98A_eecd--PeoTotalCompAmt_c20220101__20221231_zoGHyJZbiJbh" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">$7,216,340</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 7pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98C_eecd--AdjToCompAmt_c20220101__20221231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--EqtyAwrdsInSummryCompstnTblForAplblYrMember_fKGUp_zijFSTRwDKz9" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">($5,587,257)</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98C_eecd--AdjToCompAmt_c20220101__20221231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_fKGYp_z0bLeuqpqHVh" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">$4,689,996</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 7pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_982_eecd--AdjToCompAmt_c20220101__20221231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_fKGcp_zOR7dMRuabv3" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">($1,385,504)</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 7pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_984_eecd--AdjToCompAmt_c20220101__20221231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_fKGgp_zj603AnWzEs2" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">  ($215,079)</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 11pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98B_eecd--PeoActuallyPaidCompAmt_c20220101__20221231_fKGkp_zxCNN0mEKMb9" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">$4,718,496</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; text-align: left; padding: 1.5pt 0pt 1.5pt 3pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: left"><span style="text-transform: none">2021</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98E_eecd--PeoTotalCompAmt_c20210101__20211231_ztAU8dB027n9" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">$4,628,566</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 7pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98B_eecd--AdjToCompAmt_c20210101__20211231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--EqtyAwrdsInSummryCompstnTblForAplblYrMember_fKGUp_zDFEgmTMRn73" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">($2,977,494)</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98A_eecd--AdjToCompAmt_c20210101__20211231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_fKGYp_z7o9Mqn0GJV1" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">$2,402,215</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 7pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98B_eecd--AdjToCompAmt_c20210101__20211231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_fKGcp_zc5hLlTdy1hk" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">&#8194; ($495,663)</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 10pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98C_eecd--AdjToCompAmt_c20210101__20211231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_fKGgp_zyzTOoKZTUEh" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">$154,913</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 11pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_984_eecd--PeoActuallyPaidCompAmt_c20210101__20211231_fKGkp_zD4ijklw5Ul8" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">$3,712,538</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; text-align: left; padding: 1.5pt 0pt 1.5pt 3pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: left"><span style="text-transform: none">2020</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_980_eecd--PeoTotalCompAmt_c20200101__20201231_zdhn2cMbmx3b" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">$3,415,458</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 7pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98C_eecd--AdjToCompAmt_c20200101__20201231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--EqtyAwrdsInSummryCompstnTblForAplblYrMember_fKGUp_zNz1YCiWqC9k" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">($2,323,534)</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_980_eecd--AdjToCompAmt_c20200101__20201231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_fKGYp_z8lDHJMvAFRh" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">$1,931,021</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 7pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98C_eecd--AdjToCompAmt_c20200101__20201231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_fKGcp_z7fZxiI4LKxj" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">($2,326,940)</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 7pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98D_eecd--AdjToCompAmt_c20200101__20201231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_fKGgp_zDtII3fwInTk" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">($368,352)</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 11pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98F_eecd--PeoActuallyPaidCompAmt_c20200101__20201231_fKGkp_zssJsD9lBFZ5" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">&#8194; $327,652</span></p>

							</td>

						</tr>

					</table>

				<table cellpadding="0" cellspacing="0" style="font: 9pt/normal Arial, sans-serif; display: none; visibility: hidden; color: #000000; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 7pt; text-transform: none; line-height: 7pt"><sup id="xdx_F05_zBhfDSiTlHrk">(e)</sup></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span id="xdx_F15_zuBc0O9oGre3" style="text-transform: none">Represents the grant date
fair value of equity-based awards made during the covered fiscal year as reported in the Summary&#160;Compensation Table.</span></td>
</tr></table>
<table cellpadding="0" cellspacing="0" style="font: 9pt/normal Arial, sans-serif; display: none; visibility: hidden; color: #000000; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 7pt; text-transform: none; line-height: 7pt"><sup id="xdx_F09_zhLUB9FGOI76">(f)</sup></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span id="xdx_F11_z9fCcMfCAWB5" style="text-transform: none">Represents the year-end
fair value of equity awards that were made during the covered fiscal year and remained unvested as&#160;of the end of the covered fiscal
year.</span></td>
</tr></table>
<table cellpadding="0" cellspacing="0" style="font: 9pt/normal Arial, sans-serif; display: none; visibility: hidden; color: #000000; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 7pt; text-transform: none; line-height: 7pt"><sup id="xdx_F04_zJNwH9gobYo7">(g)</sup></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span id="xdx_F1D_z7HeYnvfn6F6" style="text-transform: none">Represents the change as
of the end of the covered fiscal year (from the end of the prior fiscal year) in fair value of equity-based awards granted in prior fiscal
years that were still unvested as of the covered&#160;fiscal year-end.</span></td>
</tr></table>
<table cellpadding="0" cellspacing="0" style="font: 9pt/normal Arial, sans-serif; display: none; visibility: hidden; color: #000000; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 7pt; text-transform: none; line-height: 7pt"><sup id="xdx_F00_zMc9VSmuo24k">(h)</sup></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span id="xdx_F15_zGLIg8Tf6rg7" style="text-transform: none">Represents the change as
of the vesting date (from the end of the prior fiscal year) in fair value of equity-based awards granted in prior fiscal years that vested
as of the end of or during the covered&#160;fiscal year.</span></td>
</tr></table>
<table cellpadding="0" cellspacing="0" style="font: 9pt/normal Arial, sans-serif; display: none; visibility: hidden; color: #000000; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 7pt; text-transform: none; line-height: 7pt"><sup id="xdx_F0C_zhsBSlRhRjtj">(i)</sup></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span id="xdx_F12_zqUVtIkQNNNc" style="text-transform: none">Equal to summary compensation
total plus/minus any adjustments related to equity award values as reflected in&#160;this table. For purposes of calculating &#8220;compensation
actually paid,&#8221; the fair value of equity awards at year-end 2023 and 2024, and on vesting dates for awards that vested during 2024,
were all determined consistent with the approach used to value the awards at the grant date for purposes of the Summary Compensation
Table (refer to &#8220;Executive Officer Compensation &#8211; Summary Compensation Table&#8221; for additional information). For any
awards subject to performance conditions, the change in fair value as of the end of the covered fiscal year is calculated based on the
probable outcome of such conditions as of the last day of the fiscal year. The valuation assumptions used to calculate fair values do
not differ materially from those disclosed at the time of grant, other than as reflected in the table below, which summarizes option
fair values determined using the Black-Scholes model and related assumptions used to calculate Compensation Actually Paid for fiscal&#160;year
2024.</span></td>
</tr></table>

				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 1pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(e)</sup></span><sup style="text-transform: none; font-size: 7pt; line-height: 7pt"></sup><span style="text-transform: none">Represents the grant date fair value of equity-based awards made during the covered fiscal year as reported in the </span><span style="text-transform: none">Summary&#160;Compensation Table.</span></p>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 1pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(f)</sup></span><sup style="text-transform: none; font-size: 7pt; line-height: 7pt"></sup><span style="text-transform: none">Represents the year-end fair value of equity awards that were made during the covered fiscal year and remained unvested as&#160;of the end of the covered </span><span style="text-transform: none">fiscal year.</span></p>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 1pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(g)</sup></span><sup style="text-transform: none; font-size: 7pt; line-height: 7pt"></sup><span style="text-transform: none">Represents the change as of the end of the covered fiscal year (from the end of the prior fiscal year) in fair value of equity-based awards granted in prior fiscal years that were still unvested as of the </span><span style="text-transform: none">covered&#160;fiscal year-end.</span></p>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 8pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(h)</sup></span><sup style="text-transform: none; font-size: 7pt; line-height: 7pt"></sup><span style="text-transform: none">Represents the change as of the vesting date (from the end of the prior fiscal year) in fair value of equity-based awards granted in prior fiscal years that vested as of the end of or during the </span><span style="text-transform: none">covered&#160;fiscal year.</span></p>
				<div id="xdx_893_eecd--EqtyAwrdsAdjFnTextBlock_dU_zd3NhAsLpzpa"></div>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 8pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(i)</sup></span><sup style="text-transform: none; font-size: 7pt; line-height: 7pt"></sup><span style="text-transform: none">Equal to summary compensation total plus/minus any adjustments related to equity award values as reflected in&#160;this table. For purposes of calculating &#8220;compensation actually paid,&#8221; the fair value of equity awards at year-end 2023 and 2024, and on vesting dates for awards that vested during 2024, were all determined consistent with the approach used to value the awards at the grant date for purposes of the Summary Compensation Table (refer to &#8220;Executive Officer Compensation &#8211; Summary Compensation Table&#8221; for additional information). For any awards subject to performance conditions, the change in fair value as of the end of the covered fiscal year is calculated based on the probable outcome of such conditions as of the last day of the fiscal year. The valuation assumptions used to calculate fair values do not differ materially from those disclosed at the time of grant, other than as reflected in the table below, which summarizes option fair values determined using the Black-Scholes model and related assumptions used to calculate Compensation Actually Paid for </span><span style="text-transform: none">fiscal&#160;year 2024.</span></p>
				<div style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-align: justify">
					<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 10pt; border-collapse: collapse">
						<tr style="margin: 0; height: 0">
							<td style="border-width: 0; margin: 0; padding: 0; width: 100pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 110pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 93.75pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 92.49pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 63.74pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 107.5pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 107.5pt">


							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Valuation<br/>Purpose<br/>for PVP&#160;</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>AORT<br/>Stock<br/>Price</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>AORT<br/>Option<br/>Exercise<br/>Price</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Expected<br/>Term<br/>(years)</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Stock<br/>Price<br/>Volatility</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Risk-free<br/>Rate</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Option<br/>Fair<br/>Value</b></span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Year-end 2023</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_905_eus-gaap--SharePrice_iI_pid_c20241231__us-gaap--VestingAxis__custom--YearEnd2023Member_zyoa1YBNpbDh">$17.88</span></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20241231__us-gaap--VestingAxis__custom--YearEnd2023Member__srt--RangeAxis__srt--MinimumMember_z5bT910B5iI4">$11.03</span> - <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20241231__us-gaap--VestingAxis__custom--YearEnd2023Member__srt--RangeAxis__srt--MaximumMember_zSNEB73O0Sbg">$24.90</span></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2023Member__srt--RangeAxis__srt--MinimumMember_zfuoYaTx9a6e">2.13</span> &#8211; <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2023Member__srt--RangeAxis__srt--MaximumMember_z5wuLeKbg0cf">4.93</span></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2023Member_z9yVGAlW0uoc">45</span>%</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2023Member__srt--RangeAxis__srt--MinimumMember_zDHA9XJYwQOe">3.85</span>% - <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2023Member__srt--RangeAxis__srt--MaximumMember_z0ByHjPnHdCi">4.20</span>%</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_907_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFairValuePerShare_pid_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2023Member__srt--RangeAxis__srt--MinimumMember_ze1eSKkm7EUc">$3.11</span> - <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_90D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFairValuePerShare_pid_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2023Member__srt--RangeAxis__srt--MaximumMember_z1wedYtymmOh">$9.89</span></span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">2024 Vesting</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_90A_eus-gaap--SharePrice_iI_pid_c20241231__us-gaap--VestingAxis__custom--Vesting2024Member__srt--RangeAxis__srt--MinimumMember_zeHkPyKExvF4">$18.81</span> - <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_90D_eus-gaap--SharePrice_iI_pid_c20241231__us-gaap--VestingAxis__custom--Vesting2024Member__srt--RangeAxis__srt--MaximumMember_zH7RgbVEMs58">$29.66</span></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20241231__us-gaap--VestingAxis__custom--Vesting2024Member__srt--RangeAxis__srt--MinimumMember_zsBXXbgZNSHd">$11.03</span> - <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20241231__us-gaap--VestingAxis__custom--Vesting2024Member__srt--RangeAxis__srt--MaximumMember_ziJ1ynfMcNij">$24.90</span></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20240101__20241231__us-gaap--VestingAxis__custom--Vesting2024Member__srt--RangeAxis__srt--MinimumMember_zyE2UDf1ohbd">2.00</span> &#8211; <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20240101__20241231__us-gaap--VestingAxis__custom--Vesting2024Member__srt--RangeAxis__srt--MaximumMember_z8x2k6FvKVSj">3.40</span></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20240101__20241231__us-gaap--VestingAxis__custom--Vesting2024Member_zqBT2vNbZH2e">45</span>%</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20240101__20241231__us-gaap--VestingAxis__custom--Vesting2024Member__srt--RangeAxis__srt--MinimumMember_zAf0GFsQYSJ7">4.05</span>% - <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20240101__20241231__us-gaap--VestingAxis__custom--Vesting2024Member__srt--RangeAxis__srt--MaximumMember_zruoGuGQVtce">4.64</span>%</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_906_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFairValuePerShare_pid_c20240101__20241231__us-gaap--VestingAxis__custom--Vesting2024Member__srt--RangeAxis__srt--MinimumMember_zqoe5lHLTR5k">$3.44</span> - <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFairValuePerShare_pid_c20240101__20241231__us-gaap--VestingAxis__custom--Vesting2024Member__srt--RangeAxis__srt--MaximumMember_z2zUAhP8h8wd">$19.34</span></span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Year-end 2024</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_90A_eus-gaap--SharePrice_iI_pid_c20241231__us-gaap--VestingAxis__custom--YearEnd2024Member_zIcNvc8rKnKg">$28.59</span></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20241231__us-gaap--VestingAxis__custom--YearEnd2024Member__srt--RangeAxis__srt--MinimumMember_zcefl9K22g16">$11.03</span> - <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20241231__us-gaap--VestingAxis__custom--YearEnd2024Member__srt--RangeAxis__srt--MaximumMember_z79asRnmmY7g">$18.44</span></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2024Member__srt--RangeAxis__srt--MinimumMember_zdOWKWyp5Xq4">2.15</span> &#8211; <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2024Member__srt--RangeAxis__srt--MaximumMember_zba4BTXP2Uxf">3.93</span></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2024Member_zxqzATqctpVj">45</span>%</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2024Member__srt--RangeAxis__srt--MinimumMember_zS6AZcNjtIsg">4.25</span>% - <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2024Member__srt--RangeAxis__srt--MaximumMember_zdBzYd0oKpy9">4.32</span>%</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_904_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFairValuePerShare_pid_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2024Member__srt--RangeAxis__srt--MinimumMember_zkhvEywZAjze">$13.41</span> - <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_90E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFairValuePerShare_pid_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2024Member__srt--RangeAxis__srt--MaximumMember_zL4O8QW1feQ6">$19.23</span></span></p>

							</td>

						</tr>

					</table>
					<div id="xdx_8A7_z9KbHUprOhfa"></div>
					<div id="xdx_858_zGbldmmTkFHa"></div>
				</div>
				<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonPeoNeoAvgTotalCompAmt', window );">Non-PEO NEO Average Total Compensation Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">$ 1,703,153<span></span>
</td>
<td class="nump">1,204,664<span></span>
</td>
<td class="nump">1,796,100<span></span>
</td>
<td class="nump">1,286,725<span></span>
</td>
<td class="nump">977,089<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonPeoNeoAvgCompActuallyPaidAmt', window );">Non-PEO NEO Average Compensation Actually Paid Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3],[4]</sup></td>
<td class="nump">$ 3,151,020<span></span>
</td>
<td class="nump">1,835,407<span></span>
</td>
<td class="nump">1,352,869<span></span>
</td>
<td class="nump">1,108,935<span></span>
</td>
<td class="nump">454,642<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToNonPeoNeoCompFnTextBlock', window );">Adjustment to Non-PEO NEO Compensation Footnote</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"><p id="xdx_845_eecd--AdjToNonPeoNeoCompFnTextBlock_dU_z2toD0Is021l" style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">The following table sets forth a reconciliation from the Summary Compensation Table (&#8220;SCT&#8221;) to Compensation Actually Paid (&#8220;CAP&#8221;) for the average paid to our Non-PEO NEOs for each </span><span style="text-transform: none; line-height: 12pt">fiscal year.</span></p>
				<div style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-align: left">
					<table id="xdx_30E_zR7V9Qb1fbKj" style="table-layout: fixed; width: 674.68pt; margin-top: 4pt; margin-bottom: 10pt; border-collapse: collapse" summary="xdx: Disclosure - Pay vs Performance Disclosure">
						<tr style="margin: 0; height: 0">
							<td style="text-align: left; border-width: 0; margin: 0; padding: 0; width: 142.49pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 88.74pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 89.06pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 84.37pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 90pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 84.37pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 95.62pt">


							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="text-align: left; border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none"><b>Year</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>SCT<br/>Total</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Less Sum of<br/>Stock and<br/>Option Award<br/>Values from<br/>SCT</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Value of<br/>Current<br/>Year Equity<br/>Awards at<br/>12/31</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Change in<br/>Value of<br/>Unvested Prior<br/>Year Awards at<br/>12/31</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Change in<br/>Value of Prior<br/>Year Awards<br/>That Vested<br/>In Current<br/>Year</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Total<br/>Compensation<br/>Actually Paid</b></span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="text-align: left; border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="text-align: left; margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt">&#8203;</p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b> (e) </b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b> (f) </b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b> (g) </b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b> (h) </b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>(i)</b></span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="text-align: left; border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">2024</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 11pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_988_eecd--NonPeoNeoAvgTotalCompAmt_c20240101__20241231_zkGc2nmxZYQd" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">$1,703,153</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 8pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98D_eecd--AdjToCompAmt_c20240101__20241231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--EqtyAwrdsInSummryCompstnTblForAplblYrMember_fKGUp_z2j7FEeSfoSh" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">  ($923,744)</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 11pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_988_eecd--AdjToCompAmt_c20240101__20241231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_fKGYp_z8CEuZuUuvwd" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">$1,498,338</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 13pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_989_eecd--AdjToCompAmt_c20240101__20241231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_fKGcp_zWl8QtvFYeK8" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">  $642,469</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 13pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_985_eecd--AdjToCompAmt_c20240101__20241231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_fKGgp_zqpoBld2prm7" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">$230,805</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 14pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98A_eecd--NonPeoNeoAvgCompActuallyPaidAmt_c20240101__20241231_fKGkuKQ_____z8MWU3TdMpq3" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">$3,151,020</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; text-align: left; padding: 1.5pt 0pt 1.5pt 3pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: left"><span style="text-transform: none">2023</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 11pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_986_eecd--NonPeoNeoAvgTotalCompAmt_c20230101__20231231_zFdGxPi6y5Z8" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">$1,204,664</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 8pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_985_eecd--AdjToCompAmt_c20230101__20231231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--EqtyAwrdsInSummryCompstnTblForAplblYrMember_fKGUp_zDfLteTfhPq2" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">&#8194; ($498,431)</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 11pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98A_eecd--AdjToCompAmt_c20230101__20231231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_fKGYp_zs6fl3nop6ig" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">  $639,679</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 13pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_983_eecd--AdjToCompAmt_c20230101__20231231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_fKGcp_zjaU3jnmCvfc" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">&#8194; $443,711</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 13pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98F_eecd--AdjToCompAmt_c20230101__20231231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_fKGgp_ztA47rbIUUTd" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">  $45,783</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 14pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98B_eecd--NonPeoNeoAvgCompActuallyPaidAmt_c20230101__20231231_fKGkuKQ_____zcDfIdaGiIE3" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">$1,835,407</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; text-align: left; padding: 1.5pt 0pt 1.5pt 3pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: left"><span style="text-transform: none">2022</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 11pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98C_eecd--NonPeoNeoAvgTotalCompAmt_c20220101__20221231_zeRwyvu6di9" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">$1,796,100</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 8pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_987_eecd--AdjToCompAmt_c20220101__20221231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--EqtyAwrdsInSummryCompstnTblForAplblYrMember_fKGUp_zOvzRDZgXzKf" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">($1,124,197)</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 11pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_982_eecd--AdjToCompAmt_c20220101__20221231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_fKGYp_z5rmMRSYJEPf" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">  $955,981</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_988_eecd--AdjToCompAmt_c20220101__20221231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_fKGcp_zTfCoUsB2oCh" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none"> ($239,756)</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_985_eecd--AdjToCompAmt_c20220101__20221231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_fKGgp_zfUrvVcPTK38" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">($35,259)</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 14pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_980_eecd--NonPeoNeoAvgCompActuallyPaidAmt_c20220101__20221231_fKGkuKQ_____zU4Lx60upXQd" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">$1,352,869</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; text-align: left; padding: 1.5pt 0pt 1.5pt 3pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: left"><span style="text-transform: none">2021</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 11pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98C_eecd--NonPeoNeoAvgTotalCompAmt_c20210101__20211231_zL0XxHkSKhyh" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">$1,286,725</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 8pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_984_eecd--AdjToCompAmt_c20210101__20211231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--EqtyAwrdsInSummryCompstnTblForAplblYrMember_fKGUp_zrzfmxWnnKqi" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">&#8194; ($640,635)</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 11pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98C_eecd--AdjToCompAmt_c20210101__20211231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_fKGYp_z0HJT6cwQOn9" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">  $508,720</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_984_eecd--AdjToCompAmt_c20210101__20211231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_fKGcp_zmmkvk3v0Z2c" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">&#8194; ($72,575)</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 13pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_988_eecd--AdjToCompAmt_c20210101__20211231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_fKGgp_zvJoj1Ayeqtf" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">  $26,701</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 14pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98E_eecd--NonPeoNeoAvgCompActuallyPaidAmt_c20210101__20211231_fKGkuKQ_____zOPu6wZ4y4Hl" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">$1,108,935</span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; text-align: left; padding: 1.5pt 0pt 1.5pt 3pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: left"><span style="text-transform: none">2020</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 11pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_986_eecd--NonPeoNeoAvgTotalCompAmt_c20200101__20201231_zQVsMUpIEZr5" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">&#8194;$977,089</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 8pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_988_eecd--AdjToCompAmt_c20200101__20201231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--EqtyAwrdsInSummryCompstnTblForAplblYrMember_fKGUp_zFL2z8REbYh4" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">&#8194; ($499,129)</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 11pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98C_eecd--AdjToCompAmt_c20200101__20201231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_fKGYp_zrPzWAnv5Luf" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">  $420,985</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_98F_eecd--AdjToCompAmt_c20200101__20201231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_fKGcp_zHHqSQTbWNU6" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none"> ($371,199)</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_982_eecd--AdjToCompAmt_c20200101__20201231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_fKGgp_z548VFakKFve" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none"> ($73,105)</span></p>

							</td>
							<td style="text-align: center; border-width: 0pt; padding: 1.5pt 14pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p id="xdx_981_eecd--NonPeoNeoAvgCompActuallyPaidAmt_c20200101__20201231_fKGkuKQ_____zrf2LnU9tXX2" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"><span style="text-transform: none">&#8194; $454,642</span></p>

							</td>

						</tr>

					</table>

				</div>

<table cellpadding="0" cellspacing="0" style="font: 9pt/normal Arial, sans-serif; display: none; visibility: hidden; color: #000000; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 7pt; text-transform: none; line-height: 7pt"><sup id="xdx_F04_zCsjhN8a9su7">(e)</sup></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span id="xdx_F10_zd6MihFDfz31" style="text-transform: none">Represents the grant date
fair value of equity-based awards made during the covered fiscal year as reported in the Summary&#160;Compensation Table.</span></td>
</tr></table>
<table cellpadding="0" cellspacing="0" style="font: 9pt/normal Arial, sans-serif; display: none; visibility: hidden; color: #000000; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 7pt; text-transform: none; line-height: 7pt"><sup id="xdx_F0D_zfrxqZnFmsp8">(f)</sup></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span id="xdx_F1E_zaDZYrW4evr9" style="text-transform: none">Represents the year-end
fair value of equity awards that were made during the covered fiscal year and remained unvested as&#160;of the end of the covered fiscal
year.</span></td>
</tr></table>
<table cellpadding="0" cellspacing="0" style="font: 9pt/normal Arial, sans-serif; display: none; visibility: hidden; color: #000000; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 7pt; text-transform: none; line-height: 7pt"><sup id="xdx_F00_zVKZL2f9N4jd">(g)</sup></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span id="xdx_F16_z33wktlgZdSh" style="text-transform: none">Represents the change as
of the end of the covered fiscal year (from the end of the prior fiscal year) in fair value of equity-based awards granted in prior fiscal
years that were still unvested as of the covered&#160;fiscal year-end.</span></td>
</tr></table>
<table cellpadding="0" cellspacing="0" style="font: 9pt/normal Arial, sans-serif; display: none; visibility: hidden; color: #000000; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 7pt; text-transform: none; line-height: 7pt"><sup id="xdx_F09_zDSh6BEP3mZj">(h)</sup></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span id="xdx_F1B_z9Fy81mFQbD5" style="text-transform: none">Represents the change as
of the vesting date (from the end of the prior fiscal year) in fair value of equity-based awards granted in prior fiscal years that vested
as of the end of or during the covered&#160;fiscal year.</span></td>
</tr></table>
<table cellpadding="0" cellspacing="0" style="font: 9pt/normal Arial, sans-serif; display: none; visibility: hidden; color: #000000; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 7pt; text-transform: none; line-height: 7pt"><sup id="xdx_F03_zyLPcLyHWWJe">(i)</sup></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span id="xdx_F1A_z7G5nx6ciLC7" style="text-transform: none">Equal to summary compensation
total plus/minus any adjustments related to equity award values as reflected in&#160;this table. For purposes of calculating &#8220;compensation
actually paid,&#8221; the fair value of equity awards at year-end 2023 and 2024, and on vesting dates for awards that vested during 2024,
were all determined consistent with the approach used to value the awards at the grant date for purposes of the Summary Compensation
Table (refer to &#8220;Executive Officer Compensation &#8211; Summary Compensation Table&#8221; for additional information). For any
awards subject to performance conditions, the change in fair value as of the end of the covered fiscal year is calculated based on the
probable outcome of such conditions as of the last day of the fiscal year. The valuation assumptions used to calculate fair values do
not differ materially from those disclosed at the time of grant, other than as reflected in the table below, which summarizes option
fair values determined using the Black-Scholes model and related assumptions used to calculate Compensation Actually Paid for fiscal&#160;year
2024.</span></td>
</tr></table>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 1pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(i)</sup></span><sup style="text-transform: none; font-size: 7pt; line-height: 7pt"></sup><span style="text-transform: none">Equal to summary compensation total plus/minus any adjustments related to equity award values as reflected in&#160;this table. For purposes of calculating &#8220;compensation actually paid,&#8221; the fair value of equity awards at year-end 2023 and 2024, and on vesting dates for awards that vested during 2024, were all determined consistent with the approach used to value the awards at the grant date for purposes of the Summary Compensation Table (refer to &#8220;Executive Officer Compensation &#8211; Summary Compensation Table&#8221; for additional information). For any awards subject to performance conditions, the change in fair value as of the end of the covered fiscal year is calculated based on the probable outcome of such conditions as of the last day of the fiscal year. The valuation assumptions used to calculate fair values do not differ materially from those disclosed at the time of grant, other than as reflected in the table below, which summarizes option fair values determined using the Black-Scholes model and related assumptions used to calculate Compensation Actually Paid for </span><span style="text-transform: none">fiscal&#160;year 2024.</span></p>

				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 1pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(e)</sup></span><sup style="text-transform: none; font-size: 7pt; line-height: 7pt"></sup><span style="text-transform: none">Represents the grant date fair value of equity-based awards made during the covered fiscal year as reported in the </span><span style="text-transform: none">Summary&#160;Compensation Table.</span></p>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 1pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(f)</sup></span><sup style="text-transform: none; font-size: 7pt; line-height: 7pt"></sup><span style="text-transform: none">Represents the year-end fair value of equity awards that were made during the covered fiscal year and remained unvested as&#160;of the end of the covered </span><span style="text-transform: none">fiscal year.</span></p>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 1pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(g)</sup></span><sup style="text-transform: none; font-size: 7pt; line-height: 7pt"></sup><span style="text-transform: none">Represents the change as of the end of the covered fiscal year (from the end of the prior fiscal year) in fair value of equity-based awards granted in prior fiscal years that were still unvested as of the </span><span style="text-transform: none">covered&#160;fiscal year-end.</span></p>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 8pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(h)</sup></span><sup style="text-transform: none; font-size: 7pt; line-height: 7pt"></sup><span style="text-transform: none">Represents the change as of the vesting date (from the end of the prior fiscal year) in fair value of equity-based awards granted in prior fiscal years that vested as of the end of or during the </span><span style="text-transform: none">covered&#160;fiscal year.</span></p>
				<div id="xdx_893_eecd--EqtyAwrdsAdjFnTextBlock_dU_zd3NhAsLpzpa"></div>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 8pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(i)</sup></span><sup style="text-transform: none; font-size: 7pt; line-height: 7pt"></sup><span style="text-transform: none">Equal to summary compensation total plus/minus any adjustments related to equity award values as reflected in&#160;this table. For purposes of calculating &#8220;compensation actually paid,&#8221; the fair value of equity awards at year-end 2023 and 2024, and on vesting dates for awards that vested during 2024, were all determined consistent with the approach used to value the awards at the grant date for purposes of the Summary Compensation Table (refer to &#8220;Executive Officer Compensation &#8211; Summary Compensation Table&#8221; for additional information). For any awards subject to performance conditions, the change in fair value as of the end of the covered fiscal year is calculated based on the probable outcome of such conditions as of the last day of the fiscal year. The valuation assumptions used to calculate fair values do not differ materially from those disclosed at the time of grant, other than as reflected in the table below, which summarizes option fair values determined using the Black-Scholes model and related assumptions used to calculate Compensation Actually Paid for </span><span style="text-transform: none">fiscal&#160;year 2024.</span></p>
				<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 10pt; border-collapse: collapse">
						<tr style="margin: 0; height: 0">
							<td style="border-width: 0; margin: 0; padding: 0; width: 100pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 110pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 93.75pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 92.49pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 63.74pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 107.5pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 107.5pt">


							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Valuation<br/>Purpose<br/>for PVP&#160;</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>AORT<br/>Stock<br/>Price</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>AORT<br/>Option<br/>Exercise<br/>Price</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Expected<br/>Term<br/>(years)</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Stock<br/>Price<br/>Volatility</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Risk-free<br/>Rate</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Option<br/>Fair<br/>Value</b></span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Year-end 2023</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_905_eus-gaap--SharePrice_iI_pid_c20241231__us-gaap--VestingAxis__custom--YearEnd2023Member_zyoa1YBNpbDh">$17.88</span></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20241231__us-gaap--VestingAxis__custom--YearEnd2023Member__srt--RangeAxis__srt--MinimumMember_z5bT910B5iI4">$11.03</span> - <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20241231__us-gaap--VestingAxis__custom--YearEnd2023Member__srt--RangeAxis__srt--MaximumMember_zSNEB73O0Sbg">$24.90</span></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2023Member__srt--RangeAxis__srt--MinimumMember_zfuoYaTx9a6e">2.13</span> &#8211; <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2023Member__srt--RangeAxis__srt--MaximumMember_z5wuLeKbg0cf">4.93</span></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2023Member_z9yVGAlW0uoc">45</span>%</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2023Member__srt--RangeAxis__srt--MinimumMember_zDHA9XJYwQOe">3.85</span>% - <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2023Member__srt--RangeAxis__srt--MaximumMember_z0ByHjPnHdCi">4.20</span>%</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_907_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFairValuePerShare_pid_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2023Member__srt--RangeAxis__srt--MinimumMember_ze1eSKkm7EUc">$3.11</span> - <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_90D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFairValuePerShare_pid_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2023Member__srt--RangeAxis__srt--MaximumMember_z1wedYtymmOh">$9.89</span></span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">2024 Vesting</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_90A_eus-gaap--SharePrice_iI_pid_c20241231__us-gaap--VestingAxis__custom--Vesting2024Member__srt--RangeAxis__srt--MinimumMember_zeHkPyKExvF4">$18.81</span> - <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_90D_eus-gaap--SharePrice_iI_pid_c20241231__us-gaap--VestingAxis__custom--Vesting2024Member__srt--RangeAxis__srt--MaximumMember_zH7RgbVEMs58">$29.66</span></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20241231__us-gaap--VestingAxis__custom--Vesting2024Member__srt--RangeAxis__srt--MinimumMember_zsBXXbgZNSHd">$11.03</span> - <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20241231__us-gaap--VestingAxis__custom--Vesting2024Member__srt--RangeAxis__srt--MaximumMember_ziJ1ynfMcNij">$24.90</span></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20240101__20241231__us-gaap--VestingAxis__custom--Vesting2024Member__srt--RangeAxis__srt--MinimumMember_zyE2UDf1ohbd">2.00</span> &#8211; <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20240101__20241231__us-gaap--VestingAxis__custom--Vesting2024Member__srt--RangeAxis__srt--MaximumMember_z8x2k6FvKVSj">3.40</span></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20240101__20241231__us-gaap--VestingAxis__custom--Vesting2024Member_zqBT2vNbZH2e">45</span>%</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20240101__20241231__us-gaap--VestingAxis__custom--Vesting2024Member__srt--RangeAxis__srt--MinimumMember_zAf0GFsQYSJ7">4.05</span>% - <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20240101__20241231__us-gaap--VestingAxis__custom--Vesting2024Member__srt--RangeAxis__srt--MaximumMember_zruoGuGQVtce">4.64</span>%</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_906_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFairValuePerShare_pid_c20240101__20241231__us-gaap--VestingAxis__custom--Vesting2024Member__srt--RangeAxis__srt--MinimumMember_zqoe5lHLTR5k">$3.44</span> - <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFairValuePerShare_pid_c20240101__20241231__us-gaap--VestingAxis__custom--Vesting2024Member__srt--RangeAxis__srt--MaximumMember_z2zUAhP8h8wd">$19.34</span></span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Year-end 2024</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_90A_eus-gaap--SharePrice_iI_pid_c20241231__us-gaap--VestingAxis__custom--YearEnd2024Member_zIcNvc8rKnKg">$28.59</span></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20241231__us-gaap--VestingAxis__custom--YearEnd2024Member__srt--RangeAxis__srt--MinimumMember_zcefl9K22g16">$11.03</span> - <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20241231__us-gaap--VestingAxis__custom--YearEnd2024Member__srt--RangeAxis__srt--MaximumMember_z79asRnmmY7g">$18.44</span></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2024Member__srt--RangeAxis__srt--MinimumMember_zdOWKWyp5Xq4">2.15</span> &#8211; <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2024Member__srt--RangeAxis__srt--MaximumMember_zba4BTXP2Uxf">3.93</span></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2024Member_zxqzATqctpVj">45</span>%</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2024Member__srt--RangeAxis__srt--MinimumMember_zS6AZcNjtIsg">4.25</span>% - <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2024Member__srt--RangeAxis__srt--MaximumMember_zdBzYd0oKpy9">4.32</span>%</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_904_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFairValuePerShare_pid_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2024Member__srt--RangeAxis__srt--MinimumMember_zkhvEywZAjze">$13.41</span> - <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_90E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFairValuePerShare_pid_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2024Member__srt--RangeAxis__srt--MaximumMember_zL4O8QW1feQ6">$19.23</span></span></p>

							</td>

						</tr>

					</table>
					<div id="xdx_8A7_z9KbHUprOhfa"></div>
					<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock', window );">Compensation Actually Paid vs. Total Shareholder Return</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"><div id="xdx_805_eecd--CompActuallyPaidVsTotalShareholderRtnTextBlock_dU_zO1GcF89duI8"></div>
				<div id="xdx_848_eecd--TotalShareholderRtnVsPeerGroupTextBlock_dU_zkpJ0GDUpua"></div>
				<div style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 6pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center">
					<div style="border: #2b4b74 1pt solid; padding: 0pt; overflow: hidden; display: inline-block; width: 533.75pt; height: 271.88pt; text-align: left">
						<img alt="" src="art-def14a_051325img005.gif" style="vertical-align: top; margin-left: 16.25pt; width: 500pt; margin-top: 13.75pt; height: 245pt"/>

					</div>

				</div>
				<div id="xdx_857_zEiHRh02Mcj9"></div>
				<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_CompActuallyPaidVsNetIncomeTextBlock', window );">Compensation Actually Paid vs. Net Income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"><div id="xdx_805_eecd--CompActuallyPaidVsNetIncomeTextBlock_dU_zlVd058UsQq3"></div>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 6pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: center"><span style="text-transform: none">&#8203;</span></p>
				<div style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 6pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: center">
					<div style="border: #2b4b74 1pt solid; padding: 0pt; overflow: hidden; display: inline-block; width: 533.75pt; height: 271.88pt; text-align: left">
						<img alt="" src="art-def14a_051325img006.gif" style="vertical-align: top; margin-left: 16.25pt; width: 500pt; margin-top: 13.75pt; height: 245pt"/>

					</div>

				</div>
				<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock', window );">Compensation Actually Paid vs. Company Selected Measure</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"><div id="xdx_809_eecd--CompActuallyPaidVsCoSelectedMeasureTextBlock_dU_zeNOAulayHc"></div>
						<div style="border: #2b4b74 1pt solid; padding: 0pt; overflow: hidden; display: inline-block; width: 533.75pt; height: 271.88pt; text-align: left">
						<img alt="" src="art-def14a_051325img007.gif" style="vertical-align: top; margin-left: 16.25pt; width: 500pt; margin-top: 13.75pt; height: 245pt"/>

					</div>
				<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TotalShareholderRtnVsPeerGroupTextBlock', window );">Total Shareholder Return Vs Peer Group</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"><div id="xdx_848_eecd--TotalShareholderRtnVsPeerGroupTextBlock_dU_zkpJ0GDUpua"></div>
				<div style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 6pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center">
					<div style="border: #2b4b74 1pt solid; padding: 0pt; overflow: hidden; display: inline-block; width: 533.75pt; height: 271.88pt; text-align: left">
						<img alt="" src="art-def14a_051325img005.gif" style="vertical-align: top; margin-left: 16.25pt; width: 500pt; margin-top: 13.75pt; height: 245pt"/>

					</div>

				</div>
				<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TabularListTableTextBlock', window );">Tabular List, Table</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"><p id="xdx_802_eecd--TabularListTableTextBlock_dU_z1ShjrTHVRtk" style="font: italic 11pt/normal Arial, sans-serif; margin: 0pt 0pt 8pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><b><i>Most Important Financial Measures Related to 2024 Officer Compensation</i></b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">In accordance with the Pay Versus Performance Rules, the following table lists the financial performance measures that, in the Company&#8217;s assessment, represent the most important financial performance measures used to link &#8220;compensation actually paid&#8221; to our Named Executive Officers, for fiscal year 2024, to Company performance. As discussed in the Compensation Discussion and Analysis, the annual short-term incentive plan used revenue growth (constant&#160;currency) and adjusted EBITDA as the primary financial measures for 2024. Annual PSUs granted during 2024 also were earned based on revenue growth (constant currency) and adjusted EBITDA. In 2024, we also applied an R&amp;D-related metric for our annual performance share plan, which consisted of two milestones: (1) the submission of two AMDS PMA modules (i.e., pre-clinical in Q3 2024 and QMS/MFG in Q4 2024) and (2) the submission of the Arcevo LSA IDE in </span><span style="text-transform: none; line-height: 12pt">Q4 2024.</span></p>
				<table id="xdx_30C_zwZ55xSk42o1" style="margin: 4pt auto 10pt; table-layout: fixed; width: 300pt; border-collapse: collapse" summary="xdx: Disclosure - Pay vs Performance Disclosure">
						<tr style="margin: 0; height: 0">
							<td style="border-width: 0; margin: 0; padding: 0; width: 300pt">


							</td>

						</tr>
						<tr style="min-height: 0pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Key Financial Measures</b></span></p>

							</td>

						</tr>
						<tr style="min-height: 0pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><span id="xdx_902_eecd--MeasureName_c20240101__20241231__ecd--MeasureAxis__1_z0TGH43SagAd">AORT Revenue Growth (constant currency)</span></span></p>

							</td>

						</tr>
						<tr style="min-height: 0pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><span id="xdx_908_eecd--MeasureName_c20240101__20241231__ecd--MeasureAxis__2_zJHNhr6uLbw5">Adjusted EBITDA</span></span></p>

							</td>

						</tr>

					</table>
				<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TotalShareholderRtnAmt', window );">Total Shareholder Return Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="nump">$ 106<span></span>
</td>
<td class="nump">66<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="nump">75<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PeerGroupTotalShareholderRtnAmt', window );">Peer Group Total Shareholder Return Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="nump">138<span></span>
</td>
<td class="nump">124<span></span>
</td>
<td class="nump">114<span></span>
</td>
<td class="nump">140<span></span>
</td>
<td class="nump">118<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (13,000,000)<span></span>
</td>
<td class="num">$ (31,000,000)<span></span>
</td>
<td class="num">$ (19,000,000)<span></span>
</td>
<td class="num">$ (15,000,000)<span></span>
</td>
<td class="num">$ (17,000,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_CoSelectedMeasureAmt', window );">Company Selected Measure Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[6]</sup></td>
<td class="nump">0.09<span></span>
</td>
<td class="nump">0.12<span></span>
</td>
<td class="nump">0.09<span></span>
</td>
<td class="nump">0.16<span></span>
</td>
<td class="num">(0.08)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PeoName', window );">PEO Name</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Mr. Mackin<span></span>
</td>
<td class="text">Mr. Mackin<span></span>
</td>
<td class="text">Mr. Mackin<span></span>
</td>
<td class="text">Mr. Mackin<span></span>
</td>
<td class="text">Mr. Mackin<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_EqtyAwrdsAdjFnTextBlock', window );">Equity Awards Adjustments, Footnote [Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"><div id="xdx_893_eecd--EqtyAwrdsAdjFnTextBlock_dU_zd3NhAsLpzpa"></div>
				<p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 8pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"><span style="width: 15pt; text-indent: 0; display: inline-block"><sup style="text-transform: none; font-size: 7pt; line-height: 7pt">(i)</sup></span><sup style="text-transform: none; font-size: 7pt; line-height: 7pt"></sup><span style="text-transform: none">Equal to summary compensation total plus/minus any adjustments related to equity award values as reflected in&#160;this table. For purposes of calculating &#8220;compensation actually paid,&#8221; the fair value of equity awards at year-end 2023 and 2024, and on vesting dates for awards that vested during 2024, were all determined consistent with the approach used to value the awards at the grant date for purposes of the Summary Compensation Table (refer to &#8220;Executive Officer Compensation &#8211; Summary Compensation Table&#8221; for additional information). For any awards subject to performance conditions, the change in fair value as of the end of the covered fiscal year is calculated based on the probable outcome of such conditions as of the last day of the fiscal year. The valuation assumptions used to calculate fair values do not differ materially from those disclosed at the time of grant, other than as reflected in the table below, which summarizes option fair values determined using the Black-Scholes model and related assumptions used to calculate Compensation Actually Paid for </span><span style="text-transform: none">fiscal&#160;year 2024.</span></p>
				<table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 10pt; border-collapse: collapse">
						<tr style="margin: 0; height: 0">
							<td style="border-width: 0; margin: 0; padding: 0; width: 100pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 110pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 93.75pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 92.49pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 63.74pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 107.5pt">


							</td>
							<td style="border-width: 0; margin: 0; padding: 0; width: 107.5pt">


							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Valuation<br/>Purpose<br/>for PVP&#160;</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>AORT<br/>Stock<br/>Price</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>AORT<br/>Option<br/>Exercise<br/>Price</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Expected<br/>Term<br/>(years)</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Stock<br/>Price<br/>Volatility</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Risk-free<br/>Rate</b></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><b>Option<br/>Fair<br/>Value</b></span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Year-end 2023</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_905_eus-gaap--SharePrice_iI_pid_c20241231__us-gaap--VestingAxis__custom--YearEnd2023Member_zyoa1YBNpbDh">$17.88</span></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20241231__us-gaap--VestingAxis__custom--YearEnd2023Member__srt--RangeAxis__srt--MinimumMember_z5bT910B5iI4">$11.03</span> - <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20241231__us-gaap--VestingAxis__custom--YearEnd2023Member__srt--RangeAxis__srt--MaximumMember_zSNEB73O0Sbg">$24.90</span></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2023Member__srt--RangeAxis__srt--MinimumMember_zfuoYaTx9a6e">2.13</span> &#8211; <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2023Member__srt--RangeAxis__srt--MaximumMember_z5wuLeKbg0cf">4.93</span></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2023Member_z9yVGAlW0uoc">45</span>%</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2023Member__srt--RangeAxis__srt--MinimumMember_zDHA9XJYwQOe">3.85</span>% - <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2023Member__srt--RangeAxis__srt--MaximumMember_z0ByHjPnHdCi">4.20</span>%</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_907_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFairValuePerShare_pid_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2023Member__srt--RangeAxis__srt--MinimumMember_ze1eSKkm7EUc">$3.11</span> - <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_90D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFairValuePerShare_pid_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2023Member__srt--RangeAxis__srt--MaximumMember_z1wedYtymmOh">$9.89</span></span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">2024 Vesting</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_90A_eus-gaap--SharePrice_iI_pid_c20241231__us-gaap--VestingAxis__custom--Vesting2024Member__srt--RangeAxis__srt--MinimumMember_zeHkPyKExvF4">$18.81</span> - <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_90D_eus-gaap--SharePrice_iI_pid_c20241231__us-gaap--VestingAxis__custom--Vesting2024Member__srt--RangeAxis__srt--MaximumMember_zH7RgbVEMs58">$29.66</span></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20241231__us-gaap--VestingAxis__custom--Vesting2024Member__srt--RangeAxis__srt--MinimumMember_zsBXXbgZNSHd">$11.03</span> - <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20241231__us-gaap--VestingAxis__custom--Vesting2024Member__srt--RangeAxis__srt--MaximumMember_ziJ1ynfMcNij">$24.90</span></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20240101__20241231__us-gaap--VestingAxis__custom--Vesting2024Member__srt--RangeAxis__srt--MinimumMember_zyE2UDf1ohbd">2.00</span> &#8211; <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20240101__20241231__us-gaap--VestingAxis__custom--Vesting2024Member__srt--RangeAxis__srt--MaximumMember_z8x2k6FvKVSj">3.40</span></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20240101__20241231__us-gaap--VestingAxis__custom--Vesting2024Member_zqBT2vNbZH2e">45</span>%</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20240101__20241231__us-gaap--VestingAxis__custom--Vesting2024Member__srt--RangeAxis__srt--MinimumMember_zAf0GFsQYSJ7">4.05</span>% - <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20240101__20241231__us-gaap--VestingAxis__custom--Vesting2024Member__srt--RangeAxis__srt--MaximumMember_zruoGuGQVtce">4.64</span>%</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_906_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFairValuePerShare_pid_c20240101__20241231__us-gaap--VestingAxis__custom--Vesting2024Member__srt--RangeAxis__srt--MinimumMember_zqoe5lHLTR5k">$3.44</span> - <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFairValuePerShare_pid_c20240101__20241231__us-gaap--VestingAxis__custom--Vesting2024Member__srt--RangeAxis__srt--MaximumMember_z2zUAhP8h8wd">$19.34</span></span></p>

							</td>

						</tr>
						<tr style="min-height: 3pt">
							<td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none">Year-end 2024</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_90A_eus-gaap--SharePrice_iI_pid_c20241231__us-gaap--VestingAxis__custom--YearEnd2024Member_zIcNvc8rKnKg">$28.59</span></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20241231__us-gaap--VestingAxis__custom--YearEnd2024Member__srt--RangeAxis__srt--MinimumMember_zcefl9K22g16">$11.03</span> - <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20241231__us-gaap--VestingAxis__custom--YearEnd2024Member__srt--RangeAxis__srt--MaximumMember_z79asRnmmY7g">$18.44</span></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2024Member__srt--RangeAxis__srt--MinimumMember_zdOWKWyp5Xq4">2.15</span> &#8211; <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2024Member__srt--RangeAxis__srt--MaximumMember_zba4BTXP2Uxf">3.93</span></span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2024Member_zxqzATqctpVj">45</span>%</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2024Member__srt--RangeAxis__srt--MinimumMember_zS6AZcNjtIsg">4.25</span>% - <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2024Member__srt--RangeAxis__srt--MaximumMember_zdBzYd0oKpy9">4.32</span>%</span></p>

							</td>
							<td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse">
								<p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"><span style="text-transform: none"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_904_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFairValuePerShare_pid_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2024Member__srt--RangeAxis__srt--MinimumMember_zkhvEywZAjze">$13.41</span> - <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_90E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFairValuePerShare_pid_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2024Member__srt--RangeAxis__srt--MaximumMember_zL4O8QW1feQ6">$19.23</span></span></p>

							</td>

						</tr>

					</table>
					<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_ExecutiveCategoryAxis=ecd_PeoMember', window );">PEO [Member] | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[7]</sup></td>
<td class="num">$ (3,608,101)<span></span>
</td>
<td class="num">$ (801,938)<span></span>
</td>
<td class="num">$ (5,587,257)<span></span>
</td>
<td class="num">$ (2,977,494)<span></span>
</td>
<td class="num">$ (2,323,534)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_ExecutiveCategoryAxis=ecd_PeoMember', window );">PEO [Member] | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[8]</sup></td>
<td class="nump">5,852,430<span></span>
</td>
<td class="nump">1,771,014<span></span>
</td>
<td class="nump">4,689,996<span></span>
</td>
<td class="nump">2,402,215<span></span>
</td>
<td class="nump">1,931,021<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_ExecutiveCategoryAxis=ecd_PeoMember', window );">PEO [Member] | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[9]</sup></td>
<td class="nump">3,370,222<span></span>
</td>
<td class="nump">2,775,817<span></span>
</td>
<td class="num">(1,385,504)<span></span>
</td>
<td class="num">(495,663)<span></span>
</td>
<td class="num">(2,326,940)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_ExecutiveCategoryAxis=ecd_PeoMember', window );">PEO [Member] | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[10]</sup></td>
<td class="nump">1,202,370<span></span>
</td>
<td class="nump">304,572<span></span>
</td>
<td class="num">(215,079)<span></span>
</td>
<td class="nump">154,913<span></span>
</td>
<td class="num">(368,352)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_ExecutiveCategoryAxis=ecd_NonPeoNeoMember', window );">Non-PEO NEO [Member] | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[11]</sup></td>
<td class="num">(923,744)<span></span>
</td>
<td class="num">(498,431)<span></span>
</td>
<td class="num">(1,124,197)<span></span>
</td>
<td class="num">(640,635)<span></span>
</td>
<td class="num">(499,129)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_ExecutiveCategoryAxis=ecd_NonPeoNeoMember', window );">Non-PEO NEO [Member] | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[12]</sup></td>
<td class="nump">1,498,338<span></span>
</td>
<td class="nump">639,679<span></span>
</td>
<td class="nump">955,981<span></span>
</td>
<td class="nump">508,720<span></span>
</td>
<td class="nump">420,985<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_ExecutiveCategoryAxis=ecd_NonPeoNeoMember', window );">Non-PEO NEO [Member] | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[13]</sup></td>
<td class="nump">642,469<span></span>
</td>
<td class="nump">443,711<span></span>
</td>
<td class="num">(239,756)<span></span>
</td>
<td class="num">(72,575)<span></span>
</td>
<td class="num">(371,199)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_ExecutiveCategoryAxis=ecd_NonPeoNeoMember', window );">Non-PEO NEO [Member] | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[14]</sup></td>
<td class="nump">$ 230,805<span></span>
</td>
<td class="nump">$ 45,783<span></span>
</td>
<td class="num">$ (35,259)<span></span>
</td>
<td class="nump">$ 26,701<span></span>
</td>
<td class="num">$ (73,105)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MeasureAxis=1', window );">Measure [Axis]: 1</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MeasureName', window );">Measure Name</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">AORT Revenue Growth (constant currency)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonGaapMeasureDescriptionTextBlock', window );">Non-GAAP Measure Description [Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">In the Company&#8217;s assessment, for the 2024 fiscal year, <span id="xdx_90D_eecd--CoSelectedMeasureName_c20240101__20241231_zqgOKiYCGonc">AORT revenue growth</span> represents the most important financial performance measure that is not otherwise required to be disclosed in the table that we used to link &#8220;compensation actually paid&#8221; to our NEOs, including our PEO, to our performance. AORT revenue growth is an adjusted constant currency revenue measure calculated by adjusting for the exchange rate effect on GAAP revenues. We define exchange rate effect as the year-over-year impact of foreign currency movements using current period foreign currency rates applied to prior period transactional currency amounts. As discussed in the Compensation Discussion &amp; Analysis, constant currency revenue growth as calculated in incentive plans may reflect additional adjustments to either the baseline (prior year revenue) or current year results, to exclude the impact of discontinued businesses and other unplanned events that were outside of management&#8217;s control. In 2023, we excluded the impact of the Company&#8217;s Cardiogenesis business. In 2022, we adjusted to exclude PerClot sales that occurred in 2022 and 2021. In 2021, we measured growth in the second half of the year by comparing to the second half of 2019 rather than 2020.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MeasureAxis=2', window );">Measure [Axis]: 2</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MeasureName', window );">Measure Name</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Adjusted EBITDA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Mr. Mackin&#160;served
as our only PEO for&#160;each year.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Equal to summary compensation
total plus/minus any adjustments related to equity award values as reflected in&#160;this table. For purposes of calculating &#8220;compensation
actually paid,&#8221; the fair value of equity awards at year-end 2023 and 2024, and on vesting dates for awards that vested during 2024,
were all determined consistent with the approach used to value the awards at the grant date for purposes of the Summary Compensation
Table (refer to &#8220;Executive Officer Compensation &#8211; Summary Compensation Table&#8221; for additional information). For any
awards subject to performance conditions, the change in fair value as of the end of the covered fiscal year is calculated based on the
probable outcome of such conditions as of the last day of the fiscal year. The valuation assumptions used to calculate fair values do
not differ materially from those disclosed at the time of grant, other than as reflected in the table below, which summarizes option
fair values determined using the Black-Scholes model and related assumptions used to calculate Compensation Actually Paid for fiscal&#160;year
2024.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">Our Non-PEO NEOs in 2024
were Messrs. Berry, Davis and Stanton and Ms. Holloway. Our Non-PEO NEOs in 2023 were Messrs. Lee, Berry, Davis and Mses. Horton and
Holloway. Our Non-PEO NEOs in 2022 and 2021 were&#160;Messrs. Lee,&#160;Davis,&#160;Stanton&#160;and&#160;Ms. Holloway. Our Non-PEO NEOs
in 2020 were&#160;Messrs.&#160;Lee,&#160;Davis,&#160;Simpson,&#160;and&#160;Ms. Holloway.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top">Equal to summary compensation
total plus/minus any adjustments related to equity award values as reflected in&#160;this table. For purposes of calculating &#8220;compensation
actually paid,&#8221; the fair value of equity awards at year-end 2023 and 2024, and on vesting dates for awards that vested during 2024,
were all determined consistent with the approach used to value the awards at the grant date for purposes of the Summary Compensation
Table (refer to &#8220;Executive Officer Compensation &#8211; Summary Compensation Table&#8221; for additional information). For any
awards subject to performance conditions, the change in fair value as of the end of the covered fiscal year is calculated based on the
probable outcome of such conditions as of the last day of the fiscal year. The valuation assumptions used to calculate fair values do
not differ materially from those disclosed at the time of grant, other than as reflected in the table below, which summarizes option
fair values determined using the Black-Scholes model and related assumptions used to calculate Compensation Actually Paid for fiscal&#160;year
2024.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[5]</td>
<td style="vertical-align: top;" valign="top">Shareholder returns reflect
$100 invested as of market close on December 31, 2019, the final trading day of fiscal 2019; Index Shareholder Return reflects S&amp;P
500 Health Care&#160;Equipment Index.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[6]</td>
<td style="vertical-align: top;" valign="top">In the Company&#8217;s
assessment, for the 2024 fiscal year, AORT revenue growth represents the most important financial performance measure that is not otherwise
required to be disclosed in the table that we used to link &#8220;compensation actually paid&#8221; to our NEOs, including our PEO, to
our performance. AORT revenue growth is an adjusted constant currency revenue measure calculated by adjusting for the exchange rate effect
on GAAP revenues. We define exchange rate effect as the year-over-year impact of foreign currency movements using current period foreign
currency rates applied to prior period transactional currency amounts. As discussed in the Compensation Discussion &amp; Analysis, constant
currency revenue growth as calculated in incentive plans may reflect additional adjustments to either the baseline (prior year revenue)
or current year results, to exclude the impact of discontinued businesses and other unplanned events that were outside of management&#8217;s
control. In 2023, we excluded the impact of the Company&#8217;s Cardiogenesis business. In 2022, we adjusted to exclude PerClot sales
that occurred in 2022 and 2021. In 2021, we measured growth in the second half of the year by comparing to the second half of 2019 rather
than 2020.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[7]</td>
<td style="vertical-align: top;" valign="top">Represents the grant date
fair value of equity-based awards made during the covered fiscal year as reported in the Summary&#160;Compensation Table.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[8]</td>
<td style="vertical-align: top;" valign="top">Represents the year-end
fair value of equity awards that were made during the covered fiscal year and remained unvested as&#160;of the end of the covered fiscal
year.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[9]</td>
<td style="vertical-align: top;" valign="top">Represents the change as
of the end of the covered fiscal year (from the end of the prior fiscal year) in fair value of equity-based awards granted in prior fiscal
years that were still unvested as of the covered&#160;fiscal year-end.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[10]</td>
<td style="vertical-align: top;" valign="top">Represents the change as
of the vesting date (from the end of the prior fiscal year) in fair value of equity-based awards granted in prior fiscal years that vested
as of the end of or during the covered&#160;fiscal year.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[11]</td>
<td style="vertical-align: top;" valign="top">Represents the grant date
fair value of equity-based awards made during the covered fiscal year as reported in the Summary&#160;Compensation Table.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[12]</td>
<td style="vertical-align: top;" valign="top">Represents the year-end
fair value of equity awards that were made during the covered fiscal year and remained unvested as&#160;of the end of the covered fiscal
year.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[13]</td>
<td style="vertical-align: top;" valign="top">Represents the change as
of the end of the covered fiscal year (from the end of the prior fiscal year) in fair value of equity-based awards granted in prior fiscal
years that were still unvested as of the covered&#160;fiscal year-end.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[14]</td>
<td style="vertical-align: top;" valign="top">Represents the change as
of the vesting date (from the end of the prior fiscal year) in fair value of equity-based awards granted in prior fiscal years that vested
as of the end of or during the covered&#160;fiscal year.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToCompAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToCompAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToNonPeoNeoCompFnTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToNonPeoNeoCompFnTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToPeoCompFnTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToPeoCompFnTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_CoSelectedMeasureAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 2<br> -Subparagraph vi<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_CoSelectedMeasureAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_CoSelectedMeasureName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 2<br> -Subparagraph vi<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_CoSelectedMeasureName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 5<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_CompActuallyPaidVsNetIncomeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 5<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_CompActuallyPaidVsNetIncomeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 5<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_EqtyAwrdsAdjFnTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 2<br> -Subparagraph iii<br> -Sentence B<br> -Clause 1<br> -Subclause ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_EqtyAwrdsAdjFnTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MeasureName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 2<br> -Subparagraph vi<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MeasureName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NamedExecutiveOfficersFnTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NamedExecutiveOfficersFnTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonGaapMeasureDescriptionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 2<br> -Subparagraph vi<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonGaapMeasureDescriptionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonPeoNeoAvgCompActuallyPaidAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonPeoNeoAvgCompActuallyPaidAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonPeoNeoAvgTotalCompAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonPeoNeoAvgTotalCompAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PeerGroupTotalShareholderRtnAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 2<br> -Subparagraph iv<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PeerGroupTotalShareholderRtnAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PeoActuallyPaidCompAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PeoActuallyPaidCompAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PeoName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PeoName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PeoTotalCompAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PeoTotalCompAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TabularListTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TabularListTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TotalShareholderRtnAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 2<br> -Subparagraph iv<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TotalShareholderRtnAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TotalShareholderRtnVsPeerGroupTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 5<br> -Subparagraph iv<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TotalShareholderRtnVsPeerGroupTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_ExecutiveCategoryAxis=ecd_PeoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_ExecutiveCategoryAxis=ecd_PeoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToCompAxis=ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToCompAxis=ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToCompAxis=ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToCompAxis=ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToCompAxis=ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToCompAxis=ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToCompAxis=ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToCompAxis=ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_ExecutiveCategoryAxis=ecd_NonPeoNeoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_ExecutiveCategoryAxis=ecd_NonPeoNeoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MeasureAxis=1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MeasureAxis=1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MeasureAxis=2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MeasureAxis=2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Award Timing Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardsCloseToMnpiDiscTable', window );"><strong>Awards Close in Time to MNPI Disclosures [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardTmgMnpiDiscTextBlock', window );">Award Timing MNPI Disclosure</a></td>
<td class="text"><p id="xdx_806_eecd--AwardTmgMnpiDiscTextBlock_dU_gL1ATMDTB-ZZI_zpIAA6jihWK3" style="font: italic 11pt/normal Arial, sans-serif; margin: 4pt 0pt 8pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"><span style="text-transform: none; font-style: italic"><b><i>Equity Grant Policies and Practices</i></b></span></p>
				<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">The Committee generally adheres to a policy that the Company will not make equity grants during regular quarterly financial blackout periods and until two full trading days after the conclusion of such blackout period. We do not grant equity awards in anticipation of the release of material nonpublic information that is likely to result in changes to the price </span><span style="text-transform: none; line-height: 12pt">of our</span></p>

<p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: justify"><span style="text-transform: none; line-height: 12pt">common stock, nor do we time the disclosure of material nonpublic information for the purpose of affecting the value of executive compensation. In the event of a special blackout period outside the regular quarterly financial blackout period, we consider the extent and nature of both the special blackout period and the equity grant(s) at issue. Unless the Committee determines otherwise, equity grant(s) may be made during special blackout periods outside the regular quarterly financial blackout period, depending upon the extent and nature of both the special blackout period and the equity grant(s) </span><span style="text-transform: none; line-height: 12pt">at issue.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AwardTmgMnpiDiscTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AwardTmgMnpiDiscTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AwardsCloseToMnpiDiscTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AwardsCloseToMnpiDiscTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Policies and Procedures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingPoliciesProcLineItems', window );"><strong>Insider Trading Policies and Procedures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcAdoptedFlag', window );">Insider Trading Policies and Procedures Adopted [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingPoliciesProcLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingPoliciesProcLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Assumptions used to calculate Compensation Actually Paid<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>$ / shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=aort_YearEnd2023Member', window );">Year-end 2023 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price</a></td>
<td class="nump">$ 17.88<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</a></td>
<td class="nump">45.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=aort_YearEnd2023Member', window );">Year-end 2023 [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price</a></td>
<td class="nump">$ 11.03<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</a></td>
<td class="text">2 years 1 month 17 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</a></td>
<td class="nump">3.85%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aort_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFairValuePerShare', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Fair Value per Share</a></td>
<td class="nump">$ 3.11<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=aort_YearEnd2023Member', window );">Year-end 2023 [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price</a></td>
<td class="nump">$ 24.90<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</a></td>
<td class="text">4 years 11 months 4 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</a></td>
<td class="nump">4.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aort_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFairValuePerShare', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Fair Value per Share</a></td>
<td class="nump">$ 9.89<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=aort_Vesting2024Member', window );">2024 Vesting [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</a></td>
<td class="nump">45.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=aort_Vesting2024Member', window );">2024 Vesting [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price</a></td>
<td class="nump">$ 18.81<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price</a></td>
<td class="nump">$ 11.03<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</a></td>
<td class="nump">4.05%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aort_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFairValuePerShare', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Fair Value per Share</a></td>
<td class="nump">$ 3.44<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=aort_Vesting2024Member', window );">2024 Vesting [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price</a></td>
<td class="nump">29.66<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price</a></td>
<td class="nump">$ 24.90<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</a></td>
<td class="text">3 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</a></td>
<td class="nump">4.64%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aort_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFairValuePerShare', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Fair Value per Share</a></td>
<td class="nump">$ 19.34<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=aort_YearEnd2024Member', window );">Year-end 2024 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price</a></td>
<td class="nump">$ 28.59<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</a></td>
<td class="nump">45.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=aort_YearEnd2024Member', window );">Year-end 2024 [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price</a></td>
<td class="nump">$ 11.03<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</a></td>
<td class="text">2 years 1 month 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</a></td>
<td class="nump">4.25%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aort_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFairValuePerShare', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Fair Value per Share</a></td>
<td class="nump">$ 13.41<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=aort_YearEnd2024Member', window );">Year-end 2024 [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price</a></td>
<td class="nump">$ 18.44<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</a></td>
<td class="text">3 years 11 months 4 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</a></td>
<td class="nump">4.32%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aort_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFairValuePerShare', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Fair Value per Share</a></td>
<td class="nump">$ 19.23<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aort_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFairValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value per share of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aort_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFairValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aort_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=aort_YearEnd2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=aort_YearEnd2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=aort_Vesting2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=aort_Vesting2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=aort_YearEnd2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=aort_YearEnd2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>64</ContextCount>
  <ElementCount>35</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>12</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="art-def14a_051325.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Artivion.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="art-def14a_051325.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="art-def14a_051325.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>995443 - Disclosure - Award Timing Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure</Role>
      <ShortName>Award Timing Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="art-def14a_051325.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>995447 - Disclosure - Insider Trading Policies and Procedures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc</Role>
      <ShortName>Insider Trading Policies and Procedures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="art-def14a_051325.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>999007 - Disclosure - Assumptions used to calculate Compensation Actually Paid</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Artivion.com/role/AssumptionsUsedToCalculateCompensationActuallyPaid</Role>
      <ShortName>Assumptions used to calculate Compensation Actually Paid</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>aort-20241231.xsd</File>
    <File>aort-20241231_def.xml</File>
    <File>aort-20241231_lab.xml</File>
    <File>aort-20241231_pre.xml</File>
    <File doctype="DEF 14A" isProxy="true" isUsgaap="true" original="art-def14a_051325.htm">art-def14a_051325.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>art-def14a_051325img001.gif</File>
    <File>art-def14a_051325img002.gif</File>
    <File>art-def14a_051325img003.gif</File>
    <File>art-def14a_051325img004.gif</File>
    <File>art-def14a_051325img005.gif</File>
    <File>art-def14a_051325img006.gif</File>
    <File>art-def14a_051325img007.gif</File>
    <File>proxycard001.jpg</File>
    <File>proxycard002.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="30">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="116">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>26
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "art-def14a_051325.htm": {
   "nsprefix": "aort",
   "nsuri": "http://Artivion.com/20241231",
   "dts": {
    "schema": {
     "local": [
      "aort-20241231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "aort-20241231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "aort-20241231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "aort-20241231_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "art-def14a_051325.htm"
     ]
    }
   },
   "keyStandard": 34,
   "keyCustom": 1,
   "axisStandard": 5,
   "axisCustom": 0,
   "memberStandard": 9,
   "memberCustom": 3,
   "hidden": {
    "total": 3,
    "http://xbrl.sec.gov/dei/2024": 3
   },
   "contextCount": 64,
   "entityCount": 1,
   "segmentCount": 12,
   "elementCount": 121,
   "unitCount": 4,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/ecd/2024": 116,
    "http://fasb.org/us-gaap/2024": 30,
    "http://xbrl.sec.gov/dei/2024": 4
   },
   "report": {
    "R1": {
     "role": "http://Artivion.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "art-def14a_051325.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "art-def14a_051325.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "2",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "ecd:PvpTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "art-def14a_051325.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "ecd:PvpTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "art-def14a_051325.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
     "longName": "995443 - Disclosure - Award Timing Disclosure",
     "shortName": "Award Timing Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "3",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "ecd:AwardTmgMnpiDiscTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "art-def14a_051325.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "ecd:AwardTmgMnpiDiscTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "art-def14a_051325.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc",
     "longName": "995447 - Disclosure - Insider Trading Policies and Procedures",
     "shortName": "Insider Trading Policies and Procedures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "4",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "art-def14a_051325.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "art-def14a_051325.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://Artivion.com/role/AssumptionsUsedToCalculateCompensationActuallyPaid",
     "longName": "999007 - Disclosure - Assumptions used to calculate Compensation Actually Paid",
     "shortName": "Assumptions used to calculate Compensation Actually Paid",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "5",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31_custom_YearEnd2023Member",
      "name": "us-gaap:SharePrice",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "art-def14a_051325.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31_custom_YearEnd2023Member",
      "name": "us-gaap:SharePrice",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "art-def14a_051325.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r101",
      "r111",
      "r121",
      "r149"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r104",
      "r114",
      "r124",
      "r152"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r138"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r145"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "auth_ref": [
      "r105",
      "r115",
      "r125",
      "r145",
      "r153",
      "r157",
      "r165"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "auth_ref": [
      "r163"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://Artivion.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://Artivion.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r160"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r161"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "auth_ref": [
      "r156"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r156"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r156"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r156"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r156"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r156"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r36",
      "r37",
      "r38",
      "r39",
      "r40",
      "r41",
      "r42",
      "r43",
      "r44",
      "r45",
      "r46",
      "r47",
      "r48",
      "r49",
      "r50",
      "r51",
      "r52",
      "r53",
      "r54",
      "r55",
      "r56",
      "r57",
      "r58",
      "r59",
      "r60"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r159"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r158"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r157"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r157"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r136"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r135"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r142"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r141"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r143"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r140"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://Artivion.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://Artivion.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://Artivion.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://Artivion.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r169"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r101",
      "r111",
      "r121",
      "r149"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r98",
      "r108",
      "r118",
      "r146"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r145"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r105",
      "r115",
      "r125",
      "r153"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r105",
      "r115",
      "r125",
      "r153"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r105",
      "r115",
      "r125",
      "r153"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r105",
      "r115",
      "r125",
      "r153"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name"
       }
      }
     },
     "auth_ref": [
      "r105",
      "r115",
      "r125",
      "r153"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r105",
      "r115",
      "r125",
      "r145",
      "r153",
      "r157",
      "r165"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "auth_ref": [
      "r163"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r97",
      "r168"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r97",
      "r168"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r97",
      "r168"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://Artivion.com/role/AssumptionsUsedToCalculateCompensationActuallyPaid"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r18",
      "r19",
      "r20",
      "r21",
      "r32",
      "r61",
      "r65",
      "r69",
      "r71",
      "r72",
      "r73",
      "r74",
      "r75",
      "r79",
      "r80",
      "r81",
      "r82",
      "r83",
      "r84",
      "r85",
      "r86",
      "r87",
      "r88",
      "r89",
      "r90",
      "r91",
      "r92",
      "r93",
      "r172",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://Artivion.com/role/AssumptionsUsedToCalculateCompensationActuallyPaid"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r18",
      "r19",
      "r20",
      "r21",
      "r32",
      "r61",
      "r65",
      "r69",
      "r71",
      "r72",
      "r73",
      "r74",
      "r75",
      "r79",
      "r80",
      "r81",
      "r82",
      "r83",
      "r84",
      "r85",
      "r86",
      "r87",
      "r88",
      "r89",
      "r90",
      "r91",
      "r93",
      "r172",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r156"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r164"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r5",
      "r6",
      "r7",
      "r8",
      "r9",
      "r10",
      "r11",
      "r12",
      "r13",
      "r14",
      "r15",
      "r16",
      "r17",
      "r22",
      "r23",
      "r24",
      "r25",
      "r26",
      "r27",
      "r28",
      "r29",
      "r30",
      "r62",
      "r63",
      "r64",
      "r66",
      "r70",
      "r76",
      "r77",
      "r78",
      "r95",
      "r171"
     ]
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r145"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r164"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r164"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r103",
      "r113",
      "r123",
      "r151"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r106",
      "r116",
      "r126",
      "r154"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r106",
      "r116",
      "r126",
      "r154"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "auth_ref": [
      "r129"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r136"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r136"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r145"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r129"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r129"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://Artivion.com/role/AssumptionsUsedToCalculateCompensationActuallyPaid"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r18",
      "r19",
      "r20",
      "r21",
      "r31",
      "r32",
      "r57",
      "r58",
      "r59",
      "r61",
      "r65",
      "r67",
      "r68",
      "r69",
      "r71",
      "r72",
      "r73",
      "r74",
      "r75",
      "r79",
      "r80",
      "r81",
      "r82",
      "r83",
      "r84",
      "r85",
      "r86",
      "r87",
      "r88",
      "r89",
      "r90",
      "r91",
      "r92",
      "r93",
      "r94",
      "r170",
      "r172",
      "r199",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://Artivion.com/role/AssumptionsUsedToCalculateCompensationActuallyPaid"
     ],
     "auth_ref": [
      "r18",
      "r19",
      "r20",
      "r21",
      "r31",
      "r32",
      "r57",
      "r58",
      "r59",
      "r61",
      "r65",
      "r67",
      "r68",
      "r69",
      "r71",
      "r72",
      "r73",
      "r74",
      "r75",
      "r79",
      "r80",
      "r81",
      "r82",
      "r83",
      "r84",
      "r85",
      "r86",
      "r87",
      "r88",
      "r89",
      "r90",
      "r91",
      "r92",
      "r93",
      "r94",
      "r170",
      "r172",
      "r199",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "auth_ref": [
      "r98",
      "r108",
      "r118",
      "r146"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r99",
      "r109",
      "r119",
      "r147"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r100",
      "r110",
      "r120",
      "r148"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r107",
      "r117",
      "r127",
      "r155"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r164"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r164"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://Artivion.com/role/AssumptionsUsedToCalculateCompensationActuallyPaid"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r34",
      "r35",
      "r36",
      "r37",
      "r38",
      "r39",
      "r40",
      "r41",
      "r42",
      "r43",
      "r44",
      "r45",
      "r46",
      "r47",
      "r48",
      "r49",
      "r50",
      "r51",
      "r52",
      "r53",
      "r54",
      "r55",
      "r56",
      "r57",
      "r58",
      "r59",
      "r60"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "presentation": [
      "http://Artivion.com/role/AssumptionsUsedToCalculateCompensationActuallyPaid"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price",
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://Artivion.com/role/AssumptionsUsedToCalculateCompensationActuallyPaid"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://Artivion.com/role/AssumptionsUsedToCalculateCompensationActuallyPaid"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://Artivion.com/role/AssumptionsUsedToCalculateCompensationActuallyPaid"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r34",
      "r35",
      "r36",
      "r37",
      "r38",
      "r39",
      "r40",
      "r41",
      "r42",
      "r43",
      "r44",
      "r45",
      "r46",
      "r47",
      "r48",
      "r49",
      "r50",
      "r51",
      "r52",
      "r53",
      "r54",
      "r55",
      "r56",
      "r57",
      "r58",
      "r59",
      "r60"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r36",
      "r37",
      "r38",
      "r39",
      "r40",
      "r41",
      "r42",
      "r43",
      "r44",
      "r45",
      "r46",
      "r47",
      "r48",
      "r49",
      "r50",
      "r51",
      "r52",
      "r53",
      "r54",
      "r55",
      "r56",
      "r57",
      "r58",
      "r59",
      "r60"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharePrice",
     "presentation": [
      "http://Artivion.com/role/AssumptionsUsedToCalculateCompensationActuallyPaid"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://Artivion.com/role/AssumptionsUsedToCalculateCompensationActuallyPaid"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "aort_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFairValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://Artivion.com/20241231",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFairValuePerShare",
     "presentation": [
      "http://Artivion.com/role/AssumptionsUsedToCalculateCompensationActuallyPaid"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Fair Value per Share",
        "documentation": "Fair value per share of options."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r102",
      "r112",
      "r122",
      "r150"
     ]
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r144"
     ]
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r136"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r143"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r163"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r165"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r166"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r167"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r167"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r165"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title"
       }
      }
     },
     "auth_ref": [
      "r165"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r166"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r162"
     ]
    },
    "aort_Vesting2024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://Artivion.com/20241231",
     "localname": "Vesting2024Member",
     "presentation": [
      "http://Artivion.com/role/AssumptionsUsedToCalculateCompensationActuallyPaid"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2024 Vesting [Member]",
        "documentation": "2024 Vesting."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VestingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VestingAxis",
     "presentation": [
      "http://Artivion.com/role/AssumptionsUsedToCalculateCompensationActuallyPaid"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Axis]",
        "documentation": "Information by vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198"
     ]
    },
    "us-gaap_VestingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VestingDomain",
     "presentation": [
      "http://Artivion.com/role/AssumptionsUsedToCalculateCompensationActuallyPaid"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198"
     ]
    },
    "aort_YearEnd2023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://Artivion.com/20241231",
     "localname": "YearEnd2023Member",
     "presentation": [
      "http://Artivion.com/role/AssumptionsUsedToCalculateCompensationActuallyPaid"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end 2023 [Member]",
        "documentation": "Year-end 2023."
       }
      }
     },
     "auth_ref": []
    },
    "aort_YearEnd2024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://Artivion.com/20241231",
     "localname": "YearEnd2024Member",
     "presentation": [
      "http://Artivion.com/role/AssumptionsUsedToCalculateCompensationActuallyPaid"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end 2024 [Member]",
        "documentation": "Year-end 2024."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r133"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r20": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r21": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r22": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r23": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r24": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r25": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r26": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r27": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r28": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r29": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r30": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r31": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r32": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r33": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r34": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r35": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r36": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r37": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r38": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r39": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r40": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r41": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r42": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r43": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r44": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r45": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r46": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r47": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r48": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r49": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r50": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r51": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r52": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r53": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r54": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r55": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r56": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r57": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r58": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r59": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r60": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r61": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r62": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r63": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r64": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r65": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r66": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r67": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r68": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r69": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r70": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r71": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r72": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r73": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r74": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r171": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r172": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r173": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r174": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r175": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r176": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r177": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r178": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r179": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r180": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r181": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r182": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r183": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r184": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r185": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r186": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r187": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r188": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r189": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r190": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r191": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r192": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r193": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r194": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r195": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r196": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r197": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r198": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r199": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r200": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r201": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r202": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r203": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r204": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r205": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>27
<FILENAME>0001999371-25-003629-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001999371-25-003629-xbrl.zip
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M1Q>D!;H$O(;B%R0L*[4<E+)F4-QA7/X+4$L#!!0    ( -6%@5J-]!K*)@8
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M*TM75[HY\W-F[+2Y/5M%=-K9-^<:3@-[KJ)(+6M :[(TIEW-[+=N4:HH?A7
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M>D"S#J7$P79?\B>+R,<WD%"3/)1"W)B)3A8(C/J+SE;W<4PZ.97)&J/N;&E
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M-O$?!IONBTUI&&X<-BT43@R5VE0JM<8"T!VQT5"YITOE-@D;GSON/0^T*!;
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MW.PX$$S",7)K9&-ZP4 XWG4E]M"GUT8^%[DPW'TZD$FZ8Q1VP*,@#\E_CDH
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M!4@,IS!GCNTJ) ?5YI;E><!P+(;?MV2W UR3X0)KQP6 \PLG$ DO^.YBVMX
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M0$WU_%F%_3/BB!DD\F#5%!LCGEZ>^9X5#<-7*Q2O^GPD- 8:@]-S1\'WCC>
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MF(NQ-^$!.ZZRUO"[P.2I3&^:NXS*QC @[/Y*)EAQ9NE32&>Z!-BEC!V)H9@
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M%&=KX O^?6L@8$K@I]RYYK- "EF%Y;PRDLO.?(&NN;E2?:)QOGS_0YW;,W!
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MDJGB*)JVB0D$@.CDF(>A?$]Z'6/V#<"Y"1CXH$<2ZQCP!) B$1!@991!I;9
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M5+3[0L!,?;1,#-.P+!A5UOXB72NE_ZECP+R6B4==QS'B1)Y$A9AC@.E6%5U
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MJGX7'U+/WHL.YB>:*Q5L DQ-@*D),#4!IFL9]6D"3./EKU<,HPDP7>/#><@
MT^8:P]X$F)H TPU2LE>F7+= (PI3NA<%K4R$"(.XO0\JA//KVB5M![5H.(D6
M*-!HTHV<2])M$F7Z7@I*5A/??-/I+7Y$JA, Z'4N0HZ55*36&CP#V^I-GHL(
M*X0!O9:U>(<:D\E_X4M( 2+:@/'7KM;T===;>A\N 'V3,1\H\P"7'7)5ARS;
MQQ@H1UQBORLO<@.APLW(9H!W41H$*/!%>D92KHIX:5A\<7+/(%&L2Y)R*SS[
MR_$QB3#JAWY$14>>P<5(ZG=4[E;CH')#G[5Y:"_TK^7=JS:Z/]4Q:&=?H.J#
M#F6CXF'2N'7H4;R*_&(@PFLLK7R#7S&Q,BY<$/&Q[*I2M4YL6;EZ*XBT-7%$
M0338ZVU,9M D90#F*W(H>D[L@EWL!!T(5XQLW1%Y;$_B<D72$7F_BK[D5\)U
M;++_X@(K<&+"Q2WN\8PM/F>+EG<C%828X.;B6F6$0:H;/1K0D<+$/U.&CRZ0
M0&'/&$#V_]C[UN>VC67/[_DK4+GQ+;L*8DB]%=]-E2+)L7(B2RLIR6:_#<&A
MB!@$>/"0S%/[QV\_9@:#!RE0%&6*QMW:$YDD9@8]/3W]_'5]W*H(]@T:>#:6
M'+FG?O,P:6%HQFY47<-ZS.#%'^"U-XSEOS.<!2ZJ5'@J@\!B<7,M*86/7.X6
M7^/1PV0P&#@F'8N^3JDQ-\&[45:  ?JMS00 83/!  7%!'R5;U=/3MO]/B$A
M1=HN9MAC9"-/%D\87C4I[$P=%4I-(@-?^(DE/DJD*(9K\LU!? V\1W$45'M)
M9[_#9"V5PN"-Y" +6)T [4"C(U/\*<E0H/HF<1I??^ G7I9H%#A\-QX.;C/*
MH#:S@2 FY<2.\5*R@U(BZFBH-X8T"U9\.!:#O>OU^@WI:M^W _>CE9>"74T3
M*3]3*(E^$YC8"//4<FI*[1*^=67E&L\];/VUGWQV+BF]'6CV#:@KM\M:A+.,
M #CD'HD/%*DN9Z\_C)#,E-&$HD+=TKD6'F!A!,5U40S!(3"YM9:4'#H(SQ?#
M1F$]@Q7=1* <'VCMPWDQ<C!@&8 _+UP_1:4%$YLB1.DU!TX=><MXT3*KYH55
M&Q<L*"5A49IMIDKD)Y6%WBE<Q$CS(#Y!+ZNRH.ZHGD0EKV!LTA)6\*V(68QK
M$ME2WHOE --4BO+-RTADO;5^-\7;27]A(->I?M:;JJ:3$E1*K!%@;1&AE'V@
MHRI#P-H^E,/4:R7%.M8[;OH;^/\&A1.&==6KI!3D38")X7D5RG:=489*KR>H
MM;,RZ'11%:I8O/GG(1F8^*^MG%[,;S-V"BL=(BIN("8Q*6@UJ8*ZZ!!!H@N=
M51BE""Y%S8^3B/*Y$4;-I-G0C@V%A_1<.F_;Y-)ML"""S<Q+0MU'TDS*IX;4
M !86(%20^0NN@TD4H%*0*)QEG6HXB"B# 6L!8"/E%^S!@Q*+-#X;P(XX+!54
MG@Y:I<YKH?RJVD0799;-> $2?KJ<T1SRC\3S)\SS!7Q;%I@1II/H#(6\_HV^
MM?#/3E2C!=6\H.1-1*<*Z!&@,_$*2U^[G"-BV7XTXUD<)JFJ+_L[RF AO_]^
MY1*=;74"3C0FSV)=B\:U]M I0RH<NFK<^4*Z0 X>G(HZ U*IX5QCXH46 Y7?
MD-O(9=F;GT^5MUH6_W8A4XTP-"MQ%7@A([QRC;MO2SVF=*%>LT)5"SMLWEQL
M?!C[IJ#*3W,"Y;=B66:I6NC:6;A&-O_"*KI2]T1.8SXED0=J=JP.#5@"!B@A
MW_#21:'\=I2DG4WP0N7SJ*FCZE\+7K(+3(<>H%,PL*ZO&C^X><L"E]2^*S!9
M$'GD]E:^_&NZWF=ZV%,'4UB<[5U];+5E]6MN65G)4%'([TE<A?*@('WPY2A=
MJ<8\2W20@!*KQWAE4J<$=Z[/@A+3QT QRD,=6JF9@Z(A0H-44[QG/Y\;>1$[
MHA0#-Q(O!8F\P*DNU>J7CI!]-K4@5S\A642+ATU.N #6THHH,0R-^9A^'8B'
MPK=<XVS=XW6CLWU>O\*Z 8%<T1UGEAG97)&IC05VZ8J W8D]2GHOT/ ,)1[M
M)ILK%T776-UK:<NVGB;:\4ZIEH0Z+@A+ ]:J8;JQ]P_&]5,5<;HVS^<XX*=7
MNF[HG5&6$:Y;#C@7('$^P&$'70$/6)R!_G%EKN)C4)Q-R_.3JV,+^QF%D;Z_
M]4KQ'4^BP9*F"Z++1R'"A)?MWS;-KDVS:]/LVC2[M<Q]:]/LS/+7*Y.K3;-;
MX\U999K=WAK3ODVS6_LTN\6"*]TU#*[,R K([9D+%0ASG6.NOE0?4!:;%?U2
MT$7P#-C)WT:5JD*O I&^ZW(^8%Z]1'1 ]X#TR<8$$VX"5$+O5^S<^W&:H2/;
M10]&(!$3Y6#OC?9RE&./,_:H%.68_6/RWR ,9J' BM&TR!>O0A>N'=Z>F86!
M."3V#ZTE^&/$'\*62^CU"L *,2ZA(N\L:_S9C+?1"1LS<O6H,=F##.XM9AGD
MW%AJ_D)#-MA;S;3T/8[SZ)'/T55I28:O<R<ZE7%&P!OHKZ?V,8*= NAN0B@E
M[O6FEY!&:A4<EN?IU2MRY:*?.C+THBP&FWK)O#_V21B)]0V$TBG56146/RHW
MWENWP'&2P!I06?T64F0+@GUF3OB V\TEFJ:Y(/RISIOX?DYD3'\WSWO]W@C]
MQ3R2!F4Q?YVR&WTL4^H7F+(J/R>"![]<ZL@!&RZ/2<KRK+#8^6Y_B<U\$'HF
M?V1!KRX-@;O].(ER*)E'%X5==2AEX2'2 ^NG*Y&.)^U]89;E+MV0R;?IM^VL
M(TUAGX%,O-CO(\2=!.4FWRU+V2'/6N GJNC#NG5)0U32MG8&(XL'IJ^?O^05
M5_(T5'>OZI)<\?Z5C'IE1A8<DO8-BEYP/<D\/^5.0Q=D8P_D$JZZHUZGY*VK
ML:X'SS#3(9V!U<]S=/ R\QQV7V*6@T,[3/#81+GS(Z[C(<N-NMWK'-K#-O07
M]9"V]5XC'>YHXCB:#<K'QZ\&E*_A2?\*GCQ2%+2N5:=L+LX5+<V;T+RD=K2D
M?SG2UZN3[0Z\Y [,T]C;G7BYG5C,REE@9YK?YH>=WG*7>5]XG[$C4CC8TJ0:
M#.6N%,^UV5]K*QMCZO[6<:Y$&OO>9U-7F?>]-=65[KSRRF<^<"^S,4\)W.TC
MNY5,N'UFP9K@74N#E@8M#=9"S'\CLOQV%(U%XGS(<6W771=Z!9H.W8:KN.)>
M\]EM7[0]&4C"@YWN^U:K7[^;X!1;- 8.*/<:UWQU-\'&4GME1Z$E\GK=Q!NJ
M8+<T:(V,Y[]:+D0<"N?*ZJS1*L?MBWX;AV2=-()OAI*+7/NMD?&2H0.!549_
M=73'I%8U6Z7DW%A^^^I"M66TEM'J&:V""+7TM7/0V=EKS8PFEXL<#F,Y=3YV
M\CY\!3S,5K-:9W'Z]63F'IVPDM#<4\>N-6S6UPOWNEFF^170ZRZ;@KRQ-W3C
MV^$L\/\C^A+[JW:HJ^LWHQ(>=@XKK'K(#/7-N(5?C@;?PJ'[Z@I#2^07":L?
MM79'$[LC"M&EI5M^;Y:B<U 1FP>;%]=XF9?<F).Q3N*_I>17=R]M[ W<^ 8X
M#M-1%$Z=7^ 6D&,Y>.[4J?75J[^2ZV1C6>ZKB]:6U5I6>_:[YSO]00XT^!U_
M8F &-P9O9!Y.4QG]I8RY]"0L$,+AWWY?U^= -6>0B>HV*YR'&+\('6\D8FX8
M1P#U*2)XEYK_&'Q_TTM! 947&YK5-EAPO"R.9:@;91%L"@&?Q/!=?8..GZ@=
MF:Y"426%+O>%4PG)7%)H=8KKE)Z9^V.%C(>P>75(/,.(VZS!,AEK[<S"=2F!
MK%6!EG0SX$*+/49"(X26Q.H._-__U=OOOB^U+E8$F]'".&_1-+?OL#WR/D'K
M)P1P%*<CZJ7U6"=BNYFP:W5_"-1Z\FX)!$S.;2&IRX0%>--Q/D6/=%!6+>G4
M3I0&H"Y[$?60$Z%B&=6]Q"/D.6*Z A+> OV=U1;;)']D<[%T/QE.&<%'#OW0
MU]U.8'D*(;_\"GE?$OD%CF#JZG;6(BF0OK\D?!.NZ>;L9-/1FRK214FO.Y\[
MEU9_4>S^5Y%;4].&44PFB*/%36AB27VCD*7L=D6JWY7=\D'WAK4ZR2S6=L?N
M],C]#D5@NB'2R^"<*"KY7]04U>,>BWV)H*-(-V:AY193+\!)V*CV-@J_; P;
MJ?N<D3SB-HTNK1EQ!+'#F* I23AL8?LH.#>XR4)WX[F!L:_L[D]7>5\;W)-K
M&M]UCA5-7 16O1;4O<RT&;JUAN1^&M=*'EUAQRJ)>*; T-PM/N1>,KW#]]C%
MD5_L\18T\-A2)Y/[U^Q4.H1]9ZL]WUE_MXTLVD86;2,+;:6UC2PV?"K+<&P;
M6;2-+%[SYJRRD<7^&M.^;62Q]HTL7KG=MY0&7M+H?UJ!C:RVZPD$VYI/,9M!
M/UQ^NBTK=86GS9B]PPYMH%%5_9#HTL=2FY+&5Z#IO%&[,\9KZCC>WM[/'<?\
MG\+QP]>;O;+Z8:^M/M&Z/W?B11-9:YJK=@.Y58V/A0)[[N+O9UK6:([JP;@-
M;QBJ;HMD<V)S6S1"P<@4"7"@\+$/2%^F#U*&CW7XF&^B-V7\[W\N&?,5'WW+
MY:^>RW6S8]UW0S??M+U(Z2A*I+*R\9^1[>7)&VQST^%B#^=*)V+3ME=W=&W.
MC=;QJU;"M*SXZEF1W("ZVS**,24M";AS:;<H<V)=,_D[<4>^O!A)@]Y?^N<S
MS$91GR11\8U9[9Y!_*>EGK^E!N8T6"#O5"?RW/]O=4)N?HSLP!'U!VF/TL8<
MI8^JKW,>G4@C%U@T3C+TG8/D1EY3$0[7&4CDJA0[A4RIOWJ*,2W/3\CWC7+>
M2;)^(7A6Y\Y645C5[0D;DWA6]%+%OV(<CWJ<8.S5$0$LV,5XU;T_,/$S9Y@%
MR-;:>8[K8E>\DXK/H/CX'.*:8/!W+ 92#TK/-3\#I3?8W!#7O(2!&;UHGCUO
M8,8\+Y8^,&/^IV81Y#D =A8!0P[D>0&<JM<I/3'GIZ4,@AF+KD\D* ;$9[9A
M6B2/("DD$KP5[][ZW.?]K0]_-,\K@ ,KZLE)=HX?JA0($2KQP7D$^_VM'2MW
M8"E>M!,/*B&SS3GJS^#5J.><UKFQ.0J"[=PHJ=?2X*A'C*->L@'E++QU$ GD
MO_A'R6)V8#S>SNR=:T?ZC2LE7\<BIB&OQ$ZL:+T5F\.VERI7A*^O!+599MH$
M6XN"*D%7%N;8)-@[ ),U^!OQ #=1<SZJ&R(#BQ0^MT]+X0M*WZ%^O?QQC!*5
M+S]/))@;AS$<2B;B"ZUB6:JEP@/-5VI&=6"GPJ1UB&P0MQ\KB>@Z3Q.LQ$I5
M5P.&*2<BYMM](KS/"W7#_?YGU#WUU=#RVP;QFU(*7',5LU#S,(P[]&556QA+
M%)$@SR:F33AV:(YU"IVRU7)=LLY[-TN;R.5I52-91$ F3E\DF,W3<NK&<"KW
M%@^F*E,4F^I&=Y*8I:%L=.=ILH8WH_X_: ;?JZB&Q?NH(* ; E9-CK3PCL]'
M+%-5%;#XBA)MF#^VK,*9:GX4E*QOG;V;=1B,4HR"6H"J()()<&UB^X%$.,W5
M3" L_$RH)'4,,A1,O%$&'+X 6WEB@@Y%*U"QT=X53"XO.$A._<3+DD0WG#L.
M13!-_,0DA6_OD[O.CGZ",@>;%1J#NM;?8C8LC@)VD7LR2?2MC.[P>_)NHG:H
MDNAQP.7:HQN98\N8S?6+?__SU:R@R!P7ZJ@FO/+4(,HLK_3CL92O%#59P&.X
MT7)@3DA!\\<D>I 4[P*M0& +0U,H1E_CW]S='6//>8BWI#(K=8(>U/R%[)$%
M*?$M[?W@WD^4AMYNY/-%QN::URN(D,V=[P4C97/741\Q&T99/#]@IO%2=;PL
ML9HU\#\1,L\*B"FPHT[Q\=)SY5]7 FASWZ422-/+<![@$*O"/:Y!;3":' [9
M7G N1 S6<,^MUODF%'B#NWL )DSR[&6]2S%C)7;7EI:UI65M:5E;6O8ZZKW:
MTC*S_/6J7FI+R]9X<U996G:PQK1O2\O:TK)5NP>TM;"45EYG:K3)6)OCP+_.
M(TF3B,!AL' &+#!_0.:^AI'A4/Y"A3(FZ-]F06T.OQ2RH%2V7"*#X9:\%T$F
MV+NC? -UZ1_DYC906N["&4?:>9$[>%KNVASNLJ21<GK55BOE'BQRH>4(5UBG
MVIR;JKD=;:+&!C&3$55)YF'TDE+. L&H6<5[K5+!/#_]N#F+5?(H6FFU.0QV
MQE<><)A$%_M4BK@^&:@NK.4V*B^=EZ V,V6G.7O.2^YI.75S.+71O3J*'N@K
M3GS,E;39ZIR3C*(L&""J1)+&F8>($P-796,.:GY50"+%@OZR*EA\5#_I4;DF
M/[% ;I 9N\TZVS1VMJKUQ6>9Y F1R@*9S>4YZ"_CW=[+()J0[JBS'5 (!CZ)
M9)3A>3:.G<CF&??*7>XAN<O\@402H<^TFNFV!>SHW_$]((?P0L72#6N@' %C
M8M!#W45 4S!A5(-B;&X&U;S\B?,PC.Z9UDB-CU($Z<@3,6^EVM\5YE,L./^+
MY5<LN*[Z?(O$_S([W:*8(F$5*)=PS'4-<IY\8:=2U)0Q)](>FI>/V1+T0U#P
MX\2>PXQ?'%%5.I/&5LS66) R]670+Y)G49,J@5NK644]LN#[J-4D.J%O+/[A
M_$*53ZCO[GX!VZGC;&YZ%CO29Y-QZ62W\AZTCO7-T5&.$Y:6LR%W;'"W O1.
MG;X1A7<1=2@ M2 DL'"5F>F-0MC$.PQ(PJ YJ^8IV@Q_!7]3%E'!I0''75*R
M&/[&UH7>*MS_Z_\6X\G[4X7N_\YU/* NSN5:P#^N@=T* G@]],XN4!@2X]67
M8E(P'('6G;NI9T"#N]5A357<'B45W!GE0C<0#UJ](?[CHFN;I<W'C%F%O[>Z
M>5AX56(X!-V$?_9OX%KJI) D6<Q%5OBQ/I_6 O*UH9*/9V>QU&?JIN9O_<OW
M/F/K)4H5P;ATR_<;P_?7TI-4N >2S8\&(*NY, (T=%1<:PNC9.B#0FD!KN6&
MJN'-A6)E%J/G+-MRV>9PV157X* N,0&3$.[?R)3A5:6<.TO$U8JV12YPY:MH
MG6R;Q5[J\G:=?S"Z&DSS@$8)N<[5RNRC2BPE^TUB'Y%<$5Y28$EA4J@]LF]]
MS<P3NYV.[1"SK]_R7"?1@$(J)U$XR#R>P Q$PZ-_!-155 I^/;VZ7E"\XIP?
M3JZ.YWC72M4 _W4PQ/_G]/)Z@&H*YIQ#L:L/18/SL-W?[1_L/E-J++G42FV,
M;A O9A0% W0)_#6*G+_\9(2DO,GZP!;.=5.'K.UTVT /0H%.8S'-/=6S\ZU,
M^*-1X0\=/XZ;>"*1^C HK\Z#'P3LND.WXL.(8Y.D!^MUD+]GAID:1JKPCXX:
MJ#-8Y(1KE(%""L=*);/B3I$O'H O'A1?Y//E/\]?7$=Z$N8>\GCI[\R1#L68
M<67REJ6%RF:D0^RC9XQ: SY(;#666+[41&=EYWJ8E5$$+S[R"264XU]A(KDT
MMR]IZ@$/EJ\9_@#B#PV1!K0XH@R&P5*%ISB71.7W]I/"*_6QD5L01 \Z8)&+
M/ZOU81_L]@='L$S.0MU(S CL&4D.:(>=6&&^9^D(UGWV>LVC]3G-MR,5FYGF
M5]S<HCR?)!^V\:-?)\C!^C3R)L'7Q#_2CF)QV[O$9A0ZI< BJB5@5' P/U!H
M%)D4=C:6BIU4 T;+IHAF54G:%K01$B-96%'.^.S/QII+6+@_SL:L6^H.=D4I
MAD&LB"YZF3"Z#V@ =.0_@VRRK6\_CP+S"M E+=G5K7MADI<K/Q_H@P\9\9W:
M]OF%*3IP,\E0 ;70*'5"UVVRD7K3<(7C""OC%8U@V 2+J^'#)(U)"J ?7GA4
MR/]/-KCCUHM+':T8A,H]%ESWLP3#BU8PL*V-;&LCV]K(MC9RG0L6V]I(L_SU
M*K]K:R/7>'-661MYN,:T;VLCOWYMY%&W^UR%D4\UWRKG84G;32='X7HY7CV
M >,I=[#W)3G$!_(N9GRL0CB;G Y*]7:$EX'T<DVG,]0\,1$(M@W]GYPQD[LH
MV,+))YF33\MI/'.:JCUBI/1EX$LP-<%,1#_"&&-.!J:)>QQ8^;<STB,GF!2
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M]D]H(,=Y9XA*.IUI  </>OR@;1%05HG2-+&V903_ 1V7C 4_53@6[U5QF1>
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M>,#.CV,Q0/3](BK!L7*5X=0H%,BE8P(I#L90<(BN<Z:JQ'&)(AGA-ZI^_"J
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M]O8/6AJ_:L'=$AFU9^3DY\?\:;7GIMIS%*+/XT8$]S+YYB$#GT4VMYKS*Q'
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M8P)V' 2+J7QIF (^&4F0>??PBS*U]]ZK?8/Q VQO/X)'-"?$<HS2& ;,^O_
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MS*ML*U^9O7$6R,0X7_^^.>.Q[\@ !],"A\\#2M8XK@I7Z;!(P6C%(<AC71Y
MK:>/02X'5[O=?7\.>S:1M'&&!/15[[U##F5\5QF/V4TU]%4PZD8JE^=.=^>X
MT]TFHO'?^X47^MUG/^F-,@69O-?PXL!?QUL[:/&.L^"./,T9K(/]PS!^%L.K
M GG.OBA_P[&7+F>3PKIZ1SM5)^N&G9/*.0!N2M"%4W'4#XUG'W;!DTDB<^XO
M!^-L+T7"NT/QNXF(Y2"$9]&5T9<C$0PU U3/5L>Y,+X+9Z0"%I/8)V]G+),)
ML)3?]P,<6X<*\D4F>?A!KS*F& .'.^@-RB<CF2;P#!TR'Q64$,;Q8)?C*(#5
MG(?., N&Z&B!W_L8%D!B(46+R_%1>:H3"K&\]^6##N3@E_!W[9)5@)F<O(N&
M3(;46(#=TNQV2KPL2714B,(PME<HIX'0O\5]4_OR;Y@**.P"&Z7$<+QXSY,3
MT!U\_D[]%J,B6:@H#,/ZDT"3(I8BB4)4-GC[APX0+O2'H%&%..[@CE[<-9L%
M6@)Q#?P2%Q5$28;A%>7TKB/:PC)Z)$! BT$T2<E3^1#CQ]6KX60D8F"&CG/C
MHYN3IX^!$$ :_ (GV^YV=UVS4\2MRO$X0/D)9CA&&6P"P1!C=&XJ)U[.<"R(
M=1R!7ZKTY3 +2:(JCD[4/15,M9NU_ HFD4 ,P$H$*1N3:\F99#'<$K1'_"#'
M/Y82G'D$4 5/-EF$GG(RA77D7.MLT2T<R%2=^$'D9?BQX%LYY:@@L[QR-*N#
M5SGR+)EJ!1-)(>M Y%).\SVHVY'GJY#S8X+9#[4P,T[[@J\XD2ER$L@0^*6Z
MV?_[OWK[W?>[71,;OA&8JR*3K<LO@9S29<R'A.]^<FU*_.\=AL)1-V ^+_,M
MAJD_@Z!1ZY8#/0&<FKM8"1+\MT4^G,!XQG,)C1^+ 84$X+6L/5+Y,&I4O!9(
MU -Y0WX[EICDHS;#S9+O*DK(.2R^YV23 44/;%>]-3<NZBP.DY0I^-]B##;E
MWR B[IS??[]RJWS@6QH84 ].LHQQOJP?P&QE\9*0P-KN]G9<1^MY3/,87??>
M2 XRC"26WV/,233U>R("BF%8-UFL+J*A_6H4JVC,JDM)'!R>16WCVY+I77=E
M4I+&@PP"_._LO3'#7RL1#&]OJ\?7^>9<\>8<YYOS 3=G\2M^]J+-B0+61L6$
MKPE8TEO_'3]5F<&SLS9FJDUO?3T G;+A$(_$O;G#:_BSZ9;7,Q<^YH<9OXG2
M1:NSP#J(YM9;+[&24IC,C,!BD<6343 M08,M?"008;A <]Y:_K4V<I/ORKK]
M-G*$9.P\48A=EOPD5[0#R8V8OF#"3L+;Z$03T&[P"F4M$;8>UZ34R'0$JLY\
MM9M6D:<YLI:+*MQ,Q=:/<^65;.!H(:VYPK:U,Q&')AE(;^X;!1=XBF%>3!J)
MS?U,YZ O+7U?75PUWHDIKV<R <E$@:/"':\N526X=.Z))< NS;7*ZK;6-&[.
M3CIS=I'O#G,7SE!6\3.MB]NJOYX$%*J44G+46S_WRV >(.5V-1'_Z##)0IB7
MQ<1,BF-D'^0168[FFO!DO10L[> \@A9$%\E^>WAG&$=C^P=+R2F<3#-L)4J_
MZ9*J^9Y05O,]B1#0L:*)9)4T$.H:,1=T_>:/0<%^7!KB#RCE$_X Z]+>8Y7!
M2#:=6K52TY(LX .!2Y!?!-B"RA:A#^:;()4+-;?5]=LJJ5?[>*T*L,E,5&-#
M^*2SX(WWF.Q'RN84RRE>)UHT9R9EUPXG(BDO!5QGG(E$LG( $E)X]3OUN(VH
M]SV=3J3REN6/I-(;A4#KNZD3^\GGQ"TQ#!E9 Y3H_&^4QEJ1HSQGY4@&6@3P
M+:F<319=4?=B?9.#6B"5'E?P=A$M].2D.M>\><<Y1MHFYC)I2B\P4,78GB\_
M7T#!/AY:Y(<)*.$>>0QMPL"8L4C2.//2#+.V47-($OUR3#CEZ;9=>0^8L@PO
MJXQE=3/:1B-PK^5)TI:BLG2<BISY"!Q(Q2#)9V!:_OHDZKC\+7GG_[I=[E8Y
MB:,'Z?PZ[G]L,[_:S*\V\ZO-_'H=Z5AMYI=9_GHE%[697VN\.:O,_-I=8]JW
MF5]KG/FU";8F*(T^E>$HWR?;F8F= 4"61RR',E;.0K!"[F6]4:D*TJEF!7V8
M?>E%8ZX^I60IM-K YI%()V<,=IN=N_!X?@-' =%YQG6=RA58$[PW"51SQ^O+
MY>,I,TI-^5>%>M.A3RD@QME';L\Z7P[F 4QP9]#3$OOH4M:54?.<>C79-XL%
M_IXQ)+&WBI"$L[/_\FA&V&&YN#_46[?07OG106X_7EX<WU OP9-_G5U?'(,V
M</+Q^/R:QCH]_G1^]CMUN3K[\^S/\T^7]/%O9Q\^7)_]O4"-+P)&_W']R_&G
M?VVLATQ?=?C03XZ?PI@>C.23]Q7M^+N(O#2EO$05;/83$DLJ,3$A)PKQOQ9*
MKDY,5+\<2$2PT@]01;K^A7V.V:F1C 05OZ443^$G0;[HJD?RK) @)2<[_ /%
MH?8V&;%D/8(K*SQ#Z00EU1&=6!$-I01,J?BW-N-1Y5;TCG9V*'0M6**ZZ/_*
M'[#S(EU'?L$XE!:ZZ!)2* AZIF0B/<K-"JA,T;RX*H-4>_ _/_J-3\XB#& 3
MJE.8I?4+M7ZAUB_4^H76V5G3^H7,\M?+]=#ZA=9X<U;I%]I;8]JW?J$U]@MM
M%+K-U?7EU>7-\>_.[5^79 ;UP/0Y/OWS_.;R^F_GS\O;,^?RDW/V?\Y._@!Q
M!O_X\.'\Y.P:JP:OSC[='-^"A-OPPD%3OY%(^1GQF[ 8L.\S$N$]0B52/A6&
M[0D)9A0% W22H=7&?AV5=FC!Y4R$S\FL6>Q\$FA(5M"E*)%/9;II7*<:ZW"2
MQ4DF&!+G'#[36??;:/]=FU1Z_OAFZU_EZJ8"BL]I7NA#:5VA"*:)3\D:UJ](
M%J@\C5#$JFHD=R>BUPM62J1A1*MQ% ;3HI,1":G,[AM!Z#A78JIM;WJT+SV1
M)3!$ZMS!!"7J4EXG&IQ9B)D5"+''29\J_Y))CVD>,2XM_V?!>LZ3ARL86TMB
M9&&RA_!2JM;9Y,.16#EPP*.,0Z:]O4V8BWVYC,H)3(4GHKH9Q</#632<YCJ0
M6#*FF"I-D>:NJK)RG7$$H\!)<95K&4'^:D9/16#*7A&5"2VD-%*)2#GX$7L]
MI()T=&'JP,?L\:C&M4PPJ#1 $(5W6U3_>A='#^G(Q=]SQBY57,D[WW,B0@5$
M+N=9ZX9D;Q=[ME5&OWTB\&"#7$'E TLY7&MB!JOT8DGT(^S(2B4R[C._,.%A
MXCDI$/U!FJ(T);=TC?)L^54@'9S^ -Y1GT_R+R7X>RLU#8XPL#QZ>%PKZ7\$
M#*?SEP1]1[51Y*Z"I:%S3<%Z62G_])OE:GVSN$#@33[&ISG\KPOL$OM1!C(1
MMB :^YZK2[*B>*K8D]@WPQ0W";=BB%EG 9RA.YD0NVZ_YRQ\@85N+NY=@K$)
MP@:3@<0C.8"1@K[TT0?KP8JHYLT/AX'*/=4_XQP^F:0.N1I=G<*O"T+PY7P-
MNGB6Q9A9JV'EP%*YD -4QIU320R27XC.6W7[7)Q>JVOG'>Q7@%!I6W JPBUD
M1L\J2(.W-[>*SE(L0K4YWK2/.84I^O7>XA+4'"?XN<D"/ \] I?4T^H2^3&Z
M4RD>!"(USB:Z0K!\5^6)BXK8/GSOS?IU/TO\D.K7KE65!$;W$. 2)(!&N#0U
M/* \BH'"L2NGB1M N%!BWB$67*<(?)GA#@E/@\CEO, IH9'9+LH]SH5F[;L9
M0=B!/4LF/B%1X[ F1S$?GYG!6F$JQ5C/@&"K5C$Q5C:E] >)+0\%TKW$17$-
M(!X@%&._G)_>'BM1K7$\\YSF\G(9^H]Q<N%NP'IFC@.$DJKI]KMO[%)"1IR&
M.Q/9/@("6>#7E?NR4": A<+X2J/H@7-2\1[BZH]\QUR#9J$L&Y2NP%-PG8%4
MGP&1K6$M*G7O^3V)9-57*(W^64[UM$BC@.HD9FA6A*&<D*175,WWV "EXMA]
M.8W" 8=,9Q BO]X"K.[W,H5_B Y\=7WK%&%%H=FW"+/W?%W0.@QJ%Q]PD@>A
MSC_(W "4'?P77*\^V?V$S6A"QSIV@AIL2'=VE0@A["F.YNOZI+%&)T_TYSH[
MG$+>&)_?,K&0@2627;!>Q> !+@HLG8V<H?"PJ@@3F>V;3+VIE75>W.]Y6A>F
M$Y/BQ=H KI1UOL0JD3'%N&)LCHY->LKX)J^S5:Z'A7-IU''X_S;XLD7H[O >
M)1M00,E'.M]<#ZZH";O27!<NVHIPYB6B4F#I_RB.LCLJ!JDS'_%2P$T+K*II
M^"UE== _X9&Y5IH%;_ @ WP.#_4$IJLWBG,>>>3%<C5#U[7E%7A6A6>M4,X\
M+MBV]%Q$57=,Q%+AXQ OFGQZH__'YI[$&:SEZWHM'IK.3FHL7;)HQU*@)@.T
M+UNG=R*[*YQ"QS9)F^RT*@GH.+^2+.$<_AK<UQF> G=6+HU(/B>:$VV'1=XH
M8;GZL,&]GT0,SH(N-G*W;<;I)@\:_>IG=4BN\1WO4283,U7-PH(+@XE-!B%,
M9 A%%3E:T:UQ&E5&G66!N?4N)$/\15)<S)O.BF L.%A'29$FSD/. G!ZO84<
MJH=?*414RESH8_+"M2Y+_1-%!2<O;+33%)6X>^H%X8DD5>J03Y 7H)IB=B"6
M/Y-2[J<9BD]XG7\B#>ZCVB:8HD6P$_$J0,46^!H=*#%JV1/D167!@)Z7!GPI
MD#R.PM*,/CXU4)C??JKJHG7J78>*?TWW!M$G>U65[X*21[! ! <%ATW92PJ?
M7YW]XSN$D4L+/DS2:^/HLV24<:9(/EX8J9'(*)B@/@:&-QN ZM :']1]7KI5
M=/O,$.L6&G?6'U-YJ9/?X3E9&"L]F++BK9#3AU@L35:2U@+RFFMK2?!+W3-$
M-[; +%"U </*8AV1UM[88 /LE'OU4!VKP-N<+E*%DA+Q/1TZ1_MOB%'LT9>Z
MIQ!* -==A1K?0'E4CXFE[8)KG8/+]\ZZB:NGAXGI]1'Z\I?+X^M3Q,$\/;\^
M.[F]O+YQX+^7%Q=GGTYOG-N/Q[?.WY=_</Q+'>\/E]I/1-F;C*!Y=75]^>?Q
M[QI1TXZ*.5?'YZ?.[:6C$P$4=6^<3\<79Z?.PC=F)0AWTZG9E38+KLV":[/@
MVBRXM4Q-:[/@S/+7*]&JS8);X\U991;<_AK3OLV"6X,LN(.C30?%+RCMI^<W
M)W_<W."?QY].X?\?__[WS?G-.ID_*_'6@(7?*%EG(!,O]OO2X&X;V+MR"LM0
MBI00VBKN[5D!#,)JDR8O;E;718,O12ZAD'R?%=]Y$2R;JJ/F=$0<UN?6O47Y
MQ"^%/B%<E#(&9WE<M?,GRG]Y=JD_?=?! E,54<;!EO)7X, $[?-3A3&K:O:*
M6;/,A4HV+J!E[W1VCYHHVOO-%.W&>O;3%=*=_8+66'-_#)YAEAZ<]MVCEYAI
MK[?;.6H^4WXGQG5$M[3K7F'0ADI$#V6<L]?974J9>*J(?JJ1&>,;-[IW2"3L
MOV_8K'=#J;;\]?U;9X'RZ6*_WY;TRY'>ZI$\XZ;6S9.YJW*QI4?S72L$-9[<
MW+H53JUP>ND3\COEES3G]...\XN,XVE+]^7HG@NB/S$OTP@JJY=[\TVI-"YI
M15 K@E[-4?A-BG 19N\X'RGK2[1":$G*W\C0!V._*(%<YU<%!W,296$B ZT[
MH5-"(745E*?F6W=B<AMOI(=IVHWOD592M9+JZY^7WZ+1(I+JK..<BGL_:<F^
M$C&UJ):$)1HR;M6D5OB\RE-P(6(&=VO.\3<=:DB;1JTC:44B"(M"/8+G3*2(
MO=&B"A&*,(8]T$6@RXHF'?*UPL"E .ZFPH3DN8<W?UQ<'%__O?$!T9DUB&]M
M& M=4I&HABXJ&5J7_=I]O:G2-Z]ATC5?B9WA78=#48B6FGI1S*06NB6C,Y*!
MB7-6NM#RAX3<RO6GMURF:X\[D)[/2,"I^"P5Y"3#QV(ZMXA]R8GY=L41]VG!
MP'"A>-1U^EE*,)F(<*O!$FA?N/],"5G@7HY\+Y!6FZQJ/_3"7ER-_"!*HLEH
MBNU10'9L$45TJ2673,*)] >83UZEJ%V)^+:*AE(H)1MQJ2,\]\[5*?4\G3T*
MEXKK+BXP/Q;(ZL+K4F1\JEJT<%/52#=R*_>*1C*9I:LL?U,"+<-[/XZ8G%1:
M00 6J@$,DBI5Q;\B_BQ39R!2H9J"T;]3>(M!PA5ZNM@_B;+8*Q8!VP6RI?VP
M@8<+FXELG054:+UT5[&\L/M1Z(77GY%/)1!6?<:?NGR$ZJ.O5);$J3ZGZY:3
MOPIHF9KZN5*-")R1&[L !&AW ;3K[;HJR^+HX$U-'8I=F43-D> D#L5]%.M<
M%9VT@<40M#$VCRMX(U.NQSA'(:H8*.R2-,92>WLZ5<)"1[5Y3:]]%-6B"K_C
MX^YSTU:&U\A%Z)#Q&."6H :GE*S#A5@P$I66<]DA]FB[DT"HW7(YS:-$6CI[
M15.X0-P-9NA;6Y3:H X,<%%D*-.7CV]UXL)9*52!(,W#QX9_@YDW^U#E'G6<
M7X0J!T4\!5,HIQ=D,5<:W4G*LN)&=0TO5<)?XN*YXJ#);" -8->,BM$&CL%=
M*2 &T(7X0?;C#).X^'3GYX/JS/.[NM"N>=Z%&!<JG59^)19O-5"4)#"K:O^I
M:JXS;*)N:6^X\?IBSU\W-*1@"X?ID<YBL$(1X8P"O-WFL%NHI@+3Z>;:5)2W
ME#10J&%]&40/&]U#5$&_^ .%?**VMI:B-E'*>PO?R7CL*]PS1,E#N =63,<2
MTUSRYM2TMPR'@GNKM_$]8LG(>XPT9&'@D]:OEE2<RR12,O*AZ;3A.M?4H^)T
M2^,Q\,QF8E5+:A]C=49!8!F<E[R_+]POR/V,LV#)1JNYASV6?D\2*;#G,E48
M, \$ &.##BDP&!P+86 032J 5V>4C0HFC 4H5$)]60;FA=NIED#<+#2DPM5;
M &Q3%WU*V;=^3&^D@'AT0Q9XC4+#7]V> .T0A9*1(^'DY"20#8TFA3AJC)Q1
M@O+AK<KA(%#Y@9]R.FW^TY(\+(,OY;< =Y\Q]Q+=63DN2%G-6;)EB;KTJDFR
MS]"O9+>!+Z96LFS-%RUV^<"'RT^WY9*[PM-FS-YAAR2=*23T0R)(/P#&*M7C
M%8@Y;]3NC/&>Y)WF_Q2*(_#U9J]L5GX'-:K K;V(5<X,M8)/M/<#A:%RDR2U
M]]W)ATLZSWQO4BHUJ +2Q_N1Y&4?5"1@@ !97 -[T;G8Z>R]V=KM=-]HU4(H
M5Q"+SKY0D%0EEB>D+NS[0_ %8A%/<T&STH*F H?8?#RE ^FJ#SASE?A!>SA>
M[>$HWJH:#TY=I(1= :R#M^%6--Q2#*YO3RTLT>@;.?THS!*9XZIERF@@4X2N
M( +TK&-)V]ED\9GK&+!1?9>HQ8@[/EW6L?N)#C?GZN)SO6[WS?O\P.-'^_@)
M3G61Y(DK+OV&@L-\,O"?*E2SP"F!X?=P^+:\OBVO;\OKV_+ZUU#SWI;7F^6O
M5P5W6UZ_QINSRO+Z@S6F?5M>OP;E]<_>?+BUN[Z.W76\J M7#"*#\$YV6>Z6
M*WMPE2,UM\I4R$?%4N;Z67]RWO;>S4$_5WY*'.OM]KL"$/KMZ;%K11U<'04J
MH/NJJ%52B6UHL_%!%#I!:'\UQ[R,#]>+HR1!_7M$JTY,]Q?XW=3&^R?0QL3@
M$R/ >9(6G(V#&%VJ9$[.,DUG^UJM*-DMQ4Q1:S4;8>T OI8'[X5^\12>Z+XA
MTPB3"'%A9%&KR%'"(17*_6#ZLO\71S7^H(I#)ZU.7[_#3.$@B<KKH>T*(Z 0
ML+&O@"\7\CM5EM9ZBC9'8ITCY/# SR,,"T>AM AK&A@BN%0%ZKU J&A9(43!
MK482L"+]6$JE#Y%^)0=T/0GB(S2=3E"\*@!4['B/,@0% #QR?'%ZXUQ='.,!
MS##/ZZW?D1W,69-;GLYN!3K_[QW'-$'XWQ<W/UY\^)4^WJ6/WQG97#,+=I>/
M/7D?.;_?'#OGIV?6@VI]E+LQ0SX^(@<KW0BX18-:;<&SCB\U(<Q>E-"QCLEC
MVLLP"OR(Y%^$2JO#F2IWL1BF&(P<9!['PG"T/VZ4V_#]BGH M,+FZPB;/THA
M9M-9I1S7]@C#'MNY8?9H*+C_"ZD,F'<TR2.(2I&@UG)XW-+IA)W(2I@@Y'8Z
MS=-+WV(7(1 ZG*2%?5L0G#\QC8"N;_XP>;K4H,(61C6_O\I__XY3NPQ $<V?
M]]_*@^\".Y EKHG?<]ZI0.<ZI7GAN\ Z^ 6O\ ^\W$D0^^$6;B7+/]U[JYC0
M.2NYAF"RX7UTMG%?8D<%"UFY[J%"#-9NRT,PT0$PE,H"-IUER@0G].9) #H@
M?$-)SS#Q [:+HE=<P!>OB%'QQK<2X?5*A&*@*F^>A)S$ZG/Y(-,%17>^#D'1
M181'#]5NBN*2!4&)&JK;WY :D>6MXJPDMJK*K:^NXL0Z/%8]ANKXC>7 %RK#
MC@*]D6G D)LQ$9D[_,.WA49&-!3F?V,T#=9P\^=5\LZB2#&#T^3PSZ$2+\7.
ML2S^2+==(MU )+K[HAUR,W( 3_$/.^Y^]] ]ZNY0!(YSSB@,5_Q9S]WK=ETZ
M*28(5_S%H?G>"MD5?W)PM,<_*07OBK_:YX&XFU;(=0 ZL=5D/17?&E0.5#P0
M>#_/K&?"1I2OB%D]W"\'9:.D(>U; &\E$8>:\&I8W<@(T_DQL5\K9@=[L*T+
MF5MT2P22WKR5=!LCZ<[#<N+J+#.*W(\/4?RYSN-0KY.PMT3?_(_E_N&/RYEW
M:+<%_G_JTD3SI,)ZYQ1)6S//O+4:8RXIR)NWXEW=J[+5AY:5T)8B50T]8L)I
ML8;F3::Z2I!P%?K(PBB][AOL88;^5_:5[.$'QO^EYS.)/"4!H(5NT5*L3O/#
M01=MQ8"M:_3.E.9D^?:V_^X1]XZ;>P@UZ9O0HM:<+2V!?K2#KZ]N'P*Z[#@%
MST"3U35C)I/T4? 6S' 6%!>[W7W#CLR&EG9N3GZ((E[+:9S=.<<#5+JI[Z[=
M _3#Z;%1_343O82QKI8)TUMC /V'?+*J/@=U8WLC;&I&7:94)["2I] \R<RL
MF[3<H76OJ@*94]]B6LT[1SV6DYSK0O1,NFX/?U/;-G,!X 8^+XJ5OX'"KG,C
M?:_067N<.X"_A1HNNSTX-:YT[>*%VNL06%WT S\9%5*5Z[*]9]P<=O'';,E%
M8LY>R%YE(:A+BUGV<=W=J(MV=!"AW%*5&_6RC\)V5)I!516H:6%<WSB82W;0
MH% 3EJ]TNSQ -_BN'PKS9OU >U&J+8AG%<;FQ:V3O+B'5\/.8^'\L-O9UU>@
M>?.P*#^<'[9K?U3NQXL$537,>7#&NG54W4#IO;D2V>3HSR# S'H8N+N(;\R2
MT86%]AK5%U #KSYZ,W[8.=KI],Q;@$CM'+RIN:'Y9GZ7I_.;MS0S*>DX:Z*#
MG<Y1/L\.S)*/F5#'R61V6TQ58F4*RT!'V3D\[.SEY,\WY^U19W?.*]1I%ZST
M]#H[U@*WS0)UT1F7LR72)BZO!XQTNQ![SF:5C[NZ^\K4ZNT>OJGM/FN%SF8^
MNOT&&\+9!"N?Y5#>44JD=:CGG]A9_:99,\M7$,M!YBFA4U3=C:D).]SK[?/;
M];JP4S,E8:T>OE1%!6M]185Q@V\PW6Q5Z/;FM#WLA58';<8FD:H6X%5%GD^*
MG-2(?(QMQU& 0:YL@@T,Y\ @J):S(BVV9<<[8T H^,;/A=(#K\"Y]XB*$,G.
M78>M+1@0EHL''7M><Y2:XT?&58RKPV+%!_ARND7EQ"/X'S@>6NO5$2$*)4EZ
M9SQ&:-:*.,K048UM=55-]%*\B-/IF\AM4[7;5.TV5;M-U7X5^=-MJK99_GIE
M [>IVFN\.:M,U3Y<8]JWJ=J;F*K]/&=B2?LF-VJ-RN_JM"SR_X,Y ^9)P%X+
M;J .XV*(^ YT_IVBSC^(0"(@]!N#N*"BCVW,&?8,%AJ-*0>%X_-H5L\WFV&"
MW7=Y@&F.!0W?C3EQ41LH-1Z0N\P?Y-'^MWO%M8]$4DPT'B,4'F868#-T'\N\
M;\Y.0"L"*MZQ(Y)S&<W7L423AA-Y,!@$XA!-/Y'X.EG0B\9]L\HJ+%6>@@<_
M4=@3'*BW;,(B0!T' 1'T1F<,4(1%4F;!/L9V9B.':->@G9Y-?R/*('LD^B9A
M&_VXL4R5HTB7MZL:WCR[^@YV(4EG1PI*_G_GV/,B G[ #FNEN*B.'FF+&FQ'
M:04=F\8;X;3M=-_8:=D/(Q_>T$\XK=4*H"16W*_LH.+9V>_*(Y=<V\!!!5<Q
M[ )F;N!1B'VPJK4C>0:KHZ^2QZE=SW)P>@57UB:#;!VKP"6Z0"JQA@5=_+,8
MFW9I2[="'-3$Z1YSR+/3O2 Y_0$)SJ'^HA0J-!( @X49YHDH:)R8\-GD9^3O
MW]#54GY5&AXC@"I%=\#NESXLC7ZBLH9/I4=@,BIP0=SH@6"#M^1'! DZQ,XQ
M*%BXECS H+G>?@L<G%=;7)M Z!LQ5=3P0<@R8"CYO95'M6Y+=(T%H1AA_"&-
M*,T+5\+R0@1SA4IM:$2M7,'?8&1G:H*L-?%4+4"0J BT%\44\\C][B6WG<:Z
M02I.Z*6?+KPZCZ=%O_Z8Z95 UV*\=651Y5@#R+HH,Y7.4@JNGDI,=&>*7O -
M\PT$68NB!JXTY%L"&D.59H! 5Q'5!=5W7J5C )]2LU9S)GRTM."PE\&@#%-7
M6ZZ6 ?DP_Q!..B8LX'OF6D_$R=P$VF?#=_:G"CT3CA^\)ZJ8CX'2T8@V\N]$
M+G515DN>\ @JL##*[61R5?O-BEA' EA<4IF%E01>QO2B (I/GOH[%6.HT5C+
M*&(:*- NR^#+!J&^)NK<%)$341,WV[@ TI^S=*PHOR))T6I!N#8GJ1'3QZ*8
M<Z(1JAI-!CCPAG/3*,5T6LXR&E #QR*3^8:7<5@< W$WR1M-=Z2O$=9-OO:B
M#9$JM9]M]>+F\-_-"$SM4GD-"^$!*0&F5KB R+9XRB3K=^IBQ.'5_4K#LZE>
MJ*Y[#,:1DOE9?9QQB=@34$( Z.JT<,PP,M%B3FQ0:\++.ASH \/4\/\CZV8@
M8'_2;,VUJ0ZI?6F8- V\59J?N4JZ5GOB-N?$W5I9=TG-Z:/\HSC%(CE?'<4$
M,Z53;'@0!#*\0XU%J5+V(6W.L2;K3)_8%.\@=IJH@0UZ-"F3N7*I$]U@2>2A
MRR8%TP]?*M?5- [J8C=.[CSDY;7,OSG,?SR[IK/*]EP8M,4W#[<C(0CE626E
MVI]0<WMAO1%=7^@6&3ID,PQ]\C6S5[+^>"$[J]O-K=YIND-),0_?9-BBP98R
M:B1Y3V+9GUJ'M-XJ*Y1)X+VD<C+K\5<I U_>^9YS%XE (0+'=(57+M".<X-V
MUTS:&1AK7#@YG\A_HRB'1,/':XBTB'GS_<\X\A@+T]M3O3&GFDI&Z:+*R,(F
MSRCQ5O00 N^._(F.[AC(;O:46/V,R 51\&.H6E+0,:.,RBCJ;S4-SNH(VTV
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MC]Z$K_B GN%F8ZOMZAED1D6J:G+@OQX[:$F:#;"OFH1SSQW-_O*# )C]%@X
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M9.D]2.0E67POIRRL![%X")UA'(W!/"B*6OX5+/V/SDTGG])5&@NN%XF \F$
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MJT=7?QD,][6;I7E^WTXYN0_8 4_ __I^M]'5UL*,S_ YGIC$'A4B88%9NN-
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MD@?P6UXG/AQ&^;X,\GVY@ZTHC5(:PKQI#JQ!3^*@^-S0CQ-XWRQ0B 'P\2(
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M4?$Y>!.O(7T/5(-E/#GY&RFYV-D2<_MS!7,AKU*G+U!R%X-SRO>AHY N:"8
M,+GHBOY"60 57Y]UC2EAI 6^*^0]CAU'<,;AD:?NX1*YE12$5=R"NF1RYCE9
M8<^IQ627S5%28#BKV OO$3M)YSQ5YX635=UIKW9#A$(10"C<.3W./7M7 1/9
M0X8+[D_YRU)ZGSQ4_52?OW?4K25>&0LJ0TVV-QVL69A$/\+XB&$:D9D7@X'
M8M*D_:7WSXFC-5$:)W \"]098=T#)3@+'O_>_<RM*<S:]V,OJ]PY>_>0Q%Z
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MZK 4VJ@4,M<OA::"QF7\\_167V!WO]LMOEXNA]*J5@ZE\_[$L]W[T,GR)9-
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MVA7CZE+<Q* B^X$LEM.'55&)FO[(=EWAW5 )@M#O.V3)4P48\EP^7. EM;3
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MRTSR'&(>7+Y.*84@^ C@R,<48L04K X3&X\Q'[J(944W3&",[I.L5^'U_3C
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M<B+09 +'=NR![I@G4AA/%O$*4$IP9R8EF-+Y8"E'1A)U'D\67+T*5W^U8K8
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M"AQ9?)-1=)IXO#CG\I*[*O%"UR0I<J$U/=&WL9Y>6K&*JC5BW("\NW=3_^Q
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M_N?]A__;,W],_F&Z;O_^PZ@W_K\WO__ZV^T_S#^^#_[[-[=_=_(GK-SY\1;
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M4Y4R!U;T(S%3J<=1RXW4<K$-G:X%L9M@)A WL4L&@?K"=61Q=]E?ENII%5H
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MB+%DL 6+;0N'P@X=:B&7QG[ /K]5^QX +0 >^E+4E A7=9TA6\?Z()7QGF9
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M[3I7#*,G676_^2-/.ZMI'^U;)]Q<]X;=QNYJ;3Z[QD;NOG9U1S.0O$6*/D)
MPKK=2HS7E^\;;PP3N\-LQ&6W[QN3@60@*P#D%IRFNXH:/@J6T$)-O=UI\SG
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M8=1,[B#2$2RKV9)6U>[,K8KT84]A0)-M-!JU3BLV:&6<#"U_:I/9.XWA]G!
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M2V($B<1GUO#C B6W7X31JFFGLGF="+V8627N #D8Z5"8+U*AL::5)"9L%%#
M<2EI25W#YM5I:4HX:GUL@L'V/26SB/>,6NN!B_YP$NE_">=R]W&)/G!2_!%K
M;XT:0M+[K\5W4F-L_B,K_1Q,Q!\1!@WJ%?XD"G)/B$0Z? /+M9AD]>AM:&,_
M;3(#8QC;H?M@*=K<5\)@NV9T-4!W,$8!&/J2 (KH 1P@UA=]@(\3,*ZCG?C@
M&XD&WH"PT>IHTHOA*6H!+T@2II6TL6\]Q/N(0(2(P!M@^)M[-Z/_\_POH;K%
MWA_3MY&I2%(8$F2B(^QMBX;1@ DA@3 9>%8_:4O.E^NC8PO?L[[L9O4I3(])
MC&AV.)GB4A>8.,3VW4@/^]H=\;#!,%Z&"PXE^@!).[;Z%I=_0+8P#2*)6> !
MOF(2# 4G!G &%OL,&]CP,2CE]L$ )+X[ ;7,!>+0\@>VZT?/ II'%JH+E.&6
MPZ0:SEC3OH$6\9[V$B8P/+;0(8B$F8:&%()M*;<](U1\%$!HN@J:&FHCSYW(
MA(AH@G<C8MD^-Q-@TS,.DCC(,0?0XFL"T ?"4D4F=P@:4_NAUG,-F2]HL(5@
M0/DTBM#D8!V%F%E_SR04>VV\UV[!P/1 ?J)41(OTM?6&6P5H$P,A "S(@"F)
MD4?"(?@3H-?^_ML60\)$HX!).\0IMRR! "F"3P/STHY]2IO<<X_ '8 MZT>B
M#WXII,8 R-FGL:LQ;Y7F2& =5FN]X?Z$O. AF9 H9,*)C?A@,OKL>=A?ZEG.
M3J%'TQ9#/E=QJ<J<7%>FYL3D9IQ,V51W;Q)08,44\+>>W)S;!WH0D;8P9F"2
MX/#U77K]U+F%O3+V$(9)9G#N/,T0CV#Q!S,1-G1#>\C\']  (9K=TB)94ZPP
M8(X? )O8^-*+O@%H M$"4\,C?*]W<U 5(RU<$0R$*XK '4$-YP#6'5 @#C$N
M#(QQC%%H<V$8*W.4'(@UF.-9/D!Z@7,RXI5\J/!*>JU*XJB2.*HD3G2DJ4KB
M[/E4TK&L*HFC2N+L,G+661(G[S)456"O2N)4KR3.EAS0#$\\T_N,K'J,\?+
M:KZ;(!TCXJD61L5"F_F6EC,@4S) YV084C;0>.:S(!VX!"C5T ^S;8?ZPBT
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M$I9=-)>IA!.,N<F#W@+/4DKEX:?RG#!S?VP-QGF)^?*=&Y9&H0MC")^5<Z:
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M$UJ8NB2!0B;1>,FFV9)SW).DG>1%*DEJ/Z>2,I6\7/!+=P+JJ9$+)HWEWN4
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ME&MKG-QR@'&!+83<@Y].8CN'=PEF/]?&E-CPIQ\UHANX=R##;F$X8#ED0_J
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MM#-7(WQ1%O8"'M@AMBB&!;#98"V^Z\!4N8N*UB264YP9T@M7++%#+-'8%$N
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M'(0V$1(.!P;,C&!AJ/#[-+A'J9C=2WHK<3?SIU<?009^((8863Y>GIQ1XL6
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MJT)5QN-&(I[-Y2*>.;(8(YY7#\W./_N_VH.F74K$\RGB*WHBH_(==SFJ:>S
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M>4(C[EF6K<OV#4C_^R/[LLV.S3]+^-IG?P&)W .)_+KZ>]IYE%M*<::NUN^
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ML?#%XNXC]-:AU\Z4\3!X$,N'H <_V-+ZX)4B-:]P&3-&K5?6@JG[SSW*_)L
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M%6>A;3"2+AAC%"L3P371"?T?9M/FA$(F+D26 '5FH&;%DE#*+;Z%Y2+YTU8
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MMT=M=5@4]^36@WQ/0XUJ :$>>,0HPI_"Z:TRKSKO3P-@-6&[N \>"/:N"'0
M+8$IN]FR5 F?8)#MZK4"%5YA'H(/6=Q_<#R!AH%<F W!N$OL*"ZS\9*4W?&
M?O! !AC2!YJZ3P'- T'N 1#XMQ]'8E3;,5FP*X)9 B_J'X[PN67A/4;/CU-N
MJIJ7RHX<P WTA\@M@OW>9;9PU?8(VL61D<?_\4O3Z*H63LX5.?:3"K2LFD/+
MX63!OO:[- 8D(6 XSW2 _[E2/(18I@$PZW)8P^!4H8.#NV@3PAF&,!Q=[/Z
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M$VN:Q2&=JXCG\T'"J@1.;V%AT3=T@N[:3 379.7ZA&PN)Y3$TD8D!X1.8BO
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M2$25B2^@S![(#53K3%2"F?'/N26VH+(U7IX?E\&UY]",*5)N6C8^9C ?(6B
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MX1>)F^8:1MDKIXDA\!H:JQ3%?<T  ULSN'4H(ZA%<@R$9@(/!!*M".2G;'6
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M#.3\YE)=T-%"O$CF(]B!;;,]]\'_7Q.0ZT$((RQV]^*_='?%U4H10(5/7F7
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M&>(+RRD]7;$!4&:_4[4KBNZ"A;:>\'6)',TJ-X9%7^?6>L68-+A*%N&3MU^
M[T8*@J^^ 06WW)/0P#9'T8TRG%8LN$0.MJ2PQQT[?M*0:2=+S@N7KL,UV9!E
M\79&&'\'&=6B/3. 7[QH/C5'O5CG8&XG?K1"[F7GDN6RUOXEBLW;+LO4K/U1
M'11+##9/%3,@7Y?T.!:C^C*,+RJNB A_D1VAX$%7CC,#N5-T)U)N!^T4#QD]
M:0.>WUSBP'U*PX!_X/Y#9D%O3H),?O4ZR]%A0XXY)2E IS]>>:GS*^KNA83^
M"XQRGDARE$=U=583YJ<C40>5VM&5CC&GC.*(%/X?A:J2@WBG)'\4H7T-11"M
MD!=\#,/CHXG2+*D3<#\H:VW.1S"2+O63(@T><YO4AZXYGF):EO*2<T>5!M&X
MD5Y@/H]O%S.$-;9%C:DYK1#A_5_O/=Z05];N\4\Z&1;^CRJT!$$F2!V=:_SU
M0M)]NE^1:1LW,9J/8<SQ$H3I@&AGG!C)<382<3,\Y!:@7\:)&"<<7\O*"<R%
ME&,[!&B982IK !]361UFX$F^TDIQ?E'^Y!.-ED8!<D*>A+*%*ZW@\MA2RF-^
M^]M%,AC0,#B;"KNEQUR1T"6KI5'&9A$"\L3<R> V&5$4'N3WQ18(6L^NO,/8
M9F$AA&SCP%+#X*^WX"70R74FL>);*](BS\^%RKEL\OZ\WLK[L%'>M0::V!VD
MIDG@KY*'(%T4L["JC:DA<S4),WKS]>&>G%%B.VU#QFYA6LZCD0V!FPD[6C3Q
M,$>RHLA%&7M"'R7I'5A!__94?HHL\2!L/0%@(;TJBA_ 3*03'PLMN)3!A(VA
M'BWDG;J4"8-I$Z1^\=ZF,DME8BF=$327F/W#?S-5.B,8L >J6?Q.J<'-,WHW
MZSD"WR0Q9A3U@QZ,=I)RN9P WIL:4%#Q$16"$ B.8>"1<PS?KFIWS$VL2CIM
MO57*4:-2ZE3*!PVE8*#Q@G*]Z0;'!ET_R/PT[%69>N*.Q*5=2K .A9$QK4'.
M4-0:2F&3!#16OL1,,4+(%Z5BP;2S0R8P(#YE6]-(4>;2O.*.R&2E5722YD5O
MOM*GMCMH9?;EDFC/CXCV_/*J>]V9OQAJY^+,Z9Q]/K\XO[F]7O?*HT<-\WF]
M5NNJ_-,S#Z.R9Y-TH:5&98%JG>=:SOX.2:V%"#?AZI+W\(^G@9T2N;"[L[OC
M=.(80RN?@T"6&"<EK6&.Y#,B.@?0>)^]1Y[DW1WB@-YIZ<Y222:Z0WO(^*.N
MQ7D0$ZE1QKH+&:3ETX5\6,ZK+[CRZ-V&G]PML@$(J S")ME S)BC@,)ZNB:K
MH/5EB@@C'?E=*1^W6!\;KGQ\$(A$Y1I.^B26*=L2'S!"?P250JR8@[F$1$W_
M6JN?AE>@5OW\&F2X7Q>A;8I@6-@SZ!6^DSN1-V B$# QO#7%1':-9&#PJ&L@
M_,26TTAY5Y&X:X>Z6U'TF'BX%;<:DKTS+5,1L(%[$K93%,I:H_E# )<JV'$Q
MC(0WF=:4LG:R1E3C[A3;V*5X\CA7M;"4;T77H=&5%)%8A-4%FXX^,D"E! ^\
MYR5A1@714Z[6@PPT21P+DY1\0E3:QK4*VV +*67=D0M.EE#,#.O6ZR6H7G,S
MT9WG78R!-,]DC-T<X)D!,XQ6E+-Y\-<M>0K,0@$_([^24(@"$6W>Y)\2#8W9
MOB.F)1$A$15@Y53RR*RY%-A\HQBD8>W/M15 W_!IAH=--:U/8?ATXJ%0X^QC
M_ ?7S-3S2@3G]'IR!]9;V3=0ZEIE_R7V55%!$#/:H@NQ,\LT;DJVA9;+[/VO
M7.5&AS)&Q0XB4;/!_G41]FK]0((SR6Z;,,@:K:@X68%@@S7G<#R%; T;,X9;
M'^9I&/;H2$.^0:MXK SZ&)^FDXBG Y7+?-=X1L<*[IZF[D,#-FK 1@W8Z)M
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MHEJ*)^==DCTR$P)VR*-+NGE/Y8YKWF#H^=W$8[Y3?9.>L4'37X(F:"C*T\'
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M1D-$@Z\PA^2C&%B<3(*"J<R2*S@B]:02D$"F' GBRH)C@CS(#\DDZAO!KYZ
MC ;9&%=24!85'4NM,AMZ;9\Z</#?B^Q= D"<FC7H*D3,*"8@6([G6I^:7: 3
M<%?&3[T4-=_P4=97[4D>A#)2PK$H76])&TG]++K<B"#-G7NA4$H_K8IX-YFM
MKRC>A<JF=H#/P&=8YP]A)(AY+K?L%5%A1626B;Q8?#M%*KQ1(H(K16=T)J(8
M,D**)[TLO\"5#F4)*@RLRP.$H?]4PB/E>A-<N(JR"JI^^CCFGXBHCLQVD,[Z
MU+GWHDE@EL>2C'GX&3'9&ZDE^*C1+56323,2N!93_]BH>^?#=,&N\>SZ59R
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M/F,##R%N3H1..,5RXSH]3+Q#'-4D]8<>L?M!DR[, $Q!;H-HA2[9E/7.1)A
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MQN%[6:EPS@09+G.XUI)YWPCF%,%<%2"$@,M;P (##U&">B\.#+%PP,-V+=Y
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M>1AT]H@F!>A8_E4Y"  "0RE@E' J:AK0_S2" ##D+R,* $%!$# 43$$)@U-
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M@LQB/BZBW0O4 >%;/\\@K3/RVF9=+O'PJS@%A:UH$*B(Y/W)@6U*DXX_'Z*
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MHT51IY1R<UJ![Y2J6:?('#)0[>\;1Q_P1+)TWVJC4?<JTK!/Z[!03IJ#,&/
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MMX3)D:( (NM?=QUZ0NHV\M56B#*_>X-5Y-53MGQI/E_JU*A) .WJ_"D,+'*
M,G( S$\">$E'A%T]*TM/L!GSP:$7[#7>Y]666D,9[*DH?+@F![QFSN48/\&7
MS"N4,($6R1+/<B3U6U)'BX6O2]KD/I9B8^$P#.&G\GEXIM82^LQ1:0.:0YU
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M"_!I5IID^.8+7T]*4K0[]3MYJO;V<!W"M[5]9N;)[^X8X4PA[+#10^]6=(U
M32/69Z8/T3;RS6#LHK8=(NS2@[4N'>S6H>_*/[TPY]:N1VAC/G^& NWK([RS
MCO#ZH72 DH ;YJ8?KOOF5!:F*J#_XF#G::3IF?&&NN(Y^MM6%GK&(*50?!V"
M+*R[."TX>-CNX&>;\\'^P=HB54 ..,GFZT),8"D?]WOJ_&T:.S'3#--DN:@
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MKD)N62=$$R 6Q'7_K89R]W*$34)2P9X'U)\-]QZ'V3Q_!8O^C%&I9*][]Y)
M<'(L&Q1&3-%2P27EP[Y!Y,[S+;*$:-)V;+NY\?LE]^*4??B_2L_J@);V",(#
MZ9!@Q(\J9,NI W.^>D$7W7_UZ?WE_'^O7!%PF\)@4R<6/BXL"GFH%;J"N!H,
MV57U&E0>H'P)E-!L?B4%LNP".9\'("P!2FF6,$\)6GU:K8BYPVH=Y-R*0=!R
MC^ W04=0#$H9K:& \^@)L9KJM<R'.-(9,]GMAFQW5E"4ETTB_K(BA R.8@91
M?Y+NT=ED45A+X,C;4WF/3QGISV11)?[T)UQ[/J0;::O]>L@X-Y"A9>OA ('-
MLUW6*+ -%LN!.B&I]E:YMJI)W1B/5"PYGG?+-LUGJ::AL9 .&GI%W>7Q89X+
M=M)>G+&F\Q$)RO.!N,;#ZN[0\QE"LUEU>*P Q#8)\WN4/5;989(Y<IK^^HX-
M?=D7V'*=8$_+HWXPT^>CUCDHY%:,6'WA1_L]N]0C-K6!P'(^G&[L<3+*L(5\
M33'^2%PNC'[:J5J'>:X16!/XMBPG\GJJ=RV)_<:V]&*P53.GCNMGP0*3V&0Q
M)1W87XLO71[-74._>=CK.)5FL8O-*C7I;!78.=^I50Z;,9!!'#VD!I!;39/1
M/DL/V5]-Y[>M1Z_/KF?*)H>]<*E=Z*E2^J 6L#C2$:H?Q<;-;GTD'C0RYBHY
M,W'_4/#IZSJNBG8;IV#>Q"-IWV_/52B7 V%:9R /N?D5#_4T@^1_1@PSA@K4
MAA-CR> VHJ2VL"2%>0Q0#R]6W,\C8.N7)JS/_I6S2($;U/=G(+^N %5H<#LN
M61^%+6ZX?#5%8M>IVC(\]M)51:N,- @.,LPC*AJ)]'06*MN46BK.&W'!PRBB
MD8DHOL,FLP#Y];3%RAU7+)=@&J+B5M\ YREX^:,^! ;.6Y6:7ZK6O;O7>[Q
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MF)&RLU(Q<I8?0Q-RY'^M"KGGG\ NV@5%4T3DSH6C@N+$>]_+NC;_$P)%-04
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M#=]'%3".T/R*G1M&%2U/YD..NH\WY.RCYQR>GS.=5^+.?C&>D]T=9/'IOLS
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M=@50!]J:IBO<M0&2GJ2\N ;-*S:L-Q*B/XR[(H[NGV*4 <W"+3B?0AANH>)
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M$TA0P.I.[#?R(P?'8"_Y^T&Q(HJXD^:18:X$:(6S(2I<+K2 C$H3TAW"CA1
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MWQ<<X&F360MWG6QD,.=5+#@UFB<V<! \*-[)Z&?IKFZF2S _<(![T F'JPZ
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M4W0*-0*P:M3 ^*"A:'SB:B+8TWM%/!3;D"XQ8P#VT\G\IP^P(VUJUR>2YO>
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MI !)"[_-  D(!&* -" =8"R:H!E_M_[MQC4A+?%?C+"1Z?$):?&)OUQ*-R\
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ME*"9RB$A>I4044/"DY>#5E(*\K[0]_V)2[3.O2-DP@D*(E6"*YB0?<P#UY'
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MZ7<&]4#\%I.8XJ&OU+Q2OW675E4F7&EZAR7-9+X_^E)8 T?*:C32$?)T'NP
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MTJ8O/^+-952QI3)A3%DNY-KEXH*6XFPZQX\$<2>"<!,P1I2G)V8Z-"++1\#
M*H@R#Y%NS FDL11Y[#CQRL9V<X\?5B1J7D!5KH$(D<W(4Z+DKN=Q<OB<T&DF
MD<K2'<[OG+;]D@EN:(3I<=FA%,YNXSR(@)V%LKS'6CGM=K91:)="SC<"H.Y4
MI*V;<GP[5*Z1O9VO\T4 V@XPS8<!WW:X/I-I"Q1$"V&83%B4';%16)%JA]#C
ML1 #P-8!#J,Q#Z7"M!449# YX1%EZ6NYZ\E0#)-%$#GT<R_]X%[6'W3H?%!T
MGX+4DC 3N45VAPE-?*07ZFQM()A @BL+67)"IC1HVG.HB[M%##6W0]S*; _J
MRU7B0P.J>'L>@=ETI'$<RZL*;&S'=K9S,OEP>3H3$<?R#4.F4P[4-BGL)N:!
M WE9[?4QQFQ%"3.,P>FDHY1I+'TBF"S,DP]CV?(53]CW;0P\F) )U[!CNXD!
MO!B1R2MP,H9 NSB9<?FZC3B"75X2A;JK#TP:R/>@04VH^8DDV0W<7 7C?*]+
M==KZ-\;[*M3O7*\HE"MOY 2W0Y7C<B/%UTZ2-(R2$>HDB'><UY_JY9NXN7+&
M$"U)KOUM:! 30> 6=UJJ!5T!-U!SOW&!97V7T@&$O$J9#1<1JW(I[=+1=WO8
MLB*(':E .O34H,#[<@X3CA/TB5+E7C JJU<@2'R69O/9]=PJVV3X:\G%:J K
M X!KBV%1(B1]&H:EYKHRB@J:&JJ'P3554!(-&0ZYO,P>\4,.0(K@R0*M:M0?
M&:@\)3%\!Q>,X,-P5'8HU5LU+9](@P0:<U:W QAC^%!IMXAV[UTM3)^;:RD"
M+.(0Z]WS346Y="KG[#B I^;[T: ![=S[3 YC &&?"<!(\ TJO!PFTI0"(3,$
M+U!]WB-GNAYI;>^LMU"!6@L0^_R+U9YQ&@\!(32/-\_ E $C\VF6K J$E(E1
M[V.AZ$S*0('"3GL&7:2(8NDR$.5D8C8S7VH#L*  $]Z(A,:;3_==2<QDRZB0
M-KX]L.$X@9$,P1KS'[A>*1\ 0U38<HVY&^G&6>W'<3RF/;]@9(O>KO*:70RD
M+H.)'V9"^Y@K[0H<?W2=:<TS%D,R3V+#+X%)=@A5)@#)9'KP]>?7>\3R<O4$
M^5MH^;H"P%: #')'937"%?M8<<9POGQ^^<B-GE3KG3S.1B);98!]N8L=P=?(
MYN>I,V%;): _);?T,(?&9=&$!:D2<"L)8<^$D("\"*$!@VI "D/ 90Y6)I01
MLR\UM5.UTTL,!^V=)!!+":+&_<^=1P@4%$N%*G\Z,\";"S42YKE/L[0%N=IA
M+"FDO9HJ0>8$RD65(4V-]Z  >,;PB?M]G"V9B# &<G"L?_H0P>1DGC*5Y<5;
MTKM.'?Z4LYP(&&;Z<+P+-PO9<G265QSX8KC 40C1% (,WZ?B3.4@"A0J8IZ.
M:(,6!IX<X*0(\E0:H9F7^3M1E4MY$%D58+4Q)SR^U/$(.HN.P(;E1=+9B#"6
MO01\D"*W<#KK4>JP<8"WB.,S<WNFL:B\$V'8#C%OAZD(8?$#2MF9>>K3N:N-
MX5@JFTXAAI*AIN0\?WJ>#0E0'69'\C6P92:^\=!L%;U<;\?5I>BIOA4[=Y4L
MUP-]IEEDXZM3)PV_9\J$9L/DA.QDX7YI>3^6U)B?PL &-K*-12PB@^DB=/ZJ
M5K)K&!&NQR0QD-;KM2KSP+F/5I%\F"X%\5IX?>SFPY=H)D#*V^;%->[$P67S
M30=8E@STH>&"%55]AB+$0=^UU[NYZ4R$!Q^^27BBTGI#\WG0G9N[E A"'X&B
M$8@ZK0C?EY\(=V-.(#VX-VAA3/DJ]I9AL"F]+)V42T)!R0R(82-2!=*=4T7*
MH<-R'T+15&@TD[Z#F:?6"($2 1V^89XQ#HQC@E6 IA 6T<[5VU8>HE+H@BJ7
M!+YD^J[[<UN)80LG6H6MS<O;T;%T/KMD&Q.B0$;<^K%WETJ!(Q_NC;X838=)
M3\7 MU)5OSD(M@,(!2(+I+,M.^H:FE\IKJN>=2W<240&\9$+R\S112E[F@T
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MYUY3VJOT0^V;WFO+PEV0]G2(1B-+J9VYF@\^LOWT-N7!ZJ-SX1=+@JL>>*B
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MMXD<WQVO!K1D.VW<QI]L:#R=G2X\).U N;YR?LG7+\>FDRU]D5FZ$$Y!5O*
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M2-S9V)"?<H3![&<SYZ:^A3OXR+%[-RJOD6'RAV/I1K+B82>X49ZD;G1XUL_
MU80W;0CU]]JN7I==U8]/4DVLE%T4?X]A<I9$D0Z1O2J>7T-ZN2RQ6CQ+&WF
M6-TJ,ZF*GM*YHY*)[Z?2.P*8;5 9/ FU% >U'8$<\'3Y*1Y>!Y9HL2NLA!!1
M&Q"F=,63Q]X(;TXJTS@,]];4'N:N:=7>N0BR3V1APE;DXA5+'#^,X4U%O->V
MWP,\DE<OG"UX<TDP8'XO]EXYGAMG>>P?OQOV7_L_OQ^AYH'.O#;K8=Q#$"'0
M/*A1_080W&\(_J:.)&GUZ6'*_!V10K9)Y+UN3FGW.6&]!MQ;Y0U67PD1/M._
MA>3YG(WJ=GX9@^]HE<R>.&>B$A13P24-.0_)1_?L6GOIE_*&V:O-I0>.A?8/
M#0!CSACK-WE*-9\CQ>]Z6VU>O>@."1H66A3S)-(=<1 F_#=E6Y/T8N3S"T#/
M9)+MN)5 1Q_CQ=[+>;Z+^NL-K3^;]<N/MRAP/Z"D [O6ZD*=A,2KN;BB H+_
M\"TQMJIQ?D<N[E@0*YZQ%8&?[$",[L<0^X[H2@KX*^+G_#T%ZYO^7#YF"$:&
M6%VJ:6=6-R).)$YG16L/65M=Q_=LT:3]]>^6:L)'IOS$S96K@@%KU?3Z_)CG
M+BP7:C61Q@7!Z!TEHA1:36ALE0$-Y.5CR1$<&>T<]- U?WZX,0K^N(_%=::Q
M>*O:#*"1ZJ<!ZR?1<"9'\&4#:K  T("&4J@.)BPL-FL&*'0L?JH V)@>Z!*N
M0.6.K5/\620@FEX-2@KE]'U_+'FG^ *?HND@TGF_U ,)4HHX#R%0A[%RA9$
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M<]IT^W _41NAM]54)-,8]NA 41+!6V-;F32!&O?G"_=AY8Z1#K09%O$!+H9
M5G."WM;/O+,]"$U]H24V!VZH%O,R7U,\A6E3+3]SI>$==<W#)X]](>&&?0.+
M^)-IRSQ*XS0+\?5]_B?3!0^,OI-HG+Y4XAKSQ8XA!AE+3)E\7$UUJ3Z22&-J
MM ?# HU",P;3V,VCDX(CFZ?XR!,N.]($%<T=Q*?C9'2#0%1L3=R?%,)6T2\6
MX)X=_E.Q6I>K*- P>LR7KH=AU'N2M( ^0G3J0@M!L@_IFJ\BH-O7*E9;)Y2E
MV$K2NFEC-[4OPM;-6LYZ.D,R@JO,&B+"2K(*J"^/7+,2C-,'>70'U>\44B3Y
MC<AJ['<%TL, 9+6QS0._#9Z:#!:/91&/38FFC=3H6>I&/N-6=-_*69))VL-
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M3S@/#LJ2M2K+*9[.$?$'/(P<&]IO%EB7H:?5FX0],.-L6STZ8WC380,B]#7
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MY]21+1?,3%11#CH,U-&,U("R4!YU:F)1T5S0;L5+$T+ST4\KZG+244DMU=0
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MM=R];]_]:IM7/SBZV#I<?NY??S^FZ[''7/O[*=,]_6F%=YA#VHP>XK"XP0>
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MB^ H]>IJQ-(&Q^WG=' _&20D=8+S)&8+C?.FD)/I$B  )-0]9R1")Q3&+#0
M*/0AO$  )/1##V /_USC!B04 5@, 3XT15540A5 1"L-126T!F ,1@- 1J%.
M,$MDZN;SCTA2K'2S?U[OX-#20 F0JW+I#2QP70YS*7'PT!YB2/?3 82 MO02
M6):4@QZ4Y$CT0S>T-;;T0EWL2S74-3PT  9  3[41MEB ,!4Q6AT15=4 +I3
MTFA435NL3IT./N/3IW84C:[4>WXRF/@PI*"42".P!^; ^V8&W&"2C>"2_&IM
M( V50:#Q(>9(#3SS6?BR+\GQ[G"@3-O4-3XU1;L4Q4:52UL#!SY41&M 0@7
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MN(,Y.J 11X0;U"?C\6W,4D@QFDAWK;384DTJDWR)]>? $-&:.ML,$CZ(66T
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MG- I*)&Y9.*A'7JQ'K]Q )_WF3T9FKPQFB@53:C)G_U)_Q,WJ)Z5(YU6 0.
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M FH9]+[!;$O7_GR/<N=]?1@6= #P'8J0'_C@B4?_]N2;UW]__EUZ'GKI54^
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M!1B!:_&!+_!-PE11)'3.+_"!]7P-#[!0!XD?#=U0&QU2.XL)*%B!Q801">"
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M8),M2  !$( $P'F'< ,%2!,$8 Y^7_*D&  %@/?P'W]'N &/IW_KE_]SKW^
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MA:V]E>,G6PMG9PMQ+@X^_O\U'-O_3O[G&#A4&!P\*IE2;5Y?&"HNB\EH;?Y
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MG5]"Z&B%R8HTPD6I7P30CA*^&A71I7_&62S(X%=1.M31YSE;3+_ULL<#*]N
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M0I'?#2)M?"+M0)$.K9%.JY$N3Y%N1%'N0E&>!E'>/E$^H"B_UJB U:B@TP
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M4?/R4BAEE"DE7!+A5PU'G-1C5^"865T)@*1R(;8$UZ)WU-+=5N$Z0K!8ZWS
M]:PPU1K\5V\S%?=&7( ?=]4B.);:H5K.L0*WKHAFM2AE#0P=QQ"LA'2>U9/-
MUW*KUMT;0=0P\C54LUIZ,?0VK'-.[/(B*IVDJZP=FJ5%JZ55ZS^$-%*7-7KY
M8C!#LLAN&E.96WBY$,6#(35)+;ZJ36VSB.AN1$+F+3VS]=H011U(BZX_D%<5
MXJ/:$JD*]NAH\1W# -[D1/7!I^XVI3&WQH8@?H0TA(:KG+S@NF"$JDQ@C(&)
MA7;;?C*W9/L291A##GV)(E_1PRZ(T,U;HB&M-O)-;I"<MB2,L[4FW^=6X$9[
MPFU[FFA'I%:'MS)&!X28#:[#2Q@M3RN_2%2D1+16&I;<3KE:U)G7EMF'X&O8
M%?4#K=D7X[P2SN<_'^;#\9IWD[D!>S Z,^@+VV[08XCK:H*[?, 8P&#$.%5(
M33!B;!]"C516(UQ[^$:O5WFGGWWW,J0;W-?]D[DGJ@^!%ZX+@0OQ)S,&Q!&T
MQ(K!K]+<[:=8>H&[?Q&B[H<6KHIQ/=:)[X<1V0<_*]J&[T34P=KO#<;HF$ 8
M?L6 L<(QF0"?*WL<_N2M0XC1J?J\8]H()BM\?0<3?G2U/ ]F6K3A.0%YG(@*
MC >B?@P(=PX@F@S(![3&U@TW5 YY,0]:9O6C/_5'V0WA.A&=OF(@P/7$E,/A
MCV/(5_4.0$809A$;)KHD8)W#;9K#"Z1-:IN4IS%#8*W\E@ZBU+$A:LQ^/F.@
MP20\;UYW\O-09.=(H--@(-EH6 !1RAB&MA/0Y"TOWHE(&7-"0FT$S6Z$;+4(
M2@KNB$'LV1U'"  V8 RF/O?(!1#Q^'4(^1$-=PXF.QD$G$W2L<$!N09K.R!Y
MF%TIPA-1EVV+_D0#G7UAL8B.9,.E:N,]LQ-.F)/]:I AM2R3@(:6C=HO 3V^
M)B,5#GD^G=,2<6W+ 9!MM0:+2?AJMFEOWT&$R\G$JOXY,:I&J=$G->#1!N+!
M&X8)&_AO7->I6I,/<XL^V_3Y9CLZW"R)"011/:LA=L:KK:-7;7(N=@*U;((4
M1C1 GI5%$0]<BAM,-9SJBIWS"P!R9 ,QH8-);[,F,AA0Q[8(IPD52!OV1L$X
M9H[)9+N^,?"_*.II!!$UG3"9ZC2;&CI^PVB3&D6O'=[J^,4'#5$Q'G)4@^BR
M@W^K3GB5MS7Y=S Z ^6GAC_%+W*SS)EM+*Y-C#<R]_[!S('Z]YR_8;AT#:$Z
M-R7TP9M=C=U/='I=M 8Z!SEFAU1.=):S-0AOCG=4]G6Z$6F332!>CBIDK\V1
M%9*QP9'U]C&IKK:5SPXS8YA?S;BDE.J)]V1?SM2:0HC%P(UP_9&WX\]9$Z]9
M!>]O&-W!&#5P_;QN<P%D"SZ&W<M3*P@WC>&;,SZPK5FE*[E3PR$$K-YF\%Q;
MVT+/UFPL]M#8%B4?Z58L]U:C<D<2I.7<<:YNHO-<== 'O/S2LA:_.M.ZBP[N
MQ<@,&!WLZJ9FAW/#7"S-ZL<. MYC;N]!6_LVMV+G$%U-&QJ=(>V0@47VI5CJ
M-9[ PB;P[GQL#R;'[-;[? _72NU6K[5XSRK&[C/C+J%/7@<61M\I>GOPPO'&
M7I@S463E=E3;?(3P=J3%),ZG'H*@O3[1+JQ.HM&KQ:GL_P!<://%H-SL-.M8
M958;B)(^Q.K>&O0=E!?KX#(#UK!W"27\$G$):3C#:$I" ^^B->UB! 3T; <<
M]<QN&?TC^=BYXF6XO@:;6I%&S8ISL>?L6/+;&HGM&SC]V'9\L;,+_H^B_O.W
MQK[WDQ3F4Y.)75'U0\6XM1>G^K<WC.8;-)]N1%:L%H2;^0Y(J606\/"=F'6C
M72/HN-M_L6+CM/^3?RQM)T+P[J/X:039?K_P?H#C.E[5F0C;1:,$E(BL/]7^
M.)IB*5UCCY+BY*_@"3X3' T<1M\H&@T7E&>R>QNSM2*^)[Q\,L!^5&\2HV5Z
MO\IT@6TVYRT(#'F^AJ.\B7KNX4(_\Q*&P#8NY'..;*OA4MESK-7Z:LC!%QK+
M7[/7E\T:?I/WE 0>E_R[>I8(VM<($<&*RS?'Z('K$L_K;:3"R#2>]WU>_PS[
M-2D="#QEZUMU/J3K/D7?:17](O=5I3?9[-#_<L]M8NBS1A;A^\"WJCNVZSL8
MV7W4[<TQ9(4GZ)+[]^3JZW%9]68%1^A ZTGE1Y(:L9;9BSY>N-.?]BM$N>.I
M<%WZGZ9XHJ\DOD#<8:>--X,X8I#PS?NMZ6WEW/^@6*GGR/H6,):I]>CK_Y_6
MZ<U .>2Y&<Z@M_?E79=?M)]#^EL1<?,6SD5[1DU)A -/R1/_\QU1<-!?+J6_
M7IS@"DY#2"U1:O# 1N!@\+^_7FM;O-=7RT&#OMD8Q[$;^NP8N=<#^9]);E3&
M$JB[A&N(/\%VJ#F#P#O! TPT0'\T5S%$(%5O(PQ&W-RV(#9YJ9ZS4',=6K7S
M(LE9W'BSGJOU\)!#S&/TEMYY,[#V7IO=0C!YID\^"4IZWX#-P5%+[4J%]F!2
M%/&'Y4D1U'^2R!JTR ]5;J,@T4&5.E!((!</0B+6/E1*H5?/D0-K'ZEDL)MV
MAQOB+$R"^)VW!\%?3S1RQ /]LHAU"GMC41C1?'1USK1+U#GG0\<KF=E#)*%F
M0YFZ%WK5IM+HH#V=2X-ZZUR]/^=:5-!O]7AL9-&RY[(1;BL4C1@_4_H*$?Z2
M!/P1X,0H)Y9],?7C*S<L[<Q3\,J\N&4OB5PP&\XRO+?)D!'^]8'<Z.$T49K[
M!UV%3K[\,-14LH@E^ 'FM-[DO/,;]?&/R[:*E4?W:^P**YF7K5J!26.U:?.'
M>XZW#?W>;V%M?KU'4EMWBH,5R+6_R;O/O#>/IG)[+HG?_1ZO)"%ZK.;E<,C[
M5[SO5V:PH'\O7CLH255O?!B_\Q<1-J^XC7H'E)H'2B U$DB(=#62&)R-FN*8
M@H>ULGE\<NK=!62J+OVO'QZXY/'U&\\D<;_)H;(C(-M-2V%;--;T8Y7[1\N1
M#2TDRU-';:++T23*N?,N:+R>#U,RRG$K,Y=>S@XQ8L?=U2/<NM^-KX22H<MP
M8B.EJO#.I,4P\*U\7V!XDA-QF\2U=FK0$)5OT-:XK5=S5 W+F[]719'VDYJ4
M@H60/6C(S_&Y:RE>!W@4"7T^BI]1Y!S2*15C#IR:KWX[7.3GX@[IF]5$GN+3
MI2;5;5JBIDUOG/A*?+^H:^SZSL)6QP#.'S2$%>'R:OZB9QT%JQPEK]:/#S89
M;AIX":R_Y\5_65MV2!<P5A/452F <ZSB,V"W;\RH0U=GY5MSS[;4,_Z9KG-O
MZCM7*"!HN#+T9=/W+S35.,QE3Y?Z4X N^BZQS:E%N;$?EEKPY;'#>7K8YVIL
M8VCDT$I'PNX%AY4W[I'@8>,Y?MOAPSZ]O79BX,+*=V#,80;P"#6EDBF8GH1I
MKX!C3!4^=(:F3"ZVH=_G**SY:XU5(7]0FWVEDK?(>0XL[Y/'68!TALC%1\&C
MB(@3 Z:*O1 .YG/\T$\N!BNA0QE8!E6O="L.)1:Z1K\+=Y9%KM/+ECNNIS43
MEGX71#YVN*T+'!E2D=G=^@E3N&)'(V8A4X$(^U!YRRY"@@BF'5^0M%\)^VM8
M_.PCW+GJ7?HV^#N]XI^\Q1\3>>#)-&H9AM];E;U/NG[N_$*1>-JQUJKU.<A7
MV5PZR1@Q?GP4@&)<?CM]/1(!^'W_&!4".(]%C-X@V1"%]^L%C\Q!6;9.23SM
M^.XV&8>E?9Y/2G^E'%S_FG0\^7N"ZOW/^H3T'DE("H' S1?*8XZ W]H;\59#
M/RN+J>M&E:4?<$TCA+'5X],$@H7=6%*=MR? &23%A@1?!$@JYXYX:J'I<<]&
M<.+E(?X]D20F28BL"[7X9%7&$O*0%]1[T?<:+B1'0W!KGA.F^E$70?KE)M3V
M>^PDR@1-;(C0(77,?<X:TET7[DLXM0+2 >;^7UF>95<"WC-$-<_68426.2]!
M3ZOM72)%8-&L554A+1R6(!8!$Y*):GZ!5)40P97S+77(PQKG"TT7$7\BJU-X
M$3Q]2 PI$94Q^P1MH0-0&<Z2!C>+SG03Z:>@9C]SV ?I BFB-%"(01*S$=\2
M.Y*5_,Q953(%X/#.*3A&A:HW6>S-FCF93]$"@(GF,HI$FJ2IEK/*;>539#5I
MX]UU*P=+8*L=-#E&0I3_C!X>YA*[S/!#/BG%/$44I$;#RRNKYM6.@78MAT#*
ME:_FT]P@7T!VQ)E'K/CK?1\_%3&6M8U/HNZ&)IPF''2,>BXP#C]E>/G]JUFF
MW+3[I^\%'QM+]:DRM8S[%@IOLTX4=\;F4/8]TEX]K23QV[",$=3A- =G#OUN
MNK!L/(H7/<J<MVN_YCPNEDHB.VA&B"QF#_?AJ 'T2&7#M<C.)PI(?5F4&^JU
MRLU4BBBM97EJ1.8K<@;!3S+E.+KGBG35*9P0*X T2D&P- E=TL(9^72]58_Q
M<F39SR%'LS 'U!\T6.R_Y$N%\U7FBH=+*PWRSRTN&G63QU-S8'&F)9:4#R-+
MR+RI$);D@2!I&5>6XJ2_+RN'#'LJ9UR)8::7 #/=#J/\Z?R:(/(JY8(7*G&
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MN8?":$]D@@EY7XJ19G7 _<F88M$+*LX#S>=O,]CI2O"Z^ A;JEK:'&/VU2<
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M&?2=!D P=)4F3^!82SU,1#$N1!O/O^Z3_W/_K/5 [Q"\,L=N53X4XD^&+#R
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M^4BH1]6O$Z^+@0:39[AC-V/%Q+JCS;IPDZ:MW_JAR\JN2]<X!YGV[7"Q^SA
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ML7KWFMO!FU8=&[9!U*5E7T\/8/UZHJO#;[^-NWE]^\OC;\Z^?SCD^1GO"U#
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ML6-I\#IG=3<*52"ZDS!RP?PX8"M [R;=,D56Y4IKLT?R4CYY-A9]EF@':5Z
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M,,YJ>5EX_[_1LJ^I>%(3)SIV;M'G1*$^E^KY 8CY04$+P %U?V].^V-7'BX
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M2Y@OW\RD6=/F39PY=>ZL^?)AR) #@0XE6M1HPAD"8BYEVM1I2YY1I4[="5/
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MJR=LLI);X+ UMU74W;\)OSO(R2UUPA6.: _>&]^/]C?S^(U+;9\8K>6M>.8
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M-7*_^4N_YG.Y FP_ !3 ^FM 8KH_8[J*8\DPK*I "V265_ J#:R.4^$ 9+E
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M-?SWWN9VI4H(IAQK4]$D&BHU- D]Z.VFB=Q6]+#E'7:'J_6!V_E\[+G>[Z&
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MYI3?VU<K:?ZP5L&YWJ6^[G5MY5,'62^>LZ:!;H3-6D7$]X97;,366<7W=D8
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MJ&X3U%'-KI-L^X+?8NSC%TMA)-9TD$Q+Z&@GI^TZW[F$H\4ND8;^(7LMI7$
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M@GB5V]BOWD^BP-[U11AY52YY8O7B9UP6I"3//3)+Q@*S3Z>U+T]NB>CGI;I
M<U?F1_,Q[ YXM@115?L2DPP^NT"3E6$]TW22.9QTI6L/W+> <8U3+_(?>!T;
M5AG4(BBF;4];$-XR+0;S]"0839MM>-W%C=C>9K]SK*BQC^O<-%/R(M,HJVX#
M!2R-PO35DK:.C^\<%=&IM0D;;9FGG2241R.8Q0Y(AW\9JF\,B!>X3V<QSF=;
M!MFO2EFZD^/.^^.NNJNOJ+*., 3;O<8E!WY+#?_&+?&T#$^BW?HW1;EQ3?R%
M#WF/(GT!NH]'9XE%SA(BT[&1>MD,.GA."+P?6'@RO<V[V80CYYZI5[2Z-%&2
M4NHI&/)_P+5-4ABTNU-DCT;ZQNYG@\E1J@5_?P3DQI).X/_8M_]8R)(M<+O>
M*[T;6%!75*/LWW2M/:.5?DC0%YJ*%8/C9U'^<7\I%'2Q>N%MFL*;R+Q?<N)4
MCQ]S<J*)"V;71G+X(VW.>SH0^'23]-2P&O;YYMPM\_8GI:5VH9-!O]-%.,N^
MDS ;/8P)]*(/Z4_^H?./3>I FPM5C3Q'*-_^MC1Q?\ -Y>>2JB>ZU4QWW*9/
MKLYRT4,IMU$P;M8R%[A8/=8I]*L*A)>[;C")OZ\6 F_8>S4^2T,-._M5XW1?
MU8+"KM4W;VVR374]O.4S=DW^M'^SM6KY@_#GD:9=N;C<J6.W/?KN+57.6W[P
M]N\-#92\#/+-7!#2#__M24?#U911F0WS8\@L0D9.G3^06>.GC99$>U2%4(P7
M(-_=6.I6XT.--@V " ?S?V=M4\W^-VN;EUU:5@ZC4H4%9V571PR'5]?<8ML
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M$K?[]9]R_BAMS;E<6?OBY3K&+*,PG*#NEOEN?= !*^YE:EOYMXY'A:1$J&6
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M#PUC/-/TDNCLBC-N)VN_6O/LCG/8'JK%OK/23Y;BBAF%<='FEO=2F"L0JN8
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M"Q\.-^X\Q%,.,M>^B^VUC_SZFW.@1K[9NY"$;<$Y^, NCSZ]._F_FKC+IC@
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MLY"/RDA:(%IZ6]YWK6XV>:(68'XD$<D.FQDP8/>;B N RIKJ.UCM#VJ<,U;
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M*9$A%)ZAD*/&0"4"#V1@<!9^4)6\SSD>MT1QJ/@ASNNA0W@MDK!42(%)2%D
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M2RT7>1V/:!V??AW'*<()*$/-"9YMJD[BI4Z*O%Y&M/Z+?KUD6:UB1KUJ-8+
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M.H#J?QIU*';J.1$(!R?Z?P!02P,$%     @ U86!6E,\3)OV;   BVT  !L
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M(=X44;C\&!\E^'6UYNR(3Y&<#QZ;BV4E_50H5V&$&?Y] GU_2E>!=HW7I>R
MF''\N.7+G.9'4)\EDB1;75+C31+NYR+6, 5E'+T(9PU7PW ;ID%E2G[#!KID
M3L'5)N6JFFA(\ PC]T"7T5:M^P1RL<B;[H1+^CQ5!"4-%:_","&J?,"R:Y%$
MK>>X\FQDS&JBI=1[HFDY(O1,YC[Z2](O*MY#=YGH*C:B@)5)R[-?:9UDM$F:
MMF+NM[<_EP8H![O09FS[7/QG[K/Y+A74G9;JDX JI8K#O3TH3#595Q4[E]FI
MM)JR/XI1!%>5RCT_FM#9&9UE%OWK(Y'M^Z;LCY!D*ZLSME#LQ<">,V%\Y<&B
M@O\O,;\8;FE=@.766.F8" ;A6VQ\%V)DTDZ"V%S@5G:=+32U+9)W6NPNXISU
M%0J=R3"\'?V#K2TZ_^.+XD0L-1G59ZK/=OO%-,%NL_*R-"36Q&]05/)RNU8M
M]!)5?FB^GEZA*#OI[I+]4&C&;'',T"\T42S7>&'^[6EEJ4U;3 8;C<.(=_U[
MK4RJBV2AI;E2WO++0W,/=I5SF-+&'OECRXA*E4O*^,:1V&/K3%25:XG2YIG^
M8]O*9)5[\_CFE==C^PYVM<>PTM9M^F/'B4JUU_+XUD/;8^=-5+7WL=+VR]IC
MU]-DM>_C^/:_E\=N $Z-/YKR#B+%4P^Z:DT@R<0.JOA3+UYT#3R817D7:/#4
M1SI5$RH\L8L#?NJGQ:F%R"GO$60\#;"JUH;K3.P1MS\-\D371EHK[Y.O/PV)
M3-5&@R;VJ5^?AJ5QZF+#E _H*9Y'Y%7KXE,F#IC%GT?5H^L22Y0/V0V>QW2G
MZI*;)PZYP<_CICCUJ</*1WP9SQ,VJO7IRQ-'0NW/D\Y5N$YT[_P! \]3PUEW
M%F>1QU*8*>:E@Y4R9Q/6LH1K^,&AR'GO+H]E33@S,[$K-8@[;3ZKKTU%P03R
MWT?9RH')]5(:XYP:]!CSG=-G@W=<BP4=3CXA 1;C;P(JK%7.]==?EEJF&JM
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M/O&A?,,;9T60T *^;Y A1@TUXND8PQ9$QR'A&P[5*:2T/FK^E+U3'5Q(FU.
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M PA,(WE:<R?C[(.>DU 9'#-M_ =$DU]/LRKE"H3W90N1@)SD1!1>- >G>:4
M!P):!T1IAR5F:U5U!R)3WT^L@&I2S.WO#+M+B3AM!91!83HV@-_/JC[':4:?
M)$S&]'3%BI-<<?A>6'E/,,CTR23%:*B A;"97[1R*&\/3C \%!@)9*$4%STL
MG$,QW)(<]N_9PE./A2'1R8 \9X@59C6&):JOJ6U'L*.7;6NG4.3)\@$(+_G&
M#CA?3M]M*K$/=>$K32'4A]$OR!TII/#=VAWQP#@>8&K\I;8,Y5:NI67)I8GA
MOI*/OVA;\ZU."&1+<N,4R]Q[<V _88EZ:;4]#"TS7\;W]-@.RH(/*_P2,GZT
M9MS/9!P<NX4^(S=K!W_7\:*2JQ#TRLO^7M84G^XT6I$OS:;\5>8/7P6"1NF\
M8GG&;/%!0'FZ%_ #Q"77*P'E)?O5U .NB()[9G_D534*3<'$5#\C3[X@!S(C
M*TE#I>^7K1;**)[&J)S$*J=&/"=_>[(ON^V05Y7:U=RF4P]Y50@!?7+<ZY+(
M:L7853F#HSSI:J5=:[]:EMOE5[^6 2_8O"OQX"@$TJ&7>C5[>=[&GF48$34G
M8XKO,RK&THE616J%,%5B!6!B]B04$514Y[6SIX5[:)B:>([8Z;[4UFEL!E5J
MF(T.[6HGP/I MOI_]W0)6GS6Z7&)91(&!B1&Y912K_5CK(!_QU@8+\"P$=S=
MXNB^L08GS&9L>QB,O?$KIL>M?,#T2P*Q <<#8OD"2<B2OD5 1KF9/9 F%7?O
M!<@H3P=SKLE<:JA^;3$.%UAYJC%2:.;GT UN:%I]^2+QN=J'@L1OG<)D'..H
M-$CB1%/* Y@[YF!]#E31KXLZE^,ZKZOCR/BIU)H4 6Q9KUIK:)]]D>T^S^DU
M4)4 ,Q6\UAN(E&CMP$.*8PO%4X&^L,X:Z5"YDJ9HBM9XS/;(E,XF<.)F1/UQ
M0BM1N[ 88YP:.MLA6..X'"ORI2=['&/0ON,>LP;E.,R?M2R M+N8%N4#>M4E
M! BEB.ZP[WS)Z)X=J6&[J%G/:&#R;GR"M:KO!LZ4N3UX56-G8N%U]"<'5 YK
M]FJ9AD\&A-^UTU\M5 ^2])7LA(L\]!UI=]Z@#>*0-IZE6PB1]?"?!^=00(DC
M>O0-0^SM2O,H<%W.P=D>0S8;2/FI=>^4>_^SF"\"(E>;8-/.#B6Y Q\SVZIW
MVK!9!K]Z=VI^&2PJQYV'$FD""I#;"/8^U^NN#PK^'01S5(I(#'5@#"2-PX>3
M9H8<.SR/(-&1%%ZTZ4ZH8</7D(;*\P$_[[Z%\6XLD5:>T>_5J-;@%_#02?:;
M:;0;9PU:^-C-RZ!%8G.E713@6_.]OJ)H))8597*J,L8I9M/.<KDP&P.D@V8\
M,KAB8VPY,C10.7?&-'<C(A<)' X/'TP8'1'X.U)[-NB8VMZ#1="OQ ZW3UBD
MQ$CO&)WV3KSCC%BMF/2/S.2@9)LB'4MT!S+HYS<D>R/9-"0K3QW^P%1:",;\
MVW_#/G$>,,;V>^ITK4]>M&+R8@*&.9F0-(VY.OWO;]J<1U\G6^%GNT*,L$+%
ML<*IFT)+^Q875)1>M#*LS9E4CE%^[Q[C0NEA;SC6Z$82/9<(U:9P,F6A%C#R
M2U;":\4THPJ,%7O 1=$=_5L)(*RD,K=D/-T)L%RHU!G.%]X::R<$I!PB")S]
M%#6MK3]-1CC-N[J@_KS 4#F&?3H&SFS2IB*?4J^1=%9#17,PRYHG]*:0*W+#
M9L;EM\&QRUH88U^&.B]05\X6 U:A9(N:;].L/^;0"\J-.Y<ITYQ>8R,#51J)
M)2?:9F$8$_PVF^\>2'"CL)<I;%=#=Y:<5%9+.E;-QMPSL[3_1;08/;K]W:F<
MHNT,65XNKAQ1:-"S]!$O40&'?C%;.B9.Q$J--DIKN!224N98KDR?OO3U[?#:
MW82L7P#?]#'/1.MX*^'C+]*%F)M35',;3'^H&^6H9B4W7[]N:LUN.BG\%_:V
M&*UN&\7LJVRE7C9\?:O->L2BS_":C@4,3>(JO*R.JG#A9\8<F=I$Y_K\LO84
M'L:SYYHV>=X&4.^L.F2B1>^D=XYU1WE\Y"B[-6@8MAEKORC,^=&*Y,CS:4D/
MOW,W+XGX7?(W*F["]133<A2$OY43B*8(O44&*KS(LHX&\MSK/:T'&KZ'&VZ(
MZ*&'AE/&"$N'IEU&:$.B%8*'9O:1PM% *W'_OW@H'TX \W\G\? ,N<A[UWYI
M2AH;7[D;-QWONX+,S!R/=C1&U(%%SK)]RCB&LC.$LGA'-4PGS(Z'T5*GO47P
M0TO5TU1C0Y/LTTP<0XLJ$:NI[;='OSJ>OB)J;PG3L0:>XQXKB9[SUO^OB;ML
M:@, L#5,@=+@[E"TN)7BM%!*!;<*#@5*<7<M3@@)+@&">W"7X$YPE^#NT.*:
MW;M[=V?_POOMS)QY/ 6BR0MW(TBUO^#L$9-N5&  ZY82OI( *6-V'J_"V8]P
MX\H*%-6F)66BGQ.MN!Y/\S]-%.@',?DMK__&(#5:#[U5[U7I$ ,C:YY,^SC<
MJ*_7\;,/)5[F#"N'G7INVO=U*O-V]F?(&=. KOQ/A3:P+7W[KO-0M?@%:/])
M7O\6AJ7@V;Z6BK66%YYY(/S5GSU-CA)M!$F[$YJ'\C(G[XUL*](!52/4)R.L
M_&2^:P>_W0FJ>>[:,!W_W2!PV=6&I?F*GHQ$@-75L,#2O8:VK.,V.5N,,WN\
M\WLT9/QW/V'[47:/$%RUBDB>\,;.AV9U]V44A5P9Z^ 3WE&4G5:''0^/.]C'
MO9#D.<Z:BRK?J5X3A2!3T6NF-V]6CYI-S@_2H^IB.O=4G].7[C M,9G/>2VL
MS'Q$GU6QKYJF7BC)+BLD?1/Q\,(+/,G67D(\Y&G^P,\2/[*2:7U?L[R%)! Q
M/K<>.]I.Q_LPS/#Q8>W+ X&B@;OK,(/XZ5E"%6+X6)PZ ]^%TD/^Z0?]'P!C
M-&7^XT@[C_NKH4MGXSQ^S>ESM?+D=MKN3%I;-)XC+&=>;'W#M]_\FKVP_;KX
M3P/7_&+9Z5V=@$L^#FZHPTFX[&5YP&7Q^[##+_B.:H77%VBGQ8)_CA%!_,:W
MO0X/*0Y)::MX7\<'7T&CRIB?8XZPBKZT"6!FEE"0&) /A0('V !K_^=L6]PT
M&"&I<+O K<OU4Y$'9$U+LM:(7+S#VP=)2NLB]N/3FA&\GD4 !CZ57BX=ED^O
MOK-8!JB(;FO,,YC'"(F"55]IIB*W'A]'>&7^^VM;WE:.N_%$Q"0HJV[LP#26
M4=&N[G^*)AY_V1Z(C:^%!Q3*EM7 ]#>79]]CH>2BR):(![[6?QW,(/T/3Q0^
M(:'%KNB=0&E#R:?-I]\7Y\H;AU1K\H4=;?%N=N,'$]B2)S"#<KBI"0#-S,]3
M,;*ER.U0SXF6T"/%WTKT6IN5LV?+3BN]'_$B2N9#?@X9,49>,<F'$[.)^>%[
MQ"K4N,X$@EVOS0;C?EA@0K>%*XWU!35!<-UKS='&CBQVYFULMK&7X,P<$(_H
MZ^9:V+[5DT%EC:5OEO(A/80N9'_F0"O:*&V"?W.!6+RZ[=A*P&B9[7IG^V;R
M]&=7*'>O@9=.\DYO3>X#Q4_7F.#(;AB@2 A5S36\XGCNO+R N#E=DXR6%82W
M>%T<O2Y6QZ=G^[1X4;5@?_K8P/:XTWA)^81T$B*T8 C$- V:=R8TZ0G&)I*A
MH15]_ZE 17V.0!XB^O6".5 ]UCR/D7/)+=R8XQ3RW104!P/F@ 0PT1TY.H)P
M&C;MOS/A9@;7(S<I#C)D04S*?ZI8\WAPB*BG @$\R30N"S$4"V9SS\R6-><_
M8H5JA2A@Y/QA=>[?E!/EH?@=86;]G</?(BZ%P]LF3C0B7G)TD-G!+NC2+.,5
MWN>U@%Y<+AT>7+&F-7F-&(I>\F"-<(!Z];/N 1:PQ%D/A3I-+Y48B[4P*[F'
MS+_?[S,SJ.%%N2!MGO>%WLEP/2<J)8O2NH4FZ^]>3T4YRJD8BX7E0<*ZR; N
M%4W-JAX"5I77F(!<KN1O-,\_L8(X B8*H*[-UB77TZ"T>I3S4&H#9J!-:N/E
M$I=-<^>1PLFWAKL;T\R?A'1\I8[<0UR440)H?# %#HWC>NXWP%MP73)8IZ3I
MO%:_O.N?D$%J-[%\:4I/7FA"<3-=C;)3_]?!>\I65]R2KQ3!"HXLK-_Q'.6$
M=#A8%9!:[[7+DN=8866])YXPZ*CA7Y7D,6DLPZ1Q>&MJ5=^^LXKKU'W 4>+
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M9>-(Z?+S)(M6+#V[0D-ZU,:L._LCQ"2 7% LN]R\,]C=T58HF*1_1'^02<L
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M1BV70-8#FK99#Q8O'[=-Y3:QU>I_M8T%&"TF0$BL!79ERK:1AINT+_=-_:%
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MY5S1\.O=M;MQ _N?:^_VZWMZ (;T?P!02P,$%     @ U86!6DOZO8!5*@
MLBH  !    !P<F]X>6-A<F0P,#$N:G!GC7=E4-S!M^6/P9U!$F1P]V#!W5T&
MEQ!<@KM;<'?7P3VX)A#<"1X\0 9W2P(!-O^WNV_WXSM=_>6>JMO=U:?N/??E
M^\L/ $])3E$.0  !@.6_!;R< F 93XL/O@ "@ 0 _Q4Z!W D+9W-K0#+_G\1
MA)=U(!Q ^)\#]/^ ^-_XO]Q_T0C_/_,_Q$L_ $8#V($'1 0P  (C(((17H:
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M8B14-H]I^*O'08ZS@PE5HX1J-S%)C@6,#V;5'26U"U2_S/P(9?Y<'29],_I
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M1CS7S;;FV<]_:*!.,:MV\B^ QEW_A[\R1 Z]$?N?WOZ1QPC'LA+F$HMSLHO
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M+S8+#)'MV^QS1@&/&(]LT(;#HHDSX?)E$1Q?LDB\7ER&;[JV&,;NV06K/\5
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MS5D04MVR,'F.Z R3D1F*M?78:9B\R4(-2[ED-_-KPSBV.NEFAE0K' :A*#P
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MYT*>_(/77!<6=(;B+ZO_"U!+ P04    " #5A8%:(5^MW$<!  #> 0  $
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M-6EM9S P,BYG:6902P$"% ,4    " #5A8%:Q--/ O-*  #_4   &P
M        @ &@4@, 87)T+61E9C$T85\P-3$S,C5I;6<P,#,N9VEF4$L! A0#
M%     @ U86!6K@& %G/D@  \9,  !L              ( !S)T# &%R="UD
M968Q-&%?,#4Q,S(U:6UG,# T+F=I9E!+ 0(4 Q0    ( -6%@5H=N'*67HH
M /**   ;              "  =0P! !A<G0M9&5F,31A7S U,3,R-6EM9S P
M-2YG:6902P$"% ,4    " #5A8%:N%GI+()U  #D=0  &P
M@ %KNP0 87)T+61E9C$T85\P-3$S,C5I;6<P,#8N9VEF4$L! A0#%     @
MU86!6E,\3)OV;   BVT  !L              ( !)C$% &%R="UD968Q-&%?
M,#4Q,S(U:6UG,# W+F=I9E!+ 0(4 Q0    ( -6%@5I+^KV 52H  +(J   0
M              "  56>!0!P<F]X>6-A<F0P,#$N:G!G4$L! A0#%     @
MU86!6B%?K=Q' 0  W@$  !               ( !V,@% '!R;WAY8V%R9# P
;,BYJ<&=02P4&      X #@#& P  3<H%

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>art-def14a_051325_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:aort="http://Artivion.com/20241231"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="aort-20241231.xsd" xlink:type="simple"/>
    <context id="From2024-01-01to2024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000784199</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000784199</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000784199</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000784199</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000784199</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000784199</identifier>
            <segment>
                <xbrldi:typedMember dimension="ecd:MeasureAxis">
                    <ecd:MeasureAxis.domain>1</ecd:MeasureAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_ecd_PeoMember_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000784199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:EqtyAwrdsInSummryCompstnTblForAplblYrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_ecd_PeoMember_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000784199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_ecd_PeoMember_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000784199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_ecd_PeoMember_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000784199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_ecd_PeoMember_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000784199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:EqtyAwrdsInSummryCompstnTblForAplblYrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_ecd_PeoMember_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000784199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_ecd_PeoMember_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000784199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_ecd_PeoMember_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000784199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_ecd_PeoMember_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000784199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:EqtyAwrdsInSummryCompstnTblForAplblYrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_ecd_PeoMember_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000784199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_ecd_PeoMember_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000784199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_ecd_PeoMember_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000784199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_ecd_PeoMember_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000784199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:EqtyAwrdsInSummryCompstnTblForAplblYrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_ecd_PeoMember_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000784199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_ecd_PeoMember_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000784199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_ecd_PeoMember_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000784199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_ecd_PeoMember_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000784199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:EqtyAwrdsInSummryCompstnTblForAplblYrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_ecd_PeoMember_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000784199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_ecd_PeoMember_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000784199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_ecd_PeoMember_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000784199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_ecd_NonPeoNeoMember_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000784199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:EqtyAwrdsInSummryCompstnTblForAplblYrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_ecd_NonPeoNeoMember_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000784199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_ecd_NonPeoNeoMember_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000784199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_ecd_NonPeoNeoMember_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000784199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_ecd_NonPeoNeoMember_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000784199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:EqtyAwrdsInSummryCompstnTblForAplblYrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_ecd_NonPeoNeoMember_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000784199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_ecd_NonPeoNeoMember_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000784199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_ecd_NonPeoNeoMember_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000784199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_ecd_NonPeoNeoMember_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000784199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:EqtyAwrdsInSummryCompstnTblForAplblYrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_ecd_NonPeoNeoMember_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000784199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_ecd_NonPeoNeoMember_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000784199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_ecd_NonPeoNeoMember_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000784199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_ecd_NonPeoNeoMember_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000784199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:EqtyAwrdsInSummryCompstnTblForAplblYrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_ecd_NonPeoNeoMember_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000784199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_ecd_NonPeoNeoMember_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000784199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_ecd_NonPeoNeoMember_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000784199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_ecd_NonPeoNeoMember_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000784199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:EqtyAwrdsInSummryCompstnTblForAplblYrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_ecd_NonPeoNeoMember_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000784199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_ecd_NonPeoNeoMember_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000784199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_ecd_NonPeoNeoMember_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000784199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000784199</identifier>
            <segment>
                <xbrldi:typedMember dimension="ecd:MeasureAxis">
                    <ecd:MeasureAxis.domain>2</ecd:MeasureAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_YearEnd2023Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000784199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">aort:YearEnd2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_YearEnd2023Member_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000784199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">aort:YearEnd2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_YearEnd2023Member_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000784199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">aort:YearEnd2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_YearEnd2023Member_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000784199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">aort:YearEnd2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_YearEnd2023Member_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000784199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">aort:YearEnd2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_YearEnd2023Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000784199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">aort:YearEnd2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_Vesting2024Member_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000784199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">aort:Vesting2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_Vesting2024Member_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000784199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">aort:Vesting2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_Vesting2024Member_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000784199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">aort:Vesting2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_Vesting2024Member_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000784199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">aort:Vesting2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_Vesting2024Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000784199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">aort:Vesting2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_YearEnd2024Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000784199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">aort:YearEnd2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_YearEnd2024Member_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000784199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">aort:YearEnd2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_YearEnd2024Member_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000784199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">aort:YearEnd2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_YearEnd2024Member_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000784199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">aort:YearEnd2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_YearEnd2024Member_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000784199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">aort:YearEnd2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_YearEnd2024Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000784199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">aort:YearEnd2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Ratio">
        <measure>pure</measure>
    </unit>
    <dei:AmendmentFlag contextRef="From2024-01-01to2024-12-31" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="From2024-01-01to2024-12-31" id="Fact000004">0000784199</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0010">DEF 14A</dei:DocumentType>
    <dei:EntityRegistrantName contextRef="From2024-01-01to2024-12-31" id="Fact000011">ARTIVION, INC.</dei:EntityRegistrantName>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag contextRef="From2024-01-01to2024-12-31" id="Fact000012">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
    <ecd:AwardTmgMnpiDiscTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000015">&lt;p id="xdx_806_eecd--AwardTmgMnpiDiscTextBlock_dU_gL1ATMDTB-ZZI_zpIAA6jihWK3" style="font: italic 11pt/normal Arial, sans-serif; margin: 4pt 0pt 8pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"&gt;&lt;span style="text-transform: none; font-style: italic"&gt;&lt;b&gt;&lt;i&gt;Equity Grant Policies and Practices&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
				&lt;p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"&gt;&lt;span style="text-transform: none; line-height: 12pt"&gt;The Committee generally adheres to a policy that the Company will not make equity grants during regular quarterly financial blackout periods and until two full trading days after the conclusion of such blackout period. We do not grant equity awards in anticipation of the release of material nonpublic information that is likely to result in changes to the price &lt;/span&gt;&lt;span style="text-transform: none; line-height: 12pt"&gt;of our&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: justify"&gt;&lt;span style="text-transform: none; line-height: 12pt"&gt;common stock, nor do we time the disclosure of material nonpublic information for the purpose of affecting the value of executive compensation. In the event of a special blackout period outside the regular quarterly financial blackout period, we consider the extent and nature of both the special blackout period and the equity grant(s) at issue. Unless the Committee determines otherwise, equity grant(s) may be made during special blackout periods outside the regular quarterly financial blackout period, depending upon the extent and nature of both the special blackout period and the equity grant(s) &lt;/span&gt;&lt;span style="text-transform: none; line-height: 12pt"&gt;at issue.&lt;/span&gt;&lt;/p&gt;</ecd:AwardTmgMnpiDiscTextBlock>
    <ecd:PvpTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000018">&lt;p id="xdx_803_eecd--PvpTableTextBlock_dU_gL1PTTB-LPZPJ_z3K4kbMuhbdd" style="border-bottom: #7f7f7f 1pt solid; font: 12pt/normal Arial, sans-serif; margin: 0pt 0pt 15pt; text-transform: none; color: #2b4b74; text-indent: 0pt; text-align: left"&gt;&lt;span style="text-transform: none"&gt;&lt;b&gt;Pay Versus Performance Disclosure&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
				&lt;p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"&gt;&lt;span style="text-transform: none; line-height: 12pt"&gt;This section provides disclosure about the relationship between executive compensation actually paid to our principal executive officer (&#x201c;PEO&#x201d;) and Non-PEO Named Executive Officers (NEOs) and certain financial performance measures of the Company for the fiscal years listed below. This disclosure has been prepared in accordance with Item 402(v) of Regulation S-K under the Securities Exchange Act of 1934 (the &#x201c;Pay Versus Performance Rules&#x201d;) and does not necessarily reflect how the Compensation Committee evaluates &lt;/span&gt;&lt;span style="text-transform: none; line-height: 12pt"&gt;compensation decisions.&lt;/span&gt;&lt;/p&gt;
				&lt;div style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-align: left"&gt;
					&lt;table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 10pt; border-collapse: collapse"&gt;
						&lt;tr style="margin: 0; height: 0"&gt;
							&lt;td style="border-width: 0; margin: 0; padding: 0; width: 48.75pt"&gt;


							&lt;/td&gt;
							&lt;td style="border-width: 0; margin: 0; padding: 0; width: 92.5pt"&gt;


							&lt;/td&gt;
							&lt;td style="border-width: 0; margin: 0; padding: 0; width: 92.5pt"&gt;


							&lt;/td&gt;
							&lt;td style="border-width: 0; margin: 0; padding: 0; width: 95pt"&gt;


							&lt;/td&gt;
							&lt;td style="border-width: 0; margin: 0; padding: 0; width: 95pt"&gt;


							&lt;/td&gt;
							&lt;td style="border-width: 0; margin: 0; padding: 0; width: 75pt"&gt;


							&lt;/td&gt;
							&lt;td style="border-width: 0; margin: 0; padding: 0; width: 75pt"&gt;


							&lt;/td&gt;
							&lt;td style="border-width: 0; margin: 0; padding: 0; width: 47.5pt"&gt;


							&lt;/td&gt;
							&lt;td style="border-width: 0; margin: 0; padding: 0; width: 53.75pt"&gt;


							&lt;/td&gt;

						&lt;/tr&gt;
						&lt;tr style="min-height: 24pt"&gt;
							&lt;td rowspan="2" style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;b&gt;Year&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td rowspan="2" style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;b&gt;Summary &lt;br/&gt;Compensation &lt;br/&gt;Table Total &lt;br/&gt;for PEO&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td rowspan="2" style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;b&gt;Compensation &lt;br/&gt;Actually Paid &lt;br/&gt;to PEO&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td rowspan="2" style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;b&gt;Average&lt;br/&gt;Summary &lt;br/&gt;Compensation &lt;br/&gt;Table Total for &lt;br/&gt;non-PEO NEOs&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td rowspan="2" style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;b&gt;Average&lt;br/&gt;Compensation&lt;br/&gt;Actually Paid to &lt;br/&gt;non-PEO NEOs&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td colspan="2" style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;b&gt;Value of initial fixed $100 Investment based on:&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td rowspan="2" style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;b&gt;Net &lt;br/&gt;Income/&lt;br/&gt;(Loss) &lt;br/&gt;($mm)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td rowspan="2" style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;b&gt;AORT&lt;br/&gt;Revenue&lt;br/&gt;Growth&lt;br/&gt;($mm)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;

						&lt;/tr&gt;
						&lt;tr style="min-height: 36pt"&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;b&gt;AORT Total Shareholder Return&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;b&gt;Index Total Shareholder Return&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;

						&lt;/tr&gt;
						&lt;tr style="min-height: 13.2pt"&gt;
							&lt;td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="margin: 0pt 0pt 0; text-transform: none; font-size: 11.2pt; line-height: 11.2pt"&gt;&#x200b;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;sup style="text-transform: none; font-size: 6pt; line-height: 6pt"&gt;&lt;b&gt;(a)&lt;/b&gt;&lt;/sup&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;sup style="text-transform: none; font-size: 6pt; line-height: 6pt"&gt;&lt;b&gt;(a)&lt;/b&gt;&lt;/sup&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;sup style="text-transform: none; font-size: 6pt; line-height: 6pt"&gt;&lt;b&gt;(b)&lt;/b&gt;&lt;/sup&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;sup style="text-transform: none; font-size: 6pt; line-height: 6pt"&gt;&lt;b&gt;(b)&lt;/b&gt;&lt;/sup&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;sup style="text-transform: none; font-size: 6pt; line-height: 6pt"&gt;&lt;b&gt; (c) &lt;/b&gt;&lt;/sup&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;sup style="text-transform: none; font-size: 6pt; line-height: 6pt"&gt;&lt;b&gt; (c) &lt;/b&gt;&lt;/sup&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="margin: 0pt 0pt 0; text-transform: none; font-size: 11.2pt; line-height: 11.2pt"&gt;&#x200b;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;sup style="text-transform: none; font-size: 6pt; line-height: 6pt"&gt;&lt;b&gt;(d)&lt;/b&gt;&lt;/sup&gt;&lt;/p&gt;

							&lt;/td&gt;

						&lt;/tr&gt;
						&lt;tr style="min-height: 3pt"&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"&gt;&lt;span style="text-transform: none"&gt;2024&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_980_eecd--PeoTotalCompAmt_c20240101__20241231_fKGEp_zm0QVenOj7ak" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;$5,511,940&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_98E_eecd--PeoActuallyPaidCompAmt_c20240101__20241231_fKGEp_zZereKucB3Wh" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"&gt;&lt;span style="text-transform: none"&gt;$12,328,862&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 12pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_981_eecd--NonPeoNeoAvgTotalCompAmt_c20240101__20241231_fKGIp_zMUYjSzkQlag" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"&gt;&lt;span style="text-transform: none"&gt;$1,703,153&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 12pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_98C_eecd--NonPeoNeoAvgCompActuallyPaidAmt_c20240101__20241231_fKGIp_zOynJVMxkVj6" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"&gt;&lt;span style="text-transform: none"&gt;$3,151,020&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 19pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_987_eecd--TotalShareholderRtnAmt_pp2d_c20240101__20241231_fKGMp_zd7VfqqTbKWj" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"&gt;&lt;span style="text-transform: none"&gt;$106&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_980_eecd--PeerGroupTotalShareholderRtnAmt_pp2d_c20240101__20241231_fKGMp_zyYS5HrAnjKd" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;$138&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_983_eus-gaap--NetIncomeLoss_pn6n6_c20240101__20241231_z7zuSx1flaQg" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;($13)&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 10pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"&gt;&lt;span style="text-transform: none"&gt;&lt;span id="xdx_902_eecd--CoSelectedMeasureAmt_pid_dp_uRatio_c20240101__20241231_fKGQp_z8WLIkO2T6ca"&gt;9&lt;/span&gt;%&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;

						&lt;/tr&gt;
						&lt;tr style="min-height: 3pt"&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"&gt;&lt;span style="text-transform: none"&gt;2023&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_982_eecd--PeoTotalCompAmt_c20230101__20231231_fKGEp_zfnOwfBjhYAk" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;$3,176,413&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_98B_eecd--PeoActuallyPaidCompAmt_c20230101__20231231_fKGEp_zrYEqJy72lZ9" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"&gt;&lt;span style="text-transform: none"&gt;$7,225,878&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 12pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_988_eecd--NonPeoNeoAvgTotalCompAmt_c20230101__20231231_fKGIp_zJBHUkUH2Ide" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"&gt;&lt;span style="text-transform: none"&gt;$1,204,664&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 12pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_982_eecd--NonPeoNeoAvgCompActuallyPaidAmt_c20230101__20231231_fKGIp_zXneGOu13Nkh" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"&gt;&lt;span style="text-transform: none"&gt;$1,835,407&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 19pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_98B_eecd--TotalShareholderRtnAmt_pp2d_c20230101__20231231_fKGMp_znHI0kQMHLB4" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"&gt;&lt;span style="text-transform: none"&gt;$66&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_98B_eecd--PeerGroupTotalShareholderRtnAmt_pp2d_c20230101__20231231_fKGMp_zYVNBCm6rrRe" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;$124&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_983_eus-gaap--NetIncomeLoss_pn6n6_c20230101__20231231_z9IlVv0kyaOe" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;($31)&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 10pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"&gt;&lt;span style="text-transform: none"&gt;&lt;span id="xdx_906_eecd--CoSelectedMeasureAmt_pid_dp_uRatio_c20230101__20231231_fKGQp_zJqCpv1F1gy4"&gt;12&lt;/span&gt;%&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;

						&lt;/tr&gt;
						&lt;tr style="min-height: 3pt"&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"&gt;&lt;span style="text-transform: none"&gt;2022&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_98D_eecd--PeoTotalCompAmt_c20220101__20221231_fKGEp_zR4yGZ9GY11d" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;$7,216,340&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_98C_eecd--PeoActuallyPaidCompAmt_c20220101__20221231_fKGEp_zl63HFzvzmE8" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"&gt;&lt;span style="text-transform: none"&gt;$4,718,496&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 12pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_985_eecd--NonPeoNeoAvgTotalCompAmt_c20220101__20221231_fKGIp_zI6Jdml2MAbh" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"&gt;&lt;span style="text-transform: none"&gt;$1,796,100&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 12pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_987_eecd--NonPeoNeoAvgCompActuallyPaidAmt_c20220101__20221231_fKGIp_zReOaVmnjYtj" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"&gt;&lt;span style="text-transform: none"&gt;$1,352,869&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 19pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_983_eecd--TotalShareholderRtnAmt_pp2d_c20220101__20221231_fKGMp_zmg3DunzCWL9" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"&gt;&lt;span style="text-transform: none"&gt;$45&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_98F_eecd--PeerGroupTotalShareholderRtnAmt_pp2d_c20220101__20221231_fKGMp_zqeRJJ32LCQi" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;$114&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_986_eus-gaap--NetIncomeLoss_pn6n6_c20220101__20221231_z79mLT4rGxF8" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;($19)&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 10pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"&gt;&lt;span style="text-transform: none"&gt;&lt;span id="xdx_904_eecd--CoSelectedMeasureAmt_pid_dp_uRatio_c20220101__20221231_fKGQp_zSx47QbLlc4l"&gt;9&lt;/span&gt;%&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;

						&lt;/tr&gt;
						&lt;tr style="min-height: 3pt"&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"&gt;&lt;span style="text-transform: none"&gt;2021&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_988_eecd--PeoTotalCompAmt_c20210101__20211231_fKGEp_zqKfCvggwGpd" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;$4,628,566&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_985_eecd--PeoActuallyPaidCompAmt_c20210101__20211231_fKGEp_zrwzmhzQZah" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"&gt;&lt;span style="text-transform: none"&gt;$3,712,538&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 12pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_989_eecd--NonPeoNeoAvgTotalCompAmt_c20210101__20211231_fKGIp_ztLj3I6eryra" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"&gt;&lt;span style="text-transform: none"&gt;$1,286,725&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 12pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_986_eecd--NonPeoNeoAvgCompActuallyPaidAmt_c20210101__20211231_fKGIp_znvics2Yl6J9" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"&gt;&lt;span style="text-transform: none"&gt;$1,108,935&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 19pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_984_eecd--TotalShareholderRtnAmt_pp2d_c20210101__20211231_fKGMp_zucAsI1NEMnc" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"&gt;&lt;span style="text-transform: none"&gt;$75&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_983_eecd--PeerGroupTotalShareholderRtnAmt_pp2d_c20210101__20211231_fKGMp_zMZkWisB8G2b" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;$140&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_986_eus-gaap--NetIncomeLoss_pn6n6_c20210101__20211231_z6S4MUrTXi76" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;($15)&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 10pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"&gt;&lt;span style="text-transform: none"&gt;&lt;span id="xdx_900_eecd--CoSelectedMeasureAmt_pid_dp_uRatio_c20210101__20211231_fKGQp_z1ayUznWyAX6"&gt;16&lt;/span&gt;%&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;

						&lt;/tr&gt;
						&lt;tr style="min-height: 3pt"&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"&gt;&lt;span style="text-transform: none"&gt;2020&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_982_eecd--PeoTotalCompAmt_c20200101__20201231_fKGEp_z96hQaOD7SK4" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;$3,415,458&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_98A_eecd--PeoActuallyPaidCompAmt_c20200101__20201231_fKGEp_zfws7fXhhAP" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"&gt;&lt;span style="text-transform: none"&gt;$327,652&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 12pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_98A_eecd--NonPeoNeoAvgTotalCompAmt_c20200101__20201231_fKGIp_zRyokeSdqbz4" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"&gt;&lt;span style="text-transform: none"&gt;$977,089&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 12pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_989_eecd--NonPeoNeoAvgCompActuallyPaidAmt_c20200101__20201231_fKGIp_z6QYG5t6ceQ6" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"&gt;&lt;span style="text-transform: none"&gt;$454,642&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 19pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_981_eecd--TotalShareholderRtnAmt_pp2d_c20200101__20201231_fKGMp_z6aqfg1PA1x8" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"&gt;&lt;span style="text-transform: none"&gt;$87&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_98F_eecd--PeerGroupTotalShareholderRtnAmt_pp2d_c20200101__20201231_fKGMp_znhzzYGlr6Vf" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;$118&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_983_eus-gaap--NetIncomeLoss_pn6n6_c20200101__20201231_zV4bqmjmn2Vk" style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;($17)&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 10pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-align: right"&gt;&lt;span style="text-transform: none"&gt;&lt;span id="xdx_908_eecd--CoSelectedMeasureAmt_pid_dp_uRatio_c20200101__20201231_fKGQp_zmPpCRS169Oe"&gt;-8&lt;/span&gt;%&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;

						&lt;/tr&gt;

					&lt;/table&gt;

				&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 9pt/normal Arial, sans-serif; display: none; visibility: hidden; color: #000000; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 15pt; text-align: right"&gt;&lt;span style="font-size: 7pt; text-transform: none; line-height: 7pt"&gt;&lt;sup id="xdx_F0F_zQv8MlvYYtHc"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5pt"&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_F1D_znUqSEZuFBt6" style="text-transform: none"&gt;Mr. Mackin&#160;served
as our only PEO for&#160;each year.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 9pt/normal Arial, sans-serif; display: none; visibility: hidden; color: #000000; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 15pt; text-align: right"&gt;&lt;span style="font-size: 7pt; text-transform: none; line-height: 7pt"&gt;&lt;sup id="xdx_F04_zkz5q3evZk09"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5pt"&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_F17_zTy3LCGejpx6" style="text-transform: none"&gt;Our Non-PEO NEOs in 2024
were Messrs. Berry, Davis and Stanton and Ms. Holloway. Our Non-PEO NEOs in 2023 were Messrs. Lee, Berry, Davis and Mses. Horton and
Holloway. Our Non-PEO NEOs in 2022 and 2021 were&#160;Messrs. Lee,&#160;Davis,&#160;Stanton&#160;and&#160;Ms. Holloway. Our Non-PEO NEOs
in 2020 were&#160;Messrs.&#160;Lee,&#160;Davis,&#160;Simpson,&#160;and&#160;Ms. Holloway.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 9pt/normal Arial, sans-serif; display: none; visibility: hidden; color: #000000; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 15pt; text-align: right"&gt;&lt;span style="font-size: 7pt; text-transform: none; line-height: 7pt"&gt;&lt;sup id="xdx_F00_zgpOwZGAqRzb"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5pt"&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_F1E_zitB532hdF2h" style="text-transform: none"&gt;Shareholder returns reflect
$100 invested as of market close on December 31, 2019, the final trading day of fiscal 2019; Index Shareholder Return reflects S&amp;amp;P
500 Health Care&#160;Equipment Index.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 9pt/normal Arial, sans-serif; display: none; visibility: hidden; color: #000000; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 15pt; text-align: right"&gt;&lt;span style="font-size: 7pt; text-transform: none; line-height: 7pt"&gt;&lt;sup id="xdx_F05_zyln938K39E6"&gt;(d)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5pt"&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_F11_zIX0QQRNIkx8" style="text-transform: none"&gt;In the Company&#x2019;s
assessment, for the 2024 fiscal year, AORT revenue growth represents the most important financial performance measure that is not otherwise
required to be disclosed in the table that we used to link &#x201c;compensation actually paid&#x201d; to our NEOs, including our PEO, to
our performance. AORT revenue growth is an adjusted constant currency revenue measure calculated by adjusting for the exchange rate effect
on GAAP revenues. We define exchange rate effect as the year-over-year impact of foreign currency movements using current period foreign
currency rates applied to prior period transactional currency amounts. As discussed in the Compensation Discussion &amp;amp; Analysis, constant
currency revenue growth as calculated in incentive plans may reflect additional adjustments to either the baseline (prior year revenue)
or current year results, to exclude the impact of discontinued businesses and other unplanned events that were outside of management&#x2019;s
control. In 2023, we excluded the impact of the Company&#x2019;s Cardiogenesis business. In 2022, we adjusted to exclude PerClot sales
that occurred in 2022 and 2021. In 2021, we measured growth in the second half of the year by comparing to the second half of 2019 rather
than 2020.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;div id="xdx_849_eecd--NamedExecutiveOfficersFnTextBlock_dU_z7OrBB38Rks2"&gt;&lt;/div&gt;
				&lt;p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 1pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"&gt;&lt;span style="width: 15pt; text-indent: 0; display: inline-block"&gt;&lt;sup style="text-transform: none; font-size: 7pt; line-height: 7pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;sup style="text-transform: none; font-size: 7pt; line-height: 7pt"&gt;&lt;/sup&gt;&lt;span style="text-transform: none"&gt;&lt;span id="xdx_908_eecd--PeoName_c20200101__20201231_znEPlCJI9E8b"&gt;&lt;span id="xdx_90F_eecd--PeoName_c20210101__20211231_zY0OfcfAZp01"&gt;&lt;span id="xdx_905_eecd--PeoName_c20220101__20221231_zZHCoC7y8gnc"&gt;&lt;span id="xdx_904_eecd--PeoName_c20230101__20231231_zddNZUNYL4Qf"&gt;&lt;span id="xdx_900_eecd--PeoName_c20240101__20241231_znX2Xqykizi6"&gt;Mr. Mackin&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&#160;served as our only PEO &lt;/span&gt;&lt;span style="text-transform: none"&gt;for&#160;each year.&lt;/span&gt;&lt;/p&gt;
				&lt;p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 1pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"&gt;&lt;span style="width: 15pt; text-indent: 0; display: inline-block"&gt;&lt;sup style="text-transform: none; font-size: 7pt; line-height: 7pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;sup style="text-transform: none; font-size: 7pt; line-height: 7pt"&gt;&lt;/sup&gt;&lt;span style="text-transform: none"&gt;Our Non-PEO NEOs in 2024 were Messrs. Berry, Davis and Stanton and Ms. Holloway. Our Non-PEO NEOs in 2023 were Messrs. Lee, Berry, Davis and Mses. Horton and Holloway. Our Non-PEO NEOs in 2022 and 2021 were&#160;Messrs. Lee,&#160;Davis,&#160;Stanton&#160;and&#160;Ms. Holloway. Our Non-PEO NEOs in 2020 &lt;/span&gt;&lt;span style="text-transform: none"&gt;were&#160;Messrs.&#160;Lee,&#160;Davis,&#160;Simpson,&#160;and&#160;Ms. Holloway.&lt;/span&gt;&lt;/p&gt;
&lt;div id="xdx_85A_z4Lu9NCrLOdf" style="margin-bottom: 1pt"&gt;&lt;/div&gt;
				&lt;p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 1pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"&gt;&lt;span style="width: 15pt; text-indent: 0; display: inline-block"&gt;&lt;sup style="text-transform: none; font-size: 7pt; line-height: 7pt"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;sup style="text-transform: none; font-size: 7pt; line-height: 7pt"&gt;&lt;/sup&gt;&lt;span style="text-transform: none"&gt;Shareholder returns reflect $100 invested as of market close on December 31, 2019, the final trading day of fiscal 2019; Index Shareholder Return reflects S&amp;amp;P 500 Health &lt;/span&gt;&lt;span style="text-transform: none"&gt;Care&#160;Equipment Index.&lt;/span&gt;&lt;/p&gt;
				&lt;p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 8pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"&gt;&lt;span style="width: 15pt; text-indent: 0; display: inline-block"&gt;&lt;sup style="text-transform: none; font-size: 7pt; line-height: 7pt"&gt;(d)&lt;/sup&gt;&lt;/span&gt;&lt;sup style="text-transform: none; font-size: 7pt; line-height: 7pt"&gt;&lt;/sup&gt;&lt;span style="text-transform: none"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFBheSB2cyBQZXJmb3JtYW5jZSBEaXNjbG9zdXJlAA__" id="xdx_906_eecd--NonGaapMeasureDescriptionTextBlock_c20240101__20241231__ecd--MeasureAxis__1_zGdKNsBUfWRl"&gt;In the Company&#x2019;s assessment, for the 2024 fiscal year, &lt;span id="xdx_90D_eecd--CoSelectedMeasureName_c20240101__20241231_zqgOKiYCGonc"&gt;AORT revenue growth&lt;/span&gt; represents the most important financial performance measure that is not otherwise required to be disclosed in the table that we used to link &#x201c;compensation actually paid&#x201d; to our NEOs, including our PEO, to our performance. AORT revenue growth is an adjusted constant currency revenue measure calculated by adjusting for the exchange rate effect on GAAP revenues. We define exchange rate effect as the year-over-year impact of foreign currency movements using current period foreign currency rates applied to prior period transactional currency amounts. As discussed in the Compensation Discussion &amp;amp; Analysis, constant currency revenue growth as calculated in incentive plans may reflect additional adjustments to either the baseline (prior year revenue) or current year results, to exclude the impact of discontinued businesses and other unplanned events that were outside of management&#x2019;s control. In 2023, we excluded the impact of the Company&#x2019;s Cardiogenesis business. In 2022, we adjusted to exclude PerClot sales that occurred in 2022 and 2021. In 2021, we measured growth in the second half of the year by comparing to the second half of 2019 rather than 2020.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
				&lt;p id="xdx_84D_eecd--AdjToPeoCompFnTextBlock_dU_gL2ATPCFTB-BR_z1I5XfViUMj8" style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"&gt;&lt;span style="text-transform: none; line-height: 12pt"&gt;The following table sets forth a reconciliation from the Summary Compensation Table (&#x201c;SCT&#x201d;) to Compensation Actually Paid (&#x201c;CAP&#x201d;) to our PEO and for the average paid to our Non-PEO NEOs for each &lt;/span&gt;&lt;span style="text-transform: none; line-height: 12pt"&gt;fiscal year.&lt;/span&gt;&lt;/p&gt;
				&lt;table id="xdx_308_zVWZIriixLRa" style="table-layout: fixed; width: 674.68pt; margin-top: 4pt; margin-bottom: 10pt; border-collapse: collapse" summary="xdx: Disclosure - Pay vs Performance Disclosure"&gt;
						&lt;tr style="margin: 0; height: 0"&gt;
							&lt;td style="text-align: left; border-width: 0; margin: 0; padding: 0; width: 142.49pt"&gt;


							&lt;/td&gt;
							&lt;td style="border-width: 0; margin: 0; padding: 0; width: 88.74pt"&gt;


							&lt;/td&gt;
							&lt;td style="border-width: 0; margin: 0; padding: 0; width: 89.06pt"&gt;


							&lt;/td&gt;
							&lt;td style="border-width: 0; margin: 0; padding: 0; width: 84.37pt"&gt;


							&lt;/td&gt;
							&lt;td style="border-width: 0; margin: 0; padding: 0; width: 90pt"&gt;


							&lt;/td&gt;
							&lt;td style="border-width: 0; margin: 0; padding: 0; width: 84.37pt"&gt;


							&lt;/td&gt;
							&lt;td style="border-width: 0; margin: 0; padding: 0; width: 95.62pt"&gt;


							&lt;/td&gt;

						&lt;/tr&gt;
						&lt;tr style="min-height: 3pt"&gt;
							&lt;td style="text-align: left; border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;b&gt;Year&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;b&gt;SCT&lt;br/&gt;Total&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;b&gt;Less Sum of&lt;br/&gt;Stock and&lt;br/&gt;Option Award&lt;br/&gt;Values from&lt;br/&gt;SCT&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;b&gt;Value of&lt;br/&gt;Current&lt;br/&gt;Year Equity&lt;br/&gt;Awards at&lt;br/&gt;12/31&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;b&gt;Change in&lt;br/&gt;Value of&lt;br/&gt;Unvested Prior&lt;br/&gt;Year Awards at&lt;br/&gt;12/31&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;b&gt;Change in&lt;br/&gt;Value of Prior&lt;br/&gt;Year Awards&lt;br/&gt;That Vested&lt;br/&gt;In Current&lt;br/&gt;Year&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;b&gt;Total&lt;br/&gt;Compensation&lt;br/&gt;Actually Paid&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;

						&lt;/tr&gt;
						&lt;tr style="min-height: 3pt"&gt;
							&lt;td style="text-align: left; border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="text-align: left; margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt"&gt;&#x200b;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt"&gt;&#x200b;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;b&gt; (e) &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;b&gt; (f) &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;b&gt; (g) &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;b&gt; (h) &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;b&gt;(i)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;

						&lt;/tr&gt;
						&lt;tr style="min-height: 3pt"&gt;
							&lt;td style="text-align: left; border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"&gt;&lt;span style="text-transform: none"&gt;2024&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_98F_eecd--PeoTotalCompAmt_c20240101__20241231_zemY5XBdadxg" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;$5,511,940&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 7pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_982_eecd--AdjToCompAmt_c20240101__20241231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--EqtyAwrdsInSummryCompstnTblForAplblYrMember_fKGUp_zpc4FwAn8mG" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;($3,608,101)&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_98B_eecd--AdjToCompAmt_c20240101__20241231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_fKGYp_zPM9LlTzo3K9" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;$5,852,430&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 10pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_98C_eecd--AdjToCompAmt_c20240101__20241231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_fKGcp_zobmolIoUIVj" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;$3,370,222&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 10pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_98C_eecd--AdjToCompAmt_c20240101__20241231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_fKGgp_zXPqHhvacd8d" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;$1,202,370&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 11pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_98F_eecd--PeoActuallyPaidCompAmt_c20240101__20241231_fKGkp_ziEqyW33lUP5" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;  $12,328,862&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;

						&lt;/tr&gt;
						&lt;tr style="min-height: 3pt"&gt;
							&lt;td style="border-width: 0pt; text-align: left; padding: 1.5pt 0pt 1.5pt 3pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: left"&gt;&lt;span style="text-transform: none"&gt;2023&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_983_eecd--PeoTotalCompAmt_c20230101__20231231_zy5Mge1YGukk" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;$3,176,413&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 7pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_987_eecd--AdjToCompAmt_c20230101__20231231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--EqtyAwrdsInSummryCompstnTblForAplblYrMember_fKGUp_zHj7xU8g9oBc" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&#x2002; ($801,938)&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_985_eecd--AdjToCompAmt_c20230101__20231231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_fKGYp_zMdhmvbrG5fi" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;$1,771,014&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 10pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_980_eecd--AdjToCompAmt_c20230101__20231231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_fKGcp_zP3BA88jqry" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;$2,775,817&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 10pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_980_eecd--AdjToCompAmt_c20230101__20231231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_fKGgp_zkWvh3ykRXfi" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;  $304,572&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 11pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_98A_eecd--PeoActuallyPaidCompAmt_c20230101__20231231_fKGkp_zVmA0VUBAb71" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;$7,225,878&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;

						&lt;/tr&gt;
						&lt;tr style="min-height: 3pt"&gt;
							&lt;td style="border-width: 0pt; text-align: left; padding: 1.5pt 0pt 1.5pt 3pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: left"&gt;&lt;span style="text-transform: none"&gt;2022&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_98A_eecd--PeoTotalCompAmt_c20220101__20221231_zoGHyJZbiJbh" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;$7,216,340&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 7pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_98C_eecd--AdjToCompAmt_c20220101__20221231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--EqtyAwrdsInSummryCompstnTblForAplblYrMember_fKGUp_zijFSTRwDKz9" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;($5,587,257)&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_98C_eecd--AdjToCompAmt_c20220101__20221231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_fKGYp_z0bLeuqpqHVh" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;$4,689,996&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 7pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_982_eecd--AdjToCompAmt_c20220101__20221231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_fKGcp_zOR7dMRuabv3" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;($1,385,504)&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 7pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_984_eecd--AdjToCompAmt_c20220101__20221231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_fKGgp_zj603AnWzEs2" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;  ($215,079)&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 11pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_98B_eecd--PeoActuallyPaidCompAmt_c20220101__20221231_fKGkp_zxCNN0mEKMb9" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;$4,718,496&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;

						&lt;/tr&gt;
						&lt;tr style="min-height: 3pt"&gt;
							&lt;td style="border-width: 0pt; text-align: left; padding: 1.5pt 0pt 1.5pt 3pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: left"&gt;&lt;span style="text-transform: none"&gt;2021&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_98E_eecd--PeoTotalCompAmt_c20210101__20211231_ztAU8dB027n9" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;$4,628,566&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 7pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_98B_eecd--AdjToCompAmt_c20210101__20211231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--EqtyAwrdsInSummryCompstnTblForAplblYrMember_fKGUp_zDFEgmTMRn73" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;($2,977,494)&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_98A_eecd--AdjToCompAmt_c20210101__20211231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_fKGYp_z7o9Mqn0GJV1" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;$2,402,215&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 7pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_98B_eecd--AdjToCompAmt_c20210101__20211231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_fKGcp_zc5hLlTdy1hk" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&#x2002; ($495,663)&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 10pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_98C_eecd--AdjToCompAmt_c20210101__20211231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_fKGgp_zyzTOoKZTUEh" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;$154,913&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 11pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_984_eecd--PeoActuallyPaidCompAmt_c20210101__20211231_fKGkp_zD4ijklw5Ul8" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;$3,712,538&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;

						&lt;/tr&gt;
						&lt;tr style="min-height: 3pt"&gt;
							&lt;td style="border-width: 0pt; text-align: left; padding: 1.5pt 0pt 1.5pt 3pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: left"&gt;&lt;span style="text-transform: none"&gt;2020&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_980_eecd--PeoTotalCompAmt_c20200101__20201231_zdhn2cMbmx3b" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;$3,415,458&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 7pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_98C_eecd--AdjToCompAmt_c20200101__20201231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--EqtyAwrdsInSummryCompstnTblForAplblYrMember_fKGUp_zNz1YCiWqC9k" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;($2,323,534)&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_980_eecd--AdjToCompAmt_c20200101__20201231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_fKGYp_z8lDHJMvAFRh" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;$1,931,021&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 7pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_98C_eecd--AdjToCompAmt_c20200101__20201231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_fKGcp_z7fZxiI4LKxj" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;($2,326,940)&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 7pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_98D_eecd--AdjToCompAmt_c20200101__20201231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_fKGgp_zDtII3fwInTk" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;($368,352)&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 11pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_98F_eecd--PeoActuallyPaidCompAmt_c20200101__20201231_fKGkp_zssJsD9lBFZ5" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&#x2002; $327,652&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;

						&lt;/tr&gt;

					&lt;/table&gt;

				&lt;table cellpadding="0" cellspacing="0" style="font: 9pt/normal Arial, sans-serif; display: none; visibility: hidden; color: #000000; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 15pt; text-align: right"&gt;&lt;span style="font-size: 7pt; text-transform: none; line-height: 7pt"&gt;&lt;sup id="xdx_F05_zBhfDSiTlHrk"&gt;(e)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5pt"&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_F15_zuBc0O9oGre3" style="text-transform: none"&gt;Represents the grant date
fair value of equity-based awards made during the covered fiscal year as reported in the Summary&#160;Compensation Table.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 9pt/normal Arial, sans-serif; display: none; visibility: hidden; color: #000000; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 15pt; text-align: right"&gt;&lt;span style="font-size: 7pt; text-transform: none; line-height: 7pt"&gt;&lt;sup id="xdx_F09_zhLUB9FGOI76"&gt;(f)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5pt"&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_F11_z9fCcMfCAWB5" style="text-transform: none"&gt;Represents the year-end
fair value of equity awards that were made during the covered fiscal year and remained unvested as&#160;of the end of the covered fiscal
year.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 9pt/normal Arial, sans-serif; display: none; visibility: hidden; color: #000000; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 15pt; text-align: right"&gt;&lt;span style="font-size: 7pt; text-transform: none; line-height: 7pt"&gt;&lt;sup id="xdx_F04_zJNwH9gobYo7"&gt;(g)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5pt"&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_F1D_z7HeYnvfn6F6" style="text-transform: none"&gt;Represents the change as
of the end of the covered fiscal year (from the end of the prior fiscal year) in fair value of equity-based awards granted in prior fiscal
years that were still unvested as of the covered&#160;fiscal year-end.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 9pt/normal Arial, sans-serif; display: none; visibility: hidden; color: #000000; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 15pt; text-align: right"&gt;&lt;span style="font-size: 7pt; text-transform: none; line-height: 7pt"&gt;&lt;sup id="xdx_F00_zMc9VSmuo24k"&gt;(h)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5pt"&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_F15_zGLIg8Tf6rg7" style="text-transform: none"&gt;Represents the change as
of the vesting date (from the end of the prior fiscal year) in fair value of equity-based awards granted in prior fiscal years that vested
as of the end of or during the covered&#160;fiscal year.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 9pt/normal Arial, sans-serif; display: none; visibility: hidden; color: #000000; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 15pt; text-align: right"&gt;&lt;span style="font-size: 7pt; text-transform: none; line-height: 7pt"&gt;&lt;sup id="xdx_F0C_zhsBSlRhRjtj"&gt;(i)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5pt"&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_F12_zqUVtIkQNNNc" style="text-transform: none"&gt;Equal to summary compensation
total plus/minus any adjustments related to equity award values as reflected in&#160;this table. For purposes of calculating &#x201c;compensation
actually paid,&#x201d; the fair value of equity awards at year-end 2023 and 2024, and on vesting dates for awards that vested during 2024,
were all determined consistent with the approach used to value the awards at the grant date for purposes of the Summary Compensation
Table (refer to &#x201c;Executive Officer Compensation &#x2013; Summary Compensation Table&#x201d; for additional information). For any
awards subject to performance conditions, the change in fair value as of the end of the covered fiscal year is calculated based on the
probable outcome of such conditions as of the last day of the fiscal year. The valuation assumptions used to calculate fair values do
not differ materially from those disclosed at the time of grant, other than as reflected in the table below, which summarizes option
fair values determined using the Black-Scholes model and related assumptions used to calculate Compensation Actually Paid for fiscal&#160;year
2024.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

				&lt;p id="xdx_851_zDckYHbgcnx5"&gt;&lt;/p&gt;
				&lt;p id="xdx_845_eecd--AdjToNonPeoNeoCompFnTextBlock_dU_z2toD0Is021l" style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"&gt;&lt;span style="text-transform: none; line-height: 12pt"&gt;The following table sets forth a reconciliation from the Summary Compensation Table (&#x201c;SCT&#x201d;) to Compensation Actually Paid (&#x201c;CAP&#x201d;) for the average paid to our Non-PEO NEOs for each &lt;/span&gt;&lt;span style="text-transform: none; line-height: 12pt"&gt;fiscal year.&lt;/span&gt;&lt;/p&gt;
				&lt;div style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-align: left"&gt;
					&lt;table id="xdx_30E_zR7V9Qb1fbKj" style="table-layout: fixed; width: 674.68pt; margin-top: 4pt; margin-bottom: 10pt; border-collapse: collapse" summary="xdx: Disclosure - Pay vs Performance Disclosure"&gt;
						&lt;tr style="margin: 0; height: 0"&gt;
							&lt;td style="text-align: left; border-width: 0; margin: 0; padding: 0; width: 142.49pt"&gt;


							&lt;/td&gt;
							&lt;td style="border-width: 0; margin: 0; padding: 0; width: 88.74pt"&gt;


							&lt;/td&gt;
							&lt;td style="border-width: 0; margin: 0; padding: 0; width: 89.06pt"&gt;


							&lt;/td&gt;
							&lt;td style="border-width: 0; margin: 0; padding: 0; width: 84.37pt"&gt;


							&lt;/td&gt;
							&lt;td style="border-width: 0; margin: 0; padding: 0; width: 90pt"&gt;


							&lt;/td&gt;
							&lt;td style="border-width: 0; margin: 0; padding: 0; width: 84.37pt"&gt;


							&lt;/td&gt;
							&lt;td style="border-width: 0; margin: 0; padding: 0; width: 95.62pt"&gt;


							&lt;/td&gt;

						&lt;/tr&gt;
						&lt;tr style="min-height: 3pt"&gt;
							&lt;td style="text-align: left; border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;b&gt;Year&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;b&gt;SCT&lt;br/&gt;Total&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;b&gt;Less Sum of&lt;br/&gt;Stock and&lt;br/&gt;Option Award&lt;br/&gt;Values from&lt;br/&gt;SCT&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;b&gt;Value of&lt;br/&gt;Current&lt;br/&gt;Year Equity&lt;br/&gt;Awards at&lt;br/&gt;12/31&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;b&gt;Change in&lt;br/&gt;Value of&lt;br/&gt;Unvested Prior&lt;br/&gt;Year Awards at&lt;br/&gt;12/31&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;b&gt;Change in&lt;br/&gt;Value of Prior&lt;br/&gt;Year Awards&lt;br/&gt;That Vested&lt;br/&gt;In Current&lt;br/&gt;Year&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;b&gt;Total&lt;br/&gt;Compensation&lt;br/&gt;Actually Paid&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;

						&lt;/tr&gt;
						&lt;tr style="min-height: 3pt"&gt;
							&lt;td style="text-align: left; border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="text-align: left; margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt"&gt;&#x200b;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt"&gt;&#x200b;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;b&gt; (e) &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;b&gt; (f) &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;b&gt; (g) &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;b&gt; (h) &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;b&gt;(i)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;

						&lt;/tr&gt;
						&lt;tr style="min-height: 3pt"&gt;
							&lt;td style="text-align: left; border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"&gt;&lt;span style="text-transform: none"&gt;2024&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 11pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_988_eecd--NonPeoNeoAvgTotalCompAmt_c20240101__20241231_zkGc2nmxZYQd" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;$1,703,153&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 8pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_98D_eecd--AdjToCompAmt_c20240101__20241231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--EqtyAwrdsInSummryCompstnTblForAplblYrMember_fKGUp_z2j7FEeSfoSh" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;  ($923,744)&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 11pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_988_eecd--AdjToCompAmt_c20240101__20241231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_fKGYp_z8CEuZuUuvwd" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;$1,498,338&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 13pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_989_eecd--AdjToCompAmt_c20240101__20241231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_fKGcp_zWl8QtvFYeK8" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;  $642,469&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 13pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_985_eecd--AdjToCompAmt_c20240101__20241231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_fKGgp_zqpoBld2prm7" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;$230,805&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 14pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_98A_eecd--NonPeoNeoAvgCompActuallyPaidAmt_c20240101__20241231_fKGkuKQ_____z8MWU3TdMpq3" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;$3,151,020&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;

						&lt;/tr&gt;
						&lt;tr style="min-height: 3pt"&gt;
							&lt;td style="border-width: 0pt; text-align: left; padding: 1.5pt 0pt 1.5pt 3pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: left"&gt;&lt;span style="text-transform: none"&gt;2023&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 11pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_986_eecd--NonPeoNeoAvgTotalCompAmt_c20230101__20231231_zFdGxPi6y5Z8" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;$1,204,664&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 8pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_985_eecd--AdjToCompAmt_c20230101__20231231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--EqtyAwrdsInSummryCompstnTblForAplblYrMember_fKGUp_zDfLteTfhPq2" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&#x2002; ($498,431)&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 11pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_98A_eecd--AdjToCompAmt_c20230101__20231231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_fKGYp_zs6fl3nop6ig" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;  $639,679&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 13pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_983_eecd--AdjToCompAmt_c20230101__20231231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_fKGcp_zjaU3jnmCvfc" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&#x2002; $443,711&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 13pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_98F_eecd--AdjToCompAmt_c20230101__20231231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_fKGgp_ztA47rbIUUTd" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;  $45,783&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 14pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_98B_eecd--NonPeoNeoAvgCompActuallyPaidAmt_c20230101__20231231_fKGkuKQ_____zcDfIdaGiIE3" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;$1,835,407&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;

						&lt;/tr&gt;
						&lt;tr style="min-height: 3pt"&gt;
							&lt;td style="border-width: 0pt; text-align: left; padding: 1.5pt 0pt 1.5pt 3pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: left"&gt;&lt;span style="text-transform: none"&gt;2022&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 11pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_98C_eecd--NonPeoNeoAvgTotalCompAmt_c20220101__20221231_zeRwyvu6di9" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;$1,796,100&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 8pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_987_eecd--AdjToCompAmt_c20220101__20221231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--EqtyAwrdsInSummryCompstnTblForAplblYrMember_fKGUp_zOvzRDZgXzKf" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;($1,124,197)&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 11pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_982_eecd--AdjToCompAmt_c20220101__20221231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_fKGYp_z5rmMRSYJEPf" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;  $955,981&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_988_eecd--AdjToCompAmt_c20220101__20221231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_fKGcp_zTfCoUsB2oCh" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt; ($239,756)&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_985_eecd--AdjToCompAmt_c20220101__20221231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_fKGgp_zfUrvVcPTK38" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;($35,259)&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 14pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_980_eecd--NonPeoNeoAvgCompActuallyPaidAmt_c20220101__20221231_fKGkuKQ_____zU4Lx60upXQd" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;$1,352,869&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;

						&lt;/tr&gt;
						&lt;tr style="min-height: 3pt"&gt;
							&lt;td style="border-width: 0pt; text-align: left; padding: 1.5pt 0pt 1.5pt 3pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: left"&gt;&lt;span style="text-transform: none"&gt;2021&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 11pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_98C_eecd--NonPeoNeoAvgTotalCompAmt_c20210101__20211231_zL0XxHkSKhyh" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;$1,286,725&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 8pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_984_eecd--AdjToCompAmt_c20210101__20211231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--EqtyAwrdsInSummryCompstnTblForAplblYrMember_fKGUp_zrzfmxWnnKqi" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&#x2002; ($640,635)&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 11pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_98C_eecd--AdjToCompAmt_c20210101__20211231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_fKGYp_z0HJT6cwQOn9" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;  $508,720&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_984_eecd--AdjToCompAmt_c20210101__20211231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_fKGcp_zmmkvk3v0Z2c" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&#x2002; ($72,575)&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 13pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_988_eecd--AdjToCompAmt_c20210101__20211231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_fKGgp_zvJoj1Ayeqtf" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;  $26,701&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 14pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_98E_eecd--NonPeoNeoAvgCompActuallyPaidAmt_c20210101__20211231_fKGkuKQ_____zOPu6wZ4y4Hl" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;$1,108,935&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;

						&lt;/tr&gt;
						&lt;tr style="min-height: 3pt"&gt;
							&lt;td style="border-width: 0pt; text-align: left; padding: 1.5pt 0pt 1.5pt 3pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: left"&gt;&lt;span style="text-transform: none"&gt;2020&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 11pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_986_eecd--NonPeoNeoAvgTotalCompAmt_c20200101__20201231_zQVsMUpIEZr5" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&#x2002;$977,089&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 8pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_988_eecd--AdjToCompAmt_c20200101__20201231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--EqtyAwrdsInSummryCompstnTblForAplblYrMember_fKGUp_zFL2z8REbYh4" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&#x2002; ($499,129)&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 11pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_98C_eecd--AdjToCompAmt_c20200101__20201231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_fKGYp_zrPzWAnv5Luf" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;  $420,985&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_98F_eecd--AdjToCompAmt_c20200101__20201231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_fKGcp_zHHqSQTbWNU6" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt; ($371,199)&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_982_eecd--AdjToCompAmt_c20200101__20201231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_fKGgp_z548VFakKFve" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt; ($73,105)&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 14pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_981_eecd--NonPeoNeoAvgCompActuallyPaidAmt_c20200101__20201231_fKGkuKQ_____zrf2LnU9tXX2" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&#x2002; $454,642&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;

						&lt;/tr&gt;

					&lt;/table&gt;

				&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 9pt/normal Arial, sans-serif; display: none; visibility: hidden; color: #000000; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 15pt; text-align: right"&gt;&lt;span style="font-size: 7pt; text-transform: none; line-height: 7pt"&gt;&lt;sup id="xdx_F04_zCsjhN8a9su7"&gt;(e)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5pt"&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_F10_zd6MihFDfz31" style="text-transform: none"&gt;Represents the grant date
fair value of equity-based awards made during the covered fiscal year as reported in the Summary&#160;Compensation Table.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 9pt/normal Arial, sans-serif; display: none; visibility: hidden; color: #000000; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 15pt; text-align: right"&gt;&lt;span style="font-size: 7pt; text-transform: none; line-height: 7pt"&gt;&lt;sup id="xdx_F0D_zfrxqZnFmsp8"&gt;(f)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5pt"&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_F1E_zaDZYrW4evr9" style="text-transform: none"&gt;Represents the year-end
fair value of equity awards that were made during the covered fiscal year and remained unvested as&#160;of the end of the covered fiscal
year.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 9pt/normal Arial, sans-serif; display: none; visibility: hidden; color: #000000; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 15pt; text-align: right"&gt;&lt;span style="font-size: 7pt; text-transform: none; line-height: 7pt"&gt;&lt;sup id="xdx_F00_zVKZL2f9N4jd"&gt;(g)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5pt"&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_F16_z33wktlgZdSh" style="text-transform: none"&gt;Represents the change as
of the end of the covered fiscal year (from the end of the prior fiscal year) in fair value of equity-based awards granted in prior fiscal
years that were still unvested as of the covered&#160;fiscal year-end.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 9pt/normal Arial, sans-serif; display: none; visibility: hidden; color: #000000; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 15pt; text-align: right"&gt;&lt;span style="font-size: 7pt; text-transform: none; line-height: 7pt"&gt;&lt;sup id="xdx_F09_zDSh6BEP3mZj"&gt;(h)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5pt"&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_F1B_z9Fy81mFQbD5" style="text-transform: none"&gt;Represents the change as
of the vesting date (from the end of the prior fiscal year) in fair value of equity-based awards granted in prior fiscal years that vested
as of the end of or during the covered&#160;fiscal year.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 9pt/normal Arial, sans-serif; display: none; visibility: hidden; color: #000000; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 15pt; text-align: right"&gt;&lt;span style="font-size: 7pt; text-transform: none; line-height: 7pt"&gt;&lt;sup id="xdx_F03_zyLPcLyHWWJe"&gt;(i)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5pt"&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_F1A_z7G5nx6ciLC7" style="text-transform: none"&gt;Equal to summary compensation
total plus/minus any adjustments related to equity award values as reflected in&#160;this table. For purposes of calculating &#x201c;compensation
actually paid,&#x201d; the fair value of equity awards at year-end 2023 and 2024, and on vesting dates for awards that vested during 2024,
were all determined consistent with the approach used to value the awards at the grant date for purposes of the Summary Compensation
Table (refer to &#x201c;Executive Officer Compensation &#x2013; Summary Compensation Table&#x201d; for additional information). For any
awards subject to performance conditions, the change in fair value as of the end of the covered fiscal year is calculated based on the
probable outcome of such conditions as of the last day of the fiscal year. The valuation assumptions used to calculate fair values do
not differ materially from those disclosed at the time of grant, other than as reflected in the table below, which summarizes option
fair values determined using the Black-Scholes model and related assumptions used to calculate Compensation Actually Paid for fiscal&#160;year
2024.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
				&lt;p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 1pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"&gt;&lt;span style="width: 15pt; text-indent: 0; display: inline-block"&gt;&lt;sup style="text-transform: none; font-size: 7pt; line-height: 7pt"&gt;(i)&lt;/sup&gt;&lt;/span&gt;&lt;sup style="text-transform: none; font-size: 7pt; line-height: 7pt"&gt;&lt;/sup&gt;&lt;span style="text-transform: none"&gt;Equal to summary compensation total plus/minus any adjustments related to equity award values as reflected in&#160;this table. For purposes of calculating &#x201c;compensation actually paid,&#x201d; the fair value of equity awards at year-end 2023 and 2024, and on vesting dates for awards that vested during 2024, were all determined consistent with the approach used to value the awards at the grant date for purposes of the Summary Compensation Table (refer to &#x201c;Executive Officer Compensation &#x2013; Summary Compensation Table&#x201d; for additional information). For any awards subject to performance conditions, the change in fair value as of the end of the covered fiscal year is calculated based on the probable outcome of such conditions as of the last day of the fiscal year. The valuation assumptions used to calculate fair values do not differ materially from those disclosed at the time of grant, other than as reflected in the table below, which summarizes option fair values determined using the Black-Scholes model and related assumptions used to calculate Compensation Actually Paid for &lt;/span&gt;&lt;span style="text-transform: none"&gt;fiscal&#160;year 2024.&lt;/span&gt;&lt;/p&gt;

				&lt;div id="xdx_C0B_gL2ATPCFTB-BR_zwK9StH3wMCi" style="margin-bottom: 1pt"&gt;&lt;p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 1pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"&gt;&lt;span style="width: 15pt; text-indent: 0; display: inline-block"&gt;&lt;sup style="text-transform: none; font-size: 7pt; line-height: 7pt"&gt;(e)&lt;/sup&gt;&lt;/span&gt;&lt;sup style="text-transform: none; font-size: 7pt; line-height: 7pt"&gt;&lt;/sup&gt;&lt;span style="text-transform: none"&gt;Represents the grant date fair value of equity-based awards made during the covered fiscal year as reported in the &lt;/span&gt;&lt;span style="text-transform: none"&gt;Summary&#160;Compensation Table.&lt;/span&gt;&lt;/p&gt;
				&lt;p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 1pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"&gt;&lt;span style="width: 15pt; text-indent: 0; display: inline-block"&gt;&lt;sup style="text-transform: none; font-size: 7pt; line-height: 7pt"&gt;(f)&lt;/sup&gt;&lt;/span&gt;&lt;sup style="text-transform: none; font-size: 7pt; line-height: 7pt"&gt;&lt;/sup&gt;&lt;span style="text-transform: none"&gt;Represents the year-end fair value of equity awards that were made during the covered fiscal year and remained unvested as&#160;of the end of the covered &lt;/span&gt;&lt;span style="text-transform: none"&gt;fiscal year.&lt;/span&gt;&lt;/p&gt;
				&lt;p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 1pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"&gt;&lt;span style="width: 15pt; text-indent: 0; display: inline-block"&gt;&lt;sup style="text-transform: none; font-size: 7pt; line-height: 7pt"&gt;(g)&lt;/sup&gt;&lt;/span&gt;&lt;sup style="text-transform: none; font-size: 7pt; line-height: 7pt"&gt;&lt;/sup&gt;&lt;span style="text-transform: none"&gt;Represents the change as of the end of the covered fiscal year (from the end of the prior fiscal year) in fair value of equity-based awards granted in prior fiscal years that were still unvested as of the &lt;/span&gt;&lt;span style="text-transform: none"&gt;covered&#160;fiscal year-end.&lt;/span&gt;&lt;/p&gt;
				&lt;p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 8pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"&gt;&lt;span style="width: 15pt; text-indent: 0; display: inline-block"&gt;&lt;sup style="text-transform: none; font-size: 7pt; line-height: 7pt"&gt;(h)&lt;/sup&gt;&lt;/span&gt;&lt;sup style="text-transform: none; font-size: 7pt; line-height: 7pt"&gt;&lt;/sup&gt;&lt;span style="text-transform: none"&gt;Represents the change as of the vesting date (from the end of the prior fiscal year) in fair value of equity-based awards granted in prior fiscal years that vested as of the end of or during the &lt;/span&gt;&lt;span style="text-transform: none"&gt;covered&#160;fiscal year.&lt;/span&gt;&lt;/p&gt;
				&lt;div id="xdx_893_eecd--EqtyAwrdsAdjFnTextBlock_dU_zd3NhAsLpzpa"&gt;&lt;/div&gt;
				&lt;p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 8pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"&gt;&lt;span style="width: 15pt; text-indent: 0; display: inline-block"&gt;&lt;sup style="text-transform: none; font-size: 7pt; line-height: 7pt"&gt;(i)&lt;/sup&gt;&lt;/span&gt;&lt;sup style="text-transform: none; font-size: 7pt; line-height: 7pt"&gt;&lt;/sup&gt;&lt;span style="text-transform: none"&gt;Equal to summary compensation total plus/minus any adjustments related to equity award values as reflected in&#160;this table. For purposes of calculating &#x201c;compensation actually paid,&#x201d; the fair value of equity awards at year-end 2023 and 2024, and on vesting dates for awards that vested during 2024, were all determined consistent with the approach used to value the awards at the grant date for purposes of the Summary Compensation Table (refer to &#x201c;Executive Officer Compensation &#x2013; Summary Compensation Table&#x201d; for additional information). For any awards subject to performance conditions, the change in fair value as of the end of the covered fiscal year is calculated based on the probable outcome of such conditions as of the last day of the fiscal year. The valuation assumptions used to calculate fair values do not differ materially from those disclosed at the time of grant, other than as reflected in the table below, which summarizes option fair values determined using the Black-Scholes model and related assumptions used to calculate Compensation Actually Paid for &lt;/span&gt;&lt;span style="text-transform: none"&gt;fiscal&#160;year 2024.&lt;/span&gt;&lt;/p&gt;
				&lt;div style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-align: justify"&gt;
					&lt;table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 10pt; border-collapse: collapse"&gt;
						&lt;tr style="margin: 0; height: 0"&gt;
							&lt;td style="border-width: 0; margin: 0; padding: 0; width: 100pt"&gt;


							&lt;/td&gt;
							&lt;td style="border-width: 0; margin: 0; padding: 0; width: 110pt"&gt;


							&lt;/td&gt;
							&lt;td style="border-width: 0; margin: 0; padding: 0; width: 93.75pt"&gt;


							&lt;/td&gt;
							&lt;td style="border-width: 0; margin: 0; padding: 0; width: 92.49pt"&gt;


							&lt;/td&gt;
							&lt;td style="border-width: 0; margin: 0; padding: 0; width: 63.74pt"&gt;


							&lt;/td&gt;
							&lt;td style="border-width: 0; margin: 0; padding: 0; width: 107.5pt"&gt;


							&lt;/td&gt;
							&lt;td style="border-width: 0; margin: 0; padding: 0; width: 107.5pt"&gt;


							&lt;/td&gt;

						&lt;/tr&gt;
						&lt;tr style="min-height: 3pt"&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;b&gt;Valuation&lt;br/&gt;Purpose&lt;br/&gt;for PVP&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;b&gt;AORT&lt;br/&gt;Stock&lt;br/&gt;Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;b&gt;AORT&lt;br/&gt;Option&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;b&gt;Expected&lt;br/&gt;Term&lt;br/&gt;(years)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;b&gt;Stock&lt;br/&gt;Price&lt;br/&gt;Volatility&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;b&gt;Risk-free&lt;br/&gt;Rate&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;b&gt;Option&lt;br/&gt;Fair&lt;br/&gt;Value&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;

						&lt;/tr&gt;
						&lt;tr style="min-height: 3pt"&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"&gt;&lt;span style="text-transform: none"&gt;Year-end 2023&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_905_eus-gaap--SharePrice_iI_pid_c20241231__us-gaap--VestingAxis__custom--YearEnd2023Member_zyoa1YBNpbDh"&gt;$17.88&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20241231__us-gaap--VestingAxis__custom--YearEnd2023Member__srt--RangeAxis__srt--MinimumMember_z5bT910B5iI4"&gt;$11.03&lt;/span&gt; - &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20241231__us-gaap--VestingAxis__custom--YearEnd2023Member__srt--RangeAxis__srt--MaximumMember_zSNEB73O0Sbg"&gt;$24.90&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2023Member__srt--RangeAxis__srt--MinimumMember_zfuoYaTx9a6e"&gt;2.13&lt;/span&gt; &#x2013; &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2023Member__srt--RangeAxis__srt--MaximumMember_z5wuLeKbg0cf"&gt;4.93&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2023Member_z9yVGAlW0uoc"&gt;45&lt;/span&gt;%&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2023Member__srt--RangeAxis__srt--MinimumMember_zDHA9XJYwQOe"&gt;3.85&lt;/span&gt;% - &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2023Member__srt--RangeAxis__srt--MaximumMember_z0ByHjPnHdCi"&gt;4.20&lt;/span&gt;%&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_907_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFairValuePerShare_pid_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2023Member__srt--RangeAxis__srt--MinimumMember_ze1eSKkm7EUc"&gt;$3.11&lt;/span&gt; - &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_90D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFairValuePerShare_pid_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2023Member__srt--RangeAxis__srt--MaximumMember_z1wedYtymmOh"&gt;$9.89&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;

						&lt;/tr&gt;
						&lt;tr style="min-height: 3pt"&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"&gt;&lt;span style="text-transform: none"&gt;2024 Vesting&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_90A_eus-gaap--SharePrice_iI_pid_c20241231__us-gaap--VestingAxis__custom--Vesting2024Member__srt--RangeAxis__srt--MinimumMember_zeHkPyKExvF4"&gt;$18.81&lt;/span&gt; - &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_90D_eus-gaap--SharePrice_iI_pid_c20241231__us-gaap--VestingAxis__custom--Vesting2024Member__srt--RangeAxis__srt--MaximumMember_zH7RgbVEMs58"&gt;$29.66&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20241231__us-gaap--VestingAxis__custom--Vesting2024Member__srt--RangeAxis__srt--MinimumMember_zsBXXbgZNSHd"&gt;$11.03&lt;/span&gt; - &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20241231__us-gaap--VestingAxis__custom--Vesting2024Member__srt--RangeAxis__srt--MaximumMember_ziJ1ynfMcNij"&gt;$24.90&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20240101__20241231__us-gaap--VestingAxis__custom--Vesting2024Member__srt--RangeAxis__srt--MinimumMember_zyE2UDf1ohbd"&gt;2.00&lt;/span&gt; &#x2013; &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20240101__20241231__us-gaap--VestingAxis__custom--Vesting2024Member__srt--RangeAxis__srt--MaximumMember_z8x2k6FvKVSj"&gt;3.40&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20240101__20241231__us-gaap--VestingAxis__custom--Vesting2024Member_zqBT2vNbZH2e"&gt;45&lt;/span&gt;%&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20240101__20241231__us-gaap--VestingAxis__custom--Vesting2024Member__srt--RangeAxis__srt--MinimumMember_zAf0GFsQYSJ7"&gt;4.05&lt;/span&gt;% - &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20240101__20241231__us-gaap--VestingAxis__custom--Vesting2024Member__srt--RangeAxis__srt--MaximumMember_zruoGuGQVtce"&gt;4.64&lt;/span&gt;%&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_906_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFairValuePerShare_pid_c20240101__20241231__us-gaap--VestingAxis__custom--Vesting2024Member__srt--RangeAxis__srt--MinimumMember_zqoe5lHLTR5k"&gt;$3.44&lt;/span&gt; - &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFairValuePerShare_pid_c20240101__20241231__us-gaap--VestingAxis__custom--Vesting2024Member__srt--RangeAxis__srt--MaximumMember_z2zUAhP8h8wd"&gt;$19.34&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;

						&lt;/tr&gt;
						&lt;tr style="min-height: 3pt"&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"&gt;&lt;span style="text-transform: none"&gt;Year-end 2024&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_90A_eus-gaap--SharePrice_iI_pid_c20241231__us-gaap--VestingAxis__custom--YearEnd2024Member_zIcNvc8rKnKg"&gt;$28.59&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20241231__us-gaap--VestingAxis__custom--YearEnd2024Member__srt--RangeAxis__srt--MinimumMember_zcefl9K22g16"&gt;$11.03&lt;/span&gt; - &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20241231__us-gaap--VestingAxis__custom--YearEnd2024Member__srt--RangeAxis__srt--MaximumMember_z79asRnmmY7g"&gt;$18.44&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2024Member__srt--RangeAxis__srt--MinimumMember_zdOWKWyp5Xq4"&gt;2.15&lt;/span&gt; &#x2013; &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2024Member__srt--RangeAxis__srt--MaximumMember_zba4BTXP2Uxf"&gt;3.93&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2024Member_zxqzATqctpVj"&gt;45&lt;/span&gt;%&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2024Member__srt--RangeAxis__srt--MinimumMember_zS6AZcNjtIsg"&gt;4.25&lt;/span&gt;% - &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2024Member__srt--RangeAxis__srt--MaximumMember_zdBzYd0oKpy9"&gt;4.32&lt;/span&gt;%&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_904_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFairValuePerShare_pid_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2024Member__srt--RangeAxis__srt--MinimumMember_zkhvEywZAjze"&gt;$13.41&lt;/span&gt; - &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_90E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFairValuePerShare_pid_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2024Member__srt--RangeAxis__srt--MaximumMember_zL4O8QW1feQ6"&gt;$19.23&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;

						&lt;/tr&gt;

					&lt;/table&gt;
					&lt;div id="xdx_8A7_z9KbHUprOhfa"&gt;&lt;/div&gt;
					&lt;div id="xdx_858_zGbldmmTkFHa"&gt;&lt;/div&gt;
				&lt;/div&gt;
				&lt;/div&gt;
			</ecd:PvpTableTextBlock>
    <ecd:PeoTotalCompAmt
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000019"
      unitRef="USD">5511940</ecd:PeoTotalCompAmt>
    <ecd:PeoActuallyPaidCompAmt
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000020"
      unitRef="USD">12328862</ecd:PeoActuallyPaidCompAmt>
    <ecd:NonPeoNeoAvgTotalCompAmt
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000021"
      unitRef="USD">1703153</ecd:NonPeoNeoAvgTotalCompAmt>
    <ecd:NonPeoNeoAvgCompActuallyPaidAmt
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000022"
      unitRef="USD">3151020</ecd:NonPeoNeoAvgCompActuallyPaidAmt>
    <ecd:TotalShareholderRtnAmt
      contextRef="From2024-01-01to2024-12-31"
      decimals="2"
      id="Fact000023"
      unitRef="USD">106</ecd:TotalShareholderRtnAmt>
    <ecd:PeerGroupTotalShareholderRtnAmt
      contextRef="From2024-01-01to2024-12-31"
      decimals="2"
      id="Fact000024"
      unitRef="USD">138</ecd:PeerGroupTotalShareholderRtnAmt>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="-6"
      id="Fact000025"
      unitRef="USD">-13000000</us-gaap:NetIncomeLoss>
    <ecd:CoSelectedMeasureAmt
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000026"
      unitRef="Ratio">0.09</ecd:CoSelectedMeasureAmt>
    <ecd:PeoTotalCompAmt
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000027"
      unitRef="USD">3176413</ecd:PeoTotalCompAmt>
    <ecd:PeoActuallyPaidCompAmt
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000028"
      unitRef="USD">7225878</ecd:PeoActuallyPaidCompAmt>
    <ecd:NonPeoNeoAvgTotalCompAmt
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000029"
      unitRef="USD">1204664</ecd:NonPeoNeoAvgTotalCompAmt>
    <ecd:NonPeoNeoAvgCompActuallyPaidAmt
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000030"
      unitRef="USD">1835407</ecd:NonPeoNeoAvgCompActuallyPaidAmt>
    <ecd:TotalShareholderRtnAmt
      contextRef="From2023-01-012023-12-31"
      decimals="2"
      id="Fact000031"
      unitRef="USD">66</ecd:TotalShareholderRtnAmt>
    <ecd:PeerGroupTotalShareholderRtnAmt
      contextRef="From2023-01-012023-12-31"
      decimals="2"
      id="Fact000032"
      unitRef="USD">124</ecd:PeerGroupTotalShareholderRtnAmt>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="-6"
      id="Fact000033"
      unitRef="USD">-31000000</us-gaap:NetIncomeLoss>
    <ecd:CoSelectedMeasureAmt
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000034"
      unitRef="Ratio">0.12</ecd:CoSelectedMeasureAmt>
    <ecd:PeoTotalCompAmt
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000035"
      unitRef="USD">7216340</ecd:PeoTotalCompAmt>
    <ecd:PeoActuallyPaidCompAmt
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000036"
      unitRef="USD">4718496</ecd:PeoActuallyPaidCompAmt>
    <ecd:NonPeoNeoAvgTotalCompAmt
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000037"
      unitRef="USD">1796100</ecd:NonPeoNeoAvgTotalCompAmt>
    <ecd:NonPeoNeoAvgCompActuallyPaidAmt
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000038"
      unitRef="USD">1352869</ecd:NonPeoNeoAvgCompActuallyPaidAmt>
    <ecd:TotalShareholderRtnAmt
      contextRef="From2022-01-012022-12-31"
      decimals="2"
      id="Fact000039"
      unitRef="USD">45</ecd:TotalShareholderRtnAmt>
    <ecd:PeerGroupTotalShareholderRtnAmt
      contextRef="From2022-01-012022-12-31"
      decimals="2"
      id="Fact000040"
      unitRef="USD">114</ecd:PeerGroupTotalShareholderRtnAmt>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31"
      decimals="-6"
      id="Fact000041"
      unitRef="USD">-19000000</us-gaap:NetIncomeLoss>
    <ecd:CoSelectedMeasureAmt
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact000042"
      unitRef="Ratio">0.09</ecd:CoSelectedMeasureAmt>
    <ecd:PeoTotalCompAmt
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      id="Fact000043"
      unitRef="USD">4628566</ecd:PeoTotalCompAmt>
    <ecd:PeoActuallyPaidCompAmt
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      id="Fact000044"
      unitRef="USD">3712538</ecd:PeoActuallyPaidCompAmt>
    <ecd:NonPeoNeoAvgTotalCompAmt
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      id="Fact000045"
      unitRef="USD">1286725</ecd:NonPeoNeoAvgTotalCompAmt>
    <ecd:NonPeoNeoAvgCompActuallyPaidAmt
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      id="Fact000046"
      unitRef="USD">1108935</ecd:NonPeoNeoAvgCompActuallyPaidAmt>
    <ecd:TotalShareholderRtnAmt
      contextRef="From2021-01-012021-12-31"
      decimals="2"
      id="Fact000047"
      unitRef="USD">75</ecd:TotalShareholderRtnAmt>
    <ecd:PeerGroupTotalShareholderRtnAmt
      contextRef="From2021-01-012021-12-31"
      decimals="2"
      id="Fact000048"
      unitRef="USD">140</ecd:PeerGroupTotalShareholderRtnAmt>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31"
      decimals="-6"
      id="Fact000049"
      unitRef="USD">-15000000</us-gaap:NetIncomeLoss>
    <ecd:CoSelectedMeasureAmt
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      id="Fact000050"
      unitRef="Ratio">0.16</ecd:CoSelectedMeasureAmt>
    <ecd:PeoTotalCompAmt
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      id="Fact000051"
      unitRef="USD">3415458</ecd:PeoTotalCompAmt>
    <ecd:PeoActuallyPaidCompAmt
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      id="Fact000052"
      unitRef="USD">327652</ecd:PeoActuallyPaidCompAmt>
    <ecd:NonPeoNeoAvgTotalCompAmt
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      id="Fact000053"
      unitRef="USD">977089</ecd:NonPeoNeoAvgTotalCompAmt>
    <ecd:NonPeoNeoAvgCompActuallyPaidAmt
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      id="Fact000054"
      unitRef="USD">454642</ecd:NonPeoNeoAvgCompActuallyPaidAmt>
    <ecd:TotalShareholderRtnAmt
      contextRef="From2020-01-012020-12-31"
      decimals="2"
      id="Fact000055"
      unitRef="USD">87</ecd:TotalShareholderRtnAmt>
    <ecd:PeerGroupTotalShareholderRtnAmt
      contextRef="From2020-01-012020-12-31"
      decimals="2"
      id="Fact000056"
      unitRef="USD">118</ecd:PeerGroupTotalShareholderRtnAmt>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-012020-12-31"
      decimals="-6"
      id="Fact000057"
      unitRef="USD">-17000000</us-gaap:NetIncomeLoss>
    <ecd:CoSelectedMeasureAmt
      contextRef="From2020-01-012020-12-31"
      decimals="INF"
      id="Fact000058"
      unitRef="Ratio">-0.08</ecd:CoSelectedMeasureAmt>
    <ecd:NamedExecutiveOfficersFnTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000064">&lt;div id="xdx_849_eecd--NamedExecutiveOfficersFnTextBlock_dU_z7OrBB38Rks2"&gt;&lt;/div&gt;
				&lt;p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 1pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"&gt;&lt;span style="width: 15pt; text-indent: 0; display: inline-block"&gt;&lt;sup style="text-transform: none; font-size: 7pt; line-height: 7pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;sup style="text-transform: none; font-size: 7pt; line-height: 7pt"&gt;&lt;/sup&gt;&lt;span style="text-transform: none"&gt;&lt;span id="xdx_908_eecd--PeoName_c20200101__20201231_znEPlCJI9E8b"&gt;&lt;span id="xdx_90F_eecd--PeoName_c20210101__20211231_zY0OfcfAZp01"&gt;&lt;span id="xdx_905_eecd--PeoName_c20220101__20221231_zZHCoC7y8gnc"&gt;&lt;span id="xdx_904_eecd--PeoName_c20230101__20231231_zddNZUNYL4Qf"&gt;&lt;span id="xdx_900_eecd--PeoName_c20240101__20241231_znX2Xqykizi6"&gt;Mr. Mackin&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&#160;served as our only PEO &lt;/span&gt;&lt;span style="text-transform: none"&gt;for&#160;each year.&lt;/span&gt;&lt;/p&gt;
				&lt;p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 1pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"&gt;&lt;span style="width: 15pt; text-indent: 0; display: inline-block"&gt;&lt;sup style="text-transform: none; font-size: 7pt; line-height: 7pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;sup style="text-transform: none; font-size: 7pt; line-height: 7pt"&gt;&lt;/sup&gt;&lt;span style="text-transform: none"&gt;Our Non-PEO NEOs in 2024 were Messrs. Berry, Davis and Stanton and Ms. Holloway. Our Non-PEO NEOs in 2023 were Messrs. Lee, Berry, Davis and Mses. Horton and Holloway. Our Non-PEO NEOs in 2022 and 2021 were&#160;Messrs. Lee,&#160;Davis,&#160;Stanton&#160;and&#160;Ms. Holloway. Our Non-PEO NEOs in 2020 &lt;/span&gt;&lt;span style="text-transform: none"&gt;were&#160;Messrs.&#160;Lee,&#160;Davis,&#160;Simpson,&#160;and&#160;Ms. Holloway.&lt;/span&gt;&lt;/p&gt;
</ecd:NamedExecutiveOfficersFnTextBlock>
    <ecd:PeoName contextRef="From2020-01-012020-12-31" id="Fact000065">Mr. Mackin</ecd:PeoName>
    <ecd:PeoName contextRef="From2021-01-012021-12-31" id="Fact000066">Mr. Mackin</ecd:PeoName>
    <ecd:PeoName contextRef="From2022-01-012022-12-31" id="Fact000067">Mr. Mackin</ecd:PeoName>
    <ecd:PeoName contextRef="From2023-01-012023-12-31" id="Fact000068">Mr. Mackin</ecd:PeoName>
    <ecd:PeoName contextRef="From2024-01-01to2024-12-31" id="Fact000069">Mr. Mackin</ecd:PeoName>
    <ecd:NonGaapMeasureDescriptionTextBlock contextRef="From2024-01-012024-12-31_1" id="Fact000070">In the Company&#x2019;s assessment, for the 2024 fiscal year, &lt;span id="xdx_90D_eecd--CoSelectedMeasureName_c20240101__20241231_zqgOKiYCGonc"&gt;AORT revenue growth&lt;/span&gt; represents the most important financial performance measure that is not otherwise required to be disclosed in the table that we used to link &#x201c;compensation actually paid&#x201d; to our NEOs, including our PEO, to our performance. AORT revenue growth is an adjusted constant currency revenue measure calculated by adjusting for the exchange rate effect on GAAP revenues. We define exchange rate effect as the year-over-year impact of foreign currency movements using current period foreign currency rates applied to prior period transactional currency amounts. As discussed in the Compensation Discussion &amp;amp; Analysis, constant currency revenue growth as calculated in incentive plans may reflect additional adjustments to either the baseline (prior year revenue) or current year results, to exclude the impact of discontinued businesses and other unplanned events that were outside of management&#x2019;s control. In 2023, we excluded the impact of the Company&#x2019;s Cardiogenesis business. In 2022, we adjusted to exclude PerClot sales that occurred in 2022 and 2021. In 2021, we measured growth in the second half of the year by comparing to the second half of 2019 rather than 2020.</ecd:NonGaapMeasureDescriptionTextBlock>
    <ecd:CoSelectedMeasureName contextRef="From2024-01-01to2024-12-31" id="Fact000071">AORT revenue growth</ecd:CoSelectedMeasureName>
    <ecd:AdjToPeoCompFnTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000074">&lt;p id="xdx_84D_eecd--AdjToPeoCompFnTextBlock_dU_gL2ATPCFTB-BR_z1I5XfViUMj8" style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"&gt;&lt;span style="text-transform: none; line-height: 12pt"&gt;The following table sets forth a reconciliation from the Summary Compensation Table (&#x201c;SCT&#x201d;) to Compensation Actually Paid (&#x201c;CAP&#x201d;) to our PEO and for the average paid to our Non-PEO NEOs for each &lt;/span&gt;&lt;span style="text-transform: none; line-height: 12pt"&gt;fiscal year.&lt;/span&gt;&lt;/p&gt;
				&lt;table id="xdx_308_zVWZIriixLRa" style="table-layout: fixed; width: 674.68pt; margin-top: 4pt; margin-bottom: 10pt; border-collapse: collapse" summary="xdx: Disclosure - Pay vs Performance Disclosure"&gt;
						&lt;tr style="margin: 0; height: 0"&gt;
							&lt;td style="text-align: left; border-width: 0; margin: 0; padding: 0; width: 142.49pt"&gt;


							&lt;/td&gt;
							&lt;td style="border-width: 0; margin: 0; padding: 0; width: 88.74pt"&gt;


							&lt;/td&gt;
							&lt;td style="border-width: 0; margin: 0; padding: 0; width: 89.06pt"&gt;


							&lt;/td&gt;
							&lt;td style="border-width: 0; margin: 0; padding: 0; width: 84.37pt"&gt;


							&lt;/td&gt;
							&lt;td style="border-width: 0; margin: 0; padding: 0; width: 90pt"&gt;


							&lt;/td&gt;
							&lt;td style="border-width: 0; margin: 0; padding: 0; width: 84.37pt"&gt;


							&lt;/td&gt;
							&lt;td style="border-width: 0; margin: 0; padding: 0; width: 95.62pt"&gt;


							&lt;/td&gt;

						&lt;/tr&gt;
						&lt;tr style="min-height: 3pt"&gt;
							&lt;td style="text-align: left; border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;b&gt;Year&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;b&gt;SCT&lt;br/&gt;Total&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;b&gt;Less Sum of&lt;br/&gt;Stock and&lt;br/&gt;Option Award&lt;br/&gt;Values from&lt;br/&gt;SCT&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;b&gt;Value of&lt;br/&gt;Current&lt;br/&gt;Year Equity&lt;br/&gt;Awards at&lt;br/&gt;12/31&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;b&gt;Change in&lt;br/&gt;Value of&lt;br/&gt;Unvested Prior&lt;br/&gt;Year Awards at&lt;br/&gt;12/31&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;b&gt;Change in&lt;br/&gt;Value of Prior&lt;br/&gt;Year Awards&lt;br/&gt;That Vested&lt;br/&gt;In Current&lt;br/&gt;Year&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;b&gt;Total&lt;br/&gt;Compensation&lt;br/&gt;Actually Paid&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;

						&lt;/tr&gt;
						&lt;tr style="min-height: 3pt"&gt;
							&lt;td style="text-align: left; border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="text-align: left; margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt"&gt;&#x200b;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt"&gt;&#x200b;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;b&gt; (e) &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;b&gt; (f) &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;b&gt; (g) &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;b&gt; (h) &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;b&gt;(i)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;

						&lt;/tr&gt;
						&lt;tr style="min-height: 3pt"&gt;
							&lt;td style="text-align: left; border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"&gt;&lt;span style="text-transform: none"&gt;2024&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_98F_eecd--PeoTotalCompAmt_c20240101__20241231_zemY5XBdadxg" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;$5,511,940&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 7pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_982_eecd--AdjToCompAmt_c20240101__20241231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--EqtyAwrdsInSummryCompstnTblForAplblYrMember_fKGUp_zpc4FwAn8mG" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;($3,608,101)&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_98B_eecd--AdjToCompAmt_c20240101__20241231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_fKGYp_zPM9LlTzo3K9" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;$5,852,430&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 10pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_98C_eecd--AdjToCompAmt_c20240101__20241231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_fKGcp_zobmolIoUIVj" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;$3,370,222&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 10pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_98C_eecd--AdjToCompAmt_c20240101__20241231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_fKGgp_zXPqHhvacd8d" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;$1,202,370&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 11pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_98F_eecd--PeoActuallyPaidCompAmt_c20240101__20241231_fKGkp_ziEqyW33lUP5" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;  $12,328,862&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;

						&lt;/tr&gt;
						&lt;tr style="min-height: 3pt"&gt;
							&lt;td style="border-width: 0pt; text-align: left; padding: 1.5pt 0pt 1.5pt 3pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: left"&gt;&lt;span style="text-transform: none"&gt;2023&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_983_eecd--PeoTotalCompAmt_c20230101__20231231_zy5Mge1YGukk" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;$3,176,413&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 7pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_987_eecd--AdjToCompAmt_c20230101__20231231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--EqtyAwrdsInSummryCompstnTblForAplblYrMember_fKGUp_zHj7xU8g9oBc" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&#x2002; ($801,938)&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_985_eecd--AdjToCompAmt_c20230101__20231231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_fKGYp_zMdhmvbrG5fi" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;$1,771,014&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 10pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_980_eecd--AdjToCompAmt_c20230101__20231231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_fKGcp_zP3BA88jqry" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;$2,775,817&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 10pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_980_eecd--AdjToCompAmt_c20230101__20231231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_fKGgp_zkWvh3ykRXfi" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;  $304,572&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 11pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_98A_eecd--PeoActuallyPaidCompAmt_c20230101__20231231_fKGkp_zVmA0VUBAb71" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;$7,225,878&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;

						&lt;/tr&gt;
						&lt;tr style="min-height: 3pt"&gt;
							&lt;td style="border-width: 0pt; text-align: left; padding: 1.5pt 0pt 1.5pt 3pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: left"&gt;&lt;span style="text-transform: none"&gt;2022&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_98A_eecd--PeoTotalCompAmt_c20220101__20221231_zoGHyJZbiJbh" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;$7,216,340&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 7pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_98C_eecd--AdjToCompAmt_c20220101__20221231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--EqtyAwrdsInSummryCompstnTblForAplblYrMember_fKGUp_zijFSTRwDKz9" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;($5,587,257)&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_98C_eecd--AdjToCompAmt_c20220101__20221231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_fKGYp_z0bLeuqpqHVh" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;$4,689,996&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 7pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_982_eecd--AdjToCompAmt_c20220101__20221231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_fKGcp_zOR7dMRuabv3" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;($1,385,504)&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 7pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_984_eecd--AdjToCompAmt_c20220101__20221231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_fKGgp_zj603AnWzEs2" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;  ($215,079)&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 11pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_98B_eecd--PeoActuallyPaidCompAmt_c20220101__20221231_fKGkp_zxCNN0mEKMb9" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;$4,718,496&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;

						&lt;/tr&gt;
						&lt;tr style="min-height: 3pt"&gt;
							&lt;td style="border-width: 0pt; text-align: left; padding: 1.5pt 0pt 1.5pt 3pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: left"&gt;&lt;span style="text-transform: none"&gt;2021&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_98E_eecd--PeoTotalCompAmt_c20210101__20211231_ztAU8dB027n9" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;$4,628,566&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 7pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_98B_eecd--AdjToCompAmt_c20210101__20211231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--EqtyAwrdsInSummryCompstnTblForAplblYrMember_fKGUp_zDFEgmTMRn73" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;($2,977,494)&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_98A_eecd--AdjToCompAmt_c20210101__20211231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_fKGYp_z7o9Mqn0GJV1" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;$2,402,215&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 7pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_98B_eecd--AdjToCompAmt_c20210101__20211231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_fKGcp_zc5hLlTdy1hk" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&#x2002; ($495,663)&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 10pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_98C_eecd--AdjToCompAmt_c20210101__20211231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_fKGgp_zyzTOoKZTUEh" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;$154,913&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 11pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_984_eecd--PeoActuallyPaidCompAmt_c20210101__20211231_fKGkp_zD4ijklw5Ul8" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;$3,712,538&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;

						&lt;/tr&gt;
						&lt;tr style="min-height: 3pt"&gt;
							&lt;td style="border-width: 0pt; text-align: left; padding: 1.5pt 0pt 1.5pt 3pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: left"&gt;&lt;span style="text-transform: none"&gt;2020&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_980_eecd--PeoTotalCompAmt_c20200101__20201231_zdhn2cMbmx3b" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;$3,415,458&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 7pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_98C_eecd--AdjToCompAmt_c20200101__20201231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--EqtyAwrdsInSummryCompstnTblForAplblYrMember_fKGUp_zNz1YCiWqC9k" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;($2,323,534)&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_980_eecd--AdjToCompAmt_c20200101__20201231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_fKGYp_z8lDHJMvAFRh" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;$1,931,021&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 7pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_98C_eecd--AdjToCompAmt_c20200101__20201231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_fKGcp_z7fZxiI4LKxj" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;($2,326,940)&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 7pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_98D_eecd--AdjToCompAmt_c20200101__20201231__ecd--ExecutiveCategoryAxis__ecd--PeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_fKGgp_zDtII3fwInTk" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;($368,352)&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 11pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_98F_eecd--PeoActuallyPaidCompAmt_c20200101__20201231_fKGkp_zssJsD9lBFZ5" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&#x2002; $327,652&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;

						&lt;/tr&gt;

					&lt;/table&gt;

				&lt;table cellpadding="0" cellspacing="0" style="font: 9pt/normal Arial, sans-serif; display: none; visibility: hidden; color: #000000; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 15pt; text-align: right"&gt;&lt;span style="font-size: 7pt; text-transform: none; line-height: 7pt"&gt;&lt;sup id="xdx_F05_zBhfDSiTlHrk"&gt;(e)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5pt"&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_F15_zuBc0O9oGre3" style="text-transform: none"&gt;Represents the grant date
fair value of equity-based awards made during the covered fiscal year as reported in the Summary&#160;Compensation Table.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 9pt/normal Arial, sans-serif; display: none; visibility: hidden; color: #000000; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 15pt; text-align: right"&gt;&lt;span style="font-size: 7pt; text-transform: none; line-height: 7pt"&gt;&lt;sup id="xdx_F09_zhLUB9FGOI76"&gt;(f)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5pt"&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_F11_z9fCcMfCAWB5" style="text-transform: none"&gt;Represents the year-end
fair value of equity awards that were made during the covered fiscal year and remained unvested as&#160;of the end of the covered fiscal
year.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 9pt/normal Arial, sans-serif; display: none; visibility: hidden; color: #000000; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 15pt; text-align: right"&gt;&lt;span style="font-size: 7pt; text-transform: none; line-height: 7pt"&gt;&lt;sup id="xdx_F04_zJNwH9gobYo7"&gt;(g)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5pt"&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_F1D_z7HeYnvfn6F6" style="text-transform: none"&gt;Represents the change as
of the end of the covered fiscal year (from the end of the prior fiscal year) in fair value of equity-based awards granted in prior fiscal
years that were still unvested as of the covered&#160;fiscal year-end.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 9pt/normal Arial, sans-serif; display: none; visibility: hidden; color: #000000; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 15pt; text-align: right"&gt;&lt;span style="font-size: 7pt; text-transform: none; line-height: 7pt"&gt;&lt;sup id="xdx_F00_zMc9VSmuo24k"&gt;(h)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5pt"&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_F15_zGLIg8Tf6rg7" style="text-transform: none"&gt;Represents the change as
of the vesting date (from the end of the prior fiscal year) in fair value of equity-based awards granted in prior fiscal years that vested
as of the end of or during the covered&#160;fiscal year.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 9pt/normal Arial, sans-serif; display: none; visibility: hidden; color: #000000; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 15pt; text-align: right"&gt;&lt;span style="font-size: 7pt; text-transform: none; line-height: 7pt"&gt;&lt;sup id="xdx_F0C_zhsBSlRhRjtj"&gt;(i)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5pt"&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_F12_zqUVtIkQNNNc" style="text-transform: none"&gt;Equal to summary compensation
total plus/minus any adjustments related to equity award values as reflected in&#160;this table. For purposes of calculating &#x201c;compensation
actually paid,&#x201d; the fair value of equity awards at year-end 2023 and 2024, and on vesting dates for awards that vested during 2024,
were all determined consistent with the approach used to value the awards at the grant date for purposes of the Summary Compensation
Table (refer to &#x201c;Executive Officer Compensation &#x2013; Summary Compensation Table&#x201d; for additional information). For any
awards subject to performance conditions, the change in fair value as of the end of the covered fiscal year is calculated based on the
probable outcome of such conditions as of the last day of the fiscal year. The valuation assumptions used to calculate fair values do
not differ materially from those disclosed at the time of grant, other than as reflected in the table below, which summarizes option
fair values determined using the Black-Scholes model and related assumptions used to calculate Compensation Actually Paid for fiscal&#160;year
2024.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

				&lt;p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 1pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"&gt;&lt;span style="width: 15pt; text-indent: 0; display: inline-block"&gt;&lt;sup style="text-transform: none; font-size: 7pt; line-height: 7pt"&gt;(e)&lt;/sup&gt;&lt;/span&gt;&lt;sup style="text-transform: none; font-size: 7pt; line-height: 7pt"&gt;&lt;/sup&gt;&lt;span style="text-transform: none"&gt;Represents the grant date fair value of equity-based awards made during the covered fiscal year as reported in the &lt;/span&gt;&lt;span style="text-transform: none"&gt;Summary&#160;Compensation Table.&lt;/span&gt;&lt;/p&gt;
				&lt;p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 1pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"&gt;&lt;span style="width: 15pt; text-indent: 0; display: inline-block"&gt;&lt;sup style="text-transform: none; font-size: 7pt; line-height: 7pt"&gt;(f)&lt;/sup&gt;&lt;/span&gt;&lt;sup style="text-transform: none; font-size: 7pt; line-height: 7pt"&gt;&lt;/sup&gt;&lt;span style="text-transform: none"&gt;Represents the year-end fair value of equity awards that were made during the covered fiscal year and remained unvested as&#160;of the end of the covered &lt;/span&gt;&lt;span style="text-transform: none"&gt;fiscal year.&lt;/span&gt;&lt;/p&gt;
				&lt;p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 1pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"&gt;&lt;span style="width: 15pt; text-indent: 0; display: inline-block"&gt;&lt;sup style="text-transform: none; font-size: 7pt; line-height: 7pt"&gt;(g)&lt;/sup&gt;&lt;/span&gt;&lt;sup style="text-transform: none; font-size: 7pt; line-height: 7pt"&gt;&lt;/sup&gt;&lt;span style="text-transform: none"&gt;Represents the change as of the end of the covered fiscal year (from the end of the prior fiscal year) in fair value of equity-based awards granted in prior fiscal years that were still unvested as of the &lt;/span&gt;&lt;span style="text-transform: none"&gt;covered&#160;fiscal year-end.&lt;/span&gt;&lt;/p&gt;
				&lt;p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 8pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"&gt;&lt;span style="width: 15pt; text-indent: 0; display: inline-block"&gt;&lt;sup style="text-transform: none; font-size: 7pt; line-height: 7pt"&gt;(h)&lt;/sup&gt;&lt;/span&gt;&lt;sup style="text-transform: none; font-size: 7pt; line-height: 7pt"&gt;&lt;/sup&gt;&lt;span style="text-transform: none"&gt;Represents the change as of the vesting date (from the end of the prior fiscal year) in fair value of equity-based awards granted in prior fiscal years that vested as of the end of or during the &lt;/span&gt;&lt;span style="text-transform: none"&gt;covered&#160;fiscal year.&lt;/span&gt;&lt;/p&gt;
				&lt;div id="xdx_893_eecd--EqtyAwrdsAdjFnTextBlock_dU_zd3NhAsLpzpa"&gt;&lt;/div&gt;
				&lt;p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 8pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"&gt;&lt;span style="width: 15pt; text-indent: 0; display: inline-block"&gt;&lt;sup style="text-transform: none; font-size: 7pt; line-height: 7pt"&gt;(i)&lt;/sup&gt;&lt;/span&gt;&lt;sup style="text-transform: none; font-size: 7pt; line-height: 7pt"&gt;&lt;/sup&gt;&lt;span style="text-transform: none"&gt;Equal to summary compensation total plus/minus any adjustments related to equity award values as reflected in&#160;this table. For purposes of calculating &#x201c;compensation actually paid,&#x201d; the fair value of equity awards at year-end 2023 and 2024, and on vesting dates for awards that vested during 2024, were all determined consistent with the approach used to value the awards at the grant date for purposes of the Summary Compensation Table (refer to &#x201c;Executive Officer Compensation &#x2013; Summary Compensation Table&#x201d; for additional information). For any awards subject to performance conditions, the change in fair value as of the end of the covered fiscal year is calculated based on the probable outcome of such conditions as of the last day of the fiscal year. The valuation assumptions used to calculate fair values do not differ materially from those disclosed at the time of grant, other than as reflected in the table below, which summarizes option fair values determined using the Black-Scholes model and related assumptions used to calculate Compensation Actually Paid for &lt;/span&gt;&lt;span style="text-transform: none"&gt;fiscal&#160;year 2024.&lt;/span&gt;&lt;/p&gt;
				&lt;div style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-align: justify"&gt;
					&lt;table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 10pt; border-collapse: collapse"&gt;
						&lt;tr style="margin: 0; height: 0"&gt;
							&lt;td style="border-width: 0; margin: 0; padding: 0; width: 100pt"&gt;


							&lt;/td&gt;
							&lt;td style="border-width: 0; margin: 0; padding: 0; width: 110pt"&gt;


							&lt;/td&gt;
							&lt;td style="border-width: 0; margin: 0; padding: 0; width: 93.75pt"&gt;


							&lt;/td&gt;
							&lt;td style="border-width: 0; margin: 0; padding: 0; width: 92.49pt"&gt;


							&lt;/td&gt;
							&lt;td style="border-width: 0; margin: 0; padding: 0; width: 63.74pt"&gt;


							&lt;/td&gt;
							&lt;td style="border-width: 0; margin: 0; padding: 0; width: 107.5pt"&gt;


							&lt;/td&gt;
							&lt;td style="border-width: 0; margin: 0; padding: 0; width: 107.5pt"&gt;


							&lt;/td&gt;

						&lt;/tr&gt;
						&lt;tr style="min-height: 3pt"&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;b&gt;Valuation&lt;br/&gt;Purpose&lt;br/&gt;for PVP&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;b&gt;AORT&lt;br/&gt;Stock&lt;br/&gt;Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;b&gt;AORT&lt;br/&gt;Option&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;b&gt;Expected&lt;br/&gt;Term&lt;br/&gt;(years)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;b&gt;Stock&lt;br/&gt;Price&lt;br/&gt;Volatility&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;b&gt;Risk-free&lt;br/&gt;Rate&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;b&gt;Option&lt;br/&gt;Fair&lt;br/&gt;Value&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;

						&lt;/tr&gt;
						&lt;tr style="min-height: 3pt"&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"&gt;&lt;span style="text-transform: none"&gt;Year-end 2023&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_905_eus-gaap--SharePrice_iI_pid_c20241231__us-gaap--VestingAxis__custom--YearEnd2023Member_zyoa1YBNpbDh"&gt;$17.88&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20241231__us-gaap--VestingAxis__custom--YearEnd2023Member__srt--RangeAxis__srt--MinimumMember_z5bT910B5iI4"&gt;$11.03&lt;/span&gt; - &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20241231__us-gaap--VestingAxis__custom--YearEnd2023Member__srt--RangeAxis__srt--MaximumMember_zSNEB73O0Sbg"&gt;$24.90&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2023Member__srt--RangeAxis__srt--MinimumMember_zfuoYaTx9a6e"&gt;2.13&lt;/span&gt; &#x2013; &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2023Member__srt--RangeAxis__srt--MaximumMember_z5wuLeKbg0cf"&gt;4.93&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2023Member_z9yVGAlW0uoc"&gt;45&lt;/span&gt;%&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2023Member__srt--RangeAxis__srt--MinimumMember_zDHA9XJYwQOe"&gt;3.85&lt;/span&gt;% - &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2023Member__srt--RangeAxis__srt--MaximumMember_z0ByHjPnHdCi"&gt;4.20&lt;/span&gt;%&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_907_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFairValuePerShare_pid_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2023Member__srt--RangeAxis__srt--MinimumMember_ze1eSKkm7EUc"&gt;$3.11&lt;/span&gt; - &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_90D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFairValuePerShare_pid_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2023Member__srt--RangeAxis__srt--MaximumMember_z1wedYtymmOh"&gt;$9.89&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;

						&lt;/tr&gt;
						&lt;tr style="min-height: 3pt"&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"&gt;&lt;span style="text-transform: none"&gt;2024 Vesting&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_90A_eus-gaap--SharePrice_iI_pid_c20241231__us-gaap--VestingAxis__custom--Vesting2024Member__srt--RangeAxis__srt--MinimumMember_zeHkPyKExvF4"&gt;$18.81&lt;/span&gt; - &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_90D_eus-gaap--SharePrice_iI_pid_c20241231__us-gaap--VestingAxis__custom--Vesting2024Member__srt--RangeAxis__srt--MaximumMember_zH7RgbVEMs58"&gt;$29.66&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20241231__us-gaap--VestingAxis__custom--Vesting2024Member__srt--RangeAxis__srt--MinimumMember_zsBXXbgZNSHd"&gt;$11.03&lt;/span&gt; - &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20241231__us-gaap--VestingAxis__custom--Vesting2024Member__srt--RangeAxis__srt--MaximumMember_ziJ1ynfMcNij"&gt;$24.90&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20240101__20241231__us-gaap--VestingAxis__custom--Vesting2024Member__srt--RangeAxis__srt--MinimumMember_zyE2UDf1ohbd"&gt;2.00&lt;/span&gt; &#x2013; &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20240101__20241231__us-gaap--VestingAxis__custom--Vesting2024Member__srt--RangeAxis__srt--MaximumMember_z8x2k6FvKVSj"&gt;3.40&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20240101__20241231__us-gaap--VestingAxis__custom--Vesting2024Member_zqBT2vNbZH2e"&gt;45&lt;/span&gt;%&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20240101__20241231__us-gaap--VestingAxis__custom--Vesting2024Member__srt--RangeAxis__srt--MinimumMember_zAf0GFsQYSJ7"&gt;4.05&lt;/span&gt;% - &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20240101__20241231__us-gaap--VestingAxis__custom--Vesting2024Member__srt--RangeAxis__srt--MaximumMember_zruoGuGQVtce"&gt;4.64&lt;/span&gt;%&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_906_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFairValuePerShare_pid_c20240101__20241231__us-gaap--VestingAxis__custom--Vesting2024Member__srt--RangeAxis__srt--MinimumMember_zqoe5lHLTR5k"&gt;$3.44&lt;/span&gt; - &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFairValuePerShare_pid_c20240101__20241231__us-gaap--VestingAxis__custom--Vesting2024Member__srt--RangeAxis__srt--MaximumMember_z2zUAhP8h8wd"&gt;$19.34&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;

						&lt;/tr&gt;
						&lt;tr style="min-height: 3pt"&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"&gt;&lt;span style="text-transform: none"&gt;Year-end 2024&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_90A_eus-gaap--SharePrice_iI_pid_c20241231__us-gaap--VestingAxis__custom--YearEnd2024Member_zIcNvc8rKnKg"&gt;$28.59&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20241231__us-gaap--VestingAxis__custom--YearEnd2024Member__srt--RangeAxis__srt--MinimumMember_zcefl9K22g16"&gt;$11.03&lt;/span&gt; - &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20241231__us-gaap--VestingAxis__custom--YearEnd2024Member__srt--RangeAxis__srt--MaximumMember_z79asRnmmY7g"&gt;$18.44&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2024Member__srt--RangeAxis__srt--MinimumMember_zdOWKWyp5Xq4"&gt;2.15&lt;/span&gt; &#x2013; &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2024Member__srt--RangeAxis__srt--MaximumMember_zba4BTXP2Uxf"&gt;3.93&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2024Member_zxqzATqctpVj"&gt;45&lt;/span&gt;%&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2024Member__srt--RangeAxis__srt--MinimumMember_zS6AZcNjtIsg"&gt;4.25&lt;/span&gt;% - &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2024Member__srt--RangeAxis__srt--MaximumMember_zdBzYd0oKpy9"&gt;4.32&lt;/span&gt;%&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_904_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFairValuePerShare_pid_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2024Member__srt--RangeAxis__srt--MinimumMember_zkhvEywZAjze"&gt;$13.41&lt;/span&gt; - &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_90E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFairValuePerShare_pid_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2024Member__srt--RangeAxis__srt--MaximumMember_zL4O8QW1feQ6"&gt;$19.23&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;

						&lt;/tr&gt;

					&lt;/table&gt;
					&lt;div id="xdx_8A7_z9KbHUprOhfa"&gt;&lt;/div&gt;
					&lt;div id="xdx_858_zGbldmmTkFHa"&gt;&lt;/div&gt;
				&lt;/div&gt;
				</ecd:AdjToPeoCompFnTextBlock>
    <ecd:PeoTotalCompAmt
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000075"
      unitRef="USD">5511940</ecd:PeoTotalCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2024-01-012024-12-31_ecd_PeoMember_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"
      decimals="0"
      id="Fact000076"
      unitRef="USD">-3608101</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2024-01-012024-12-31_ecd_PeoMember_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"
      decimals="0"
      id="Fact000077"
      unitRef="USD">5852430</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2024-01-012024-12-31_ecd_PeoMember_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"
      decimals="0"
      id="Fact000078"
      unitRef="USD">3370222</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2024-01-012024-12-31_ecd_PeoMember_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"
      decimals="0"
      id="Fact000079"
      unitRef="USD">1202370</ecd:AdjToCompAmt>
    <ecd:PeoActuallyPaidCompAmt
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000080"
      unitRef="USD">12328862</ecd:PeoActuallyPaidCompAmt>
    <ecd:PeoTotalCompAmt
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000081"
      unitRef="USD">3176413</ecd:PeoTotalCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2023-01-012023-12-31_ecd_PeoMember_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"
      decimals="0"
      id="Fact000082"
      unitRef="USD">-801938</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2023-01-012023-12-31_ecd_PeoMember_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"
      decimals="0"
      id="Fact000083"
      unitRef="USD">1771014</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2023-01-012023-12-31_ecd_PeoMember_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"
      decimals="0"
      id="Fact000084"
      unitRef="USD">2775817</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2023-01-012023-12-31_ecd_PeoMember_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"
      decimals="0"
      id="Fact000085"
      unitRef="USD">304572</ecd:AdjToCompAmt>
    <ecd:PeoActuallyPaidCompAmt
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000086"
      unitRef="USD">7225878</ecd:PeoActuallyPaidCompAmt>
    <ecd:PeoTotalCompAmt
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000087"
      unitRef="USD">7216340</ecd:PeoTotalCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2022-01-012022-12-31_ecd_PeoMember_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"
      decimals="0"
      id="Fact000088"
      unitRef="USD">-5587257</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2022-01-012022-12-31_ecd_PeoMember_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"
      decimals="0"
      id="Fact000089"
      unitRef="USD">4689996</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2022-01-012022-12-31_ecd_PeoMember_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"
      decimals="0"
      id="Fact000090"
      unitRef="USD">-1385504</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2022-01-012022-12-31_ecd_PeoMember_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"
      decimals="0"
      id="Fact000091"
      unitRef="USD">-215079</ecd:AdjToCompAmt>
    <ecd:PeoActuallyPaidCompAmt
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000092"
      unitRef="USD">4718496</ecd:PeoActuallyPaidCompAmt>
    <ecd:PeoTotalCompAmt
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      id="Fact000093"
      unitRef="USD">4628566</ecd:PeoTotalCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2021-01-012021-12-31_ecd_PeoMember_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"
      decimals="0"
      id="Fact000094"
      unitRef="USD">-2977494</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2021-01-012021-12-31_ecd_PeoMember_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"
      decimals="0"
      id="Fact000095"
      unitRef="USD">2402215</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2021-01-012021-12-31_ecd_PeoMember_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"
      decimals="0"
      id="Fact000096"
      unitRef="USD">-495663</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2021-01-012021-12-31_ecd_PeoMember_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"
      decimals="0"
      id="Fact000097"
      unitRef="USD">154913</ecd:AdjToCompAmt>
    <ecd:PeoActuallyPaidCompAmt
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      id="Fact000098"
      unitRef="USD">3712538</ecd:PeoActuallyPaidCompAmt>
    <ecd:PeoTotalCompAmt
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      id="Fact000099"
      unitRef="USD">3415458</ecd:PeoTotalCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2020-01-012020-12-31_ecd_PeoMember_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"
      decimals="0"
      id="Fact000100"
      unitRef="USD">-2323534</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2020-01-012020-12-31_ecd_PeoMember_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"
      decimals="0"
      id="Fact000101"
      unitRef="USD">1931021</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2020-01-012020-12-31_ecd_PeoMember_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"
      decimals="0"
      id="Fact000102"
      unitRef="USD">-2326940</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2020-01-012020-12-31_ecd_PeoMember_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"
      decimals="0"
      id="Fact000103"
      unitRef="USD">-368352</ecd:AdjToCompAmt>
    <ecd:PeoActuallyPaidCompAmt
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      id="Fact000104"
      unitRef="USD">327652</ecd:PeoActuallyPaidCompAmt>
    <ecd:AdjToNonPeoNeoCompFnTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000111">&lt;p id="xdx_845_eecd--AdjToNonPeoNeoCompFnTextBlock_dU_z2toD0Is021l" style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"&gt;&lt;span style="text-transform: none; line-height: 12pt"&gt;The following table sets forth a reconciliation from the Summary Compensation Table (&#x201c;SCT&#x201d;) to Compensation Actually Paid (&#x201c;CAP&#x201d;) for the average paid to our Non-PEO NEOs for each &lt;/span&gt;&lt;span style="text-transform: none; line-height: 12pt"&gt;fiscal year.&lt;/span&gt;&lt;/p&gt;
				&lt;div style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-align: left"&gt;
					&lt;table id="xdx_30E_zR7V9Qb1fbKj" style="table-layout: fixed; width: 674.68pt; margin-top: 4pt; margin-bottom: 10pt; border-collapse: collapse" summary="xdx: Disclosure - Pay vs Performance Disclosure"&gt;
						&lt;tr style="margin: 0; height: 0"&gt;
							&lt;td style="text-align: left; border-width: 0; margin: 0; padding: 0; width: 142.49pt"&gt;


							&lt;/td&gt;
							&lt;td style="border-width: 0; margin: 0; padding: 0; width: 88.74pt"&gt;


							&lt;/td&gt;
							&lt;td style="border-width: 0; margin: 0; padding: 0; width: 89.06pt"&gt;


							&lt;/td&gt;
							&lt;td style="border-width: 0; margin: 0; padding: 0; width: 84.37pt"&gt;


							&lt;/td&gt;
							&lt;td style="border-width: 0; margin: 0; padding: 0; width: 90pt"&gt;


							&lt;/td&gt;
							&lt;td style="border-width: 0; margin: 0; padding: 0; width: 84.37pt"&gt;


							&lt;/td&gt;
							&lt;td style="border-width: 0; margin: 0; padding: 0; width: 95.62pt"&gt;


							&lt;/td&gt;

						&lt;/tr&gt;
						&lt;tr style="min-height: 3pt"&gt;
							&lt;td style="text-align: left; border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;b&gt;Year&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;b&gt;SCT&lt;br/&gt;Total&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;b&gt;Less Sum of&lt;br/&gt;Stock and&lt;br/&gt;Option Award&lt;br/&gt;Values from&lt;br/&gt;SCT&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;b&gt;Value of&lt;br/&gt;Current&lt;br/&gt;Year Equity&lt;br/&gt;Awards at&lt;br/&gt;12/31&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;b&gt;Change in&lt;br/&gt;Value of&lt;br/&gt;Unvested Prior&lt;br/&gt;Year Awards at&lt;br/&gt;12/31&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;b&gt;Change in&lt;br/&gt;Value of Prior&lt;br/&gt;Year Awards&lt;br/&gt;That Vested&lt;br/&gt;In Current&lt;br/&gt;Year&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;b&gt;Total&lt;br/&gt;Compensation&lt;br/&gt;Actually Paid&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;

						&lt;/tr&gt;
						&lt;tr style="min-height: 3pt"&gt;
							&lt;td style="text-align: left; border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="text-align: left; margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt"&gt;&#x200b;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="margin: 0pt 0pt 0; text-transform: none; font-size: 1pt; line-height: 1pt"&gt;&#x200b;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;b&gt; (e) &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;b&gt; (f) &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;b&gt; (g) &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;b&gt; (h) &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 8pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;b&gt;(i)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;

						&lt;/tr&gt;
						&lt;tr style="min-height: 3pt"&gt;
							&lt;td style="text-align: left; border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"&gt;&lt;span style="text-transform: none"&gt;2024&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 11pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_988_eecd--NonPeoNeoAvgTotalCompAmt_c20240101__20241231_zkGc2nmxZYQd" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;$1,703,153&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 8pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_98D_eecd--AdjToCompAmt_c20240101__20241231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--EqtyAwrdsInSummryCompstnTblForAplblYrMember_fKGUp_z2j7FEeSfoSh" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;  ($923,744)&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 11pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_988_eecd--AdjToCompAmt_c20240101__20241231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_fKGYp_z8CEuZuUuvwd" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;$1,498,338&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 13pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_989_eecd--AdjToCompAmt_c20240101__20241231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_fKGcp_zWl8QtvFYeK8" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;  $642,469&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 13pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_985_eecd--AdjToCompAmt_c20240101__20241231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_fKGgp_zqpoBld2prm7" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;$230,805&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 14pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_98A_eecd--NonPeoNeoAvgCompActuallyPaidAmt_c20240101__20241231_fKGkuKQ_____z8MWU3TdMpq3" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;$3,151,020&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;

						&lt;/tr&gt;
						&lt;tr style="min-height: 3pt"&gt;
							&lt;td style="border-width: 0pt; text-align: left; padding: 1.5pt 0pt 1.5pt 3pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: left"&gt;&lt;span style="text-transform: none"&gt;2023&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 11pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_986_eecd--NonPeoNeoAvgTotalCompAmt_c20230101__20231231_zFdGxPi6y5Z8" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;$1,204,664&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 8pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_985_eecd--AdjToCompAmt_c20230101__20231231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--EqtyAwrdsInSummryCompstnTblForAplblYrMember_fKGUp_zDfLteTfhPq2" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&#x2002; ($498,431)&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 11pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_98A_eecd--AdjToCompAmt_c20230101__20231231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_fKGYp_zs6fl3nop6ig" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;  $639,679&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 13pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_983_eecd--AdjToCompAmt_c20230101__20231231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_fKGcp_zjaU3jnmCvfc" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&#x2002; $443,711&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 13pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_98F_eecd--AdjToCompAmt_c20230101__20231231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_fKGgp_ztA47rbIUUTd" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;  $45,783&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 14pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_98B_eecd--NonPeoNeoAvgCompActuallyPaidAmt_c20230101__20231231_fKGkuKQ_____zcDfIdaGiIE3" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;$1,835,407&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;

						&lt;/tr&gt;
						&lt;tr style="min-height: 3pt"&gt;
							&lt;td style="border-width: 0pt; text-align: left; padding: 1.5pt 0pt 1.5pt 3pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: left"&gt;&lt;span style="text-transform: none"&gt;2022&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 11pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_98C_eecd--NonPeoNeoAvgTotalCompAmt_c20220101__20221231_zeRwyvu6di9" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;$1,796,100&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 8pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_987_eecd--AdjToCompAmt_c20220101__20221231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--EqtyAwrdsInSummryCompstnTblForAplblYrMember_fKGUp_zOvzRDZgXzKf" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;($1,124,197)&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 11pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_982_eecd--AdjToCompAmt_c20220101__20221231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_fKGYp_z5rmMRSYJEPf" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;  $955,981&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_988_eecd--AdjToCompAmt_c20220101__20221231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_fKGcp_zTfCoUsB2oCh" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt; ($239,756)&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_985_eecd--AdjToCompAmt_c20220101__20221231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_fKGgp_zfUrvVcPTK38" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;($35,259)&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 14pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_980_eecd--NonPeoNeoAvgCompActuallyPaidAmt_c20220101__20221231_fKGkuKQ_____zU4Lx60upXQd" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;$1,352,869&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;

						&lt;/tr&gt;
						&lt;tr style="min-height: 3pt"&gt;
							&lt;td style="border-width: 0pt; text-align: left; padding: 1.5pt 0pt 1.5pt 3pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: left"&gt;&lt;span style="text-transform: none"&gt;2021&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 11pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_98C_eecd--NonPeoNeoAvgTotalCompAmt_c20210101__20211231_zL0XxHkSKhyh" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;$1,286,725&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 8pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_984_eecd--AdjToCompAmt_c20210101__20211231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--EqtyAwrdsInSummryCompstnTblForAplblYrMember_fKGUp_zrzfmxWnnKqi" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&#x2002; ($640,635)&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 11pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_98C_eecd--AdjToCompAmt_c20210101__20211231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_fKGYp_z0HJT6cwQOn9" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;  $508,720&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_984_eecd--AdjToCompAmt_c20210101__20211231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_fKGcp_zmmkvk3v0Z2c" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&#x2002; ($72,575)&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 13pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_988_eecd--AdjToCompAmt_c20210101__20211231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_fKGgp_zvJoj1Ayeqtf" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;  $26,701&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 14pt 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_98E_eecd--NonPeoNeoAvgCompActuallyPaidAmt_c20210101__20211231_fKGkuKQ_____zOPu6wZ4y4Hl" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;$1,108,935&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;

						&lt;/tr&gt;
						&lt;tr style="min-height: 3pt"&gt;
							&lt;td style="border-width: 0pt; text-align: left; padding: 1.5pt 0pt 1.5pt 3pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: left"&gt;&lt;span style="text-transform: none"&gt;2020&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 11pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_986_eecd--NonPeoNeoAvgTotalCompAmt_c20200101__20201231_zQVsMUpIEZr5" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&#x2002;$977,089&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 8pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_988_eecd--AdjToCompAmt_c20200101__20201231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--EqtyAwrdsInSummryCompstnTblForAplblYrMember_fKGUp_zFL2z8REbYh4" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&#x2002; ($499,129)&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 11pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_98C_eecd--AdjToCompAmt_c20200101__20201231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_fKGYp_zrPzWAnv5Luf" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;  $420,985&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_98F_eecd--AdjToCompAmt_c20200101__20201231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_fKGcp_zHHqSQTbWNU6" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt; ($371,199)&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 9pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_982_eecd--AdjToCompAmt_c20200101__20201231__ecd--ExecutiveCategoryAxis__ecd--NonPeoNeoMember__ecd--AdjToCompAxis__ecd--ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_fKGgp_z548VFakKFve" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt; ($73,105)&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="text-align: center; border-width: 0pt; padding: 1.5pt 14pt 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p id="xdx_981_eecd--NonPeoNeoAvgCompActuallyPaidAmt_c20200101__20201231_fKGkuKQ_____zrf2LnU9tXX2" style="font: 10pt/normal Arial, sans-serif; margin-top: 0; margin-bottom: 0; text-transform: none; color: #000000; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&#x2002; $454,642&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;

						&lt;/tr&gt;

					&lt;/table&gt;

				&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 9pt/normal Arial, sans-serif; display: none; visibility: hidden; color: #000000; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 15pt; text-align: right"&gt;&lt;span style="font-size: 7pt; text-transform: none; line-height: 7pt"&gt;&lt;sup id="xdx_F04_zCsjhN8a9su7"&gt;(e)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5pt"&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_F10_zd6MihFDfz31" style="text-transform: none"&gt;Represents the grant date
fair value of equity-based awards made during the covered fiscal year as reported in the Summary&#160;Compensation Table.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 9pt/normal Arial, sans-serif; display: none; visibility: hidden; color: #000000; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 15pt; text-align: right"&gt;&lt;span style="font-size: 7pt; text-transform: none; line-height: 7pt"&gt;&lt;sup id="xdx_F0D_zfrxqZnFmsp8"&gt;(f)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5pt"&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_F1E_zaDZYrW4evr9" style="text-transform: none"&gt;Represents the year-end
fair value of equity awards that were made during the covered fiscal year and remained unvested as&#160;of the end of the covered fiscal
year.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 9pt/normal Arial, sans-serif; display: none; visibility: hidden; color: #000000; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 15pt; text-align: right"&gt;&lt;span style="font-size: 7pt; text-transform: none; line-height: 7pt"&gt;&lt;sup id="xdx_F00_zVKZL2f9N4jd"&gt;(g)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5pt"&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_F16_z33wktlgZdSh" style="text-transform: none"&gt;Represents the change as
of the end of the covered fiscal year (from the end of the prior fiscal year) in fair value of equity-based awards granted in prior fiscal
years that were still unvested as of the covered&#160;fiscal year-end.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 9pt/normal Arial, sans-serif; display: none; visibility: hidden; color: #000000; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 15pt; text-align: right"&gt;&lt;span style="font-size: 7pt; text-transform: none; line-height: 7pt"&gt;&lt;sup id="xdx_F09_zDSh6BEP3mZj"&gt;(h)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5pt"&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_F1B_z9Fy81mFQbD5" style="text-transform: none"&gt;Represents the change as
of the vesting date (from the end of the prior fiscal year) in fair value of equity-based awards granted in prior fiscal years that vested
as of the end of or during the covered&#160;fiscal year.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 9pt/normal Arial, sans-serif; display: none; visibility: hidden; color: #000000; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 15pt; text-align: right"&gt;&lt;span style="font-size: 7pt; text-transform: none; line-height: 7pt"&gt;&lt;sup id="xdx_F03_zyLPcLyHWWJe"&gt;(i)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5pt"&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_F1A_z7G5nx6ciLC7" style="text-transform: none"&gt;Equal to summary compensation
total plus/minus any adjustments related to equity award values as reflected in&#160;this table. For purposes of calculating &#x201c;compensation
actually paid,&#x201d; the fair value of equity awards at year-end 2023 and 2024, and on vesting dates for awards that vested during 2024,
were all determined consistent with the approach used to value the awards at the grant date for purposes of the Summary Compensation
Table (refer to &#x201c;Executive Officer Compensation &#x2013; Summary Compensation Table&#x201d; for additional information). For any
awards subject to performance conditions, the change in fair value as of the end of the covered fiscal year is calculated based on the
probable outcome of such conditions as of the last day of the fiscal year. The valuation assumptions used to calculate fair values do
not differ materially from those disclosed at the time of grant, other than as reflected in the table below, which summarizes option
fair values determined using the Black-Scholes model and related assumptions used to calculate Compensation Actually Paid for fiscal&#160;year
2024.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
				&lt;p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 1pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"&gt;&lt;span style="width: 15pt; text-indent: 0; display: inline-block"&gt;&lt;sup style="text-transform: none; font-size: 7pt; line-height: 7pt"&gt;(i)&lt;/sup&gt;&lt;/span&gt;&lt;sup style="text-transform: none; font-size: 7pt; line-height: 7pt"&gt;&lt;/sup&gt;&lt;span style="text-transform: none"&gt;Equal to summary compensation total plus/minus any adjustments related to equity award values as reflected in&#160;this table. For purposes of calculating &#x201c;compensation actually paid,&#x201d; the fair value of equity awards at year-end 2023 and 2024, and on vesting dates for awards that vested during 2024, were all determined consistent with the approach used to value the awards at the grant date for purposes of the Summary Compensation Table (refer to &#x201c;Executive Officer Compensation &#x2013; Summary Compensation Table&#x201d; for additional information). For any awards subject to performance conditions, the change in fair value as of the end of the covered fiscal year is calculated based on the probable outcome of such conditions as of the last day of the fiscal year. The valuation assumptions used to calculate fair values do not differ materially from those disclosed at the time of grant, other than as reflected in the table below, which summarizes option fair values determined using the Black-Scholes model and related assumptions used to calculate Compensation Actually Paid for &lt;/span&gt;&lt;span style="text-transform: none"&gt;fiscal&#160;year 2024.&lt;/span&gt;&lt;/p&gt;

				&lt;p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 1pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"&gt;&lt;span style="width: 15pt; text-indent: 0; display: inline-block"&gt;&lt;sup style="text-transform: none; font-size: 7pt; line-height: 7pt"&gt;(e)&lt;/sup&gt;&lt;/span&gt;&lt;sup style="text-transform: none; font-size: 7pt; line-height: 7pt"&gt;&lt;/sup&gt;&lt;span style="text-transform: none"&gt;Represents the grant date fair value of equity-based awards made during the covered fiscal year as reported in the &lt;/span&gt;&lt;span style="text-transform: none"&gt;Summary&#160;Compensation Table.&lt;/span&gt;&lt;/p&gt;
				&lt;p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 1pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"&gt;&lt;span style="width: 15pt; text-indent: 0; display: inline-block"&gt;&lt;sup style="text-transform: none; font-size: 7pt; line-height: 7pt"&gt;(f)&lt;/sup&gt;&lt;/span&gt;&lt;sup style="text-transform: none; font-size: 7pt; line-height: 7pt"&gt;&lt;/sup&gt;&lt;span style="text-transform: none"&gt;Represents the year-end fair value of equity awards that were made during the covered fiscal year and remained unvested as&#160;of the end of the covered &lt;/span&gt;&lt;span style="text-transform: none"&gt;fiscal year.&lt;/span&gt;&lt;/p&gt;
				&lt;p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 1pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"&gt;&lt;span style="width: 15pt; text-indent: 0; display: inline-block"&gt;&lt;sup style="text-transform: none; font-size: 7pt; line-height: 7pt"&gt;(g)&lt;/sup&gt;&lt;/span&gt;&lt;sup style="text-transform: none; font-size: 7pt; line-height: 7pt"&gt;&lt;/sup&gt;&lt;span style="text-transform: none"&gt;Represents the change as of the end of the covered fiscal year (from the end of the prior fiscal year) in fair value of equity-based awards granted in prior fiscal years that were still unvested as of the &lt;/span&gt;&lt;span style="text-transform: none"&gt;covered&#160;fiscal year-end.&lt;/span&gt;&lt;/p&gt;
				&lt;p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 8pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"&gt;&lt;span style="width: 15pt; text-indent: 0; display: inline-block"&gt;&lt;sup style="text-transform: none; font-size: 7pt; line-height: 7pt"&gt;(h)&lt;/sup&gt;&lt;/span&gt;&lt;sup style="text-transform: none; font-size: 7pt; line-height: 7pt"&gt;&lt;/sup&gt;&lt;span style="text-transform: none"&gt;Represents the change as of the vesting date (from the end of the prior fiscal year) in fair value of equity-based awards granted in prior fiscal years that vested as of the end of or during the &lt;/span&gt;&lt;span style="text-transform: none"&gt;covered&#160;fiscal year.&lt;/span&gt;&lt;/p&gt;
				&lt;div id="xdx_893_eecd--EqtyAwrdsAdjFnTextBlock_dU_zd3NhAsLpzpa"&gt;&lt;/div&gt;
				&lt;p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 8pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"&gt;&lt;span style="width: 15pt; text-indent: 0; display: inline-block"&gt;&lt;sup style="text-transform: none; font-size: 7pt; line-height: 7pt"&gt;(i)&lt;/sup&gt;&lt;/span&gt;&lt;sup style="text-transform: none; font-size: 7pt; line-height: 7pt"&gt;&lt;/sup&gt;&lt;span style="text-transform: none"&gt;Equal to summary compensation total plus/minus any adjustments related to equity award values as reflected in&#160;this table. For purposes of calculating &#x201c;compensation actually paid,&#x201d; the fair value of equity awards at year-end 2023 and 2024, and on vesting dates for awards that vested during 2024, were all determined consistent with the approach used to value the awards at the grant date for purposes of the Summary Compensation Table (refer to &#x201c;Executive Officer Compensation &#x2013; Summary Compensation Table&#x201d; for additional information). For any awards subject to performance conditions, the change in fair value as of the end of the covered fiscal year is calculated based on the probable outcome of such conditions as of the last day of the fiscal year. The valuation assumptions used to calculate fair values do not differ materially from those disclosed at the time of grant, other than as reflected in the table below, which summarizes option fair values determined using the Black-Scholes model and related assumptions used to calculate Compensation Actually Paid for &lt;/span&gt;&lt;span style="text-transform: none"&gt;fiscal&#160;year 2024.&lt;/span&gt;&lt;/p&gt;
				&lt;table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 10pt; border-collapse: collapse"&gt;
						&lt;tr style="margin: 0; height: 0"&gt;
							&lt;td style="border-width: 0; margin: 0; padding: 0; width: 100pt"&gt;


							&lt;/td&gt;
							&lt;td style="border-width: 0; margin: 0; padding: 0; width: 110pt"&gt;


							&lt;/td&gt;
							&lt;td style="border-width: 0; margin: 0; padding: 0; width: 93.75pt"&gt;


							&lt;/td&gt;
							&lt;td style="border-width: 0; margin: 0; padding: 0; width: 92.49pt"&gt;


							&lt;/td&gt;
							&lt;td style="border-width: 0; margin: 0; padding: 0; width: 63.74pt"&gt;


							&lt;/td&gt;
							&lt;td style="border-width: 0; margin: 0; padding: 0; width: 107.5pt"&gt;


							&lt;/td&gt;
							&lt;td style="border-width: 0; margin: 0; padding: 0; width: 107.5pt"&gt;


							&lt;/td&gt;

						&lt;/tr&gt;
						&lt;tr style="min-height: 3pt"&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;b&gt;Valuation&lt;br/&gt;Purpose&lt;br/&gt;for PVP&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;b&gt;AORT&lt;br/&gt;Stock&lt;br/&gt;Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;b&gt;AORT&lt;br/&gt;Option&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;b&gt;Expected&lt;br/&gt;Term&lt;br/&gt;(years)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;b&gt;Stock&lt;br/&gt;Price&lt;br/&gt;Volatility&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;b&gt;Risk-free&lt;br/&gt;Rate&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;b&gt;Option&lt;br/&gt;Fair&lt;br/&gt;Value&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;

						&lt;/tr&gt;
						&lt;tr style="min-height: 3pt"&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"&gt;&lt;span style="text-transform: none"&gt;Year-end 2023&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_905_eus-gaap--SharePrice_iI_pid_c20241231__us-gaap--VestingAxis__custom--YearEnd2023Member_zyoa1YBNpbDh"&gt;$17.88&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20241231__us-gaap--VestingAxis__custom--YearEnd2023Member__srt--RangeAxis__srt--MinimumMember_z5bT910B5iI4"&gt;$11.03&lt;/span&gt; - &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20241231__us-gaap--VestingAxis__custom--YearEnd2023Member__srt--RangeAxis__srt--MaximumMember_zSNEB73O0Sbg"&gt;$24.90&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2023Member__srt--RangeAxis__srt--MinimumMember_zfuoYaTx9a6e"&gt;2.13&lt;/span&gt; &#x2013; &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2023Member__srt--RangeAxis__srt--MaximumMember_z5wuLeKbg0cf"&gt;4.93&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2023Member_z9yVGAlW0uoc"&gt;45&lt;/span&gt;%&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2023Member__srt--RangeAxis__srt--MinimumMember_zDHA9XJYwQOe"&gt;3.85&lt;/span&gt;% - &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2023Member__srt--RangeAxis__srt--MaximumMember_z0ByHjPnHdCi"&gt;4.20&lt;/span&gt;%&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_907_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFairValuePerShare_pid_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2023Member__srt--RangeAxis__srt--MinimumMember_ze1eSKkm7EUc"&gt;$3.11&lt;/span&gt; - &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_90D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFairValuePerShare_pid_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2023Member__srt--RangeAxis__srt--MaximumMember_z1wedYtymmOh"&gt;$9.89&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;

						&lt;/tr&gt;
						&lt;tr style="min-height: 3pt"&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"&gt;&lt;span style="text-transform: none"&gt;2024 Vesting&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_90A_eus-gaap--SharePrice_iI_pid_c20241231__us-gaap--VestingAxis__custom--Vesting2024Member__srt--RangeAxis__srt--MinimumMember_zeHkPyKExvF4"&gt;$18.81&lt;/span&gt; - &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_90D_eus-gaap--SharePrice_iI_pid_c20241231__us-gaap--VestingAxis__custom--Vesting2024Member__srt--RangeAxis__srt--MaximumMember_zH7RgbVEMs58"&gt;$29.66&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20241231__us-gaap--VestingAxis__custom--Vesting2024Member__srt--RangeAxis__srt--MinimumMember_zsBXXbgZNSHd"&gt;$11.03&lt;/span&gt; - &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20241231__us-gaap--VestingAxis__custom--Vesting2024Member__srt--RangeAxis__srt--MaximumMember_ziJ1ynfMcNij"&gt;$24.90&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20240101__20241231__us-gaap--VestingAxis__custom--Vesting2024Member__srt--RangeAxis__srt--MinimumMember_zyE2UDf1ohbd"&gt;2.00&lt;/span&gt; &#x2013; &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20240101__20241231__us-gaap--VestingAxis__custom--Vesting2024Member__srt--RangeAxis__srt--MaximumMember_z8x2k6FvKVSj"&gt;3.40&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20240101__20241231__us-gaap--VestingAxis__custom--Vesting2024Member_zqBT2vNbZH2e"&gt;45&lt;/span&gt;%&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20240101__20241231__us-gaap--VestingAxis__custom--Vesting2024Member__srt--RangeAxis__srt--MinimumMember_zAf0GFsQYSJ7"&gt;4.05&lt;/span&gt;% - &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20240101__20241231__us-gaap--VestingAxis__custom--Vesting2024Member__srt--RangeAxis__srt--MaximumMember_zruoGuGQVtce"&gt;4.64&lt;/span&gt;%&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_906_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFairValuePerShare_pid_c20240101__20241231__us-gaap--VestingAxis__custom--Vesting2024Member__srt--RangeAxis__srt--MinimumMember_zqoe5lHLTR5k"&gt;$3.44&lt;/span&gt; - &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFairValuePerShare_pid_c20240101__20241231__us-gaap--VestingAxis__custom--Vesting2024Member__srt--RangeAxis__srt--MaximumMember_z2zUAhP8h8wd"&gt;$19.34&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;

						&lt;/tr&gt;
						&lt;tr style="min-height: 3pt"&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"&gt;&lt;span style="text-transform: none"&gt;Year-end 2024&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_90A_eus-gaap--SharePrice_iI_pid_c20241231__us-gaap--VestingAxis__custom--YearEnd2024Member_zIcNvc8rKnKg"&gt;$28.59&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20241231__us-gaap--VestingAxis__custom--YearEnd2024Member__srt--RangeAxis__srt--MinimumMember_zcefl9K22g16"&gt;$11.03&lt;/span&gt; - &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20241231__us-gaap--VestingAxis__custom--YearEnd2024Member__srt--RangeAxis__srt--MaximumMember_z79asRnmmY7g"&gt;$18.44&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2024Member__srt--RangeAxis__srt--MinimumMember_zdOWKWyp5Xq4"&gt;2.15&lt;/span&gt; &#x2013; &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2024Member__srt--RangeAxis__srt--MaximumMember_zba4BTXP2Uxf"&gt;3.93&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2024Member_zxqzATqctpVj"&gt;45&lt;/span&gt;%&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2024Member__srt--RangeAxis__srt--MinimumMember_zS6AZcNjtIsg"&gt;4.25&lt;/span&gt;% - &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2024Member__srt--RangeAxis__srt--MaximumMember_zdBzYd0oKpy9"&gt;4.32&lt;/span&gt;%&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_904_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFairValuePerShare_pid_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2024Member__srt--RangeAxis__srt--MinimumMember_zkhvEywZAjze"&gt;$13.41&lt;/span&gt; - &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_90E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFairValuePerShare_pid_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2024Member__srt--RangeAxis__srt--MaximumMember_zL4O8QW1feQ6"&gt;$19.23&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;

						&lt;/tr&gt;

					&lt;/table&gt;
					&lt;div id="xdx_8A7_z9KbHUprOhfa"&gt;&lt;/div&gt;
					</ecd:AdjToNonPeoNeoCompFnTextBlock>
    <ecd:NonPeoNeoAvgTotalCompAmt
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000112"
      unitRef="USD">1703153</ecd:NonPeoNeoAvgTotalCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2024-01-012024-12-31_ecd_NonPeoNeoMember_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"
      decimals="0"
      id="Fact000113"
      unitRef="USD">-923744</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2024-01-012024-12-31_ecd_NonPeoNeoMember_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"
      decimals="0"
      id="Fact000114"
      unitRef="USD">1498338</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2024-01-012024-12-31_ecd_NonPeoNeoMember_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"
      decimals="0"
      id="Fact000115"
      unitRef="USD">642469</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2024-01-012024-12-31_ecd_NonPeoNeoMember_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"
      decimals="0"
      id="Fact000116"
      unitRef="USD">230805</ecd:AdjToCompAmt>
    <ecd:NonPeoNeoAvgCompActuallyPaidAmt
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000117"
      unitRef="USD">3151020</ecd:NonPeoNeoAvgCompActuallyPaidAmt>
    <ecd:NonPeoNeoAvgTotalCompAmt
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000118"
      unitRef="USD">1204664</ecd:NonPeoNeoAvgTotalCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2023-01-012023-12-31_ecd_NonPeoNeoMember_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"
      decimals="0"
      id="Fact000119"
      unitRef="USD">-498431</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2023-01-012023-12-31_ecd_NonPeoNeoMember_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"
      decimals="0"
      id="Fact000120"
      unitRef="USD">639679</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2023-01-012023-12-31_ecd_NonPeoNeoMember_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"
      decimals="0"
      id="Fact000121"
      unitRef="USD">443711</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2023-01-012023-12-31_ecd_NonPeoNeoMember_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"
      decimals="0"
      id="Fact000122"
      unitRef="USD">45783</ecd:AdjToCompAmt>
    <ecd:NonPeoNeoAvgCompActuallyPaidAmt
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000123"
      unitRef="USD">1835407</ecd:NonPeoNeoAvgCompActuallyPaidAmt>
    <ecd:NonPeoNeoAvgTotalCompAmt
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000124"
      unitRef="USD">1796100</ecd:NonPeoNeoAvgTotalCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2022-01-012022-12-31_ecd_NonPeoNeoMember_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"
      decimals="0"
      id="Fact000125"
      unitRef="USD">-1124197</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2022-01-012022-12-31_ecd_NonPeoNeoMember_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"
      decimals="0"
      id="Fact000126"
      unitRef="USD">955981</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2022-01-012022-12-31_ecd_NonPeoNeoMember_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"
      decimals="0"
      id="Fact000127"
      unitRef="USD">-239756</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2022-01-012022-12-31_ecd_NonPeoNeoMember_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"
      decimals="0"
      id="Fact000128"
      unitRef="USD">-35259</ecd:AdjToCompAmt>
    <ecd:NonPeoNeoAvgCompActuallyPaidAmt
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000129"
      unitRef="USD">1352869</ecd:NonPeoNeoAvgCompActuallyPaidAmt>
    <ecd:NonPeoNeoAvgTotalCompAmt
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      id="Fact000130"
      unitRef="USD">1286725</ecd:NonPeoNeoAvgTotalCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2021-01-012021-12-31_ecd_NonPeoNeoMember_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"
      decimals="0"
      id="Fact000131"
      unitRef="USD">-640635</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2021-01-012021-12-31_ecd_NonPeoNeoMember_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"
      decimals="0"
      id="Fact000132"
      unitRef="USD">508720</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2021-01-012021-12-31_ecd_NonPeoNeoMember_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"
      decimals="0"
      id="Fact000133"
      unitRef="USD">-72575</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2021-01-012021-12-31_ecd_NonPeoNeoMember_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"
      decimals="0"
      id="Fact000134"
      unitRef="USD">26701</ecd:AdjToCompAmt>
    <ecd:NonPeoNeoAvgCompActuallyPaidAmt
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      id="Fact000135"
      unitRef="USD">1108935</ecd:NonPeoNeoAvgCompActuallyPaidAmt>
    <ecd:NonPeoNeoAvgTotalCompAmt
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      id="Fact000136"
      unitRef="USD">977089</ecd:NonPeoNeoAvgTotalCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2020-01-012020-12-31_ecd_NonPeoNeoMember_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"
      decimals="0"
      id="Fact000137"
      unitRef="USD">-499129</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2020-01-012020-12-31_ecd_NonPeoNeoMember_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"
      decimals="0"
      id="Fact000138"
      unitRef="USD">420985</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2020-01-012020-12-31_ecd_NonPeoNeoMember_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"
      decimals="0"
      id="Fact000139"
      unitRef="USD">-371199</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2020-01-012020-12-31_ecd_NonPeoNeoMember_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"
      decimals="0"
      id="Fact000140"
      unitRef="USD">-73105</ecd:AdjToCompAmt>
    <ecd:NonPeoNeoAvgCompActuallyPaidAmt
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      id="Fact000141"
      unitRef="USD">454642</ecd:NonPeoNeoAvgCompActuallyPaidAmt>
    <ecd:EqtyAwrdsAdjFnTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000148">&lt;div id="xdx_893_eecd--EqtyAwrdsAdjFnTextBlock_dU_zd3NhAsLpzpa"&gt;&lt;/div&gt;
				&lt;p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 8pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: justify"&gt;&lt;span style="width: 15pt; text-indent: 0; display: inline-block"&gt;&lt;sup style="text-transform: none; font-size: 7pt; line-height: 7pt"&gt;(i)&lt;/sup&gt;&lt;/span&gt;&lt;sup style="text-transform: none; font-size: 7pt; line-height: 7pt"&gt;&lt;/sup&gt;&lt;span style="text-transform: none"&gt;Equal to summary compensation total plus/minus any adjustments related to equity award values as reflected in&#160;this table. For purposes of calculating &#x201c;compensation actually paid,&#x201d; the fair value of equity awards at year-end 2023 and 2024, and on vesting dates for awards that vested during 2024, were all determined consistent with the approach used to value the awards at the grant date for purposes of the Summary Compensation Table (refer to &#x201c;Executive Officer Compensation &#x2013; Summary Compensation Table&#x201d; for additional information). For any awards subject to performance conditions, the change in fair value as of the end of the covered fiscal year is calculated based on the probable outcome of such conditions as of the last day of the fiscal year. The valuation assumptions used to calculate fair values do not differ materially from those disclosed at the time of grant, other than as reflected in the table below, which summarizes option fair values determined using the Black-Scholes model and related assumptions used to calculate Compensation Actually Paid for &lt;/span&gt;&lt;span style="text-transform: none"&gt;fiscal&#160;year 2024.&lt;/span&gt;&lt;/p&gt;
				&lt;table style="table-layout: fixed; width: 675pt; margin-top: 4pt; margin-bottom: 10pt; border-collapse: collapse"&gt;
						&lt;tr style="margin: 0; height: 0"&gt;
							&lt;td style="border-width: 0; margin: 0; padding: 0; width: 100pt"&gt;


							&lt;/td&gt;
							&lt;td style="border-width: 0; margin: 0; padding: 0; width: 110pt"&gt;


							&lt;/td&gt;
							&lt;td style="border-width: 0; margin: 0; padding: 0; width: 93.75pt"&gt;


							&lt;/td&gt;
							&lt;td style="border-width: 0; margin: 0; padding: 0; width: 92.49pt"&gt;


							&lt;/td&gt;
							&lt;td style="border-width: 0; margin: 0; padding: 0; width: 63.74pt"&gt;


							&lt;/td&gt;
							&lt;td style="border-width: 0; margin: 0; padding: 0; width: 107.5pt"&gt;


							&lt;/td&gt;
							&lt;td style="border-width: 0; margin: 0; padding: 0; width: 107.5pt"&gt;


							&lt;/td&gt;

						&lt;/tr&gt;
						&lt;tr style="min-height: 3pt"&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;b&gt;Valuation&lt;br/&gt;Purpose&lt;br/&gt;for PVP&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;b&gt;AORT&lt;br/&gt;Stock&lt;br/&gt;Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;b&gt;AORT&lt;br/&gt;Option&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;b&gt;Expected&lt;br/&gt;Term&lt;br/&gt;(years)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;b&gt;Stock&lt;br/&gt;Price&lt;br/&gt;Volatility&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;b&gt;Risk-free&lt;br/&gt;Rate&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;b&gt;Option&lt;br/&gt;Fair&lt;br/&gt;Value&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;

						&lt;/tr&gt;
						&lt;tr style="min-height: 3pt"&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"&gt;&lt;span style="text-transform: none"&gt;Year-end 2023&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_905_eus-gaap--SharePrice_iI_pid_c20241231__us-gaap--VestingAxis__custom--YearEnd2023Member_zyoa1YBNpbDh"&gt;$17.88&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20241231__us-gaap--VestingAxis__custom--YearEnd2023Member__srt--RangeAxis__srt--MinimumMember_z5bT910B5iI4"&gt;$11.03&lt;/span&gt; - &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20241231__us-gaap--VestingAxis__custom--YearEnd2023Member__srt--RangeAxis__srt--MaximumMember_zSNEB73O0Sbg"&gt;$24.90&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2023Member__srt--RangeAxis__srt--MinimumMember_zfuoYaTx9a6e"&gt;2.13&lt;/span&gt; &#x2013; &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2023Member__srt--RangeAxis__srt--MaximumMember_z5wuLeKbg0cf"&gt;4.93&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2023Member_z9yVGAlW0uoc"&gt;45&lt;/span&gt;%&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2023Member__srt--RangeAxis__srt--MinimumMember_zDHA9XJYwQOe"&gt;3.85&lt;/span&gt;% - &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2023Member__srt--RangeAxis__srt--MaximumMember_z0ByHjPnHdCi"&gt;4.20&lt;/span&gt;%&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_907_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFairValuePerShare_pid_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2023Member__srt--RangeAxis__srt--MinimumMember_ze1eSKkm7EUc"&gt;$3.11&lt;/span&gt; - &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_90D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFairValuePerShare_pid_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2023Member__srt--RangeAxis__srt--MaximumMember_z1wedYtymmOh"&gt;$9.89&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;

						&lt;/tr&gt;
						&lt;tr style="min-height: 3pt"&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"&gt;&lt;span style="text-transform: none"&gt;2024 Vesting&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_90A_eus-gaap--SharePrice_iI_pid_c20241231__us-gaap--VestingAxis__custom--Vesting2024Member__srt--RangeAxis__srt--MinimumMember_zeHkPyKExvF4"&gt;$18.81&lt;/span&gt; - &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_90D_eus-gaap--SharePrice_iI_pid_c20241231__us-gaap--VestingAxis__custom--Vesting2024Member__srt--RangeAxis__srt--MaximumMember_zH7RgbVEMs58"&gt;$29.66&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20241231__us-gaap--VestingAxis__custom--Vesting2024Member__srt--RangeAxis__srt--MinimumMember_zsBXXbgZNSHd"&gt;$11.03&lt;/span&gt; - &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20241231__us-gaap--VestingAxis__custom--Vesting2024Member__srt--RangeAxis__srt--MaximumMember_ziJ1ynfMcNij"&gt;$24.90&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20240101__20241231__us-gaap--VestingAxis__custom--Vesting2024Member__srt--RangeAxis__srt--MinimumMember_zyE2UDf1ohbd"&gt;2.00&lt;/span&gt; &#x2013; &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20240101__20241231__us-gaap--VestingAxis__custom--Vesting2024Member__srt--RangeAxis__srt--MaximumMember_z8x2k6FvKVSj"&gt;3.40&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20240101__20241231__us-gaap--VestingAxis__custom--Vesting2024Member_zqBT2vNbZH2e"&gt;45&lt;/span&gt;%&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20240101__20241231__us-gaap--VestingAxis__custom--Vesting2024Member__srt--RangeAxis__srt--MinimumMember_zAf0GFsQYSJ7"&gt;4.05&lt;/span&gt;% - &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20240101__20241231__us-gaap--VestingAxis__custom--Vesting2024Member__srt--RangeAxis__srt--MaximumMember_zruoGuGQVtce"&gt;4.64&lt;/span&gt;%&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_906_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFairValuePerShare_pid_c20240101__20241231__us-gaap--VestingAxis__custom--Vesting2024Member__srt--RangeAxis__srt--MinimumMember_zqoe5lHLTR5k"&gt;$3.44&lt;/span&gt; - &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFairValuePerShare_pid_c20240101__20241231__us-gaap--VestingAxis__custom--Vesting2024Member__srt--RangeAxis__srt--MaximumMember_z2zUAhP8h8wd"&gt;$19.34&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;

						&lt;/tr&gt;
						&lt;tr style="min-height: 3pt"&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt 1.5pt 3pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"&gt;&lt;span style="text-transform: none"&gt;Year-end 2024&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_90A_eus-gaap--SharePrice_iI_pid_c20241231__us-gaap--VestingAxis__custom--YearEnd2024Member_zIcNvc8rKnKg"&gt;$28.59&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20241231__us-gaap--VestingAxis__custom--YearEnd2024Member__srt--RangeAxis__srt--MinimumMember_zcefl9K22g16"&gt;$11.03&lt;/span&gt; - &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20241231__us-gaap--VestingAxis__custom--YearEnd2024Member__srt--RangeAxis__srt--MaximumMember_z79asRnmmY7g"&gt;$18.44&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2024Member__srt--RangeAxis__srt--MinimumMember_zdOWKWyp5Xq4"&gt;2.15&lt;/span&gt; &#x2013; &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2024Member__srt--RangeAxis__srt--MaximumMember_zba4BTXP2Uxf"&gt;3.93&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2024Member_zxqzATqctpVj"&gt;45&lt;/span&gt;%&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2024Member__srt--RangeAxis__srt--MinimumMember_zS6AZcNjtIsg"&gt;4.25&lt;/span&gt;% - &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2024Member__srt--RangeAxis__srt--MaximumMember_zdBzYd0oKpy9"&gt;4.32&lt;/span&gt;%&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_904_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFairValuePerShare_pid_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2024Member__srt--RangeAxis__srt--MinimumMember_zkhvEywZAjze"&gt;$13.41&lt;/span&gt; - &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEFzc3VtcHRpb25zIHVzZWQgdG8gY2FsY3VsYXRlIENvbXBlbnNhdGlvbiBBY3R1YWxseSBQYWlkAA__" id="xdx_90E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFairValuePerShare_pid_c20240101__20241231__us-gaap--VestingAxis__custom--YearEnd2024Member__srt--RangeAxis__srt--MaximumMember_zL4O8QW1feQ6"&gt;$19.23&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;

						&lt;/tr&gt;

					&lt;/table&gt;
					</ecd:EqtyAwrdsAdjFnTextBlock>
    <us-gaap:SharePrice
      contextRef="AsOf2024-12-31_custom_YearEnd2023Member"
      decimals="INF"
      id="Fact000149"
      unitRef="USDPShares">17.88</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2024-12-31_custom_YearEnd2023Member_srt_MinimumMember"
      decimals="INF"
      id="Fact000150"
      unitRef="USDPShares">11.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2024-12-31_custom_YearEnd2023Member_srt_MaximumMember"
      decimals="INF"
      id="Fact000151"
      unitRef="USDPShares">24.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2024-01-012024-12-31_custom_YearEnd2023Member_srt_MinimumMember"
      id="Fact000152">P2Y1M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2024-01-012024-12-31_custom_YearEnd2023Member_srt_MaximumMember"
      id="Fact000153">P4Y11M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2024-01-012024-12-31_custom_YearEnd2023Member"
      decimals="INF"
      id="Fact000154"
      unitRef="Ratio">0.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2024-01-012024-12-31_custom_YearEnd2023Member_srt_MinimumMember"
      decimals="INF"
      id="Fact000155"
      unitRef="Ratio">0.0385</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2024-01-012024-12-31_custom_YearEnd2023Member_srt_MaximumMember"
      decimals="INF"
      id="Fact000156"
      unitRef="Ratio">0.0420</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <aort:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFairValuePerShare
      contextRef="From2024-01-012024-12-31_custom_YearEnd2023Member_srt_MinimumMember"
      decimals="INF"
      id="Fact000157"
      unitRef="USDPShares">3.11</aort:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFairValuePerShare>
    <aort:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFairValuePerShare
      contextRef="From2024-01-012024-12-31_custom_YearEnd2023Member_srt_MaximumMember"
      decimals="INF"
      id="Fact000158"
      unitRef="USDPShares">9.89</aort:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFairValuePerShare>
    <us-gaap:SharePrice
      contextRef="AsOf2024-12-31_custom_Vesting2024Member_srt_MinimumMember"
      decimals="INF"
      id="Fact000159"
      unitRef="USDPShares">18.81</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="AsOf2024-12-31_custom_Vesting2024Member_srt_MaximumMember"
      decimals="INF"
      id="Fact000160"
      unitRef="USDPShares">29.66</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2024-12-31_custom_Vesting2024Member_srt_MinimumMember"
      decimals="INF"
      id="Fact000161"
      unitRef="USDPShares">11.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2024-12-31_custom_Vesting2024Member_srt_MaximumMember"
      decimals="INF"
      id="Fact000162"
      unitRef="USDPShares">24.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2024-01-012024-12-31_custom_Vesting2024Member_srt_MinimumMember"
      id="Fact000163">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2024-01-012024-12-31_custom_Vesting2024Member_srt_MaximumMember"
      id="Fact000164">P3Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2024-01-012024-12-31_custom_Vesting2024Member"
      decimals="INF"
      id="Fact000165"
      unitRef="Ratio">0.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2024-01-012024-12-31_custom_Vesting2024Member_srt_MinimumMember"
      decimals="INF"
      id="Fact000166"
      unitRef="Ratio">0.0405</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2024-01-012024-12-31_custom_Vesting2024Member_srt_MaximumMember"
      decimals="INF"
      id="Fact000167"
      unitRef="Ratio">0.0464</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <aort:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFairValuePerShare
      contextRef="From2024-01-012024-12-31_custom_Vesting2024Member_srt_MinimumMember"
      decimals="INF"
      id="Fact000168"
      unitRef="USDPShares">3.44</aort:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFairValuePerShare>
    <aort:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFairValuePerShare
      contextRef="From2024-01-012024-12-31_custom_Vesting2024Member_srt_MaximumMember"
      decimals="INF"
      id="Fact000169"
      unitRef="USDPShares">19.34</aort:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFairValuePerShare>
    <us-gaap:SharePrice
      contextRef="AsOf2024-12-31_custom_YearEnd2024Member"
      decimals="INF"
      id="Fact000170"
      unitRef="USDPShares">28.59</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2024-12-31_custom_YearEnd2024Member_srt_MinimumMember"
      decimals="INF"
      id="Fact000171"
      unitRef="USDPShares">11.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2024-12-31_custom_YearEnd2024Member_srt_MaximumMember"
      decimals="INF"
      id="Fact000172"
      unitRef="USDPShares">18.44</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2024-01-012024-12-31_custom_YearEnd2024Member_srt_MinimumMember"
      id="Fact000173">P2Y1M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2024-01-012024-12-31_custom_YearEnd2024Member_srt_MaximumMember"
      id="Fact000174">P3Y11M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2024-01-012024-12-31_custom_YearEnd2024Member"
      decimals="INF"
      id="Fact000175"
      unitRef="Ratio">0.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2024-01-012024-12-31_custom_YearEnd2024Member_srt_MinimumMember"
      decimals="INF"
      id="Fact000176"
      unitRef="Ratio">0.0425</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2024-01-012024-12-31_custom_YearEnd2024Member_srt_MaximumMember"
      decimals="INF"
      id="Fact000177"
      unitRef="Ratio">0.0432</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <aort:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFairValuePerShare
      contextRef="From2024-01-012024-12-31_custom_YearEnd2024Member_srt_MinimumMember"
      decimals="INF"
      id="Fact000178"
      unitRef="USDPShares">13.41</aort:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFairValuePerShare>
    <aort:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFairValuePerShare
      contextRef="From2024-01-012024-12-31_custom_YearEnd2024Member_srt_MaximumMember"
      decimals="INF"
      id="Fact000179"
      unitRef="USDPShares">19.23</aort:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsFairValuePerShare>
    <ecd:CompActuallyPaidVsTotalShareholderRtnTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000181">&lt;div id="xdx_805_eecd--CompActuallyPaidVsTotalShareholderRtnTextBlock_dU_zO1GcF89duI8"&gt;&lt;/div&gt;
				&lt;div id="xdx_848_eecd--TotalShareholderRtnVsPeerGroupTextBlock_dU_zkpJ0GDUpua"&gt;&lt;/div&gt;
				&lt;div style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 6pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;
					&lt;div style="border: #2b4b74 1pt solid; padding: 0pt; overflow: hidden; display: inline-block; width: 533.75pt; height: 271.88pt; text-align: left"&gt;
						&lt;img alt="" src="art-def14a_051325img005.gif" style="vertical-align: top; margin-left: 16.25pt; width: 500pt; margin-top: 13.75pt; height: 245pt"/&gt;

					&lt;/div&gt;

				&lt;/div&gt;
				&lt;div id="xdx_857_zEiHRh02Mcj9"&gt;&lt;/div&gt;
				</ecd:CompActuallyPaidVsTotalShareholderRtnTextBlock>
    <ecd:TotalShareholderRtnVsPeerGroupTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000183">&lt;div id="xdx_848_eecd--TotalShareholderRtnVsPeerGroupTextBlock_dU_zkpJ0GDUpua"&gt;&lt;/div&gt;
				&lt;div style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 6pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;
					&lt;div style="border: #2b4b74 1pt solid; padding: 0pt; overflow: hidden; display: inline-block; width: 533.75pt; height: 271.88pt; text-align: left"&gt;
						&lt;img alt="" src="art-def14a_051325img005.gif" style="vertical-align: top; margin-left: 16.25pt; width: 500pt; margin-top: 13.75pt; height: 245pt"/&gt;

					&lt;/div&gt;

				&lt;/div&gt;
				</ecd:TotalShareholderRtnVsPeerGroupTextBlock>
    <ecd:CompActuallyPaidVsNetIncomeTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000185">&lt;div id="xdx_805_eecd--CompActuallyPaidVsNetIncomeTextBlock_dU_zlVd058UsQq3"&gt;&lt;/div&gt;
				&lt;p style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 6pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;
				&lt;div style="font: 9pt/normal Arial, sans-serif; margin: 0pt 0pt 6pt 15pt; text-transform: none; color: #000000; text-indent: -15pt; text-align: center"&gt;
					&lt;div style="border: #2b4b74 1pt solid; padding: 0pt; overflow: hidden; display: inline-block; width: 533.75pt; height: 271.88pt; text-align: left"&gt;
						&lt;img alt="" src="art-def14a_051325img006.gif" style="vertical-align: top; margin-left: 16.25pt; width: 500pt; margin-top: 13.75pt; height: 245pt"/&gt;

					&lt;/div&gt;

				&lt;/div&gt;
				</ecd:CompActuallyPaidVsNetIncomeTextBlock>
    <ecd:CompActuallyPaidVsCoSelectedMeasureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000187">&lt;div id="xdx_809_eecd--CompActuallyPaidVsCoSelectedMeasureTextBlock_dU_zeNOAulayHc"&gt;&lt;/div&gt;
						&lt;div style="border: #2b4b74 1pt solid; padding: 0pt; overflow: hidden; display: inline-block; width: 533.75pt; height: 271.88pt; text-align: left"&gt;
						&lt;img alt="" src="art-def14a_051325img007.gif" style="vertical-align: top; margin-left: 16.25pt; width: 500pt; margin-top: 13.75pt; height: 245pt"/&gt;

					&lt;/div&gt;
				</ecd:CompActuallyPaidVsCoSelectedMeasureTextBlock>
    <ecd:TabularListTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000189">&lt;p id="xdx_802_eecd--TabularListTableTextBlock_dU_z1ShjrTHVRtk" style="font: italic 11pt/normal Arial, sans-serif; margin: 0pt 0pt 8pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: left"&gt;&lt;span style="text-transform: none; font-style: italic"&gt;&lt;b&gt;&lt;i&gt;Most Important Financial Measures Related to 2024 Officer Compensation&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
				&lt;p style="font: 10pt/normal Arial, sans-serif; margin: 0pt 0pt 10pt; text-transform: none; color: #000000; text-indent: 22.5pt; text-align: justify"&gt;&lt;span style="text-transform: none; line-height: 12pt"&gt;In accordance with the Pay Versus Performance Rules, the following table lists the financial performance measures that, in the Company&#x2019;s assessment, represent the most important financial performance measures used to link &#x201c;compensation actually paid&#x201d; to our Named Executive Officers, for fiscal year 2024, to Company performance. As discussed in the Compensation Discussion and Analysis, the annual short-term incentive plan used revenue growth (constant&#160;currency) and adjusted EBITDA as the primary financial measures for 2024. Annual PSUs granted during 2024 also were earned based on revenue growth (constant currency) and adjusted EBITDA. In 2024, we also applied an R&amp;amp;D-related metric for our annual performance share plan, which consisted of two milestones: (1) the submission of two AMDS PMA modules (i.e., pre-clinical in Q3 2024 and QMS/MFG in Q4 2024) and (2) the submission of the Arcevo LSA IDE in &lt;/span&gt;&lt;span style="text-transform: none; line-height: 12pt"&gt;Q4 2024.&lt;/span&gt;&lt;/p&gt;
				&lt;table id="xdx_30C_zwZ55xSk42o1" style="margin: 4pt auto 10pt; table-layout: fixed; width: 300pt; border-collapse: collapse" summary="xdx: Disclosure - Pay vs Performance Disclosure"&gt;
						&lt;tr style="margin: 0; height: 0"&gt;
							&lt;td style="border-width: 0; margin: 0; padding: 0; width: 300pt"&gt;


							&lt;/td&gt;

						&lt;/tr&gt;
						&lt;tr style="min-height: 0pt"&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="border-bottom: #000000 1pt solid; font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;b&gt;Key Financial Measures&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;

						&lt;/tr&gt;
						&lt;tr style="min-height: 0pt"&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; background-color: #dfe4ea; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;span id="xdx_902_eecd--MeasureName_c20240101__20241231__ecd--MeasureAxis__1_z0TGH43SagAd"&gt;AORT Revenue Growth (constant currency)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;

						&lt;/tr&gt;
						&lt;tr style="min-height: 0pt"&gt;
							&lt;td style="border-width: 0pt; padding: 1.5pt 0pt; vertical-align: bottom; border-collapse: collapse"&gt;
								&lt;p style="font: 10pt/normal Arial, sans-serif; margin: 0 0pt; text-transform: none; color: #000000; text-indent: 0pt; text-align: center"&gt;&lt;span style="text-transform: none"&gt;&lt;span id="xdx_908_eecd--MeasureName_c20240101__20241231__ecd--MeasureAxis__2_zJHNhr6uLbw5"&gt;Adjusted EBITDA&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

							&lt;/td&gt;

						&lt;/tr&gt;

					&lt;/table&gt;
				</ecd:TabularListTableTextBlock>
    <ecd:MeasureName contextRef="From2024-01-012024-12-31_1" id="Fact000190">AORT Revenue Growth (constant currency)</ecd:MeasureName>
    <ecd:MeasureName contextRef="From2024-01-012024-12-31_2" id="Fact000191">Adjusted EBITDA</ecd:MeasureName>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Fact000019"
          xlink:label="Fact000019"
          xlink:type="locator"/>
        <link:footnote id="Footnote000059" xlink:label="Footnote000059" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Mr. Mackin&#160;served
as our only PEO for&#160;each year.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000019"
          xlink:to="Footnote000059"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000020"
          xlink:label="Fact000020"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000020"
          xlink:to="Footnote000059"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000027"
          xlink:label="Fact000027"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000027"
          xlink:to="Footnote000059"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000028"
          xlink:label="Fact000028"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000028"
          xlink:to="Footnote000059"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000035"
          xlink:label="Fact000035"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000035"
          xlink:to="Footnote000059"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000036"
          xlink:label="Fact000036"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000036"
          xlink:to="Footnote000059"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000043"
          xlink:label="Fact000043"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000043"
          xlink:to="Footnote000059"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000044"
          xlink:label="Fact000044"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000044"
          xlink:to="Footnote000059"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000051"
          xlink:label="Fact000051"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000051"
          xlink:to="Footnote000059"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000052"
          xlink:label="Fact000052"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000052"
          xlink:to="Footnote000059"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000021"
          xlink:label="Fact000021"
          xlink:type="locator"/>
        <link:footnote id="Footnote000060" xlink:label="Footnote000060" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Our Non-PEO NEOs in 2024
were Messrs. Berry, Davis and Stanton and Ms. Holloway. Our Non-PEO NEOs in 2023 were Messrs. Lee, Berry, Davis and Mses. Horton and
Holloway. Our Non-PEO NEOs in 2022 and 2021 were&#160;Messrs. Lee,&#160;Davis,&#160;Stanton&#160;and&#160;Ms. Holloway. Our Non-PEO NEOs
in 2020 were&#160;Messrs.&#160;Lee,&#160;Davis,&#160;Simpson,&#160;and&#160;Ms. Holloway.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000021"
          xlink:to="Footnote000060"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000022"
          xlink:label="Fact000022"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000022"
          xlink:to="Footnote000060"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000029"
          xlink:label="Fact000029"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000029"
          xlink:to="Footnote000060"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000030"
          xlink:label="Fact000030"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000030"
          xlink:to="Footnote000060"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000037"
          xlink:label="Fact000037"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000037"
          xlink:to="Footnote000060"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000038"
          xlink:label="Fact000038"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000038"
          xlink:to="Footnote000060"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000045"
          xlink:label="Fact000045"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000045"
          xlink:to="Footnote000060"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000046"
          xlink:label="Fact000046"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000046"
          xlink:to="Footnote000060"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000053"
          xlink:label="Fact000053"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000053"
          xlink:to="Footnote000060"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000054"
          xlink:label="Fact000054"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000054"
          xlink:to="Footnote000060"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000023"
          xlink:label="Fact000023"
          xlink:type="locator"/>
        <link:footnote id="Footnote000061" xlink:label="Footnote000061" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Shareholder returns reflect
$100 invested as of market close on December 31, 2019, the final trading day of fiscal 2019; Index Shareholder Return reflects S&amp;P
500 Health Care&#160;Equipment Index.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000023"
          xlink:to="Footnote000061"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000024"
          xlink:label="Fact000024"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000024"
          xlink:to="Footnote000061"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000031"
          xlink:label="Fact000031"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000031"
          xlink:to="Footnote000061"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000032"
          xlink:label="Fact000032"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000032"
          xlink:to="Footnote000061"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000039"
          xlink:label="Fact000039"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000039"
          xlink:to="Footnote000061"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000040"
          xlink:label="Fact000040"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000040"
          xlink:to="Footnote000061"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000047"
          xlink:label="Fact000047"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000047"
          xlink:to="Footnote000061"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000048"
          xlink:label="Fact000048"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000048"
          xlink:to="Footnote000061"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000055"
          xlink:label="Fact000055"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000055"
          xlink:to="Footnote000061"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000056"
          xlink:label="Fact000056"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000056"
          xlink:to="Footnote000061"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000026"
          xlink:label="Fact000026"
          xlink:type="locator"/>
        <link:footnote id="Footnote000062" xlink:label="Footnote000062" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">In the Company&#x2019;s
assessment, for the 2024 fiscal year, AORT revenue growth represents the most important financial performance measure that is not otherwise
required to be disclosed in the table that we used to link &#x201c;compensation actually paid&#x201d; to our NEOs, including our PEO, to
our performance. AORT revenue growth is an adjusted constant currency revenue measure calculated by adjusting for the exchange rate effect
on GAAP revenues. We define exchange rate effect as the year-over-year impact of foreign currency movements using current period foreign
currency rates applied to prior period transactional currency amounts. As discussed in the Compensation Discussion &amp; Analysis, constant
currency revenue growth as calculated in incentive plans may reflect additional adjustments to either the baseline (prior year revenue)
or current year results, to exclude the impact of discontinued businesses and other unplanned events that were outside of management&#x2019;s
control. In 2023, we excluded the impact of the Company&#x2019;s Cardiogenesis business. In 2022, we adjusted to exclude PerClot sales
that occurred in 2022 and 2021. In 2021, we measured growth in the second half of the year by comparing to the second half of 2019 rather
than 2020.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000026"
          xlink:to="Footnote000062"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000034"
          xlink:label="Fact000034"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000034"
          xlink:to="Footnote000062"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000042"
          xlink:label="Fact000042"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000042"
          xlink:to="Footnote000062"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000050"
          xlink:label="Fact000050"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000050"
          xlink:to="Footnote000062"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000058"
          xlink:label="Fact000058"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000058"
          xlink:to="Footnote000062"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000076"
          xlink:label="Fact000076"
          xlink:type="locator"/>
        <link:footnote id="Footnote000105" xlink:label="Footnote000105" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Represents the grant date
fair value of equity-based awards made during the covered fiscal year as reported in the Summary&#160;Compensation Table.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000076"
          xlink:to="Footnote000105"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000082"
          xlink:label="Fact000082"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000082"
          xlink:to="Footnote000105"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000088"
          xlink:label="Fact000088"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000088"
          xlink:to="Footnote000105"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000094"
          xlink:label="Fact000094"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000094"
          xlink:to="Footnote000105"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000100"
          xlink:label="Fact000100"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000100"
          xlink:to="Footnote000105"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000077"
          xlink:label="Fact000077"
          xlink:type="locator"/>
        <link:footnote id="Footnote000106" xlink:label="Footnote000106" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Represents the year-end
fair value of equity awards that were made during the covered fiscal year and remained unvested as&#160;of the end of the covered fiscal
year.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000077"
          xlink:to="Footnote000106"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000083"
          xlink:label="Fact000083"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000083"
          xlink:to="Footnote000106"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000089"
          xlink:label="Fact000089"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000089"
          xlink:to="Footnote000106"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000095"
          xlink:label="Fact000095"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000095"
          xlink:to="Footnote000106"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000101"
          xlink:label="Fact000101"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000101"
          xlink:to="Footnote000106"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000078"
          xlink:label="Fact000078"
          xlink:type="locator"/>
        <link:footnote id="Footnote000107" xlink:label="Footnote000107" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Represents the change as
of the end of the covered fiscal year (from the end of the prior fiscal year) in fair value of equity-based awards granted in prior fiscal
years that were still unvested as of the covered&#160;fiscal year-end.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000078"
          xlink:to="Footnote000107"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000084"
          xlink:label="Fact000084"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000084"
          xlink:to="Footnote000107"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000090"
          xlink:label="Fact000090"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000090"
          xlink:to="Footnote000107"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000096"
          xlink:label="Fact000096"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000096"
          xlink:to="Footnote000107"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000102"
          xlink:label="Fact000102"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000102"
          xlink:to="Footnote000107"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000079"
          xlink:label="Fact000079"
          xlink:type="locator"/>
        <link:footnote id="Footnote000108" xlink:label="Footnote000108" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Represents the change as
of the vesting date (from the end of the prior fiscal year) in fair value of equity-based awards granted in prior fiscal years that vested
as of the end of or during the covered&#160;fiscal year.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000079"
          xlink:to="Footnote000108"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000085"
          xlink:label="Fact000085"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000085"
          xlink:to="Footnote000108"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000091"
          xlink:label="Fact000091"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000091"
          xlink:to="Footnote000108"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000097"
          xlink:label="Fact000097"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000097"
          xlink:to="Footnote000108"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000103"
          xlink:label="Fact000103"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000103"
          xlink:to="Footnote000108"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000080"
          xlink:label="Fact000080"
          xlink:type="locator"/>
        <link:footnote id="Footnote000109" xlink:label="Footnote000109" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Equal to summary compensation
total plus/minus any adjustments related to equity award values as reflected in&#160;this table. For purposes of calculating &#x201c;compensation
actually paid,&#x201d; the fair value of equity awards at year-end 2023 and 2024, and on vesting dates for awards that vested during 2024,
were all determined consistent with the approach used to value the awards at the grant date for purposes of the Summary Compensation
Table (refer to &#x201c;Executive Officer Compensation &#x2013; Summary Compensation Table&#x201d; for additional information). For any
awards subject to performance conditions, the change in fair value as of the end of the covered fiscal year is calculated based on the
probable outcome of such conditions as of the last day of the fiscal year. The valuation assumptions used to calculate fair values do
not differ materially from those disclosed at the time of grant, other than as reflected in the table below, which summarizes option
fair values determined using the Black-Scholes model and related assumptions used to calculate Compensation Actually Paid for fiscal&#160;year
2024.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000080"
          xlink:to="Footnote000109"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000086"
          xlink:label="Fact000086"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000086"
          xlink:to="Footnote000109"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000092"
          xlink:label="Fact000092"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000092"
          xlink:to="Footnote000109"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000098"
          xlink:label="Fact000098"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000098"
          xlink:to="Footnote000109"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000104"
          xlink:label="Fact000104"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000104"
          xlink:to="Footnote000109"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000113"
          xlink:label="Fact000113"
          xlink:type="locator"/>
        <link:footnote id="Footnote000142" xlink:label="Footnote000142" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Represents the grant date
fair value of equity-based awards made during the covered fiscal year as reported in the Summary&#160;Compensation Table.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000113"
          xlink:to="Footnote000142"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000119"
          xlink:label="Fact000119"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000119"
          xlink:to="Footnote000142"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000125"
          xlink:label="Fact000125"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000125"
          xlink:to="Footnote000142"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000131"
          xlink:label="Fact000131"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000131"
          xlink:to="Footnote000142"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000137"
          xlink:label="Fact000137"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000137"
          xlink:to="Footnote000142"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000114"
          xlink:label="Fact000114"
          xlink:type="locator"/>
        <link:footnote id="Footnote000143" xlink:label="Footnote000143" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Represents the year-end
fair value of equity awards that were made during the covered fiscal year and remained unvested as&#160;of the end of the covered fiscal
year.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000114"
          xlink:to="Footnote000143"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000120"
          xlink:label="Fact000120"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000120"
          xlink:to="Footnote000143"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000126"
          xlink:label="Fact000126"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000126"
          xlink:to="Footnote000143"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000132"
          xlink:label="Fact000132"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000132"
          xlink:to="Footnote000143"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000138"
          xlink:label="Fact000138"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000138"
          xlink:to="Footnote000143"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000115"
          xlink:label="Fact000115"
          xlink:type="locator"/>
        <link:footnote id="Footnote000144" xlink:label="Footnote000144" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Represents the change as
of the end of the covered fiscal year (from the end of the prior fiscal year) in fair value of equity-based awards granted in prior fiscal
years that were still unvested as of the covered&#160;fiscal year-end.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000115"
          xlink:to="Footnote000144"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000121"
          xlink:label="Fact000121"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000121"
          xlink:to="Footnote000144"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000127"
          xlink:label="Fact000127"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000127"
          xlink:to="Footnote000144"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000133"
          xlink:label="Fact000133"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000133"
          xlink:to="Footnote000144"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000139"
          xlink:label="Fact000139"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000139"
          xlink:to="Footnote000144"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000116"
          xlink:label="Fact000116"
          xlink:type="locator"/>
        <link:footnote id="Footnote000145" xlink:label="Footnote000145" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Represents the change as
of the vesting date (from the end of the prior fiscal year) in fair value of equity-based awards granted in prior fiscal years that vested
as of the end of or during the covered&#160;fiscal year.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000116"
          xlink:to="Footnote000145"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000122"
          xlink:label="Fact000122"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000122"
          xlink:to="Footnote000145"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000128"
          xlink:label="Fact000128"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000128"
          xlink:to="Footnote000145"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000134"
          xlink:label="Fact000134"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000134"
          xlink:to="Footnote000145"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000140"
          xlink:label="Fact000140"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000140"
          xlink:to="Footnote000145"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000117"
          xlink:label="Fact000117"
          xlink:type="locator"/>
        <link:footnote id="Footnote000146" xlink:label="Footnote000146" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Equal to summary compensation
total plus/minus any adjustments related to equity award values as reflected in&#160;this table. For purposes of calculating &#x201c;compensation
actually paid,&#x201d; the fair value of equity awards at year-end 2023 and 2024, and on vesting dates for awards that vested during 2024,
were all determined consistent with the approach used to value the awards at the grant date for purposes of the Summary Compensation
Table (refer to &#x201c;Executive Officer Compensation &#x2013; Summary Compensation Table&#x201d; for additional information). For any
awards subject to performance conditions, the change in fair value as of the end of the covered fiscal year is calculated based on the
probable outcome of such conditions as of the last day of the fiscal year. The valuation assumptions used to calculate fair values do
not differ materially from those disclosed at the time of grant, other than as reflected in the table below, which summarizes option
fair values determined using the Black-Scholes model and related assumptions used to calculate Compensation Actually Paid for fiscal&#160;year
2024.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000117"
          xlink:to="Footnote000146"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000123"
          xlink:label="Fact000123"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000123"
          xlink:to="Footnote000146"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000129"
          xlink:label="Fact000129"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000129"
          xlink:to="Footnote000146"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000135"
          xlink:label="Fact000135"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000135"
          xlink:to="Footnote000146"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000141"
          xlink:label="Fact000141"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000141"
          xlink:to="Footnote000146"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
